FN Thomson Reuters Web of Science™ VR 1.0 PT J AU King, AE Mintz, J Royall, DR AF King, Alisha E. Mintz, Jim Royall, Donald R. TI Meta-Analysis of I-123-MIBG Cardiac Scintigraphy for the Diagnosis of Lewy Body-Related Disorders SO MOVEMENT DISORDERS LA English DT Article DE dementia with Lewy bodies; Parkinson's disease; multiple system atrophy; Alzheimer's disease; parasomnias ID MULTIPLE SYSTEM ATROPHY; PURE AUTONOMIC FAILURE; PARKINSONS-DISEASE; SYMPATHETIC DENERVATION; ALPHA-SYNUCLEIN; BODIES; DEMENTIA; DEGENERATION; NERVE AB Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac I-123-metaiodo-benzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered I-123-metaiodobenzylguanidine cardiac scintigraphy a "supportive'' diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of I-123-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of I-123-metaiodobenzylguanidine uptake. I-123-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. I-123-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. (C) 2011 Movement Disorder Society C1 [King, Alisha E.; Mintz, Jim; Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78284 USA. [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78284 USA. [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78284 USA. [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78284 USA. [Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div GRECC, San Antonio, TX USA. RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM Royall@uthscsa.edu FU estate of Julia and Van Buren Parr FX This study has been supported by the estate of Julia and Van Buren Parr. NR 33 TC 32 Z9 33 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2011 VL 26 IS 7 BP 1218 EP 1224 DI 10.1002/mds.23659 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 780NF UT WOS:000291863600010 PM 21480373 ER PT J AU Jain, S Siegle, GJ Gu, C Moore, CG Ivanco, LS Studenski, S Greenamyre, JT Steinhauer, SR AF Jain, Samay Siegle, Greg J. Gu, Chen Moore, Charity G. Ivanco, Larry S. Studenski, Stephanie Greenamyre, J. Timothy Steinhauer, Stuart R. TI Pupillary Unrest Correlates With Arousal Symptoms and Motor Signs in Parkinson Disease SO MOVEMENT DISORDERS LA English DT Article DE nonmotor features; Parkinson's disease; pupil; sleep disorders; autonomic dysfunction ID NONMOTOR SYMPTOMS; DIAGNOSIS; SCALE AB Background: Arousal symptoms (e. g., sleepiness) are common in Parkinson's disease, and pupillary unrest (spontaneous changes in pupil diameter) is positively associated with sleepiness. We explored pupillary unrest in Parkinson's disease. Methods: Arousal symptoms (Epworth sleepiness scale and sleep/fatigue domain of the nonmotor symptoms scale for Parkinson's disease) and pupillary unrest were assessed in 31 participants (14 patients with Parkinson's disease, 17 controls). Effect sizes and t tests compared patients with Parkinson's disease with control participants. Correlation coefficients were calculated among arousal symptoms, pupillary unrest, and Unified Parkinson Disease Rating Scale Part III. Linear regression was performed with arousal symptoms or pupillary unrest as outcome. Results: Participants with Parkinson's disease reported more arousal symptoms than controls. Pupillary unrest, arousal symptoms, and Unified Parkinson Disease Rating Scale Part III were positively correlated. The association between nonmotor symptoms scale-sleep score and pupillary unrest was higher in participants with Parkinson's disease than controls and higher in those with more Parkinsonian motor signs. Unified Parkinson Disease Rating Scale Part III was positively associated with pupillary unrest. Conclusions: Pupillary unrest correlates with motor and nonmotor features associated with Lewy-related pathology, suggesting it may be a nonmotor marker of progression in Parkinson's disease. (C) 2011 Movement Disorder Society C1 [Jain, Samay] Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med,Movement Disorders Div, Pittsburgh, PA 15213 USA. [Jain, Samay; Greenamyre, J. Timothy] Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA USA. [Greenamyre, J. Timothy; Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Jain, S (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med,Movement Disorders Div, 3471 5th Ave,Suite 811,Kaufmann Med Bldg, Pittsburgh, PA 15213 USA. EM jains@upmc.edu OI Greenamyre, J. Timothy/0000-0003-3468-7878; Moore, Charity/0000-0002-0060-0124 FU NIH [KL2 RR024154, KMH082998, MH55762, UL1 RR024153, P30 AG-024827]; Department of Veterans Affairs; American Parkinson Disease Association Center for Advanced Research at the University of Pittsburgh FX This study was funded by NIH grants KL2 RR024154, KMH082998, MH55762, UL1 RR024153, and P30 AG-024827, the Department of Veterans Affairs, and the American Parkinson Disease Association Center for Advanced Research at the University of Pittsburgh. NR 10 TC 7 Z9 7 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2011 VL 26 IS 7 BP 1344 EP 1347 DI 10.1002/mds.23628 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 780NF UT WOS:000291863600028 PM 21506163 ER PT J AU Dubin, R Shlipak, M Li, YM Ix, J de Boer, IH Jenny, N Peralta, CA AF Dubin, Ruth Shlipak, Michael Li, Yongmei Ix, Joachim de Boer, Ian H. Jenny, Nancy Peralta, Carmen A. TI Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE C-reactive protein; estimated glomerular filtration rate by cystatin; pentraxin-3; race/ethnicity; serum amyloid protein ID ACUTE MYOCARDIAL-INFARCTION; STAGE RENAL-DISEASE; SERUM CYSTATIN-C; CARDIOVASCULAR-DISEASE; ELDERLY PERSONS; UNITED-STATES; PTX3; HYPERTENSION; MORTALITY; ADULTS AB Background. Pentraxin-3 (PTX3), an inflammatory marker thought to be related to vascular inflammation, is elevated in advanced chronic kidney disease (CKD). Whether PTX3 is associated with mild to moderate kidney dysfunction is unknown. Methods. We tested associations of proteins in the pentraxin family [PTX3, C-reactive protein (CRP) and serum amyloid protein (SAP)] with estimated glomerular filtration rate by cystatin C (eGFRcys) and microalbuminuria among 2824 participants in the Multi-Ethnic Study of Atherosclerosis. Associations were tested using multivariable linear regression with adjustment for demographics (age, gender, annual income), comorbidities (diabetes, hypertension, smoking, body mass index, low-density lipoprotein, high-density lipoprotein, triglycerides, ACE inhibitor and statin use) and systemic inflammation [interleukin-6 (IL-6)]. Results. Among the 2824 participants, mean age was 62 years and mean eGFRcys was 94 mL/min/1.73 m(2); 25% were white, 25% Chinese, 25% African-American and 25% Hispanic. Among all participants after full adjustment, higher PTX3 was associated with lower eGFRcys independently of IL-6 (beta-3.0 mL/min/1.73 m(2) per unit increase in lnPTX3, P < 0.001). In contrast, CRP and SAP were associated with eGFRcys in demographic adjusted models, but these associations were attenuated after adjustment for comorbidities and IL-6 (lnCRP beta-0.06, P = 0.9; lnSAP beta-0.35, P = 0.7). There was a significant interaction with race/ethnicity (P < 0.001) in the association of PTX3 and eGFRcys. After adjustment for demographics, comorbidities and IL-6, this association was significant in blacks (beta-5.7 mL/min/1.73 m(2) per unit increase in lnPTX3, P = 0.002) but not in Hispanics (beta-2.4, P = 0.1), Chinese (beta-0.91, P = 0.5) or whites (beta-0.26, P = 0.9). PTX3 and CRP, but not SAP, had correlations with microalbuminuria in unadjusted models (Spearman coefficients PTX3 0.05, P = 0.005; CRP 0.07, P < 0.001; SAP 0.013, P = 0.5), but these were attenuated after full adjustment. Conclusions. Endovascular inflammation may be an important mechanism associated with early kidney dysfunction, particularly among blacks. This mechanism appears to be independent of IL-6-regulated pathways. C1 [Dubin, Ruth; Shlipak, Michael; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA. [Shlipak, Michael; Peralta, Carmen A.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Ix, Joachim] Univ Calif San Diego, San Diego Vet Affairs Healthcare Syst, La Jolla, CA 92093 USA. [de Boer, Ian H.] Univ Washington, Dept Nephrol, Seattle, WA 98195 USA. [Jenny, Nancy] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. RP Dubin, R (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA. EM ruth.dubin@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169]; NIH, NIDDK [1K23DK082793-01] FX This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute. The authors thank the other investigators, the staff and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. C.P. is supported with NIH funding by NIDDK Grant #1K23DK082793-01. NR 30 TC 17 Z9 17 U1 3 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD JUN PY 2011 VL 26 IS 6 BP 1903 EP 1908 DI 10.1093/ndt/gfq648 PG 6 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 786SV UT WOS:000292329100022 PM 21079193 ER PT J AU Day, EC Li, YM Diez-Roux, A Kandula, N Moran, A Rosas, S Shlipak, MG Peralta, CA AF Day, Erica Chan Li, Yongmei Diez-Roux, Ana Kandula, Namratha Moran, Andrew Rosas, Sylvia Shlipak, Michael G. Peralta, Carmen A. TI Associations of acculturation and kidney dysfunction among Hispanics and Chinese from the Multi-Ethnic Study of Atherosclerosis (MESA) SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE acculturation; cystatin C; kidney function ID STAGE RENAL-DISEASE; UNITED-STATES; CYSTATIN-C; RACIAL-DIFFERENCES; CARDIOVASCULAR EVENTS; SOCIOECONOMIC-STATUS; HEALTH BEHAVIORS; AFRICAN-AMERICAN; ASIAN-AMERICANS; ELDERLY PERSONS AB Background. Acculturation affects health, but it has never been studied with kidney disease. Methods. We studied the association of language spoken at home, generation and birth place with kidney function among Hispanics and Chinese in the Multi-Ethnic Study of Atherosclerosis (n = 2999). Kidney function was determined by cystatin C (eGFRcys) and albumin/creatinine ratio (ACR). We evaluated mediators in models: Model 1 = age, sex, income, education; Model 2 = Model 1 + behaviors; and Model 3 = Model 1 + comorbidities. Results. Among Hispanics, speaking mixed Spanish/English was significantly associated with lower eGFRcys (-2.83 mL/min/1.73 m(2), -5.69-0.04) and higher ACR (RD 40%, 17-68%) compared with speaking Spanish only; this was mildly attenuated by behaviors (-2.29, -5.33-0.75; RD 42%, 18-72%) but not comorbidities (-3.04, -5.83 to -0.23); RD 35%, 14-59%). US-born Hispanics had lower eGFRcys compared with foreign-born Hispanics [1.83 mL/min/1.73 m(2) lower (0.97-1.31) for Generation 1; 1.37 mL/min/1.73 m(2) lower (0.75-1.57) for Generation >= 2]. In contrast, Chinese who spoke any English had higher eGFRcys (2.53, 95% CI: -1.70-6.78), but similar ACR (RD -5%, 95% CI: -26-23%) compared with those speaking Chinese only, but associations were not statistically significant. Conclusion. Higher acculturation was associated with worse kidney function in Hispanics, mediated perhaps by behavioral factors but not comorbidities. Associations may be in the opposite direction among Chinese. Future studies are needed to elucidate these mechanisms. C1 [Day, Erica Chan; Li, Yongmei; Shlipak, Michael G.; Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Diez-Roux, Ana] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Kandula, Namratha] Northwestern Univ, Sch Publ Hlth, Chicago, IL 60611 USA. [Moran, Andrew] Columbia Univ, New York, NY USA. [Rosas, Sylvia] Univ Penn, Philadelphia, PA 19104 USA. [Shlipak, Michael G.; Peralta, Carmen A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Day, EC (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. EM erica.chan@va.gov RI Rosas, Sylvia/D-1106-2009 FU National Heart, Lung, and Blood Institute [N01-HC-95159] FX This research was supported by contracts N01-HC-95159 from the National Heart, Lung, and Blood Institute. The authors thank the other investigators, the staff and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. NR 49 TC 7 Z9 7 U1 3 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD JUN PY 2011 VL 26 IS 6 BP 1909 EP 1916 DI 10.1093/ndt/gfq676 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 786SV UT WOS:000292329100023 PM 21051500 ER PT J AU Osguthorpe, JD AF Osguthorpe, J. David TI The Evolution of Understanding Inhalant Allergy SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Inhalant allergy; Atopy; Immunotherapy; Skin testing; Pharmacotherapy; Allergen; Immunoglobulin E ID HOUSE-DUST ALLERGEN; HAY-FEVER; PROPHYLACTIC INOCULATION; OTOLARYNGIC ALLERGY; POLLEN THERAPY; T-CELLS; IMMUNOTHERAPY; ASTHMA; RHINITIS; MECHANISMS AB This article summarizes the developments that led to the current approach to immunotherapy. These developments were characterized in the early years by empirically derived successive approximations to arrive at effective injection regimens, in the middle years by a sorting through of the wide variations in practice with placebo-controlled clinical trials, and more recently by a closer association of clinical and laboratory measures to better define evidence-based practices. The pace of investigation along with the scientific quality continues to increase. C1 [Osguthorpe, J. David] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Osguthorpe, JD (reprint author), Ralph Johnson Vet Adm Hosp, Surg Serv, 109 Bee St, Charleston, SC 29401 USA. EM John.Osguthorpe@va.gov NR 94 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0030-6665 EI 1557-8259 J9 OTOLARYNG CLIN N AM JI Otolaryngol. Clin. N. Am. PD JUN PY 2011 VL 44 IS 3 BP 519 EP + DI 10.1016/j.otc.2011.03.008 PG 18 WC Otorhinolaryngology SC Otorhinolaryngology GA 782KK UT WOS:000292007200002 PM 21621043 ER PT J AU Oldham, RL Dobscha, SK Goy, ER Ganzini, L AF Oldham, Robert L. Dobscha, Steven K. Goy, Elizabeth R. Ganzini, Linda TI Attachment styles of Oregonians who request physician-assisted death SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Physician-assisted death; Terminally ill; Attachment styles; Oregon Death with Dignity Act ID ASSOCIATION; SUICIDE; PATIENT; MODEL AB Objective: Qualitative analyses suggest that requests for physician-assisted death (PAD) may often be the culmination of a person's lifelong pattern of concern with issues such as control, autonomy, self-sufficiency, distrust of others, and avoidance of intimacy. Such characteristics may be measured by attachment style. We compared family members' reports of attachment style in Oregonians who did and did not request PAD. Method: Eighty-four family members of terminally ill patients who requested PAD before death and 63 members of a comparison group that included family members of terminally ill Oregonians who died without requesting PAD rated their loved ones' attachment style in a one-time survey. Results: Individuals who requested PAD were most often described as having dismissive personality styles (56%) compared to 41% of comparison individuals, and on continuous measures of relational style, the highest mean score among PAD requesters was for dismissive style. There were marginally significant differences in the proportions of each attachment style when comparing the two groups (p = 0.08). Significance of results: Patients' attachment styles may be an important factor in requests for PAD. Recognition of a patient's attachment style may improve the ability of the physician to maintain a constructive relationship with the patient throughout the dying process. C1 [Oldham, Robert L.; Dobscha, Steven K.; Goy, Elizabeth R.; Ganzini, Linda] Dept Vet Affairs, Portland, OR USA. [Oldham, Robert L.; Dobscha, Steven K.; Goy, Elizabeth R.; Ganzini, Linda] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Div Mental Hlth, R&D 66,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM linda.ganzini@va.gov NR 19 TC 4 Z9 4 U1 5 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD JUN PY 2011 VL 9 IS 2 BP 123 EP 128 DI 10.1017/S1478951510000660 PG 6 WC Health Policy & Services SC Health Care Sciences & Services GA 022WR UT WOS:000309995400002 PM 24468479 ER PT J AU Collinger, JL Dicianno, BE Weber, DJ Cui, XT Wang, W Brienza, DM Boninger, ML AF Collinger, Jennifer L. Dicianno, Brad E. Weber, Douglas J. Cui, Xinyan Tracy Wang, Wei Brienza, David M. Boninger, Michael L. TI Integrating Rehabilitation Engineering Technology With Biologics SO PM&R LA English DT Article ID FUNCTIONAL ELECTRICAL-STIMULATION; SPINAL-CORD-INJURY; NEURAL STEM-CELLS; ACUTE INFLAMMATORY RESPONSE; COMMON PERONEAL NERVE; MOTOR CORTICAL REPRESENTATION; SILICON MICROELECTRODE ARRAYS; REDUCED MATHEMATICAL-MODEL; FAST-TWITCH MUSCLE; CEREBRAL-CORTEX AB Rehabilitation engineers apply engineering principles to improve function or to solve challenges faced by persons with disabilities. It is critical to integrate the knowledge of biologics into the process of rehabilitation engineering to advance the field and maximize potential benefits to patients. Some applications in particular demonstrate the value of a symbiotic relationship between biologics and rehabilitation engineering. In this review we illustrate how researchers working with neural interfaces and integrated prosthetics, assistive technology, and biologics data collection are currently integrating these 2 fields. We also discuss the potential for further integration of biologics and rehabilitation engineering to deliver the best technologies and treatments to patients. Engineers and clinicians must work together to develop technologies that meet clinical needs and are accessible to the intended patient population. PM 122011;3:S148-S157 C1 [Collinger, Jennifer L.; Dicianno, Brad E.; Weber, Douglas J.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA. [Collinger, Jennifer L.; Dicianno, Brad E.; Weber, Douglas J.; Wang, Wei; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Dicianno, Brad E.; Brienza, David M.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Weber, Douglas J.; Cui, Xinyan Tracy; Wang, Wei; Brienza, David M.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Collinger, JL (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 6425 Penn Ave,4th Floor, Pittsburgh, PA 15206 USA. EM collingr@pitt.edu FU Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs [B6789C]; National Institute on Disability and Rehabilitation Research Rehabilitation Engineering Research Center on Spinal Cord Injury [H133E070024]; National Institute on Disability and Rehabilitation Research Model Center on Spinal Cord Injury [H133N060019] FX This study was supported by the Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs, grant No. B6789C; the National Institute on Disability and Rehabilitation Research Rehabilitation Engineering Research Center on Spinal Cord Injury, grant No. H133E070024; and the National Institute on Disability and Rehabilitation Research Model Center on Spinal Cord Injury, grant No. H133N060019. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States government. NR 118 TC 1 Z9 1 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD JUN PY 2011 VL 3 IS 6 SU S BP S148 EP S157 DI 10.1016/j.pmrj.2011.03.011 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 961BB UT WOS:000305437800024 PM 21703573 ER PT J AU Xie, AL Bedekar, A Skatrud, JB Teodorescu, M Gong, YS Dempsey, JA AF Xie, Ailiang Bedekar, Ajay Skatrud, James B. Teodorescu, Mihaela Gong, Yuansheng Dempsey, Jerome A. TI The Heterogeneity of Obstructive Sleep Apnea (Predominant Obstructive vs Pure Obstructive Apnea) SO SLEEP LA English DT Article DE CO2 reserve; Pcrit; OSA ID UPPER AIRWAY COLLAPSIBILITY; CONTROL MECHANISMS; RESPIRATORY DRIVE; NEGATIVE-PRESSURE; MUSCLE-ACTIVITY; PATHOGENESIS; RESISTANCE; STABILITY; INSTABILITY; THRESHOLD AB Study Objectives: To compare the breathing instability and upper airway collapsibility between patients with pure OSA (i.e. 100% of apneas are obstructive) and patients with predominant OSA (i.e., coexisting obstructive and central apneas). Design: A cross-sectional study with data scored by a fellow being blinded to the subjects' classification. The results were compared between the 2 groups with unpaired student t-test. Setting and interventions: Standard polysomnography technique was used to document sleep-wake state. Ventilator in pressure support mode was used to introduce hypocapnic apnea during CO2 reserve measurement. CPAP with both positive and negative pressures was used to produce obstructive apnea during upper airway collapsibility measurement. Participants: 21 patients with OSA: 12 with coexisting central/mixed apneas and hypopneas (28% +/- 6% of total), and 9 had pure OSA. Measurements: The upper airway collapsibility was measured by assessing the critical closing pressure (Pcrit). Breathing stability was assessed by measuring CO2 reserve (i.e.,Delta PCO2 [eupnea-apnea threshold]) during NREM sleep. Results: There was no difference in Pcrit between the 2 groups (pure OSA vs. predominant OSA: 2.0 +/- 0.4 vs. 2.7 +/- 0.4 cm H2O, P = 0.27); but the CO2 reserve was significantly smaller in predominant OSA group (1.6 +/- 0.7 mm Hg) than the pure OSA group (3.8 +/- 0.6 mm Hg) (P = 0.02). Conclusions: The present data indicate that breathing stability rather than upper airway collapsibility distinguishes OSA patients with a combination of obstructive and central events from those with pure OSA. C1 [Bedekar, Ajay; Skatrud, James B.; Teodorescu, Mihaela; Gong, Yuansheng] Univ Wisconsin, Dept Med, Madison, WI USA. [Xie, Ailiang; Skatrud, James B.; Teodorescu, Mihaela] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Xie, AL (reprint author), VA Hosp, Pulm Physiol Lab, 2500 Overlook Terrace, Madison, WI 53705 USA. EM axie@wisc.edu FU VA Medical Research Service; American Lung Association of Wisconsin; NIH-NHLB1 [1RC1HL099724-01] FX We would like to thanks Dominic S. Puleo for technique assistance. Research work performed at Pulmonary Physiology Laboratory, VA Hospital, Madison, WI. This work was supported by the VA Medical Research Service; American Lung Association of Wisconsin; and NIH-NHLB1 (Grant 1RC1HL099724-01). NR 35 TC 15 Z9 15 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JUN 1 PY 2011 VL 34 IS 6 BP 745 EP 750 DI 10.5665/SLEEP.1040 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 771LE UT WOS:000291158000010 PM 21629362 ER PT J AU Lee, KB Murray, SS Taghavi, CE Song, KJ Brochmann, EJ Johnson, JS Keorochana, G Liao, JC Wang, JC AF Lee, Kwang-Bok Murray, Samuel S. Taghavi, Cyrus E. Song, Kyung-Jin Brochmann, Elsa J. Johnson, Jared S. Keorochana, Gun Liao, Jen-Chung Wang, Jeffrey C. TI Bone morphogenetic protein-binding peptide reduces the inflammatory response to recombinant human bone morphogenetic protein-2 and recombinant human bone morphogenetic protein-7 in a rodent model of soft-tissue inflammation SO SPINE JOURNAL LA English DT Article DE Soft-tissue edema; rhBMP-7; rhBMP-2; BMP-binding peptide; MIPAV ID ANTERIOR CERVICAL-SPINE; SAFETY PROFILE; FUSION; RHBMP-2; SURGERY; CARRIER; MATRIX; BMP-2; RATS AB BACKGROUND CONTEXT: Bone morphogenetic protein (BMP)-2 and BMP-7 are used to enhance bone formation in spine surgery, but the use of these materials is associated with side effects including inflammation, especially in the soft tissues of the neck. Bone morphogenetic protein-binding peptide (BBP) binds BMP-2 and BMP-7 and imparts a "slow-release" property to collagen carrier. PURPOSE: To test the hypothesis that the addition of BBP will reduce the soft-tissue inflammation induced by the implantation of BMP-2 and BMP-7 on a collagen sponge. STUDY DESIGN/SETTING: Prospective in vivo rodent model of inflammation. METHODS: We implanted six different materials absorbed onto collagen sponges: absorbable collagen sponge (ACS) alone; BBP alone; recombinant human bone morphogenetic protein (rhBMP)-2 alone; rhBMP-2 plus BBP; rhBMP-7 alone; and rhBMP-7 plus BBP. Sponges were implanted bilaterally (subcutaneously [SC] and intramuscularly [IM]) into the backs of rats. Using magnetic resonance imaging, inflammation was assessed in terms of soft-tissue edema volume at 3 hours and at 2, 4, and 7 days. The animal subjects were killed on Day 7, and the dimensions of the inflammatory mass were measured manually in the case of SC tissue and those of the inflammatory zone were determined subsequently by microscopic examination in the case of muscle. RESULTS: Both the SC and the IM soft-tissue edema volumes in the rhBMP-2 plus BBP and the rhBMP-7 plus BBP groups were significantly lower than those observed in the rhBMP-2 alone and rhBMP-7 alone groups. The edema volume associated with BBP alone was greater than that associated with ACS alone but less than that associated with the other treatment groups. The measurements of inflammatory masses and zone yielded similar results. CONCLUSIONS: Bone morphogenetic protein-binding peptide may reduce the inflammatory response associated with the use of rhBMP-2 and rhBMP-7 in a rodent model of inflammation and in a form that has previously been shown to enhance the activity of BMPs. These preliminary studies suggest that BBP may have the potential to be used in the future to improve healing and reduce soft-tissue swelling in surgical applications of BMPs. (C) 2011 Elsevier Inc. All rights reserved. C1 [Lee, Kwang-Bok; Taghavi, Cyrus E.; Johnson, Jared S.; Keorochana, Gun; Liao, Jen-Chung; Wang, Jeffrey C.] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90404 USA. [Lee, Kwang-Bok; Song, Kyung-Jin] Chonbuk Natl Univ, Sch Med, Chonbuk Natl Univ Hosp, Dept Orthopaed Surg,Res Inst Clin Med, Jeonju 561712, South Korea. [Murray, Samuel S.; Brochmann, Elsa J.] VA Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA 90073 USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Murray, Samuel S.; Wang, Jeffrey C.] Univ Calif Los Angeles, Biomed Engn Interdept Program, Los Angeles, CA 90095 USA. [Keorochana, Gun] Mahidol Univ, Ramathibodi Hosp, Dept Orthopaed, Bangkok 10400, Thailand. [Liao, Jen-Chung] Chang Gung Univ, Chang Gung Mem Hosp, Dept Orthopaed, Tao Yuan 333, Taiwan. RP Wang, JC (reprint author), Univ Calif Los Angeles, Dept Orthopaed Surg, Comprehens Spine Ctr, 1250 16th St,7th Floor Tower,745, Santa Monica, CA 90404 USA. EM jwang@mednet.ucla.edu FU UCLA; Lanx; IsoTis [01/2010]; Medtronics; Department of Veterans Affairs FX K-BL: Nothing to disclose. SSM: Royalties: UCLA (A); Consulting: Lanx (E, paid directly to institution/employer); Research Support (Staff and/or Materials): Lanx (E, paid directly to institution/employer); Grants: Lanx (E, paid directly to institution/employer); Other: IsoTis (Nonfinancial); Relationships Outside the One-Year Requirement: IsoTis (01/2010, sponsored research, F). CET: Nothing to disclose. K-JS: Nothing to disclose. EJB: Disclosure unavailable. JSJ: Nothing to disclose. GK: Nothing to disclose. J-CL: Nothing to disclose. JCW: Royalties: Medtronics (D), Stryker (C), Seaspine (E), Osprey (C), Aesculap (C), Biomet (F), Amedica (C), Zimmer (D), Alphatech (F); Stock Ownership: Fziomed (2,500 Shares, < 1% of entity); Private Investments: Promethean Spine (B, < 1% of entity), Paradigm spine (B, < 1% of entity), Benevenue (C, < 1% of entity), NexGen (B, < 1% of entity), K2 medical (B, < 1% of entity), Pioneer (B, < 1% of entity), Amedica (D, < 1% of entity), Vertiflex (B, < 1% of entity), Electrocore (C, < 1% of entity), Surgitech (C, < 1% of entity), Invuity (10,000 Shares, < 1% of entity), Axiomed (25,000 Shares, < 1% of entity); Board of Directors: North American Spine Society (Nonfinancial), Cervical Spine Research Society (Nonfinancial); Scientific Advisory Board: VG Innovations (5,000 options, < 1% of entity), Corespine (2,000 options, < 1% of entity), Expanding Orthopaedics (33,000, < 1% of entity), Syndicom (66,125 shares, < 1% of entity), Osprey (10 options, < 1% of entity), Amedica (35,416 options, < 1% of entity), Bone Biologics (51,255 shares, < 1% of entity), Curative Biosciences (1,875 options, < 1% of entity), Facet Solutions (35,000 options, < 1% of entity), PearlDiver (25,000 options, < 1% of entity), Pioneer (3,636 options, < 1% of entity), Seaspine (11 options, < 1% of entity), Axis (Nonfinancial).; This work was supported, in part, by the Department of Veterans Affairs. NR 30 TC 23 Z9 23 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 EI 1878-1632 J9 SPINE J JI Spine Journal PD JUN PY 2011 VL 11 IS 6 BP 568 EP 576 DI 10.1016/j.spinee.2011.02.001 PG 9 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 786PJ UT WOS:000292320100020 PM 21729805 ER PT J AU Ruggiero, KJ Gros, DF McCauley, J de Arellano, MA Danielson, CK AF Ruggiero, Kenneth J. Gros, Daniel F. McCauley, Jenna de Arellano, Michael A. Danielson, Carla Kmett TI Rural Adults' Use of Health-Related Information Online: Data from a 2006 National Online Health Survey SO TELEMEDICINE AND E-HEALTH LA English DT Article DE rural; Internet; health information ID URBAN DIFFERENCES; DIGITAL DIVIDE; MENTAL-HEALTH; INTERNET; CARE; ACCESS; COMMUNICATION; CHALLENGES; PROGRAM; TRIAL AB Objective: The objective of this study was to examine access and use of health-related information online in rural versus nonrural Internet users, using national data from the 2006 Pew Internet and American Life Project. Materials and Methods: A national telephone survey of 2,928 adults in August 2006 yielded a sample of 1,992 adults who use the Internet regularly. A structured interview was administered to assess frequency of Internet use and access and use of health-related information online. Results: Most Internet-using rural adults search for health-related information online; two-thirds seek information about specific medical problems and over half seek information about treatment. Three-fifths of rural adults surveyed stated that online health-related information affected the decisions they made in health maintenance and managing treatment of an illness. More than one-third reported being significantly helped by information they found, whereas one-fourth reported being confused. Comparisons between rural and nonrural Internet users suggested that rural users were more likely to seek information about smoking cessation (chi(2) [1, N = 1,990] = 7.91, p < 0.01) and mental health issues (chi(2) [1, N = 1,988] = 3.71, p = 0.05), less likely to seek information about a particular doctor or hospital (chi(2) [1, N = 1,983] = 15.49, p < 0.001), and more likely to report being helped (chi(2) [1, N = 1,534] = 5.24, p < 0.05)-but also confused (chi(2) [1, N = 1,592] = 9.83, p < 0.01)-by information they found. Conclusions: Rural Americans are increasingly using the Internet to acquire information about chronic disease, mental health, doctors, and treatment options. Priorities should include further development and rigorous evaluation of online resources to ensure high-quality, more direct tailoring of resources to rural families and development of tools to assist consumers in assessing the credibility of online information. C1 [Ruggiero, Kenneth J.; Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Ruggiero, Kenneth J.; Gros, Daniel F.; McCauley, Jenna; de Arellano, Michael A.; Danielson, Carla Kmett] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA. EM ruggierk@musc.edu FU VA HSRD Grant [MHI 08-105-2]; NIMH [R34 MH77149, R01 MH81056, P60 MH082598, T32 MH018869, R21 MH086313]; NIDA [K23 DA018686] FX K.J. Ruggiero is a core investigator of VA HSR&D REAP (REA 08261; PI: Egede) and is supported by VA HSR&D Grant MHI 08-105-2 and NIMH Grants R34 MH77149 (PI: Ruggiero), R01 MH81056 (PI: Ruggiero), and P60 MH082598 (PI: Norris). Dr. J. McCauley is supported by NIMH Grant T32 MH018869. Dr. C.K. Danielson is supported by NIDA K23 DA018686 and NIMH R21 MH086313 (PI: C.K. Danielson). The authors thank Wendy Muzzy of the Medical University of South Carolina and Susannah Fox of the Pew Internet and American Life Project for their valuable assistance. NR 38 TC 9 Z9 9 U1 1 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED E-HEALTH JI Telemed. e-Health PD JUN PY 2011 VL 17 IS 5 BP 329 EP 334 DI 10.1089/tmj.2010.0195 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 784ZX UT WOS:000292198300004 PM 21524201 ER PT J AU Knapp, H Chan, K Anaya, HD Goetz, MB AF Knapp, Herschel Chan, Kee Anaya, Henry D. Goetz, Matthew B. TI Interactive Internet-Based Clinical Education: An Efficient and Cost-Savings Approach to Point-of-Care Test Training SO TELEMEDICINE AND E-HEALTH LA English DT Article DE HIV; online; Internet; in-service; education; cost savings; distance learning ID EMERGENCY-DEPARTMENT; HIV; RECOMMENDATIONS; BARRIERS; DISEASE; WOMEN; RISK AB Background: We successfully created and implemented an effective HIV rapid testing training and certification curriculum using traditional in-person trainings at multiple sites within the U. S. Department of Veterans Affairs (VA) Healthcare System. Objective: Considering the multitude of geographically remote facilities in the nationwide VA system, coupled with the expansion of HIV diagnostics, we developed an alternate training method that is affordable, efficient, and effective. Methods: Using materials initially developed for in-person HIV rapid test in-services, we used a distance learning model to offer this training via live audiovisual online technology to educate clinicians at a remote outpatient primary care VA facility. Results: Participants' evaluation metrics showed that this form of remote education is equivalent to in-person training; additionally, HIV testing rates increased considerably in the months following this intervention. Although there is a one-time setup cost associated with this remote training protocol, there is potential cost savings associated with the point-of-care nurse manager's time productivity by using the Internet in-service learning module for teaching HIV rapid testing. If additional in-service training modules are developed into Internet-based format, there is the potential for additional cost savings. Our cost analysis demonstrates that the remote in-service method provides a more affordable and efficient alternative compared with in-person training. Conclusions: The online in-service provided training that was equivalent to in-person sessions based on first-hand supervisor observation, participant satisfaction surveys, and follow-up results. This method saves time and money, requires fewer personnel, and affords access to expert trainers regardless of geographic location. Further, it is generalizable to trainings beyond HIV rapid testing. Based on these consistent implementation successes, we plan to expand use of online training to include remote VA satellite facilities spanning several states for a variety of diagnostic devices. Ultimately, Internet-based training has the potential to provide "big city'' quality of care to patients at remote (rural) clinics. C1 [Knapp, Herschel; Chan, Kee; Anaya, Henry D.; Goetz, Matthew B.] VA Greater Los Angeles Hlth Serv Res, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90073 USA. [Knapp, Herschel; Chan, Kee; Anaya, Henry D.; Goetz, Matthew B.] VA Greater Los Angeles Healthcare Syst, Dev Ctr Excellence, Los Angeles, CA 90073 USA. [Chan, Kee] Edith Nurse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Chan, Kee] Boston Univ, Dept Hlth Sci, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA. [Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Goetz, Matthew B.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Dept Med, Los Angeles, CA USA. RP Knapp, H (reprint author), VA Greater Los Angeles Hlth Serv Res, Ctr Study Healthcare Provider Behav, 11301 Wilshire Blvd,M-C 111-G, Los Angeles, CA 90073 USA. EM herschel.knapp@va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 17 TC 6 Z9 7 U1 1 U2 9 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED E-HEALTH JI Telemed. e-Health PD JUN PY 2011 VL 17 IS 5 BP 335 EP 340 DI 10.1089/tmj.2010.0187 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 784ZX UT WOS:000292198300005 PM 21492031 ER PT J AU Vaidya, S Dighe, M Bhargava, P Dick, AA AF Vaidya, S. Dighe, M. Bhargava, P. Dick, A. A. TI Chronic Hepatic Artery Occlusion with Collateral Formation: Imaging Findings and Outcomes SO TRANSPLANTATION PROCEEDINGS LA English DT Article ID LIVER-TRANSPLANTATION; PSEUDOSTRING SIGN; VASA VASORUM; THROMBOSIS; DOPPLER AB Objective. The imaging findings, clinical presentation, and outcome in post liver transplantation patients with hepatic arterial collaterals are reviewed. Materials and Methods. Adult post orthotopic liver transplantation patients who underwent an angiography at our institution for suspected hepatic arterial abnormality during an approximately 10-year period were included in our study. A retrospective review of all cases that had hepatic arterial collaterals detected on angiography was then performed. Angiographic findings were correlated with the findings on ultrasound and other imaging studies. Liver function at the time of angiography was recorded. Clinical outcomes were reviewed. Results. Of the 129 angiographies performed in the approximately 10-year period, 24 (19.4%) were found to have collaterals on angiography. Maximum size of the collaterals seen on angiography was 3 mm. Twenty patients (83%) with collaterals are currently alive. Twelve patients (50%) had a normal outcome and did not develop any complications on follow-up; however, the rest developed complications. Eleven patients (41.7%) had complication related to the liver ischemia and 2 patients (8.3%) developed malignancy (posttransplant lymphoproliferative disease). Conclusion. Collaterals seen in patients with chronic hepatic artery occlusion are usually small in caliber and their significance is unclear. Recognition and understanding of this phenomenon is important as this subset of patients may not need urgent surgical re-exploration/vascular intervention. C1 [Vaidya, S.; Dighe, M.; Bhargava, P.] Univ Washington, Dept Radiol, Med Ctr, Seattle, WA 98195 USA. [Bhargava, P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Dick, A. A.] Univ Washington, Dept Surg, Div Transplant Surg, Med Ctr, Seattle, WA 98195 USA. RP Dighe, M (reprint author), Univ Washington, Dept Radiol, Med Ctr, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM dighe@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 10 TC 8 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 J9 TRANSPL P JI Transplant. Proc. PD JUN PY 2011 VL 43 IS 5 BP 1770 EP 1776 DI 10.1016/j.transproceed.2011.03.034 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 786CI UT WOS:000292279800073 PM 21693276 ER PT J AU Cooperberg, MR AF Cooperberg, Matthew R. TI Bone Scan Overuse in Staging of Prostate Cancer: An Analysis of a Veterans Affairs Cohort EDITORIAL COMMENT SO UROLOGY LA English DT Editorial Material ID CONTEMPORARY TRENDS; UPDATE C1 [Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Cooperberg, Matthew R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Cooperberg, MR (reprint author), UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD JUN PY 2011 VL 77 IS 6 BP 1336 EP 1337 DI 10.1016/j.urology.2011.02.010 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 769VX UT WOS:000291047500021 PM 21624594 ER PT J AU Lustgarten, MS Jang, YC Liu, YH Qi, WB Qin, YJ Dahia, PL Shi, Y Bhattacharya, A Muller, FL Shimizu, T Shirasawa, T Richardson, A Van Remmen, H AF Lustgarten, Michael S. Jang, Youngmok C. Liu, Yuhong Qi, Wenbo Qin, Yuejuan Dahia, Patricia L. Shi, Yun Bhattacharya, Arunabh Muller, Florian L. Shimizu, Takahiko Shirasawa, Takuji Richardson, Arlan Van Remmen, Holly TI MnSOD deficiency results in elevated oxidative stress and decreased mitochondrial function but does not lead to muscle atrophy during aging SO AGING CELL LA English DT Article DE age-related muscle atrophy; oxidative stress; mitochondrial function ID BODY-COMPOSITION ANALYSIS; HUMAN SKELETAL-MUSCLE; SUCCINATE-DEHYDROGENASE; SUPEROXIDE-DISMUTASE; ACONITASE ACTIVITY; ESCHERICHIA-COLI; MAMMALIAN-CELLS; MOUSE HINDLIMB; COMPLEX I; MICE AB P>In a previous study, we reported that a deficiency in MnSOD activity (approximately 80% reduction) targeted to type IIB skeletal muscle fibers was sufficient to elevate oxidative stress and to reduce muscle function in young adult mice (TnIFastCreSod2fl/fl mice). In this study, we used TnIFastCreSod2fl/fl mice to examine the effect of elevated oxidative stress on mitochondrial function and to test the hypothesis that elevated oxidative stress and decreased mitochondrial function over the lifespan of the TnIFastCreSod2fl/fl mice would be sufficient to accelerate muscle atrophy associated with aging. We found that mitochondrial function is reduced in both young and old TnIFastCreSod2fl/fl mice, when compared with control mice. Complex II activity is reduced by 47% in young and by approximately 90% in old TnIFastCreSod2fl/fl mice, and was found to be associated with reduced levels of the catalytic subunits for complex II, SDHA and SDHB. Complex II-linked mitochondrial respiration is reduced by approximately 70% in young TnIFastCreSod2fl/fl mice. Complex II-linked mitochondrial Adenosine-Tri-Phosphate (ATP) production is reduced by 39% in young and was found to be almost completely absent in old TnIFastCreSod2fl/fl mice. Furthermore, in old TnIFastCreSod2fl/fl mice, aconitase activity is almost completely abolished; mitochondrial superoxide release remains > 2-fold elevated; and oxidative damage (measured as F(2)- isoprostanes) is increased by 30% relative to age-matched controls. These data show that despite elevated skeletal muscle-specific mitochondrial oxidative stress, oxidative damage, and complex II-linked mitochondrial dysfunction, age-related muscle atrophy was not accelerated in old TnIFastCreSod2fl/fl mice, suggesting mitochondrial oxidative stress may not be causal for age-related muscle atrophy. C1 [Lustgarten, Michael S.; Jang, Youngmok C.; Qi, Wenbo; Bhattacharya, Arunabh; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Lustgarten, Michael S.; Shi, Yun] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Jang, Youngmok C.; Liu, Yuhong; Bhattacharya, Arunabh; Muller, Florian L.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Qin, Yuejuan; Dahia, Patricia L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Hematol & Med Oncol, San Antonio, TX 78229 USA. [Shimizu, Takahiko; Shirasawa, Takuji] Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Tokyo, Japan. [Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu FU NIH [P01AG020591]; VA Merit grant; NIA [5T3-AG021890-02] FX We thank Corinne Price for editing the manuscript. This work was funded by NIH grant P01AG020591, a VA Merit grant (HVR), and NIA Training Grant 5T3-AG021890-02. NR 54 TC 30 Z9 31 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD JUN PY 2011 VL 10 IS 3 BP 493 EP 505 DI 10.1111/j.1474-9726.2011.00695.x PG 13 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 763CR UT WOS:000290531900013 PM 21385310 ER PT J AU Qu, WC Stineman, MG Streim, JE Xie, DW AF Qu, Wenchun Stineman, Margaret G. Streim, Joel E. Xie, Dawei TI Understanding the Linkages Between Perceived Causative Impairment and Activity Limitations Among Older People Living in the Community A Population-Based Assessment SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Activities of Daily Living; Brain Disease; Aging; Classification; ICF ID HOME CARE; DISABILITY; REHABILITATION; OUTCOMES; SYSTEM; COSTS AB Qu W, Stineman MG, Streim JE, Xie D: Understanding the linkages between perceived causative impairment and activity limitations among older people living in the community: a population-based assessment. Am J Phys Med Rehabil 2011;90:466-476. Objective: The aim of this study was to better understand the linkages between impairment and activity limitation among groups of elderly community-living persons. Design: This study used a United States population-based complex survey with weights used to make accurate population prevalence estimates from the 1994 National Health Interview Survey on Disability. Included were 2429 persons 70 yrs or older with one or more activity of daily living or instrumental activity of daily living-only activity limitations. Limitations were addressed according to the impairment(s) perceived to be causing them. Results: Musculoskeletal impairments accounted for more than one-third of all perceived causes. The odds of having any activity of daily living limitations for persons whose limitations were attributed to musculoskeletal impairments and to brain or behavioral impairments were 2.12 times (95% confidence interval, 1.63-2.76) and 3.00 times (95% confidence interval, 2.23-4.03) the odds for the reference group of cardiopulmonary and hematology impairment. Conclusions: Although musculoskeletal impairments were the most common cause of activity limitation, impairments associated with brain or behavioral disturbance were perceived as most disabling. C1 [Qu, Wenchun; Stineman, Margaret G.] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. [Stineman, Margaret G.; Xie, Dawei] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Streim, Joel E.] Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. [Qu, Wenchun] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA. [Streim, Joel E.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA USA. RP Stineman, MG (reprint author), 101 Ralston Penn Ctr,3615 Chestnut St, Philadelphia, PA 19104 USA. FU National Institute of Aging of the National Institutes of Health [AG032420-01A1]; Ruth L. Kirschstein National Research Service Award [(T32) 5-T32-HD-007425] FX Supported by the National Institute of Aging of the National Institutes of Health (AG032420-01A1) and by the Ruth L. Kirschstein National Research Service Award Institutional Research Training grant (T32) 5-T32-HD-007425 (supported W.Q. while at the University of Pennsylvania). NR 34 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD JUN PY 2011 VL 90 IS 6 BP 466 EP 476 DI 10.1097/PHM.0b013e318214ec02 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 761WV UT WOS:000290433200004 PM 21430511 ER PT J AU Liu, XH AF Liu, Xuhui TI Emerging Ideas: Matrix Metalloproteinase-2 in Muscle Atrophy SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID SKELETAL-MUSCLE; HINDLIMB IMMOBILIZATION; EXPRESSION; RECOVERY; RATS AB Muscle atrophy impacts almost every patient seen for orthopaedic conditions. Unfortunately, no effective treatment is available to date. Matrix metalloproteinases (MMPs), especially MMP-2, are involved in skeletal muscle atrophy. MMP-2 null mice reportedly have substantially reduced muscle atrophy after tendon transection compared with wild-type mice, suggesting MMP-2 plays an important role in muscle atrophy. Although the exact mechanisms remain unknown, a newly-discovered intracellular form of MMP-2 suggests a possible novel mechanism of MMP-2 digesting muscle matrix during muscle atrophy. I propose a new pharmacologic treatment for muscle atrophy using selective MMP-2 inhibitors. I hypothesize: (1) intracellular MMP-2 plays an important role during muscle atrophy by digesting intramuscular matrix; (2) AP-1 and NFAT signal transduction pathways are responsible for expression and activation of the intracellular MMP-2 during muscle atrophy; and (3) specific MMP-2 inhibitors can serve as a novel pharmacologic strategy in treating disuse-induced muscle atrophy. Expression and activity of extracellular and intracellular MMP-2 will be determined in a mouse tendon transection model. The role of AP-1 and NFAT signal transduction pathways in MMP-2 transcriptional regulation in muscle atrophy will be determined using chromatin-immunoprecipitation (ChIP) and small interfering RNA (siRNA). I also will test the feasibility of treating muscle atrophy using selective MMP-2 inhibitors. Understanding the signaling transduction pathway of extracellular and intracellular MMP-2 expression during muscle atrophy may lead to novel treatments for muscle atrophy that preserve the normal physiologic function of MMP-2. C1 [Liu, Xuhui] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94121 USA. [Liu, Xuhui] San Francisco VA Med Ctr, San Francisco, CA USA. RP Liu, XH (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 4150 Clement St,Bldg 2,Room 639, San Francisco, CA 94121 USA. EM liux@orthosurg.ucsf.edu FU Orthopaedic Research & Education Foundation; Illinois Bone and Joint Institute FX I thank the ORS Grant Writing Workshop for the education provided. I appreciate my mentors, Drs Hubert T. Kim and David H. Lovett (SFVAMC and UCSF), for their intensive mentorship. I also thank the Orthopaedic Research & Education Foundation and the Illinois Bone and Joint Institute for research support. NR 10 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD JUN PY 2011 VL 469 IS 6 BP 1797 EP 1799 DI 10.1007/s11999-010-1726-5 PG 3 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 763PE UT WOS:000290571400040 PM 21132408 ER PT J AU Thukkani, N Williams, JL Sonnenberg, A AF Thukkani, Nundhini Williams, J. Lucas Sonnenberg, Amnon TI Epidemiologic Characteristics of Patients with Inflammatory Bowel Disease Undergoing Colonoscopy SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE colonoscopy; Crohn's disease; epidemiology of inflammatory bowel disease; ethnic variation; geographic variation; practice patterns; ulcerative colitis ID CROHNS-DISEASE; UNITED-STATES; ULCERATIVE-COLITIS; AGE DISTRIBUTION; APPROPRIATE USE; CORI DATABASE; VITAMIN-D; HOSPITALIZATION; PREVALENCE; IBD AB Background: The aim was too describe the demographic characteristics of patients with inflammatory bowel disease (IBD) undergoing colonoscopy. Methods: The Clinical Outcomes Research Initiative (CORI) maintains a database of endoscopic procedures in diverse clinical practices distributed throughout the US. The data from 2000-2007 were used to analyze the demographic characteristics of patients with Crohn's disease (CD) and ulcerative colitis (UC). Results: During the period 2000-2007, 4631 patients with CD and 6619 patients with UC were compared to a control population of 826,207 patients without IBD. CD and UC patients were significantly (P < 0.0001) younger than controls: 41.7 +/- 18.4, 47.3 +/- 17.4, 59.2 +/- 14.0 years, respectively. CD and UC were less common among nonwhite than white endoscopy patients: odds ratio (OR) = 0.64 (0.58-0.70) for CD and OR = 0.71 (0.66-0.77) for UC. Endoscopy for IBD was only slightly less common among female than male CD patients (0.94, 0.89-1.00), but significantly less common among female than male UC patients (0.72, 0.68-0.75). Compared with community/private practices, relatively more endoscopies were performed among IBD patients in academic institutions: OR = 1.68 (1.56-1.81) for CD and OR = 27 (1.19-1.36) for UC. The race-, sex-, and age-adjusted rates of CD and UC were both significantly higher in the northern than southern regions of the US, with a significant correlation of r = 0.89, degrees of freedom = 4, P = 0.017 between the geographic distributions of the two diagnoses. Conclusions: The endoscopy patterns of IBD patients may be influenced in part by the epidemiology of these two diagnoses, as well as by underlying trends in the utilization of colonoscopy. C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU NIDDK [UO1 CA 89389-01, U01 DK057132, R33-DK61778-01]; AstraZeneca; Bard International; Pentax USA; ProVation; Endosoft; GIVEN Imaging; Ethicon FX Supported with funding from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132 and R33-DK61778-01. In addition, the practice network (CORI) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. The commercial entities had no involvement in this research. NR 23 TC 4 Z9 7 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JUN PY 2011 VL 17 IS 6 BP 1333 EP 1337 DI 10.1002/ibd.21513 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 761ZQ UT WOS:000290442400032 PM 21560196 ER PT J AU Foley, JM Wright, MJ Gooding, AL Ettenhofer, M Kim, M Choi, M Castellon, SA Sadek, J Heaton, RK van Gorp, WG Marcotte, TD Hinkin, CH AF Foley, J. M. Wright, M. J. Gooding, A. L. Ettenhofer, M. Kim, M. Choi, M. Castellon, S. A. Sadek, J. Heaton, R. K. van Gorp, W. G. Marcotte, T. D. Hinkin, C. H. TI Operationalization of the updated diagnostic algorithm for classifying HIV-related cognitive impairment and dementia SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE HIV; cognitive impairment; classification; dementia ID NEUROCOGNITIVE DISORDERS; CONFIRMATION; INFECTION AB Background: This study applies the updated HIV-Associated Neurocognitive Disorders (HAND) diagnostic algorithm. Methods: Participants were 210 HIV-infected-adults, classified using proposed HAND criteria: HIV-Associated Dementia (HAD), Mild Neurocognitive Disorder (MND), Asymptomatic Neurocognitive Impairment (ANI). Results: The algorithm yielded: normal = 32.8%, ANI = 21.4%, MND = 34.3%, and HAD = 11.4%. Normal participants performed superior to HAND-defined participants on cognition, and HAD participants performed more poorly on global cognition and executive functioning. Two distinct subgroups of interest emerged: (1) functional decline without cognitive impairment; (2) severe cognitive impairment and minimal functional compromise. Conclusions: The algorithm discriminates between HIV-infected cognitively impaired individuals. Diagnosis yields two unique profiles requiring further investigation. Findings largely support the algorithm's utility for diagnosing HIV-cognitive-impairment, but suggest distinct subsets of individuals with discrepant cognitive/functional performances that may not be readily apparent by conventional application of HAND diagnosis. C1 [Foley, J. M.; Wright, M. J.; Ettenhofer, M.; Castellon, S. A.; Hinkin, C. H.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Gooding, A. L.; Kim, M.; Castellon, S. A.; Hinkin, C. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Choi, M.; Heaton, R. K.; Marcotte, T. D.] UCSD Dept Psychiat, San Diego, CA USA. [Sadek, J.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [van Gorp, W. G.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY USA. RP Foley, JM (reprint author), 150 S,Huntington Ave, Boston, MA 02130 USA. EM Jfoley@post.harvard.edu FU NIMH [R01 MH58522]; VA Merit Review: Aging and HIV/AIDS: Neurocognitive Sequelae and Functional Consequences FX This study was conducted at the University of California Los Angeles, and the West Los Angeles Veteran's Affairs Medical Center and was supported by: NIMH R01 MH58522, VA Merit Review: Aging and HIV/AIDS: Neurocognitive Sequelae and Functional Consequences to CHH. NR 29 TC 4 Z9 5 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JUN PY 2011 VL 23 IS 5 BP 835 EP 843 DI 10.1017/S1041610210002085 PG 9 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 757TB UT WOS:000290109500017 PM 21092351 ER PT J AU Johnson, JS Meliton, V Kim, WK Lee, KB Wang, JC Nguyen, K Yoo, D Jung, ME Atti, E Tetradis, S Pereira, RC Magyar, C Nargizyan, T Hahn, TJ Farouz, F Thies, S Parhami, F AF Johnson, Jared S. Meliton, Vicente Kim, Woo Kyun Lee, Kwang-Bok Wang, Jeffrey C. Nguyen, KhanhLinh Yoo, Dongwon Jung, Michael E. Atti, Elisa Tetradis, Sotirios Pereira, Renata C. Magyar, Clara Nargizyan, Taya Hahn, Theodore J. Farouz, Francine Thies, Scott Parhami, Farhad TI Novel Oxysterols Have Pro-Osteogenic and Anti-Adipogenic Effects In Vitro and Induce Spinal Fusion In Vivo SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE OXYSTEROLS; SPINAL FUSION; BMP2; OSTEOGENESIS; ADIPOGENESIS ID BONE MORPHOGENETIC PROTEIN-2; MARROW STROMAL CELLS; MESENCHYMAL PRECURSOR CELLS; OSTEOBLASTIC DIFFERENTIATION; FRACTURE REPAIR; SONIC HEDGEHOG; GENE-THERAPY; RODENT MODEL; EXPRESSION; 20(S)-HYDROXYCHOLESTEROL AB Stimulation of bone formation by osteoinductive materials is of great clinical importance in spinal fusion surgery, repair of bone fractures, and in the treatment of osteoporosis. We previously reported that specific naturally occurring oxysterols including 20(S)-hydroxycholesterol (20S) induce the osteogenic differentiation of pluripotent mesenchymal cells, while inhibiting their adipogenic differentiation. Here we report the characterization of two structural analogues of 20S, Oxy34 and Oxy49, which induce the osteogenic and inhibit the adipogenic differentiation of bone marrow stromal cells (MSC) through activation of Hedgehog (Hh) signaling. Treatment of M2-10B4 MSC with Oxy34 or Oxy49 induced the expression of osteogenic differentiation markers Runx2, Osterix (Osx), alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteocalcin (OCN), as well as ALP enzymatic activity and robust mineralization. Treatment with oxysterols together with PPAR gamma activator, troglitazone (Tro), inhibited mRNA expression for adipogenic genes PPAR gamma, LPL, and aP2, and inhibited the formation of adipocytes. Efficacy of Oxy34 and Oxy49 in stimulating bone formation in vivo was assessed using the posterolateral intertransverse process rat spinal fusion model. Rats receiving collagen implants with Oxy 34 or Oxy49 showed comparable osteogenic efficacy to BMP2/collagen implants as measured by radiography, MicroCT, and manual inspection. Histological analysis showed trabecular and cortical bone formation by oxysterols and rhBMP2 within the fusion mass, with robust adipogenesis in BMP2-induced bone and significantly less adipocytes in oxysterol-induced bone. These data suggest that Oxy34 and Oxy49 are effective novel osteoinductive molecules and may be suitable candidates for further development and use in orthopedic indications requiring local bone formation. J. Cell. Biochem. 112: 1673-1684, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Parhami, Farhad] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Med, Los Angeles, CA 90095 USA. [Johnson, Jared S.; Lee, Kwang-Bok; Wang, Jeffrey C.] Univ Calif Los Angeles, Dept Orthoped Surg, Los Angeles, CA 90095 USA. [Nguyen, KhanhLinh; Yoo, Dongwon; Jung, Michael E.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA. [Atti, Elisa; Tetradis, Sotirios] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Pereira, Renata C.] Univ Calif Los Angeles, Dept Pediat Nephrol, Los Angeles, CA 90024 USA. [Magyar, Clara] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA. [Hahn, Theodore J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hahn, Theodore J.] Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Farouz, Francine; Thies, Scott] Fate Therapeut Inc, San Diego, CA USA. RP Parhami, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Med, A2-237,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM fparhami@mednet.ucla.edu FU NIAMS/NIH [RO1AR050426]; Fate Therapeutics, Inc.; Fate Therapeutics, Inc. (San Diego, CA, USA) FX Grant sponsor: NIAMS/NIH; Grant number: RO1AR050426; Grant sponsor: Fate Therapeutics, Inc..; This work was supported by NIAMS/NIH Grant RO1AR050426 and in part by a sponsored research award from Fate Therapeutics, Inc. (San Diego, CA, USA). NR 52 TC 30 Z9 31 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD JUN PY 2011 VL 112 IS 6 BP 1673 EP 1684 DI 10.1002/jcb.23082 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 762NX UT WOS:000290487800023 PM 21503957 ER PT J AU John, LK Loewenstein, G Troxel, AB Norton, L Fassbender, JE Volpp, KG AF John, Leslie K. Loewenstein, George Troxel, Andrea B. Norton, Laurie Fassbender, Jennifer E. Volpp, Kevin G. TI Financial Incentives for Extended Weight Loss: A Randomized, Controlled Trial SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE behavioral medicine; obesity; psychology; randomized trials; behavioral economics ID REDUCTION; CHOICE; HEALTH AB BACKGROUND: Previous efforts to use incentives for weight loss have resulted in substantial weight regain after 16 weeks. OBJECTIVE: To evaluate a longer term weight loss intervention using financial incentives. DESIGN: A 32-week, three-arm randomized controlled trial of financial incentives for weight loss consisting of a 24-week weight loss phase during which all participants were given a weight loss goal of 1 pound per week, followed by an 8-week maintenance phase. PARTICIPANTS: Veterans who were patients at the Philadelphia Veterans Affairs Medical Center with BMIs of 30-40. INTERVENTION: Participants were randomly assigned to participate in either a weight-monitoring program involving a consultation with a dietician and monthly weigh-ins (control condition), or the same program with one of two financial incentive plans. Both incentive arms used deposit contracts (DC) in which participants put their own money at risk (matched 1:1), which they lost if they failed to lose weight. In one incentive arm participants were told that the period after 24 weeks was for weight-loss maintenance; in the other, no such distinction was made. MAIN MEASURE: Weight loss after 32 weeks. KEY RESULTS: Results were analyzed using intention-to-treat. There was no difference in weight loss between the incentive arms (P = 0.80). Incentive participants lost more weight than control participants [mean DC = 8.70 pounds, mean control = 1.17, P = 0.04, 95% CI of the difference in means (0.56, 14.50)]. Follow-up data 36 weeks after the 32-week intervention had ended indicated weight regain; the net weight loss between the incentive and control groups was no longer significant (mean DC = 1.2 pounds, 95% CI, -2.58-5.00; mean control = 0.27, 95% CI, -3.77-4.30, P = 0.76). CONCLUSIONS: Financial incentives produced significant weight loss over an 8-month intervention; however, participants regained weight post-intervention. C1 [John, Leslie K.; Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. [Loewenstein, George; Troxel, Andrea B.; Norton, Laurie; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Fassbender, Jennifer E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Fassbender, Jennifer E.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Norton, Laurie; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Norton, Laurie; Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP John, LK (reprint author), Carnegie Mellon Univ, Dept Social & Decis Sci, 208 Porter Hall,5000 Forbes Ave, Pittsburgh, PA 15213 USA. EM lkjohn@andrew.cmu.edu OI Troxel, Andrea/0000-0002-1393-3075 FU USDA; Economic Research Service [58-4000-7-0058]; Hewlett Foundation FX USDA, Economic Research Service (grant no. 58-4000-7-0058) and the Hewlett Foundation. NR 20 TC 97 Z9 97 U1 4 U2 29 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2011 VL 26 IS 6 BP 621 EP 626 DI 10.1007/s11606-010-1628-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 763RE UT WOS:000290576600013 PM 21249462 ER PT J AU Trivedi, RB Nieuwsma, JA Williams, JW AF Trivedi, Ranak B. Nieuwsma, Jason A. Williams, John W., Jr. TI Examination of the Utility of Psychotherapy for Patients with Treatment Resistant Depression: A Systematic Review SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE treatment resistant depression; depression treatment; primary care; psychotherapy ID RANDOMIZED CONTROLLED-TRIAL; STAR-ASTERISK-D; PRIMARY-CARE PATIENTS; COGNITIVE-BEHAVIORAL THERAPY; ACUTE MAJOR DEPRESSION; RESIDUAL DEPRESSION; COLLABORATIVE CARE; COST-EFFECTIVENESS; PSYCHOLOGICAL INTERVENTIONS; 2ND-STEP TREATMENTS AB OBJECTIVE: To examine the utility of psychotherapy in managing treatment resistant depression. DATA SOURCES: PubMed, PsycInfo, Embase, Cochrane Registry of Controlled Clinical Trials, article bibliographies. REVIEW METHODS: Eligible articles had to be in English and include English-speaking adult outpatients from general medical or mental health clinics. Studies had to be randomized clinical trials (RCT) involving at least one of the following psychotherapy modalities: cognitive therapy, interpersonal therapy, or behavior therapy. Patients were considered treatment resistant if they reported partial or no remission following treatment with an adequate antidepressant dose for >= 6 weeks. Exclusion criteria included receiving psychotherapy at the time of recruitment, and/or comorbid psychiatric conditions unlikely to be treated outside of specialized mental health care (e.g., severe substance abuse). Due to heterogeneity in study designs, a summary estimate of effect was not calculated. Studies were critically analyzed and a qualitative synthesis was conducted. RESULTS: Of 941 original titles, 13 articles evaluating 7 unique treatment comparisons were included. Psychotherapy was examined as an augmentation to antidepressants in five studies and as substitution treatment in two studies. A total of 592 patients were evaluated (Mean age similar to 40 y; Females = 50-85%; Caucasians >= 75%). The STAR*D trial used an equipoise stratified randomization design; the remaining studies were RCTs. Compared to active management, two good quality trials showed similar benefit from augmenting antidepressants with psychotherapy; one fair quality and one poor quality trial showed benefit from psychotherapy augmentation; and one good and one poor trial found similar benefit from substituting psychotherapy for antidepressants. One fair quality trial showed lithium augmentation to be more beneficial than psychotherapy. CONCLUSIONS: Review demonstrates the utility of psychotherapy in managing treatment resistant depression. However, evidence is sparse and results are mixed. Given that quality trials are lacking, rigorous clinical trials are recommended to guide practice. In the interim, primary care providers should consider psychotherapy when treating patients with treatment resistant depression. C1 [Trivedi, Ranak B.] Univ Washington, Sch Publ Hlth, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. [Nieuwsma, Jason A.] Duke Univ, Med Ctr, Durham VA MIRECC, Durham, NC USA. [Williams, John W., Jr.] Duke Univ, Med Ctr, Durham VA Med Ctr, Evidence Based Practice Ctr, Durham, NC USA. RP Trivedi, RB (reprint author), Univ Washington, Sch Publ Hlth, VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM ranak.trivedi@va.gov FU Duke University Medical Center; VA Mid-Atlantic MIRECC fellowship; VA Health Services FX Dr. Trivedi was partly supported by an AHRQ T-32 fellowship at Duke University Medical Center, and resources within the VA Puget Sound Health Care System. Dr. Nieuwsma was partly supported by a VA Mid-Atlantic MIRECC fellowship. The views and opinions in this manuscript are those of the authors and do not reflect those of the VA.; This project was funded by the VA Health Services Research and Development Evidence Synthesis Program. NR 51 TC 19 Z9 19 U1 3 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2011 VL 26 IS 6 BP 643 EP 650 DI 10.1007/s11606-010-1608-2 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 763RE UT WOS:000290576600016 PM 21184287 ER PT J AU Bartzokis, G Lu, PH Tingus, K Peters, DG Amar, CP Tishler, TA Finn, JP Villablanca, P Altshuler, LL Mintz, J Neely, E Connor, JR AF Bartzokis, George Lu, Po H. Tingus, Kathleen Peters, Douglas G. Amar, Chetan P. Tishler, Todd A. Finn, J. Paul Villablanca, Pablo Altshuler, Lori L. Mintz, Jim Neely, Elizabeth Connor, James R. TI Gender and Iron Genes May Modify Associations Between Brain Iron and Memory in Healthy Aging SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE memory; iron; gene; sex; dementia; treatment ID MILD COGNITIVE IMPAIRMENT; ONSET PARKINSONS-DISEASE; POPULATION-BASED COHORTS; ALZHEIMERS-DISEASE; FERRITIN IRON; RECOGNITION MEMORY; MOUSE HIPPOCAMPUS; OXIDATIVE STRESS; MAJOR SUBTYPES; SERUM IRON AB Brain iron increases with age and is abnormally elevated early in the disease process in several neurodegenerative disorders that impact memory including Alzheimer's disease (AD). Higher brain iron levels are associated with male gender and presence of highly prevalent allelic variants in genes encoding for iron metabolism proteins (hemochromatosis H63D (HFE H63D) and transferrin C2 (TfC2)). In this study, we examined whether in healthy older individuals memory performance is associated with increased brain iron, and whether gender and gene variant carrier (IRON+) vs noncarrier (IRON-) status (for HFE H63D/TfC2) modify the associations. Tissue iron deposited in ferritin molecules can be measured in vivo with magnetic resonance imaging utilizing the field-dependent relaxation rate increase (FDRI) method. FDRI was assessed in hippocampus, basal ganglia, and white matter, and IRON+ vs IRON- status was determined in a cohort of 63 healthy older individuals. Three cognitive domains were assessed: verbal memory (delayed recall), working memory/attention, and processing speed. Independent of gene status, worse verbal-memory performance was associated with higher hippocampal iron in men (r = -0.50, p = 0.003) but not in women. Independent of gender, worse verbal working memory performance was associated with higher basal ganglia iron in IRON- group (r = -0.49, p = 0.005) but not in the IRON+ group. Between-group interactions (p = 0.006) were noted for both of these associations. No significant associations with white matter or processing speed were observed. The results suggest that in specific subgroups of healthy older individuals, higher accumulations of iron in vulnerable gray matter regions may adversely impact memory functions and could represent a risk factor for accelerated cognitive decline. Combining genetic and MRI biomarkers may provide opportunities to design primary prevention clinical trials that target high-risk groups. Neuropsychopharmacology (2011) 36, 1375-1384; doi:10.1038/npp.2011.22; published online 9 March 2011 C1 [Bartzokis, George; Peters, Douglas G.; Amar, Chetan P.; Tishler, Todd A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, Div Brain Mapping, Dept Neurol, Lab Neuroimaging, Los Angeles, CA 90095 USA. [Bartzokis, George; Peters, Douglas G.; Amar, Chetan P.; Tishler, Todd A.] Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Lu, Po H.; Tingus, Kathleen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Finn, J. Paul; Villablanca, Pablo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Neely, Elizabeth; Connor, James R.] Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA. RP Bartzokis, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIH [AG027342, MH0266029]; Department of Veterans Affairs; RCS Alzheimer's Foundation; George M Leader Family FX This work was supported in part by NIH grants (AG027342 and MH0266029), the Department of Veterans Affairs, the RCS Alzheimer's Foundation, and the George M Leader Family. This work was presented in part at the 451st Annual Winter Conference on Brain Research, Snowbird, Utah, January 2008, and the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), Vienna, Austria, July 2009. NR 105 TC 39 Z9 39 U1 1 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JUN PY 2011 VL 36 IS 7 BP 1375 EP 1384 DI 10.1038/npp.2011.22 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 764GL UT WOS:000290617500007 PM 21389980 ER PT J AU Enestvedt, BK Williams, JL Sonnenberg, A AF Enestvedt, B. K. Williams, J. L. Sonnenberg, A. TI Epidemiology and practice patterns of achalasia in a large multi-centre database SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID UNITED-STATES; BOTULINUM TOXIN; PREVALENCE; CONSORTIUM; HOSPITALIZATION; COLONOSCOPY; POPULATION; HEMORRHAGE; ENDOSCOPY AB Background Due to its rarity, achalasia remains a difficult disease to study. Aims To describe the epidemiology of achalasia and practice patterns in its endoscopic management, utilising patient records from a large national database of endoscopic procedures. Methods The Clinical Outcomes Research Initiative maintains a database of endoscopic procedures in diverse clinical practices. The data from 89 endoscopy practices distributed throughout the US during 2000-2008 were used to analyse the characteristics and therapy of patients with achalasia. Results Among 521 497 upper endoscopies during the study period, we identified 896 patients with achalasia. Compared with the entirety of all other endoscopic diagnoses, achalasia was more common in men than in women (OR = 1.39, CI 1.22-1.59), but similar among nonwhites and whites (OR = 0.87, CI 0.74-1.03). Relatively, more achalasia patients were treated at university than at community practices (OR = 1.52, CI 1.30-1.78). Botox injection was most frequently used as first choice of endoscopic therapy in 41%, followed by balloon dilation in 21%, Savary dilation in 20%, Maloney dilation in 10%, Rigiflex in 4% and other modalities in 4% of patients. One quarter of achalasia patients treated endoscopically underwent a repeat therapy about every 14 months. Conclusions Botox has become the primary choice of initial endoscopic therapy in achalasia. Despite their partial deviation from guidelines and recommendations, these endoscopic patterns reflect the current clinical practice in the United States. C1 [Enestvedt, B. K.; Williams, J. L.; Sonnenberg, A.] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97201 USA. [Williams, J. L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Sonnenberg, A.] Portland VA Med Ctr, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-G1,3710 SW S Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu FU NIDDK [UO1 CA 89389-01, U01 DK057132, R33-DK61778-01]; AstraZeneca; Bard International; Pentax USA; ProVation; Endosoft; GIVEN Imaging; Ethicon FX Declaration of funding interests: The study was supported with funding from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132 and R33-DK61778-01. In addition, the practice network (CORI) has received support from the following entities to support the infrastructure of the practice based network: AstraZeneca, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging and Ethicon. The commercial entities had no involvement in this research. NR 31 TC 12 Z9 13 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD JUN 1 PY 2011 VL 33 IS 11 BP 1209 EP 1214 DI 10.1111/j.1365-2036.2011.04655.x PG 6 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 758OL UT WOS:000290174300004 PM 21480936 ER PT J AU Nadeau, KJ Reusch, JEB AF Nadeau, Kristen J. Reusch, Jane E. B. TI Cardiovascular Function/Dysfunction in Adolescents with Type 1 Diabetes SO CURRENT DIABETES REPORTS LA English DT Article DE Type 1 diabetes; Youth; Children; Adolescents; Cardiovascular; Cardiac dysfunction; Diastolic dysfunction; Systolic dysfunction; Insulin resistance; Glycemic control; Atherosclerosis ID INTIMA-MEDIA THICKNESS; INSULIN-RESISTANCE; ARTERIAL STIFFNESS; BLOOD-PRESSURE; RISK-FACTORS; EARLY SIGNS; CHILDREN; MELLITUS; ATHEROSCLEROSIS; DYSFUNCTION AB Type 1 diabetes mellitus (T1D) is associated with an increased risk of cardiovascular disease (CVD) that begins in childhood. Youth with T1D develop concerning functional cardiac and vascular defects and evidence of early atherosclerosis, despite modern advancements in risk reduction and glycemic management. Such early defects predict poor long-term outcomes. Women with T1D also have higher CVD risk than expected for unexplained reasons. Insulin resistance (IR) is recently recognized as a prominent factor in T1D youth and adults, but with an atypical clinical phenotype. This IR may contribute to early cardiac and vascular dysfunction and long-term CVD in T1D. A better understanding of potential contributors to cardiovascular dysfunction in T1D youth such as IR and its unique phenotype in T1D, subtle lipid abnormalities, and gender differences is now required to address the current knowledge gaps and to prevent cardiovascular morbidity and mortality in T1D. C1 [Nadeau, Kristen J.] Univ Colorado, Childrens Hosp, Aurora, CO 80045 USA. [Reusch, Jane E. B.] Denver VAMC, Denver, CO 80220 USA. [Reusch, Jane E. B.] Univ Colorado, Denver, CO 80220 USA. RP Nadeau, KJ (reprint author), Univ Colorado, Childrens Hosp, 13123 E 16th Ave,B265, Aurora, CO 80045 USA. EM nadeau.kristen@tchden.org; jane.reusch@ucdenver.edu OI Nadeau, Kristen/0000-0002-0477-3356 FU Amylin; GlaxoSmithKline; Bristol-Myers Squibb; Juvenile Diabetes Research Foundation [K23 020038, DK61242]; University of Colorado Center for Women's Health Research [UL1 RR025780]; VA Merit Review [DK57516, HL14985]; NIH/CRR [UL1 RR025780] FX We K.J. Nadeau: none; J.E.B. Reusch: has received ITT grant funding from Amylin, GlaxoSmithKline, and Bristol-Myers Squibb.; We would like to acknowledge funding from the following sources: KJN (K23 020038Award, DK61242, Juvenile Diabetes Research Foundation [PI Nadeau]); KJN and JEBR (UL1 RR025780, University of Colorado Center for Women's Health Research), JEBR (VA Merit Review, ADA research Award, DK57516, HL14985), NIH/CRR Colorado CTSI Grant Number UL1 RR025780. We would also like to acknowledge Amy West for her assistance with literature searches used to prepare this manuscript. NR 56 TC 8 Z9 8 U1 0 U2 2 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD JUN PY 2011 VL 11 IS 3 BP 185 EP 192 DI 10.1007/s11892-011-0180-4 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 758MN UT WOS:000290169000006 PM 21336845 ER PT J AU Samadi, H Sultzer, D AF Samadi, Hossein Sultzer, David TI Solanezumab for Alzheimer's disease SO EXPERT OPINION ON BIOLOGICAL THERAPY LA English DT Article DE Alzheimer's disease; biomarkers; immunotherapy; monoclonal antibody; solanezumab; beta-amyloid ID A-BETA ANTIBODY; AMYLOID-BETA; INTRAVENOUS IMMUNOGLOBULINS; MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; DOUBLE-BLIND; MOUSE MODEL; IMMUNIZATION; PATHOLOGY; SAFETY AB Areas covered: This paper reviews literature on solanezumab that is available in PubMed from 2008 to 2010, other treatment trials in clinicaltrials.gov and published abstracts from conferences. The article also provides a discussion of the early trials of AN1792 and an overview of the immunotherapies currently in development. The authors provide the reader with a critical appraisal of the to-date clinical trial data on solanezumab and its implications for the broader field of immunotherapies for AD. Expert opinion: Solanezumab can neutralize soluble A beta beta peptides, which may represent the more neurotoxic of the A beta beta species. Phase II findings support the compound's safety, which has been a concern for some A beta beta immunotherapies. Cerebrospinal and plasma biomarker changes with solanezumab treatment are encouraging. Results of the ongoing Phase III trials will be instrumental in determining the drug's clinical significance. C1 [Sultzer, David] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Sultzer, David] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Samadi, Hossein] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Samadi, Hossein] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Sultzer, D (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, 11301 Wilshire Blvd,Bldg 401,Room A215,116AE, Los Angeles, CA 90073 USA. EM dsultzer@ucla.edu FU Department of Veterans Affairs (Geriatric Psychiatry Training, Office of Academic Affiliations; CSRD Merit Review); Eli Lilly and Company FX The authors are supported in part by the Department of Veterans Affairs (Geriatric Psychiatry Training, Office of Academic Affiliations; CSR&D Merit Review). D Sultzer is the principal investigator and H Samadi a clinical investigator of a Phase III clinical trial of solanezumab sponsored by Eli Lilly and Company. NR 55 TC 28 Z9 31 U1 6 U2 35 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1471-2598 J9 EXPERT OPIN BIOL TH JI Expert Opin. Biol. Ther. PD JUN PY 2011 VL 11 IS 6 BP 787 EP 798 DI 10.1517/14712598.2011.578573 PG 12 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 760JU UT WOS:000290321400010 PM 21504387 ER PT J AU Bartzokis, G AF Bartzokis, George TI Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Article DE White matter; oligodendrocyte; neuregulin; ErbB; DISC1; nardilysin; apolipoprotein; secretase; medication; degeneration; MRI; Review ID CATECHOL-O-METHYLTRANSFERASE; CENTRAL-NERVOUS-SYSTEM; N-ACETYL-CYSTEINE; NICOTINIC ACETYLCHOLINE-RECEPTOR; FATTY-ACID-COMPOSITION; POSTMORTEM ORBITOFRONTAL CORTEX; MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED-TRIAL; OLIGODENDROCYTE PRECURSOR CELLS; DORSOLATERAL PREFRONTAL CORTEX AB Psychotropic treatments such as second generation or "atypical" antipsychotics are efficacious in a wide spectrum of psychiatric disorders ranging from schizophrenia to depression, bipolar disorder, and autism. These treatments are associated with peripheral metabolic derangements that are often also present in drug-naive patients. Furthermore, altering lipid composition/levels (with omega 3 fatty acids) and ameliorating oxidative toxicities may treat/prevent disease. The above observations are reexamined from the perspective of a myelin-centered model of the human brain. The model proposes that the human brain's extensive myelination required higher metabolic resources that caused evolutionary adaptations resulting in our quadratic (inverted U) myelination trajectory that peaks in the sixth decade of life. It further proposes that optimal brain function depends on exquisite action potential synchronization that myelin makes possible and that myelin's exceptional vulnerability to subtle metabolic/oxidative abnormalities may promote both developmental and degenerative diseases. Available data are integrated herein to suggest that widely used psychotropic treatments have under-appreciated CNS metabolic and neurotransmitter effects on myelination, its plasticity, and repair that may substantially contribute to their mechanisms of action. C1 [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Div Brain Mapping, Lab Neuroimaging,Dept Neurol, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIH [MH 0266029, AG027342]; Research and Psychiatry Services of the Department of Veterans Affairs; RCS Foundation FX This work was supported in part by NIH grants (MH 0266029; AG027342), Research and Psychiatry Services of the Department of Veterans Affairs, and the RCS Foundation. The author thanks Lori L. Altshuler, M.D., and Keith H. Nuechterlein, Ph.D. for reading the manuscript and providing suggestions for improving it. NR 521 TC 23 Z9 23 U1 4 U2 11 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JUN 1 PY 2011 VL 16 BP 2695 EP 2733 DI 10.2741/3881 PG 39 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 757OK UT WOS:000290097400020 PM 21622204 ER PT J AU Kohen, R Shofer, JB Korvatska, O Petrie, EC Wang, LY Schellenberg, GD Peskind, ER Wilkinson, CW AF Kohen, R. Shofer, J. B. Korvatska, O. Petrie, E. C. Wang, L. Y. Schellenberg, G. D. Peskind, E. R. Wilkinson, C. W. TI ABCB1 Genotype and CSF beta-Amyloid in Alzheimer Disease SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE Alzheimer disease; dementia; P-glycoprotein; MDR1; ABCB1; association study ID BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN EXPRESSION; MDR1; RESISTANCE; TRANSPORT; POLYMORPHISMS; PATHOGENESIS; DEPOSITION; RELEVANCE; GENE AB The ABCB1 gene, coding for the efflux transporter P-glycoprotein (PGP), is a candidate gene for Alzheimer disease (AD). P-glycoprotein is heavily expressed at the blood-brain barrier, where it mediates the efflux of beta-amyloid (A beta) from the brain. In this study, we investigated a possible association between 2 common ABCB1 polymorphisms, G2677T/A (Ala893Ser/Thr) and C3435T, AD, and cerebrospinal fluid (CSF) levels of A beta. No strong evidence for association was found. C1 [Kohen, R.; Korvatska, O.; Petrie, E. C.; Wang, L. Y.; Schellenberg, G. D.; Peskind, E. R.; Wilkinson, C. W.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Shofer, J. B.; Petrie, E. C.; Wang, L. Y.; Peskind, E. R.] VA Puget Sound Hlth Care Syst, MIRECC, Washington, DC USA. [Schellenberg, G. D.; Wilkinson, C. W.] Vet Affairs VA Puget Sound Hlth Care Syst, GRECC, Tacoma, WA USA. RP Kohen, R (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, HSB BB1537,1959 Pacific Ave NE, Seattle, WA 98195 USA. EM ruko@uw.edu FU NIH/NIA [P50AG005136]; Northwest Network VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC); VA Puget Sound Geriatric Research, Education and Clinical Center (GRECC); Office of Research and Development Medical Research Service, Department of Veterans Affairs FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: NIH/NIA grant P50AG005136 and by the Northwest Network VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), the VA Puget Sound Geriatric Research, Education and Clinical Center (GRECC), and the Office of Research and Development Medical Research Service, Department of Veterans Affairs. NR 27 TC 6 Z9 7 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD JUN PY 2011 VL 24 IS 2 BP 63 EP 66 DI 10.1177/0891988711402325 PG 4 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 759MZ UT WOS:000290251600001 PM 21478475 ER PT J AU Brumlik, MJ Nkhoma, S Kious, MJ Thompson, GR Patterson, TF Siekierka, JJ Anderson, TJC Curiel, TJ AF Brumlik, Michael J. Nkhoma, Standwell Kious, Mark J. Thompson, George R., III Patterson, Thomas F. Siekierka, John J. Anderson, Tim J. C. Curiel, Tyler J. TI Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Indole-5-carboxamide; Mitogen-activated protein kinase; Plasmodium falciparum; Pyridinylimidazole; Pyrrolobenzimidazole ID TOXOPLASMA-GONDII; MAP KINASE; IDENTIFICATION; RESISTANCE; POTENT AB We recently demonstrated that human p38 mitogen-activated protein kinase (MAPK) inhibitors reduced in vitro and in vivo replication of the protozoan parasites Toxoplasma gondii and Encephalitozoon cuniculi. In this study, we assessed the efficacy of five p38 MAPK inhibitors to block the replication of Plasmodium falciparum in human erythrocytes cultured ex vivo and demonstrate that the pyridinylimidazole RWJ67657 and the pyrrolobenzimidazole RWJ68198 reduced P. falciparum replication, yielded trophozoites that were greatly diminished in size at 24 h, and that these two agents interfered with stage differentiation. Interestingly, the chloroquine-resistant strain W2 was significantly more sensitive to these drugs than was the chloroquine-sensitive strain HB3. These results suggest that pyridinylimidazoles and pyrrolobenzimidazoles designed to inhibit human p38 MAPK activation can be developed to treat malaria. (C) 2011 Elsevier Inc. All rights reserved. C1 [Brumlik, Michael J.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Div Infect Dis, Dept Internal Med, San Antonio, TX 78229 USA. [Nkhoma, Standwell; Anderson, Tim J. C.] SW Fdn Biomed Res, San Antonio, TX 78245 USA. [Thompson, George R., III] Calif State Univ Sacramento, Davis Sch Med, Sacramento, CA 95817 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Siekierka, John J.] Montclair State Univ, Dept Chem & Biochem, Montclair, NJ 07043 USA. [Siekierka, John J.] Montclair State Univ, Sokol Inst Pharmaceut Life Sci, Montclair, NJ 07043 USA. RP Brumlik, MJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Div Infect Dis, Dept Internal Med, 2040 Babcock Rd,Suite 201, San Antonio, TX 78229 USA. EM brumlik@UTHSCSA.edu FU Johnson Johnson; NIH [R01 AI060424]; National Center for Research Resources, National Institutes of Health [C06 RR013556] FX This research was supported by a Johnson & Johnson Focused Giving Award and NIH R01 AI060424 (to T.J.C.). The work at the Southwest Foundation for Biomedical Research was conducted in facilities constructed with support from Research Facilities Improvement Program Grant C06 RR013556 from the National Center for Research Resources, National Institutes of Health. NR 28 TC 11 Z9 12 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 J9 EXP PARASITOL JI Exp. Parasitol. PD JUN PY 2011 VL 128 IS 2 BP 170 EP 175 DI 10.1016/j.exppara.2011.02.016 PG 6 WC Parasitology SC Parasitology GA 753ZR UT WOS:000289820600014 PM 21338604 ER PT J AU Drye, LT Martin, BK Frangakis, CE Meinert, CL Mintzer, JE Munro, CA Porsteinsson, AP Rabins, PV Rosenberg, PB Schneider, LS Weintraub, D Lyketsos, CG AF Drye, Lea T. Martin, Barbara K. Frangakis, Constantine E. Meinert, Curtis L. Mintzer, Jacobo E. Munro, Cynthia A. Porsteinsson, Anton P. Rabins, Peter V. Rosenberg, Paul B. Schneider, Lon S. Weintraub, Daniel Lyketsos, Constantine G. CA DIADS-2 Res Grp TI Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study +/- 2 (DIADS-2)? SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer's dementia; depression; randomized trial; sertraline ID DOUBLE-BLIND; NEUROPSYCHIATRIC SYMPTOMS; CLINICAL-TRIAL; SERTRALINE; DEMENTIA; METAANALYSIS; PREVALENCE; EFFICACY AB Objective: To determine if the effect of sertraline in the depression in Alzheimer's disease study - 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria. Methods: DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression in patients with Alzheimer's disease. DIADS-2 enrolled 131 patients who met criteria for the depression of Alzheimer's disease (dAD). Analyses reported here examined if the effect of sertraline differed in various subgroups, including those meeting criteria for major depressive episode (MaD), minor depressive episode (MiD), and Alzheimer's-associated affective disorder (AAAD) at baseline. Results: At baseline, 52 of 131 participants (39.7%) met criteria for MaD, 54 (41.2%) for MiD, and 90 (68.7%) for AAAD. For the primary outcome of modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) scores at 12 weeks of follow-up, the odds of being at or better than a given mADCS-CGIC category did not significantly differ between the two treatment groups for those patients with MaD at baseline (ORsertraline = 0.66 [95% CI: 0.24, 1.82], p = 0.42); tests for interactions between treatment group and baseline depression diagnostic subgroup were not significant for MaD versus MiD versus neither (chi(2) = 1.05 (2df), p = 0.59) or AAAD versus no AAAD (chi(2) = 0.06 (1df), p = 0.81). Conclusions: There was no evidence that sertraline treatment was more efficacious in those patients meeting baseline criteria for MaD compared to MiD or to neither. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Drye, Lea T.; Martin, Barbara K.; Frangakis, Constantine E.; Meinert, Curtis L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Mintzer, Jacobo E.] Med Univ S Carolina, Charleston, SC 29425 USA. [Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Munro, Cynthia A.; Rabins, Peter V.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Bayview & Johns Hopkins Sch Med, Baltimore, MD USA. [Porsteinsson, Anton P.] Univ Rochester, Sch Med, Rochester, NY USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Weintraub, Daniel] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Drye, LT (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. EM ldrye@jhsph.edu OI Drye, Lea/0000-0002-2964-1878 FU Pfizer; Merck; Abbot; AstraZeneca; Eli Lilly; Forest; Janssen; Boehringer Ingelheim; National Institute of Mental Health [1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066176, 1U01MH066177] FX Paul Rosenberg has served as a consultant for Forest regarding the drug memantine, and has received research funds from Pfizer and Merck in amounts greater than $10 000.; Jacobo Mintzer has received research support from Abbot to study donepezil and divalproex sodium, from AstraZeneca to study quetiapine, from BMS to study aripiprazole, from Eli Lilly to study olanzapine, from Forest to study both citalopram and memantine, from Janssen to study galantamine and risperidone, and from Pfizer to study donepezil and memantine; Dr Mintzer also has been a consultant, paid directly or indirectly, for AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer, Forest, and Aventis. He has also been an unpaid consultant for Targacept and has participated in Speaker's Bureaus for Janssen, Forest, and Pfizer.; Daniel Weintraub has received research support from Boehringer Ingelheim; Dr Weintraub also has been a paid consultant for Acadia Pharmaceuticals, Novartis Pharmaceuticals, Boehringer Ingelheim, Osmotica Pharmaceutical, BrainCells Inc., EMD Serono, and Sanofi Aventis, and has participated on a Speaker's Bureau for Pfizer.; Sources of support: Grant funding-National Institute of Mental Health, 1U01MH066136, 1U01MH068014, 1U01MH066174, 1U01MH066175, 1U01MH066176, 1U01MH066177; NIMH scientific collaborators participated on the trial's Steering Committee. DrugSertraline and matching placebo provided by Pfizer, Inc.; Pfizer did not participate in the design or conduct of the trial; Manisha Hong, PharmD at Johns Hopkins Hospital Investigational Drug Service packaged and shipped drug. Steering Committee (responsibilities: study design and conduct): Resource center representatives (voting)-Constantine Lyketsos, MD, MHS (study chair), Johns Hopkins School of Medicine, Baltimore; Barbara Martin, PhD (coordinating center former director), Johns Hopkins Bloomberg School of Public Health, Baltimore; George Niederehe, PhD (scientific collaborator), National Institute of Mental Health, Bethesda. Clinic directors (voting)-Paul Rosenberg, MD, Johns Hopkins School of Medicine, Baltimore; Jacobo Mintzer, MD, PhD, Medical University of South Carolina, Charleston; Daniel Weintraub, MD, University of Pennsylvania School of Medicine, Philadelphia; Anton Porsteinsson, MD, University of Rochester School of Medicine, Rochester; Lon Schneider, MD, University of Southern California Keck School of Medicine, Los Angeles. Other nonvoting members-Anne Shanklin Casper, MA, CCRP, Johns Hopkins Bloomberg School of Public Health, Baltimore; Lea Drye, PhD, Johns Hopkins Bloomberg School of Public Health, Baltimore; Crystal Evans, MS, Johns Hopkins School of Medicine, Baltimore; Curtis Meinert, PhD, Johns Hopkins Bloomberg School of Public Health, Baltimore; Cynthia Munro, PhD, Johns Hopkins School of Medicine, Baltimore; Peter Rabins, MD, MPH, Johns Hopkins School of Medicine, Baltimore. Research group: Resource centers (responsibilities: study administration)-Chairman's Office, Johns Hopkins School of Medicine, Baltimore: Constantine Lyketsos, MD, MHS, chairman; Crystal Evans, MS, coordinator; Cynthia Munro, PhD, study neuropsychologist; Peter Rabins, MD, MPH; Krissi Boehmer, BA; Adrian Mosely, MSW; Dimitrios Avramopoulos, MD, PhD. Coordinating Center, Johns Hopkins Bloomberg School of Public Health, Baltimore-Curtis Meinert, PhD, director; Barbara Martin, PhD, former director; Lea Drye, PhD, epidemiologist; Constantine Frangakis, PhD, biostatistician; Anne Shanklin Casper, MA, CCRP, coordinator; Vijay Vaidya, MPH; Jill Meinert. Project Office, National Institute of Mental Health, BethesdaGeorge Niederehe, PhD, scientific collaborator; Jovier Evans, PhD, project officer; Joanna Chisar, RN; Louise Ritz, MBA; Elizabeth Zachariah, MS. Clinics (responsibilities: data collection): Johns Hopkins School of Medicine, Baltimore-Paul Rosenberg, MD, director; Ann Morrison, RN, PhD, coordinator; Crystal Evans, MS; Pramit Rastogi, MD, MPH; Krissi Boehner, BS; Chiadi Onyike, MD. Medical University of South Carolina, Charleston-Jacobo Mintzer, MD, PhD, director; Crystal Longmire, PhD, coordinator; Warachal E. Faison, MD; Martie Hatchell, RN; Marilyn Stuckey, RN. University of Pennsylvania School of Medicine, Philadelphia-Daniel Weintraub, MD, director; Ira Katz, MD, PhD, former director; Trisha Stump, RN, coordinator; Joel Streim, MD; Suzanne DiFilippo, RN; Kate O'Neill. University of Rochester School of Medicine, Rochester-Anton Porsteinsson, MD, director; Bonnie Goldstein, RN, coordinator; Jeanne LaFountain, RN; Colleen McCallum, MSW; Laura Jakimovich, MNS; Kim Martin, RN; Kelly Cosman, MS.; University of Southern California Keck School of Medicine, Los Angeles-Lon Schneider, MD, director; Sonia Pawlucyk, MD; Karen Dagerman, MS; Randall Sanabria; Liberty Teodoro, RN; Yanli Wang, MS; Ju Zhang; Liberty Teodoro. NR 26 TC 10 Z9 10 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JUN PY 2011 VL 26 IS 6 BP 573 EP 583 DI 10.1002/gps.2565 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 748FF UT WOS:000289374700004 PM 20672243 ER PT J AU Khalsa, SR McCarthy, KS Sharpless, BA Barrett, MS Barber, JP AF Khalsa, Shabad-Ratan McCarthy, Kevin S. Sharpless, Brian A. Barrett, Marna S. Barber, Jacques P. TI Beliefs About the Causes of Depression and Treatment Preferences SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE psychotherapy; major depressive disorder; gender; patient preferences; psychodynamics ID PRIMARY-CARE PATIENTS; GENDER DIFFERENCES; METAANALYSIS; ETIOLOGY; REASONS; ILLNESS; INTERVENTIONS; QUESTIONNAIRE; PSYCHOTHERAPY; ATTRIBUTION AB The relation between patients' beliefs about the causes of their depression, treatment preferences, and demographic variables was studied in a sample of 156 patients in a randomized controlled trial for depression (supportive-expressive psychotherapy vs. medication vs. placebo). No gender differences were found in beliefs or preferences. Racial differences were found for causes endorsed, but not preferences. Treatment experience predicted endorsement of characterological and biological causes. Psychotherapy experience predicted preference for medication. Finally, patients preferring psychotherapy endorsed childhood and complex causes more than those preferring medication, but the groups did not differ in other reasons endorsed. Implications of findings are discussed. (C) 2011 Wiley Periodicals, Inc. J Clin Psychol 67:539-549, 2011. C1 [Barber, Jacques P.] Univ Penn, Sch Med, Dept Psychiat, Ctr Psychotherapy Res, Philadelphia, PA 19104 USA. [Barber, Jacques P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Psychotherapy Res, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Mood Disorder Sect, Philadelphia, PA 19104 USA. RP Barber, JP (reprint author), Univ Penn, Sch Med, Dept Psychiat, Ctr Psychotherapy Res, Suite 648,3535 Market St, Philadelphia, PA 19104 USA. EM barberj@mail.med.upenn.edu FU NIMH NIH HHS [R01 MH 061410] NR 36 TC 15 Z9 16 U1 4 U2 20 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD JUN PY 2011 VL 67 IS 6 BP 539 EP 549 DI 10.1002/jclp.20785 PG 11 WC Psychology, Clinical SC Psychology GA 750ZJ UT WOS:000289586700002 PM 21365652 ER PT J AU Kazlouski, D Rollin, MDH Tregellas, J Shott, ME Jappe, LM Hagman, JO Pryor, T Yang, TT Frank, GKW AF Kazlouski, Demitry Rollin, Michael D. H. Tregellas, Jason Shott, Megan E. Jappe, Leah M. Hagman, Jennifer O. Pryor, Tamara Yang, Tony T. Frank, Guido K. W. TI Altered fimbria-fornix white matter integrity in anorexia nervosa predicts harm avoidance SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Eating disorder; White matter; Fractional anisotropy; Anxiety ID BODY-IMAGE DISTORTION; CEREBRAL-BLOOD-FLOW; EATING-DISORDERS; PERSONALITY-CHARACTERISTICS; BRAIN; AMYGDALA; BEHAVIOR; WOMEN; SEGMENTATION; INDIVIDUALS AB The eating disorder anorexia nervosa (AN) is associated with high anxiety. The brain mechanisms that drive those behaviors are unknown. In this study we wanted to test whether brain white matter (WM) integrity is altered in AN, and related to heightened anxiety. Sixteen adult women with AN (mean age 24 +/- 7 years) and 17 healthy control women (CW, mean age 25 +/- 4 years) underwent diffusion tensor imaging (DTI) of the brain. The DTI brain images were used to calculate the fractional anisotropy (FA) of WM tracts, which is a measure for WM integrity. AN individuals compared to CW showed clusters of significantly reduced FA (p<0.05, corrected) in the bilateral fimbria-fornix and the fronto-occipital fasciculus, as well as the posterior cingulum WM. In the AN group, Harm Avoidance was predicted by FA in the left and right fimbria-fornix. Those findings were not due to WM volume deficits in AN. This study indicates that WM integrity is abnormal in AN in limbic and association pathways, which could contribute to disturbed feeding, emotion processing and body perception in AN. The prediction of Harm Avoidance in AN by fimbria-fornix WM integrity suggests that this pathway may be mechanistically involved in high anxiety in AN. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Kazlouski, Demitry; Rollin, Michael D. H.; Tregellas, Jason; Shott, Megan E.; Hagman, Jennifer O.; Frank, Guido K. W.] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason; Frank, Guido K. W.] Univ Colorado Denver, Neurosci Program, Aurora, CO 80045 USA. [Tregellas, Jason] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Jappe, Leah M.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. [Pryor, Tamara] Eating Disorders Ctr Denver, Glendale, CO USA. [Yang, Tony T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Frank, GKW (reprint author), Univ Colorado Denver, Childrens Hosp, Dept Psychiat, Gary Pavilion A036 B-130,13123 E 16th Ave, Aurora, CO 80045 USA. EM Guido.Frank@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Frank, Guido/0000-0002-6590-3441 FU NIMH [K23 MH080135-01A2]; Davis Foundation of the Klarman Family Foundation; AACAP; Lilly USA, LLC; APIRE/Janssen FX The entirety of this project was supported by NIMH grant K23 MH080135-01A2 and a Davis Foundation Award of the Klarman Family Foundation Grants Program in Eating Disorders, awarded to Dr. Frank. Dr. Frank is also on the scientific advisory board for the Eating Disorders Center Denver. Dr. Rollin has received funding through an AACAP Pilot Research Award, supported by Lilly USA, LLC, as well funding from the APIRE/Janssen Resident Psychiatric Research Scholars Program for an unaffiliated project. Drs. Hagman, Pryor, Yang, and Tregellas, as well as Mss. Shott, Jappe, and Mr. Kazlouski, report no competing interests or financial disclosures. NR 61 TC 37 Z9 39 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD MAY 31 PY 2011 VL 192 IS 2 BP 109 EP 116 DI 10.1016/j.pscychresns.2010.12.006 PG 8 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 771VV UT WOS:000291189700006 PM 21498054 ER PT J AU Gentile, NE Andrekanic, JD Karwoski, TE Czambel, RK Rubin, RT Rhodes, ME AF Gentile, Natalie E. Andrekanic, Julie D. Karwoski, Tracy E. Czambel, R. Kenneth Rubin, Robert T. Rhodes, Michael E. TI Sexually diergic hypothalamic-pituitary-adrenal (HPA) responses to single-dose nicotine, continuous nicotine infusion, and nicotine withdrawal by mecamylamine in rats SO BRAIN RESEARCH BULLETIN LA English DT Article DE ACTH; CORT; HPA axis; Mecamylamine; Nicotine; Sexual diergism ID CORTICOTROPIN-RELEASING-FACTOR; RECEPTOR KNOCKOUT MICE; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; SEX-DIFFERENCES; PARAVENTRICULAR NUCLEUS; AXIS RESPONSES; NOREPINEPHRINE SECRETION; CHOLINERGIC STIMULATION; ADRENOCORTICAL ACTIVITY AB Hypothalamic-pituitary-adrenal (HPA) responses to single-dose nicotine (NIC) are sexually diergic: Female rats have higher adrenocorticotropic hormone (ACTH) and corticosterone (CORT) responses than do males. In the present study we determined HPA responses in male and female rats following single doses of NIC, a single-dose of NIC immediately following continuous NIC for two weeks, and NIC withdrawal by single-dose mecamylamine (MEC) following continuous NIC infusion for two weeks. Blood sampling occurred before and after MEC and NIC administrations for the determination of ACTH and CORT. In accordance with our previous findings, female ACTH and COAT responses to single-dose NIC were greater than male responses. This sex difference remained after single-dose NIC followed continuous NIC infusion, but HPA responses in both sexes were significantly lower in magnitude and duration than in the single-dose NIC alone groups. Sex differences also were observed following NIC withdrawal by MEC: the HPA responses to pretreatment with MEC were significantly higher in magnitude and duration in the continuous NIC groups than in the single-dose NIC groups. These results demonstrate that HPA responses to NIC are reduced and transient following continuous NIC infusion but are enhanced and sustained following NIC withdrawal by MEC after continuous NIC, suggesting that NIC habituation and withdrawal influence the stress responses in a diergic manner. These findings highlight the importance of sex differences in the effect of NIC on HPA axis activity and stress responsiveness, which may have implications for directing NIC-addiction treatment specifically towards men and women. (C) 2011 Elsevier Inc. All rights reserved. C1 [Gentile, Natalie E.; Andrekanic, Julie D.; Rhodes, Michael E.] St Vincent Coll, Dept Biol, Latrobe, PA 15650 USA. [Karwoski, Tracy E.; Czambel, R. Kenneth] Allegheny Gen Hosp, Ctr Neurosci Res, Pittsburgh, PA 15212 USA. [Rubin, Robert T.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. [Gentile, Natalie E.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Andrekanic, Julie D.] Duquesne Univ, Mylan Sch Pharm, Pittsburgh, PA 15282 USA. RP Rhodes, ME (reprint author), St Vincent Coll, Dept Biol, 300 Fraser Purchase Rd, Latrobe, PA 15650 USA. EM michael.rhodes@email.stvincent.edu FU PA Dept of Health; NIH [MH28380] FX Supported by 2004 PA Dept of Health Tobacco Settlement Funds to Michael E. Rhodes and NIH grant MH28380 to Robert T. Rubin. NR 78 TC 12 Z9 12 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0361-9230 J9 BRAIN RES BULL JI Brain Res. Bull. PD MAY 30 PY 2011 VL 85 IS 3-4 BP 145 EP 152 DI 10.1016/j.brainresbull.2011.03.001 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 788FQ UT WOS:000292431200010 PM 21396990 ER PT J AU Penfold, RB Kullgren, JT Miroshnik, I Galbraith, AA Hinrichsen, VL Lieu, TA AF Penfold, Robert B. Kullgren, Jeffrey T. Miroshnik, Irina Galbraith, Alison A. Hinrichsen, Virginia L. Lieu, Tracy A. TI Reliability of a patient survey assessing cost-related changes in health care use among high deductible health plan enrollees SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID MAXIMUM-LIKELIHOOD-ESTIMATION; RISK BEHAVIOR SURVEY; KAPPA-COEFFICIENT; SURVEY QUESTIONNAIRE; STANDARD ERROR; WEIGHTED KAPPA; AGREEMENT; VALIDITY; SAMPLE; CONSISTENCY AB Background: Recent increases in patient cost-sharing for health care have lent increasing importance to monitoring cost-related changes in health care use. Despite the widespread use of survey questions to measure changes in health care use and related behaviors, scant data exists on the reliability of such questions. Methods: We administered a cross-sectional survey to a stratified random sample of families in a New England health plan's high deductible health plan (HDHP) with >= $500 in annualized out-of-pocket expenditures. Enrollees were asked about their knowledge of their plan, information seeking, behavior change associated with having a deductible, experience of delay in care due in part to cost, and hypothetical delay in care due in part to cost. Initial respondents were mailed a follow-up survey within two weeks of each family returning the original survey. We computed several agreement statistics to measure the test-retest reliability for select questions. We also conducted continuity adjusted chi-square, and McNemar tests in both the original and follow-up samples to measure the degree to which our results could be reproduced. Analyses were stratified by self-reported income. Results: The test-retest reliability was moderate for the majority of questions (0.41 - 0.60) and the level of test-retest reliability did not differ substantially across each of the broader domains of questions. The observed proportions of respondents with delayed or foregone pediatric, adult, or any family care were similar when comparing the original and follow-up surveys. In the original survey, respondents in the lower-income group were more likely to delay or forego pediatric care, adult care, or any family care. All of the tests comparing income groups in the follow-up survey produced the same result as in the original survey. Conclusions: In this population of HDHP beneficiaries, we found that survey questions concerning plan knowledge, information seeking, and delayed or foregone care were moderately reliable. Our results offer reassurance for researchers using survey information to study the effects cost sharing on health care utilization. C1 [Penfold, Robert B.; Miroshnik, Irina; Galbraith, Alison A.; Hinrichsen, Virginia L.; Lieu, Tracy A.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02115 USA. [Penfold, Robert B.; Miroshnik, Irina; Galbraith, Alison A.; Hinrichsen, Virginia L.; Lieu, Tracy A.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Penfold, Robert B.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Kullgren, Jeffrey T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kullgren, Jeffrey T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Lieu, Tracy A.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. RP Penfold, RB (reprint author), Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02115 USA. EM penfold.r@ghc.org FU National Institute of Child Health and Human Development (NICHD), Bethesda, Md [HD053440]; NICHD [HD047667, HD052742]; Group Health Research Institute FX This study was supported by an R21 grant (HD053440) from the National Institute of Child Health and Human Development (NICHD), Bethesda, Md. Dr Lieu's effort was supported in part by a K24 Mid-Career Development Award from NICHD (HD047667). Dr Galbraith's effort was supported in part by a K23 Mentored Career Development Award from NICHD (HD052742). Dr Penfold's effort was supported in part by the Group Health Research Institute. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript. NR 40 TC 2 Z9 2 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD MAY 27 PY 2011 VL 11 AR 133 DI 10.1186/1472-6963-11-133 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 778IF UT WOS:000291696700001 PM 21619647 ER PT J AU Bacchetti, P Boylan, R Astemborski, J Shen, H Mehta, SH Thomas, DL Terrault, NA Monto, A AF Bacchetti, Peter Boylan, Ross Astemborski, Jacquie Shen, Hui Mehta, Shruti H. Thomas, David L. Terrault, Norah A. Monto, Alexander TI Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis SO PLOS ONE LA English DT Article ID INJECTION-DRUG USERS; UNITED-STATES; VIRUS-INFECTION; DISEASE; CLASSIFICATION; IMPUTATION; DIAGNOSIS; SEVERITY; RISKS; AGE AB Background: Fibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but analysis is challenging due to their ordered but non-numeric nature, infrequent measurement, misclassification, and unknown infection times. Methods: We used a non-Markov multistate model, accounting for misclassification, with multiple imputation of unknown infection times, applied to 1062 participants of whom 159 had multiple biopsies. Odds ratios (OR) quantified the estimated effects of covariates on progression risk at any given time. Results: Models estimated that progression risk decreased the more time participants had already spent in the current stage, African American race was protective (OR 0.75, 95% confidence interval 0.60 to 0.95, p = 0.018), and older current age increased risk (OR 1.33 per decade, 95% confidence interval 1.15 to 1.54, p = 0.0002). When controlled for current age, older age at infection did not appear to increase risk (OR 0.92 per decade, 95% confidence interval 0.47 to 1.79, p = 0.80). There was a suggestion that co-infection with human immunodeficiency virus increased risk of progression in the era of highly active antiretroviral treatment beginning in 1996 (OR 2.1, 95% confidence interval 0.97 to 4.4, p = 0.059). Other examined risk factors may influence progression risk, but evidence for or against this was weak due to wide confidence intervals. The main results were essentially unchanged using different assumed misclassification rates or imputation of age of infection. Discussion: The analysis avoided problems inherent in simpler methods, supported the previously suspected protective effect of African American race, and suggested that current age rather than age of infection increases risk. Decreasing risk of progression with longer time already spent in a stage was also previously found for post-transplant progression. This could reflect varying disease activity, with recent progression indicating active disease and high risk, while longer time already spent in a stage indicates quiescent disease and low risk. C1 [Bacchetti, Peter; Boylan, Ross] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Astemborski, Jacquie; Thomas, David L.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Astemborski, Jacquie; Mehta, Shruti H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Shen, Hui; Terrault, Norah A.; Monto, Alexander] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shen, Hui; Monto, Alexander] San Francisco VA Med Ctr, Div Gastroenterol, San Francisco, CA USA. [Terrault, Norah A.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Bacchetti, P (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. EM peter@biostat.ucsf.edu FU United States National Institutes of Health [R01AI069952, R01DA016078, R01DA004334, R01DA012568, R01AA012879, P30DK26743, M01RR00079, U19AI40034]; Veterans Administration [CX000295] FX This work was supported by grant R01AI069952 from the United States National Institutes of Health. The studies providing data were supported by grants R01DA016078, R01DA004334, R01DA012568, R01AA012879, P30DK26743, M01RR00079, and U19AI40034 from the United States NIH and by Veterans Administration Merit grant CX000295. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 8 Z9 8 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 27 PY 2011 VL 6 IS 5 AR e20104 DI 10.1371/journal.pone.0020104 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 769XV UT WOS:000291052500029 PM 21637766 ER PT J AU Yang, SY Xu, HY Yu, SB Cao, HL Fan, J Ge, CX Fransceschi, RT Dong, HH Xiao, GZ AF Yang, Shengyong Xu, Haiyan Yu, Shibing Cao, Huiling Fan, Jie Ge, Chunxi Fransceschi, Renny T. Dong, Henry H. Xiao, Guozhi TI Foxo1 Mediates Insulin-like Growth Factor 1 (IGF1)/Insulin Regulation of Osteocalcin Expression by Antagonizing Runx2 in Osteoblasts SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ACTIVATING TRANSCRIPTION FACTOR-4; MARROW STROMAL CELLS; GENE-EXPRESSION; PARATHYROID-HORMONE; SIGNALING PATHWAYS; BONE-FORMATION; CLEIDOCRANIAL DYSPLASIA; IN-VIVO; DEPENDENT ACTIVATION; SKELETAL DEVELOPMENT AB In this study, we determined the molecular mechanisms whereby forkhead transcription factor Foxo1, a key downstream signaling molecule of insulin-like growth factor 1 (IGF1)/insulin actions, regulates Runx2 activity and expression of the mouse osteocalcin gene 2 (Bglap2) in osteoblasts in vitro. We showed that Foxo1 inhibited Runx2-dependent transcriptional activity and osteocalc in mRNA expression and Bglap2 promoter activity in MC-4 preosteoblasts. Co-immunoprecipitation assay showed that Foxo1 physically interacted with Runx2 via its C-terminal region in osteoblasts or when co-expressed in COS-7 cells. Electrophoretic mobility shift assay demonstrated that Foxo1 suppressed Runx2 binding to its cognate site within the Bglap2 promoter. IGF1 and insulin prevented Foxo1 from inhibiting Runx2 activity by promoting Foxo1 phosphorylation and nuclear exclusion. In contrast, a neutralizing anti-IGF1 antibody decreased Runx2 activity and osteocalcin expression in osteoblasts. Chromatin immunoprecipitation assay revealed that IGF1 increased Runx2 interaction with a chromatin fragment of the proximal Bglap2 promoter in a PI3K/AKT-dependent manner. Conversely, knockdown of Foxo1 increased Runx2 interaction with the promoter. This study establishes that Foxo1 is a novel negative regulator of osteoblast-specific transcription factor Runx2 and modulates IGF1/insulin-dependent regulation of osteocalcin expression in osteoblasts. C1 [Yang, Shengyong; Yu, Shibing; Cao, Huiling; Xiao, Guozhi] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15240 USA. [Yang, Shengyong] Chongqing Med Univ, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China. [Xu, Haiyan] Rhode Isl Hosp, Brown Med Sch, Hallett Ctr Diabet & Endocrinol, Providence, RI 02901 USA. [Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA. [Ge, Chunxi; Fransceschi, Renny T.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA. [Fransceschi, Renny T.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA. [Dong, Henry H.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15240 USA. [Xiao, Guozhi] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China. RP Xiao, GZ (reprint author), VA Pittsburgh Healthcare Syst, Rm 2E-107,151-U, Pittsburgh, PA 15240 USA. EM xiaog@upmc.edu RI YU, SHIBING/B-7648-2012 OI Dong, H. Henry/0000-0003-0279-5241 FU National Institutes of Health [DK072230, AR059647, DK066301]; Department of Defense [W81XWH-07-1-0160]; Chinese Ministry of Science and Technology [2009CB918902] FX This work was supported, in whole or in part, by National Institutes of Health Grants DK072230, AR059647, and DK066301 and by Department of Defense Grant W81XWH-07-1-0160 and by Chinese Ministry of Science and Technology Grant 2009CB918902. NR 65 TC 35 Z9 40 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 27 PY 2011 VL 286 IS 21 BP 19149 EP 19158 DI 10.1074/jbc.M110.197905 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 766ME UT WOS:000290785700084 PM 21471200 ER PT J AU Jha, AR Nixon, DF Rosenberg, MG Martin, JN Deeks, SG Hudson, RR Garrison, KE Pillai, SK AF Jha, Aashish R. Nixon, Douglas F. Rosenberg, Michael G. Martin, Jeffrey N. Deeks, Steven G. Hudson, Richard R. Garrison, Keith E. Pillai, Satish K. TI Human Endogenous Retrovirus K106 (HERV-K106) Was Infectious after the Emergence of Anatomically Modern Humans SO PLOS ONE LA English DT Article ID HUMAN GENOME; INSERTIONAL POLYMORPHISMS; RECOMBINATION RATE; HUMAN-POPULATIONS; DNA POLYMORPHISM; EVOLUTION; ELEMENTS; IDENTIFICATION; PERSISTENCE; FAMILIES AB HERV-K113 and HERV-K115 have been considered to be among the youngest HERVs because they are the only known full-length proviruses that are insertionally polymorphic and maintain the open reading frames of their coding genes. However, recent data suggest that HERV-K113 is at least 800,000 years old, and HERV-K115 even older. A systematic study of HERV-K HML2 members to identify HERVs that may have infected the human genome in the more recent evolutionary past is lacking. Therefore, we sought to determine how recently HERVs were exogenous and infectious by examining sequence variation in the long terminal repeat (LTR) regions of all full-length HERV-K loci. We used the traditional method of inter-LTR comparison to analyze all full length HERV-Ks and determined that two insertions, HERV-K106 and HERV-K116 have no differences between their 5' and 3' LTR sequences, suggesting that these insertions were endogenized in the recent evolutionary past. Among these insertions with no sequence differences between their LTR regions, HERV-K106 had the most intact viral sequence structure. Coalescent analysis of HERV-K106 3' LTR sequences representing 51 ethnically diverse individuals suggests that HERV-K106 integrated into the human germ line approximately 150,000 years ago, after the emergence of anatomically modern humans. C1 [Jha, Aashish R.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA. [Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA. [Rosenberg, Michael G.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Martin, Jeffrey N.; Deeks, Steven G.] Univ Calif San Francisco, Div HIV AIDS, Dept Med, San Francisco Gen Hosp, San Francisco, CA USA. [Hudson, Richard R.] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA. [Garrison, Keith E.] St Marys Coll Calif, Dept Biol, Moraga, CA USA. [Pillai, Satish K.] Univ Calif San Francisco, Div Infect Dis, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Jha, AR (reprint author), Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA. EM nepaliaashish@gmail.com; satish.pillai@ucsf.edu RI Evolutionary Ecology, Ecologia Evolutiva/M-3553-2014 OI Nixon, Douglas/0000-0002-2801-1786 FU National Institutes of Health [AI076059, AI060379, AI084113]; UCSF CFAR [P-30 AI27763]; UCSF CTSI [UL1 RR024131]; CNICS [R24 AI067039]; NIAID [K24AI069994]; [1K01DA024654] FX This work was supported by National Institutes of Health grants AI076059, AI060379, AI084113, UCSF CFAR (P-30 AI27763), UCSF CTSI (UL1 RR024131), CNICS (R24 AI067039), NIAID (K24AI069994), and 1K01DA024654 grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 22 Z9 22 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 25 PY 2011 VL 6 IS 5 AR e20234 DI 10.1371/journal.pone.0020234 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 769IQ UT WOS:000291006500044 PM 21633511 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Responsiveness differences in outcome instruments after revision hip arthroplasty: What are the implications? SO BMC MUSCULOSKELETAL DISORDERS LA English DT Editorial Material DE Responsiveness hip arthroplasty; harris hip score; short-form 36; SF-36; HHS ID CLINICALLY IMPORTANT DIFFERENCES; TOTAL KNEE ARTHROPLASTY; SF-36; WOMAC; REPLACEMENT; OSTEOARTHRITIS; TRIALS; INDEX; SCORE AB Responsiveness to change is an important psychometric property of an outcome instrument. Assessment of health-related quality of life (HRQoL) is critical to outcome assessment after total joint replacement, a surgery aimed at improving pain, function and HRQoL of the patients undergoing these procedures. In a recent study, Shi et al. examined the responsiveness to change of various subscales of two instruments, physician-administered Harris Hip Score and patient self-administered Short Form-36 (SF-36), 6 months after revision total hip arthroplasty. The responsiveness statistics for both scales were reasonable, higher for Harris Hip Score than SF-36. This is the first study to examine responsiveness of these instruments in revision THA patients in a systematic fashion. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 NR 14 TC 1 Z9 1 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD MAY 23 PY 2011 VL 12 AR 107 DI 10.1186/1471-2474-12-107 PG 3 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 778ZO UT WOS:000291748100001 PM 21605397 ER PT J AU Miake-Lye, IM Amulis, A Saliba, D Shekelle, PG Volkman, LK Ganz, DA AF Miake-Lye, Isomi M. Amulis, Angel Saliba, Debra Shekelle, Paul G. Volkman, Linda K. Ganz, David A. TI Formative evaluation of the telecare fall prevention project for older veterans SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID HEALTH-CARE-SYSTEM; QUALITY-OF-CARE; CONTROLLED-TRIAL; ELDERLY-PEOPLE; RISK; METAANALYSIS; IMPROVEMENT; PROGRAM; ADULTS AB Background: Fall prevention interventions for community-dwelling older adults have been found to reduce falls in some research studies. However, wider implementation of fall prevention activities in routine care has yielded mixed results. We implemented a theory-driven program to improve care for falls at our Veterans Affairs healthcare facility. The first project arising from this program used a nurse advice telephone line to identify patients' risk factors for falls and to triage patients to appropriate services. Here we report the formative evaluation of this project. Methods: To evaluate the intervention we: 1) interviewed patient and employee stakeholders, 2) reviewed participating patients' electronic health record data and 3) abstracted information from meeting minutes. We describe the implementation process, including whether the project was implemented according to plan; identify barriers and facilitators to implementation; and assess the incremental benefit to the quality of health care for fall prevention received by patients in the project. We also estimate the cost of developing the pilot project. Results: The project underwent multiple changes over its life span, including the addition of an option to mail patients educational materials about falls. During the project's lifespan, 113 patients were considered for inclusion and 35 participated. Patient and employee interviews suggested support for the project, but revealed that transportation to medical care was a major barrier in following up on fall risks identified by nurse telephone triage. Medical record review showed that the project enhanced usual medical care with respect to home safety counseling. We discontinued the program after 18 months due to staffing limitations and competing priorities. We estimated a cost of $9194 for meeting time to develop the project. Conclusions: The project appeared feasible at its outset but could not be sustained past the first cycle of evaluation due to insufficient resources and a waning of local leadership support due to competing national priorities. Future projects will need both front-level staff commitment and prolonged high-level leadership involvement to thrive. C1 [Miake-Lye, Isomi M.; Saliba, Debra; Shekelle, Paul G.; Ganz, David A.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA 91343 USA. [Miake-Lye, Isomi M.; Saliba, Debra; Shekelle, Paul G.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Amulis, Angel; Volkman, Linda K.] Vet Affairs Vet Integrated Serv Network, Los Angeles, CA 90073 USA. [Saliba, Debra; Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Saliba, Debra] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA 90095 USA. [Saliba, Debra] Los Angeles Jewish Home, Los Angeles, CA 90095 USA. RP Miake-Lye, IM (reprint author), VA Greater Los Angeles HSR&D Ctr Excellence, 16111 Plummer St, Sepulveda, CA 91343 USA. EM isomi.miake-lye@va.gov NR 30 TC 3 Z9 3 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD MAY 23 PY 2011 VL 11 AR 119 DI 10.1186/1472-6963-11-119 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 785TK UT WOS:000292252600001 PM 21605438 ER PT J AU Pena, A AF Pena, Adolfo TI Philosophy, medicine and clinical reasoning SO MEDICINA CLINICA LA Spanish DT Editorial Material ID CATEGORIZATION C1 Univ Alabama, UAB VAQS Qual Scholars Fellowship Program, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Pena, A (reprint author), Univ Alabama, UAB VAQS Qual Scholars Fellowship Program, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. EM adolfope@uab.edu NR 31 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER DOYMA SL PI BARCELONA PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN SN 0025-7753 J9 MED CLIN-BARCELONA JI Med. Clin. PD MAY 21 PY 2011 VL 136 IS 14 BP 633 EP 636 DI 10.1016/j.medcli.2009.10.014 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 772ZP UT WOS:000291277100007 PM 20022068 ER PT J AU Quesada, A Bui, PH Homanics, GE Hankinson, O Handforth, A AF Quesada, Arnulfo Bui, Peter H. Homanics, Gregg E. Hankinson, Oliver Handforth, Adrian TI Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Article DE Essential tremor; Harmaline; Mibefradil; NNC 55-0396; T-type calcium channel; Anti-tremor drug ID CALCIUM-CHANNEL ANTAGONIST; HARMALINE-INDUCED TREMOR; GABA(A) RECEPTOR; NEURONS; POTENT; NNC-55-0396; CEREBELLUM; DEFICIENCY; INHIBITOR; ALKALOIDS AB NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2, 3,4tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride], is a mibefradil derivative that retains potent in vitro T-type calcium channel antagonist efficacy. We compared the two compounds for behavioral toxicity, effects on cytochrome P450 activity, and efficacy against tremor in the gamma-aminobutyric acid type A (GABA(A)) receptor subunit alpha 1-null mouse, and the harmaline tremor model of essential tremor in wild-type mice. NNC 55-0396 was better tolerated than mibefradil in the horizontal wire test of sedation/motor function, with 3/6 failing at 300 and 30 mg/kg respectively. To assess for a potential interaction with harmaline, mice were given the drugs, followed by harmaline or vehicle, and tested 30 min later in the inverted wire grid test. Mibefradil exacerbated, whereas NNC 55-0396 ameliorated harmaline-induced test deficits. In mouse liver microsomes, NNC 55-0396 was a less potent inhibitor of harmaline O-demethylation than mibefradil (K(i): 0.95 and 0.29 mu M respectively), and also less potent at inhibiting testosterone 6-beta-hydroxylation (K(i): 0.71 and 0.12 mu M respectively). In the GABA(A) alpha 1-null model, NNC 550396 but not mibefradil, (each at 20 mg/kg), suppressed tremor while NNC 55-0396 at 12.5 mg/kg suppressed harmaline-induced tremor by half by 20-100 min, whereas mibefradil at the same dose did not significantly affect tremor. In contrast to mibefradil, NNC 55-0396 is well tolerated and suppresses tremor, and exerts less cytochrome P450 inhibition. These results suggest potential clinical utility for NNC 55-0396 or similar derivatives as a T-type calcium antagonist. Published by Elsevier B.V. C1 [Quesada, Arnulfo] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Quesada, Arnulfo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Bui, Peter H.; Hankinson, Oliver] Univ Calif Los Angeles, David Geffen Sch Med, Mol Toxicol Interdept Program, Dept Pathol & Lab Med,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Homanics, Gregg E.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Homanics, Gregg E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. [Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA. RP Quesada, A (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv W151, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM aquesada@mednet.ucla.edu; pbui@mednet.ucla.edu; homanicsge@anes.upmc.edu; ohank@mednet.ucla.edu; charles.handforth@va.gov OI Homanics, Gregg/0000-0003-3641-8153 FU International Essential Tremor Foundation; Ralph M. Parsons Foundation; National Institute of Environmental Health Sciences [RO1ES015384]; National Institutes of Health [AA10422] FX This work was supported by grants from the International Essential Tremor Foundation to A.Q., The Ralph M. Parsons Foundation to A.H., Veterans Affairs, the National Institute of Environmental Health Sciences [Grant RO1ES015384 to O. H.], and the National Institutes of Health [Grant AA10422 to G. H.]. P.B. was supported by a predoctoral fellowship from the National Institute of Environmental Health Sciences [training grant T32-ES015457]. We thank Brandon Bunker and Christopher Shin for technical assistance, and Dr. Curt Eckhert for permitting us to use his HPLC equipment. NR 40 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD MAY 20 PY 2011 VL 659 IS 1 BP 30 EP 36 DI 10.1016/j.ejphar.2011.01.004 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 770WN UT WOS:000291119300005 PM 21256842 ER PT J AU Marconi, VC Grandits, G Okulicz, JF Wortmann, G Ganesan, A Crum-Cianflone, N Polis, M Landrum, M Dolan, MJ Ahuja, SK Agan, B Kulkarni, H AF Marconi, Vincent C. Grandits, Greg Okulicz, Jason F. Wortmann, Glenn Ganesan, Anuradha Crum-Cianflone, Nancy Polis, Michael Landrum, Michael Dolan, Matthew J. Ahuja, Sunil K. Agan, Brian Kulkarni, Hemant CA Infect Dis Clinical Res Program TI Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS SO PLOS ONE LA English DT Article ID PROTEASE INHIBITOR THERAPY; VIRUS TYPE-1 RNA; TERM-FOLLOW-UP; CELL COUNT; HIV-1-INFECTED PATIENTS; DISEASE PROGRESSION; DRUG-RESISTANCE; INTERMITTENT VIREMIA; PROGNOSTIC MARKERS; CLINICAL-OUTCOMES AB Background: The impact of viral load (VL) decay and cumulative VL on CD4 recovery and AIDS after highly-active antiretroviral therapy (HAART) is unknown. Methods and Findings: Three virologic kinetic parameters (first year and overall exponential VL decay constants, and first year VL slope) and cumulative VL during HAART were estimated for 2,278 patients who initiated HAART in the U. S. Military HIV Natural History Study. CD4 and VL trajectories were computed using linear and nonlinear Generalized Estimating Equations models. Multivariate Poisson and linear regression models were used to determine associations of VL parameters with CD4 recovery, adjusted for factors known to correlate with immune recovery. Cumulative VL higher than the sample median was independently associated with an increased risk of AIDS (relative risk 2.38, 95% confidence interval 1.56-3.62, p < 0.001). Among patients with VL suppression, first year VL decay and slope were independent predictors of early CD4 recovery (p = 0.001) and overall gain (p < 0.05). Despite VL suppression, those with slow decay during the first year of HAART as well as during the entire therapy period (overall), in general, gained less CD4 cells compared to the other subjects (133 vs. 195.4 cells/mu L; p = 0.001) even after adjusting for potential confounders. Conclusions: In a cohort with free access to healthcare, independent of established predictors of AIDS and CD4 recovery during HAART, cumulative VL and virologic decay patterns were associated with AIDS and distinct aspects of CD4 reconstitution. C1 [Marconi, Vincent C.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA. [Marconi, Vincent C.; Grandits, Greg; Okulicz, Jason F.; Wortmann, Glenn; Ganesan, Anuradha; Crum-Cianflone, Nancy; Polis, Michael; Landrum, Michael; Agan, Brian] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. [Grandits, Greg] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Okulicz, Jason F.; Landrum, Michael] Brooke Army Med Ctr, San Antonio Mil Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA. [Wortmann, Glenn] Walter Reed Army Med Ctr, Infect Dis Serv, Washington, DC 20307 USA. [Ganesan, Anuradha] Natl Naval Med Ctr, Infect Dis Clin, Bethesda, MD USA. [Crum-Cianflone, Nancy] USN, Infect Dis Clin, San Diego Med Ctr, San Diego, CA 92152 USA. [Polis, Michael] NIAID, NIH, Bethesda, MD 20892 USA. [Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA. [Ahuja, Sunil K.; Kulkarni, Hemant] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV 1 Infect, San Antonio, TX USA. [Ahuja, Sunil K.; Kulkarni, Hemant] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. RP Marconi, VC (reprint author), Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA. EM vcmarco@emory.edu; kulkarnih@uthscsa.edu RI Marconi, Vincent/N-3210-2014 OI Marconi, Vincent/0000-0001-8409-4689; Polis, Michael/0000-0002-9151-2268; Agan, Brian/0000-0002-5114-1669 FU Infectious Disease Clinical Research Program [IDCRP-000-03]; Department of Defense through the Uniformed Services University of the Health Sciences; National Institute of Allergy and Infectious Diseases, National Institutes of Health [Y1-AI-5072]; Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System; NIH [R37046326]; VA; Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist Award; Doris Duke Distinguished Clinical Scientist Award FX Support for this work (IDCRP-000-03) was provided by the Infectious Disease Clinical Research Program, a Department of Defense program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072. This work was also supported by the Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and a MERIT (R37046326) award from the NIH to SKA. SKA is also supported by a VA MERIT award and is a recipient of the Elizabeth Glaser Scientist Award, the Burroughs Wellcome Clinical Scientist Award in Translational Research, and the Doris Duke Distinguished Clinical Scientist Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 25 Z9 25 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 20 PY 2011 VL 6 IS 5 AR e17956 DI 10.1371/journal.pone.0017956 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 766OI UT WOS:000290793400001 PM 21625477 ER PT J AU Ansbaugh, NJ Shannon, J Mori, M Farris, PE Collins, L Garzotto, M AF Ansbaugh, N. J. Shannon, J. Mori, M. Farris, P. E. Collins, L. Garzotto, M. TI Agent orange as a risk factor for high-grade prostate cancer detected on initial prostate biopsy SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Hosp, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 4667 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880300707 PM 28023892 ER PT J AU Bohanes, PO Goldman, BH Leichman, LP Blanke, CD Iqbal, S Thomas, CR Corless, CL Billingsley, KG Danenberg, KD Zhang, W Benedetti, JK Gold, PJ Lenz, H AF Bohanes, P. O. Goldman, B. H. Leichman, L. P. Blanke, C. D. Iqbal, S. Thomas, C. R. Corless, C. L. Billingsley, K. G. Danenberg, K. D. Zhang, W. Benedetti, J. K. Gold, P. J. Lenz, H. TI Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Southwest Oncol Grp, Ctr Stat, Seattle, WA USA. Desert Reg Med Ctr, Ctr Comprehens Canc, Palm Springs, CA USA. Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Response Genet Inc, Los Angeles, CA USA. Swedish Canc Inst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 4023 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880300434 PM 28020537 ER PT J AU Dunlap, J Corless, CL Fleming, WH Braziel, R Leeborg, N Gatter, K Loriaux, M Kelemen, K Kovacsovics, T Fan, G AF Dunlap, J. Corless, C. L. Fleming, W. H. Braziel, R. Leeborg, N. Gatter, K. Loriaux, M. Kelemen, K. Kovacsovics, T. Fan, G. TI High-throughput mutation analysis in acute myeloid leukemia (AML) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 6529 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880302036 PM 28019961 ER PT J AU Garzotto, M Hung, A Beer, TM Alumkal, JJ Graff, JN Farris, PE Fiamiatos, JF Mongoue-Tchokote, S Carter, SN AF Garzotto, M. Hung, A. Beer, T. M. Alumkal, J. J. Graff, J. N. Farris, P. E. Fiamiatos, J. F. Mongoue-Tchokote, S. Carter, S. N. TI Phase I/II study of neoadjuvant docetaxel plus intensity-modulated radiotherapy (IMRT) prior to surgery for high-risk prostate cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 4662 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880300702 PM 28023873 ER PT J AU Heinrich, MC Griffith, D McKinley, A Presnell, A Ramachandran, A AF Heinrich, M. C. Griffith, D. McKinley, A. Presnell, A. Ramachandran, A. TI The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. AROG Pharmaceut LLC, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 10012 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880301029 PM 28021118 ER PT J AU Indio, V Pantaleo, MA Astolfi, A Casadio, R Paterini, P Formica, S Martelli, P Moore, R Thiessen, N di Battista, M Catena, F Santini, D Heinrich, MC Gnocchi, C Dei Tos, AP Biasco, G AF Indio, V. Pantaleo, M. A. Astolfi, A. Casadio, R. Paterini, P. Formica, S. Martelli, P. Moore, R. Thiessen, N. di Battista, M. Catena, F. Santini, D. Heinrich, M. C. Gnocchi, C. Dei Tos, A. P. Biasco, G. TI Identification of single nucleotide variants in gastrointestinal stromal tumor KIT/PDGFRA wild-type (WT GISTs) by massively parallel sequencing. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Bologna, Giorgio Prodi Canc Res Ctr, Bologna, Italy. Univ Bologna, Seragnoli Dept, Bologna, Italy. Univ Bologna, GIST Study Grp, Bologna, Italy. Interdept Ctr Canc Res, Bologna, Italy. Univ Bologna, Bologna, Italy. Univ Bologna, Interdept Ctr Canc Res G Prodi, Bologna, Italy. BC Canc Agcy Genome Sci Ctr, Vancouver, BC, Canada. Univ Bologna, S Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, Bologna, Italy. St Orsola Marcello Malpighi Hosp, Pathol Unit, Bologna, Italy. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Novartis Oncol, Varese, Italy. Azienda ULSS 9 Treviso, Treviso, Italy. RI Casadio, Rita/K-4814-2015 OI Casadio, Rita/0000-0002-7462-7039 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 10046 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880301062 PM 28021143 ER PT J AU Kelley, RK Knight, SJ Wang, G Phillips, KA Venook, AP AF Kelley, R. K. Knight, S. J. Wang, G. Phillips, K. A. Venook, A. P. TI Evidence for drugs and biomarkers in oncology guidelines (GLs): A survey of the National Comprehensive Cancer Network (NCCN) colon cancer panel SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Ctr Translat & Policy Res Personalized Med TRANSP, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA e16578 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880304290 PM 28022090 ER PT J AU Madhusudanannair, V Medina, G Lee, S Mita, MM Karnad, AB AF Madhusudanannair, V. Medina, G. Lee, S. Mita, M. M. Karnad, A. B. TI Phase I trials in patients with salivary gland cancers (SGCs): The Cancer Therapy and Research Center (CTRC) experience. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA. South Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA e16017 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880304198 PM 28023614 ER PT J AU Pantaleo, MA Astolfi, A Indio, V Paterini, P Formica, S Casadio, R Martelli, P Maleddu, A Nannini, M Dei Tos, AP Heinrich, MC Santini, D Catena, F Ceccarelli, C Fiorentino, M di Battista, M Moore, R Thiessen, N Gnocchi, C Biasco, G AF Pantaleo, M. A. Astolfi, A. Indio, V. Paterini, P. Formica, S. Casadio, R. Martelli, P. Maleddu, A. Nannini, M. Dei Tos, A. P. Heinrich, M. C. Santini, D. Catena, F. Ceccarelli, C. Fiorentino, M. di Battista, M. Moore, R. Thiessen, N. Gnocchi, C. Biasco, G. TI Identification of SDHA (subunit A of the succinate dehydrogenase) mutations in KIT/PDGFRA WT gastrointestinal stromal tumors (GISTs). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Bologna, Seragnoli Dept, Bologna, Italy. Univ Bologna, GIST Study Grp, Bologna, Italy. Interdept Ctr Canc Res, Bologna, Italy. Univ Bologna, Giorgio Prodi Canc Res Ctr, Bologna, Italy. Univ Bologna, Interdept Ctr Canc Res G Prodi, Bologna, Italy. Univ Bologna, Bologna, Italy. Azienda ULSS 9 Treviso, Treviso, Italy. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. St Orsola Marcello Malpighi Hosp, Pathol Unit, Bologna, Italy. Univ Bologna, S Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, Bologna, Italy. St Orsola Marcello Malpighi Hosp, Bologna, Italy. Policlin St Orsola Malpighi, Bologna, Italy. BC Canc Agcy Genome Sci Ctr, Vancouver, BC, Canada. Novartis Oncol, Varese, Italy. RI Casadio, Rita/K-4814-2015; nannini, margherita/J-9866-2016 OI Casadio, Rita/0000-0002-7462-7039; NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 10045 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880301061 PM 28021144 ER PT J AU Ryoo, JJ Kim, B Ordin, DL Oishi, SM Asch, SM Antonio, ALM He, R Gould, MK Malin, J AF Ryoo, J. J. Kim, B. Ordin, D. L. Oishi, S. M. Asch, S. M. Antonio, A. L. M. He, R. Gould, M. K. Malin, J. TI Quality of non-small cell lung cancer (NSCLC) care in the Veterans Health Administration (VHA): Impact of patient preference and clinical judgment SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Off Qual & Performance, Washington, DC USA. VA Greater Los Angeles Healthcare Syst, North Hills, CA USA. Univ So Calif, Los Angeles, CA USA. Univ Calif Los Angeles, Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 6011 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880300715 PM 28021983 ER PT J AU Wright, JD Neugut, AI Wilde, ET Buono, D Malin, J Tsai, W Hershman, DL AF Wright, J. D. Neugut, A. I. Wilde, E. T. Buono, D. Malin, J. Tsai, W. Hershman, D. L. TI Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Columbia Univ, New York, NY USA. Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA. Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. Univ Calif Los Angeles, Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 6020 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880300722 PM 28021963 ER PT J AU Young, P Kim, B Malin, J AF Young, P. Kim, B. Malin, J. TI Preoperative breast MRI in early-stage breast cancer: A decision analysis SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2011 VL 29 IS 15 SU S MA 6035 PG 1 WC Oncology SC Oncology GA V31JQ UT WOS:000208880300731 PM 28021941 ER PT J AU Goldberg, NRS Meshul, CK AF Goldberg, N. R. S. Meshul, C. K. TI EFFECT OF INTERMITTENT WASHOUT PERIODS ON PROGRESSIVE LESIONING OF THE NIGROSTRIATAL PATHWAY WITH 1-METHYL-2-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) SO NEUROSCIENCE LA English DT Article DE dopamine; progressive; MPTP; tyrosine hydroxylase; motor control; Parkinson's disease ID PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; ALPHA-SYNUCLEIN; MODEL; MICE; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; DEGENERATION; STRESS; RAT AB We have previously reported that a progressively increased dose of MPTP over the course of 4 weeks induces the gradual impairment of the nigrostriatal dopamine (DA) pathway and several behaviors [Goldberg et al. (in press) Neuroscience]. To our knowledge, this is the first report of specific behavioral deficits correlated with discrete thresholds of DA loss in this pathway. In that study, MPTP was administered 5 d/wk, with behavioral and tissue analysis being carried out 3 days following the final injection at each dose. However, in order to better represent long-term progressive neurodegeneration the present study introduced a washout period of 10 days between each increased dose of MPTP. This implementation also controlled for any transient de-activation of tyrosine hydroxylase (TH), the enzyme that catalyzes synthesis of DA, caused by MPTP-induced oxidative stress which has been suggested following acute administration of the toxin [Smeyne and Jackson-Lewis (2005) Brian Res Mol Brain Res 134:57-66]. Additionally, by the end of the previous study, there was an ultimate decrease of 62% in the mean number of TH-labeled neurons/section in the substantia nigra pars compacta (SNpc) and a 74% decrease in caudate putamen (CPu) TH optical density with continuous MPTP. In the present study, we find that the washout periods lead to a final 79% decrease in the mean number of TH-labeled SNpc neurons/section, and a similar 74% decrease in CPu TH following the 32 mg/kg MPTP dose. Additionally, a dose-dependent decrease was observed in the mean number of SNpc TH-ir neurons/section in the current study which was not seen in the continuous MPTP protocol. These results suggest that a washout period following each increased MPTP dose allows for observation of continued cell death that might occur during the week following MPTP administration, and for therapeutic interventions to be applied at any of several stages during progressive neurodegeneration. Published by Elsevier Ltd on behalf of IBRO. C1 [Goldberg, N. R. S.; Meshul, C. K.] Portland VA Med Ctr, Portland, OR USA. [Meshul, C. K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA. RP Meshul, CK (reprint author), VA Med Ctr RD 29, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM meshulc@ohsu.edu FU Department of Veterans Affairs FX This work was funded by the Department of Veterans Affairs Merit Review Program. NR 25 TC 6 Z9 6 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD MAY 19 PY 2011 VL 182 BP 203 EP 207 DI 10.1016/j.neuroscience.2011.03.015 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 762FP UT WOS:000290460600020 PM 21402128 ER PT J AU Escartin, C Won, SJ Malgorn, C Auregan, G Berman, AE Chen, PC Deglon, N Johnson, JA Suh, SW Swanson, RA AF Escartin, Carole Won, Seok Joon Malgorn, Carole Auregan, Gwennaelle Berman, Ari E. Chen, Pei-Chun Deglon, Nicole Johnson, Jeffrey A. Suh, Sang Won Swanson, Raymond A. TI Nuclear Factor Erythroid 2-Related Factor 2 Facilitates Neuronal Glutathione Synthesis by Upregulating Neuronal Excitatory Amino Acid Transporter 3 Expression SO JOURNAL OF NEUROSCIENCE LA English DT Article ID ANTIOXIDANT RESPONSE ELEMENT; CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; GLUTAMATE TRANSPORTER; OXIDATIVE STRESS; CORTICAL-NEURONS; HEME OXYGENASE-1; GENE-EXPRESSION; TRANSCRIPTION FACTOR; HUNTINGTONS-DISEASE; CONSENSUS SEQUENCE AB Astrocytes support neuronal antioxidant capacity by releasing glutathione, which is cleaved to cysteine in brain extracellular space. Free cysteine is then taken up by neurons through excitatory amino acid transporter 3 [EAAT3; also termed Slc1a1 (solute carrier family 1 member 1)] to support de novo glutathione synthesis. Activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant responsive element (ARE) pathway by oxidative stress promotes astrocyte release of glutathione, but it remains unknown how this release is coupled to neuronal glutathione synthesis. Here we evaluated transcriptional regulation of the neuronal cysteine transporter EAAT3 by the Nrf2-ARE pathway. Nrf2 activators and Nrf2 overexpression both produced EAAT3 transcriptional activation in C6 cells. A conserved ARE-related sequence was found in the EAAT3 promoter of several mammalian species. This ARE-related sequence was bound by Nrf2 in mouse neurons in vivo as observed by chromatin immunoprecipitation. Chemical activation of the Nrf2-ARE pathway in mouse brain increased both neuronal EAAT3 levels and neuronal glutathione content, and these effects were abrogated in mice genetically deficient in either Nrf2 or EAAT3. Selective overexpression of Nrf2 in brain neurons by lentiviral gene transfer was sufficient to upregulate both neuronal EAAT3 protein and glutathione content. These findings identify a mechanism whereby Nrf2 activation can coordinate astrocyte glutathione release with neuronal glutathione synthesis through transcriptional upregulation of neuronal EAAT3 expression. C1 [Escartin, Carole; Malgorn, Carole; Auregan, Gwennaelle; Deglon, Nicole] Commissariat Energie Atom & Energies Alternat, CNRS, URA2210, Mol Imaging Res Ctr, F-92265 Fontenay Aux Roses, France. [Escartin, Carole; Won, Seok Joon; Berman, Ari E.; Suh, Sang Won; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Escartin, Carole; Won, Seok Joon; Berman, Ari E.; Suh, Sang Won; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA 94121 USA. [Chen, Pei-Chun; Johnson, Jeffrey A.] Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA. RP Escartin, C (reprint author), CEA, CNRS, URA 2210, MIRCen, 18 Route Panorama, F-92265 Fontenay Aux Roses, France. EM carole.escartin@cea.fr RI Escartin, Carole/A-1952-2010 OI Escartin, Carole/0000-0003-3613-4118; Swanson, Raymond/0000-0002-3664-5359; Deglon, Nicole/0000-0003-4475-9476 FU NIH [P50 NS14543, R01 ES10042]; Department of Veterans Affairs; Centre National de la Recherche Scientifique and Commissariat a l'Energie Atomique et aux Energies Alternatives FX This work was supported by the NIH (Grant P50 NS14543 to R.A.S.; and Grant R01 ES10042 to J.A.J.), the Department of Veterans Affairs Merit Review Program (R.A.S.), and Centre National de la Recherche Scientifique and Commissariat a l'Energie Atomique et aux Energies Alternatives (C.E.). We thank C. Hefner, M. Chaigneau, M. Guillermier, D. Houitte and, F. Petit for expert technical assistance. We are grateful to Dr. E. Brouillet, Dr. G. Bonvento, and Dr. M.C. Gaillard for helpful scientific discussions. NR 53 TC 45 Z9 46 U1 0 U2 7 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 18 PY 2011 VL 31 IS 20 BP 7392 EP 7401 DI 10.1523/JNEUROSCI.6577-10.2011 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 765OA UT WOS:000290716600018 PM 21593323 ER PT J AU Thase, ME AF Thase, Michael E. TI Cognitive-behavioral therapy reduced risk for recurrence in patients recently hospitalized with cardiovascular disease events SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Thase, ME (reprint author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 2 TC 0 Z9 0 U1 0 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 17 PY 2011 VL 154 IS 10 AR JC5-4 DI 10.7326/0003-4819-154-10-201105170-02004 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 764HK UT WOS:000290620300003 PM 21576522 ER PT J AU Heath, RR Schuller, JL Sauer, WH Varosy, PD Nguyen, DT Aleong, RG AF Heath, Russell R. Schuller, Joseph L. Sauer, William H. Varosy, Paul D. Nguyen, Duy T. Aleong, Ryan G. TI A Mobile Tubular Mass Visualized by Transesophageal Echocardiography After Successful Lead Extraction SO CIRCULATION LA English DT Editorial Material ID EMBOLIZATION; COMPLICATION C1 Univ Colorado Denver, Aurora, CO USA. Denver Vet Affairs Med Ctr, Aurora, CO USA. RP Aleong, RG (reprint author), Univ Colorado, 12401 E 17th Ave,B-136, Aurora, CO 80045 USA. EM ryan.aleong@ucdenver.edu NR 3 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 17 PY 2011 VL 123 IS 19 BP E590 EP E591 DI 10.1161/CIRCULATIONAHA.110.009886 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 764GC UT WOS:000290616600001 PM 21576675 ER PT J AU Carrico, AW Bangsberg, DR Weiser, SD Chartier, M Dilworth, SE Riley, ED AF Carrico, Adam W. Bangsberg, David R. Weiser, Sheri D. Chartier, Maggie Dilworth, Samantha E. Riley, Elise D. TI Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons SO AIDS LA English DT Article DE cocaine; HAART; HIV; mental health; methamphetamine; severe mental illness ID ACTIVE ANTIRETROVIRAL THERAPY; DIAGNOSTIC INTERVIEW SCHEDULE; INJECTION-DRUG USE; DISEASE PROGRESSION; INFECTED PATIENTS; MENTAL-ILLNESS; CRACK-COCAINE; SAN-FRANCISCO; AIDS; MORTALITY AB Objective: Research on the role psychiatric factors in HIV disease management has yielded discrepant findings, possibly because prior studies did not include comprehensive psychiatric screeners. This study administered a validated screener to examine psychiatric correlates of highly active antiretroviral therapy (HAART) utilization and viral load. Design: Community-recruited, HIV-positive impoverished persons provided sociodemographic information, completed a Diagnostic Interview Schedule that screened for psychiatric disorders, and provided a blood sample to measure HIV disease markers. Methods: In this cross-sectional investigation with 227 participants, a multiple logistic regression model examined correlates of HAART utilization compared to a reference group that was eligible for (i.e. CD4(+) cell count < 350 cells/mu l) but not taking HAART. A multiple linear regression model examined correlates of HIV viral load among 147 participants on HAART. Results: Sleeping on the street [adjusted OR (AOR) = 0.06; 95% confidence interval (CI) = 0.01-0.26] and screening positive for a stimulant use disorder (AOR = 0.29; 95% CI = 0.13-0.65) were independently associated with lower odds of HAART utilization. Conversely, enrollment in the AIDS Drug Assistance Program (AOR = 3.94; 95% CI = 1.45-10.73) and receipt of mental health treatment (AOR = 4.78; 95% CI = 1.77-12.87) were independently associated with increased odds of HAART utilization. Among those on HAART, screening positive for a severe mental illness was independently associated with a six-fold higher viral load. Conclusion: Providing psychiatric treatment could optimize health outcomes among HIV-positive impoverished persons and boost the effectiveness of ` test and treat' approaches to HIV prevention. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Carrico, Adam W.; Weiser, Sheri D.; Dilworth, Samantha E.; Riley, Elise D.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94105 USA. [Bangsberg, David R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Global Hlth, Harvard, CA USA. [Weiser, Sheri D.; Riley, Elise D.] San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA. [Chartier, Maggie] San Francisco VA Med Ctr, San Francisco, CA USA. RP Carrico, AW (reprint author), Univ Calif San Francisco, Ctr AIDS Prevent Studies, 50 Beale St,Suite 1300, San Francisco, CA 94105 USA. EM adam.carrico@ucsf.edu FU NIH [R01-DA15605, R01-MH54907, UL1 RR024131] FX For making this study possible, the authors thank the study participants, Study Project Director, Jennifer Cohen, and study team, including Sujana Bhattacharyya, Shemena Campbell, Kara Marson and Deb Schneider. We also thank the teams of collaborating researchers including Richard Clark, John Day, Nelia Dela Cruz, Carina Flores, Minoo Gorji, David Guzman, Scot Hammond, Jackie Haslam, Zizi Hawthorne, Jay Jankowski, Rhonda Johnson, Mac McMaster, Sandra Monk, Rebecca Packard, Joyce Powell, Kathleen Ragland, Mathew Reynolds, Paul Rueckhaus, Jacqueline So, John Weeks and Kelly Winslow. This study was funded by NIH R01-DA15605, R01-MH54907, and UL1 RR024131. NR 30 TC 19 Z9 19 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD MAY 15 PY 2011 VL 25 IS 8 BP 1113 EP 1118 DI 10.1097/QAD.0b013e3283463f09 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 758FB UT WOS:000290145800011 PM 21399478 ER PT J AU Hoffman, RE Grasemann, U Gueorguieva, R Quinlan, D Lane, D Miikkulainen, R AF Hoffman, Ralph E. Grasemann, Uli Gueorguieva, Ralitza Quinlan, Donald Lane, Douglas Miikkulainen, Risto TI Using Computational Patients to Evaluate Illness Mechanisms in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Artificial neural network; delusions; derailment; memory; narrative language; prediction-error; schizophrenia ID FORMAL THOUGHT-DISORDER; PREFRONTAL CORTEX DYSFUNCTION; WORKING-MEMORY; COMMUNICATION DISTURBANCES; 1ST-EPISODE PSYCHOSIS; DOPAMINERGIC MIDBRAIN; SPREADING ACTIVATION; LINGUISTIC CONTEXT; BRAIN ACTIVITY; MODEL AB Background: Various malfunctions involving working memory, semantics, prediction error, and dopamine neuromodulation have been hypothesized to cause disorganized speech and delusions in schizophrenia. Computational models may provide insights into why some mechanisms are unlikely, suggest alternative mechanisms, and tie together explanations of seemingly disparate symptoms and experimental findings. Methods: Eight corresponding illness mechanisms were simulated in DISCERN, an artificial neural network model of narrative understanding and recall. For this study, DISCERN learned sets of autobiographical and impersonal crime stories with associated emotion coding. In addition, 20 healthy control subjects and 37 patients with schizophrenia or schizoaffective disorder matched for age, gender, and parental education were studied using a delayed story recall task. A goodness-of-fit analysis was performed to determine the mechanism best reproducing narrative breakdown profiles generated by healthy control subjects and patients with schizophrenia. Evidence of delusion-like narratives was sought in simulations best matching the narrative breakdown profile of patients. Results: All mechanisms were equivalent in matching the narrative breakdown profile of healthy control subjects. However, exaggerated prediction-error signaling during consolidation of episodic memories, termed hyperlearning, was statistically superior to other mechanisms in matching the narrative breakdown profile of patients. These simulations also systematically confused autobiographical agents with impersonal crime story agents to model fixed, self-referential delusions. Conclusions: Findings suggest that exaggerated prediction-error signaling in schizophrenia intermingles and corrupts narrative memories when incorporated into long-term storage, thereby disrupting narrative language and producing fixed delusional narratives. If further validated by clinical studies, these computational patients could provide a platform for developing and testing novel treatments. C1 [Hoffman, Ralph E.; Quinlan, Donald] Yale Univ Sch Med, Dept Psychiat, New Haven, CT 06519 USA. [Gueorguieva, Ralitza] Yale Univ Sch Med, Sch Publ Hlth, New Haven, CT 06519 USA. [Grasemann, Uli; Miikkulainen, Risto] Univ Texas Austin, Dept Comp Sci, Austin, TX 78712 USA. [Lane, Douglas] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care Serv, Tacoma, WA USA. RP Hoffman, RE (reprint author), Yale Univ Sch Med, Yale New Haven Psychiat Hosp, Dept Psychiat, 184 Liberty St, New Haven, CT 06519 USA. EM ralph.hoffman@yale.edu OI Gueorguieva, Ralitza/0000-0003-0944-5973 FU National Institute of Mental Health [R01MH066228]; National Institutes of Health [R21-DC009446]; National Science Foundation [EIA-0303609]; Dana Foundation; National Alliance for Research on Schizophrenia and Depression; Department of Mental Health and Addiction Services of the State of Connecticut through Abraham Ribicoff Research Center at the Connecticut Mental Health Center FX This work was supported by National Institute of Mental Health Grant R01MH066228, National Institutes of Health Grant R21-DC009446, National Science Foundation Grant EIA-0303609, a Dana Foundation Grant, a National Alliance for Research on Schizophrenia and Depression Independent Investigator Award, Peterson 50th Anniversary Research Partner, and the Department of Mental Health and Addiction Services of the State of Connecticut through its support of the Abraham Ribicoff Research Center at the Connecticut Mental Health Center. NR 82 TC 13 Z9 13 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 15 PY 2011 VL 69 IS 10 BP 997 EP 1005 DI 10.1016/j.biopsych.2010.12.036 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 760DF UT WOS:000290302700018 PM 21397213 ER PT J AU Artinyan, A Anaya, DA McKenzie, S Ellenhorn, JDI Kim, J AF Artinyan, Avo Anaya, Daniel A. McKenzie, Shaun Ellenhorn, Joshua D. I. Kim, Joseph TI Neoadjuvant Therapy Is Associated With Improved Survival in Resectable Pancreatic Adenocarcinoma SO CANCER LA English DT Article DE pancreatic cancer; surgery; chemotherapy; neoadjuvant therapy ID COMPARING STANDARD PANCREATICODUODENECTOMY; GEMCITABINE-BASED CHEMORADIATION; RANDOMIZED CONTROLLED-TRIAL; CANCER COOPERATIVE GROUP; PHASE-III TRIAL; CURATIVE RESECTION; EXTENDED LYMPHADENECTOMY; PREOPERATIVE GEMCITABINE; ADJUVANT RADIOTHERAPY; PERIAMPULLARY REGION AB BACKGROUND: Neoadjuvant therapy has been used to improve survival in operable pancreatic cancer. The authors' objective was to compare long-term outcomes in patients receiving neoadjuvant versus adjuvant therapy for resectable pancreatic adenocarcinoma. METHODS: The California Cancer Surveillance Program for Los Angeles County retrospectively identified 458 patients with nonmetastatic pancreatic adenocarcinoma who underwent definitive pancreatic resection and received systemic chemotherapy between 1987 and 2006. The cohort was grouped by timing of systemic therapy-neoadjuvant or adjuvant. Clinicopathologic characteristics and overall survival were compared. Multivariate Cox regression analysis was used to determine the benefit of neoadjuvant therapy, independent of other significant factors. RESULTS: Of the 458 patients, 39 (8.5%) received neoadjuvant therapy, and 419 (91.5%) received adjuvant therapy. There was a significantly lower rate of lymph node positivity in the neoadjuvant group (45% vs 65%; P =.011) despite a higher rate of extrapancreatic tumor extension. On Kaplan-Meier analysis, the neoadjuvant group had significantly better overall survival compared with the adjuvant group (median survival, 34 vs 19 months; P=.003). Overall survival was also improved in the neoadjuvant therapy patients with extrapancreatic disease (median survival, 31 vs 19 months; P=.018). On multivariate Cox regression analysis, neoadjuvant therapy was an independent predictor of improved survival (hazard ratio, 0.57; 95% confidence interval, 0.37-0.89; P=.013). CONCLUSIONS: This is the first population-based study to compare neoadjuvant versus adjuvant treatment strategies in resectable pancreatic cancer. Neoadjuvant therapy is associated with a lower rate of lymph node positivity and improved overall survival and should be considered an acceptable alternative to the surgery-first paradigm in operable pancreatic cancer. Cancer 2011; 117: 2044-9. (C) 2010 American Cancer Society C1 [Artinyan, Avo; Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Artinyan, Avo; Anaya, Daniel A.] Baylor Coll Med, Houston Hlth Serv, Houston, TX 77030 USA. [Artinyan, Avo; Anaya, Daniel A.] Baylor Coll Med, Res Ctr Excellence, Houston, TX 77030 USA. [Artinyan, Avo; Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [McKenzie, Shaun] Univ Kentucky, Sch Med, Dept Surg, Lexington, KY 40536 USA. [Ellenhorn, Joshua D. I.; Kim, Joseph] City Hope Comprehens Canc Ctr, Dept Surg Oncol, Duarte, CA USA. RP Kim, J (reprint author), City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM jokim@coh.org FU Houston Veterans Affairs Health Services & Research Center of Excellence [HFP90-020] FX This work was supported in part by the Houston Veterans Affairs Health Services & Research Center of Excellence (HFP90-020). The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 26 TC 47 Z9 51 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD MAY 15 PY 2011 VL 117 IS 10 BP 2044 EP 2049 DI 10.1002/cncr.25763 PG 6 WC Oncology SC Oncology GA 758JQ UT WOS:000290161100004 PM 21523715 ER PT J AU Guthrie, CR Greenup, L Leverenz, JB Kraemer, BC AF Guthrie, Chris R. Greenup, Lynne Leverenz, James B. Kraemer, Brian C. TI MSUT2 is a determinant of susceptibility to tau neurotoxicity SO HUMAN MOLECULAR GENETICS LA English DT Article ID CAENORHABDITIS-ELEGANS MODEL; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; ANIMAL-MODELS; TAUOPATHY; GENE; DEGENERATION; AGGREGATION; STRATEGIES; MUTATIONS AB Lesions containing abnormal aggregated tau protein are one of the diagnostic hallmarks of Alzheimer's disease (AD) and related tauopathy disorders. How aggregated tau leads to dementia remains enigmatic, although neuronal dysfunction and loss clearly contribute. We previously identified sut-2 as a gene required for tau neurotoxicity in a transgenic Caenorhabditis elegans model of tauopathy. Here, we further explore the role of sut-2 and show that overexpression of SUT-2 protein enhances tau-induced neuronal dysfunction, neurotoxicity and accumulation of insoluble tau. We also explore the relationship between sut-2 and its human homolog, mammalian SUT-2 (MSUT2) and find both proteins to be predominantly nuclear and localized to SC35-positive nuclear speckles. Using a cell culture model for the accumulation of pathological tau, we find that high tau levels lead to increased expression of MSUT2 protein. We analyzed MSUT2 protein in age-matched post-mortem brain samples from AD patients and observe a marked decrease in overall MSUT2 levels in the temporal lobe of AD patients. Analysis of post-mortem tissue from AD cases shows a clear reduction in neuronal MSUT2 levels in brain regions affected by tau pathology, but little change in regions lacking tau pathology. RNAi knockdown of MSUT2 in cultured human cells overexpressing tau causes a marked decrease in tau aggregation. Both cell culture and post-mortem tissue studies suggest that MSUT2 levels may influence neuronal vulnerability to tau toxicity and aggregation. Thus, neuroprotective strategies targeting MSUT2 may be of therapeutic interest for tauopathy disorders. C1 [Guthrie, Chris R.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Greenup, Lynne; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Mental Illness Res Educ Ctr, Seattle, WA 98108 USA. [Greenup, Lynne; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Ctr Clin, Seattle, WA 98108 USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Parkinsons Dis Res Educ Ctr, Seattle, WA 98108 USA. [Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98104 USA. [Kraemer, Brian C.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98104 USA. RP Kraemer, BC (reprint author), Seattle Vet Affairs Puget Sound Hlth Care Syst, S182,1660 S Columbian Way, Seattle, WA 98108 USA. EM kraemerb@u.washington.edu FU Department of Veterans Affairs [1147891]; National Institutes of Health [R01NS064131, 2P50AG005136-27, 5P50NS2062684-02] FX This work was supported by grants from the Department of Veterans Affairs (Merit Review Grant #1147891 to B.C.K.) and National Institutes of Health (R01NS064131 to B.C.K., 2P50AG005136-27 and 5P50NS2062684-02 to J.B.L.). NR 28 TC 16 Z9 18 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAY 15 PY 2011 VL 20 IS 10 BP 1989 EP 1999 DI 10.1093/hmg/ddr079 PG 11 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 754EU UT WOS:000289837400011 PM 21355046 ER PT J AU O'Donovan, A Pantell, MS Puterman, E Dhabhar, FS Blackburn, EH Yaffe, K Cawthon, RM Opresko, PL Hsueh, WC Satterfield, S Newman, AB Ayonayon, HN Rubin, SM Harris, TB Epel, ES AF O'Donovan, Aoife Pantell, Matthew S. Puterman, Eli Dhabhar, Firdaus S. Blackburn, Elizabeth H. Yaffe, Kristine Cawthon, Richard M. Opresko, Patricia L. Hsueh, Wen-Chi Satterfield, Suzanne Newman, Anne B. Ayonayon, Hilsa N. Rubin, Susan M. Harris, Tamara B. Epel, Elissa S. CA Hlth Aging Body Composition Study TI Cumulative Inflammatory Load Is Associated with Short Leukocyte Telomere Length in the Health, Aging and Body Composition Study SO PLOS ONE LA English DT Article ID C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; CALORIE RESTRICTION; HUMAN HEPATOCYTES; DNA-DAMAGE; MORTALITY; RISK; INTERLEUKIN-6; CANCER; CELLS AB Background: Leukocyte telomere length (LTL) is an emerging marker of biological age. Chronic inflammatory activity is commonly proposed as a promoter of biological aging in general, and of leukocyte telomere shortening in particular. In addition, senescent cells with critically short telomeres produce pro-inflammatory factors. However, in spite of the proposed causal links between inflammatory activity and LTL, there is little clinical evidence in support of their covariation and interaction. Methodology/Principal Findings: To address this issue, we examined if individuals with high levels of the systemic inflammatory markers interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and C-reactive protein (CRP) had increased odds for short LTL. Our sample included 1,962 high-functioning adults who participated in the Health, Aging and Body Composition Study (age range: 70-79 years). Logistic regression analyses indicated that individuals with high levels of either IL-6 or TNF-alpha had significantly higher odds for short LTL. Furthermore, individuals with high levels of both IL-6 and TNF-alpha had significantly higher odds for short LTL compared with those who had neither high (OR = 0.52, CI = 0.37-0.72), only IL-6 high (OR = 0.57, CI = 0.39-0.83) or only TNF-alpha high (OR = 0.67, CI = 0.46-0.99), adjusting for a wide variety of established risk factors and potential confounds. In contrast, CRP was not associated with LTL. Conclusions/Significance: Results suggest that cumulative inflammatory load, as indexed by the combination of high levels of IL-6 and TNF-alpha, is associated with increased odds for short LTL. In contrast, high levels of CRP were not accompanied by short LTL in this cohort of older adults. These data provide the first large-scale demonstration of links between inflammatory markers and LTL in an older population. C1 [O'Donovan, Aoife; Puterman, Eli; Yaffe, Kristine; Epel, Elissa S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [O'Donovan, Aoife; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Pantell, Matthew S.] Univ Calif Berkeley, Univ Calif, San Francisco Joint Med Program, Berkeley, CA 94720 USA. [Pantell, Matthew S.] Univ Calif Berkeley, Univ Calif, San Francisco Joint Med Program, San Francisco, CA USA. [Dhabhar, Firdaus S.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Blackburn, Elizabeth H.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine; Hsueh, Wen-Chi; Ayonayon, Hilsa N.; Rubin, Susan M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cawthon, Richard M.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA. [Opresko, Patricia L.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA. [Hsueh, Wen-Chi] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Satterfield, Suzanne] Univ Tennessee, Dept Prevent Med, Memphis, TN 38163 USA. [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Harris, Tamara B.] NIH, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. RP O'Donovan, A (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM aoife.odonovan@ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Opresko, Patricia/0000-0002-6470-2189; Puterman, Eli/0000-0002-5898-2348 FU National Institutes of Health (NIH) National Institute on Aging (NIA) [AG-6-2101, AG-6-2103, AG-6-2106, AG021918]; Society in Science: The Branco Weiss Fellowship FX The study was conducted on behalf of the Health, Aging and Body Composition (Health ABC) Study and was funded by National Institutes of Health (NIH) National Institute on Aging (NIA) grants AG-6-2101, AG-6-2103, AG-6-2106, and AG021918. This work was also supported by the Intramural Research Program of the NIH, NIA as well as by Society in Science: The Branco Weiss Fellowship (AOD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 82 Z9 84 U1 3 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 13 PY 2011 VL 6 IS 5 AR e19687 DI 10.1371/journal.pone.0019687 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 763LP UT WOS:000290558500023 PM 21602933 ER PT J AU Hu, W Ross, J Geng, TY Brice, SE Cowart, LA AF Hu, Wei Ross, Jessica Geng, Tuoyu Brice, Sarah E. Cowart, L. Ashley TI Differential Regulation of Dihydroceramide Desaturase by Palmitate versus Monounsaturated Fatty Acids IMPLICATIONS FOR INSULIN RESISTANCE SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SKELETAL-MUSCLE CELLS; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM; METABOLIC SYNDROME; SPHINGOLIPID METABOLISM; CELLULAR-RESPONSES; CERAMIDE SYNTHASES; SPHINGOSINE KINASE; INDUCED APOPTOSIS; C2C12 MYOTUBES AB Much data implicate saturated fatty acids in deleterious processes associated with obesity, diabetes, and the metabolic syndrome. Many of these changes may be due to aberrant generation of bioactive lipids when saturated fatty acid availability to tissues is increased. On the other hand, studies are emerging that implicate the monounsaturated fatty acid oleate in protection from saturated fat mediated toxicity; however, the mechanisms are not well understood. Our data demonstrate a novel role for palmitate in increasing mRNA encoding DES1, which is the enzyme responsible for generating ceramide from its precursor dihydroceramide and thus controls synthesis of the bioactive lipid ceramide. Moreover, co-treatment with oleate prevented the increase in ceramide, and this occurred through attenuation of the increase in message and activity of DES1. Knockdown of DES1 also protected from palmitate-induced insulin resistance, and overexpression of this enzyme ameliorated the protective effect of oleate. Together, these findings provide insight into the mechanisms of oleate-mediated protection against metabolic disease and provide novel evidence for fatty acid-mediated regulation of a key enzyme of ceramide biosynthesis. C1 [Hu, Wei; Ross, Jessica; Geng, Tuoyu; Brice, Sarah E.; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA. [Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. RP Cowart, LA (reprint author), 114 Doughty St,Strom Thurmond Bldg,Rm 423, Charleston, SC 29403 USA. EM cowartl@musc.edu FU Department of Veterans Affairs; National Institutes of Health COBRE in Lipidomics and Pathobiology at the Medical University of South Carolina; Centers of Biomedical Research Excellence in Lipidomics in Pathobiology (NIH) [P20RR017077] FX This work was supported by a Merit Award from the Department of Veterans Affairs (to L. A. C.) and the National Institutes of Health COBRE in Lipidomics and Pathobiology at the Medical University of South Carolina (to L. A. C.). Lipidomics were supported by the Centers of Biomedical Research Excellence in Lipidomics in Pathobiology (NIH P20RR017077). NR 61 TC 34 Z9 35 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 13 PY 2011 VL 286 IS 19 BP 16596 EP 16605 DI 10.1074/jbc.M110.186916 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 760CZ UT WOS:000290301900008 PM 21454530 ER PT J AU Voors, AA Dittrich, HC Massie, BM DeLucca, P Mansoor, GA Metra, M Cotter, G Weatherley, BD Ponikowski, P Teerlink, JR Cleland, JGF O'Connor, CM Givertz, MM AF Voors, Adriaan A. Dittrich, Howard C. Massie, Barry M. DeLucca, Paul Mansoor, George A. Metra, Marco Cotter, Gad Weatherley, Beth D. Ponikowski, Piotr Teerlink, John R. Cleland, John G. F. O'Connor, Christopher M. Givertz, Michael M. TI Effects of the Adenosine A(1) Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction Results From PROTECT (Placebo-Controlled Randomized Study of the Selective A(1) Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE adenosine receptor antagonist; diuretics; heart failure; renal function; rolofylline ID VENOUS CONGESTION; IMPAIRMENT; OUTCOMES; IMPACT; PREVALENCE; CREATININE; PRESSURE; KW-3902 AB Objectives This study sought to assess the effects of rolofylline on renal function in patients with acute heart failure (AHF) and renal dysfunction randomized in PROTECT (Placebo-Controlled Randomized Study of the Selective A(1) Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Background Small studies have indicated that adenosine A(1) receptor antagonists enhance diuresis and may improve renal function in patients with chronic heart failure or AHF. Methods A total of 2,033 patients with AHF, volume overload, estimated creatinine clearance between 20 and 80 ml/min, and elevated natriuretic peptide levels were randomized (2: 1) within 24 h of hospital presentation to rolofylline 30 mg/day or intravenous placebo for up to 3 days. Creatinine was measured daily until discharge or day 7 and on day 14. Persistent worsening renal function was defined as an increase in serum creatinine >= 0.3 mg/dl at both days 7 and 14, or initiation of hemofiltration or dialysis or death by day 7. Results At baseline, mean +/- SD estimated creatinine clearance was 51.0 +/- 20.5 ml/min in the placebo group and 50.4 +/- 20.0 ml/min in the rolofylline group. Changes in creatinine and estimated creatinine clearance were similar between placebo-and rolofylline-treated patients during hospitalization and at day 14. After 4 days, mean body weight was reduced by 2.6 and 3.0 kg in placebo and rolofylline patients, respectively (p = 0.005). Persistent worsening renal function occurred in 13.7% of the placebo group and 15.0% of the rolofylline group (odds ratio vs. placebo: 1.11 [95% confidence interval: 0.85 to 1.46]; p = 0.44). Conclusions In this large, phase III clinical trial, the adenosine A(1) receptor antagonist rolofylline did not prevent persistent worsening renal function in AHF patients with volume overload and renal dysfunction. (A Study of the Selective A(1) Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function [PROTECT-1], NCT00328692; and [PROTECT-2], NCT00354458) (J Am Coll Cardiol 2011;57:1899-907) (C) 2011 by the American College of Cardiology Foundation C1 [Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA. [Voors, Adriaan A.] Univ Groningen, Groningen, Netherlands. [Dittrich, Howard C.] NovaCardia Inc, San Diego, CA USA. [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [DeLucca, Paul] Merck Res Labs, N Wales, PA USA. [Mansoor, George A.] Merck Res Labs, Rahway, NJ USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Cotter, Gad; Weatherley, Beth D.] Momentum Res Inc, Durham, NC USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. RP Givertz, MM (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM mgivertz@partners.org RI Teerlink, John/D-2986-2012; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU NovaCardia, Inc.; Merck; Merck-NovaCardia; Averion; NovaCardia; Corthera; Novartis; Cardiokine; Servier FX This study was funded by NovaCardia, Inc. As of September 2007, NovaCardia is a wholly owned subsidiary of Merck & Co, Inc. Dr. Voors has received speakers' fees from and served as a consultant to Merck. Dr. Dittrich has ownership in NovaCardia, and has served as a consultant to and is a minor shareholder in Merck. Dr. Massie has received speaking honorarium from CME providers for satellite symposia supported by Merck-NovaCardia, and has received compensation from Averion for his role as Co-Principal Investigator of the PROTECT trial. Drs. DeLucca and Mansoor are employees of Merck. Dr. Metra has received honoraria and travel reimbursement from NovaCardia, Merck, Corthera, Novartis, Cardiokine, and Servier. Dr. Ponikowski has received honoraria from Merck, NovaCardia, and Corthera. Drs. Cotter and Weatherley are employees of Momentum Research. Drs. Teerlink, Cleland, and Givertz have received research grants from NovaCardia and served as consultants to Merck. Gregg Fonarow, MD, served as Guest Editor for this paper. Please note: Based upon the results of the Phase III PROTECT trial assessing the effects of rolofylline on short- and long-term outcomes presented at the European Society of Cardiology in 2009, Merck and Co., Inc. determined that the lack of efficacy did not support further development of this compound for the treatment of patients with acute decompensated HF. NR 30 TC 55 Z9 57 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 10 PY 2011 VL 57 IS 19 BP 1899 EP 1907 DI 10.1016/j.jacc.2010.11.057 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 759AA UT WOS:000290210100009 PM 21545947 ER PT J AU Wiener, RS Schwartz, LM Woloshin, S AF Wiener, Renda Soylemez Schwartz, Lisa M. Woloshin, Steven TI Time Trends in Pulmonary Embolism in the United States Evidence of Overdiagnosis SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID COMPUTED-TOMOGRAPHY; VENOUS THROMBOEMBOLISM; CLINICAL-OUTCOMES; CANCER; CT; MORTALITY; ANGIOGRAPHY; METAANALYSIS; PREVALENCE; GUIDELINES AB Background: Computed tomographic pulmonary angiography (CTPA) may improve detection of life-threatening pulmonary embolism (PE), but this sensitive test may have a downside: overdiagnosis and overtreatment (finding clinically unimportant emboli and exposing patients to harms from unnecessary treatment). Methods: To assess the impact of CTPA on national PE incidence, mortality, and treatment complications, we conducted a time trend analysis using the Nationwide Inpatient Sample and Multiple Cause-of-Death databases. We compared age-adjusted incidence, mortality, and treatment complications (in-hospital gastrointestinal tract or intracranial hemorrhage or secondary thrombocytopenia) of PE among US adults before (1993-1998) and after (1998-2006) CTPA was introduced. Results: Pulmonary embolism incidence was unchanged before CTPA (P =. 64) but increased substantially after CTPA (81% increase, from 62.1 to 112.3 per 100 000; P < .001). Pulmonary embolism mortality de-reduction, from 13.4 to 12.3 per 100 000; P < .001) than after (3% reduction, from 12.3 to 11.9 per 100 000; P=.02). Case fatality improved slightly before (8% decrease, from 13.2% to 12.1%; P=.02) and substantially after CTPA (36% decrease, from 12.1% to 7.8%; P < .001). Meanwhile, CTPA was associated with an increase in presumed complications of anticoagulation for PE: before CTPA, the complication rate was stable ( =.24), but after it increased by 71% (from 3.1 to 5.3 per 100 000; P < .001). Conclusions: The introduction of CTPA was associated with changes consistent with overdiagnosis: rising incidence, minimal change in mortality, and lower case fatality. Better technology allows us to diagnose more emboli, but to minimize harms of overdiagnosis we must learn which ones matter. C1 [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Schwartz, Lisa M.; Woloshin, Steven] US Dept Vet Affairs, VA Outcomes Grp, White River Jct, VT USA. [Wiener, Renda Soylemez; Schwartz, Lisa M.; Woloshin, Steven] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. [Wiener, Renda Soylemez; Schwartz, Lisa M.; Woloshin, Steven] Dartmouth Med Sch, Dept Med, Hanover, NH USA. [Wiener, Renda Soylemez; Schwartz, Lisa M.; Woloshin, Steven] Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA. RP Wiener, RS (reprint author), Boston Univ, Sch Med, Ctr Pulm, 72 E Concord St,R-304, Boston, MA 02118 USA. EM rwiener@bu.edu OI Wiener, Renda/0000-0001-7712-2135 FU Wiener; National Cancer Institute [K07 CA138772]; Department of Veterans Affairs; Robert Wood Johnson Foundation FX Wiener. Administrative, technical, and material support: Schwartz and Woloshin.; Dr Wiener is supported by a career development award through the National Cancer Institute (grant K07 CA138772) and the Department of Veterans Affairs. Drs Schwartz and Woloshin are supported by the Robert Wood Johnson Foundation and the Department of Veterans Affairs. NR 42 TC 206 Z9 207 U1 2 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 9 PY 2011 VL 171 IS 9 BP 831 EP 837 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 761QS UT WOS:000290413400007 PM 21555660 ER PT J AU Boockvar, KS Blum, S Kugler, A Livote, E Mergenhagen, KA Nebeker, JR Signor, D Sung, S Yeh, J AF Boockvar, Kenneth S. Blum, Sharon Kugler, Anne Livote, Elayne Mergenhagen, Kari A. Nebeker, Jonathan R. Signor, Daniel Sung, Soojin Yeh, Jessica TI Effect of Admission Medication Reconciliation on Adverse Drug Events From Admission Medication Changes SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID HOSPITAL ADMISSION; DISCHARGE; ERRORS C1 [Boockvar, Kenneth S.; Livote, Elayne; Signor, Daniel; Yeh, Jessica] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA. [Boockvar, Kenneth S.] Jewish Home Lifecare, New York, NY USA. [Boockvar, Kenneth S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Blum, Sharon] Brookdale Univ Hosp, Brooklyn, NY USA. [Kugler, Anne] Long Isl Univ, Coll Pharm, Brooklyn, NY USA. [Mergenhagen, Kari A.] VA Western New York Healthcare Syst, Buffalo, NY USA. [Nebeker, Jonathan R.] Univ Utah, Salt Lake City, UT USA. [Nebeker, Jonathan R.] Ctr Geriatr Res Educ & Clin, Salt Lake City, UT USA. [Sung, Soojin] Lutheran Med Ctr, Brooklyn, NY USA. RP Boockvar, KS (reprint author), James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 NR 9 TC 22 Z9 22 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 9 PY 2011 VL 171 IS 9 BP 860 EP 861 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 761QS UT WOS:000290413400015 PM 21555668 ER PT J AU Luo, C Ramachandran, D Ware, DL Ma, TS Clark, JW AF Luo, Chuan Ramachandran, Deepa Ware, David L. Ma, Tony S. Clark, John W., Jr. TI Modeling left ventricular diastolic dysfunction: classification and key in dicators SO THEORETICAL BIOLOGY AND MEDICAL MODELLING LA English DT Article ID PRESERVED EJECTION FRACTION; HEART-FAILURE; PULSUS PARADOXUS; INPUT IMPEDANCE; RELAXATION; PRESSURE; SYSTEM AB Background: Mathematical modeling can be employed to overcome the practical difficulty of isolating the mechanisms responsible for clinical heart failure in the setting of normal left ventricular ejection fraction (HFNEF). In a human cardiovascular respiratory system (H-CRS) model we introduce three cases of left ventricular diastolic dysfunction (LVDD): (1) impaired left ventricular active relaxation (IR-type); (2) increased passive stiffness (restrictive or R-type); and (3) the combination of both (pseudo-normal or PN-type), to produce HFNEF. The effects of increasing systolic contractility are also considered. Model results showing ensuing heart failure and mechanisms involved are reported. Methods: We employ our previously described H-CRS model with modified pulmonary compliances to better mimic normal pulmonary blood distribution. IR-type is modeled by changing the activation function of the left ventricle (LV), and R-type by increasing diastolic stiffness of the LV wall and septum. A 5(th)-order Cash-Karp Runge-Kutta numerical integration method solves the model differential equations. Results: IR-type and R-type decrease LV stroke volume, cardiac output, ejection fraction (EF), and mean systemic arterial pressure. Heart rate, pulmonary pressures, pulmonary volumes, and pulmonary and systemic arterial-venous O(2) and CO(2) differences increase. IR-type decreases, but R-type increases the mitral E/A ratio. PN-type produces the well-described, pseudo-normal mitral inflow pattern. All three types of LVDD reduce right ventricular (RV) and LV EF, but the latter remains normal or near normal. Simulations show reduced EF is partly restored by an accompanying increase in systolic stiffness, a compensatory mechanism that may lead clinicians to miss the presence of HF if they only consider LVEF and other indices of LV function. Simulations using the H-CRS model indicate that changes in RV function might well be diagnostic. This study also highlights the importance of septal mechanics in LVDD. Conclusion: The model demonstrates that abnormal LV diastolic performance alone can result in decreased LV and RV systolic performance, not previously appreciated, and contribute to the clinical syndrome of HF. Furthermore, alterations of RV diastolic performance are present and may be a hallmark of LV diastolic parameter changes that can be used for better clinical recognition of LV diastolic heart disease. C1 [Luo, Chuan; Ramachandran, Deepa; Clark, John W., Jr.] Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA. [Ware, David L.] Univ Texas Med Branch, Div Cardiol, Galveston, TX 77555 USA. [Ma, Tony S.] Baylor Coll Med, Houston, TX 77030 USA. [Ma, Tony S.] VA Med Ctr, Div Cardiol, Houston, TX 77030 USA. RP Clark, JW (reprint author), Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA. EM jwc@rice.edu FU Keck Center for Interdisciplinary Bioscience Training of the Gulf Coast Consortia [5T15LM07093] FX This work was partly supported by a training fellowship from the Keck Center for Interdisciplinary Bioscience Training of the Gulf Coast Consortia (NLM Grant No. 5T15LM07093). NR 22 TC 9 Z9 9 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4682 J9 THEOR BIOL MED MODEL JI Theor. Biol. Med. Model. PD MAY 9 PY 2011 VL 8 AR 14 DI 10.1186/1742-4682-8-14 PG 46 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 780SQ UT WOS:000291879700001 PM 21554684 ER PT J AU Martin, J Masri, J Cloninger, C Holmes, B Artinian, N Funk, A Ruegg, T Anderson, L Bashir, T Bernath, A Lichtenstein, A Gera, J AF Martin, Jheralyn Masri, Janine Cloninger, Cheri Holmes, Brent Artinian, Nicholas Funk, Alexander Ruegg, Teresa Anderson, Lauren Bashir, Tariq Bernath, Andrew Lichtenstein, Alan Gera, Joseph TI Phosphomimetic Substitution of Heterogeneous Nuclear Ribonucleoprotein A1 at Serine 199 Abolishes AKT-dependent Internal Ribosome Entry Site-transacting Factor (ITAF) Function via Effects on Strand Annealing and Results in Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitor Sensitivity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RNA-BINDING-PROTEINS; TRANS-ACTING FACTORS; MESSENGER-RNA; CYCLIN D1; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ENHANCED SENSITIVITY; GENE-EXPRESSION; TRANSLATION; PHOSPHORYLATION; PATHWAY AB The relative activity of the AKT kinase has been demonstrated to be a major determinant of sensitivity of tumor cells to mammalian target of rapamycin (mTOR) complex 1 inhibitors. Our previous studies have shown that the multifunctional RNA-binding protein heterogeneous nuclear ribonucleoprotein (hnRNP) A1 regulates a salvage pathway facilitating internal ribosome entry site (IRES)-dependent mRNA translation of critical cellular determinants in an AKT-dependent manner following mTOR inhibitor exposure. This pathway functions by stimulating IRES-dependent translation in cells with relatively quiescent AKT, resulting in resistance to rapamycin. However, the pathway is repressed in cells with elevated AKT activity, rendering them sensitive to rapamycin-induced G(1) arrest as a result of the inhibition of global eIF-4E-mediated translation. AKT phosphorylation of hnRNP A1 at serine 199 has been demonstrated to inhibit IRES-mediated translation initiation. Here we describe a phosphomimetic mutant of hnRNP A1 (S199E) that is capable of binding both the cyclin D1 and c-MYC IRES RNAs in vitro but lacks nucleic acid annealing activity, resulting in inhibition of IRES function in dicistronic mRNA reporter assays. Utilizing cells in which AKT is conditionally active, we demonstrate that overexpression of this mutant renders quiescent AKT-containing cells sensitive to rapamycin in vitro and in xenografts. We also demonstrate that activated AKT is strongly correlated with elevated Ser(P)(199)-hnRNP A1 levels in a panel of 22 glioblastomas. These data demonstrate that the phosphorylation status of hnRNP A1 serine 199 regulates the AKT-dependent sensitivity of cells to rapamycin and functionally links IRES-transacting factor annealing activity to cellular responses to mTOR complex 1 inhibition. C1 [Martin, Jheralyn; Masri, Janine; Cloninger, Cheri; Holmes, Brent; Artinian, Nicholas; Funk, Alexander; Ruegg, Teresa; Anderson, Lauren; Bashir, Tariq; Bernath, Andrew; Lichtenstein, Alan; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. [Lichtenstein, Alan; Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA. [Lichtenstein, Alan; Gera, Joseph] Univ Calif Los Angeles, Jonnson Comprehens Canc Ctr, Los Angeles, CA 90048 USA. [Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90048 USA. RP Gera, J (reprint author), 16111 Plummer Str 151,Bldg 1,Rm C111A, Sepulveda, CA 91343 USA. EM jgera@mednet.ucla.edu FU National Institutes of Health [R01CA111448, R01CA109312]; Department of Veterans Affairs; Department of Defense FX This work was supported, in whole or in part, by National Institutes of Health Grants R01CA111448 (to A. L.) and R01CA109312 (to J. G.). This work was also supported by funds from the Department of Veterans Affairs and the Department of Defense. NR 39 TC 5 Z9 5 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 6 PY 2011 VL 286 IS 18 DI 10.1074/jbc.M110.205096 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 756ON UT WOS:000290022800078 PM 21454539 ER PT J AU Mullen, TD Jenkins, RW Clarke, CJ Bielawski, J Hannun, YA Obeid, LM AF Mullen, Thomas D. Jenkins, Russell W. Clarke, Christopher J. Bielawski, Jacek Hannun, Yusuf A. Obeid, Lina M. TI Ceramide Synthase-dependent Ceramide Generation and Programmed Cell Death INVOLVEMENT OF SALVAGE PATHWAY IN REGULATING POSTMITOCHONDRIAL EVENTS SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RADIATION-INDUCED APOPTOSIS; LONGEVITY ASSURANCE GENE-1; LONG-CHAIN CERAMIDE; ACID SPHINGOMYELINASE; SPHINGOLIPID METABOLISM; BCL-2 FAMILY; RESPIRATORY-CHAIN; FUMONISIN B1; PROTEIN BAK; DNA-DAMAGE AB The sphingolipid ceramide has been widely implicated in the regulation of programmed cell death or apoptosis. The accumulation of ceramide has been demonstrated in a wide variety of experimental models of apoptosis and in response to a myriad of stimuli and cellular stresses. However, the detailed mechanisms of its generation and regulatory role during apoptosis are poorly understood. We sought to determine the regulation and roles of ceramide production in a model of ultraviolet light-C (UV-C)-induced programmed cell death. We found that UV-C irradiation induces the accumulation of multiple sphingolipid species including ceramide, dihydroceramide, sphingomyelin, and hexosylceramide. Late ceramide generation was also found to be regulated by Bcl-xL, Bak, and caspases. Surprisingly, inhibition of de novo synthesis using myriocin or fumonisin B1 resulted in decreased overall cellular ceramide levels basally and in response to UV-C, but only fumonisin B1 inhibited cell death, suggesting the presence of a ceramide synthase (CerS)-dependent, sphingosine-derived pool of ceramide in regulating programmed cell death. We found that this pool did not regulate the mitochondrial pathway, but it did partially regulate activation of caspase-7 and, more importantly, was necessary for late plasma membrane permeabilization. Attempting to identify the CerS responsible for this effect, we found that combined knockdown of CerS5 and CerS6 was able to decrease long-chain ceramide accumulation and plasma membrane permeabilization. These data identify a novel role for CerS and the sphingosine salvage pathway in regulating membrane permeability in the execution phase of programmed cell death. C1 [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Jenkins, Russell W.; Clarke, Christopher J.; Bielawski, Jacek; Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,Rm 603 STRB,MSC 779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health, NIEHS [5T32ES012878]; NIEHS [1 F30 ES016975-01]; NCI [R01 AG016583, P01 CA097132]; National Center for Research Resources [GM08716, C06 RR018823]; American Heart Association [081509E]; Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC FX This work was supported, in whole or in part, by National Institutes of Health Grant 5T32ES012878 from the NIEHS (through the Medical University of South Carolina (MUSC) Department of Pharmaceutical Sciences training program in environmental stress signaling) and Ruth L. Kirschstein National Research Service Award 1 F30 ES016975-01 from the NIEHS (to T. D. M.), Grant R01 AG016583 (to L. M. O.), Grant P01 CA097132 from the NCI (to Y. A. H.), Medical Scientist Training Program Grant GM08716 (to R. W. J.), and Grant C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources (for the HPLC/MS analysis at the MUSC Lipidomics Core Facility). This work was also supported by American Heart Association Predoctoral Fellowship 081509E (to R. W. J.) and in part by a Method to Extend Research in Time award (to L. M. O.) from the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC. NR 75 TC 44 Z9 46 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 6 PY 2011 VL 286 IS 18 DI 10.1074/jbc.M111.230870 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 756ON UT WOS:000290022800033 PM 21388949 ER PT J AU Kumar, S Alam, MN Rai, S Bashir, T McGinty, D Szymusiak, R AF Kumar, S. Alam, M. N. Rai, S. Bashir, T. McGinty, D. Szymusiak, R. TI CENTRAL NERVOUS SYSTEM SITES OF THE SLEEP PROMOTING EFFECTS OF ESZOPICLONE IN RATS SO NEUROSCIENCE LA English DT Article DE GABA-A receptors; hypnotic medication; hypocretin; orexin; preoptic hypothalamus ID WAKING DISCHARGE PATTERNS; MEDIAN PREOPTIC NUCLEUS; FOS PROTEIN EXPRESSION; GABA(A) RECEPTORS; PRIMARY INSOMNIA; C-FOS; LATERAL HYPOTHALAMUS; BEHAVIORAL STATE; AREA NEURONS; WAKEFULNESS AB We examined the effects of eszopiclone (ESZ), a GABA-A receptor agonist in current clinical use as a hypnotic medication, on the activity of subcortical wake- and sleep-active neuronal populations in the rat brain. Sleep-wake states were quantified after i.p. injections of ESZ (3 and 10 mg/kg) or vehicle administered early in the dark phase, when rats are spontaneously awake. Rats were euthanized 2 h post-injection and brain tissue was processed for c-Fos protein immunoreactivity (IR) and for neurotransmitter markers. ESZ at 3 and 10 mg/kg increased time spent in non-rapid-eye-movement (nonREM) sleep, but had no significant effect on Fos-IR in GABAergic neurons in the preoptic hypothalamus that normally express c-Fos during sleep. Among wake-active cell types examined, Fos-IR in hypocretin (HCRT) neurons in the perifornical lateral hypothalamus (LH) was reduced following 3 and 10 mg/kg ESZ. At 10 mg/kg, ESZ suppressed Fos-IR in cholinergic and noncholinergic neurons in the basal forebrain and in serotonergic and nonserotonegic neurons in the dorsal raphe. Having determined that HCRT neurons were responsive to the low dose of systemic ESZ, we unilaterally perfused ESZ directly into the LH of awake rats, using reverse microdialysis. Perfusion of ESZ at 50 mu M into the LH for 2 h suppressed waking-related Fos-IR in HCRT neurons, but not in nonHCRT neurons ipsilateral to the dialysis probe. Bilateral LH perfusion of ESZ at 50 mu M for 2 h early in the dark phase significantly increased sleep. These findings demonstrate that sleep induction by ESZ does not require activation of GABAergic sleep-regulatory neurons in the preoptic hypothalamus, and identify suppression of HCRT neurons in the LH and suppression of basal forebrain and dorsal raphe neurons as potential mechanisms underlying the sleep-promoting effects of ESZ. Published by Elsevier Ltd on behalf of IBRO. C1 [Kumar, S.; Alam, M. N.; Rai, S.; Bashir, T.; McGinty, D.; Szymusiak, R.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Alam, M. N.; McGinty, D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Szymusiak, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Szymusiak, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM rszym@ucla.edu FU Department of Veterans Affairs; Sepracor, Inc. FX Supported by the Department of Veterans Affairs and by Sepracor, Inc. NR 53 TC 8 Z9 9 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD MAY 5 PY 2011 VL 181 BP 67 EP 78 DI 10.1016/j.neuroscience.2011.03.006 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 751HB UT WOS:000289607000006 PM 21382446 ER PT J AU Epstein, AJ Polsky, D Yang, FF Yang, L Groeneveld, PW AF Epstein, Andrew J. Polsky, Daniel Yang, Feifei Yang, Lin Groeneveld, Peter W. TI Coronary Revascularization Trends in the United States, 2001-2008 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CARDIOVASCULAR DATA REGISTRY; AMERICAN-COLLEGE; ELUTING STENTS; THROMBOSIS AB Context Coronary revascularization is among the most common hospital-based major interventional procedures performed in the United States. It is uncertain how new revascularization technologies, new clinical evidence from trials, and updated clinical guidelines have influenced the volume and distribution of coronary revascularizations over the past decade. Objective To examine national time trends in the rates and types of coronary revascularizations. Design, Setting, and Patients A serial cross-sectional study with time trends of patients undergoing coronary artery bypass graft (CABG) surgery or percutaneous coronary interventions (PCIs) between 2001 and 2008 at US hospitals in the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample, which reports inpatient coronary revascularizations. These data were supplemented by Medicare outpatient hospital claims. Main Outcome Measures Annual procedure rates of coronary revascularizations, CABG surgery, and PCI. Results A 15% decrease (P<.001) in the annual rate of coronary revascularizations was observed from 2001-2002 to 2007-2008. The annual CABG surgery rate decreased steadily from 1742 (95% confidence interval [CI], 1663-1825) CABG surgeries per million adults per year in 2001-2002 to 1081 (95% CI, 1032-1133) CABG surgeries per million adults per year in 2007-2008 (P<.001), but PCI rates did not significantly change (3827 [95% CI, 3578-4092] PCI per million adults per year in 2001-2002 vs 3667 [95% CI, 3429-3922] PCI per million adults per year in 2007-2008, P=.74). Between 2001 and 2008, the number of hospitals in the Nationwide Inpatient Sample providing CABG surgery increased by 12% (212 in 2001 vs 241 in 2008, P=.03), and the number of PCI hospitals increased by 26% (246 in 2001 vs 331 in 2008, P<.001). The median CABG surgery caseload per hospital decreased by 28% (median [interquartile range], 253 [161-458] in 2001 vs 183 [98-292] in 2008; P<.001) and the number of CABG surgery hospitals providing fewer than 100 CABG surgeries per year increased from 23 (11%) in 2001 to 62 (26%) in 2008 (P<.001). Conclusions In US hospitals between 2001 and 2008, a substantial decrease in CABG surgery utilization rates was observed, but PCI utilization rates remained unchanged. JAMA. 2011;305(17):1769-1776 www.jama.com C1 [Epstein, Andrew J.; Polsky, Daniel; Yang, Feifei; Yang, Lin; Groeneveld, Peter W.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Epstein, Andrew J.; Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Epstein, Andrew J.; Polsky, Daniel; Groeneveld, Peter W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Groeneveld, PW (reprint author), Univ Penn, Sch Med, Dept Med, 1229 Blockley Hall,423 Serv Dr, Philadelphia, PA 19104 USA. EM petergro@mail.med.upenn.edu FU National Heart, Lung, and Blood Institute [1R01HL086919]; Agency for Healthcare Research and Quality [1R01HS018403]; Pennsylvania Department of Health FX This work was supported by grants 1R01HL086919 from the National Heart, Lung, and Blood Institute and 1R01HS018403 from the Agency for Healthcare Research and Quality. This work was also funded in part under a grant from the Pennsylvania Department of Health. NR 29 TC 209 Z9 216 U1 1 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 4 PY 2011 VL 305 IS 17 BP 1769 EP 1776 DI 10.1001/jama.2011.551 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 758HZ UT WOS:000290156200017 PM 21540420 ER PT J AU Kar, UK Srivastava, MK Andersson, A Baratelli, F Huang, M Kickhoefer, VA Dubinett, SM Rome, LH Sharma, S AF Kar, Upendra K. Srivastava, Minu K. Andersson, Asa Baratelli, Felicita Huang, Min Kickhoefer, Valerie A. Dubinett, Steven M. Rome, Leonard H. Sharma, Sherven TI Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth SO PLOS ONE LA English DT Article ID VAULT RIBONUCLEOPROTEIN-PARTICLES; BRONCHOALVEOLAR CELL-CARCINOMA; MODIFIED DENDRITIC CELLS; REGULATORY T-CELLS; TUMOR-BEARING MICE; BONE-MARROW CELLS; SUPPRESSOR-CELLS; ANTITUMOR RESPONSES; MYELOID CELLS; IMMUNITY AB Background: Based on our preclinical findings, we are assessing the efficacy of intratumoral injection of dendritic cells (DC) transduced with an adenoviral vector expressing the secondary lymphoid chemokine (CCL21) gene (Ad-CCL21-DC) in a phase I trial in advanced non-small cell lung cancer (NSCLC). While this approach shows immune enhancement, the preparation of autologous DC for CCL21 genetic modification is cumbersome, expensive and time consuming. We are evaluating a non-DC based approach which utilizes vault nanoparticles for intratumoral CCL21 delivery to mediate antitumor activity in lung cancer. Principal Findings: Here we describe that vault nanocapsule platform for CCL21 delivery elicits antitumor activity with inhibition of lung cancer growth. Vault nanocapsule packaged CCL21 (CCL21-vaults) demonstrated functional activity in chemotactic and antigen presenting activity assays. Recombinant vaults impacted chemotactic migration of T cells and this effect was predominantly CCL21 dependent as CCL21 neutralization abrogated the CCL21 mediated enhancement in chemotaxis. Intratumoral administration of CCL21-vaults in mice bearing lung cancer enhanced leukocytic infiltrates (CXCR3(+)T, CCR7(+)T, IFN gamma(+)T lymphocytes, DEC205(+) DC), inhibited lung cancer tumor growth and reduced the frequencies of immune suppressive cells [myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), IL-10 T cells]. CCL21-vaults induced systemic antitumor responses by augmenting splenic T cell lytic activity against parental tumor cells. Significance: This study demonstrates that the vault nanocapsule can efficiently deliver CCL21 to sustain antitumor activity and inhibit lung cancer growth. The vault nanocapsule can serve as an "off the shelf" approach to deliver antitumor cytokines to treat a broad range of malignancies. C1 [Kar, Upendra K.; Kickhoefer, Valerie A.; Rome, Leonard H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA. [Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Srivastava, Minu K.; Andersson, Asa; Baratelli, Felicita; Huang, Min; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Srivastava, Minu K.; Andersson, Asa; Huang, Min; Dubinett, Steven M.; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA USA. [Kickhoefer, Valerie A.; Dubinett, Steven M.; Rome, Leonard H.; Sharma, Sherven] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA. RP Kar, UK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA. EM sdubinett@mednet.ucla.edu; lrome@mednet.ucla.edu; ssharma@mednet.ucla.edu RI Rome, Leonard/E-8786-2016 OI Rome, Leonard/0000-0002-1236-2063; Kickhoefer, Valerie/0000-0002-0048-0580 FU University of California [15RT-0207]; Jonnson Comprehensive Cancer Center; National Institutes of Health [RO1 CA95686, RO1 CAl26944] FX This work was supported by a University of California Discovery Grant (to LHR and VAK) a Jonnson Comprehensive Cancer Center Fellowship to UKK) and by National Institutes of Health Grants (RO1 CA95686 and RO1 CAl26944), University of California Los Angeles Lung Cancer Program, Department of Veterans Affairs Medical Research Funds and Tobacco Related Disease Program Award Program of University of California (15RT-0207). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 40 Z9 41 U1 1 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 3 PY 2011 VL 6 IS 5 AR e18758 DI 10.1371/journal.pone.0018758 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 759EM UT WOS:000290223500003 PM 21559281 ER PT J AU Cho, CS Kooby, DA Schmidt, CM Nakeeb, A Bentrem, DJ Merchant, NB Parikh, AA Martin, RCG Scoggins, CR Ahmad, SA Kim, HJ Hamilton, N Hawkins, WG Weber, SM AF Cho, Clifford S. Kooby, David A. Schmidt, C. Max Nakeeb, Attila Bentrem, David J. Merchant, Nipun B. Parikh, Alexander A. Martin, Ronald C. G. Scoggins, Charles R. Ahmad, Syed A. Kim, Hong J. Hamilton, Nicholas Hawkins, William G. Weber, Sharon M. TI Laparoscopic Versus Open Left Pancreatectomy Can Preoperative Factors Indicate the Safer Technique? SO ANNALS OF SURGERY LA English DT Article ID HIGH-RISK SURGERY; DISTAL PANCREATECTOMY; SPLENIC PRESERVATION; SINGLE INSTITUTION; FISTULA; MORTALITY; OUTCOMES; RATES AB Background: Laparoscopic left pancreatectomy (LLP) is associated with favorable outcomes compared with open left pancreatectomy (OLP). However, it is unclear if the risk factors associated with operative morbidity differ between these two techniques. Guidelines for determining which patients should undergo OLP versus LLP do not exist. Methods: A multi-institutional analysis of OLP and LLP performed in 9 academic medical centers was undertaken. LLP cases were defined in an intent-to-treat manner. Perioperative variables were analyzed to identify factors associated with complications and pancreatic fistulae after OLP and LLP. In addition, complication and fistula rates for patients undergoing OLP and LLP were compared in matched cohorts to determine if one approach resulted in superior outcomes over the other. Results: Six hundred and ninety-three left pancreatectomy cases (439 OLP, 254 LLP) were analyzed. OLP and LLP cases were similar with respect to patient age and American Society of Anesthesiologists score. Body mass index (BMI) was higher in patients undergoing LLP. OLP was more often performed for adenocarcinoma and larger tumors, resulted in longer resected specimen lengths, and more commonly involved concomitant splenectomy. Estimated blood loss was higher and operative times were longer during OLP. On multivariate analysis, variables associated with major complications and clinically significant fistulae differed between OLP and LLP. Patients with body mass index <= 27, without adenocarcinoma, and with pancreatic specimen length <= 8.5 cm had significantly higher rates of significant fistulae after OLP than after LLP; in contrast, no preoperatively evaluable variables were associated with a higher likelihood of significant fistula after LLP versus OLP. Conclusions: Risk factors for complications and pancreatic fistulae after left pancreatectomy differ when open versus laparoscopic techniques are employed. Preoperative characteristics may identify cohorts of patients who will benefit more from LLP, and no patient cohorts had higher postoperative complication rates after LLP than OLP. These observations suggest that LLP may be the operative procedure of choice for most patients with left-sided pancreatic lesions; a more definitive prospective and randomized comparison may be warranted. C1 [Cho, Clifford S.] Univ Wisconsin, Sch Med & Publ Hlth, Sect Surg Oncol, Cent Pancreas Consortium,Clin Sci Ctr K4 752, Madison, WI 53792 USA. [Cho, Clifford S.; Weber, Sharon M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Cho, Clifford S.; Weber, Sharon M.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. [Kooby, David A.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA. [Schmidt, C. Max; Nakeeb, Attila] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN USA. [Bentrem, David J.] Northwestern Univ, Feinberg Sch Med, Jesse Brown Vet Affairs Med Ctr, Dept Surg, Chicago, IL 60611 USA. [Merchant, Nipun B.; Parikh, Alexander A.] Vanderbilt Univ, Dept Surg, Sch Med, Nashville, TN 37240 USA. [Martin, Ronald C. G.; Scoggins, Charles R.] Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA. [Ahmad, Syed A.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Kim, Hong J.] Univ N Carolina, Sch Med, Dept Surg, Chapel Hill, NC USA. [Hamilton, Nicholas; Hawkins, William G.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. RP Cho, CS (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Sect Surg Oncol, Cent Pancreas Consortium,Clin Sci Ctr K4 752, 600 Highland Ave, Madison, WI 53792 USA. EM cho@surgery.wisc.edu NR 18 TC 46 Z9 47 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAY PY 2011 VL 253 IS 5 BP 975 EP 980 DI 10.1097/SLA.0b013e3182128869 PG 6 WC Surgery SC Surgery GA 749ZD UT WOS:000289510600020 PM 21394014 ER PT J AU Ramirez, LM Cirnigliaro, CM Asselin, P Swaby, S Wielopolski, L Spungen, AM Bauman, WA AF Ramirez, L. M. Cirnigliaro, C. M. Asselin, P. Swaby, S. Wielopolski, L. Spungen, A. M. Bauman, W. A. TI Comparison of Regional and Total Body Skeletal Muscle Mass by BIA, DEXA, and Lower Extremity PBK in Persons with Spinal Cord Injury SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Meeting Abstract CT 9th International Symposium on In Vivo Body Composition Studies CY MAY, 2011 CL Hangzhou, PEOPLES R CHINA C1 [Ramirez, L. M.; Asselin, P.; Swaby, S.; Spungen, A. M.; Bauman, W. A.] James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences Spinal Co, Bronx, NY USA. [Cirnigliaro, C. M.] Kessler Inst Rehabil, W Orange, NJ USA. [Wielopolski, L.] Brookhaven Natl Lab, Upton, NY 11973 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD MAY PY 2011 VL 35 SU 2 BP S61 EP S61 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 836UZ UT WOS:000296141100204 ER PT J AU Walter, ND Rice, PL Redente, EF Kauvar, EF Lemond, L Aly, T Wanebo, K Chan, ED AF Walter, Nicholas D. Rice, Pamela L. Redente, Elizabeth F. Kauvar, Emily F. Lemond, Lisa Aly, Theresa Wanebo, Kevin Chan, Edward D. TI Wound Healing after Trauma May Predispose to Lung Cancer Metastasis Review of Potential Mechanisms SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Review DE inflammatory oncotaxis; metastasis; lung cancer; tumor-associated macrophages; trauma ID TUMOR-ASSOCIATED MACROPHAGES; INFLAMMATORY ONCOTAXIS; SUPPRESSOR-CELLS; BREAST-CANCER; SURGERY; GROWTH; ANGIOGENESIS; ACTIVATION; MICROENVIRONMENT; LOCALIZATION AB Inflammatory oncotaxis, the phenomenon in which mechanically injured tissues are predisposed to cancer metastases, has been reported for a number of tumor types, but not previously for histologically proven lung cancer. We review clinical and experimental evidence and mechanisms that may underlie inflammatory oncotaxis, and provide illustrative examples of two patients with squamous cell carcinoma of the lung who developed distant, localized metastatic disease at sites of recent physical trauma. Trauma may predispose to metastasis through two distinct, but not mutually exclusive, mechanisms: (1) physical trauma induces tissue damage and local inflammation, creating a favorable environment that is permissive for seeding of metastatic cells from distant sites; and/or (2) micrometastatic foci are already present at the time of physical injury, and trauma initiates changes in the micro-environment that stimulate the proliferation of the metastatic cells. Further exploration of post-traumatic inflammatory oncotaxis may elucidate fundamental mechanisms of metastasis and could provide novel strategies to prevent cancer metastasis C1 [Chan, Edward D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Redente, Elizabeth F.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA. [Chan, Edward D.] Natl Jewish Hlth, Cell Biol Program, Denver, CO 80206 USA. [Walter, Nicholas D.; Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Walter, Nicholas D.; Rice, Pamela L.; Kauvar, Emily F.; Lemond, Lisa; Chan, Edward D.] Univ Colorado, Dept Med, Denver, CO USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Div Resp Med, Denver, CO USA. [Rice, Pamela L.] Denver Vet Affairs Med Ctr, Div Gastroenterol, Denver, CO USA. [Aly, Theresa] Denver Vet Affairs Med Ctr, Dept Pathol, Denver, CO USA. [Wanebo, Kevin] Denver Vet Affairs Med Ctr, Dept Radiol, Denver, CO USA. RP Chan, ED (reprint author), Natl Jewish Hlth, Dept Med, D509,Neustadt Bldg,1,400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 41 TC 21 Z9 22 U1 0 U2 7 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1044-1549 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD MAY PY 2011 VL 44 IS 5 BP 591 EP 596 DI 10.1165/rcmb.2010-0187RT PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 808AO UT WOS:000293945500002 PM 21177982 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Contrast-Induced Acute Kidney Injury: Short- and Long-Term Implications SO SEMINARS IN NEPHROLOGY LA English DT Review DE Acute kidney injury; contrast media; angiography; outcomes ID RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS CORONARY INTERVENTION; RADIOCONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; INTRAVENOUS N-ACETYLCYSTEINE; HIGH-RISK PATIENTS; ISOTONIC SODIUM-BICARBONATE; CARDIAC-CATHETERIZATION; DIABETES-MELLITUS; INDUCED NEPHROTOXICITY C1 [Weisbord, Steven D.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 FU VA Health Services [RCD 03-176-2] FX The views expressed in this article are those of the authors and do not necessarily represent the views of the United Slates Department of Veterans Affairs. Dr Weisbord is supported by a VA Health Services Research and Development Career Development Transition Award (RCD 03-176-2) NR 121 TC 30 Z9 32 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0270-9295 J9 SEMIN NEPHROL JI Semin. Nephrol. PD MAY PY 2011 VL 31 IS 3 BP 300 EP 309 DI 10.1016/j.semnephrol.2011.05.009 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 801KE UT WOS:000293436800009 PM 21784279 ER PT J AU Haass, M Kitzman, DW Anand, IS Miller, A Zile, MR Massie, BM Carson, PE AF Haass, Markus Kitzman, Dalane W. Anand, Inder S. Miller, Alan Zile, Michael R. Massie, Barry M. Carson, Peter E. TI Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial SO CIRCULATION-HEART FAILURE LA English DT Article DE heart failure; body mass index; diastolic dysfunction; obesity; prognosis ID MORBIDITY CHARM PROGRAM; OBESITY PARADOX; WEIGHT-LOSS; RISK-FACTOR; MORTALITY; PROGNOSIS; CANDESARTAN; REDUCTION; COMMUNITY; INSIGHTS AB Background-Obesity is a major risk factor for incident heart failure (HF). Paradoxically, in HF with reduced left ventricular ejection fraction (HFREF), a high body mass index (BMI) appears to be beneficial. Approximately 50% of HF patients have a preserved left ventricular ejection fraction (HFPEF). However, there are few data regarding the relationship between BMI and outcomes in HFPEF. Methods and Results-Baseline characteristics and cardiovascular outcomes were assessed in the 4109 patients (mean age, 72 years; mean follow-up, 49.5 months) in the Irbesartan in HF with Preserved Ejection Fraction (I-PRESERVE) trial. Based on the BMI distribution, 5 BMI categories were defined: <23.5, 23.5 to 26.4, 26.5 to 30.9, 31 to 34.9, and >= 35 kg/m(2). Most patients (71%) had a BMI >= 26.5, 21% had a BMI between 23.5 and 26.4, and 8% had a BMI <23.5 kg/m(2). Patients with higher BMI were younger, more often women, and more likely to have hypertension and diabetes and higher left ventricular ejection fraction. Patients with BMI of 26.5 to 30.9 kg/m2 had the lowest rate for the primary composite outcome (death or cardiovascular hospitalization) and were used as reference group. After adjustment for 21 risk variables including age, sex, and N-terminal pro-brain natriuretic peptide, the hazard ratio for the primary outcome was increased in patients with BMI <23.5 (hazard ratio, 1.27; 95% confidence interval, 1.04 to 1.56; P=0.019) and in those with BMI >= 35 kg/m(2) (hazard ratio, 1.27; 95% confidence interval, 1.06 to 1.52; P=0.011) compared with the referent group. A similar relationship was found for all-cause mortality and for HF hospitalization. Conclusions-Obesity is common in HFPEF patients and is accompanied by multiple differences in clinical characteristics. Independent of other key prognostic variables, there was a U-shaped relationship, with the greatest rate of adverse outcomes in the lowest and highest BMI categories. C1 [Haass, Markus] Theresienkrankenhaus, Dept Cardiol, D-68165 Mannheim, Germany. [Kitzman, Dalane W.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Anand, Inder S.] VA Med Ctr, Minneapolis, MN USA. [Miller, Alan] Univ Florida, Jacksonville, FL USA. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Carson, Peter E.] Washington VAMC, Washington, DC USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. RP Haass, M (reprint author), Theresienkrankenhaus, Dept Cardiol, Bassermannstr 1, D-68165 Mannheim, Germany. EM m.haass@theresienkrankenhaus.de FU Bristol-Myers Squibb; Sanofi-Aventis; National Institutes of Health [37AG18915, P30AG21222] FX The I-PRESERVE trial was funded by Bristol-Myers Squibb and Sanofi-Aventis, as was the present subanalysis. The study was also supported in part by National Institutes of Health grants 37AG18915 and P30AG21222 (Dr Kitzman). NR 27 TC 53 Z9 58 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAY PY 2011 VL 4 IS 3 BP 324 EP 331 DI 10.1161/CIRCHEARTFAILURE.110.959890 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 794BN UT WOS:000292869800017 PM 21350053 ER PT J AU Bailey, RR Stuckey, DR Norman, BA Duggan, AP Bacon, KM Connor, DL Lee, I Muder, RR Lee, BY AF Bailey, Rachel R. Stuckey, Dianna R. Norman, Bryan A. Duggan, Andrew P. Bacon, Kristina M. Connor, Diana L. Lee, Ingi Muder, Robert R. Lee, Bruce Y. TI Economic Value of Dispensing Home-Based Preoperative Chlorhexidine Bathing Cloths to Prevent Surgical Site Infection SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID COLONY-STIMULATING FACTOR; HEPATITIS-B VACCINATION; CHRONIC-RENAL-FAILURE; HEMODIALYSIS-PATIENTS; COST; ADJUVANT; SHOWER; MRSA AB OBJECTIVE. To estimate the economic value of dispensing preoperative home-based chlorhexidine bathing cloth kits to orthopedic patients to prevent surgical site infection (SSI). METHODS. A stochastic decision-analytic computer simulation model was developed from the hospital's perspective depicting the decision of whether to dispense the kits preoperatively to orthopedic patients. We varied patient age, cloth cost, SSI-attributable excess length of stay, cost per bed-day, patient compliance with the regimen, and cloth antimicrobial efficacy to determine which variables were the most significant drivers of the model's outcomes. RESULTS. When all other variables remained at baseline and cloth efficacy was at least 50%, patient compliance only had to be half of baseline (baseline mean, 15.3%; range, 8.23%-20.0%) for chlorhexidine cloths to remain the dominant strategy (ie, less costly and providing better health outcomes). When cloth efficacy fell to 10%, 1.5 times the baseline bathing compliance also afforded dominance of the preoperative bath. CONCLUSIONS. The results of our study favor the routine distribution of bathing kits. Even with low patient compliance and cloth efficacy values, distribution of bathing kits is an economically beneficial strategy for the prevention of SSI. Infect Control Hosp Epidemiol 2011;32(5):465-471 C1 [Bailey, Rachel R.] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Publ Hlth Computat & Operat Res Grp, Pittsburgh, PA 15213 USA. [Bailey, Rachel R.; Stuckey, Dianna R.; Bacon, Kristina M.; Connor, Diana L.; Lee, Bruce Y.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Bailey, Rachel R.; Stuckey, Dianna R.; Bacon, Kristina M.; Connor, Diana L.; Lee, Bruce Y.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Norman, Bryan A.; Duggan, Andrew P.] Univ Pittsburgh, Dept Ind Engn, Pittsburgh, PA 15213 USA. [Lee, Ingi] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Lee, Ingi] Univ Penn, Sch Med, Ctr Evidence Based Practice, Philadelphia, PA 19104 USA. [Muder, Robert R.] Vet Affairs Pittsburgh Healthcare Syst, Div Infect Dis, Pittsburgh, PA USA. RP Bailey, RR (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Publ Hlth Computat & Operat Res Grp, 3520 Forbes Ave,1st Floor, Pittsburgh, PA 15213 USA. EM RRB16@pitt.edu OI Norman, Bryan/0000-0001-6488-7788; Slayton, Rachel/0000-0003-4699-8040 FU National Institute of General Medical Sciences Models of Infectious Disease Agent Study [1U54GM088491-0109]; Pennsylvania Department of Health [4100047864] FX This study was supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (grant 1U54GM088491-0109) and the Pennsylvania Department of Health (grant 4100047864). NR 27 TC 10 Z9 11 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY PY 2011 VL 32 IS 5 BP 465 EP 471 DI 10.1086/659763 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 791GE UT WOS:000292652100008 PM 21515977 ER PT J AU Williams, BA Hough, KA Tsui, BYK Ibinson, JW Gold, MS Gebhart, GF AF Williams, Brian A. Hough, Karen A. Tsui, Becky Y. K. Ibinson, James W. Gold, Michael S. Gebhart, G. F. TI Neurotoxicity of Adjuvants Used in Perineural Anesthesia and Analgesia in Comparison With Ropivacaine SO REGIONAL ANESTHESIA AND PAIN MEDICINE LA English DT Article ID BRACHIAL-PLEXUS BLOCK; LOCAL-ANESTHETICS; PERIPHERAL-NERVE; REGIONAL ANESTHESIA; POSTOPERATIVE ANALGESIA; BUPIVACAINE; CLONIDINE; PROLONGS; BUPRENORPHINE; DEXAMETHASONE AB Background and Objectives: Clonidine, buprenorphine, dexamethasone, and midazolam (C, B, D, M) have been used to prolong perineural local anesthesia in the absence of data on the influence of these adjuvants on local anesthetic-induced neurotoxicity. Therefore, the impact of these adjuvants on ropivacaine (R)-induced death of isolated sensory neurons was assessed. Methods: The trypan blue exclusion assay was used to assess death of sensory neurons isolated from adult male Sprague-Dawley rats. Drugs were applied, alone or in combination, for 2 or 24 hrs at 37 degrees C. Results: Neuronal viability was halved by 24-hr exposure to R (2.5 mg/mL), far exceeding the neurotoxicity of C, B, D, or M (at 2-100 times estimated clinical concentrations). Plain M at twice the estimated clinical concentration produced a small but significant increase in neurotoxicity at 24 hrs. After 2-hr exposure, high concentrations of B, C, and M increased the neurotoxicity of R; the combination of R + M killed more than 90% of neurons. Estimated clinical concentrations of C + B (plus 66 mu g/mL D) had no influence on (i) R-induced neurotoxicity, (ii) the increased neurotoxicity associated with the combination of R + M, or (iii) the neurotoxicity associated with estimated clinical concentrations of M. There was increased neurotoxicity with 133 mu g/mL D combined with R + C + B. Conclusions: Results with R reaffirm the need to identify ways to mitigate local anesthetic-induced neurotoxicity. While having no protective effect on R-induced neurotoxicity in vitro, future research with adjuvants should address if the C + B + D combination can enable reducing R concentrations needed to achieve equianalgesia (and/or provide equal or superior duration, in preclinical in vivo models). C1 [Williams, Brian A.] Univ Pittsburgh, Dept Anesthesiol, Ctr Pain Res, Sch Med, Pittsburgh, PA 15261 USA. [Williams, Brian A.; Ibinson, James W.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Williams, BA (reprint author), Univ Pittsburgh, Dept Anesthesiol, Ctr Pain Res, Sch Med, Pittsburgh, PA 15261 USA. EM williamsba@anes.upmc.edu OI Ibinson, James/0000-0002-5525-5225; Gold, Michael/0000-0002-2083-6206 FU National Institutes of Health [DA025146, RR024153, T32GM075770, NS063010]; Office of the Senior Vice Chancellor for the Health Sciences, University of Pittsburgh; B. Braun USA FX This research is supported by National Institutes of Health grants DA025146, RR024153 (to B. A. W.), T32GM075770 (to J.W.I.), and NS063010 (to M. S. G.), as well as a special grant from the Office of the Senior Vice Chancellor for the Health Sciences, University of Pittsburgh. Dr. Williams received consulting fees from B. Braun USA (2010); B. Braun USA was not involved with the design or conduct of this study, and this article or its contents have not been made available to B. Braun USA before publication. NR 23 TC 66 Z9 66 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-7339 J9 REGION ANESTH PAIN M JI Region. Anesth. Pain Med. PD MAY-JUN PY 2011 VL 36 IS 3 BP 225 EP 230 DI 10.1097/AAP.0b013e3182176f70 PG 6 WC Anesthesiology SC Anesthesiology GA 792TZ UT WOS:000292774600006 PM 21519308 ER PT J AU Brizendine, KD Vishin, S Baddley, JW AF Brizendine, Kyle D. Vishin, Sonia Baddley, John W. TI Antifungal prophylaxis in solid organ transplant recipients SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Review DE amphotericin B; antifungal prophylaxis; fluconazole; heart transplant; itraconazole; kidney transplant; liver transplant; lung transplant; solid organ transplantation; voriconazole ID INVASIVE FUNGAL-INFECTIONS; LIPOSOMAL AMPHOTERICIN-B; ORTHOTOPIC LIVER-TRANSPLANTATION; RISK-FACTORS; LUNG TRANSPLANTATION; ITRACONAZOLE PROPHYLAXIS; ASPERGILLUS INFECTION; HEART-TRANSPLANTATION; CONTROLLED TRIAL; LIPID COMPLEX AB Solid organ transplantation is life saving for thousands of patients worldwide with end-stage organ failure, but post-transplantation invasive fungal infections (IFIs) remain a significant cause of morbidity and mortality. To improve patient outcomes, investigators have explored various strategies of prevention, including the use of antifungal prophylaxis with both systemic and topical nonabsorbable agents. Often, the strategy is to identify those patients at highest risk for IFIs who would be expected to derive the most benefit from antifungal prophylaxis. Currently, data support the use of antifungal prophylaxis in liver, lung, small bowel and pancreas transplant recipients. By understanding the epidemiology of post-transplant IFIs and antifungal adverse effects, clinicians may target antifungal prophylaxis more optimally. Herein, we review antifungal prophylaxis with systemic agents among solid organ transplant recipients. C1 [Brizendine, Kyle D.; Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Vishin, Sonia] Univ Alabama, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35233 USA. RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, THT 229,1900 Univ Blvd, Birmingham, AL 35294 USA. EM jbaddley@uab.edu FU Pfizer FX John W Baddley received a research grant from Pfizer. He also provides consulting for Pfizer and Merck. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 66 TC 3 Z9 3 U1 1 U2 3 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD MAY PY 2011 VL 9 IS 5 BP 571 EP 581 DI 10.1586/ERI.11.29 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 779DT UT WOS:000291759000016 PM 21609268 ER PT J AU Duszak, RS Duszak, R AF Duszak, Robert S. Duszak, Richard, Jr. TI Adverse action reports against optometrists: Perspectives from the National Practitioner Data Bank over 18 years SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION LA English DT Article DE National Practitioner Data Bank; Optometrist; Adverse action; Professional misconduct ID PATIENT SAFETY AB PURPOSE: The aim of this analysis is to describe characteristics of National Provider Data Bank (NPDB) adverse action reports against optometrists. METHODS: NPDB public use files were analyzed for details of reported optometrist adverse actions from 1991 through 2008. Types of actions, basis for actions, and reporting source were identified, along with geographic and demographic data. RESULTS: Between 1991 and 2008, a total of 216 adverse actions against optometrists were recorded nationally. Exclusion from Medicare or another government program accounted for 92% of all reports; the remaining 8% were related to unfavorable privileging decisions. Most cases with identifiable explanations were the result of either defaults on student loans (55%) or charges of fraud and abuse (39%). Over two thirds of all reports originated in just 12 states, and 74% involved younger optometrists (age 30 to 49). Repeat offenses were reported for 38% of sanctioned optometrists. CONCLUSION: NPDB reported adverse actions against optometrists are infrequent but most commonly involve exclusion from Medicare or similar government programs. Student loan default, particularly by younger optometrists, is the single most common cause, followed by allegations of fraud and abuse. Because this national database is permanently archived and widely used by licensing and credentialing bodies, optometrists should endeavor to be ethically responsible and strive to avoid behaviors that mandate such action reports. Optometry 2011;82:318-321 C1 [Duszak, Robert S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Duszak, Richard, Jr.] Midsouth Imaging & Therapeut, Memphis, TN USA. [Duszak, Richard, Jr.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. RP Duszak, RS (reprint author), Philadelphia Vet Affairs Med Ctr, 3800 Woodland Ave, Philadelphia, PA 19104 USA. EM bduszak@mac.com RI Duszak, Richard/L-1811-2016 OI Duszak, Richard/0000-0003-0425-3008 NR 27 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-1839 J9 OPTOMETRY JI Optometry PD MAY PY 2011 VL 82 IS 5 BP 318 EP 321 DI 10.1016/j.optm.2010.09.015 PG 4 WC Ophthalmology SC Ophthalmology GA 778MQ UT WOS:000291708800010 PM 21524604 ER PT J AU Ahern, DK Woods, SS Lightowler, MC Finley, SW Houston, TK AF Ahern, David K. Woods, Susan S. Lightowler, Marie C. Finley, Scott W. Houston, Thomas K. TI Promise of and Potential for Patient-Facing Technologies to Enable Meaningful Use SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CONGESTIVE-HEART-FAILURE; RANDOMIZED-TRIAL; MEDICAL-RECORD; ELECTRONIC COMMUNICATION; E-MAIL; SYSTEM; CARE; SATISFACTION; EXPERIENCES; PHYSICIAN AB Patients are using healthcare technologies for a variety of reasons. Recently, the Meaningful-Use rule was released by the Centers for Medicare and Medicaid Services, providing some initial guidance for patient-facing technologies. There needs to be more of an understanding of patients' needs and how these technologies can be utilized effectively. This article provides a framework for organizing patient-facing technologies into categories of meaningful use, and how these technologies can improve healthcare quality, safety, and population health. Barriers to achieving meaningful use of HIT and unintended consequences of patient-facing technologies are discussed. The success of healthcare reform is predicated on achieving improved health outcomes and reduced costs, which can be accomplished only by activating patients to become more engaged in their own care. Patient-facing technologies are likely to play a critical role in supporting patients to become more informed and activated and may also improve efficiencies. Further research is needed to identify the most useful and effective technologies for patients. (Am J Prev Med 2011;40(5S2):S162-S172) (C) 2011 American Journal of Preventive Medicine C1 [Ahern, David K.; Lightowler, Marie C.] Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Psychiat,Program Behav, Hlth Informat Technol Resource Ctr Aligning Force, Boston, MA 02215 USA. [Houston, Thomas K.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Boston, MA 02125 USA. [Houston, Thomas K.] Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. [Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Woods, Susan S.] Portland VA Med Ctr, Portland, OR USA. [Finley, Scott W.] WESTAT Corp, Rockville, MD 20850 USA. [Finley, Scott W.] Off Hlth Informat, Rockville, MD USA. Vet Hlth Adm, Rockville, MD USA. RP Ahern, DK (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Psychiat,Program Behav, Hlth Informat Technol Resource Ctr Aligning Force, 1249 Boylston St,3rd Floor, Boston, MA 02215 USA. EM dahern@partners.org RI Houston, Thomas/F-2469-2013 FU National Institutes of Health FX Publication of this article was supported by the National Institutes of Health. NR 62 TC 57 Z9 58 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2011 VL 40 IS 5 SU 2 BP S162 EP S172 DI 10.1016/j.amepre.2011.01.005 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 754DR UT WOS:000289833200012 PM 21521591 ER PT J AU Gordon, PL Doyle, JW Johansen, KL AF Gordon, P. L. Doyle, J. W. Johansen, K. L. TI Postdialysis fatigue is associated with sedentary behavior SO CLINICAL NEPHROLOGY LA English DT Article DE postdialysis fatigue; hemodialysis; physical activity ID QUALITY-OF-LIFE; PHYSICAL-ACTIVITY LEVELS; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; EXERCISE AB Postdialysis fatigue (PDF) is a common and debilitating phenomenon that adversely affects the quality of life of hemodialysis patients. Excessive ultrafiltration and rapid osmolar flux are implicated in the pathogenesis of PDF, but simple adjustments do not always ameliorate this symptom. Increased physical activity has long been associated with reduced fatigue in sedentary fatigued patients. The aim of the study was to examine the extent to which physical activity is associated with PDF. This was a retrospective cross-sectional study of hemodialysis patients (n = 58, age 55 +/- 13 years, 38 M, 20 F). Physical activity was measured by self-report using the Human Activity Profile (HAP) (n = 58) and accelerometry (n = 26). Postdialysis fatigue was assessed by a questionnaire rating frequency, severity, and duration of symptoms. 86% (50/58) of patients reported PDF ranging from mild to severe. The PDF index was inversely correlated with the adjusted score of the HAP (p < 0.05). Least squares linear regression was used to assess the association of physical activity with PDF, controlling for Kt/V and dialysis vintage. In the adjusted model (R(2) = 0.40), physical activity remained the most significant predictor (p < 0.01) of PDF after adjusting for Kt/V and/or vintage. Further studies are needed to evaluate whether increasing habitual physical activity can mitigate PDF symptoms. C1 [Gordon, P. L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Doyle, J. W.] San Francisco VA Med Ctr, No Calif Inst Res & Educ, San Francisco, CA USA. [Gordon, P. L.; Johansen, K. L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. RP Gordon, PL (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco Vet Affairs Med Ctr, Box 111J,4150 Clement St, San Francisco, CA 94121 USA. EM patricia.gordon@ucsf.edu FU NIH/NIDDK [R01-DK56182] FX This project was supported by a grant from NIH/NIDDK (R01-DK56182). This work was done at the San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94221, and University of California, San Francisco. We are grateful for the kind and valuable cooperation of the patient volunteers who made this study possible. Results were presented, in part, at the American Society of Nephrology Meeting in Philadelphia, PA in November, 2008. NR 26 TC 15 Z9 15 U1 0 U2 3 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD MAY PY 2011 VL 75 IS 5 BP 426 EP 433 DI 10.5414/CNP75426 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 775BI UT WOS:000291431100006 PM 21543022 ER PT J AU Pope, C Davis, BH AF Pope, Charlene Davis, Boyd H. TI Finding a balance: The Carolinas Conversation Collection SO CORPUS LINGUISTICS AND LINGUISTIC THEORY LA English DT Article DE sociolinguistics; health; chronic disease; Alzheimer's disease; ONZE Miner; ethnic groups; social determinants of health ID VISTA-CLINICAL-TRIAL; ALZHEIMERS-DISEASE; CULTURAL COMPETENCE; VERBAL REPETITION; INFORMATION; HEALTH; GALANTAMINE; PEOPLE; COMMUNICATION; DEMENTIA AB The Carolinas Conversations Collection is a password-protected digital collection of transcribed audio and video recordings of conversations about health, supported by the National Libraries of Medicine. It has two cohorts: 125 unimpaired multiethnic older speakers with any of 12 chronic conditions and a longitudinal set of 400 conversations with 125 persons having dementia. Information about health literacy, health status, and cognitive function requires high standards for privacy and confidentiality, and restricted data use agreements. Since contents are housed in an adaptation of the well-established ONZE Miner, users can search and perform online analysis of sound, word or syntax with increasing specificity. C1 [Pope, Charlene] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Pope, Charlene] Ralph H Johnson Vet Affairs VA Med Ctr, Charleston, SC USA. [Davis, Boyd H.] Univ N Carolina Charlotte, Charlotte, NC USA. RP Pope, C (reprint author), Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. EM popec@musc.edu; boydhdavis@yahoo.com OI Davis, Boyd/0000-0003-4773-7715 NR 64 TC 3 Z9 3 U1 0 U2 3 PU MOUTON DE GRUYTER PI BERLIN PA GENTHINER STRASSE 13, 10785 BERLIN, GERMANY SN 1613-7027 J9 CORPUS LINGUIST LING JI Corpus Linguist. Linguist. Theo. PD MAY PY 2011 VL 7 IS 1 SI SI BP 143 EP 161 DI 10.1515/CLLT.2011.007 PG 19 WC Linguistics; Language & Linguistics SC Linguistics GA 776MK UT WOS:000291539000007 ER PT J AU Bell, PD Fitzgibbon, W Sas, K Stenbitt, AE Amria, M Houston, A Reichert, R Gilley, S Siegal, GP Bissler, J Bilgen, M Chou, PCT Guay-Woodford, L Yoder, B Haycraft, CJ Siroky, B AF Bell, P. Darwin Fitzgibbon, Wayne Sas, Kelli Stenbitt, Antine E. Amria, May Houston, Amber Reichert, Ryan Gilley, Sandra Siegal, Gene P. Bissler, John Bilgen, Mehmet Chou, Peter Cheng-te Guay-Woodford, Lisa Yoder, Brad Haycraft, Courtney J. Siroky, Brian TI Loss of Primary Cilia Upregulates Renal Hypertrophic Signaling and Promotes Cystogenesis SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID POLYCYSTIC KIDNEY-DISEASE; REVERSIBLE COMPENSATORY HYPERTROPHY; PLANAR CELL POLARITY; CYST FORMATION; TUBULOGLOMERULAR FEEDBACK; UNILATERAL NEPHRECTOMY; RAT KIDNEYS; SLOW-ONSET; ADULT MICE; PKD1 AB Primary cilia dysfunction alters renal tubular cell proliferation and differentiation and associates with accelerated cyst formation in polycystic kidney disease. However, the mechanism leading from primary ciliary dysfunction to renal cyst formation is unknown. We hypothesize that primary cilia prevent renal cyst formation by suppressing pathologic tubular cell hypertrophy and proliferation. Unilateral nephrectomy initiates tubular cell hypertrophy and proliferation in the contralateral kidney and provides a tool to examine primary cilia regulation of renal hypertrophy. Conditional knockout of the primary cilia ift88 gene leads to delayed, adult-onset renal cystic disease, which provides a window of opportunity to conduct unilateral nephrectomy and examine downstream kinetics of renal hypertrophy and cyst formation. In wild-type animals, unilateral nephrectomy activated the mTOR pathway and produced appropriate structural and functional hypertrophy without renal cyst formation. However, in ift88 conditional knockout animals, unilateral nephrectomy triggered increased renal hypertrophy and accelerated renal cyst formation, leading to renal dysfunction. mTOR signaling also increased compared with wild-type animals, suggesting a mechanistic cascade starting with primary ciliary dysfunction, leading to excessive mTOR signaling and renal hypertrophic signaling and culminating in cyst formation. These data suggest that events initiating hypertrophic signaling, such as structural or functional loss of renal mass, may accelerate progression of adult polycystic kidney disease toward end-stage renal disease. C1 [Bell, P. Darwin; Fitzgibbon, Wayne; Sas, Kelli; Stenbitt, Antine E.; Amria, May; Houston, Amber; Reichert, Ryan; Gilley, Sandra; Haycraft, Courtney J.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Bell, P. Darwin] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Siegal, Gene P.; Yoder, Brad] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. [Siegal, Gene P.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Guay-Woodford, Lisa] Univ Alabama, Dept Genet, Birmingham, AL USA. [Bissler, John; Siroky, Brian] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH USA. [Bilgen, Mehmet; Chou, Peter Cheng-te] Univ Malaya, Fac Med, Med Ctr, Dept Biomed Imaging, Kuala Lumpur, Malaysia. RP Bell, PD (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 173 Ashley Ave,210 CRI, Charleston, SC 29425 USA. EM Bellpd@musc.edu FU VA Merit Grants [P30DK074038, DK32032, P30 AR 46031, P30 DK 079337, DK35534, DK065655, DK061458]; Dialysis Clinic, Inc. FX This project was supported by VA Merit Grants (P.D.B.), P30DK074038 (L.G.W.), DK32032 (P.D.B.), P30 AR 46031 (Siegal Core PI), and P30 DK 079337 (Siegal Core PI), DK35534 (L.G.W.), DK065655 (B.Y.) and DK061458 (J.B.) in addition to funds from Dialysis Clinic, Inc. NR 40 TC 28 Z9 28 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAY PY 2011 VL 22 IS 5 BP 839 EP 848 DI 10.1681/ASN.2010050526 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 776FI UT WOS:000291519500011 PM 21493775 ER PT J AU Fuller, BE Rodriguez, VL Linke, A Sikirica, M Dirani, R Hauser, P AF Fuller, Bret E. Rodriguez, Veronica L. Linke, Alex Sikirica, Mirko Dirani, Riad Hauser, Peter TI Prevalence of liver disease in veterans with bipolar disorder or schizophrenia SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Liver disease; Veterans; Bipolar disorder; Schizophrenia ID SUBSTANCE USE DISORDERS; SEVERE MENTAL-ILLNESS; HEPATITIS-C; UNITED-STATES; PSYCHIATRIC-DISORDERS; CARE; COMORBIDITY; MANAGEMENT; INFECTION; HEALTH AB Objective: To assess the prevalence of three liver diseases [hepatitis C virus (HCV), nonalcoholic fatty liver disease and alcohol-induced cirrhosis] in patients (veterans) with/without schizophrenia/schizoaffective disorder and bipolar disorder. Methods: A retrospective electronic chart review of Veterans Integrated Services Network 20 facilities from January 1, 2001 to December 21, 2006 selected patients to one of two groups: schizophrenia/schizoaffective disorder or bipolar disorder. Patients in both groups were compared with veterans in an equal-sized random sample from the same data set of veterans without psychiatric diagnoses. Logistic regression models evaluated risk for overall liver diseases as well as HCV, nonalcoholic fatty liver disease and alcoholic-induced cirrhosis. Results: Patients with schizophrenia (n=6521) had a higher prevalence of liver disease [22.4% versus 3.2%; odds ratio (OR)=8.73]; HCV (16.5% versus 1.9%; OR=10.21); and alcohol-related cirrhosis (1.6% versus 0.4%; OR=4.09) than matched controls. Patients with bipolar disorder (n=5319) had a higher prevalence of liver disease (21.5% versus 3.5%; OR=7.58); HCV (15.5% versus 2.1%; OR=8.60); and alcohol-related cirrhosis (1.6% versus 0.4%; OR=3.82) than matched controls. Risk factors for liver disease in patients with schizophrenia (versus matched controls) included diabetes (OR=1.29), hypertension (OR=1.27), HIV (OR=3.54), substance use disorder (SUD) (OR=2.28), alcohol use disorder (OR=3.05) and schizophrenia (OR=2.74). Risk factors for development of liver disease for patients with bipolar disorder: diabetes (OR=1.40), HIV (OR=3.66), SUD (OR=2.68), alcohol use disorder (OR=3.22) and bipolar disorder (OR=2.27). Conclusions: This study in veterans shows that the presence of mental illness and its comorbidities represents a significant risk factor for the diagnosis of liver disease, including HCV and alcohol-related cirrhosis. Published by Elsevier Inc. C1 [Fuller, Bret E.; Rodriguez, Veronica L.; Linke, Alex] Portland VA Med Ctr, Portland, OR 97210 USA. [Sikirica, Mirko; Dirani, Riad] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA. [Fuller, Bret E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Hauser, Peter] Long Beach Vet Affairs Med Ctr, Vet Integrated Serv Network 22, Network Off, Long Beach, CA USA. RP Fuller, BE (reprint author), Portland VA Med Ctr, 3170 SW US Vet Pk Rd,Mailcode P3MHDC, Portland, OR 97210 USA. EM bret.fuller@va.gov FU Ortho-McNeil Janssen Scientific Affairs FX This study was funded by a grant from Ortho-McNeil Janssen Scientific Affairs. NR 24 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAY-JUN PY 2011 VL 33 IS 3 BP 232 EP 237 DI 10.1016/j.genhosppsych.2011.03.006 PG 6 WC Psychiatry SC Psychiatry GA 773IR UT WOS:000291300700004 PM 21601719 ER PT J AU La Fountaine, MF Gossett, JD De Meersman, RE Bauman, WA AF La Fountaine, Michael F. Gossett, James D. De Meersman, Ronald E. Bauman, William A. TI Increased QT Interval Variability in 3 Recently Concussed Athletes: An Exploratory Observation SO JOURNAL OF ATHLETIC TRAINING LA English DT Article DE autonomic nervous system; heart; cardiovascular system; return to play ID HEART-RATE-VARIABILITY; AUTONOMIC NERVOUS-SYSTEM; POWER SPECTRAL-ANALYSIS; SUDDEN CARDIAC DEATH; EXERCISE; MODULATION; CASCADE; RISK AB Context: The QT interval variability index (QTVI) is a noninvasive measure of beat-to-beat fluctuations of the QT interval as seen from a single electrocardiographic lead. It represents the relationship between the respective variabilities of the QT and R-R intervals. Recently, the QTVI was demonstrated to be an index of vagal cardiac autonomic modulation in resting conditions. Objective: To determine whether QTVI varied in athletes at 48 hours, 1 week, and 2 weeks after a concussive head injury. Design: Case series. Setting: Testing facility. Patients or Other Participants: Three athletes with recent concussions and 3 uninjured athletes with similar demographic factors. Main Outcome Measure(s): Continuous 3-lead electrocardiograms were obtained in a seated, resting position over 2 successive weeks. Separate, unpaired t tests were performed to determine whether group-visit differences were present in the QTVI at 48 hours, 1 week, or 2 weeks. Results: No demographic differences were present between groups. At 48 hours, the QTVI was greater in the concussion group than in the matched controls. At weeks 1 and 2, the QTVI in the concussion group was lower than at 48 hours and not different from that of the control group. Conclusions: Vagal cardiac autonomic modulation, as quantified by the QTVI, appeared to be negatively affected in concussed athletes within 48 hours of injury, resolved within 1 week, and remained at control group levels 2 weeks later. Serial assessments of QTVI may be of clinical utility in identifying suspected cases of acute concussion and may provide helpful information for determining when an athlete can return to play safely. C1 [La Fountaine, Michael F.; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [La Fountaine, Michael F.; Bauman, William A.] James J Peters VA Med Ctr, SCI Serv, Bronx, NY 10468 USA. [La Fountaine, Michael F.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Gossett, James D.] Columbia Univ, Dept Sports Med, New York, NY USA. [De Meersman, Ronald E.] Columbia Univ, Teachers Coll, Dept Biobehav Sci, New York, NY 10027 USA. [Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP La Fountaine, MF (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 7A-13M,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM michael.lafountaine@va.gov NR 32 TC 6 Z9 6 U1 0 U2 5 PU NATL ATHLETIC TRAINERS ASSOC INC PI DALLAS PA 2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA SN 1062-6050 J9 J ATHL TRAINING JI J. Athl. Train. PD MAY-JUN PY 2011 VL 46 IS 3 BP 230 EP 233 PG 4 WC Sport Sciences SC Sport Sciences GA 770YC UT WOS:000291123400002 PM 21669090 ER PT J AU Smith, EG Craig, TJ Ganoczy, D Walters, HM Valenstein, M AF Smith, Eric G. Craig, Thomas J. Ganoczy, Dara Walters, Heather M. Valenstein, Marcia TI Treatment of Veterans With Depression Who Died by Suicide: Timing and Quality of Care at Last Veterans Health Administration Visit SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PSYCHOLOGICAL AUTOPSY; MENTAL-HEALTH; UNITED-STATES; ANTIDEPRESSANTS; CONTACT; SWEDEN; PEOPLE; ACCESS; PRESCRIPTION; PREVENTION AB Objective: To examine the recency and quality of the last Veterans Health Administration (VHA) visit for patients with depression who died by suicide. Method: We obtained services and pharmacy data for all 1,843 VHA patients with diagnosed depressive disorders (DSM-IV criteria) who died by suicide from April 1999 through September 2004. We ascertained the location and timing of their final VHA visit. For visits occurring within 30 days of suicide, we examined 3 quality indicators: (1) evidence that mental illness was a focus of the final visit, (2) adequacy of antidepressant dosage, and (3) recent receipt of mental health services. Results: Just over half of the patients (51%) with depression diagnoses had a VHA visit within 30 days of suicide. A minority of these patients (43%) died by suicide within 30 days of a final visit with mental health services, although 64% had received such services within 91 days of their suicide. Among the 57% of patients who died by suicide within 30 days and who were seen in non-mental health settings for their final visit, only 34% had a mental health condition coded at the final visit, and only 41% were receiving adequate dosages of antidepressant (versus 55% for those last seen by mental health services) (P <. 0005). Conclusions: Veterans Health Administration patients with depression who died by suicide within 30 days of their final visit received relatively high rates of mental health services, but most final visits still occurred in non-mental health settings. Increased referrals to mental health services, attention to mental health issues in non-mental health settings, and focus on antidepressant treatment adequacy by all providers might have reduced suicide risks for these patients. J Clin Psychiatry 2011;72(5):622-629 (C) Copyright 2010 Physicians Postgraduate Press, Inc. C1 [Smith, Eric G.] Vet Hlth Adm VHA Hlth Serv Res & Dev Ctr Hlth Qua, Bedford, MA USA. [Smith, Eric G.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. [Craig, Thomas J.] US Dept Vet Affairs, Washington, DC USA. [Ganoczy, Dara; Walters, Heather M.; Valenstein, Marcia] Serious Mental Illness Treatment Resource & Evalu, Ann Arbor Ctr Excellence COE, Dept Vet Affairs, Ann Arbor, MI USA. [Valenstein, Marcia] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. RP Smith, EG (reprint author), Edith Nourse Rogers Mem VA Hosp, Room B-29,Bldg 70,200 Springs Rd, Bedford, MA 01730 USA. EM Eric.Smith5@va.gov FU Forest Research Institute, an affiliate of Forest Laboratories, a manufacturer of antidepressants (among other medications); Department of Veterans Affairs [IIR 04-211]; National Institute of Mental Health [R01 MH078698]; Serious Mental Illness Treatment Resource and Evaluation Center; Ann Arbor; VHA Health Services Research and Development [RCD 98-350] FX Dr Smith receives grant funding from Forest Research Institute, an affiliate of Forest Laboratories, a manufacturer of antidepressants (among other medications), for unrelated investigator-initiated research concerning the safety of antidepressants. Dr Smith declares that he received no funds from this grant during the period of preparation of this article and that the grant did not influence this article in any way. Drs Craig and Valenstein and Mss Ganoczy and Walters have no competing financial interests to disclose.\; Supported by Department of Veterans Affairs grant IIR 04-211, by National Institute of Mental Health grant R01 MH078698, and by the Serious Mental Illness Treatment Resource and Evaluation Center, Ann Arbor, Michigan. Dr Smith receives salary support through VHA Health Services Research and Development Center of Excellence funding to the Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts. Support for database and research provided by VHA Health Services Research and Development grant RCD 98-350 (Dr Valenstein, principal investigator). NR 39 TC 14 Z9 14 U1 0 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2011 VL 72 IS 5 BP 622 EP 629 DI 10.4088/JCP.09m05608b1u PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 772NM UT WOS:000291240600008 PM 20868636 ER PT J AU Gitlin, MJ Mintz, J Sokolski, K Hammen, C Altshuler, LL AF Gitlin, Michael J. Mintz, Jim Sokolski, Kenneth Hammen, Constance Altshuler, Lori L. TI Subsyndromal Depressive Symptoms After Symptomatic Recovery From Mania Are Associated With Delayed Functional Recovery SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PROSPECTIVE FOLLOW-UP; BIPOLAR-II DISORDER; LONG-TERM COURSE; PSYCHOSOCIAL DISABILITY; NATURAL-HISTORY; RATING-SCALE; IMPAIRMENT; HOSPITALIZATION; REMISSION; IMPACT AB Objective: This study examined whether the presence of subsyndromal depressive symptoms predicted functional recovery after an acute manic episode. Method: Subjects with bipolar I disorder (according to the Structured Clinical Interview for DSM-IV) who, at the time of symptomatic recovery from an acute manic or hypomanic episode, had a concomitant functional recovery (n = 52) were compared on demographic variables and mood symptoms to those who had symptomatically recovered but not functionally recovered (n = 33). Demographic and mood variables were examined in the nonfunctionally recovered group to assess predictors of time to functional recovery. The primary functional outcome measure used was the Life Functioning Questionnaire, a 5-minute, gender-neutral self-report scale to measure role function in 4 domains: workplace, duties at home, leisure time with family, and leisure time with friends. Participants in the study were recruited from July 2000 through February 2005. Results: Depressive symptoms, even at a subsyndromal level, were significantly associated with persisting functional impairment after symptomatic recovery from a manic episode (P<.02). Subsyndromal depressive symptoms also significantly predicted a slower time to functional recovery over the next 9 months (P=.006). Conclusion: The presence of even mild subsyndromal depressive symptoms may interfere with functional recovery in patients with bipolar disorder after symptomatic recovery from a manic or hypomanic episode. J Clin Psychiatry 2011;72(5):692-697 (C) Copyright 2010 Physicians Postgraduate Press, Inc. C1 [Gitlin, Michael J.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [Sokolski, Kenneth] Vet Affairs VA Long Beach Healthcare Syst, Mental Hlth Care Grp, Long Beach, CA USA. [Sokolski, Kenneth] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine Sch Med, Irvine, CA 92717 USA. [Hammen, Constance] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Gitlin, MJ (reprint author), 300 UCLA Med Plaza,Ste 2200, Los Angeles, CA 90095 USA. EM mgitlin@mednet.ucla.edu FU National Institute of Mental Health, Bethesda, Maryland [1R01MH057762]; Abbott Laboratories, Abbott Park, Illinois FX Funding for this study was provided by the National Institute of Mental Health (1R01MH057762) (Dr Altshuler), Bethesda, Maryland. Abbott Laboratories (Dr Altshuler), Abbott Park, Illinois, provided funding to obtain divalproex sodium levels at the UCLA laboratory and provided divalproex sodium for some study subjects. NR 39 TC 18 Z9 18 U1 0 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2011 VL 72 IS 5 BP 692 EP 697 DI 10.4088/JCP.09m05291gre PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 772NM UT WOS:000291240600016 PM 20673560 ER PT J AU Martin, LF Olincy, A Ross, RG Du, YPP Singel, D Shatti, S Tregellas, JR AF Martin, Laura Frances Olincy, Ann Ross, Randy G. Du, Yiping P. Singel, Debra Shatti, Shireen Tregellas, Jason R. TI Cerebellar hyperactivity during smooth pursuit eye movements in bipolar disorder SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Magnetic resonance imaging; Uvula; Cerebellum; Hippocampus; Affective symptoms; Depression ID REGIONAL CEREBRAL METABOLISM; COGNITIVE-AFFECTIVE SYNDROME; SCHIZOPHRENIC-PATIENTS; NEUROLEPTIC TREATMENT; UNAFFECTED RELATIVES; UNIPOLAR DEPRESSION; GLUCOSE-METABOLISM; PSYCHOTIC-PATIENTS; MAJOR DEPRESSION; BRAIN ACTIVATION AB Introduction: Smooth pursuit eye movements (SPEM) are abnormal in individuals with schizophrenia and individuals with bipolar disorder. Functional imaging methods have revealed greater hippocampal activity and less frontotemporal, visual, and posterior cerebellar activity in individuals with schizophrenia when performing a SPEM task. The underlying neurobiology of SPEM deficits in bipolar disorder is unknown. Methods: Functional magnetic resonance imaging at 3T was performed on fourteen subjects with bipolar disorder and 14 subjects without psychiatric illness during a block design SPEM task. Clinical measures were assessed on the day of testing and related to imaging measures. Results: Subjects with bipolar disorder had greater hemodynamic response than control subjects in cerebellar vermis. Responses were associated with levels of depressive symptoms on the day of study. Discussion: Increased cerebellar vermis activity during the smooth pursuit eye movement task in individuals with bipolar disorder further implicates cerebellar involvement in bipolar disorder. Increased hemodynamic response within the hippocampus was not seen in these individuals and may be a finding specific to schizophrenia. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Martin, Laura Frances; Olincy, Ann; Ross, Randy G.; Du, Yiping P.; Singel, Debra; Shatti, Shireen; Tregellas, Jason R.] Univ Colorado Denver, Sch Med, Aurora, CO 80045 USA. [Tregellas, Jason R.] Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA. RP Martin, LF (reprint author), Univ Colorado Denver, Sch Med, Mail Stop F546,13001 E 17th Pl, Aurora, CO 80045 USA. EM laura.martin@ucdenver.edu RI Tregellas, Jason/J-3637-2015 FU Research Service of the Denver VAMC; NARSAD; [829/RCD- 006-05S] FX This work was supported by the Research Service of the Denver VAMC and Program/Study No: 829/RCD- 006-05S (LFM, JRT) and NARSAD (LFM). Neither the Department of Veterans Affairs nor NARSAD had any further role in study design, data collection, data analysis, manuscript preparation or decision to publish the manuscript. NR 97 TC 4 Z9 4 U1 8 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD MAY PY 2011 VL 45 IS 5 BP 670 EP 677 DI 10.1016/j.jpsychires.2010.09.015 PG 8 WC Psychiatry SC Psychiatry GA 771OR UT WOS:000291171100013 PM 20950824 ER PT J AU Garbelotti, K AF Garbelotti, Kelly TI PHANTOM LIMB PAIN RELIEVED WITH PULSED RADIO FREQUENCY ENERGY (PRFE) THERAPY SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Meeting Abstract C1 [Garbelotti, Kelly] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM kelly.garbelotti@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1071-5754 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD MAY-JUN PY 2011 VL 38 IS 3 SU S MA 5426 BP S83 EP S83 PG 1 WC Nursing SC Nursing GA 772LI UT WOS:000291235000232 ER PT J AU Weintraub, D Burn, DJ AF Weintraub, Daniel Burn, David J. TI Parkinson's Disease: The Quintessential Neuropsychiatric Disorder SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's; dementia; neuropsychiatric; depression; psychosis ID DEEP-BRAIN-STIMULATION; IMPULSE CONTROL DISORDERS; SLEEP BEHAVIOR DISORDER; RANDOMIZED CONTROLLED-TRIAL; VOXEL-BASED MORPHOMETRY; SUBTHALAMIC NUCLEUS STIMULATION; EXCESSIVE DAYTIME SLEEPINESS; MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; DRUG-INDUCED PSYCHOSIS AB Although diagnosed by characteristic motor features, Parkinson's disease may be preceded, and is frequently accompanied by, a wide range of cognitive and neuropsychiatric features. In addition to the most commonly studied disorders of dementia, depression, and psychosis, other relatively common and clinically significant psychiatric complications include impulse control disorders, anxiety symptoms, disorders of sleep and wakefulness, and apathy. These problems may be underrecognized and are frequently under-treated. The emergent focus on nonmotor aspects of Parkinson's disease over the past quarter of a century is highlighted by a nonlinear increase in the number of articles published devoted to this topic. Although the development of newer antidepressants, atypical antipsychotics, and cholinesterase inhibitors in recent years has had a positive benefit on the management of these troublesome and distressing symptoms, responses are frequently suboptimal, and this remains an area of major unmet therapeutic need. (C) 2011 Movement Disorder Society C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr PADRECC & MIRE, Philadelphia, PA USA. [Burn, David J.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Burn, David J.] Newcastle Univ, Clin Ageing Res Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU NIMH NIH HHS [K23 MH067894] NR 186 TC 117 Z9 119 U1 5 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY PY 2011 VL 26 IS 6 BP 1022 EP 1031 DI 10.1002/mds.23664 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 774AO UT WOS:000291353900011 PM 21626547 ER PT J AU Zhao, J Wu, H Khosravi, M Cui, HJ Qian, XX Kelly, JA Kaufman, KM Langefeld, CD Williams, AH Comeau, ME Ziegler, JT Marion, MC Adler, A Glenn, SB Alarcon-Riquelme, ME Pons-Estel, BA Harley, JB Bae, SC Bang, SY Cho, SK Jacob, CO Vyse, TJ Niewold, TB Gaffney, PM Moser, KL Kimberly, RP Edberg, JC Brown, EE Alarcon, GS Petri, MA Ramsey-Goldman, R Vila, LM Reveille, JD James, JA Gilkeson, GS Kamen, DL Freedman, BI Anaya, JM Merrill, JT Criswell, LA Scofield, RH Stevens, AM Guthridge, JM Chang, DM Song, YW Park, JA Lee, EY Boackle, SA Grossman, JM Hahn, BH Goodship, THJ Cantor, RM Yu, CY Shen, N Tsao, BP AF Zhao, Jian Wu, Hui Khosravi, Melanie Cui, Huijuan Qian, Xiaoxia Kelly, Jennifer A. Kaufman, Kenneth M. Langefeld, Carl D. Williams, Adrienne H. Comeau, Mary E. Ziegler, Julie T. Marion, Miranda C. Adler, Adam Glenn, Stuart B. Alarcon-Riquelme, Marta E. Pons-Estel, Bernardo A. Harley, John B. Bae, Sang-Cheol Bang, So-Young Cho, Soo-Kyung Jacob, Chaim O. Vyse, Timothy J. Niewold, Timothy B. Gaffney, Patrick M. Moser, Kathy L. Kimberly, Robert P. Edberg, Jeffrey C. Brown, Elizabeth E. Alarcon, Graciela S. Petri, Michelle A. Ramsey-Goldman, Rosalind Vila, Luis M. Reveille, John D. James, Judith A. Gilkeson, Gary S. Kamen, Diane L. Freedman, Barry I. Anaya, Juan-Manuel Merrill, Joan T. Criswell, Lindsey A. Scofield, R. Hal Stevens, Anne M. Guthridge, Joel M. Chang, Deh-Ming Song, Yeong Wook Park, Ji Ah Lee, Eun Young Boackle, Susan A. Grossman, Jennifer M. Hahn, Bevra H. Goodship, Timothy H. J. Cantor, Rita M. Yu, Chack-Yung Shen, Nan Tsao, Betty P. CA BIOLUPUS Network GENLES Network TI Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility SO PLOS GENETICS LA English DT Article ID HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; MACULAR DEGENERATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; ALLOTYPIC VARIANT; INFLUENCES RISK; CFH; C3; HAPLOTYPE; POLYMORPHISMS AB Systemic lupus erythematosus (SLE), a complex polygenic autoimmune disease, is associated with increased complement activation. Variants of genes encoding complement regulator factor H (CFH) and five CFH-related proteins (CFHR1-CFHR5) within the chromosome 1q32 locus linked to SLE, have been associated with multiple human diseases and may contribute to dysregulated complement activation predisposing to SLE. We assessed 60 SNPs covering the CFH-CFHRs region for association with SLE in 15,864 case-control subjects derived from four ethnic groups. Significant allelic associations with SLE were detected in European Americans (EA) and African Americans (AA), which could be attributed to an intronic CFH SNP (rs6677604, in intron 11, P(meta) = 6.6x10(-8), OR = 1.18) and an intergenic SNP between CFHR1 and CFHR4 (rs16840639, P(meta) = 2.9x10(-7), OR = 1.17) rather than to previously identified disease-associated CFH exonic SNPs, including I62V, Y402H, A474A, and D936E. In addition, allelic association of rs6677604 with SLE was subsequently confirmed in Asians (AS). Haplotype analysis revealed that the underlying causal variant, tagged by rs6677604 and rs16840639, was localized to a similar to 146 kb block extending from intron 9 of CFH to downstream of CFHR1. Within this block, the deletion of CFHR3 and CFHR1 (CFHR3-1 Delta), a likely causal variant measured using multiplex ligation-dependent probe amplification, was tagged by rs6677604 in EA and AS and rs16840639 in AA, respectively. Deduced from genotypic associations of tag SNPs in EA, AA, and AS, homozygous deletion of CFHR3-1D (P(meta) = 3.2x10(-7), OR = 1.47) conferred a higher risk of SLE than heterozygous deletion (P(meta) = 3.5x10(-4), OR = 1.14). These results suggested that the CFHR3-1D deletion within the SLE-associated block, but not the previously described exonic SNPs of CFH, might contribute to the development of SLE in EA, AA, and AS, providing new insights into the role of complement regulators in the pathogenesis of SLE. C1 [Zhao, Jian; Wu, Hui; Khosravi, Melanie; Grossman, Jennifer M.; Hahn, Bevra H.; Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA. [Cui, Huijuan; Qian, Xiaoxia; Shen, Nan] Inst Hlth Sci, Joint Mol Rheumatol Lab, Shanghai, Peoples R China. [Cui, Huijuan; Qian, Xiaoxia; Shen, Nan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Biol Sci, Shanghai Renji Hosp, Shanghai 200030, Peoples R China. [Cui, Huijuan; Qian, Xiaoxia; Shen, Nan] Chinese Acad Sci, Shanghai, Peoples R China. [Kelly, Jennifer A.; Kaufman, Kenneth M.; Adler, Adam; Glenn, Stuart B.; Alarcon-Riquelme, Marta E.; Gaffney, Patrick M.; Moser, Kathy L.; James, Judith A.; Scofield, R. Hal; Guthridge, Joel M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Kaufman, Kenneth M.; Scofield, R. Hal] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Langefeld, Carl D.; Williams, Adrienne H.; Comeau, Mary E.; Ziegler, Julie T.; Marion, Miranda C.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Wake Forest, NC USA. [Alarcon-Riquelme, Marta E.] Pfizer Univ Granada Junta Andalucia, Ctr Genom & Oncol Res, Granada, Spain. [Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Bae, Sang-Cheol; Bang, So-Young; Cho, Soo-Kyung] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea. [Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Vyse, Timothy J.] Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Div Immunol, London WC2R 2LS, England. [Niewold, Timothy B.] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA. [Niewold, Timothy B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA. [Kimberly, Robert P.; Edberg, Jeffrey C.; Brown, Elizabeth E.; Alarcon, Graciela S.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Brown, Elizabeth E.] Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA. [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA. [Vila, Luis M.] Univ Puerto Rico Med Sci Campus, Dept Med, Div Rheumatol, San Juan, PR USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. [James, Judith A.; Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Gilkeson, Gary S.; Kamen, Diane L.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. [Freedman, Barry I.] Wake Forest Univ Hlth Sci, Dept Internal Med, Winston Salem, NC USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia. [Merrill, Joan T.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA. [Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA. [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Chang, Deh-Ming] Natl Def Med Ctr, Taipei, Taiwan. [Song, Yeong Wook; Park, Ji Ah; Lee, Eun Young] Seoul Natl Univ, Div Rheumatol, Seoul, South Korea. [Boackle, Susan A.] Univ Colorado Denver, Sch Med, Div Rheumatol, Aurora, CO USA. [Adler, Adam; Goodship, Timothy H. J.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA. [Yu, Chack-Yung] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. RP Zhao, J (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA. EM btsao@mednet.ucla.edu RI Yu, Chack-Yung/E-4360-2011; Song, Yeong Wook/J-2765-2012; Lee, Eun Young/J-5594-2012; Zhao, Jian/E-6292-2012; D'Alfonso, Sandra/K-7295-2014; Anaya, Juan-Manuel/J-1960-2016 OI Kimberly, Robert/0000-0002-5330-3086; D'Alfonso, Sandra/0000-0002-3983-9925; Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Silva, Berta/0000-0001-6579-5068; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660 FU US National Institutes of Health [R01AR043814, R01AR043274, R01AI063274, N01AR62277, R37AI024717, R01AR042460, P01AI083194, P20RR020143, P01AR049084, R01AR33062, K08AI083790, LRPAI071651, R01CA141700, RC1AR058621, UL1RR024999, R01AR051545-01A2, P30AR053483, AR43727, UL1RR025005, K24AR002138, P602AR30692, P01AR49084, UL1RR025741, P20RR015577, RC1AR058554, U19AI082714, N01AI50026, R21AI070304, P60AR053308, M01RR00079, UL1RR029882, P60AR049459, R01AR054459]; Arthritis National Research Foundation; Ministry for Health and Welfare, Republic of Korea [A080588]; MKE/KEIT [10035615]; US Department of Veterans Affairs; US Department of Defense [PR094002]; Lupus Research Institute; Alliance for Lupus Research; Arthritis Foundation; Lupus Foundation; Swedish Research Council; Swedish Association Against Rheumatism; King Gustaf Vth 80th Jubilee; Fundacion Instituto de Salud Carlos III [PS0900129]; Consejeria de Salud de Andalucia [PI-0012]; Welcome Trust; Arthritis Research UK; UK Medical Research Council [G0701325]; CTSA [I ULI RR025014-02]; National Center for Research Resources (NCRR); Kirkland Scholar Award; Federico Wilhelm Agricola Foundation; Networking Programmers European Science Foundation; ESF FX ` Support for this work was obtained from the US National Institutes of Health grants: R01AR043814 (BP Tsao), R01AR043274 (KL Moser), R01AI063274 (PM Gaffney), N01AR62277 (JB Harley), R37AI024717 (JB Harley), R01AR042460 (JB Harley), P01AI083194 (JB Harley), P20RR020143 (JB Harley), P01AR049084 (RP Kimberly), R01AR33062 (RP Kimberly, EE Brown), K08AI083790 (TB Niewold), LRPAI071651 (TB Niewold), R01CA141700 (ME Alarcon-Riquelme), RC1AR058621 (ME Alarcon-Riquelme) and UL1RR024999 (TB Niewold), R01AR051545-01A2 (AM Stevens), P30AR053483 (JA James and JM Guthridge), AR43727 (MA Petri), UL1RR025005 (MA Petri), K24AR002138 (R Ramsey-Goldman), P602AR30692 (R Ramsey-Goldman), P01AR49084 (R Ramsey-Goldman), UL1RR025741 (R Ramsey-Goldman), P20RR015577 (JA James), RC1AR058554 (JA James), U19AI082714 (JA James), N01AI50026 (JA James and JM Guthridge), R21AI070304 (SA Boackle), P60AR053308 (LA Criswell), M01RR00079 (LA Criswell), UL1RR029882 (GS Gilkeson and DL Kamen), P60AR049459 (GS Gilkeson and DL Kamen), and R01AR054459 (C-Y Yu). The first author (J Zhao) is an Eng Tan Scholar supported by the Arthritis National Research Foundation. This study was also supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A080588; S-C Bae), Korean R&D Program of MKE/KEIT (10035615; YW Song), the Merit Award from the US Department of Veterans Affairs (JB Harley and GS Gilkeson), the US Department of Defense PR094002 (JB Harley), Lupus Research Institute (BP Tsao, AM Stevens, and TB Niewold), The Alliance for Lupus Research (KL Moser, TB Niewold, LA Criswell, and CO Jacob), the Arthritis National Research Foundation Eng Tan Scholar Award (TB Niewold), the Arthritis Foundation (AM Stevens and PM Gaffney), and the Lupus Foundation (AM Stevens). Additional funding awarded from the Swedish Research Council, Swedish Association Against Rheumatism, and the King Gustaf Vth 80th Jubilee. Foundation and the Fundacion Instituto de Salud Carlos III PS0900129 and the Consejeria de Salud de Andalucia PI-0012 (ME Alarcon-Riquelme), the Welcome Trust (TJ Vyse), Arthritis Research UK (TJ Vyse), UK Medical Research Council grant (G0701325; THJ Goodship), CTSA Grant Number I ULI RR025014-02 (AM Stevens) from the National Center for Research Resources (NCRR), Kirkland Scholar Award (LA Criswell and JA James), and Federico Wilhelm Agricola Foundation Research Grant (BA Pons-Estel). The work reported on in this publication has been in part financially supported by the ESF, in the framework of the Research Networking Programmers European Science Foundation - The Identification of Novel Genes and Biomarkers for Systemic Lupus Erythematosus (BIOLUPUS)-RNP-083. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 68 Z9 69 U1 2 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD MAY PY 2011 VL 7 IS 5 AR e1002079 DI 10.1371/journal.pgen.1002079 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 769LI UT WOS:000291014600024 PM 21637784 ER PT J AU Tsai, AC Rosenlicht, NZ Jureidini, JN Parry, PI Spielmans, GI Healy, D AF Tsai, Alexander C. Rosenlicht, Nicholas Z. Jureidini, Jon N. Parry, Peter I. Spielmans, Glen I. Healy, David TI Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature SO PLOS MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIALS; CLINICAL-PRACTICE GUIDELINES; CONTROLLED 18-MONTH TRIAL; CONFLICT-OF-INTEREST; I-DISORDER; DOUBLE-BLIND; LONG-TERM; MOOD STABILIZERS; PHARMACOLOGICAL-TREATMENT; PHARMACEUTICAL-INDUSTRY AB Background: Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005. Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance treatment of bipolar disorder and examine how that evidence has been disseminated in the scientific literature. Methods and Findings: We systematically searched multiple databases to identify double-blind, randomized controlled trials of aripiprazole for the maintenance treatment of bipolar disorder while excluding other types of studies, such as open-label, acute, and adjunctive studies. We then used a citation search to identify articles that cited these trials and rated the quality of their citations. Our evidence search protocol identified only two publications, both describing the results of a single trial conducted by Keck et al., which met criteria for inclusion in this review. We describe four issues that limit the interpretation of that trial as supporting the use of aripiprazole for bipolar maintenance: (1) insufficient duration to demonstrate maintenance efficacy; (2) limited generalizability due to its enriched sample; (3) possible conflation of iatrogenic adverse effects of abrupt medication discontinuation with beneficial effects of treatment; and (4) a low overall completion rate. Our citation search protocol yielded 80 publications that cited the Keck et al. trial in discussing the use of aripiprazole for bipolar maintenance. Of these, only 24 (30%) mentioned adverse events reported and four (5%) mentioned study limitations. Conclusions: A single trial by Keck et al. represents the entirety of the literature on the use of aripiprazole for the maintenance treatment of bipolar disorder. Although careful review identifies four critical limitations to the trial's interpretation and overall utility, the trial has been uncritically cited in the subsequent scientific literature. C1 [Tsai, Alexander C.] Harvard Univ, Robert Wood Johnson Hlth & Soc Scholars Program, Cambridge, MA 02138 USA. [Rosenlicht, Nicholas Z.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Rosenlicht, Nicholas Z.] San Francisco VA Med Ctr, San Francisco, CA USA. [Jureidini, Jon N.] Univ Adelaide, Discipline Psychiat, Adelaide, SA, Australia. [Parry, Peter I.] Flinders Univ S Australia, Div Mental Hlth, Child & Adolescent Mental Hlth Serv, Adelaide, SA 5001, Australia. [Spielmans, Glen I.] Metropolitan State Univ, Dept Psychol, St Paul, MN USA. [Healy, David] Cardiff Univ, Dept Psychol Med, Cardiff, S Glam, Wales. RP Tsai, AC (reprint author), Harvard Univ, Robert Wood Johnson Hlth & Soc Scholars Program, Cambridge, MA 02138 USA. EM nicholas.rosenlicht@ucsf.edu RI Parry, Peter/G-7663-2015 OI Parry, Peter/0000-0003-1086-0138; Tsai, Alexander/0000-0001-6397-7917 FU Harvard University; Robert Wood Johnson Foundation Health and Society; Vanguard Healthcare FX The authors received no specific funding for this study. ACT received salary support as a Robert Wood Johnson Health and Society Scholar at Harvard University. No funding bodies had any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; ACT receives salary support through the Robert Wood Johnson Foundation Health and Society Scholars Program. The Robert Wood Johnson Foundation's stated mission is to improve the health and health care of all Americans. NZR is a member of the National Physicians Alliance, a not-for-profit organisation whose stated primary goal is to restore physicians' primary emphasis on the core values of service, integrity, and advocacy. The National Physicians Alliance rejects funding from commercial health care interests and encourages its members to do the same. NZR, JNJ, and PIP are members of Healthy Skepticism, an international not-for-profit organisation whose stated aim is to improve health by reducing harm from misleading drug promotion; GIS joined Healthy Skepticism after this article was accepted for publication. GIS is a current shareholder (<$10,000) in a mutual fund, Vanguard Healthcare, that invests heavily in pharmaceutical companies. DH reports no links to pharmaceutical companies in the past 5 years. ACT is a former board member of the ethics committee, and former member, of the National Physicians Alliance. ACT and NZR are former members of No Free Lunch, a not-for-profit organisation whose stated mission was to encourage health care providers to practice medicine on the basis of scientific evidence rather than on the basis of pharmaceutical promotion. JNJ was engaged by the law firm of Baum, Hedlund, Aristei & Goldman to provide an independent analysis of the data in Glaxo SmithKline's Study 329 of paroxetine in adolescents. DH has been an expert witness in ten legal cases involving antidepressant medications and one case involving the patent on olanzapine (Zyprexa). NR 117 TC 15 Z9 15 U1 5 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD MAY PY 2011 VL 8 IS 5 AR e1000434 DI 10.1371/journal.pmed.1000434 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 771IW UT WOS:000291151400001 PM 21559324 ER PT J AU DeBonis, K Pierre, JM AF DeBonis, Katrina Pierre, Joseph M. TI Psychosis, Ivermectin Toxicity, and "Morgellons Disease" SO PSYCHOSOMATICS LA English DT Letter C1 [DeBonis, Katrina] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. W Los Angeles VA Med Ctr, Dept Psychiat, Los Angeles, CA USA. RP DeBonis, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. NR 6 TC 2 Z9 2 U1 0 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAY-JUN PY 2011 VL 52 IS 3 BP 295 EP 296 PG 2 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 771UU UT WOS:000291187000015 PM 21565604 ER PT J AU Sanz, F Restrepo, MI Fernandez, E Mortensen, EM Aguar, MC Cervera, A Chiner, E Blanquer, J AF Sanz, Francisco Restrepo, Marcos I. Fernandez, Estrella Mortensen, Eric M. Carmen Aguar, Maria Cervera, Angela Chiner, Eusebi Blanquer, Jose CA Neumonia Adquirida Comunidad TI Hypoxemia Adds to the CURB-65 Pneumonia Severity Score in Hospitalized Patients With Mild Pneumonia SO RESPIRATORY CARE LA English DT Article DE hypoxemia; prognosis; pneumonia; CURB-65; outcomes; oxygenation ID COMMUNITY-ACQUIRED PNEUMONIA; LOW-RISK PATIENTS; PREDICTION RULE; MORTALITY; VALIDATION; DISEASE; ABNORMALITIES; OXYGENATION; GUIDELINES; MANAGEMENT AB BACKGROUND: Hypoxemia may influence the prognosis of patients with mild pneumonia, regardless of the initial CURB-65 score (confusion, blood urea nitrogen > 20 mg/dL, respiratory rate > 30 breaths/min, blood pressure < 90/60 mm Hg, and age >= 65 y). OBJECTIVE: To determine the risk factors associated with hypoxemia and the influence of hypoxemia on clinical outcomes in hospitalized patients with mild pneumonia. METHODS: We performed a multicenter prospective cohort study of 585 consecutive hospitalized patients with mild pneumonia (CURB-65 groups 0 and 1). We stratified the patients according to the presence of hypoxemia, defined as a P(aO2)/F(IO2) < 300 mm Hg on admission. We assessed the risk factors associated with hypoxemia, hypoxemia's influence on the course of pneumonia, and clinical outcomes (mortality, hospital stay, and need for intensive care unit admission), with multivariable regression. RESULTS: Fifty percent of the patients (294 cases) had hypoxemia on admission. The risk factors independently associated with hypoxemia were: bilateral radiological involvement (odds ratio 2.8, 95% CI 1.1-7.5), history of COPD (odds ratio 2.5, 95% CI 1.4-4.3), and hypoalbuminemia (odds ratio 2.0, 95% CI 1.1-3.5). The hypoxemic patients had longer hospital stay, higher intensive care unit admission rate, higher rate of severe sepsis, and higher mortality than the non-hypoxemic patients. CONCLUSIONS: Hypoxemia in patients with mild pneumonia is independently associated with several adverse clinical and radiological variables, and the hypoxemic patients had worse clinical outcomes than the non-hypoxemic patients. Therefore, additional attention should be paid to the presence of hypoxemia, regardless of a low CURB-65 score. C1 [Sanz, Francisco] Univ Valencia, Consorci Hosp Gen, Serv Neumol, Valencia 46014, Spain. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pulm & Crit Care Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Fernandez, Estrella; Cervera, Angela] Hosp Univ Doctor Peset Valencia, Serv Neumol, Valencia, Spain. [Mortensen, Eric M.] S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA. [Carmen Aguar, Maria] Hosp Arnau Vilanova, Serv Neumol, Valencia, Spain. [Chiner, Eusebi] Hosp St Joan, Serv Neumol, Alacant, Spain. [Blanquer, Jose] Hosp Clin Univ Valencia, Serv Med Intens, Valencia, Spain. RP Sanz, F (reprint author), Univ Valencia, Consorci Hosp Gen, Serv Neumol, Tres Cruces 2, Valencia 46014, Spain. EM sanz_fraher@gva.es RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 FU Department of Veteran Affairs Veterans Integrated Service Network [17]; National Institutes of Health [KL2 RR025766]; Clinical and Translational Science Award [KL2 RR025766/VISN-17] FX Dr Restrepo was partly supported by a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant, by National Institutes of Health grant KL2 RR025766, and by Clinical and Translational Science Award KL2 RR025766/VISN-17. Dr Restrepo has disclosed relationships with Johnson & Johnson, CR Bard, Pfizer, Covidien, Ortho McNeil-Janssen, Whyeth, Theravan. Dr Mortensen EM has disclosed a relationship with the United States National Institutes of Health. The other authors have disclosed no conflicts of interest. The organizations that supported this research had no role in conducting the study or preparing, reviewing, or approving this paper. NR 31 TC 11 Z9 11 U1 0 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD MAY PY 2011 VL 56 IS 5 BP 612 EP 618 DI 10.4187/respcare.00853 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 771XO UT WOS:000291194200008 PM 21276314 ER PT J AU Stone, WS Giuliano, AJ Tsuang, MT Braff, DL Cadenhead, KS Calkins, ME Dobie, DJ Faraone, SV Freedman, R Green, MF Greenwood, TA Gur, RE Gur, RC Light, GA Mintz, J Nuechterlein, KH Olincy, A Radant, AD Roe, AH Schork, NJ Siever, LJ Silverman, JM Swerdlow, NR Thomas, AR Tsuang, DW Turetsky, BI Seidman, LJ AF Stone, William S. Giuliano, Anthony J. Tsuang, Ming T. Braff, David L. Cadenhead, Kristin S. Calkins, Monica E. Dobie, Dorcas J. Faraone, Stephen V. Freedman, Robert Green, Michael F. Greenwood, Tiffany A. Gur, Raquel E. Gur, Ruben C. Light, Gregory A. Mintz, Jim Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Roe, Andrea H. Schork, Nicholas J. Siever, Larry J. Silverman, Jeremy M. Swerdlow, Neal R. Thomas, Alison R. Tsuang, Debby W. Turetsky, Bruce I. Seidman, Larry J. TI Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: Findings from the Consortium on the Genetics of Schizophrenia (COGS) SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Verbal declarative memory; Schizophrenia; Endophenotype ID ANTISACCADE PERFORMANCE; NONPSYCHOTIC RELATIVES; 1ST-EPISODE SCHIZOPHRENIA; BIOLOGICAL RELATIVES; COGNITIVE DEFICITS; MEMORY IMPAIRMENTS; DECLARATIVE MEMORY; WORKING-MEMORY; METAANALYSIS; ENDOPHENOTYPES AB Genetic studies of schizophrenia focus increasingly on putative endophenotypes because their genetic etiology may be simpler than clinical diagnosis. The Consortium on the Genetics of Schizophrenia (COGS), a multisite family study, aims to identify the genetic basis of several endophenotypes including verbal declarative memory (VDM), a neurocognitive function that shows robust impairment in schizophrenia. We present data on one type of measure of VDM, the California Verbal Learning Test, Second Edition (CVLT-II), in schizophrenia probands (n = 305), their full biological siblings (n = 449) and parents (n = 232), and in community comparison subjects (CCS: n = 509) across seven sites. Probands performed more poorly on each of five CVLT-II measures compared to related sibling and parent groups and CCS. Siblings and parents performed significantly worse than CCS on one measure (Discriminability), but with smaller effect sizes and less impairment than observed previously. The results raise questions about the homogeneity of VDM as an endophenotype, about methodological issues related to sampling, and about psychometric issues that impact the utility of the CVLT for detecting VDM deficits in nonpsychotic relatives of persons with schizophrenia. (C) 2011 Elsevier B.V. All rights reserved. C1 [Stone, William S.; Giuliano, Anthony J.; Roe, Andrea H.; Thomas, Alison R.; Seidman, Larry J.] Harvard Univ, Massachusetts Mental Hlth Ctr, Beth Israel Deaconess Med Ctr, Publ Psychiat Div,Med Sch, Boston, MA 02215 USA. [Stone, William S.; Tsuang, Ming T.; Seidman, Larry J.] Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. [Tsuang, Ming T.; Braff, David L.; Cadenhead, Kristin S.; Greenwood, Tiffany A.; Light, Gregory A.; Schork, Nicholas J.; Swerdlow, Neal R.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Med Genet Res Program, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY 13210 USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Dobie, Dorcas J.; Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Dobie, Dorcas J.; Radant, Allen D.; Tsuang, Debby W.] Dept Vet Affairs VISN 20 Mental Illness Res Educ, Seattle, WA USA. [Green, Michael F.; Mintz, Jim; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.] James J Peters VA & VISN3 Mental Illness Res Educ, Bronx, NY USA. RP Stone, WS (reprint author), Harvard Univ, Sch Med, Dept Psychiat BIDMC, 2nd Floor E,401 Pk Dr, Boston, MA 02215 USA. EM wstone@bidmc.harvard.edu; dbraff@ncsd.edu RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016 OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang, Debby/0000-0002-4716-1894; Faraone, Stephen/0000-0002-9217-3982 FU NIMH [RO1 -MH065562]; Mount Sinai School of Medicine [RO1-MH065554]; University of California Los Angeles [RO1-MH65707]; University of California San Diego [RO1-MH065571]; University of Colorado [RO1-MH65588]; University of Pennsylvania [RO1-MH65578]; University of Washington [RO1-MH65558] FX This work was supported by the NIMH through grants to Harvard University (RO1 -MH065562), Mount Sinai School of Medicine (RO1-MH065554), University of California Los Angeles (RO1-MH65707), University of California San Diego (RO1-MH065571), University of Colorado (RO1-MH65588), University of Pennsylvania (RO1-MH65578) and the University of Washington (RO1-MH65558). NR 46 TC 17 Z9 17 U1 3 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAY PY 2011 VL 128 IS 1-3 BP 102 EP 110 DI 10.1016/j.schres.2011.01.005 PG 9 WC Psychiatry SC Psychiatry GA 771QL UT WOS:000291175700018 PM 21288694 ER PT J AU Wain, RM Wilbourne, PL Harris, KW Pierson, H Teleki, J Burling, TA Lovett, S AF Wain, R. Morgan Wilbourne, Paula L. Harris, Keith W. Pierson, Heather Teleki, Jasmine Burling, Thomas A. Lovett, Steven TI Motivational interview improves treatment entry in homeless veterans SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Motivational interview; Homeless veterans; Treatment retention; Wait-list attrition ID SUBSTANCE-ABUSE TREATMENT; BRIEF INTERVENTIONS; RANDOMIZED-TRIAL; CLINICAL-TRIALS; USE DISORDERS; DRUG; EFFICACY; SERVICES; OUTCOMES; LENGTH AB Motivational Interviewing (MI) has successfully been used to facilitate entry and compliance in drug and alcohol treatment programs. Some questions have been raised as to the effectiveness of MI in severely distressed populations. This study aims to assess the effectiveness of MI in a population of homeless, unemployed, and substance dependent veterans who are being wait-listed for entry into a residential treatment program. Seventy-five veterans placed on a wait-list were randomized to receive a single MI or standard (Std) intake interview. Outcomes assessed were entry, and length of stay (LOS). Secondary outcomes assessed included program completion and rates of graduation. Readiness to change and self-efficacy were assessed before and after the interview. Significantly more participants entered the program in the MI group (95%) than in the Std group (71%). Although those in the MI group remained in the program longer, and had higher program completion and graduation rates, these differences were not statistically significant. No significant between-group or within-group differences were found in readiness or self-efficacy. This study demonstrates that a single, easily administered intervention can increase program entry. Also based on the study findings, further research into the question of whether MI can increase program retention, in a severely distressed population, is warranted. Published by Elsevier Ireland Ltd. C1 [Harris, Keith W.] VHA Off Mental Hlth Serv, Homeless & Residential Rehabil Treatment Program, Fremont, CA 94538 USA. [Wilbourne, Paula L.] VA Palo Alto Hlth Care Syst, Addict Treatment Serv, Menlo Pk, CA 94025 USA. [Pierson, Heather] VA Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. [Teleki, Jasmine] Behav Med Clin, Stanford, CA 94304 USA. [Lovett, Steven] VA Palo Alto Hlth Care Syst, Psychol Serv 116B, Palo Alto, CA 94304 USA. RP Harris, KW (reprint author), VHA Off Mental Hlth Serv, Homeless & Residential Rehabil Treatment Program, 39199 Liberty St, Fremont, CA 94538 USA. EM Keith.Harris@va.gov NR 39 TC 8 Z9 8 U1 3 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2011 VL 115 IS 1-2 BP 113 EP 119 DI 10.1016/j.drugalcdep.2010.11.006 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 770IE UT WOS:000291079400018 PM 21145181 ER PT J AU Rumsfeld, JS Allen, LA AF Rumsfeld, John S. Allen, Larry A. TI Reducing Readmission Rates Does Coronary Artery Bypass Graft Surgery Provide Clarity? SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material DE coronary artery bypass graft surgery; outcomes; quality measures; readmission; rehospitalization ID HEART-FAILURE AB Because hospital readmissions are costly and potentially avoidable, reducing hospital readmission rates has been touted as a means to improve quality and reduce costs. Cardiovascular disease is a natural focus for this because of overall costs of treatment and frequency of readmission (e.g., nearly 1 in 4 Medicare patients is readmitted within 30 days after hospitalization for heart failure) (1). Since 2009, hospital-level 30-day risk-standardized readmission rates for acute myocardial infarction and heart failure have been publicly reported for Medicare patients (1). C1 [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Rumsfeld, John S.; Allen, Larry A.] Colorado Cardiovasc Outcomes Res Consortium, Denver, CO USA. [Rumsfeld, John S.; Allen, Larry A.] Univ Colorado, Div Cardiol, Aurora, CO USA. RP Rumsfeld, JS (reprint author), VA Eastern Colorado Hlth Care Syst, Cardiol 111B,1055 Clermont St, Denver, CO 80220 USA. EM john.rumsfeld@va.gov NR 8 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD MAY PY 2011 VL 4 IS 5 BP 577 EP 578 DI 10.1016/j.jcin.2011.04.002 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 769KR UT WOS:000291012500015 PM 21596332 ER PT J AU Goebel, JR Compton, P Zubkoff, L Lanto, A Asch, SM Sherbourne, CD Shugarman, L Lorenz, KA AF Goebel, Joy R. Compton, Peggy Zubkoff, Lisa Lanto, Andy Asch, Steven M. Sherbourne, Cathy D. Shugarman, Lisa Lorenz, Karl A. TI Prescription Sharing, Alcohol Use, and Street Drug Use to Manage Pain Among Veterans SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Prescription sharing; substance use disorders; substance misuse; street drugs; mental health; pain management; symptoms; quality of life; spiritual well-being ID SUBSTANCE USE DISORDERS; CHRONIC NONCANCER PAIN; PHYSICAL-DEPENDENCE; ANALGESIC THERAPY; NONMALIGNANT PAIN; OPIOID MISUSE; PRIMARY-CARE; ABUSE; PSEUDOADDICTION; PREVALENCE AB Context. Efforts to promote awareness and management of chronic pain have been accompanied by a troubling increase in prescription medication abuse. At the same time, some patients may misuse substances in an effort to manage chronic pain. Objectives. This study examines self-reported substance misuse for pain management among veterans and identifies the contributing factors. Methods. We analyzed cross-sectional data from the Help Veterans Experience Less Pain study. Results. Of 343 veterans, 35.3% reported an aberrant pain management behavior (24% reported using alcohol, 11.7% reported using street drugs, and 16.3% reported sharing prescriptions to manage pain). Poorer mental health, younger age, substance use disorders (SUDs), number of nonpain symptoms, and greater pain severity and interference were associated with aberrant pain management behaviors. In multivariate analysis, SUDs (odds ratio [OR]: 3.9, 95% confidence interval [CI]: 2.3-6.7, P < 0.000) and poorer mental health (OR: 2.3, 95% CI: 1.3-4.3, P = 0.006) were associated with using alcohol or street drugs to manage pain; SUDs (OR: 2.4, 95% CI: 1.3-4.4, P - 0.006) and pain interference (OR: 1.1, 95% CI: 1.0-1.2, P = 0.047) were associated with prescription sharing; and SUDs (OR: 3.6, 95% CI: 2.2-6.1, P < 0.000) and number of nonpain symptoms (OR: 6.5, 95% CI: 1.2-35.4, P = 0.031) were associated with any aberrant pain management behavior. Conclusion. Veterans with a history of SUDs, greater pain interference, more nonpain symptoms, and mental health concerns should be carefully managed to deter substance misuse for pain management. J Pain Symptom Manage 2011; 41:848-858. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Goebel, Joy R.] Calif State Univ Long Beach, Sch Nursing, Long Beach, CA 90840 USA. [Compton, Peggy] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Asch, Steven M.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Zubkoff, Lisa] Vet Affairs Med Ctr, New England HealthCare Engn Partnership, White River Jct, VT USA. [Lanto, Andy; Asch, Steven M.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven M.; Sherbourne, Cathy D.; Shugarman, Lisa; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA. RP Goebel, JR (reprint author), Calif State Univ Long Beach, Sch Nursing, 1250 Bellflower Blvd, Long Beach, CA 90840 USA. EM jgoebel@csulb.edu FU Department of Veterans Affairs Health Services Research Development [IIR 03-152] FX This study was funded by the Department of Veterans Affairs Health Services Research & Development Merit Award IIR 03-152. K. L. is the recipient of a VA HSR&D Advanced Career Development Award. The authors declare no conflicts of interest. NR 69 TC 16 Z9 16 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAY PY 2011 VL 41 IS 5 BP 848 EP 858 DI 10.1016/j.jpainsymman.2010.07.009 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 768NQ UT WOS:000290942200008 PM 21256706 ER PT J AU Raval, MV Wang, X Cohen, ME Ingraham, AM Bentrem, DJ Dimick, JB Flynn, T Hall, BL Ko, CY AF Raval, Mehul V. Wang, Xue Cohen, Mark E. Ingraham, Angela M. Bentrem, David J. Dimick, Justin B. Flynn, Timothy Hall, Bruce L. Ko, Clifford Y. TI The Influence of Resident Involvement on Surgical Outcomes SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID QUALITY IMPROVEMENT PROGRAM; RISK ADJUSTMENT; PATIENT SAFETY; NONTEACHING HOSPITALS; TEACHING HOSPITALS; INPATIENT SURGERY; MEDICARE PATIENTS; AMERICAN-COLLEGE; GENERAL-SURGERY; MORTALITY AB BACKGROUND: Although the training of surgical residents is often considered in national policy addressing complications and safety, the influence of resident intraoperative involvement on surgical outcomes has not been well studied. STUDY DESIGN: We identified 607,683 surgical cases from 234 hospitals from the 2006 to 2009 American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). Outcomes were compared by resident involvement for all general and vascular cases as well as for specific general surgical procedures. RESULTS: After typical ACS NSQIP comorbidity risk adjustment and further adjustment for hospital teaching status and operative time in modeling, resident intraoperative involvement was associated with slightly increased morbidity when assessing overall general or vascular procedures (odds ratio [OR] 1.06; 95% CI 1.04 to 1.09), pancreatectomy or esophagectomy (OR 1.26; 95% CI 1.08 to 1.45), and colorectal resections (OR 1.15; 95% CI 1.09 to 1.22). In contrast, for mortality, resident intraoperative involvement was associated with reductions for overall general and vascular procedures (OR 0.91; 95% CI 0.84 to 0.99), colorectal resections (OR 0.88; 95% CI 0.78 to 0.99), and abdominal aortic aneurysm repair (OR 0.71; 95% CI 0.53 to 0.95). Results were moderated somewhat after hierarchical modeling was performed to account for hospital-level variation, with mortality results no longer reaching significance (overall morbidity OR 1.07; 95% CI 1.03 to 1.10, overall mortality OR 0.97; 95% CI 0.90 to 1.05). Based on risk-adjusted event rates, resident intraoperative involvement is associated with approximately 6.1 additional morbidity events but 1.4 fewer deaths per 1,000 general and vascular surgery procedures. CONCLUSIONS: Resident intraoperative participation is associated with slightly higher morbidity rates but slightly decreased mortality rates across a variety of procedures and is minimized further after taking into account hospital-level variation. These clinically small effects may serve to reassure patients and others that resident involvement in surgical care is safe and possibly protective with regard to mortality. (J Am Coll Surg 2011;212:889-898. (C) 2011 by the American College of Surgeons) C1 [Raval, Mehul V.; Wang, Xue; Cohen, Mark E.; Ingraham, Angela M.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Raval, Mehul V.; Bentrem, David J.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Dimick, Justin B.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Flynn, Timothy] Univ Florida, Gainesville, FL USA. Washington Univ, Dept Surg, John Cochran Vet Affairs Med Ctr, St Louis, MO USA. Barnes Jewish Hosp, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO 63130 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM m-raval@md.northwestern.edu OI Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F and Ada L Rice Foundation; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FX Drs Raval and Ingraham participate in the American College of Surgeons Clinical Scholars in Residence Program. Dr Raval is supported by the John Gray Research Fellowship and the Daniel F and Ada L Rice Foundation. Dr Bentrem is supported by a career development award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. Dr Hall assists with the conduct of the ACS NSQIP nationally. NR 46 TC 101 Z9 101 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAY PY 2011 VL 212 IS 5 BP 889 EP 898 DI 10.1016/j.jamcollsurg.2010.12.029 PG 10 WC Surgery SC Surgery GA 768RU UT WOS:000290956000019 PM 21398151 ER PT J AU Filley, CM Brodtmann, A AF Filley, Christopher M. Brodtmann, Amy TI Lacunes and cognitive decline Little things matter SO NEUROLOGY LA English DT Editorial Material ID SMALL VESSEL DISEASE; DEMENTIA; ATROPHY; MRI C1 [Filley, Christopher M.] Univ Colorado, Dept Neurol, Sch Med, Aurora, CO USA. [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Brodtmann, Amy] Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic, Australia. RP Filley, CM (reprint author), Behav Neurol Sect, 12631 E 17th Ave,POB 6511, Aurora, CO 80045 USA. EM filley@ucdenver.edu NR 15 TC 8 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY PY 2011 VL 76 IS 22 BP 1856 EP 1857 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 769WN UT WOS:000291049100005 PM 21543732 ER PT J AU Groessl, EJ Weingart, KR Gifford, AL Asch, SM Ho, SB AF Groessl, Erik J. Weingart, Kimberly R. Gifford, Allen L. Asch, Steven M. Ho, Samuel B. TI Development of the Hepatitis C Self-Management Program SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Patient self-management; Cognitive/behavioral interventions; Hepatitis C ID QUALITY-OF-LIFE; PRIMARY-CARE PATIENTS; VIRUS-INFECTION; ANTIVIRAL THERAPY; WEIGHT-REDUCTION; CHRONIC DISEASE; PLUS RIBAVIRIN; UNITED-STATES; HEALTH-CARE; VETERANS AB Objective: Chronic hepatitis C infection (HCV) is a major health problem that disproportionately affects people with limited resources. Many people with HCV are ineligible or refuse antiviral treatment, but less curative treatment options exist. These options include adhering to follow-up health visits, lifestyle changes, and avoiding hepatotoxins like alcohol. Herein, we describe a recently developed self-management program designed to assist HCV-infected patients with adherence and improve their health-related quality of life (HRQOL). Methods: The development of the Hepatitis C Self-Management Program (HCV-SMP) was informed by scientific literature, qualitative interviews with HCV-infected patients, self-management training, and feedback from HCV clinical experts. Results: The Hepatitis C Self-Management Program (HCV-SMP) is a multi-faceted program that employs cognitive-behavioral principles and is designed to provide HCV-infected people with knowledge and skills for improving their HRQOL. The program consists of six 2-h workshop sessions which are held weekly. The sessions consist of a variety of group activities, including disease-specific information dissemination, action planning, and problem-solving. Conclusion: The intervention teaches skills for adhering to challenging treatment recommendations using a validated theoretical model. A randomized trial will test the efficacy of this novel HCV self-management program for improving HRQOL in a difficult to reach population. Published by Elsevier Ireland Ltd. C1 [Groessl, Erik J.; Weingart, Kimberly R.; Ho, Samuel B.] VA San Diego Healthcare Syst, San Diego, CA 92161 USA. [Groessl, Erik J.; Ho, Samuel B.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven M.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA. RP Groessl, EJ (reprint author), VA San Diego Healthcare Syst, 3350 La Jolla Village Dr 111 N-1, San Diego, CA 92161 USA. EM egroessl@ucsd.edu FU VA HSRD [IAC 05-067] FX This study is funded by a research grant from the VA HSR&D, Project # IAC 05-067. NR 41 TC 5 Z9 5 U1 1 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD MAY PY 2011 VL 83 IS 2 BP 252 EP 255 DI 10.1016/j.pec.2010.06.006 PG 4 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 768JC UT WOS:000290929200020 PM 20638216 ER PT J AU McTigue, KM Bhargava, T Bryce, CL Conroy, M Fischer, GS Hess, R Simkin-Silverman, LR Zickmund, S AF McTigue, Kathleen M. Bhargava, Tina Bryce, Cindy L. Conroy, Molly Fischer, Gary S. Hess, Rachel Simkin-Silverman, Laurey R. Zickmund, Susan TI Patient perspectives on the integration of an intensive online behavioral weight loss intervention into primary care SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Primary health care; Internet; Obesity; Counseling; Preventive medicine ID LIFE-STYLE INTERVENTION; OBESITY; PHYSICIANS; HEALTH; MANAGEMENT; ADULTS; PREVENTION; ATTITUDES; INTERNET; ADVICE AB Objective: To examine patients' perception of how a referral-based online lifestyle intervention contributed to primary care medicine. Methods: We invited 50 adults to complete a semi-structured interview after a 1-year online behavioral weight loss intervention (average weight change: -4.79 kg). We developed an iterative codebook using content analysis. Two coders independently coded all transcripts (kappa = 0.895). We analyzed responses regarding the integration of the program with primary care. Results: Among the 35 participants who completed the interview, 46% described a positive experience between the program and their routine medical care; 14% noted it was fine/OK; 9% reported no effect, 3% were negative, 11% said that the program was unrelated to their medical care, and 14% that the only connection was the referral. Factors such as physician feedback and support, coordination with routine health care, and improved cardiovascular risk factors were cited in support of a positive experience. Physician feedback was reported by 89%, and 80% stated that the program helped them to follow their physician's advice. Conclusion: Physician referral to online education and counseling may facilitate the integration of evidence-based behavioral counseling with primary care. Practice implications: Internet technology may enable improved access to evidence-based counseling for chronic health problems. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [McTigue, Kathleen M.; Bhargava, Tina; Bryce, Cindy L.; Conroy, Molly; Fischer, Gary S.; Hess, Rachel; Zickmund, Susan] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA. [McTigue, Kathleen M.; Conroy, Molly; Hess, Rachel; Simkin-Silverman, Laurey R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Bhargava, Tina] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15213 USA. [Zickmund, Susan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP McTigue, KM (reprint author), Univ Pittsburgh, Dept Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM kmm34@pitt.edu; tdb11@pitt.edu; brycecl@upmc.edu; conroymb@upmc.edu; fischerg@upmc.edu; rah67@pitt.edu; lrs@pitt.edu; Susan.Zickmund@va.gov OI Bryce, Cindy/0000-0001-6356-6675; Simkin-Silverman, Lauren/0000-0003-1572-8726 FU Department of Defense through University of Pittsburgh Diabetes Institute [USAMRAA W81XWH-04-2-0030] FX This project was supported with a grant from the Department of Defense [USAMRAA W81XWH-04-2-0030 Siminerio (PI)]. through the University of Pittsburgh Diabetes Institute. While the University of Pittsburgh has licensed the online program's contents to DPS Health, the authors have assigned the copyright to the University and receive no personal royalties from its commercial use. Support for Dr. Zickmund was provided in part by the Veteran's Administration Health Services Research and Development Merit Review funds. NR 33 TC 8 Z9 8 U1 1 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD MAY PY 2011 VL 83 IS 2 BP 261 EP 264 DI 10.1016/j.pec.2010.05.009 PG 4 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 768JC UT WOS:000290929200022 PM 21459256 ER PT J AU Chen, YX Gelfond, J McManus, LM Shireman, PK AF Chen, Yongxin Gelfond, Jonathan McManus, Linda M. Shireman, Paula K. TI Temporal microRNA expression during in vitro myogenic progenitor cell proliferation and differentiation: regulation of proliferation by miR-682 SO PHYSIOLOGICAL GENOMICS LA English DT Article DE muscle regeneration; muscle differentiation; muscle regeneration; satellite cell ID MUSCLE SATELLITE CELLS; SKELETAL-MUSCLE; GENE-EXPRESSION; MICROARRAY DATA; STEM-CELLS; REGENERATION; GROWTH; REPRESSION; APOPTOSIS; MIR-206 AB Chen Y, Gelfond J, McManus LM, Shireman PK. Temporal microRNA expression during in vitro myogenic progenitor cell proliferation and differentiation: regulation of proliferation by miR-682. Physiol Genomics 43: 621-630, 2011. First published September 14, 2010; doi:10.1152/physiolgenomics.00136.2010.MicroRNAs (miRNAs) regulate gene expression by repressing target genes at the posttranscriptional level. Since miRNAs have unique expression profiles in different tissues, they provide pivotal regulation of many biological processes. The present study defined miRNA expression during murine myogenic progenitor cell (MPC) proliferation and differentiation to identify miRNAs involved in muscle regeneration. Muscle-related gene expression analyses revealed that the time course and expression of myosin heavy chain (MHC) and transcription factors (Myf5, MyoD, myogenin, and Pax7) were similar during in vitro MPC proliferation/differentiation and in vivo muscle regeneration. Comprehensive profiling revealed that 139 or 16 miRNAs were significantly changed more than twofold [false discovery rate (FDR) < 0.05] during MPC differentiation or proliferation, respectively; cluster analyses revealed five distinct patterns of miRNA expression during the time course of MPC differentiation. Not unexpectedly, the largest miRNA changes occurred in muscle-specific miRNAs (miR-1, -133a, and -499), which were upregulated > 10-fold during MPC differentiation (FDR < 0.01). However, several previously unreported miRNAs were differentially expressed, including miR-10b, -335-3p, and -682. Interestingly, the temporal patterns of miR-1, -499, and -682 expression during in vitro MPC proliferation/differentiation were remarkably similar to those observed during in vivo muscle regeneration. Moreover, in vitro inhibition of miR-682, the only miRNA upregulated in proliferating compared with quiescent MPC, led to decreased MPC proliferation, further validating our in vitro assay system for the identification of miRNAs involved in muscle regeneration. Thus the differentially expressed miRNAs identified in the present study could represent new regulatory elements in MPC proliferation and differentiation. C1 [Chen, Yongxin; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Gelfond, Jonathan] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Chen, Yongxin; Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Chen, YX (reprint author), 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM cheny4@uthscsa.edu FU Department of Veterans Affairs; National Institutes of Health [R01-HL-074236, T32-HL-07446, KL2-RR-025766] FX These studies were supported, in part, by a Department of Veterans Affairs Merit Review grant and National Institutes of Health Grants R01-HL-074236, T32-HL-07446, and KL2-RR-025766. NR 63 TC 29 Z9 30 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 EI 1531-2267 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD MAY PY 2011 VL 43 IS 10 BP 621 EP 630 DI 10.1152/physiolgenomics.00136.2010 PG 10 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 769LK UT WOS:000291014800013 PM 20841498 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Iodinated Contrast Media and the Role of Renal Replacement Therapy SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE Contrast media; Acute kidney injury; Dialysis; Hemofiltration ID RADIOCONTRAST-INDUCED NEPHROPATHY; RANDOMIZED CONTROLLED-TRIAL; OXYGEN-FREE-RADICALS; DIURESIS DVD TRIAL; PROPHYLACTIC HEMODIALYSIS; IOPROMIDE ELIMINATION; CORONARY-ANGIOGRAPHY; DIALYSIS; PREVENTION; FAILURE AB Iodinated contrast media are among the most commonly used pharmacologic agents in medicine. Although generally highly safe, iodinated contrast media are associated with several adverse effects, most significantly the risk of acute kidney injury, particularly in patients with underlying renal dysfunction. By virtue of their pharmacokinetic characteristics, these contrast agents are efficiently cleared by hemodialysis and to a lesser extent, hemofiltration. This has led to research into the capacity for renal replacement therapies to prevent certain adverse effects of iodinated contrast. This review examines the molecular and pharmacokinetic characteristics of iodinated contrast media and critically analyzes data from past studies on the role of renal replacement therapy to prevent adverse effects of these diagnostic agents. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Dept Med, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Ctr Hlth Equ Res & Promot, Univ Dr Div,7 East,Room 120 111F U, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU VA Health Services Research and Development Career Development Transition Award [RCD 03-176] FX Dr. Weisbord is the recipient of a VA Health Services Research and Development Career Development Transition Award (RCD 03-176). NR 49 TC 3 Z9 4 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD MAY PY 2011 VL 18 IS 3 BP 199 EP 206 DI 10.1053/j.ackd.2010.11.008 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 765KC UT WOS:000290703500008 PM 21531326 ER PT J AU Lysack, C Lichtenberg, P Schneider, B AF Lysack, Cathy Lichtenberg, Peter Schneider, Brooke TI Effect of a DVD Intervention on Therapists' Mental Health Practices With Older Adults SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY LA English DT Article DE clinical competence; depression; education, continuing; educational measurement; mental health services ID LATE-LIFE DEPRESSION; HOME-CARE; OCCUPATIONAL-THERAPY; TREATING DEPRESSION; RECOGNITION; COMPETENCE; SCALE AB PURPOSE. We tested the effectiveness of an educational intervention in DVD format aimed at strengthening the mental health practices of occupational therapists working with older adults. METHOD. The DVD intervention was tested in a pretest-posttest design. Occupational therapists (n = 30) completed a brief knowledge and attitude questionnaire; a chart review (n = 383) of therapists' (n = 20) patients at 3 mo before and 3 mo after DVD training was also conducted. RESULTS. Questionnaire data showed that the percentage of therapists with correct answers increased 20%-30% for 5 of the 11 knowledge items. Chart review data showed therapists spoke more often with their older patients about mood, depression, and cognitive impairment; screened more often for depression and cognitive impairment; and reported findings more often to the treatment team after training. CONCLUSION. Educational interventions can significantly improve therapists' mental health practice with older adults. C1 [Lysack, Cathy; Lichtenberg, Peter] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA. [Schneider, Brooke] W Los Angeles Vet Affairs Med Ctr, Psychol Serv, Los Angeles, CA 90073 USA. RP Lysack, C (reprint author), Wayne State Univ, Inst Gerontol, Room 231,Knapp Bldg,87 E Ferry St, Detroit, MI 48202 USA. EM c.lysack@wayne.edu NR 30 TC 5 Z9 5 U1 1 U2 2 PU AMER OCCUPATIONAL THERAPY ASSOC, INC PI BETHESDA PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA SN 0272-9490 J9 AM J OCCUP THER JI Am. J. Occup. Ther. PD MAY-JUN PY 2011 VL 65 IS 3 SI SI BP 297 EP 305 DI 10.5014/ajot.2011.001354 PG 9 WC Rehabilitation SC Rehabilitation GA 765KQ UT WOS:000290704900008 PM 21675335 ER PT J AU Chren, MM Torres, JS Stuart, SE Bertenthal, D Labrador, RJ Boscardin, J AF Chren, Mary-Margaret Torres, Jeanette S. Stuart, Sarah E. Bertenthal, Daniel Labrador, Remedios J. Boscardin, John TI Recurrence After Treatment of Nonmelanoma Skin Cancer A Prospective Cohort Study SO ARCHIVES OF DERMATOLOGY LA English DT Article ID BASAL-CELL CARCINOMA; MOHS MICROGRAPHIC SURGERY; FACE AB Objective: To determine long-term tumor recurrence rates after treatment of primary nonmelanoma skin cancer (NMSC). Data are currently insufficient to permit evidence-based choices among treatments for NMSC. Design: Prospective study of an inception cohort observed for a median of 6.6 years after treatment. Setting: Dermatology clinic at a Veterans Affairs hospital. Care was provided by dermatology resident or attending physicians. Patients: Consecutive sample of all 495 patients with 616 primary NMSCs diagnosed in 1999 and 2000 and treated with electrodessication and curettage (ED&C), excision, or Mohs surgery. Follow-up was available for 608 tumors (99%). Main Outcome Measure: Tumor recurrence, deter-mined by medical record review, with validation by clinical examination. Results: The mean age at diagnosis was 71 years; 97% were men. Overall, 127 tumors were treated with ED&C (20.9%); 309 with excision (50.8%); and 172 with Mohs surgery (28.3%). Over the course of the study, 21 tumors recurred (3.5% [95% confidence interval (CI), 2.2%-5.2%]): 2 after ED&C (1.6% [95% CI, 0.2%-5.6%]), 13 after excision (4.2% [95% CI, 2.2%-7.1%]), and 6 after Mohs surgery (3.5% [95% CI, 1.3%-7.4%]). Conclusions: Recurrence of primary NMSC after treatment occurred in less than 5% of tumors. The recurrence rate after ED&C was lower than expected, and the recurrence rate after Mohs surgery was higher than expected. These findings may be related to the risk for recurrence in the treatment groups. C1 [Chren, Mary-Margaret; Torres, Jeanette S.; Stuart, Sarah E.; Bertenthal, Daniel; Labrador, Remedios J.; Boscardin, John] San Francisco VA Med Ctr, Res Enhancement Award Program, Hlth Serv Res & Dev Serv, Dept Vet Affairs, San Francisco, CA USA. [Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Boscardin, John] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Boscardin, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Chren, MM (reprint author), San Francisco VA Med Ctr 151R, 4150 Clement St, San Francisco, CA 94121 USA. EM chrenm@derm.ucsf.edu FU Investigator-Initiated Research Grant [IIR 04-043-3]; Health Services Research and Development Service of the Department of Veterans Affairs; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health [K24 AR052667, R01 AR 054983] FX This work was supported by Investigator-Initiated Research Grant IIR 04-043-3 and the San Francisco Research Enhancement Award Program (REAP) of the Health Services Research and Development Service of the Department of Veterans Affairs, and by grants K24 AR052667 and R01 AR 054983 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health. NR 16 TC 35 Z9 38 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD MAY PY 2011 VL 147 IS 5 BP 540 EP 546 PG 7 WC Dermatology SC Dermatology GA 764LX UT WOS:000290632100004 PM 21576572 ER PT J AU Ripoll, LH Zaki, J Perez-Rodriguez, M New, AS AF Ripoll, Luis H. Zaki, Jamil Perez-Rodriguez, Mercedes New, Antonia S. TI Empathic Accuracy and Social Cognition in Personality Disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Ripoll, Luis H.; New, Antonia S.] James J Peters VA Med Ctr, MIRECC, Bronx, NY USA. [Zaki, Jamil] Harvard Univ, Dept Psychol, Boston, MA 02115 USA. [Perez-Rodriguez, Mercedes] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 177 BP 50S EP 50S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800162 ER PT J AU Bevilacqua, L Hadjulis, M Enoch, MA New, AS Hodgkinson, CA Yuan, QP Shen, PH Siever, LJ Roy, A Goldman, D AF Bevilacqua, Laura Hadjulis, Michael Enoch, Mary-Anne New, Antonia S. Hodgkinson, Colin A. Yuan, Qiaoping Shen, Pei-Hong Siever, Larry J. Roy, Alec Goldman, David TI An HTR2B Low-expression Haplotype Predicts Risk of Cocaine Dependence and Aggression SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Bevilacqua, Laura; Enoch, Mary-Anne; Hodgkinson, Colin A.; Yuan, Qiaoping; Shen, Pei-Hong; Goldman, David] NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA. [Hadjulis, Michael; New, Antonia S.; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA. [Hadjulis, Michael; New, Antonia S.; Siever, Larry J.] James J Peters VA Med Ctr, New York, NY USA. [Roy, Alec] New Jersey VA Hlth Care Syst, Dept Vet Affairs, E Orange, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 211 BP 60S EP 61S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800196 ER PT J AU Alexander, PR Garrett, CT Fisher, M Vinogradov, S AF Alexander, Phillip R. Garrett, Coleman T. Fisher, Melissa Vinogradov, Sophia TI Insight into Cognition Predicts Response to Cognitive Training in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Alexander, Phillip R.; Garrett, Coleman T.; Fisher, Melissa; Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Alexander, Phillip R.; Garrett, Coleman T.; Fisher, Melissa; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 485 BP 145S EP 145S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800462 ER PT J AU Tyrka, AR Price, LH Marsit, C Walters, C Wilkinson, CW Carpenter, LL AF Tyrka, Audrey R. Price, Lawrence H. Marsit, Carmen Walters, Chris Wilkinson, Charles W. Carpenter, Linda L. TI Epigenetic Modulation of Leukocyte Glucocorticoid Receptor in Healthy Adults: Effects of Childhood Parenting Experiences SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Tyrka, Audrey R.; Price, Lawrence H.; Marsit, Carmen; Carpenter, Linda L.] Brown Med Sch, Providence, RI USA. [Walters, Chris] Butler Hosp, Mood Disorders Res Program, Providence, RI 02906 USA. [Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 517 BP 154S EP 155S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800493 ER PT J AU Yao, JK Condray, R Reddy, RD Montrose, DM Keshavan, MS AF Yao, Jeffrey K. Condray, Ruth Reddy, Ravinder D. Montrose, Debra M. Keshavan, Matcheri S. TI Defective Purine Catabolism in High Risk Relatives of Patients with Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Yao, Jeffrey K.; Condray, Ruth; Reddy, Ravinder D.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey K.; Condray, Ruth; Reddy, Ravinder D.; Montrose, Debra M.; Keshavan, Matcheri S.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Keshavan, Matcheri S.] Harvard Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 529 BP 158S EP 158S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800505 ER PT J AU Bartzokis, G Lu, PH Raven, EP Amar, CP DeTore, NR Altshuler, LL Mintz, J Ventura, J Casaus, LR Luo, JS Subotnik, KL Nuechterlein, KH AF Bartzokis, George Lu, Po H. Raven, Erika P. Amar, Chetan P. DeTore, Nicole R. Altshuler, Lori L. Mintz, Jim Ventura, Joseph Casaus, Laurie R. Luo, John S. Subotnik, Kenneth L. Nuechterlein, Keith H. TI Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Treatment Response and Outcomes SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Bartzokis, George; Lu, Po H.; Raven, Erika P.; Amar, Chetan P.; DeTore, Nicole R.; Altshuler, Lori L.; Ventura, Joseph; Casaus, Laurie R.; Luo, John S.; Subotnik, Kenneth L.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Los Angeles, CA USA. [Lu, Po H.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RI Bartzokis, George/K-2409-2013; Mintz, Jim/N-7385-2014 OI Mintz, Jim/0000-0002-8299-5851 NR 0 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 611 BP 185S EP 185S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800587 ER PT J AU Siever, LJ AF Siever, Larry J. TI 5-HT2b Alleles, Frontal Activation, and Aggressive Behavior SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Siever, Larry J.] James J Peters VAMC, Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 667 BP 202S EP 202S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800643 ER PT J AU Xie, PX Kranzler, HR Krauthammer, M Oslin, D Anton, RF Zhao, HY Farrer, LA Gelernter, J AF Xie, Pingxing Kranzler, Henry R. Krauthammer, Michael Oslin, David Anton, Raymond F. Zhao, Hongyu Farrer, Lindsay A. Gelernter, Joel TI Protective Effect of Rare Nonsynonymous Variants In the Alpha-4 Subunit of Nicotinic Acetylcholine Receptor Gene (chrna4) for Nicotine Dependence SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Xie, Pingxing] Yale Univ, Dept Genet, West Haven, CT USA. [Xie, Pingxing; Gelernter, Joel] VA CT Healthcare Ctr, West Haven, CT USA. [Kranzler, Henry R.; Oslin, David] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Kranzler, Henry R.; Oslin, David] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Krauthammer, Michael] Yale Univ, Dept Pathol, New Haven, CT USA. [Anton, Raymond F.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Zhao, Hongyu] Yale Univ, Dept Genet, New Haven, CT USA. [Farrer, Lindsay A.] Boston Univ, Dept Med, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Neurol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Genet & Genom, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Epidemiol & Biostat, Boston, MA 02215 USA. [Gelernter, Joel] Yale Univ, Dept Genet & Psychiat, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 671 BP 203S EP 204S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800647 ER PT J AU Siever, LJ AF Siever, Larry J. TI Schizophrenia Susceptibility Genes and Intermediate Phenotypes in Schizotypal Personality Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Siever, Larry J.] James J Peters VAMC, Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 694 BP 209S EP 209S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800663 ER PT J AU Raskind, MA Redila, VA Olson, VG AF Raskind, Murray A. Redila, Van A. Olson, Valerie G. TI Prazosin Blocks Development of Ethanol, Morphine and Cocaine Conditioned Place Preference in Mice SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Raskind, Murray A.; Olson, Valerie G.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA. [Redila, Van A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 745 BP 223S EP 223S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800706 ER PT J AU Frid, SA Pavlidis, P Dracheya, S Byne, W AF Frid, Simon A. Pavlidis, Paul Dracheya, Stella Byne, William TI Differential Gene Expression in Schizophrenia and Bipolar Disorder in the Corpus Collosum SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Frid, Simon A.; Dracheya, Stella; Byne, William] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Pavlidis, Paul] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada. [Dracheya, Stella; Byne, William] Bronx Vet Affairs Med Ctr, Dept Psychiat, New York, NY USA. RI Pavlidis, Paul/H-8406-2013 OI Pavlidis, Paul/0000-0002-0426-5028 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 756 BP 226S EP 226S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800717 ER PT J AU Radant, AD Braff, D Calkins, M Cadenhead, K Dobie, D Freedman, R Green, M Greenwood, T Gur, R Gur, R Horan, W Light, G Meichle, S Millard, S Olincy, A Nuechterlein, K Seidman, L Siever, L Silverman, J Stone, W Sprock, J Swerdlow, N Tsuang, M Turetsky, B Tsuang, D AF Radant, Allen D. Braff, David Calkins, Monica Cadenhead, Kristin Dobie, Dorcas Freedman, Robert Green, Michael Greenwood, Tiffany Gur, Raquel Gur, Ruben Horan, William Light, Gregory Meichle, Sean Millard, Steve Olincy, Ann Nuechterlein, Keith Seidman, Larry Siever, Larry Silverman, Jeremy Stone, William Sprock, Joyce Swerdlow, Neal Tsuang, Ming Turetsky, Bruce Tsuang, Debby TI Influence of Duration of Schizophrenia on Antisaccade Performance SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Radant, Allen D.; Dobie, Dorcas; Meichle, Sean; Millard, Steve; Tsuang, Debby] Puget Sound Hlth Care Syst, Vet Adm, Educ & Clin Ctr, Mental Illness Res,Seattle Div, Seattle, WA USA. [Radant, Allen D.; Meichle, Sean; Millard, Steve; Tsuang, Debby] Univ Washington, Seattle, WA 98195 USA. [Braff, David; Cadenhead, Kristin; Greenwood, Tiffany; Sprock, Joyce; Swerdlow, Neal; Tsuang, Ming] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Calkins, Monica; Gur, Raquel; Gur, Ruben; Turetsky, Bruce] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Green, Michael; Horan, William; Nuechterlein, Keith] Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. [Green, Michael; Horan, William; Nuechterlein, Keith] Greater Angeles Hlth Care Syst, Vet Adm, Los Angeles Div, Los Angeles, CA USA. [Seidman, Larry; Stone, William] Harvard Univ, Sch Med, Dept Psychiat, MA Mental Hlth Ctr Publ Psychiat Div,Beth Israel, Boston, MA 02115 USA. [Siever, Larry; Silverman, Jeremy] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry; Silverman, Jeremy] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 791 BP 237S EP 237S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800752 ER PT J AU Goldstein, KE Alloy, LB Drabick, DAG New, AS Siever, LJ Hazlett, EA AF Goldstein, Kim E. Alloy, Lauren B. Drabick, Deborah A. G. New, Antonia S. Siever, Larry J. Hazlett, Erin A. TI Cingulum Integrity in Schizotypal Personality Disorder and Borderline Personality Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Goldstein, Kim E.; Alloy, Lauren B.; Drabick, Deborah A. G.] Temple Univ, Philadelphia, PA 19122 USA. [New, Antonia S.; Siever, Larry J.; Hazlett, Erin A.] Mt Sinai Sch Med, New York, NY USA. [New, Antonia S.; Siever, Larry J.; Hazlett, Erin A.] James J Peters VAMC, Mental Illness Res & Clin Ctr MIRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 851 BP 256S EP 256S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800812 ER PT J AU Hazlett, EA Goodman, M Carpenter, D Avedon, J Goldstein, KE New, AS Siever, LJ AF Hazlett, Erin A. Goodman, Marianne Carpenter, David Avedon, Jennifer Goldstein, Kim E. New, Antonia S. Siever, Larry J. TI Exaggerated Amygdala and Startle Response Predicts Positive Dialectical Behavior Therapy Outcome in Borderline Patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Hazlett, Erin A.; Goodman, Marianne; Carpenter, David; Avedon, Jennifer; Goldstein, Kim E.; New, Antonia S.; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA. [Hazlett, Erin A.; Goodman, Marianne; New, Antonia S.; Siever, Larry J.] James J Peters VAMC, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 852 BP 256S EP 256S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800813 ER PT J AU Fryer, SL Watson, TD Jorgensen, KW Yetter, EJ Krystal, JH Mathalon, DH AF Fryer, Susanna L. Watson, Todd D. Jorgensen, Kasper W. Yetter, Elizabeth J. Krystal, John H. Mathalon, Daniel H. TI Cue Reactivity across Stages of Alcohol Dependence: FMRI Reveals Evidence of Altered Attentional Functioning SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Fryer, Susanna L.; Jorgensen, Kasper W.; Yetter, Elizabeth J.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fryer, Susanna L.; Jorgensen, Kasper W.; Yetter, Elizabeth J.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Watson, Todd D.] Lewis & Clark Coll, Portland, OR 97219 USA. [Krystal, John H.; Mathalon, Daniel H.] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 897 BP 272S EP 272S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800858 ER PT J AU Attumi, TA Graham, DY AF Attumi, Taraq A. Graham, David Y. TI Follow-up Testing After Treatment of Helicobacter Pylori Infections: Cautions, Caveats, and Recommendations SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID STOOL ANTIGEN TEST; UREA BREATH TESTS; DIAGNOSIS; GASTRITIS; ANTRUM; CORPUS C1 [Attumi, Taraq A.; Graham, David Y.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Attumi, TA (reprint author), Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. FU NCI NIH HHS [CA116845]; NIDDK NIH HHS [DK56338, DK067366] NR 13 TC 10 Z9 10 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAY PY 2011 VL 9 IS 5 BP 373 EP 375 DI 10.1016/j.cgh.2010.12.025 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 764TV UT WOS:000290657200010 PM 21195791 ER PT J AU Davis, BH Pope, C Mason, PR Magwood, G Jenkins, CM AF Davis, Boyd H. Pope, Charlene Mason, Peyton R. Magwood, Gayenell Jenkins, Carolyn M. TI "It's a Wild Thing, Waiting to Get Me": Stance Analysis of African Americans With Diabetes SO DIABETES EDUCATOR LA English DT Article ID SELF-MANAGEMENT; EDUCATION; CULTURE; HEALTH; CARE; COMMUNICATION AB Purpose This mixed methods study uses a unique approach from social science and linguistics methodologies, a combination of positioning theory and stance analysis, to examine how 20 African Americans with type 2 diabetes make sense of the practices that led to recurrent emergency department visits to identify needs for more effective intervention. Methods In a purposive sample of postemergency department visit interviews with a same-race interviewer, people responded to open-ended questions reflecting on the decision to seek emergency department care. As applied to diabetes education, positioning theory explains that people use their language to position themselves toward their disease, their medications, and the changes in their lives. Transcriptions were coded using discourse analysis to categorize themes. As a form of triangulation, stance analysis measured language patterns using factor analysis to see when and how speakers revealed affect, attitude, and agentive choices for action. Conclusion Final analysis revealed that one third of the sample exhibited high scores for positive agency or capacity for decision-making and self-management, while the rest expressed less control and more negative emotions and fears that may preclude self-management. This approach suggests a means to tailor diabetes education considering alternative approaches focused on communication for those facing barriers. C1 [Pope, Charlene; Magwood, Gayenell; Jenkins, Carolyn M.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Davis, Boyd H.] Univ N Carolina, Dept English Appl Linguist, Charlotte, NC 28223 USA. [Pope, Charlene] Charleston REAP, Ralph H Johnson Dept, Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Mason, Peyton R.] Next Generat Mkt Insights, Charlotte, NC USA. RP Pope, C (reprint author), Med Univ S Carolina, Coll Nursing, 99 Jonathan Lucas St, Charleston, SC 29425 USA. EM popec@musc.edu OI Davis, Boyd/0000-0003-4773-7715 FU Medical University of South Carolina Center for Health Disparities Research; [NIH/NINR 1 R15 NR009486-01A1] FX This study was supported by Grant #NIH/NINR 1 R15 NR009486-01A1, 2006, entitled "Emergency Department Use-African American with Diabetes," (Dr Carolyn Jenkins, principal investigator), and an intramural grant from the Medical University of South Carolina Center for Health Disparities Research, 2008 (Dr Charlene Pope, principal investigator). Dr Pope's contribution is the result of work supported with resources and the use of facilities at the Charleston, SC, Ralph H. Johnson VAMC, and the HSR&D REAP Center for Disease Prevention and Health Interventions for Diverse Populations (REA 08-261). Disclaimer: The views expressed in this article are those of the authors and do not necessarily represent the views of the US Department of Veterans Affairs. NR 38 TC 2 Z9 2 U1 0 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 J9 DIABETES EDUCATOR JI Diabetes Educ. PD MAY-JUN PY 2011 VL 37 IS 3 BP 409 EP 418 DI 10.1177/0145721711404439 PG 10 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA 764US UT WOS:000290660500007 PM 21515541 ER PT J AU Wander, PL Boyko, EJ Leonetti, DL McNeely, MJ Kahn, SE Fujimoto, WY AF Wander, P. L. Boyko, E. J. Leonetti, D. L. McNeely, M. J. Kahn, S. E. Fujimoto, W. Y. TI Greater hand-grip strength predicts a lower risk of developing type 2 diabetes over 10 years in leaner Japanese Americans SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Epidemiology; Muscle; Hand strength; Japanese-American ID BODY-COMPOSITION; MUSCLE STRENGTH; LIFETIME RISK; GRIP STRENGTH; MELLITUS; CLASSIFICATION; DIAGNOSIS; ADULTS; HEALTH AB Aims: Much is known about body composition and type 2 diabetes risk but less about body function such as strength. We assessed whether hand-grip strength predicted incident diabetes. Methods: We followed 394 nondiabetic Japanese-American subjects (mean age 51.9) for the development of diabetes. We fit a logistic regression model to examine the association between hand-grip strength at baseline and type 2 diabetes risk over 10 years, adjusted for age, sex, and family history. Results: A statistically significant (p = 0.008) and negative (coefficient -0.208) association was observed between hand-grip strength and diabetes risk that diminished at higher BMI levels. Adjusted ORs for a 10-pound hand-grip strength increase with BMI set at the 25th, 50th or 75th percentiles were 0.68, 0.79, and 0.98, respectively. Conclusions: Among leaner individuals, greater hand-grip strength was associated with lower risk of type 2 diabetes, suggesting it may be a useful marker of risk in this population. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Wander, P. L.; Boyko, E. J.; McNeely, M. J.; Kahn, S. E.; Fujimoto, W. Y.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Boyko, E. J.; Kahn, S. E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Leonetti, D. L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Wander, PL (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,Box 356421, Seattle, WA 98195 USA. EM lwander@u.washington.edu OI Wander, Pandora/0000-0003-3671-1464; Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU National Institutes of Health [DK-31170, HL-49293, DK-02654]; Diabetes and Endocrinology Research Center [DK-17047]; Clinical Nutrition Research Unit [DK-35816]; General Clinical Research Center at the University of Washington [RR-00037]; VA Puget Sound Health Care System; King County Japanese-American Community FX This work was supported by National Institutes of Health Grants DK-31170, HL-49293, and DK-02654; by facilities and services provided by the Diabetes and Endocrinology Research Center (DK-17047), Clinical Nutrition Research Unit (DK-35816), and the General Clinical Research Center (RR-00037) at the University of Washington. VA Puget Sound Health Care System provides support for Drs. Boyko and Kahn's involvement in this research. We are grateful to the King County Japanese-American Community for support and cooperation. NR 15 TC 10 Z9 10 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD MAY PY 2011 VL 92 IS 2 BP 261 EP 264 DI 10.1016/j.diabres.2011.01.007 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 764ER UT WOS:000290612200020 PM 21281974 ER PT J AU Jackson, LT Aubin, PM Cowley, MS Sangeorzan, BJ Ledoux, WR AF Jackson, Lyle T. Aubin, Patrick M. Cowley, Matthew S. Sangeorzan, Bruce J. Ledoux, William R. TI A Robotic Cadaveric Flatfoot Analysis of Stance Phase SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE pes planus; flatfoot; foot structure; cadaver; stance phase; robot ID DEFORMITY; JOINTS AB The symptomatic flatfoot deformity (pes planus with peri-talar subluxation) can be a debilitating condition. Cadaveric flatfoot models have been employed to study the etiology of the deformity, as well as invasive and noninvasive surgical treatment strategies, by evaluating bone positions. Prior cadaveric flatfoot simulators, however, have not leveraged industrial robotic technologies, which provide several advantages as compared with the previously developed custom fabricated devices. Utilizing a robotic device allows the researcher to experimentally evaluate the flatfoot model at many static instants in the gait cycle, compared with most studies, which model only one to a maximum of three instances. Furthermore, the cadaveric tibia can be statically positioned with more degrees of freedom and with a greater accuracy, and then a custom device typically allows. We created a six degree of freedom robotic cadaveric simulator and used it with a flatfoot model to quantify static bone positions at ten discrete instants over the stance phase of gait. In vivo tibial gait kinematics and ground reaction forces were averaged from ten flatfoot subjects. A fresh frozen cadaveric lower limb was dissected and mounted in the robotic gait simulator (RGS). Biomechanically realistic extrinsic tendon forces, tibial kinematics, and vertical ground reaction forces were applied to the limb. In vitro bone angular position of the tibia, calcaneus, talus, navicular, medial cuneiform, and first metatarsal were recorded between 0% and 90% of stance phase at discrete 10% increments using a retroreflective six-camera motion analysis system. The foot was conditioned flat through ligament attenuation and axial cyclic loading. Post-flat testing was repeated to study the pes planus deformity. Comparison was then made between the pre-flat and post-flat conditions. The RGS was able to recreate ten gait positions of the in vivo pes planus subjects in static increments. The in vitro vertical ground reaction force was within +/- 1 standard deviation (SD) of the in vivo data. The in vitro sagittal, coronal, and transverse plane tibial kinematics were almost entirely within +/- 1 SD of the in vivo data. The model showed changes consistent with the flexible flatfoot pathology including the collapse of the medial arch and abduction of the forefoot, despite unexpected hindfoot inversion. Unlike previous static flatfoot models that use simplified tibial degrees of freedom to characterize only the midpoint of the stance phase or at most three gait positions, our simulator represented the stance phase of gait with ten discrete positions and with six tibial degrees of freedom. This system has the potential to replicate foot function to permit both noninvasive and surgical treatment evaluations throughout the stance phase of gait, perhaps eliciting unknown advantages or disadvantages of these treatments at other points in the gait cycle. [DOI: 10.1115/1.4003869] C1 [Jackson, Lyle T.; Aubin, Patrick M.; Cowley, Matthew S.; Sangeorzan, Bruce J.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Jackson, Lyle T.] Univ Washington, Sch Med, Seattle, WA USA. [Aubin, Patrick M.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU VA Rehabilitation Research and Development Service [A2661C, A4843C]; University of Washington FX The authors thank the VA Rehabilitation Research and Development Service Grant Nos. A2661C and A4843C and the University of Washington Medical Student Research Training Program. NR 14 TC 5 Z9 5 U1 2 U2 8 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD MAY PY 2011 VL 133 IS 5 AR 051005 DI 10.1115/1.4003869 PG 6 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 765EQ UT WOS:000290686600005 PM 21599096 ER PT J AU Jessup, M Albert, NM Lanfear, DE Lindenfeld, J Massie, BM Walsh, MN Zucker, MJ AF Jessup, Mariell Albert, Nancy M. Lanfear, David E. Lindenfeld, Joann Massie, Barry M. Walsh, Mary Norine Zucker, Mark J. CA Aha Heart Failure Transplantation Heart Failure Soc Amer TI ACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE ACCF/AHA/HFSA Survey Report; heart failure; heart transplant; mechanical circulatory support device; staffing profile ID TASK-FORCE; MANAGEMENT; CARDIOLOGY; GUIDELINES; STATEMENT; OUTCOMES; SOCIETY AB Objectives: There have been no published recommendations about staffing needs for a heart failure (HF),clinic or an office setting focused on heart transplant. The goal of this survey was to understand the current staffing environment of HF, transplant, and mechanical circulatory support device (MCSD) programs in the United States and abroad. This report identifies current staffing patterns but does not endorse a particular staffing model. Methods: An online survey, jointly sponsored by the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and the Heart Failure Society of America (HFSA), was sent to the members of all 3 organizations who had identified themselves as interested in HF, heart transplant, or both, between March 12, 2009, and May 12, 2009. Results: The overall response rate to the 1,823 e-mail surveys was 23%. There were 257 unique practices in the United States (81% of total sites) and 58 international sites (19%); approximately 30% of centers were in a cardiovascular group practice and 30% in a medical school hospital setting. The large majority of practices delivered HF care in both an inpatient and outpatient environment, and slightly more centers were implanting MCSDs (47%) than performing cardiac transplantation (39%). Most practices (43%) were small, with <4 staff members, or small- to medium-sized (34%), with 4 to 10 staff members, with only 23% being medium (11-20 staff) or large programs (> 20 staff). On average, a U.S. HF practice cared for 1,641 outpatients annually. An average HF program with transplant performed 10 transplants. Although larger programs were able to perform more transplants and see more outpatient HF visits, their clinician staffing volume tended to double for approximately every 500 to 700 additional HF visits annually. The average staffing utilization was 2.65 physician full-time equivalents (FTEs), 2.21 nonphysician practitioner (nurse practitioner or physician assistant) FTEs, and 2.61 nurse coordinator FTEs annually. Conclusions: The HF patient population is growing in number in the United States and internationally, and the clinicians who provide the highly skilled and time-consuming care to this population are under intense scrutiny as a result of focused quality improvement initiatives and reduced financial resources. Staffing guidelines should be developed to ensure that an adequate number of qualified professionals are hired for a given practice volume. These survey results are an initial step in developing such standards. (J Cardiac Fail 2011;17:349-358) C1 [Jessup, Mariell] Univ Penn, Philadelphia, PA 19104 USA. [Albert, Nancy M.] Cleveland Clin, Cleveland, OH USA. [Lindenfeld, Joann] Univ Colorado, Boulder, CO 80309 USA. [Massie, Barry M.] UCSF, San Francisco VAMC, San Francisco, CA USA. [Zucker, Mark J.] Newark Beth Israel Med Ctr, Newark, NJ USA. RP Jessup, M (reprint author), Univ Penn, Philadelphia, PA 19104 USA. NR 15 TC 3 Z9 4 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD MAY PY 2011 VL 17 IS 5 BP 349 EP 358 DI 10.1016/j.cardfail.2011.04.001 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 766JE UT WOS:000290777600001 PM 21549290 ER PT J AU Meo, N Hwang, U Morrison, RS AF Meo, Nicholas Hwang, Ula Morrison, R. Sean TI Resident Perceptions of Palliative Care Training in the Emergency Department SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID END-OF-LIFE; EDUCATION AB Objectives: To characterize the level of formal training and perceived educational needs in palliative care of emergency medicine (EM) residents. Methods: This descriptive study used a 16-question survey administered at weekly resident didactic sessions in 2008 to EM residency programs in New York City. Survey items asked residents to: (1) respond to Likert-scaled statements about the role of palliative care in the emergency department (ED); (2) quantify their level of formal training and personal comfort in symptom management, discussion of bad news and prognosis, legal issues, and withdrawing/withholding therapy; and (3) express their interest in future palliative care training. Results: Of 228 total residents, 159 (70%) completed the survey. Of those surveyed, 50% completed some palliative care training before residency; 71.1% agreed or strongly agreed that palliative care was an important competence for an EM physician. However, only 24.3% reported having a "clear idea of the role of palliative care in EM." The highest self-reported level of formal training was in the area of advanced directives or legal issues at the end of life; the lowest levels were in areas of patient management at the end of life. The highest level of self-reported comfort was in giving bad news and the lowest was in withholding/withdrawing therapy. A slight majority of residents (54%) showed positive interest in receiving future training in palliative care. Conclusions: New York City EM residents reported palliative care as an important competency for emergency medicine physicians, yet also reported low levels of formal training in palliative care. The majority of residents surveyed favored additional training. C1 [Meo, Nicholas; Hwang, Ula] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Meo, Nicholas; Hwang, Ula; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Care, New York, NY 10029 USA. [Hwang, Ula; Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, REAP, Bronx, NY USA. [Hwang, Ula; Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, Gustave L Levy Pl,Box 1620, New York, NY 10029 USA. EM ula.hwang@mountsinai.org FU American Federation on Aging Research (AFAR); National Institute on Aging (NIA) [K23 AG031218, K24 AG022345] FX Nicholas Meo was supported by a Medical Student Training on Aging Research summer program award from the American Federation on Aging Research (AFAR). Ula Hwang is supported by a National Institute on Aging (NIA) K23 career development award (K23 AG031218). R. Sean Morrison is supported by a NIA K24 mid-career mentoring award (K24 AG022345). NR 19 TC 25 Z9 25 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAY PY 2011 VL 14 IS 5 BP 548 EP 555 DI 10.1089/jpm.2010.0343 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 766CE UT WOS:000290756700007 PM 21291326 ER PT J AU Zerzan, J Lee, CA Haverhals, LM Nowels, CT AF Zerzan, Judy Lee, Courtney A. Haverhals, Leah M. Nowels, Carolyn T. TI Exploring Physician Decisions about End-of-Life Opiate Prescribing: A Qualitative Study SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID HEALTH-CARE PROVIDERS; PAIN MANAGEMENT; KNOWLEDGE; ATTITUDES; COMMUNICATION; BARRIERS; STATE AB Background: Opiates are commonly used for symptoms at the end of life (EOL). Little is known about the decision-making process physicians go through when deciding to prescribe opiates for their EOL patients. The study's objective was to explore physician factors affecting EOL opiate prescribing. Methods: Qualitative study of 38 physicians in the Denver area in the specialties of outpatient and inpatient medicine, geriatrics, oncology, and palliative care. Semi-structured qualitative interviews by trained interviewers asked physicians about their knowledge, attitudes, and experiences in prescribing opiates, reasons for prescribing opiates, barriers to prescribing opiates, changes in prescribing habits, and perceived patient factors that influence prescribing. Interviews were analyzed using ATLAS.ti qualitative analysis software and independently coded by two reviewers. Results: We found a spectrum of beliefs ranging from the viewpoint that opiates are underused at EOL to overused. We found five key themes: practices in when and how to use opiates, barriers to prescribing, personal experiences drive prescribing, social meaning of opiates, and differences in the role of physician. Physicians interviewed described experiences, both personal and professional, that influenced their opiate-prescribing habits. All respondents expressed positive experiences with prescribing opiates in being able to ease patients' suffering at EOL and to improve their functionality and quality of life. Conclusions: Differences in prescribing habits, attitudes, and experiences of physicians influence opiate prescribing, which may lead to over- and underprescribing. Knowledge, barriers, and fears about EOL opiate prescribing need to be addressed to ensure EOL patients are receiving appropriate symptom relief. C1 [Zerzan, Judy; Nowels, Carolyn T.] Univ Colorado Denver, Div Gen Internal Med, Aurora, CO 80045 USA. [Lee, Courtney A.] Univ Colorado Denver, Dept Hlth & Behav Sci, Aurora, CO 80045 USA. [Haverhals, Leah M.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Denver, CO USA. RP Zerzan, J (reprint author), Univ Colorado Denver, Div Gen Internal Med, 12631 E 17th Ave,Mail Stop B180, Aurora, CO 80045 USA. EM Judy.Zerzan@ucdenver.edu FU University of Colorado Denver FX The results of this study were presented at the 32nd SGIM Annual Meeting in May 2009. This study was funded from the University of Colorado Denver General Internal Medicine Small Grants Program. NR 14 TC 3 Z9 3 U1 2 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAY PY 2011 VL 14 IS 5 BP 567 EP 572 DI 10.1089/jpm.2010.0505 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 766CE UT WOS:000290756700011 PM 21413855 ER PT J AU Malin, JL O'Neill, SM Asch, SM Dy, SM Walling, AM Tisnado, D Antonio, AL Lorenz, KA AF Malin, Jennifer L. O'Neill, Sean M. Asch, Steven M. Dy, Sydney M. Walling, Anne M. Tisnado, Diana Antonio, Anna Liza Lorenz, Karl A. TI Quality of Supportive Care for Patients with Advanced Cancer in a VA Medical Center SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID EVIDENCE-BASED RECOMMENDATIONS; SYMPTOM PREVALENCE; TELEHEALTH; MANAGEMENT; LIFE AB Purpose: Using the Assessing Symptoms Side Effects and Indicators of Supportive Treatment (ASSIST) quality indicators (QIs), we conducted a comprehensive evaluation of the quality of care provided in our institution to patients diagnosed with advanced cancer in 2006. Methods: Patients diagnosed with a Stage IV solid tumor were identified from the hospital's cancer registry. Using data abstracted from medical records, care was assessed using 41 explicit QIs. Mean percent adherence to QIs was calculated overall, as well as across five clinical domains: (1) Pain, (2) Depression and Psychosocial Distress, (3) Dyspnea, (4) Treatment Toxicity, (5) Other Symptoms, and (6) Information and Care Planning. Results: The study cohort (n = 118) was almost all male (2% female) and mean age was 65.9 years (standard deviation [SD] 9.9 years). The most common cancers were lung and head and neck cancer (23% each); 17% had prostate cancer; 13% had colorectal cancer; and the rest (24%) had breast, esophageal, stomach, genitourinary, liver/biliary, or pancreas cancer. Patients received 51% (95% confidence interval [CI] 48%-54%) of recommended care. Adherence to recommended care within domains ranged from 38% (95% CI 35%-42%) for Other Symptoms to 79% (95% CI 73%-86%) for Information and Care Planning. Conclusions: This study suggests that the quality of supportive care for patients with advanced cancer can be greatly improved. Future efforts should use the ASSIST indicators to evaluate the quality of supportive care in larger and more diverse cohorts of advanced cancer patients. C1 [Malin, Jennifer L.] Univ Calif Los Angeles, Div Hematol Oncol 111H, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med,RAND Hlth, Los Angeles, CA 90073 USA. [O'Neill, Sean M.] Northwestern Univ, Feinberg Sch Med, Pardee RAND Grad Sch, Chicago, IL 60611 USA. [Dy, Sydney M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA. [Dy, Sydney M.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA. [Dy, Sydney M.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Walling, Anne M.; Tisnado, Diana] Univ Calif Los Angeles, VA Greater Los Angeles, Div Gen Internal Med & Hlth Serv Res, Sch Publ Hlth, Los Angeles, CA 90073 USA. RP Malin, JL (reprint author), Univ Calif Los Angeles, Div Hematol Oncol 111H, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med,RAND Hlth, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jennifer.malin@va.gov OI O'Neill, Sean/0000-0001-7759-8942 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [SHP 08-196] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service SHP 08-196. The authors are solely responsible for its content and the views do not necessarily represent the views of the Department of Veterans Affairs. NR 17 TC 9 Z9 9 U1 0 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAY PY 2011 VL 14 IS 5 BP 573 EP 577 DI 10.1089/jpm.2010.0464 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 766CE UT WOS:000290756700012 PM 21413885 ER PT J AU Htoon, J Nadig, A Hughes, T Yavuz, S Direskenel, H Saruhan-Direskeneli, G Sawalha, AH AF Htoon, Jasmine Nadig, Ajay Hughes, Travis Yavuz, Sule Direskenel, Haner Saruhan-Direskeneli, Guher Sawalha, Amr H. TI IL18 Polymorphism Is Associated with Behcet's Disease But Not Lupus in Patients from Turkey SO JOURNAL OF RHEUMATOLOGY LA English DT Letter ID PROMOTER POLYMORPHISMS; INTERLEUKIN-18 LEVELS; SERUM INTERLEUKIN-18; GENE POLYMORPHISMS; ERYTHEMATOSUS; IL-18; CRITERIA C1 [Htoon, Jasmine; Nadig, Ajay; Hughes, Travis; Sawalha, Amr H.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Yavuz, Sule; Direskenel, Haner] Marmara Univ, Dept Rheumatol, Sch Med, Istanbul, Turkey. [Saruhan-Direskeneli, Guher] Istanbul Univ, Istanbul Sch Med, Dept Physiol, Istanbul, Turkey. [Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Sawalha, Amr H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu FU NCRR NIH HHS [P20RR020143, P20 RR020143]; NIAID NIH HHS [R03 AI076729, R03AI076729, R03 AI076729-02, R03 AI076729-01]; NIAMS NIH HHS [P30 AR053483, P30AR053483] NR 14 TC 12 Z9 12 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD MAY PY 2011 VL 38 IS 5 BP 962 EP 963 DI 10.3899/jrheum.101202 PG 2 WC Rheumatology SC Rheumatology GA 766KJ UT WOS:000290780700028 PM 21532063 ER PT J AU Pugh, MJ Tabares, J Finley, E Bollinger, M Tortorice, K VanCott, AC AF Pugh, Mary Jo Tabares, Jeffrey Finley, Erin Bollinger, Mary Tortorice, Kathy VanCott, Anne C. TI CHANGES IN ANTIEPILEPTIC DRUG CHOICE FOR OLDER VETERANS WITH NEW-ONSET EPILEPSY: 2002 TO 2006 SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Pugh, Mary Jo; Tabares, Jeffrey; Finley, Erin; Bollinger, Mary] VERDICT REAP, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Tortorice, Kathy] Hines Vet Affairs, Pharm Benefits Management Strateg Hlth Grp, Hines, IL USA. [VanCott, Anne C.] Univ Pittsburgh, Dept Neurol, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. RP Pugh, MJ (reprint author), VERDICT REAP, S Texas Vet Hlth Care Syst, San Antonio, TX USA. OI Pugh, Mary Jo/0000-0003-4196-7763; Finley, Erin/0000-0003-4497-7721 FU NINR NIH HHS [R01-NR010828] NR 6 TC 5 Z9 5 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2011 VL 59 IS 5 BP 955 EP 956 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 763RZ UT WOS:000290578700038 PM 21568976 ER PT J AU Dighe, MK Wieseler, KM Bhargava, P Kanal, KM Vaidya, S Stewart, BK AF Dighe, Manjiri K. Wieseler, Karen M. Bhargava, Puneet Kanal, Kalpana M. Vaidya, Sandeep Stewart, Brent K. TI Re: More Cautions on Imaging of Pregnant Patients Response SO RADIOGRAPHICS LA English DT Letter C1 [Dighe, Manjiri K.; Wieseler, Karen M.; Bhargava, Puneet; Kanal, Kalpana M.; Vaidya, Sandeep; Stewart, Brent K.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] Vet Affairs Puget Sound Healthcare Syst, Dept Radiol, Seattle, WA USA. [Vaidya, Sandeep] Univ Washington, Harborview Med Ctr, Dept Radiol, Seattle, WA 98104 USA. RP Dighe, MK (reprint author), Univ Washington, Med Ctr, Dept Radiol, Box 357115,1959 NE Pacific St, Seattle, WA 98195 USA. EM dighe@u.washington.edu RI Bhargava, Puneet /F-1330-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD MAY-JUN PY 2011 VL 31 IS 3 BP 891 EP 892 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 763WN UT WOS:000290590500023 ER PT J AU Porter, MP Kerrigan, MC Donato, BMK Ramsey, SD AF Porter, Michael P. Kerrigan, Matthew C. Donato, Bonnie M. K. Ramsey, Scott D. TI Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE Bladder neoplasms; Drug therapy; Delivery of health care; SEER program; Medicare ID NEOADJUVANT CHEMOTHERAPY; ELDERLY-PATIENTS; CARCINOMA; METHOTREXATE; METAANALYSIS; CARBOPLATIN; PACLITAXEL; MANAGEMENT; TRIAL AB Objectives: Examine the association between clinical, demographic, and socioeconomic factors and the receipt of systemic chemotherapy for bladder cancer. Examine factors influencing the use of combination chemotherapy plus cystectomy and use of specific chemotherapy drugs over time for bladder cancer. Materials and methods: Data from the SEER-Medicare database were analyzed for patients diagnosed with urothelial carcinoma of the bladder between 1992 and 2002. Cox proportional hazards regression analyses were used to assess differences in use of systemic chemotherapy based on demographic and clinical factors, site of care, and year of diagnosis. We assessed the proportion of patients who received chemotherapy in the adjuvant and neoadjuvant settings as well as use of chemotherapy in the monotherapy setting. We estimated the proportion of claims made for several commonly used chemotherapy agents in the outpatient setting by year. Results: During follow-up, 13%, 28%, 37%, and 57% of patients with stages 1 through 4, respectively, received systemic chemotherapy for bladder cancer. Chemotherapy use in the neoadjunvant or adjuvant settings within 6 months of diagnosis was not commonly found. Neoadjuvant chemotherapy was delivered to 1.4% Of stage 2 patients and 11% of stage 4 patients. In 2003, the most frequent claims for intravenous chemotherapy were for gemcitabine, carboplatin, and placlitaxel. Conclusions: Chemotherapy was not generally used as recommended for persons with invasive bladder cancer in this patient population. Studies to clarify potential underutilization and variation in patterns of;administration are warranted. (C) 2011 Elsevier Inc. All rights reserved. C1 [Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Porter, Michael P.] Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Kerrigan, Matthew C.] GlaxoSmithKline Inc, Philadelphia, PA 19102 USA. [Donato, Bonnie M. K.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. EM sramsey@fhcrc.org FU Bristol-Myers Squibb FX This study was funded by Bristol-Myers Squibb. The study has been approved by the Fred Hutchinson Cancer Research Center Institutional Review Board and by the SEER Medicare Institutional Review Board. NR 22 TC 58 Z9 59 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD MAY-JUN PY 2011 VL 29 IS 3 BP 252 EP 258 DI 10.1016/j.urolonc.2009.03.021 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 766JW UT WOS:000290779400005 PM 19450992 ER PT J AU Caposio, P Orloff, SL Streblow, DN AF Caposio, Patrizia Orloff, Susan L. Streblow, Daniel N. TI The role of cytomegalovirus in angiogenesis SO VIRUS RESEARCH LA English DT Article DE Angiogenesis; Cytomegalovirus; Endothelial cell ID SMOOTH-MUSCLE-CELLS; TRANSPLANT VASCULAR SCLEROSIS; APOE KNOCKOUT MICE; ENDOTHELIAL-CELLS; CHRONIC REJECTION; EXTRACELLULAR-MATRIX; ADHESION MOLECULES; ALTERED EXPRESSION; CORONARY-ARTERIES; HEART-TRANSPLANTS AB Human cytomegalovirus (HCMV) infection has been associated with the acceleration of vascular disease including atherosclerosis and transplant associated vasculopathy in solid organ transplants. HCMV promotes vascular disease at many of the different stages of the disease development. These include the initial injury phase, enhancing the response to injury and inflammation, as well as by increasing SMC hyperplasia and foamy macrophage cell formation. Angiogenesis is a critical process involved in the development of vascular diseases. Recently, HCMV has been shown to induce angiogenesis and this process is thought to contribute to HCMV-accelerated vascular disease and may also be important for HCMV-enhanced tumor formation. This review will highlight the role of HCMV in promoting angiogenesis. (C) 2010 Elsevier B.V. All rights reserved. C1 [Caposio, Patrizia; Orloff, Susan L.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Caposio, Patrizia; Orloff, Susan L.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97239 USA. [Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA. [Orloff, Susan L.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Streblow, DN (reprint author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 SW 185th, Beaverton, OR 97006 USA. EM streblow@ohsu.edu FU National Institutes of Health [HL 083194, HL 085451, HL 088603] FX This work was supported by research grants from the National Institutes of Health to D.N. Streblow (HL 083194), S.L. Orloff (HL 085451) and J.A. Nelson (HL 088603). NR 89 TC 33 Z9 33 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD MAY PY 2011 VL 157 IS 2 SI SI BP 204 EP 211 DI 10.1016/j.virusres.2010.09.011 PG 8 WC Virology SC Virology GA 767WM UT WOS:000290889500010 PM 20869406 ER PT J AU Hwang, U McCarthy, ML Aronsky, D Asplin, B Crane, PW Craven, CK Epstein, SK Fee, C Handel, DA Pines, JM Rathlev, NK Schafermeyer, RW Zwemer, FL Bernstein, SL AF Hwang, Ula McCarthy, Melissa L. Aronsky, Dominik Asplin, Brent Crane, Peter W. Craven, Catherine K. Epstein, Stephen K. Fee, Christopher Handel, Daniel A. Pines, Jesse M. Rathlev, Niels K. Schafermeyer, Robert W. Zwemer, Frank L., Jr. Bernstein, Steven L. TI Measures of Crowding in the Emergency Department: A Systematic Review SO ACADEMIC EMERGENCY MEDICINE LA English DT Review ID LENGTH-OF-STAY; PATIENT FLOW; REAL-TIME; OVERCROWDING SCALE; SAFETY NET; MODELS; SIMULATION; MORTALITY; VARIABLES; CAPACITY AB Objectives: Despite consensus regarding the conceptual foundation of crowding, and increasing research on factors and outcomes associated with crowding, there is no criterion standard measure of crowding. The objective was to conduct a systematic review of crowding measures and compare them in conceptual foundation and validity. Methods: This was a systematic, comprehensive review of four medical and health care citation databases to identify studies related to crowding in the emergency department (ED). Publications that "describe the theory, development, implementation, evaluation, or any other aspect of a 'crowding measurement/definition' instrument (qualitative or quantitative)" were included. A "measurement/definition" instrument is anything that assigns a value to the phenomenon of crowding in the ED. Data collected from papers meeting inclusion criteria were: study design, objective, crowding measure, and evidence of validity. All measures were categorized into five measure types (clinician opinion, input factors, throughput factors, output factors, and multidimensional scales). All measures were then indexed to six validation criteria (clinician opinion, ambulance diversion, left without being seen (LWBS), times to care, forecasting or predictions of future crowding, and other). Results: There were 2,660 papers identified by databases; 46 of these papers met inclusion criteria, were original research studies, and were abstracted by reviewers. A total of 71 unique crowding measures were identified. The least commonly used type of crowding measure was clinician opinion, and the most commonly used were numerical counts (number or percentage) of patients and process times associated with patient care. Many measures had moderate to good correlation with validation criteria. Conclusions: Time intervals and patient counts are emerging as the most promising tools for measuring flow and nonflow (i.e., crowding), respectively. Standardized definitions of time intervals (flow) and numerical counts (nonflow) will assist with validation of these metrics across multiple sites and clarify which options emerge as the metrics of choice in this "crowded" field of measures. ACADEMIC EMERGENCY MEDICINE 2011; 18:527-538 (C) 2011 by the Society for Academic Emergency Medicine C1 [Hwang, Ula] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. [Hwang, Ula] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [McCarthy, Melissa L.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA. [Craven, Catherine K.] Johns Hopkins Univ, Sch Med, William H Welch Med Lib, Baltimore, MD USA. [Aronsky, Dominik] Vanderbilt Univ, Med Ctr, Dept Biomed Informat & Emergency Med, Nashville, TN USA. [Asplin, Brent] Mayo Clin, Dept Emergency Med, Rochester, MN USA. [Crane, Peter W.] Univ Rochester, Dept Emergency Med, Rochester, NY USA. [Epstein, Stephen K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Emergency Med, Boston, MA 02215 USA. [Fee, Christopher] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA. [Handel, Daniel A.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. [Pines, Jesse M.] George Washington Univ, Med Ctr, Dept Emergency Med, Washington, DC 20037 USA. [Pines, Jesse M.] George Washington Univ, Med Ctr, Dept Hlth Policy, Washington, DC 20037 USA. [Rathlev, Niels K.] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA. [Schafermeyer, Robert W.] Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28203 USA. [Zwemer, Frank L., Jr.] Virginia Commonwealth Univ, Dept Emergency Med, McGuire VA Med Ctr, Richmond, VA USA. [Bernstein, Steven L.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA. RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. EM ula.hwang@mountsinai.org NR 77 TC 61 Z9 67 U1 8 U2 60 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAY PY 2011 VL 18 IS 5 BP 526 EP 537 DI 10.1111/j.1553-2712.2011.01054.x PG 12 WC Emergency Medicine SC Emergency Medicine GA 763SJ UT WOS:000290579700011 PM 21569171 ER PT J AU Kontos, MC Diercks, DB Ho, PM Wang, TY Chen, AY Roe, MT AF Kontos, Michael C. Diercks, Debra B. Ho, P. Michael Wang, Tracy Y. Chen, Anita Y. Roe, Matthew T. TI Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: Results from the American College of Cardiology's NCDR (R) SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE CORONARY SYNDROMES; INTERNATIONAL TRIAL; HEART-DISEASE; ELEVATION; THROMBOLYSIS; PREDICTORS; METOPROLOL; MORTALITY AB Background Although beta-blockers (BBs) reduce long-term mortality in patients after myocardial infarction (MI), data regarding acute usage are conflicting. Methods We examined acute (<= 24 hours) BB use in 34,661 patients with ST-elevation MI (STEMI) and non-ST-segment MI (NSTEMI) included in the NCDR (R) ACTION Registry (R)-GWTG (TM) (291 US hospitals) between January 2007 and June 2008. Patients with contraindications or did not receive BBs or with missing data were excluded. We analyzed the use and impact of BB stratified by variables associated with increased risk for shock specified in the recent guidelines: age > 70 years, symptoms > 12 hours (STEMI patients), systolic blood pressure < 120 mm Hg, and heart rate > 110 beat/min on presentation. Results Among patients without contraindications, at least 1 high-risk variable was found in 45% of STEMI and 63% of NSTEMI patients. In-hospital complications including cardiogenic shock, mortality, and the composite outcome of shock or mortality were significantly increased with more shock risk factors in both STEMI and NSTEMI patients. Very early use in the emergency department was associated with a significantly increased risk of shock for both STEMI and NSTEMI patients compared to patients treated later but within 24 hours. Conclusions Risk factors for shock are common in STEMI and NSTEMI patients treated with early BBs. Increasing numbers of risk factors were associated with increased risk for shock or death in patients treated with BBs. These results are consistent with current recommendations for avoiding early BB treatment for patients with acute MI. (Am Heart J 2011;161:864-70.) C1 [Kontos, Michael C.] Virginia Commonwealth Univ, Dept Internal Med, Div Cardiol, Pauley Heart Ctr, Richmond, VA USA. [Diercks, Debra B.] Univ Calif Davis, Sacramento, CA 95817 USA. [Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA. [Wang, Tracy Y.; Chen, Anita Y.; Roe, Matthew T.] Duke Clin Res Inst, Durham, NC USA. RP Kontos, MC (reprint author), Rm 285,Gateway Bldg,2nd Floor,POB 980051,1200 E M, Richmond, VA 23298 USA. EM mkontos@mcvh-vcu.edu NR 24 TC 23 Z9 23 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAY PY 2011 VL 161 IS 5 BP 864 EP 870 DI 10.1016/j.ahj.2011.01.006 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 763LV UT WOS:000290559300015 PM 21570515 ER PT J AU Chen, JC Goetz, MB Feld, JE Taylor, A Anaya, H Burgess, J Flores, RD Gidwani, RA Knapp, H Ocampo, EH Asch, SM AF Chen, Jennifer C. Goetz, Matthew Bidwell Feld, Jamie E. Taylor, Anne Anaya, Henry Burgess, Jane Flores, Richard de Mesa Gidwani, Risha A. Knapp, Herschel Ocampo, Elizabeth H. Asch, Steven M. TI A provider participatory implementation model for HIV testing in an ED SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID FOR-DISEASE-CONTROL; EMERGENCY-DEPARTMENT; MISSED OPPORTUNITIES; PREVALENCE AREA; CARE SETTINGS; INFECTION; HEALTH; RECOMMENDATIONS; DIAGNOSIS; WOMEN AB Background: The Centers for Disease Control and Prevention recommends routine HIV screening for adults. Objectives: Community-based participatory research incorporates subjects in the design and conduct of research. We included nurses and physicians in the implementation of HIV rapid test use in the emergency department (ED). We explored the process, facilitators, and barriers. Methods: We identified clinical champions and trained staff. Physicians obtained consent and ordered HIV testing; nurses performed rapid testing. Testing rates were tracked by electronic medical record. We conducted regular meetings between staff and researchers. Semistructured qualitative interviews with providers were conducted at 3 months. Results: By week 15, we administered 121 tests. After the eligibility protocol evolved to incorporate ED nursing concerns regarding staffing limitations from a random sampling model to one focused on testing during nonpeak hours, the weekly number of tests increased. Eighteen percent of providers favored nontargeted HIV screening, 27% favored the current model of testing at nonpeak hours, 32% supported diagnostic testing, and 18% favored no testing or "other." Barriers include written consent, electronic documentation, time constraints, and belief that screening is not a core ED duty. Facilitators include ease of test administration, belief that ED patients are at higher risk, and flexibility to tailor screening efforts according to patient volume. Conclusions: The ED-based HIV testing is feasible within a Veterans Hospital Administration setting. Involvement of nursing in a community-based participatory research implementation model may facilitate staff acceptance of nontargeted HIV screening and be a mechanism to initiate administration of clinical preventive services to ED patients with limited primary care contact. Published by Elsevier Inc. C1 [Chen, Jennifer C.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Chen, Jennifer C.; Goetz, Matthew Bidwell; Asch, Steven M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. [Gidwani, Risha A.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Chen, JC (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. OI Chen, Jennifer/0000-0002-4801-5397; Goetz, Matthew/0000-0003-4542-992X NR 24 TC 14 Z9 14 U1 2 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD MAY PY 2011 VL 29 IS 4 BP 418 EP 426 DI 10.1016/j.ajem.2009.11.016 PG 9 WC Emergency Medicine SC Emergency Medicine GA 763QK UT WOS:000290574600010 PM 20825814 ER PT J AU Bartels, CM Kind, AJH Everett, C Mell, M McBride, P Smith, M AF Bartels, Christie M. Kind, Amy J. H. Everett, Christine Mell, Matthew McBride, Patrick Smith, Maureen TI Low Frequency of Primary Lipid Screening Among Medicare Patients With Rheumatoid Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Article ID GLUCOCORTICOID-INDUCED OSTEOPOROSIS; POSITIVE PREDICTIVE-VALUE; PRIMARY-CARE PHYSICIANS; QUALITY-OF-CARE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK; ADMINISTRATIVE DATA; ORTHOPEDIC-SURGERY; ISCHEMIC-STROKE; CLAIMS AB Objective. Although studies have demonstrated suboptimal preventive care in RA patients, performance of primary lipid screening (i.e., testing before cardiovascular disease [CVD], CVD risk equivalents, or hyperlipidemia is evident) has not been systematically examined. The purpose of this study was to examine associations between primary lipid screening and visits to primary care providers (PCPs) and rheumatologists among a national sample of older RA patients. Methods. This retrospective cohort study examined a 5% Medicare sample that included 3,298 RA patients without baseline CVD, diabetes mellitus, or hyperlipidemia, who were considered eligible for primary lipid screening during the years 2004-2006. The outcome was probability of lipid screening by the relative frequency of primary care and rheumatology visits, or seeing a PCP at least once each year. Results. Primary lipid screening was performed in only 45% of RA patients. Overall, 65% of patients received both primary and rheumatology care, and 50% saw a rheumatologist as often as a PCP. Any primary care predicted more lipid screening than lone rheumatology care (26% [95% confidence interval (95% CI) 21-32]). As long as a PCP was involved, performance of lipid screening was similar regardless of the balance between primary and rheumatology visits (44-48% [95% CI 41-51]). Not seeing a PCP at least annually decreased screening by 22% (adjusted risk ratio 0.78 [95% CI 0.71-0.84]). Conclusion. Primary lipid screening was performed in fewer than half of eligible RA patients, highlighting a key target for CVD risk reduction efforts. Annual visits to a PCP improved lipid screening, although performance remained poor (51%). Half of RA patients saw their rheumatologist as often or more often than they saw a PCP, illustrating the need to study optimal partnerships between PCPs and rheumatologists for screening patients for CVD risks. C1 [Bartels, Christie M.] Univ Wisconsin, Sch Med & Publ Hlth, Clin Sci Ctr H6, Madison, WI 53792 USA. [Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Mell, Matthew] Stanford Univ, Palo Alto, CA 94304 USA. RP Bartels, CM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Clin Sci Ctr H6, Box 3244,600 Highland Ave, Madison, WI 53792 USA. EM cb4@medicine.wisc.edu FU University of Wisconsin Institute for Clinical and Translational Research from National Center for Research Resources, NIH [1UL1-RR-025011]; University of Wisconsin Institute for Clinical and Translational Research (NIH) [5KL2-RR-025012-02] FX Supported by the Health Innovation Program and the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (grant 1UL1-RR-025011 from the Clinical and Translational Science Award program of the National Center for Research Resources, NIH) and by the University of Wisconsin Institute for Clinical and Translational Research (NIH training grant 5KL2-RR-025012-02). NR 49 TC 21 Z9 23 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD MAY PY 2011 VL 63 IS 5 BP 1221 EP 1230 DI 10.1002/art.30239 PG 10 WC Rheumatology SC Rheumatology GA 764DY UT WOS:000290609800009 PM 21305507 ER PT J AU Morita, Y Chu, CQ AF Morita, Yoshiaki Chu, Cong-Qiu TI Is transforming growth factor beta always necessary for generation of pathogenic Th17 cells in autoimmune disease? Comment on the article by Morita et al Reply SO ARTHRITIS AND RHEUMATISM LA English DT Letter ID TGF-BETA; T-CELLS; INTERLEUKIN-23 PROMOTES; DIFFERENTIATION; DISTINCT; LINEAGE; INFLAMMATION C1 [Morita, Yoshiaki] Astellas Pharma, Tsukuba, Ibaraki, Japan. [Chu, Cong-Qiu] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR USA. RP Morita, Y (reprint author), Astellas Pharma, Tsukuba, Ibaraki, Japan. NR 9 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD MAY PY 2011 VL 63 IS 5 BP 1467 EP 1468 DI 10.1002/art.30304 PG 2 WC Rheumatology SC Rheumatology GA 764DY UT WOS:000290609800040 ER PT J AU Hausmann, LRM Hanusa, BH Kresevic, DM Zickmund, S Ling, BS Gordon, HS Kwoh, CK Mor, MK Hannon, MJ Cohen, PZ Grant, R Ibrahim, SA AF Hausmann, Leslie R. M. Hanusa, Barbara H. Kresevic, Denise M. Zickmund, Susan Ling, Bruce S. Gordon, Howard S. Kwoh, C. Kent Mor, Maria K. Hannon, Michael J. Cohen, Peter Z. Grant, Richard Ibrahim, Said A. TI Orthopedic Communication About Osteoarthritis Treatment: Does Patient Race Matter? SO ARTHRITIS CARE & RESEARCH LA English DT Article ID INTERACTION ANALYSIS SYSTEM; INFORMED DECISION-MAKING; TOTAL KNEE REPLACEMENT; PRIMARY-CARE VISITS; JOINT REPLACEMENT; PHYSICIAN COMMUNICATION; ETHNIC-DIFFERENCES; AFRICAN-AMERICANS; RACIAL DISPARITIES; UNITED-STATES AB Objective. To understand racial disparities in the use of total joint replacement, we examined whether there were racial differences in patient-provider communication about treatment of chronic knee and hip osteoarthritis in a sample of African American and white patients referred to Veterans Affairs orthopedic clinics. Methods. Audio recorded visits between patients and orthopedic surgeons were coded using the Roter Interaction Analysis System and the Informed Decision-Making model. Racial differences in communication outcomes were assessed using linear regression models adjusted for study design, patient characteristics, and clustering by provider. Results. The sample (n = 402) included 296 white and 106 African American patients. Most patients were men (95%) and ages 50-64 years (68%). Almost half (41%) reported an income <$20,000. African American patients were younger and reported lower incomes than white patients. Visits with African American patients contained less discussion of biomedical topics (beta = -9.14; 95% confidence interval [95% CI] -16.73, -1.54) and more rapport-building statements (beta = 7.84; 95% CI 1.85, 13.82) than visits with white patients. However, no racial differences were observed with regard to length of visit, overall amount of dialogue, discussion of psychosocial issues, patient activation/engagement statements, physician verbal dominance, display of positive affect by patients or providers, or discussion related to informed decision making. Conclusion. In this sample, communication between orthopedic surgeons and patients regarding the management of chronic knee and hip osteoarthritis did not, for the most part, vary by patient race. These findings diminish the potential role of communication in Veterans Affairs orthopedic settings as an explanation for well-documented racial disparities in the use of total joint replacement. C1 [Hausmann, Leslie R. M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA. [Hausmann, Leslie R. M.; Hanusa, Barbara H.; Zickmund, Susan; Ling, Bruce S.; Kwoh, C. Kent; Mor, Maria K.; Hannon, Michael J.] Univ Pittsburgh, Pittsburgh, PA USA. [Kresevic, Denise M.; Grant, Richard] Univ Hosp Case Med Ctr, Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Gordon, Howard S.] Univ Illinois, Coll Med, Chicago, IL USA. [Gordon, Howard S.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Cohen, Peter Z.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Ibrahim, Said A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Ibrahim, Said A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM leslie.hausmann@gmail.com RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [IIR 04-137]; VA Health Services Research and Development Career Development [RCD 06-287, ER 0280-1]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [1K24AR055259-01]; Harold Amos Robert Wood Johnson Scholar FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (study IIR 04-137). Dr. Hausmann's work was supported by the VA Health Services Research and Development Career Development Program (awards RCD 06-287 and ER 0280-1). Dr. Ibrahim's work was supported in part by a K24 Award (grant 1K24AR055259-01) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and is recipient of a VA Health Services Research Career Development Award and the Harold Amos Robert Wood Johnson Scholar Award. NR 43 TC 7 Z9 7 U1 3 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAY PY 2011 VL 63 IS 5 BP 635 EP 642 DI 10.1002/acr.20429 PG 8 WC Rheumatology SC Rheumatology GA 761ZK UT WOS:000290441800001 PM 21225676 ER PT J AU Pratchett, LC Yehuda, R AF Pratchett, Laura C. Yehuda, Rachel TI Foundations of posttraumatic stress disorder: Does early life trauma lead to adult posttraumatic stress disorder? SO DEVELOPMENT AND PSYCHOPATHOLOGY LA English DT Article ID CHILD SEXUAL-ABUSE; CORTICOTROPIN-RELEASING-FACTOR; NATIONAL COMORBIDITY SURVEY; URINARY CORTISOL EXCRETION; INTIMATE PARTNER VIOLENCE; FOLLOW-UP; HOLOCAUST SURVIVORS; MALTREATED CHILDREN; NEGLECTED CHILDREN; PHYSICAL ABUSE AB The effects of childhood abuse are diverse, and although pathology is not the only outcome, psychiatric illness, including posttraumatic stress disorder (PTSD), can develop. However, adult PTSD is less common among those who experienced single-event traumas as children than it is among those who experienced childhood abuse. In addition, PTSD is more common among adults than children who experienced childhood abuse. Such evidence raises doubt about the direct, causal link between childhood trauma and adult PTSD. The experience of childhood trauma, and in particular abuse, has been identified as a risk factor for subsequent development of PTSD following exposure to adult trauma, and a substantial literature identifies revictimization as a factor that plays a pivotal role in this trajectory. The literature on the developmental effects of childhood abuse and pathways to revictimization, when considered in tandem with the biological effects of early stress in animal models, may provide some explanations for this. Specifically, it seems possible that permanent sensitization of the hypothalamic-pituitary-adrenal axis and behavioral outcomes are a consequence of childhood abuse, and these combine with the impact of retraumatization to sustain, perpetuate, and amplify symptomatology of those exposed to maltreatment in childhood. C1 [Pratchett, Laura C.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Yehuda, Rachel] Mt Sinai Sch Med, New York, NY 10029 USA. RP Pratchett, LC (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM laura.pratchett@va.gov FU NIMH NIH HHS [MH088101] NR 206 TC 20 Z9 21 U1 16 U2 37 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0954-5794 J9 DEV PSYCHOPATHOL JI Dev. Psychopathol. PD MAY PY 2011 VL 23 IS 2 BP 477 EP 491 DI 10.1017/S0954579411000186 PG 15 WC Psychology, Developmental SC Psychology GA 757OP UT WOS:000290097900009 PM 23786690 ER PT J AU Kellogg, DL Zhao, JL Wu, YB Johnson, JM AF Kellogg, Dean L., Jr. Zhao, Joan L. Wu, Yubo Johnson, John M. TI Antagonism of soluble guanylyl cyclase attenuates cutaneous vasodilation during whole body heat stress and local warming in humans SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE nitric oxide; guanosine 3 ',5 '-cyclic monophosphate; microdialysis; skin; thermoregulation ID SKIN BLOOD-FLOW; HUMAN CARDIOVASCULAR ADJUSTMENTS; SYNTHASE CONTROL MECHANISMS; NITRIC-OXIDE CONCENTRATION; ACTIVE VASODILATATION; S-NITROSYLATION; IN-VIVO; REACTIVE HYPEREMIA; VASCULAR-RESPONSES; MUNC18-1 BINDING AB Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM. Antagonism of soluble guanylyl cyclase attenuates cutaneous vasodilation during whole body heat stress and local warming in humans. J Appl Physiol 110: 1406-1413, 2011. First published February 3, 2011; doi: 10.1152/japplphysiol.00702.2010.-We hypothesized that nitric oxide activation of soluble guanylyl cyclase (sGC) participates in cutaneous vasodilation during whole body heat stress and local skin warming. We examined the effects of the sGC inhibitor, 1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one (ODQ), on reflex skin blood flow responses to whole body heat stress and on nonreflex responses to increased local skin temperature. Blood flow was monitored by laser-Doppler flowmetry, and blood pressure by Finapres to calculate cutaneous vascular conductance (CVC). Intradermal microdialysis was used to treat one site with 1 mM ODQ in 2% DMSO and Ringer, a second site with 2% DMSO in Ringer, and a third site received Ringer. In protocol 1, after a period of normothermia, whole body heat stress was induced. In protocol 2, local heating units warmed local skin temperature from 34 to 41 C to cause local vasodilation. In protocol 1, in normothermia, CVC did not differ among sites [ ODQ, 15 +/- 3% maximum CVC (CVC(max)); DMSO, 14 +/- 3% CVC(max); Ringer, 17 +/- 6% CVC(max); P > 0.05]. During heat stress, ODQ attenuated CVC increases (ODQ, 54 +/- 4% CVC(max); DMSO, 64 +/- 4% CVC(max); Ringer, 63 +/- 4% CVC(max); P < 0.05, ODQ vs. DMSO or Ringer). In protocol 2, at 34 degrees C local temperature, CVC did not differ among sites (ODQ, 17 +/- 2% CVC(max); DMSO, 18 +/- 4% CVC(max); Ringer, 18 +/- 3% CVC(max); P < 0.05). ODQ attenuated CVC increases at 41 degrees C local temperature (ODQ, 54 +/- 5% CVC(max); DMSO, 86 +/- 4% CVC(max); Ringer, 90 +/- 2% CVCmax; P < 0.05 ODQ vs. DMSO or Ringer). sGC participates in neurogenic active vasodilation during heat stress and in the local response to direct skin warming. C1 [Kellogg, Dean L., Jr.; Zhao, Joan L.; Wu, Yubo] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Kellogg, Dean L., Jr.; Johnson, John M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Kellogg, Dean L., Jr.; Zhao, Joan L.; Wu, Yubo] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Kellogg, DL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kelloggd@uthscsa.edu FU National Heart, Lung, and Blood Institute [HL-065599] FX This work was supported in part by National Heart, Lung, and Blood Institute Grant HL-065599. NR 64 TC 14 Z9 14 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAY PY 2011 VL 110 IS 5 BP 1406 EP 1413 DI 10.1152/japplphysiol.00702.2010 PG 8 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 762JL UT WOS:000290472400036 PM 21292837 ER PT J AU Zarraga, IGE MacMurdy, KS Raitt, MH AF Zarraga, Ignatius Gerardo E. MacMurdy, Karen S. Raitt, Merritt H. TI Tachycardia With Typical Left Bundle Branch Block Morphology and VA Block: What is the Differential Diagnosis? SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Editorial Material ID REENTRY; MECHANISM C1 [Zarraga, Ignatius Gerardo E.; MacMurdy, Karen S.; Raitt, Merritt H.] Portland VA Med Ctr, Div Cardiol, Portland, OR 97239 USA. RP Zarraga, IGE (reprint author), Portland VA Med Ctr, Div Cardiol, 3710 SW,US Vet Hos Rd, Portland, OR 97239 USA. EM Ignatius.Zarraga@va.gov OI Raitt, Merritt/0000-0001-5638-7732 NR 6 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD MAY PY 2011 VL 22 IS 5 BP 601 EP 604 DI 10.1111/j.1540-8167.2010.01965.x PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 762OT UT WOS:000290490000021 PM 21561505 ER PT J AU Rodriguez, A Lisboa, T Martin-Loeches, I Diaz, E Trefler, S Restrepo, MI Rello, J AF Rodriguez, Alejandro Lisboa, Thiago Martin-Loeches, Ignacio Diaz, Emili Trefler, Sandra Restrepo, Marcos I. Rello, Jordi TI Mortality and Regional Oxygen Saturation Index in Septic Shock Patients: A Pilot Study SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article DE Near-infrared spectroscopy; Sepsis; Microcirculation; Tissue oxygenation; Hypoxia ID NEAR-INFRARED SPECTROSCOPY; MUSCLE-TISSUE OXYGENATION; SEVERE SEPSIS; TRAUMA PATIENTS; BLOOD-FLOW; PERFUSION; RESUSCITATION; CONSUMPTION; DYSFUNCTION; INSTRUMENT AB Background: Peripheral muscle tissue oxygenation determined noninvasively using near-infrared spectroscopy may help to identify tissue hypoperfusion in septic patients. The aim of this study was to investigate regional oxygen saturation index (rSO(2)) in the brachioradialis (forearm) muscle by comparing measurements in healthy subjects and in intensive care unit (ICU) septic shock patients, and determine whether brachioradialis muscle rSO2 is associated with poor outcome in ICU septic shock patients. Methods: We conducted a prospective observational study in healthy volunteers (n = 50) and ICU septic shock patients (n = 19). Brachioradialis (forearm) rSO2 measurements in healthy volunteers at rest and in ICU septic shock patients were compared. Pulmonary artery catheter monitoring was used in ICU patients. Results: Significant differences in rSO(2) were observed between healthy volunteers and ICU septic shock patients at ICU admission (68.7 +/- 4.9 vs. 55.0 +/- 13.0; p < 0.001). When comparing septic shock survivors and nonsurvivors, significant differences were observed in rSO(2) at baseline (64.5 +/- 8.9 vs. 47.5 +/- 10.7; p < 0.01), 12 hours (67.3 +/- 9.6 vs. 45.0 +/- 14.9; p < 0.01), and 24 hours (65.7 +/- 7.0 vs. 50.1 +/- 10.3; p < 0.01). Lactate concentration was lower in survivors than nonsurvivors at 24 hours (12.0 +/- 7.5 mmol/L vs. 23.2 +/- 12.5 mmol/L; p < 0.04). Cardiac index was greater in nonsurvivors than survivors at baseline (4.6 + 1.9 L/min/m(2) vs. 3.0 + 0.9 L/min/m(2); p < 0.05) and 12 h (3.9 + 0.5 L/min/m(2) vs. 3.1 + 0.3 L/min/m(2); p < 0.05). Conclusions: We observed that septic shock patients with forearm skeletal muscle rSO(2) <= 60% throughout first 24 hours after ICU admission had significantly greater mortality rate than patients with forearm skeletal muscle rSO2 >60% throughout this critical time. C1 [Rodriguez, Alejandro; Lisboa, Thiago; Martin-Loeches, Ignacio; Diaz, Emili; Trefler, Sandra] Univ Rovira & Virgili, Crit Care Dept, Joan XXIII Univ Hosp, IISPV,CIBER Enfermedades Resp, Tarragona 43007, Spain. [Lisboa, Thiago] Clin Univ Hosp, Crit Care Dept, Porto Alegre, RS, Brazil. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. [Rello, Jordi] Vall Hebron Univ Hosp, Crit Care Dept, CIBER Enfermedades Resp, Barcelona, Spain. RP Rodriguez, A (reprint author), Univ Rovira & Virgili, Crit Care Dept, Joan XXIII Univ Hosp, IISPV,CIBER Enfermedades Resp, Carrer Dr Mallafre Guasch 4, Tarragona 43007, Spain. EM ahr1161@yahoo.es RI Martin-Loeches, Ignacio/H-4633-2013; Restrepo, Marcos/H-4442-2014 OI Rodriguez Oviedo, Alejandro/0000-0001-8828-5984; Rello, Jordi/0000-0003-0676-6210; martin-loeches, ignacio/0000-0002-5834-4063 FU Instituto de Salud Carlos III [FIS PI10/01538]; CIBER Enfermedades respiratorias; AGAUR [2009/SGR/1226]; Department of Veterans Affairs, Veterans Integrated Service Network; National Health Institute [KL2 RR025766] FX Supported by FIS PI10/01538 Instituto de Salud Carlos III (FEDER), CIBER Enfermedades respiratorias, and AGAUR (2009/SGR/1226).; Dr. Restrepo is supported by a Department of Veterans Affairs, Veterans Integrated Service Network 17 new faculty grant and National Health Institute Grant KL2 RR025766. NR 52 TC 14 Z9 15 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD MAY PY 2011 VL 70 IS 5 BP 1145 EP 1152 DI 10.1097/TA.0b013e318216f72c PG 8 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 762LQ UT WOS:000290480300035 PM 21610429 ER PT J AU Kozora, E Brown, MS Filley, CM Zhang, L Miller, DE West, SG Pelzman, J Arciniegas, DB AF Kozora, E. Brown, M. S. Filley, C. M. Zhang, L. Miller, D. E. West, S. G. Pelzman, J. Arciniegas, D. B. TI Memory impairment associated with neurometabolic abnormalities of the hippocampus in patients with non-neuropsychiatric systemic lupus erythematosus SO LUPUS LA English DT Article DE hippocampal volume; lupus; memory function; neurometabolites ID MAGNETIC-RESONANCE-SPECTROSCOPY; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL BATTERY; H-1-MR SPECTROSCOPY; LEARNING-ABILITY; GLIAL-CELLS; ANTI-DNA; BRAIN; ATROPHY AB Objective: Memory impairment is common in patients with systemic lupus erythematosus (SLE). This study examined hippocampal volumes and neurometabolic alterations in relation to memory function in SLE patients without a history of neuropsychiatric syndromes (nonNPSLE). Methods: Subjects included 81 nonNPSLE patients and 34 healthy controls. Volumetric magnetic resonance imaging and magnetic resonance spectroscopy of the right and left hippocampal areas (RH, LH) were performed. Verbal and visual memory tests were administered and a Memory Impairment Index (MII) was derived from standardized tests. Results: Higher memory impairment (MII) was correlated with lower RH glutamate + glutamine/creatine (p = 0.009) and lower RH N-acetylaspartic acid/creatine (p = 0.012) in nonNPSLE patients. A trend for a negative correlation between RH and LH volumes and MII was evident for absolute hippocampal volumes. Lower RH glutamate + glutamine/creatine was also correlated with worse performance in a mean visual memory index (p = 0.017). Conclusions: An association between reduced memory and lower N-acetylaspartic acid/creatine in the RH suggests neuronal damage in nonNPSLE patients with very mild and early disease. Alterations in glutamate + glutamine/creatine further indicate early metabolic changes in nonNPSLE are related to memory impairment, a finding that might suggest that memory impairment relates to presynaptic glutamatergic dysfunction in the hippocampus. Lupus (2011) 20, 598-606. C1 [Kozora, E.; Zhang, L.; Pelzman, J.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Kozora, E.; Filley, C. M.; Arciniegas, D. B.] Univ Colorado, Denver Sch Med, Dept Neurol, Denver, CO 80202 USA. [Kozora, E.; Filley, C. M.; Arciniegas, D. B.] Univ Colorado, Denver Sch Med, Dept Psychiat, Denver, CO 80202 USA. [Brown, M. S.; Miller, D. E.] Univ Colorado, Denver Sch Med, Dept Radiol, Denver, CO 80202 USA. [West, S. G.] Univ Colorado, Denver Sch Med, Dept Rheumatol, Denver, CO 80202 USA. [Filley, C. M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kozora, E (reprint author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA. EM kozorae@njhealth.org FU National Institute of Musculoskeletal and Skin Diseases [RO1 AR049152] FX This funding was supported by the National Institute of Musculoskeletal and Skin Diseases (grant number RO1 AR049152). NR 52 TC 16 Z9 18 U1 2 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PD MAY PY 2011 VL 20 IS 6 BP 598 EP 606 DI 10.1177/0961203310392425 PG 9 WC Rheumatology SC Rheumatology GA 761DX UT WOS:000290376600007 PM 21335397 ER PT J AU Filippova, N Yang, XH Wang, YM Gillespie, GY Langford, C King, PH Wheeler, C Nabors, LB AF Filippova, Natalia Yang, Xiuhua Wang, Yimin Gillespie, G. Yancey Langford, Cathy King, Peter H. Wheeler, Crystal Nabors, L. Burt TI The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance SO MOLECULAR CANCER RESEARCH LA English DT Article ID INCREASED CYCLOOXYGENASE-2 EXPRESSION; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; STABILITY FACTOR; XENOGRAFT MODEL; BREAST-CANCER; RICH ELEMENTS; CARCINOMA; CELLS AB Posttranscriptional regulation is a critical control point for the expression of genes that promote or retard tumor growth. We previously found that the mRNA-binding protein, ELAV 1 (HuR), is upregulated in primary brain tumors and stabilizes growth factor mRNAs such as VEGF and IL-8. To better understand the role of HuR in brain tumor growth, we altered levels of HuR in glioma cells by short hairpin RNA or ectopic expression and measured tumor cell phenotype using in vitro and in vivo models. In HuR-silenced cells, we found a significant decrease in anchorage-independent growth and cell proliferation with a concomitant induction of apoptosis. Using an intracranial tumor model with primary glioblastoma cells, HuR silencing produced a significant decrease in tumor volume. In contrast, overexpression of HuR produced in vitro chemoresistance to standard glioma therapies. Because bcl-2 is abundantly expressed in glioma and associated with tumor growth and survival, we determined the impact of HuR on its regulation as a molecular validation to the cellular and animal studies. Using UV cross-linking and RNA immunoprecipitation, we show that HuR bound to the 3'-untranslated region of all bcl-2 family members. Silencing of HuR led to transcript destabilization and reduced protein expression. Polysome profiling indicated loss of HuR from the translational apparatus. In summary, these findings reveal a HuR-dependent mechanism for cancer cell survival and sensitivity to chemotherapeutic drugs suggesting that HuR should be considered as a new therapeutic target. Mol Cancer Res; 9(5); 648-59. (C) 2011 AACR. C1 [Nabors, L. Burt] Univ Alabama, Dept Neurol, Neurooncol Program, Birmingham, AL 35294 USA. [Gillespie, G. Yancey; Langford, Cathy] Univ Alabama, Dept Surg, Div Neurosurg, Birmingham, AL 35294 USA. [Wang, Yimin] So Res Inst, Div Drug Discovery, Birmingham, AL 35255 USA. [King, Peter H.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Nabors, LB (reprint author), Univ Alabama, Dept Neurol, Neurooncol Program, 510 20th St S,FOT 1020, Birmingham, AL 35294 USA. EM bnabors@uab.edu FU NCI [R01 CA112397]; VA Merit Review; UAB Small Animal Imaging Shared Facility [P30CA013148] FX This study was supported by NCI R01 CA112397 (L. B. Nabors), VA Merit Review (P. H. King), and by UAB Small Animal Imaging Shared Facility (P30CA013148). NR 33 TC 44 Z9 46 U1 2 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 J9 MOL CANCER RES JI Mol. Cancer Res. PD MAY PY 2011 VL 9 IS 5 BP 648 EP 659 DI 10.1158/1541-7786.MCR-10-0325 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 764EF UT WOS:000290610600012 PM 21498545 ER PT J AU Shalaby, A Atwood, CW Selzer, F Suffoletto, M Gorcsan, J Strollo, P AF Shalaby, Alaa Atwood, Charles W. Selzer, Faith Suffoletto, Matthew Gorcsan, John, III Strollo, Patrick TI Cardiac Resynchronization Therapy and Obstructive Sleep-Related Breathing Disorder in Patients with Congestive Heart Failure SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE congestive heart failure; CRT; pacing ID POSITIVE AIRWAY PRESSURE; CHEYNE-STOKES RESPIRATION; RESYNCHRONISATION THERAPY; VENTRICULAR DYSSYNCHRONY; RATE-VARIABILITY; APNEA; TRIAL; DYSFUNCTION; IMPROVEMENT; PREDICTORS AB Introduction: CRT may have a positive influence on SRBD in patients who qualify for the therapy. Data are inconclusive in patients with obstructive SRBD. Methods: Consenting patients eligible for CRT underwent a baseline polysomnography (PSG) 2 weeks after implantation during which pacing was withheld. Patients with an apnea hypopnea index (AHI) >= 15 but < 50 were enrolled and randomized to atrial overdrive pacing (DDD) versus atrial synchronous pacing (VDD) with biventricular pacing in both arms. Patients underwent two further PSGs 12 weeks apart. Results: Nineteen men with New York Heart Association class III congestive heart failure participated in the study (age 67.2 +/- 7.5, Caucasian 78.9%, ischemic 73.7%). The score on Epworth Sleepiness Score was 7.3 +/- 4.0, Pittsburgh Sleep Quality Index 7.4 +/- 3.1, and Minnesota Living with Heart Failure Questionnaire 36.9 +/- 21.9. There were no differences between the groups. At baseline, patients exhibited poor sleep efficiency (65.3 +/- 16.6%) with nadir oxygen saturation of 83.5 +/- 5.3% and moderate to severe SRBD (AHI 21.5 +/- 15.3) that was mainly obstructive (central apnea index 3.3 +/- 6.7/hour). On both follow-up assessments, there was no improvement in indices of SRBD (sleep efficiency [68.3 +/- 17.9%], nadir oxygen saturation of 82.8 +/- 4.6%, and AHI 24.9 +/- 21.9). Conclusion: In a cohort of elderly male CHF patients receiving CRT, CRT had no impact on obstructive SRBD burden with or without atrial overdrive pacing. (PACE 2011; 34:593-603). C1 [Shalaby, Alaa; Atwood, Charles W.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Shalaby, Alaa; Suffoletto, Matthew; Gorcsan, John, III] Univ Pittsburgh, Med Ctr, Div Cardiol, Pittsburgh, PA USA. [Atwood, Charles W.; Strollo, Patrick] Univ Pittsburgh, Grad Sch Publ Hlth, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Selzer, Faith] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA. RP Shalaby, A (reprint author), 111C Univ Dr, Pittsburgh, PA 15240 USA. EM Alaa.Shalaby@va.gov FU Boston Scientific, Inc. Cardiac Rhythm Management Division; Boston Scientific FX This study was supported by Boston Scientific, Inc. Cardiac Rhythm Management Division.; Alaa Shalaby: Research support from Boston Scientific. NR 41 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD MAY PY 2011 VL 34 IS 5 BP 593 EP 603 DI 10.1111/j.1540-8159.2010.03015.x PG 11 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 762CK UT WOS:000290449700014 PM 21609340 ER PT J AU Spiegel, BMR Talley, J Shekelle, P Agarwal, N Snyder, B Bolus, R Kurzbard, N Chan, M Ho, A Kaneshiro, M Cordasco, K Cohen, H AF Spiegel, Brennan M. R. Talley, Jennifer Shekelle, Paul Agarwal, Nikhil Snyder, Bradley Bolus, Roger Kurzbard, Nicole Chan, Michael Ho, Andrew Kaneshiro, Marc Cordasco, Kristina Cohen, Hartley TI Development and Validation of a Novel Patient Educational Booklet to Enhance Colonoscopy Preparation SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID BOWEL PREPARATION; COLORECTAL-CANCER; PREPARATION QUALITY; IMPACT; ENDOSCOPY; VETERANS; SCALE; COST AB OBJECTIVES: The success of colonoscopy depends on high-quality bowel preparation by patients; yet inadequate preparation is common. We developed and tested an educational booklet to improve bowel preparation quality. METHODS: We conducted patient cognitive interviews to identify knowledge and belief barriers to colonoscopy preparation. We used these interviews to create an educational booklet to enhance preparatory behaviors. We then prospectively randomized patients scheduled for outpatient colonoscopy at a VA Medical Center to receive usual instructions vs. the booklet before colonoscopy. Patients in both groups received standard pharmacy instructions for single-dose bowel preparation; the protocol did not specify which purgatives to prescribe. The primary outcome was preparation quality based on blinded ratings using the validated Ottawa score. We performed bivariate analyses to compare mean scores between groups using a t-test, and logistic regression to measure the booklet effect on preparation quality, adjusting for potential confounders. RESULTS: A total of 436 patients were randomized between arms. In an intention-to-treat analysis of the primary outcome, mean Ottawa scores were superior in patients allocated to booklet vs. controls (P = 0.03). An intention-to-treat analysis of the secondary outcome revealed a "good" preparation in 68 vs. 46% of booklet and control patients, respectively (P = 0.054). In a per-protocol analysis limited to patients who actually received the booklet, preparation was good in 76 vs. 46% patients, respectively (P < 0.00001). Regression analysis revealed that booklet receipt increased the odds of good preparation by 3.7 times (95% confi dence interval = 2.3-5.8). CONCLUSIONS: Provision of a novel educational booklet considerably improves preparation quality in patients receiving single-dose purgatives. The effect of the booklet on split-dose purgatives remains untested and will be evaluated in future research. C1 [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, UCLA VA Ctr Outcomes Res & Educ CORE,Dept Med, Los Angeles, CA 90073 USA. [Spiegel, Brennan M. R.; Snyder, Bradley; Bolus, Roger; Kurzbard, Nicole; Chan, Michael; Cohen, Hartley] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90073 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90073 USA. CURE Digest Dis Res Ctr, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, UCLA VA Ctr Outcomes Res & Educ CORE,Dept Med, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Veteran's Affairs Health Services Research and Development (HSRD) [RCD 03-179-2]; Veterans Affairs [IIR 08-310] FX This research was supported by a Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award (RCD 03-179-2) and by a Veterans Affairs Merit Award (IIR 08-310) to Dr Spiegel. NR 24 TC 55 Z9 58 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2011 VL 106 IS 5 BP 875 EP 883 DI 10.1038/ajg.2011.75 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 759MP UT WOS:000290250100010 PM 21483463 ER PT J AU Harston, RK McKillop, JC Moschella, PC Van Laer, A Quinones, LS Baicu, CF Balasubramanian, S Zile, MR Kuppuswamy, D AF Harston, Rebecca K. McKillop, John C. Moschella, Phillip C. Van Laer, An Quinones, Lakeya S. Baicu, Catalin F. Balasubramanian, Sundaravadivel Zile, Michael R. Kuppuswamy, Dhandapani TI Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE hypertrophy; mammalian target of rapamycin; signal transduction; cell survival ID NF-KAPPA-B; CARDIAC-HYPERTROPHY; IN-VIVO; VENTRICULAR HYPERTROPHY; LIFE-SPAN; MTOR; MICE; PROTEASOME; PATHWAY; GROWTH AB Harston RK, McKillop JC, Moschella PC, Van Laer A, Quinones LS, Baicu CF, Balasubramanian S, Zile MR, Kuppuswamy D. Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. Am J Physiol Heart Circ Physiol 300: H1696-H1706, 2011. First published February 25, 2011; doi:10.1152/ajpheart.00545.2010.-Ubiquitin-mediated protein degradation is necessary for both increased ventricular mass and survival signaling for compensated hypertrophy in pressure-overloaded (PO) myocardium. Another molecular keystone involved in the hypertrophic growth process is the mammalian target of rapamycin (mTOR), which forms two distinct functional complexes: mTORC1 that activates p70S6 kinase-1 to enhance protein synthesis and mTORC2 that activates Akt to promote cell survival. Independent studies in animal models show that rapamycin treatment that alters mTOR complexes also reduces hypertrophic growth and increases lifespan by an unknown mechanism. We tested whether the ubiquitin-mediated regulation of growth and survival in hypertrophic myocardium is linked to the mTOR pathway. For in vivo studies, right ventricle PO in rats was conducted by pulmonary artery banding; the normally loaded left ventricle served as an internal control. Rapamycin (0.75 mg/kg per day) or vehicle alone was administered intraperitoneally for 3 days or 2 wk. Immunoblot and immunofluorescence imaging showed that the level of ubiquitylated proteins in cardiomyocytes that increased following 48 h of PO was enhanced by rapamycin. Rapamycin pretreatment also significantly increased PO-induced Akt phosphorylation at S473, a finding confirmed in cardiomyocytes in vitro to be downstream of mTORC2. Analysis of prosurvival signaling in vivo showed that rapamycin increased PO-induced degradation of phosphorylated inhibitor of kappa B, enhanced expression of cellular inhibitor of apoptosis protein 1, and decreased active caspase-3. Long-term rapamycin treatment in 2-wk PO myocardium blunted hypertrophy, Unproved contractile function, and reduced caspase-3 and calpain activation. These data indicate potential cardioprotective benefits of rapamycin in PO hypertrophy. C1 [Harston, Rebecca K.; McKillop, John C.; Moschella, Phillip C.; Van Laer, An; Quinones, Lakeya S.; Baicu, Catalin F.; Balasubramanian, Sundaravadivel; Zile, Michael R.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29425 USA. [Zile, Michael R.; Kuppuswamy, Dhandapani] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Kuppuswamy, D (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, 114 Doughty St, Charleston, SC 29425 USA. EM kuppusd@musc.edu FU National Institutes of Health [RHL092124A, T32HL07260]; Research Service of the Department of Veterans Affairs; AHA [061546811] FX This study was supported by the National Institutes of Health (RHL092124A to D. Kuppuswamy), and by Merit Award from the Research Service of the Department of Veterans Affairs (to M. Zile), by AHA predoctoral fellowship 061546811 (to R. K. Harston), and by NIH predoctoral fellowship NIH T32HL07260 (to R. K. Harston). NR 42 TC 13 Z9 13 U1 1 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAY PY 2011 VL 300 IS 5 BP H1696 EP H1706 DI 10.1152/ajpheart.00545.2010 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 757NA UT WOS:000290092800016 PM 21357504 ER PT J AU Sas, KM Janech, MG Favre, E Arthur, JM Bell, PD AF Sas, Kelli M. Janech, Michael G. Favre, Elizabeth Arthur, John M. Bell, P. Darwin TI Cilia movement regulates expression of the Raf-1 kinase inhibitor protein SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE polycystic kidney disease; renal epithelial cells; renal cysts ID POLYCYSTIC KIDNEY-DISEASE; PROSTATE-CANCER METASTASIS; AUTOSOMAL-DOMINANT; CYST FORMATION; EPITHELIAL-CELLS; COLLECTING DUCT; B-RAF; FLUID; MICE; ACTIVATION AB Sas KM, Janech MG, Favre E, Arthur JM, Bell PD. Cilia movement regulates expression of the Raf-1 kinase inhibitor protein. Am J Physiol Renal Physiol 300: F1163-F1170, 2011. First published February 23, 2011; doi:10.1152/ajprenal.00602.2010.-Renal epithelial cell primary cilia act as mechanosensors in response to changes in luminal fluid flow. To determine the role of cilia bending in the mechanosensory function of cilia, we performed proteomic analysis of collecting duct cell lines with or without cilia that were kept stationary or rotated to stimulate cilia bending. Expression of the Raf-1 kinase inhibitor protein (RKIP), an inhibitor of the MAPK pathway, was significantly elevated in rotated cilia (+) cells. This was compared with RKIP levels in cilia (-) cells that were stationary or rotated as well as in cilia (+) cells that were stationary. This result was confirmed in cilia knockout adult mice that had lower renal RKIP levels compared with adult mice with cilia. Downstream of RKIP, expression of phosphorylated ERK was decreased only in cells that had cilia and were subjected to constant cilia bending. Furthermore, elevated RKIP levels were associated with reduced cell proliferation. Blockade of PKC abrogated ciliary bending-induced increases in RKIP. In summary, we found that ciliary movement may help control the expression of the Raf-1 kinase inhibitor protein and thus maintain cell differentiation. In terms of polycystic kidney disease, loss of cilia and therefore sensitivity to flow may lead to reduced RKIP levels, activation of the MAPK pathway, and contribute to the formation of cysts. C1 [Janech, Michael G.; Arthur, John M.; Bell, P. Darwin] MUSC, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Sas, Kelli M.; Janech, Michael G.; Favre, Elizabeth; Arthur, John M.; Bell, P. Darwin] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Bell, PD (reprint author), MUSC, Ralph H Johnson Vet Affairs Med Ctr, 173 Ashley Ave,CRI 211, Charleston, SC 29425 USA. EM bellpd@musc.edu OI Janech, Michael/0000-0002-3202-4811 FU Veterans Affairs (VA); National Institutes of Health (NIH) [DK32032, P30 DK074038, T32 DK007752]; Dialysis Clinic, Inc.; Nephcure Foundation; Foundation Young Investigator Award; NIH, National Center for Research Resources [C06 RR015455] FX This work was supported by Veterans Affairs (VA) Merit Awards (P. D. Bell, J. M. Arthur), a VA Career Development Award (M. G. Janech), National Institutes of Health (NIH) Grants DK32032 (P. D. Bell), P30 DK074038 (P. D. Bell; UAB Core Center, Lisa Guay-Woodford, PI) and T32 DK007752 (K. M. Sas; P. D. Bell, PI). Support was also provided by Dialysis Clinic, Inc., and a Nephcure Foundation Young Investigator Award (M. G. Janech). Foundation Young Investigator Award (M. G. Janech). This work was conducted in a facility constructed with support from NIH Grant C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. NR 54 TC 5 Z9 5 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAY PY 2011 VL 300 IS 5 BP F1163 EP F1170 DI 10.1152/ajprenal.00602.2010 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 758YY UT WOS:000290206100014 PM 21345975 ER PT J AU Dodrill, CL Helmer, DA Kosten, TR AF Dodrill, Carrie L. Helmer, Drew A. Kosten, Thomas R. TI Prescription Pain Medication Dependence SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID CHRONIC NONMALIGNANT PAIN; OPIOID DEPENDENCE; ADDICTION TREATMENT; DRUG-ABUSE; BACK-PAIN; BUPRENORPHINE; METHADONE; THERAPY; DETOXIFICATION; PREVALENCE C1 [Dodrill, Carrie L.] Baylor Coll Med, Dept Psychiat, Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Dodrill, CL (reprint author), Baylor Coll Med, Dept Psychiat, Michael E Debakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,Bldg 110,Rm 223, Houston, TX 77030 USA. EM dodrill@bcm.edu FU NIDA NIH HHS [K05-DA0454] NR 44 TC 16 Z9 16 U1 2 U2 9 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAY PY 2011 VL 168 IS 5 BP 466 EP 471 DI 10.1176/appi.ajp.2010.10020260 PG 6 WC Psychiatry SC Psychiatry GA 757MG UT WOS:000290089000007 PM 21536702 ER PT J AU Foland-Ross, LC Thompson, PM Sugar, CA Madsen, SK Shen, JK Penfold, C Ahlf, K Rasser, PE Fischer, J Yang, YL Townsend, J Bookheimer, SY Altshuler, LL AF Foland-Ross, Lara C. Thompson, Paul M. Sugar, Catherine A. Madsen, Sarah K. Shen, Jim K. Penfold, Conor Ahlf, Kyle Rasser, Paul E. Fischer, Jeffrey Yang, Yilan Townsend, Jennifer Bookheimer, Susan Y. Altshuler, Lori L. TI Investigation of Cortical Thickness Abnormalities in Lithium-Free Adults With Bipolar I Disorder Using Cortical Pattern Matching SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID VOXEL-BASED MORPHOMETRY; GRAY-MATTER DENSITY; CINGULATE CORTEX VOLUME; PREFRONTAL CORTEX; ORBITOFRONTAL CORTEX; RATING-SCALE; GREY-MATTER; HUMAN BRAIN; AMYGDALA; SCHIZOPHRENIA AB Objective: Although several lines of evidence implicate gray matter abnormalities in the prefrontal cortex and anterior cingulate cortex in patients with bipolar disorder, findings have been largely inconsistent across studies. Differences in patients' medication status or mood state or the application of traditional volumetric methods that are insensitive to subtle neuroanatomical differences may have contributed to variations in findings. The authors used MRI in conjunction with cortical pattern matching methods to assess cortical thickness abnormalities in euthymic bipolar patients who were not receiving lithium treatment. Method: Thirty-four lithium-free euthymic patients with bipolar I disorder and 31 healthy comparison subjects under-went MRI scanning. Data were processed to measure cortical gray matter thickness. Thickness maps were spatially normalized using cortical pattern matching and were analyzed to assess illness effects and associations with clinical variables. Results: Relative to healthy comparison subjects, euthymic bipolar patients had significantly thinner gray matter in the left and right prefrontal cortex (Brodmann's areas 11, 10, 8, and 44) and the left anterior cingulate cortex (Brodmann's areas 24/32). Thinning in these regions was more pronounced in patients with a history of psychosis. No areas of thicker cortex were detected in bipolar patients relative to healthy comparison subjects. Conclusions: Using a technique that is highly sensitive to subtle neuroanatomical differences, significant regional cortical thinning was found in lithium-free euthymic patients with bipolar disorder. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab NeuroImaging, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Schizophrenia Res Inst, Darlinghurst, NSW, Australia. Univ Newcastle, Prior Ctr Brain & Mental Hlth Res, Callaghan, NSW 2308, Australia. VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. W Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Altshuler, LL (reprint author), 300 UCLA Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu FU NIMH [MH078556, MH075944, MH01848]; NARSAD; National Center for Research Resources [AG016570, EB01651, RR019771, RR12169, RR13642, RR00865]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; Northstar Fund FX Supported by NIMH grants MH078556, MH075944, and MH01848; NARSAD; National Center for Research Resources grants AG016570, EB01651, RR019771, RR12169, RR13642, and RR00865; and the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Brain Mapping Medical Research Organization, the Brain Mapping Support Foundation, the Pierson-Lovelace Foundation, the Ahmanson Foundation, the William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, the Tamkin Foundation, the Jennifer Jones-Simon Foundation, the Capital Group Companies Charitable Foundation, the Robson Family, and the Northstar Fund. NR 59 TC 36 Z9 37 U1 0 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAY PY 2011 VL 168 IS 5 BP 530 EP 539 DI 10.1176/appi.ajp.2010.10060896 PG 10 WC Psychiatry SC Psychiatry GA 757MG UT WOS:000290089000014 PM 21285139 ER PT J AU Sandweiss, DA Slymen, DJ LeardMann, CA Smith, B White, MR Boyko, EJ Hooper, TI Gackstetter, GD Amoroso, PJ Smith, TC AF Sandweiss, Donald A. Slymen, Donald J. LeardMann, Cynthia A. Smith, Besa White, Martin R. Boyko, Edward J. Hooper, Tomoko I. Gackstetter, Gary D. Amoroso, Paul J. Smith, Tyler C. CA Millennium Cohort Study Team TI Preinjury Psychiatric Status, Injury Severity, and Postdeployment Posttraumatic Stress Disorder SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID MOTOR-VEHICLE ACCIDENTS; READJUSTMENT RATING-SCALE; COMBAT TRAUMA REGISTRY; MENTAL-HEALTH PROBLEMS; MILLENNIUM COHORT; PRIMARY-CARE; MILITARY SERVICE; RISK-FACTORS; US MILITARY; PERCEIVED THREAT AB Context: Physical injury has been associated with the development of posttraumatic stress disorder (PTSD). Previous studies have retrospectively examined the relationship of preinjury psychiatric status and postinjury PTSD with conflicting results, but no prospective studies regarding this subject have been conducted, to our knowledge. Objective: To prospectively assess the relationship of predeployment psychiatric status and injury severity with postdeployment PTSD. Design: Prospective, longitudinal study. Setting: United States military personnel deployed in support of the conflicts in Iraq and Afghanistan. Participants: United States service member participants in the Millennium Cohort Study who completed a baseline questionnaire (from July 1, 2001, through June 30, 2003) and at least 1 follow-up questionnaire (from June 1, 2004, through February 14, 2006, and from May 15, 2007, through December 31, 2008) and who were deployed in the intervening period. Self-reported health information was used to prospectively examine the relationship between baseline psychiatric status and follow-up PTSD in injured and uninjured deployed individuals. Main Outcome Measures: A positive screening result using the PTSD Checklist-Civilian Version. Results: Of 22 630 eligible participants, 1840 (8.1%) screened positive for PTSD at follow-up, and 183 (0.8%) sustained a deployment-related physical injury that was documented in the Joint Theater Trauma Registry or the Navy-Marine Corps Combat Trauma Registry Expeditionary Medical Encounter Database. The odds of screening positive for PTSD symptoms were 2.52 (95% confidence interval, 2.01-3.16) times greater in those with 1 or more defined baseline mental health disorder and 16.1% (odds ratio, 1.16; 95% confidence interval, 1.01-1.34) greater for every 3-unit increase in the Injury Severity Score. Irrespective of injury severity, self-reported preinjury psychiatric status was significantly associated with PTSD at follow-up. Conclusions: Baseline psychiatric status and deployment-related physical injuries were associated with screening positive for postdeployment PTSD. More vulnerable members of the deployed population might be identified and benefit from interventions targeted to prevent or to ensure early identification and treatment of postdeployment PTSD. C1 [Sandweiss, Donald A.; LeardMann, Cynthia A.; Smith, Besa; White, Martin R.; Smith, Tyler C.] USN, Hlth Res Ctr, Dept Deployment Hlth Res, San Diego, CA 92106 USA. [Slymen, Donald J.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Gackstetter, Gary D.] Analyt Serv Inc, Arlington, VA USA. [Amoroso, Paul J.] Madigan Army Med Ctr, Dept Clin Invest, Tacoma, WA 98431 USA. RP LeardMann, CA (reprint author), USN, Hlth Res Ctr, Dept Deployment Hlth Res, 140 Sylvester Rd, San Diego, CA 92106 USA. EM cynthia.leardmann@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X FU US Department of Defense; Veterans Affairs Puget Sound Health Care System FX This work represents report 10-03, supported by the US Department of Defense, within work unit 60002. The work of Dr Boyko in this project was supported by the Veterans Affairs Puget Sound Health Care System. NR 75 TC 19 Z9 19 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD MAY PY 2011 VL 68 IS 5 BP 496 EP 504 PG 9 WC Psychiatry SC Psychiatry GA 757UY UT WOS:000290114500010 PM 21536979 ER PT J AU Culbertson, CS Bramen, J Cohen, MS London, ED Olmstead, RE Gan, JJ Costello, MR Shulenberger, S Mandelkern, MA Brody, AL AF Culbertson, Christopher S. Bramen, Jennifer Cohen, Mark S. London, Edythe D. Olmstead, Richard E. Gan, Joanna J. Costello, Matthew R. Shulenberger, Stephanie Mandelkern, Mark A. Brody, Arthur L. TI Effect of Bupropion Treatment on Brain Activation Induced by Cigarette-Related Cues in Smokers SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID SUSTAINED-RELEASE BUPROPION; ANTERIOR CINGULATE CORTEX; SMOKING-CESSATION; NICOTINE DEPENDENCE; TOBACCO DEPENDENCE; CONTROLLED-TRIAL; RECEPTOR SUBTYPES; RANDOMIZED-TRIAL; DRUG-ADDICTION; FMRI AB Context: Nicotine-dependent smokers exhibit craving and brain activation in the prefrontal and limbic regions when presented with cigarette-related cues. Bupropion hydrochloride treatment reduces cue-induced craving in cigarette smokers; however, the mechanism by which bupropion exerts this effect has not yet been described. Objective: To assess changes in regional brain activation in response to cigarette-related cues from before to after treatment with bupropion (vs placebo). Design: Randomized, double-blind, before-after controlled trial. Setting: Academic brain imaging center. Participants: Thirty nicotine-dependent smokers (paid volunteers). Interventions: Participants were randomly assigned to receive 8 weeks of treatment with either bupropion or a matching placebo pill (double-blind). Main Outcome Measures: Subjective cigarette craving ratings and regional brain activations (blood oxygen level-dependent response) in response to viewing cue videos. Results: Bupropion-treated participants reported less craving and exhibited reduced activation in the left ventral striatum, right medial orbitofrontal cortex, and bilateral anterior cingulate cortex from before to after treatment when actively resisting craving compared with placebo-treated participants. When resisting craving, reduction in self-reported craving correlated with reduced regional brain activation in the bilateral medial orbitofrontal and left anterior cingulate cortices in all participants. Conclusions: Treatment with bupropion is associated with improved ability to resist cue-induced craving and a reduction in cue-induced activation of limbic and prefrontal brain regions, while a reduction in craving, regardless of treatment type, is associated with reduced activation in prefrontal brain regions. C1 [Culbertson, Christopher S.; Bramen, Jennifer; Cohen, Mark S.; London, Edythe D.; Gan, Joanna J.; Costello, Matthew R.; Brody, Arthur L.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. [London, Edythe D.; Brody, Arthur L.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Olmstead, Richard E.; Shulenberger, Stephanie; Mandelkern, Mark A.; Brody, Arthur L.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Nucl Med, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. RP Brody, AL (reprint author), 300 UCLA Med Plaza,Ste 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu RI Cohen, Mark/C-6610-2011 OI Cohen, Mark/0000-0001-6731-4053 FU National Institute on Drug Abuse [R01 DA20872, DA245482]; Tobacco-Related Disease Research Program, a Veterans Affairs Type I Merit Review Award [16RT-0098]; Richard Metzner Chair in Clinical Neuropharmacology; Thomas P. and Katherine K. Pike Chair in Addiction Studies; Marjorie M. Greene Trust FX This study was supported by grants R01 DA20872 (Dr Brody) and DA245482 (Mr Culbertson) from the National Institute on Drug Abuse; grant 16RT-0098 from the Tobacco-Related Disease Research Program, a Veterans Affairs Type I Merit Review Award, and endowments from the Richard Metzner Chair in Clinical Neuropharmacology (Dr Brody); and endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies and the Marjorie M. Greene Trust (Dr London). NR 92 TC 32 Z9 33 U1 2 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD MAY PY 2011 VL 68 IS 5 BP 505 EP 515 DI 10.1001/archgenpsychiatry.2010.193 PG 11 WC Psychiatry SC Psychiatry GA 757UY UT WOS:000290114500012 PM 21199957 ER PT J AU Jegga, AG Schneider, L Ouyang, XS Zhang, J AF Jegga, Anil G. Schneider, Lonnie Ouyang, Xiaosen Zhang, Jianhua TI Systems biology of the autophagy-lysosomal pathway SO AUTOPHAGY LA English DT Article DE systems biology; autophagy; lysosome; transcription factors; microRNA ID CATHEPSIN-D DEFICIENCY; ALZHEIMERS-DISEASE; LIPID-METABOLISM; TRANSCRIPTION FACTORS; MICRORNA EXPRESSION; MUSCLE-CELLS; NEURONS; ACCUMULATION; KINASE; GENES AB The mechanisms of the control and activity of the autophagy-lysosomal protein degradation machinery are emerging as an important theme for neurodevelopment and neurodegeneration. However, the underlying regulatory and functional networks of known genes controlling autophagy and lysosoma I function and their role in disease are relatively unexplored. We performed a systems biology-based integrative computational analysis to study the interactions between molecular components and to develop models for regulation and function of genes involved in autophagy and lysosomal function. Specifically, we analyzed transcriptional and microRNA-based post-transcriptional regulation of these genes and performed functional enrichment analyses to understand their involvement in nervous system-related diseases and phenotypes. Transcriptional regulatory network analysis showed that binding sites for transcription factors, SREBP1, USF, AP-1 and NFE2, are common among autophagy and lysosomal genes. MicroRNA enrichment analysis revealed miR-130, 98, 124, 204 and 142 as the putative post-transcriptional regulators of the autophagy-lysosomal pathway genes. Pathway enrichment analyses revealed that the mTOR and insulin signaling pathways are important in the regulation of genes involved in autophagy. In addition, we found that glycosaminoglycan and glycosphingolipid pathways also make a major contribution to lysosoma I gene regulation. The analysis confirmed the known contribution of the autophagy-lysosomal genes to Alzheimer and Parkinson diseases and also revealed potential involvement in tuberous sclerosis, neuronal ceroid-lipofuscinoses, sepsis and lung, liver and prostatic neoplasms. To further probe the impact of autophagy-lysosomal gene deficits on neurologically-linked phenotypes, we also mined the mouse knockout phenotype data for the autophagy-lysosomal genes and found them to be highly predictive of nervous system dysfunction. Overall this study demonstrates the utility of systems biology-based approaches for understanding the autophagy-lysosomal pathways and gaining additional insights into the potential impact of defects in these complex biological processes. C1 [Schneider, Lonnie; Ouyang, Xiaosen; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Jegga, Anil G.] Cincinnati Childrens Hosp, Med Ctr, Div Biomed Informat, Cincinnati, OH USA. [Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL 35294 USA. [Ouyang, Xiaosen; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. RP Zhang, J (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. EM zhanja@uab.edu RI zhang, jianhua/D-3404-2009; Jegga, Anil/H-6140-2011; di Ronza, Alberto/H-7674-2016 OI Jegga, Anil/0000-0002-4881-7752; di Ronza, Alberto/0000-0002-9813-5143; Zhang, Jianhua/0000-0002-2128-9574 FU National Institutes of Health [DK078392]; University of Alabama at Birmingham [NIHR01-NS064090]; VA FX We thank Dr. Victor Darley-Usmar for critical discussions and for editing the manuscript. We acknowledge the help of Ron Bryson, Technical Writer, Division of Biomedical Informatics, CCHMC, OH USA, in editing the article. This work was partially supported by the grants from National Institutes of Health DK078392 (Gene Expression and Sequencing Core and Bioinformatics Core, Digestive Disease Research Core Center in Cincinnati) (A.J.), and University of Alabama at Birmingham start-up support, NIHR01-NS064090 and a VA merit award (J.Z.). NR 71 TC 58 Z9 60 U1 1 U2 17 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD MAY PY 2011 VL 7 IS 5 BP 477 EP 489 DI 10.4161/auto.7.5.14811 PG 13 WC Cell Biology SC Cell Biology GA 757LW UT WOS:000290087600004 PM 21293178 ER PT J AU Lachin, JM Viberti, G Zinman, B Haffner, SM Aftring, RP Paul, G Kravitz, BG Herman, WH Holman, RR Kahn, SE AF Lachin, John M. Viberti, Giancarlo Zinman, Bernard Haffner, Steven M. Aftring, R. Paul Paul, Gitanjali Kravitz, Barbara G. Herman, William H. Holman, Rury R. Kahn, Steven E. CA ADOPT Study Grp TI Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID AMBULATORY BLOOD-PRESSURE; GLUCOSE CONTROL; FOLLOW-UP; MICROALBUMINURIA; NEPHROPATHY; COMPLICATIONS; MELLITUS; METAANALYSIS; PROGRESSION; PREVENTION AB Background and objectives In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups. Design, setting, participants, & measurements A total of 4351 recently diagnosed, drug-naive patients with type 2 diabetes were treated and followed for up to 5 years with rosiglitazone, metformin, or glyburide and were examined with periodic assessments of albumin/creatinine ratio (ACR), modification of diet in renal disease (MDRD)-estimated GFR, and BP. Results The ACR rose slowly with metformin. It fell with rosiglitazone and less so with glyburide over the first 2 years, and then rose slowly over time. Estimated GFR (eGFR) with all therapies rose into the high normal range over the first 3 to 4 years, more so with rosiglitazone, and then declined, more so with glyburide. Systolic BP was stable over time, values with rosiglitazone being lower, and diastolic BP declined over time, more so with rosiglitazone than with metformin or glyburide. There was no difference among groups in the incidence of emergent albuminuria (ACR >= 30 mg/g), hypertension, or impaired eGFR (<60 ml/min per 1.73 m(2)). Conclusions Over a 5-year period, initial monotherapy with rosiglitazone retards the rise of ACR compared with metformin, preserves eGFR compared with glyburide, and lowers BP relative to both comparators. Clin J Ant Sac Nephrol 6: 1032-1040, 2011. doi: 10.2215/CJN.09291010 C1 [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Viberti, Giancarlo] Kings Coll London, Kings Coll London Sch Med, London WC2R 2LS, England. [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Zinman, Bernard] Univ Toronto, Toronto, ON, Canada. [Aftring, R. Paul; Paul, Gitanjali; Kravitz, Barbara G.] GlaxoSmithKline, King Of Prussia, PA USA. [Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Herman, William H.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Holman, Rury R.] Univ Oxford, Diabet Trials Unit, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Lachin, JM (reprint author), George Washington Univ, Ctr Biostat, 6110 Execut Blvd, Rockville, MD 20852 USA. EM jml@bsc.gwu.edu RI Zinman, Bernard/E-7266-2013 OI Lachin, John/0000-0001-9838-2841; Kahn, Steven/0000-0001-7307-9002 NR 34 TC 21 Z9 23 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAY PY 2011 VL 6 IS 5 BP 1032 EP 1040 DI 10.2215/CJN.09291010 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 761CK UT WOS:000290372600013 PM 21454723 ER PT J AU Kahn, SE Lachin, JM Zinman, B Haffner, SM Aftring, RP Pau, G Kravitz, BG Herman, WH Viberti, G Holman, RR AF Kahn, Steven E. Lachin, John M. Zinman, Bernard Haffner, Steven M. Aftring, R. Paul Pau, Gitanjali Kravitz, Barbara G. Herman, William H. Viberti, Giancarlo Holman, Rury R. CA ADOPT Study Grp TI Effects of Rosiglitazone, Glyburide, and Meiformin on beta-Cell Function and Insulin Sensitivity in ADOPT SO DIABETES LA English DT Article ID HUMAN PANCREATIC-ISLETS; GLUCOSE-TOLERANCE; DIABETES-MELLITUS; RESISTANCE; SECRETION; METFORMIN; DYSFUNCTION; THERAPY; INDEX AB OBJECTIVE-ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of beta-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS-Recently diagnosed, drug-naive patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic testing using an OGTT. RESULTS-Measures of beta-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide. Persistent improvements were seen in those who completed 4 years of monotherapy and marked deterioration of beta-cell function in those who failed to maintain adequate glucose control with initial monotherapy. CONCLUSIONS-The favorable combined changes in beta-cell function and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes. Diabetes 60:1552-1560, 2011 C1 [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Zinman, Bernard] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON, Canada. [Aftring, R. Paul; Pau, Gitanjali; Kravitz, Barbara G.] GlaxoSmithKline Inc, King Of Prussia, PA USA. [Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Herman, William H.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Viberti, Giancarlo] Kings Coll London, Kings Coll London Sch Med, London WC2R 2LS, England. [Holman, Rury R.] Univ Oxford, Diabet Trials Unit, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. EM skahn@u.washington.edu RI Zinman, Bernard/E-7266-2013 OI Kahn, Steven/0000-0001-7307-9002 FU GlaxoSmithKline FX The study was supported by GlaxoSmithKline. Academic members of the ADOPT Steering Committee have received honoraria, consulting fees, and/or grant/research support from GlaxoSmithKline. R.P.A., G.P., and B.G.K are employees of the company. No other potential conflicts of interest relevant to this article were reported. NR 21 TC 62 Z9 64 U1 0 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD MAY PY 2011 VL 60 IS 5 BP 1552 EP 1560 DI 10.2337/db10-1392 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 760UP UT WOS:000290349700023 PM 21415383 ER PT J AU Jeffries, MA Dozmorov, M Tang, YH Merrill, JT Wren, JD Sawalha, AH AF Jeffries, Matlock A. Dozmorov, Mikhail Tang, Yuhong Merrill, Joan T. Wren, Jonathan D. Sawalha, Amr H. TI Genome-wide DNA methylation patterns in CD4(+) T cells from patients with systemic lupus erythematosus SO EPIGENETICS LA English DT Article DE lupus; T cells; CD4(+) T cells; methylation; methylome ID MATRIX METALLOPROTEINASES; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASE; GENE-EXPRESSION; IN-VITRO; OVEREXPRESSION; DEMETHYLATION; LYMPHOCYTES; INFECTION; CD11A AB Systemic lupus erythematosus is a chronic-relapsing autoimmune disease of incompletely understood etiology. Recent evidence strongly supports an epigenetic contribution to the pathogenesis of lupus. To understand the extent and nature of dysregulated DNA methylation in lupus T cells, we performed a genome-wide DNA methylation study in CD4(+) T cells in lupus patients compared to normal healthy controls. Cytosine methylation was quantified in 27,578 CG sites located within the promoter regions of 14,495 genes. We identified 236 hypomethylated and 105 hypermethylated CG sites in lupus CD4(+) T cells compared to normal controls, consistent with widespread DNA methylation changes in lupus T cells. Of interest, hypomethylated genes in lupus T cells include CD9, which is known to provide potent T-cell co-stimulation signals. Other genes with known involvement in autoimmunity such as MMP9 and PDGFRA were also hypomethylated. The BST2 gene, an interferon-inducible membrane-bound protein that helps restrict the release of retroviral particles was also hypomethylated in lupus patients. Genes involved in folate biosynthesis, which plays a role in DNA methylation, were overrepresented among hypermethylated genes. In addition, the transcription factor RUNX3 was hypermethylated in patients, suggesting an impact on T-cell maturation. Protein-protein interaction maps identified a transcription factor, HNF4a, as a regulatory hub affecting a number of differentially methylated genes. Apoptosis was also an overrepresented ontology in these interaction maps. Further, our data suggest that the methylation status of RAB22A, STX1B2, LGALS3BP, DNASE1L1 and PREX1 correlates with disease activity in lupus patients. C1 [Jeffries, Matlock A.; Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Jeffries, Matlock A.; Dozmorov, Mikhail; Wren, Jonathan D.; Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Tang, Yuhong] Samuel Roberts Noble Fdn Inc, Oklahoma City, OK USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA. [Sawalha, Amr H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Sawalha, AH (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. EM amr-sawalha@omrf.ouhsc.edu RI Wren, Jonathan/E-5611-2011; Dozmorov, Mikhail/B-1374-2009 OI Wren, Jonathan/0000-0003-2776-3545; Dozmorov, Mikhail/0000-0002-0086-8358; Jeffries, Matlock/0000-0001-9516-4312 FU NIH from the National Institute of Allergy and Infectious Diseases [R03AI076729]; NIH [P20RR020143, P30AR053483]; Lupus Research Institute FX This work was made possible by NIH Grant Number R03AI076729 from the National Institute of Allergy and Infectious Diseases and NIH Grants Number P20RR020143 and P30AR053483 and the Lupus Research Institute. We are thankful to the genotyping core at OMRF and in particular to Adam Adler and Kenneth Kaufman, Ph.D., for their help with this study. NR 53 TC 83 Z9 83 U1 0 U2 6 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1559-2294 J9 EPIGENETICS-US JI Epigenetics PD MAY PY 2011 VL 6 IS 5 BP 593 EP 601 DI 10.4161/epi.6.5.15374 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 758YH UT WOS:000290203600009 PM 21436623 ER PT J AU Nguyen, DM El-Serag, HB Shub, M Integlia, M Henderson, L Richardson, P Fairly, K Gager, MA AF Nguyen, Dang M. El-Serag, Hashem B. Shub, Mitchell Integlia, Mark Henderson, Louise Richardson, Peter Fairly, Kenneth Gager, Mark A. TI Barrett's esophagus in children and adolescents without neurodevelopmental or tracheoesophageal abnormalities: a prospective study SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; NATURAL-HISTORY; PREVALENCE; CHILDHOOD; SYMPTOMS; POPULATION; DEFINITION; METAPLASIA; VALIDATION; GERD AB Background: Barrett's esophagus (BE) in children has been examined in retrospective studies, consisting of case series and cross-sectional studies. Objective: To evaluate the prevalence and determinants of BE in children who are free from neurodevelopmental disorders and tracheoesophageal abnormalities. Design: A prospective, cross-sectional study. Setting: Three pediatric GI Centers in Houston, Texas; Phoenix, Arizona; and Portland, Maine between February 2006 and December 2007. Patients: This study involved children and adolescents consecutively presenting for elective upper endoscopy. Patients with neurodevelopmental and tracheoesophageal disorders were excluded. Intervention: Endoscopic pictures of all cases with suspected BE were independently reviewed and verified by two experienced investigators. Esophageal biopsy specimens were obtained in all patients, and targeted biopsy specimens also were obtained from suspected BE. Main Outcome Measurements: Endoscopically suspected BE and histologically confirmed BE. Results: A total of 840 patients (mean age 9.5 years) were enrolled and had complete questionnaire and endoscopic data. Twelve patients were suspected of having BE (prevalence of 1.43%; 95% confidence interval [CI], 0.73-2.45), and only 1 patient had intestinal metaplasia, for a prevalence of 0.12% (95% Cl, 0-0.65), whereas the rest had gastric oxyntic glands (n = 6) or squamous esophageal epithelium (n = 5). Patients with suspected BE had a higher mean body mass index (23.0 vs 19.1, P =.05) and more chest pain (50% vs 13%, P < .01.) than patients without BE or reflux esophagitis. There was a trend toward a higher frequency of dysphagia, heartburn, and regurgitation in patients with suspected BE. Limitations: The accuracy of BE prevalence estimates is limited by the small number of cases. Conclusion: BE is rare in children without neurodevelopmental delay or tracheoesophageal anomalies presenting for elective upper endoscopy. (Gastrointest Enclose 201:1;73:875-80.) C1 [El-Serag, Hashem B.; Richardson, Peter] Michael E DeBakey Vet Affairs Med Ctr 152, Houston, TX 77030 USA. [Nguyen, Dang M.; El-Serag, Hashem B.; Richardson, Peter; Fairly, Kenneth; Gager, Mark A.] Baylor Coll Med, Houston, TX 77030 USA. [Fairly, Kenneth; Gager, Mark A.] Texas Childrens Hosp, Houston, TX 77030 USA. [Integlia, Mark] Barbara Bush Childrens Hosp, Portland, ME USA. [Shub, Mitchell] Phoenix Childrens Hosp, Phoenix, AZ USA. [Henderson, Louise] Univ N Carolina, Chapel Hill, NC USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. FU NIH [1-R03-DK068148-01]; Texas Gulf Coast Digestive Diseases Center [NIH P50 DK56338]; Houston Veterans Affairs HSR&D center of Excellence [HFP90-020] FX M. Gilger and H. El-Serag are supported by grants R03 (NIH 1-R03-DK068148-01). H. El-Serag also is supported in part by grants from the Texas Gulf Coast Digestive Diseases Center (NIH P50 DK56338) and the Houston Veterans Affairs HSR&D center of Excellence (HFP90-020). No other financial relationships relevant to this publication were disclosed. NR 22 TC 7 Z9 7 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2011 VL 73 IS 5 BP 875 EP 880 DI 10.1016/j.gie.2011.01.017 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 760AK UT WOS:000290292800004 PM 21354565 ER PT J AU Koh, H Hayashi, T Sato, KK Harita, N Maeda, I Nishizawa, Y Endo, G Fujimoto, WY Boyko, EJ Hikita, Y AF Koh, Hideo Hayashi, Tomoshige Sato, Kyoko Kogawa Harita, Nobuko Maeda, Isseki Nishizawa, Yoshiki Endo, Ginji Fujimoto, Wilfred Y. Boyko, Edward J. Hikita, Yonezo TI Visceral adiposity, not abdominal subcutaneous fat area, is associated with high blood pressure in Japanese men: the Ohtori study SO HYPERTENSION RESEARCH LA English DT Article DE computed tomography; epidemiology; high normal blood pressure; visceral adiposity ID CORONARY-HEART-DISEASE; BODY-FAT; RISK-FACTORS; FOLLOW-UP; WAIST CIRCUMFERENCE; INSULIN-RESISTANCE; METABOLIC SYNDROME; DIABETES-MELLITUS; VASCULAR-DISEASE; HYPERTENSION AB Visceral adiposity is considered to have a key role in cardiometabolic diseases. The purpose of this study is to investigate cross-sectionally the association between intra-abdominal fat area (IAFA) measured by computed tomography (CT) and high blood pressure independent of abdominal subcutaneous fat area (ASFA) and insulin resistance. Study participants included 624 Japanese men not taking oral hypoglycemic medications or insulin. Abdominal, thoracic and thigh fat areas were measured by CT. Total fat area (TFA) was calculated as the sum of abdominal, thoracic and thigh fat area. Total subcutaneous fat area (TSFA) was defined as TFA minus IAFA. Hypertension and high normal blood pressure were defined using the 1999 criteria of the World Health Organization. Multiple-adjusted odds ratios of hypertension for tertiles of IAFA were 2.64 (95% confidence interval, 1.35-5.16) for tertile 2, and 5.08 (2.48-10.39) for tertile 3, compared with tertile 1 after adjusting for age, fasting immunoreactive insulin, diabetes status, ASFA, alcohol consumption, regular physical exercise and smoking habit. IAFA remained significantly associated with hypertension even after adjustment for ASFA, TSFA, TFA, body mass index or waist circumference, and no other measure of regional or total adiposity was associated with the odds of hypertension in models, which included IAFA. Similar results were obtained for the association between IAFA and the prevalence of high normal blood pressure or hypertension. In conclusion, greater visceral adiposity was associated with a higher odds of high blood pressure in Japanese men. Hypertension Research (2011) 34, 565-572; doi:10.1038/hr.2010.271; published online 13 January 2011 C1 [Hayashi, Tomoshige] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, Osaka 5458585, Japan. [Hayashi, Tomoshige; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Nishizawa, Yoshiki] Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka 5458585, Japan. [Fujimoto, Wilfred Y.; Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. [Hikita, Yonezo] Ohtori Hlth Promot Ctr, Sakai, Osaka, Japan. RP Hayashi, T (reprint author), Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan. EM thayashi@med.osaka-cu.ac.jp RI Hayashi, Tomoshige/N-8508-2015 OI Boyko, Edward/0000-0002-3695-192X FU Ministry of Education, Culture, Sports, Science and Technology [17390177, 20390187] FX This work was supported by a Grant-in-Aid for Scientific Research (17390177, 20390187) from the Ministry of Education, Culture, Sports, Science and Technology, as well as by the facilities and services provided by the Ohtori Health Promotion Center. The funding sources had no role in the decision to submit the paper for publication. We thank the participants in the Ohtori Study for their dedication. NR 43 TC 10 Z9 11 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0916-9636 J9 HYPERTENS RES JI Hypertens. Res. PD MAY PY 2011 VL 34 IS 5 BP 565 EP 572 DI 10.1038/hr.2010.271 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 759MQ UT WOS:000290250200006 PM 21228782 ER PT J AU Davis, LL Gilliss, CL Deshefy-Longhi, T Chestnutt, DH Molloy, M AF Davis, Linda Lindsey Gilliss, Catherine L. Deshefy-Longhi, Tess Chestnutt, Deborah H. Molloy, Margory TI The Nature and Scope of Stressful Spousal Caregiving Relationships SO JOURNAL OF FAMILY NURSING LA English DT Article DE spousal caregivers; spousal relationships; relationship quality; relational stress; caregiving burden; Alzheimer's disease; Parkinson's disease ID PARKINSONS-DISEASE; DEPRESSIVE SYMPTOMS; FAMILY CAREGIVERS; PHYSICAL HEALTH; DEMENTIA; BURDEN; MUTUALITY; GENDER; INTERVENTION; METAANALYSIS AB The caregiving literature provides compelling evidence that caregiving burden and depressive symptoms are linked with stressful care relationships, however, relational difficulties around caregiving are seldom described in the literature. This article presents findings from content analysis of baseline interviews with 40 Alzheimer's disease (AD) and Parkinson's disease (PD) spousal caregivers enrolled in a home care skill-training trial who identified their care relationship as a source of care burden. Disappointment and sadness about the loss of the relationship; tension within the relationship; and care decision conflicts within the relationship were recurrent themes of relational stress in caregiving. These spousal caregivers had relationship quality scores below the mean and burden and depressive symptom scores above the means of other caregivers in the study. These findings provide support for developing dyadic interventions that help spouses manage relational losses, care-related tensions, and care decision-making conflicts. C1 [Davis, Linda Lindsey; Molloy, Margory] Duke Univ, Sch Nursing, Ctr Nursing Discovery, Durham, NC 27710 USA. [Deshefy-Longhi, Tess] Fairfield Univ, Sch Nursing, Fairfield, CT 06430 USA. [Chestnutt, Deborah H.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Davis, LL (reprint author), Duke Univ, Sch Nursing, Ctr Nursing Discovery, 307 Trent Dr,DUMC 3322, Durham, NC 27710 USA. EM davis317@mc.duke.edu FU National Institute for Nursing Research [RO1 NR008285]; Duke University Center for the Study of Aging and Human Development [AG00029] FX Project ASSIST for Chronic Illness Caregivers was funded by the National Institute for Nursing Research: Grant number: RO1 NR008285. (L. Davis, Principal Investigator). Dr. Deshefy-Longhi's work with the ASSIST study was supported by the Duke University Center for the Study of Aging and Human Development, where she completed postdoctoral training under T-32 Grant number: AG00029. NR 40 TC 22 Z9 23 U1 2 U2 20 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1074-8407 J9 J FAM NURS JI J. Fam. Nurs. PD MAY PY 2011 VL 17 IS 2 BP 224 EP 240 DI 10.1177/1074840711405666 PG 17 WC Family Studies; Nursing SC Family Studies; Nursing GA 756PS UT WOS:000290027300006 PM 21531858 ER PT J AU Peterson, SL Rayan, GM AF Peterson, Steven L. Rayan, Ghazi M. TI Shoulder and Upper Arm Muscle Architecture SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Muscle architecture; musculotendinous transfer; shoulder muscles ID TENDON TRANSFER; POTENTIAL EXCURSION; RELATIVE TENSION; HAND; TRANSFERS; RELEVANCE; FOREARM AB Purpose To examine the architecture of the shoulder and upper arm muscles and generate data that could serve as a guide for comparison, compatibility, and relative performance among these muscles for use in transfer. Method Eleven shoulder and arm muscles were dissected bilaterally in 5 fresh cadavers. Of these 110 potentially available muscles, 107 were suitable for evaluation and were grouped according to similarities in architecture. Resting muscle length, required excursion, muscle fiber length, pennation angle, and mass were determined. Physiologic cross-sectional area (PCSA) was then calculated from these parameters using a standard formula. Results Based on the gross appearance of muscle fiber orientation, the 11 muscles were subdivided into 3 groups. Required excursion was found to be less than fiber length in all muscles except for the teres major and middle deltoid with abduction. The middle deltoid muscle was found to have a short fiber length, complex multipennate structure, and high PCSA. Comparison showed the biceps and posterior deltoid to have fiber lengths greater than any portion of the triceps; however, neither demonstrated architectural features that would generate the force (represented by PCSA) determined for the combined triceps. Conclusions Data presented in this study offer the opportunity for direct comparison of architectural features of select shoulder and arm musculature. Clinical relevance This information might help in the evaluation of compatibility of various musculotendinous transfers around the shoulder and elbow. (J Hand Surg 2011;36A:881-889. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.) C1 [Rayan, Ghazi M.] Univ Oklahoma, Hlth Sci Ctr, Dept Orthoped & Rehabil, Oklahoma City, OK 73112 USA. [Rayan, Ghazi M.] Integris Baptist Hosp, Dept Orthoped & Rehabil, Oklahoma City, OK 73112 USA. Portland VA Med Ctr, Hand & Plast Surg Sect, Operat Care Div, Portland, OR USA. RP Rayan, GM (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Orthoped & Rehabil, 3366 NW Expressway,Bldg D 700, Oklahoma City, OK 73112 USA. EM ouhsgmr@aol.com NR 26 TC 7 Z9 7 U1 0 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD MAY PY 2011 VL 36A IS 5 BP 881 EP 889 DI 10.1016/j.jhsa.2011.01.008 PG 9 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 758SC UT WOS:000290185700019 PM 21527142 ER PT J AU Marcus, SC Durkin, M AF Marcus, Steven C. Durkin, Michael TI Stimulant Adherence and Academic Performance in Urban Youth With Attention-Deficit/Hyperactivity Disorder SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE stimulant; adherence; academic performance; school; ADHD ID DEFICIT HYPERACTIVITY DISORDER; TERM SCHOOL OUTCOMES; AFRICAN-AMERICAN; CHILDREN; ADHD; METHYLPHENIDATE; MEDICATION; ADOLESCENTS; ACHIEVEMENT; CHILDHOOD AB Objective: This analysis assessed whether stimulant adherence was associated with improvement in academic grade point average (GPA) among children diagnosed with and treated for attention-deficit/hyperactivity disorder (ADHD). Method: Medicaid claims were merged with academic records from Philadelphia public schools of Medicaid-eligible children in first through eighth grades who were diagnosed with ADHD and who had filled one or more stimulant prescription. Students diagnosed with mental retardation, autism, or speech, hearing, visual, or language impairments were excluded. Marking periods were scored for GPA (range: 0-4.0) based on English, mathematics, social studies, and science grades and for stimulant adherence (medication possession ratio >= 0.70). Random and fixed-effects models estimated the effects of stimulant adherence on GPA, between all adherent and nonadherent marking periods in aggregate and within individual student's marking periods, respectively. Results: A total of 3,543 students contributed 29,992 marking periods, of which 18.6% were adherent. Mean GPA was significantly higher during stimulant-adherent (2.18) than stimulant-nonadherent (1.99) marking periods in aggregate (p < .0001). The regression coefficient representing within-student association between stimulant adherence and GPA over time was 0.108 (p < .0001), indicating that adherence was associated with a 0.108 increase in GPA. In stratified analyses, analogous coefficients were 0.106 for boys, 0.111 for girls, 0.078 for elementary students, and 0.118 for middle school students (all p < .0001). The association was stronger among students with (0.139) than without (0.088) comorbid disruptive behavior disorders (both p < .0001). Conclusions: Stimulant adherence, although found to be low among urban elementary and middle school students diagnosed with ADHD, was associated with a marginal improvement in GPA. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(5):480-489. C1 [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19103 USA. [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Durkin, Michael] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA. RP Marcus, SC (reprint author), Univ Penn, Sch Social Policy & Practice, 3701 Locust Walk, Philadelphia, PA 19103 USA. EM marcuss@sp2.upenn.edu FU Ortho-McNeil Janssen Scientific Affairs, LLC; Eli Lilly and Co., Bristol-Myers Squibb; Johnson and Johnson FX This project was funded by Ortho-McNeil Janssen Scientific Affairs, LLC.; Dr. Marcus has received grant support from Ortho-McNeil Janssen, and has served as a consultant to Eli Lilly and Co., Bristol-Myers Squibb, and AstraZeneca. Mr. Durkin holds stock in Johnson and Johnson. NR 35 TC 18 Z9 18 U1 0 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD MAY PY 2011 VL 50 IS 5 BP 480 EP 489 DI 10.1016/j.jaac.2011.02.007 PG 10 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 757GH UT WOS:000290073000009 PM 21515197 ER PT J AU Kozora, E Filley, CM AF Kozora, Elizabeth Filley, Christopher M. TI Cognitive Dysfunction and White Matter Abnormalities in Systemic Lupus Erythematosus SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Review DE Lupus; Neuropsychology; Magnetic resonance imaging; Magnetic resonance spectroscopy; Mechanisms; Methodology ID MAGNETIC-RESONANCE SPECTROSCOPY; CENTRAL-NERVOUS-SYSTEM; PROTON MR SPECTROSCOPY; BRAIN-LESIONS; ACUTE ONSET; DEFICITS; INJURY; SLE; MANIFESTATIONS; IMPAIRMENT AB Brain abnormalities have been documented by neuropsychological assessment as well as a variety of neuroimaging techniques in patients with systemic lupus erythematosus (SLE). Conventional neuroimaging in patients with neuropsychiatric disease (NPSLE) typically discloses periventricular white matter (WM) hyperintensities, infarcts, hemorrhages, and cerebral atrophy. In SLE patients with none of these findings, sophisticated neuroimaging techniques have recently supported associations between microstructural WM abnormalities and abnormal attention, executive function, and processing speed. This mild cognitive dysfunction in SLE (MCD-SLE), which may result from early myelinopathy, precedes the more severe cognitive dysfunction of NPSLE, related to more obvious WM and neuronal damage. (JINS, 2011, 17, 385-392) C1 [Kozora, Elizabeth] Natl Jewish Hlth, Denver, CO 80206 USA. [Kozora, Elizabeth; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. [Kozora, Elizabeth; Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kozora, E (reprint author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA. EM kozorae@njhealth.org RI Burleson, Andrew/B-5609-2016 OI Burleson, Andrew/0000-0002-4857-3583 FU National Institute of Musculoskeletal and Skin Diseases [RO1 AR049152] FX The authors report no conflicts of interest. This manuscript has not been published previously either electronically or in print. Supported in part by the National Institute of Musculoskeletal and Skin Diseases, (Grant RO1 AR049152). NR 40 TC 21 Z9 21 U1 1 U2 12 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAY PY 2011 VL 17 IS 3 BP 385 EP 392 DI 10.1017/S1355617711000191 PG 8 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 757QU UT WOS:000290103600001 PM 21338548 ER PT J AU Herrle, SR Corbett, EC Fagan, MJ Moore, CG Elnicki, DM AF Herrle, Scott R. Corbett, Eugene C., Jr. Fagan, Mark J. Moore, Charity G. Elnicki, D. Michael TI Bayes' Theorem and the Physical Examination: Probability Assessment and Diagnostic Decision Making SO ACADEMIC MEDICINE LA English DT Article ID CLINICAL EXAMINATION; INTERNAL-MEDICINE; AUSCULTATORY SKILLS; FAMILY-PRACTICE; PATIENT; CARE; HEURISTICS; JUDGMENT; HISTORY; ERRORS AB Purpose To determine how examination findings influence the probability assessment and diagnostic decision making of third-and fourth-year medical students, internal medicine residents, and academic general internists. Method In a 2008 cross-sectional, Web-based survey, participants from three medical schools were asked questions about their training and eight examination scenarios representing four conditions. Participants were given literature-derived preexamination probabilities for each condition and were asked to (1) estimate postexamination probabilities (post-EPs) and (2) select a diagnostic choice (report that condition is present, order more tests, or report that condition is absent). Participants' inverse transformed logit (ITL) mean post-EPs were compared with corresponding literature-derived post-EPs. Results Of 906 individuals invited to participate, 684 (75%) submitted a completed survey. In two of four scenarios with positive findings, the participants' ITL mean post-EPs were significantly less than corresponding literature-derived post-EP point estimates (P < .001 for each). In three of four scenarios with negative findings, ITL mean post-EPs were significantly greater than corresponding literature-derived post-EP point estimates (P < .001 for each). In the four scenarios with positive findings, 17% to 38% of participants ordered more diagnostic tests when the literature indicated a > 85% probability that the condition was present. In the four scenarios with largely negative findings, 70% to 85% chose to order diagnostic tests to further reduce diagnostic uncertainty. Conclusions All three groups tended to similarly underestimate the impact of examination findings on condition probability assessment, especially negative findings, and often ordered more tests when probabilities indicated that additional testing was unnecessary. C1 [Herrle, Scott R.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Gen Internal Med, Dept Med,Sect Gen Internal Med, Pittsburgh, PA 15240 USA. [Corbett, Eugene C., Jr.] Univ Virginia, Dept Med, Div Gen Med Geriatr & Palliat Care, Charlottesville, VA USA. [Fagan, Mark J.] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912 USA. [Moore, Charity G.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Ctr Res Hlth Care Data Ctr, Pittsburgh, PA 15240 USA. RP Herrle, SR (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Div Gen Internal Med, Dept Med,Sect Gen Internal Med, 130-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM herrles@pitt.edu RI liu, jing/D-9482-2012 OI Moore, Charity/0000-0002-0060-0124 FU National Center for Research Resources (NCRR), National Institutes of Health (NIH) [UL1 RR024153]; NIH Roadmap for Medical Research FX This study was made possible by Grant Number UL1 RR024153 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Additional funding for this study was provided by the Shadyside Hospital Foundation. The Shadyside Hospital Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 41 TC 10 Z9 10 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD MAY PY 2011 VL 86 IS 5 BP 618 EP 627 DI 10.1097/ACM.0b013e318212eb00 PG 10 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 755WU UT WOS:000289971300025 PM 21436660 ER PT J AU Korthuis, PT Saha, S Chander, G McCarty, D Moore, RD Cohn, JA Sharp, VL Beach, MC AF Korthuis, P. Todd Saha, Somnath Chander, Geetanjali McCarty, Dennis Moore, Richard D. Cohn, Jonathan A. Sharp, Victoria L. Beach, Mary Catherine TI Substance Use and the Quality of Patient-Provider Communication in HIV Clinics SO AIDS AND BEHAVIOR LA English DT Article DE Alcoholism; Substance-related disorders; Communication; HIV; Quality of health care; Patient satisfaction ID ADDICTION SEVERITY INDEX; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; ABUSE TREATMENT; UNITED-STATES; DRUG-USERS; SERVICES UTILIZATION; MEDICAL INTERACTIONS; RELAPSE PREVENTION; INFECTED ADULTS AB The objective of this study was to estimate the influence of substance use on the quality of patient-provider communication during HIV clinic encounters. Patients were surveyed about unhealthy alcohol and illicit drug use and rated provider communication quality. Audio-recorded encounters were coded for specific communication behaviors. Patients with vs. without unhealthy alcohol use rated the quality of their provider's communication lower; illicit drug user ratings were comparable to non-users. Visit length was shorter, with fewer activating/engaging and psychosocial counseling statements for those with vs. without unhealthy alcohol use. Providers and patients exhibited favorable communication behaviors in encounters with illicit drug users vs. non-users, demonstrating greater evidence of patient-provider engagement. The quality of patient-provider communication was worse for HIV-infected patients with unhealthy alcohol use but similar or better for illicit drug users compared with non-users. Interventions should be developed that encourage providers to actively engage patients with unhealthy alcohol use. C1 [Korthuis, P. Todd; Saha, Somnath] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97239 USA. [Korthuis, P. Todd; Saha, Somnath; McCarty, Dennis] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. [Chander, Geetanjali; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA. [Cohn, Jonathan A.] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA. [Sharp, Victoria L.] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Ctr Comprehens Care, New York, NY USA. RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA. EM korthuis@ohsu.edu FU AHRQ HHS [K08 HS013903, K08 HS013903-05]; NIAAA NIH HHS [K23 AA015313, K23AA015313, R01 AA016893, R01 AA016893-01A2, R01 AA16893]; NIAID NIH HHS [U01 AI069918-05, U01 AI069918]; NIDA NIH HHS [K23 DA019809, K23DA019809, K24 DA000432, K24 DA000432-10, R01 DA011602, R01 DA011602-13, R01 DA11602]; NIMH NIH HHS [R34 MH089279, R34 MH089279-01A1, R34 MH089279-02]; PHS HHS [AHRQ 290-01-0012] NR 51 TC 16 Z9 17 U1 3 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2011 VL 15 IS 4 BP 832 EP 841 DI 10.1007/s10461-010-9779-8 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 754YS UT WOS:000289894400017 PM 20703792 ER PT J AU Oslin, D AF Oslin, David TI Personalized Addiction Treatment: How Close Are We? SO ALCOHOL AND ALCOHOLISM LA English DT Editorial Material ID OPIOID RECEPTOR GENE; NALTREXONE RESPONSE; ALCOHOL DEPENDENCE; OPRM1; CUES C1 [Oslin, David] Univ Penn, Philadelphia, PA 19104 USA. [Oslin, David] Philadelphia VA Med Ctr, Treatment Res Ctr, Philadelphia, PA 19104 USA. RP Oslin, D (reprint author), Univ Penn, 3600 Chestnut St, Philadelphia, PA 19104 USA. EM oslin@upenn.edu NR 10 TC 3 Z9 4 U1 3 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD MAY-JUN PY 2011 VL 46 IS 3 BP 231 EP 232 DI 10.1093/alcalc/agr030 PG 2 WC Substance Abuse SC Substance Abuse GA 754ET UT WOS:000289837300003 PM 21508195 ER PT J AU Pandol, SJ Lugea, A Mareninova, OA Smoot, D Gorelick, FS Gukovskaya, AS Gukovsky, I AF Pandol, Stephen J. Lugea, Aurelia Mareninova, Olga A. Smoot, Duane Gorelick, Fred S. Gukovskaya, Anna S. Gukovsky, Ilya TI Investigating the Pathobiology of Alcoholic Pancreatitis SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcoholic Pancreatitis; Inflammation; Autophagy; Mitochondrial Permeabilization; Endoplasmic Reticulum Stress; Pancreatic Stellate Cell ID CERULEIN-INDUCED PANCREATITIS; ENDOPLASMIC-RETICULUM STRESS; PERMEABILITY TRANSITION PORE; KEY PATHOLOGICAL RESPONSES; UNFOLDED PROTEIN RESPONSE; KAPPA-B ACTIVATION; STELLATE CELLS; ACINAR-CELLS; ZYMOGEN ACTIVATION; BASOLATERAL EXOCYTOSIS AB Alcohol abuse is one of the most common causes of pancreatitis. The risk of developing alcohol-induced pancreatitis is related to the amount and duration of drinking. However, only a small portion of heavy drinkers develop disease, indicating that other factors (genetic, environmental, or dietary) contribute to disease initiation. Epidemiologic studies suggest roles for cigarette smoking and dietary factors in the development of alcoholic pancreatitis. The mechanisms underlying alcoholic pancreatitis are starting to be understood. Studies from animal models reveal that alcohol sensitizes the pancreas to key pathobiologic processes that are involved in pancreatitis. Current studies are focussed on the mechanisms responsible for the sensitizing effect of alcohol; recent findings reveal disordering of key cellular organelles including endoplasmic reticulum, mitochondria, and lysosomes. As our understanding of alcohol's effects continue to advance to the level of molecular mechanisms, insights into potential therapeutic strategies will emerge providing opportunities for clinical benefit. C1 [Pandol, Stephen J.; Lugea, Aurelia; Mareninova, Olga A.; Gukovskaya, Anna S.; Gukovsky, Ilya] Univ Calif Los Angeles, Pancreat Res Grp, Dept Vet Affairs Greater Los Angeles, Los Angeles, CA USA. So Calif Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. [Smoot, Duane] Howard Univ, Washington, DC 20059 USA. [Gorelick, Fred S.] Yale Univ, New Haven, CT USA. RP Pandol, SJ (reprint author), UCLA VA Greater Los Angeles, Pancreat Res Grp, W Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd,Blg 258,Rm 340, Los Angeles, CA 90073 USA. EM stephen.pandol@va.gov; igukovsk@ucla.edu FU AGA Foundation FX Southern California Research Center for Alcoholic Liver and Pancreatic Diseases (P50AA11999); UCLA Center for Excellence in Pancreatic Diseases (P01AT003960); NIH/NIAAA (U56 AA0114643, R21AA016010, R21AA015781, R21AA017276); NIH/NCI (R01CA119025); NIH/NIDDK (R01DK059936, R01DK54021); and the AGA Foundation Designated Research Scholar Award in Pancreatitis. NR 88 TC 22 Z9 23 U1 0 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2011 VL 35 IS 5 BP 830 EP 837 DI 10.1111/j.1530-0277.2010.01408.x PG 8 WC Substance Abuse SC Substance Abuse GA 754ZK UT WOS:000289896200013 PM 21284675 ER PT J AU Reinke, LF Griffith, RG Wolpin, S Donesky-Cuenco, D Carrieri-Kohlman, V Nguyen, HQ AF Reinke, Lynn F. Griffith, Randall G. Wolpin, Seth Donesky-Cuenco, DorAnne Carrieri-Kohlman, Virginia Nguyen, Huong Q. TI Feasibility of a Webinar for Coaching Patients With Chronic Obstructive Pulmonary Disease on End-of-Life Communication SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE webinar; end-of-life communication; chronic obstructive pulmonary disease; patient education; advanced care planning; technology ID ADVANCE DIRECTIVE EDUCATION; CARE; REHABILITATION; BARRIERS; OUTCOMES; SUPPORT; CANCER; COPD AB Rationale: Previous research has shown that patients with chronic obstructive pulmonary disease (COPD) desire conversations about end-of-life wishes. However, most clinicians do not initiate these discussions. We explored whether educating patients via Web conferencing (webinar) would equip them with knowledge and skills to engage in conversations about end-of-life care. Results: Prewebinar, 6 of the 7 patients had completed advanced care planning forms but only half had shared these with their clinicians. Most patients felt confident about discussing end-of-life preferences. At 3 months, all participants had taken further action on end-of-life planning. Five felt the webinar was an acceptable option if unable to participate in person. All patients voiced that adding a video stream would have promoted interaction in the context of these sensitive conversations. Conclusions: This pilot project demonstrated that a webinar to educate patients on end-of-life communication was acceptable for the majority of patients. Improvements in audio and video bandwidth may facilitate more interaction among virtual participants. This may be particularly useful for patient education on sensitive topics. C1 [Reinke, Lynn F.] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA 98101 USA. [Donesky-Cuenco, DorAnne; Carrieri-Kohlman, Virginia] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Reinke, LF (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Vet Affairs, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM reinkl@u.washington.edu FU [R01 NR008938]; [1KL2RR025015-01]; [TPP-61-021] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article:; R01 NR008938 (Carrieri-Kohlman); 1KL2RR025015-01 (Nguyen); TPP-61-021 (Reinke). NR 18 TC 7 Z9 7 U1 2 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAY PY 2011 VL 28 IS 3 BP 147 EP 152 DI 10.1177/1049909110376807 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 756FQ UT WOS:000289997500002 PM 20834035 ER PT J AU Moss, M Au, DH AF Moss, Marc Au, David H. TI ATS International Conference Preview Where Today's Science Will Meet Tomorrow's Care SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material C1 [Moss, Marc] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, ATS Int Conf Comm 2010 2011, Aurora, CO USA. [Au, David H.] Univ Washington, VA Puget Sound Hlth Care Syst, ATS Int Conf Comm 2010 2011, Seattle, WA USA. RP Moss, M (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, ATS Int Conf Comm 2010 2011, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAY 1 PY 2011 VL 183 IS 9 BP 1117 EP 1118 DI 10.1164/rccm.201103-0386ED PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 756IO UT WOS:000290005100001 PM 21531948 ER PT J AU Kuna, ST Gurubhagavatula, I Maislin, G Hin, S Hartwig, KC McCloskey, S Hachadoorian, R Hurley, S Gupta, R Staley, B Atwood, CW AF Kuna, Samuel T. Gurubhagavatula, Indira Maislin, Greg Hin, Sakhena Hartwig, Kathryn C. McCloskey, Sue Hachadoorian, Robert Hurley, Sharon Gupta, Rajesh Staley, Bethany Atwood, Charles W. TI Noninferiority of Functional Outcome in Ambulatory Management of Obstructive Sleep Apnea SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE polysomnogram; portable monitor testing; obstructive sleep apnea; continuous positive airway pressure ID POSITIVE AIRWAY PRESSURE; PRACTICE PARAMETERS; POLYSOMNOGRAPHY; DISORDERS; DIAGNOSIS AB Rationale: Home portable monitor testing is increasingly being used to diagnose patients with obstructive sleep apnea (OSA) and to initiate them on continuous positive airway pressure (CPAP) treatment. Objectives: To compare functional outcome and treatment adherence in patients who receive ambulatory versus in-laboratory testing for OSA. Methods: Veterans with suspected OSA were randomized to either home testing or standard in-laboratory testing. Home testing consisted of a type 3 portable monitor recording followed by at least three nights using an automatically adjusting positive airway pressure apparatus. Participants diagnosed with OSA were treated with (PAP for 3 months. Measurements and Main Results: We measured the change in Functional Outcomes of Sleep Questionnaire score, with an a priori noninferiority delta of -1, and the mean daily hours of objectively measured CPAP adherence, with an a priori noninferiority delta of -0.75 hour/day. Of the 296 subjects enrolled, 260 (88%) were diagnosed with OSA, and 213 (75%) were initiated on CPAP. Mean +/- SD functional outcome score improved 1.74 +/- 2.81 in the home group (P < 0.001) and 1.85 +/- 2.46 in the in-laboratory group (P < 0.0001). The lower bound of the one-sided 95% noninferiority confidence interval was -0.54. Mean +/- SD hours of daily (PAP adherence were 3.5 +/- 2.5 hours/day in the home group and 2.9 +/- 2.3 hours/day in the in-laboratory group (P = 0.08). The lower bound of the one-sided 95% noninferiority confidence interval was 0.03. Conclusions: Functional outcome and treatment adherence in patients evaluated according to a home testing algorithm is not clinically inferior to that in patients receiving standard in-laboratory polysomnography. C1 [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, VISN Eastern Reg Sleep Ctr 111P 4, Dept Med, Philadelphia, PA 19104 USA. [Kuna, Samuel T.; Gurubhagavatula, Indira; Staley, Bethany] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Maislin, Greg; Hachadoorian, Robert; Hurley, Sharon] Biomed Stat Consulting, Wynnewood, PA USA. [Hartwig, Kathryn C.; Atwood, Charles W.] Vet Affairs Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA. [Atwood, Charles W.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Kuna, ST (reprint author), Philadelphia Vet Affairs Med Ctr, VISN Eastern Reg Sleep Ctr 111P 4, Dept Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Samuel.Kuna@va.gov FU Veterans Health Administration, Health Services Research and Development [IIR-04-021-2]; Center for Health Equity Research and Promotion at the Philadelphia VA Medical Center; Philips; Embla, Inc.; Philips-Respironics; NIH; Resmed; Vapotherm; Boston Scientific FX Supported by Veterans Health Administration, Health Services Research and Development grant IIR-04-021-2; the Center for Health Equity Research and Promotion at the Philadelphia VA Medical Center; Philips; and Embla, Inc.; S.T.K. received grant support from Philips-Respironics. I.G. received loaned portable monitoring equipment for use in an NIH-funded clinical research study from Embla Corp. G.M., S.H., K.C.H., S.M., R.H., S.H., R.G., and B.S. do not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. C.W.A. was on the Board or Advisory Board for Cephalon and received lecture fees from Embla. He received grant support from Philips-Respironics, Resmed, Vapotherm, Boston Scientific, and the VA HSR&D. NR 23 TC 84 Z9 88 U1 0 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAY 1 PY 2011 VL 183 IS 9 BP 1238 EP 1244 DI 10.1164/rccm.201011-1770OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 756IO UT WOS:000290005100020 PM 21471093 ER PT J AU Livhits, M Ko, CY Leonardi, MJ Zingmond, DS Gibbons, MM de Virgilio, C AF Livhits, Masha Ko, Clifford Y. Leonardi, Michael J. Zingmond, David S. Gibbons, Melinda Maggard de Virgilio, Christian TI Risk of Surgery Following Recent Myocardial Infarction SO ANNALS OF SURGERY LA English DT Article ID MAJOR NONCARDIAC SURGERY; RANDOMIZED CONTROLLED-TRIAL; BETA-BLOCKER THERAPY; VASCULAR-SURGERY; CARDIAC RISK; CARDIOVASCULAR EVENTS; ADMINISTRATIVE DATA; MORTALITY; ATORVASTATIN; ANESTHESIA AB Objective: We aimed to assess the impact of recentmyocardial infarction (MI) on outcomes after subsequent surgery in the contemporary clinical setting. Background: Prior work shows that a history of a recent MI is a risk factor for complications following noncardiac surgery. However, this data does not reflect current advances in clinical management. Methods: Using the California Patient Discharge Database, we retrospectively analyzed patients undergoing hip surgery, cholecystectomy, colectomy, elective abdominal aortic aneurysm repair, and lower extremity amputation from 1999 to 2004 (n = 563,842). Postoperative 30-day MI rate, 30-day mortality, and 1-year mortality were compared for patients with and without a recent MI using univariate analyses and multivariate logistic regression. Relative risks (RR) with 95% confidence intervals were estimated using bootstrapping with 1000 repetitions. Results: Postoperative MI rate for the recent MI cohort decreased substantially as the length of time from MI to operation increased (0-30 days = 32.8%, 31-60 days = 18.7%, 61-90 days = 8.4%, and 91-180 days = 5.9%), as did 30-day mortality (0-30 days = 14.2%, 31-60 days = 11.5%, 61-90 days = 10.5%, and 91-180 days = 9.9%). MI within 30 days of an operation was associated with a higher risk of postoperative MI (RR range = 9.98-44.29 for the 5 procedures), 30-day mortality (RR range, 1.83-3.84), and 1-year mortality (RR range, 1.56-3.14). Conclusions: A recent MI remains a significant risk factor for postoperative MI and mortality following surgery. Strategies such as delaying elective operations for at least 8 weeks and medical optimization should be considered. C1 [de Virgilio, Christian] Harbor UCLA Med Ctr, Dept Surg, Torrance, CA 90509 USA. [de Virgilio, Christian] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Livhits, Masha; Ko, Clifford Y.; Leonardi, Michael J.; Gibbons, Melinda Maggard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Livhits, Masha; Ko, Clifford Y.; Gibbons, Melinda Maggard] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Gibbons, Melinda Maggard] Olive View UCLA, Dept Surg, Sylmar, CA USA. RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, 1000 W Carson St, Torrance, CA 90509 USA. EM cdevirgilio@labiomed.org FU VA Department of Surgery; Robert Wood Johnson Physician Faculty FX Supported by VA Department of Surgery and Robert Wood Johnson Physician Faculty Scholars program. NR 31 TC 20 Z9 20 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAY PY 2011 VL 253 IS 5 BP 857 EP 864 DI 10.1097/SLA.0b013e3182125196 PG 8 WC Surgery SC Surgery GA 749ZD UT WOS:000289510600003 PM 21372685 ER PT J AU Lan, JG Heneghan, AF Sano, Y Jonker, MA Omata, J Xu, WT Pierre, JF Kudsk, KA AF Lan, Jinggang Heneghan, Aaron F. Sano, Yoshifumi Jonker, Mark A. Omata, Jiro Xu, Wentong Pierre, Joseph F. Kudsk, Kenneth A. TI Parenteral Nutrition Impairs Lymphotoxin beta Receptor Signaling via NF-kappa B SO ANNALS OF SURGERY LA English DT Article ID GUT ISCHEMIC INSULT; LYMPHOID-TISSUE; ENTERAL NUTRITION; MUCOSAL IMMUNITY; INTEGRIN EXPRESSION; MICE; HOMEOSTASIS; INTESTINE; BLOCKADE; SELECTIN AB Objective: To determine effects of (1) parenteral nutrition (PN), (2) exogenous Lymphotoxin beta receptor (LT beta R) stimulation in PN animals, and (3) exogenous LT beta R blockade in chow animals on NF-kappa B activation pathways and products: MAdCAM-1, chemokine (C-C motif) Ligand (CCL) 19, CCL20, CCL25, interleukin (IL)-4, and IL-10. Background: LT stimulates LT beta R in Peyer's patches (PP) to activate NF-kappa B via the noncanonical pathway. The p100/RelB precursor yields p52/RelB producingMAdCAM-1, cytokines, and chemokines important in cell trafficking. TNF alpha, IL-1 beta, and bacterial products stimulate the inflammatory canonical NF-kappa B pathway producing p65/p50 and c-Rel/p50. PN decreases LT beta R, MAdCAM-1, and chemokines in PP and lowers small intestinal IgA compared with chow. Methods: Canonical (p50 and p65) and noncanonical (p52 and Rel B) NF-kappa B proteins in PP were analyzed by TransAM NF-kappa B kit after 5 days of chow or PN, 2 days of LT beta R stimulation or 3 days of LT beta R blockade. MAdCAM-1, chemokines, and cytokines in PP were measured by ELISA after LT beta R stimulation or blockade. Results: PN significantly reduced all NF-kappa B proteins in PP compared with chow. Exogenous LT beta R stimulation during PN increased p50, p52, Rel B, MAdCAM-1, IL-4, and IL-10 in PP, but not p65, CCL19, CCL20, or CCL25 compared with PN. LT beta R blockade reduced noncanonical products (p52 and Rel B), MAdCAM-1, CCL19, CCL20, CCL25, IL-4, and IL-10 but had no effect on the inflammatory pathway (p50 and p65) compared with chow. Conclusion: Lack of enteral stimulation during PN decreases both canonical and noncanonical NF-kappa B pathways in PP. LT beta R stimulation during PN feeding completely restores PP noncanonical NF-kappa B activity, MAdCAM-1, IL-4, IL-10, and partly the canonical pathway. LT beta R blockade decreases the noncanonical NF-kappa B activity, MAdCAM-1, chemokines, and cytokines without effect on the canonical LT beta R activity in PP. C1 [Lan, Jinggang; Heneghan, Aaron F.; Sano, Yoshifumi; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA. [Lan, Jinggang; Heneghan, Aaron F.; Sano, Yoshifumi; Jonker, Mark A.; Omata, Jiro; Xu, Wentong; Pierre, Joseph F.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,G5-341 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU National Institute of Health (NIH) [R01 GM53439]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service FX Supported by the National Institute of Health (NIH) grant R01 GM53439. This material is also based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 34 TC 8 Z9 9 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD MAY PY 2011 VL 253 IS 5 BP 996 EP 1003 DI 10.1097/SLA.0b013e31821224eb PG 8 WC Surgery SC Surgery GA 749ZD UT WOS:000289510600024 PM 21368655 ER PT J AU Tallaj, JA Singla, I Bourge, RC AF Tallaj, Jose A. Singla, Ish Bourge, Robert C. TI Implantable Hemodynamic Monitors SO CARDIOLOGY CLINICS LA English DT Article DE Congestive heart failure; Diastolic heart failure; BNP; Implantable monitors; Hypervolemia; Chronicle IHM; CardioMEMS ID ADVANCED HEART-FAILURE; PULMONARY-ARTERY PRESSURE; RIGHT-VENTRICULAR PRESSURE; NATRIURETIC PEPTIDE; INITIAL-EXPERIENCE; SENSOR; MULTICENTER; MANAGEMENT; DIAGNOSIS; THERAPY AB The evaluation and management of volume status in patients with heart failure is a challenge for most clinicians. In addition, such an evaluation is possible only during a personal clinician patient interface. The ability to acquire hemodynamic data continuously with the help of implanted devices with remote monitoring capability can provide early warning of heart failure decompensation and thus may aid in preventing hospitalizations for heart failure. The data obtained also may improve the understanding of the disease process. It is important for the clinician treating patients who have heart failure to become acquainted with this type of technology and learn to interpret and use these data appropriately. This article reviews the implantable hemodynamics monitors currently available. C1 [Bourge, Robert C.] Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Tallaj, Jose A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bourge, RC (reprint author), Univ Alabama, Dept Med, Div Cardiovasc Dis, 1900 Univ Blvd, Birmingham, AL 35294 USA. EM bbourge@uab.edu NR 29 TC 4 Z9 4 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8651 J9 CARDIOL CLIN JI Cardiol. Clin. PD MAY PY 2011 VL 29 IS 2 BP 289 EP + DI 10.1016/j.ccl.2011.03.002 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 756IZ UT WOS:000290006200013 PM 21459250 ER PT J AU Klein, AJ Garcia, JA Hudson, PA Kim, MS Messenger, JC Casserly, IP Wink, O Hattler, B Tsai, TT Chen, SYJ Hansgen, A Carroll, JD AF Klein, Andrew J. Garcia, Joel A. Hudson, Paul A. Kim, Michael S. Messenger, John C. Casserly, Ivan P. Wink, Onno Hattler, Brack Tsai, Thomas T. Chen, S. Y. James Hansgen, Adam Carroll, John D. TI Safety and Efficacy of Dual-Axis Rotational Coronary Angiography Vs. Standard Coronary Angiography SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE coronary angiography; rotational coronary angiography; dual-axis angiography ID INTRAVASCULAR ULTRASOUND; ARTERY-DISEASE; CLINICAL UTILITY; INTERVENTION AB Objective: To determine the safety and efficacy of dual-axis rotational coronary angiography (DARCA) by directly comparing it to standard coronary angiography (SA). Background: Standard coronary angiography (SA) requires numerous fixed static images of the coronary tree and has multiple well-documented limitations. Dual-axis rotational coronary angiography (DARCA) is a new rotational acquisition technique that entails simultaneous LAO/RAO and cranial/caudal gantry movement. This technological advancement obtains numerous unique images of the left or right coronary tree with a single coronary injection. We sought to assess the safety and efficacy of DARCA as well as determine DARCA's adequacy for CAD screening and assessment. Methods: Thirty patients underwent SA following by DARCA. Contrast volume, radiation dose (DAP) and procedural time were recorded for each method to assess safety. For DARCA acquisitions, blood pressure (BP), heart rate (HR), symptoms and any arrhythmias were recorded. All angiograms were reviewed for CAD screening adequacy by two independent invasive cardiologists. Results: Compared to SA, use of DARCA was associated with a 51% reduction in contrast, 35% less radiation exposure, and 18% shorter procedural time. Both independent reviewers noted DARCA to be at least equivalent to SA with respect to the ability to screen for CAD. Conclusion: DARCA represents a new angiographic technique which is equivalent in terms of image quality and is associated with less contrast use, radiation exposure, and procedural time than SA. (C) 2011 Wiley-Liss, Inc. C1 [Klein, Andrew J.; Garcia, Joel A.; Hudson, Paul A.; Kim, Michael S.; Messenger, John C.; Casserly, Ivan P.; Chen, S. Y. James; Hansgen, Adam; Carroll, John D.] Univ Colorado Denver, Div Cardiol, Aurora, CO 80045 USA. [Wink, Onno] Philips Healthcare, Clin Res, Aurora, CO USA. [Hattler, Brack; Tsai, Thomas T.] Denver VA Med Ctr, Div Cardiol, Denver, CO USA. RP Carroll, JD (reprint author), Univ Colorado Denver, Div Cardiol, Campus Box 132,12401 E 17th Ave, Aurora, CO 80045 USA. EM John.Carroll@ucdenver.edu NR 21 TC 15 Z9 20 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY 1 PY 2011 VL 77 IS 6 BP 820 EP 827 DI 10.1002/ccd.22804 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 757DD UT WOS:000290063700011 PM 20853352 ER PT J AU Shlipak, MG Weekley, CC Li, YM Hansson, LO Larsson, A Whooley, M AF Shlipak, Michael G. Weekley, Cristin C. Li, Yongmei Hansson, Lars-Olof Larsson, Anders Whooley, Mary TI Comparison of Cardiovascular Prognosis by 3 Serum Cystatin C Methods in the Heart and Soul Study SO CLINICAL CHEMISTRY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; BODY-COMPOSITION; RISK; CREATININE; MORTALITY; DISEASE; MARKER; HEALTH; ASSOCIATION; FAILURE AB BACKGROUND: Cystatin C is a promising new biomarker to determine the estimated glomerular filtration. However, the Siemens' cystatin C assay (Siemens), used in many longitudinal studies, has had limited clinical applicability because it requires a specific, dedicated instrument. Other companies, including Gentian and Roche, have developed cystatin C assays that can be used with most routine clinical chemistry analyzers. METHODS: We compared the agreement of Gentian and Roche with Siemens assays in 948 participants at the baseline visit of the Heart and Soul Study, a cohort of participants with established coronary artery disease who were followed for an average of 8 years. We then compared associations of all 3 cystatin C measures and eGFR-Modification of Diet in Renal Disease (MDRD) with clinical outcomes. RESULTS: The Gentian assay had higher correlation with Siemens (r = 0.96) than did Roche (r = 0.93, P < 0.001). After cross-tabulating quartiles of each cystatin Cmeasure, agreements (kappa statistic) were higher for Siemens and Gentian (0.73, 95% CI 0.72-0.75) than for Roche and Siemens (0.64, 0.63-0.66) or for Roche and Gentian (0.69, 0.65-0.71). These differences in agreement had minimal impact on associations with clinical outcomes; the hazard ratios (HRs) for mortality comparing the high vs low quartiles were 3.2 (95% CI 2.1-4.8) for Siemens, 3.1 (CI 2.1-4.7) for Gentian, 3.1 (CI 2.1-4.7) for Roche, and 1.6 (CI 1.1-2.3) for eGFR-MDRD, after multivariate adjustment. CONCLUSIONS: In summary, agreement with the Siemens' assay was modestly higher for the Gentian compared with the Roche assay, although all 3 methods for cystatin C measurement had similar utility as predictors of clinical outcomes. (C) 2011 American Association for Clinical Chemistry C1 [Shlipak, Michael G.; Weekley, Cristin C.; Li, Yongmei; Whooley, Mary] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Shlipak, Michael G.; Weekley, Cristin C.; Whooley, Mary] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hansson, Lars-Olof; Larsson, Anders] Uppsala Univ, Uppsala, Sweden. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, Box 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU NIH [R01 DK066488-01]; American Heart Association; Siemens; Gentian; Roche FX M.G. Shlipak, NIH (R01 DK066488-01) and the American Heart Association Established Investigator Award. Siemens cystatin C measures were supported by a grant by Siemens (Dade-Behring) to the Heart and Soul Study. The Gentian and Roche measures were funded by a grant from Gentian and Roche, respectively, to the Heart and Soul Study. These funding sources had no involvement in the design or execution of this study. NR 18 TC 14 Z9 14 U1 0 U2 2 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD MAY PY 2011 VL 57 IS 5 BP 737 EP 745 DI 10.1373/clinchem.2010.158915 PG 9 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 756AY UT WOS:000289985100014 PM 21310869 ER PT J AU Larsson, A Hansson, LO Flodin, M Katz, R Shlipak, MG AF Larsson, Anders Hansson, Lars-Olof Flodin, Mats Katz, Ronit Shlipak, Michael G. TI Calibration of the Siemens Cystatin C Immunoassay Has Changed over Time SO CLINICAL CHEMISTRY LA English DT Letter ID KIDNEY-FUNCTION; CREATININE; VALUES; MG/L C1 [Larsson, Anders; Hansson, Lars-Olof; Flodin, Mats] Uppsala Univ, Uppsala, Sweden. [Katz, Ronit] Univ Washington, Seattle, WA 98195 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Larsson, A (reprint author), Univ Hosp, Dept Med Sci, S-75185 Uppsala, Sweden. EM anders.larsson@akademiska.se NR 5 TC 29 Z9 30 U1 1 U2 3 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD MAY PY 2011 VL 57 IS 5 BP 777 EP 778 DI 10.1373/clinchem.2010.159848 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 756AY UT WOS:000289985100021 PM 21364028 ER PT J AU Gourcerol, G Wu, SV Yuan, PQ Pham, H Miampamba, M Larauche, M Sanders, P Amano, T Mulak, A Im, E Pothoulakis, C Rivier, J Tache, Y Million, M AF Gourcerol, Guillaume Wu, S. Vincent Yuan, Pu-Qing Hung Pham Miampamba, Marcel Larauche, Muriel Sanders, Paul Amano, Tomofumi Mulak, Agata Im, Eunok Pothoulakis, Charalabos Rivier, Jean Tache, Yvette Million, Mulugeta TI Activation of Corticotropin-Releasing Factor Receptor 2 Mediates the Colonic Motor Coping Response to Acute Stress in Rodents SO GASTROENTEROLOGY LA English DT Article DE Colonic Contraction; Myenteric Neurons; nNOS; Stress Response ID GIANT MIGRATING CONTRACTIONS; INFLAMMATORY-BOWEL-DISEASE; ENTERIC NERVOUS-SYSTEM; C-FOS EXPRESSION; MYENTERIC NEURONS; CRF RECEPTORS; PHARMACOLOGICAL CHARACTERIZATION; NITRERGIC REGULATION; TRANSGENIC MICE; CONSCIOUS RATS AB BACKGROUND & AIMS: Corticotropin-releasing factor receptor-1 (CRF1) mediates the stress-induced colonic motor activity. Less is known about the role of CRF(2) in the colonic response to stress. METHODS: We studied colonic contractile activity in rats and CRF(2)-/-, CRF-overexpressing, and wild-type mice using still manometry; we analyzed defecation induced by acute partial-restraint stress (PRS), and/or intraperitoneal injection of CRF ligands. In rats, we monitored activation of the colonic longitudinal muscle myenteric plexus (LMMP) neurons and localization of CRF(1) and CRF(2) using immunohistochemical and immunoblot analyses. We measured phosphorylation of extracellular signal-regulated kinase 1/2 by CRF ligands in primary cultures of LMMP neurons (PC-LMMPn) and cyclic adenosine monophosphate (cAMP) production in human embryonic kidney-293 cells transfected with CRF(1) and/or CRF(2). RESULTS: In rats, a selective agonist of CRF(2) (urocortin 2) reduced CRF-induced defecation (> 50%), colonic contractile activity, and Fos expression in the colonic LMMP. A selective antagonist of CRF(2) (astressin(2)-B) increased these responses. Urocortin 2 reduced PRS-induced colonic contractile activity in wild-type and CRF-overexpressing mice, whereas disruption of CRF(2) increased PRS-induced colonic contractile activity and CRF-induced defecation. CRF(2) colocalized with CRF(1) and neuronal nitric oxide synthase in the rat colon, LMMP, and PC-LMMPn. CRF-induced phosphorylation of extracellular signal-regulated kinase in PC-LMMPn; this was inhibited or increased by a selective antagonist of CRF(1) (NBI35965) or astressin(2)-B, respectively. The half maximal effective concentration, EC(50), for the CRF-induced cAMP response was 8.6 nmol/L in human embryonic kidney-293 cells that express only CRF(1); this response was suppressed 10-fold in cells that express CRF(1) and CRF(2). CONCLUSIONS: In colon tissues of rodents, CRF(2) activation inhibits CRF(1) signaling in myenteric neurons and the stress-induced colonic motor responses. Disruption of CRF(2) function impairs colonic coping responses to stress. C1 [Million, Mulugeta] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, Los Angeles, CA 90073 USA. [Gourcerol, Guillaume; Wu, S. Vincent; Yuan, Pu-Qing; Hung Pham; Miampamba, Marcel; Larauche, Muriel; Sanders, Paul; Amano, Tomofumi; Mulak, Agata; Im, Eunok; Pothoulakis, Charalabos; Tache, Yvette; Million, Mulugeta] Univ Calif Los Angeles, Dept Med, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. [Gourcerol, Guillaume] Univ Rouen, Rouen Univ Hosp, Dept Physiol & Appareil Digestif Environm Nutr AD, Equipe Accueil 4311,IFRMP23, F-76821 Mont St Aignan, France. [Rivier, Jean] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA. RP Million, M (reprint author), Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, CURE Bldg 115,Room 118B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM millionmulugeta@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675; Sanders, Paul/0000-0002-2915-5714 FU National Institute for Diabetes and Digestive and Kidney Diseases [R21 DK-068155, RO1 DK078676, DK-57238, DK-41301]; VA Career Scientist Award; French Foreign Office; French Society of Gastroenterology; NIH [DK PO1-26741, P01 DK 33506, KO1 DK083336] FX This work was supported by National Institute for Diabetes and Digestive and Kidney Diseases grants R21 DK-068155 and RO1 DK078676 (M.M.), DK-57238 (Y.T.), and DK-41301 (Center Grant, Animal core, Y.T.); a VA Career Scientist Award (Y.T.); the French Foreign Office (Egide program); the French Society of Gastroenterology (G.G.); NIH DK PO1-26741 (J.R.); NIH P01 DK 33506 (C.P.); NIH KO1 DK083336 (E.I.). NR 55 TC 28 Z9 28 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2011 VL 140 IS 5 BP 1586 EP U313 DI 10.1053/j.gastro.2011.01.039 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 756QA UT WOS:000290028200039 PM 21277852 ER PT J AU Bernjak, A Deitrick, GA Bauman, WA Stefanovska, A Tuckman, J AF Bernjak, A. Deitrick, G. A. Bauman, W. A. Stefanovska, A. Tuckman, J. TI Basal sympathetic activity to the microcirculation in tetraplegic man revealed by wavelet transform of laser Doppler flowmetry SO MICROVASCULAR RESEARCH LA English DT Article DE Blood flow; Autonomic; Sympathetic; Wave, wavelet transform; Laser Doppler flowmetry ID SPINAL-CORD-INJURY; BLOOD-FLOW OSCILLATIONS; HUMAN SKIN; CIRCULATION; RESPONSES; CLONIDINE; OUTFLOW; LESIONS; HUMANS; MUSCLE AB Background: The 1984/86 published neurogram results showing only rare sympathetic nerve activity (SNA) to the muscles and skin in tetraplegia are still accepted. The present study by a different method attempted to confirm or deny those findings. Methods and results: The effect of basal SNA to the microcirculation of the feet and calf in 10 complete (AIS A) traumatic tetraplegic and 10 healthy age matched subjects were evaluated by wavelet transform of laser Doppler flowmetry (LDF) recordings. The results clearly indicated there is significant basal SNA from the decentralized spinal cord in tetraplegia. In addition, wavelet analysis allowed a study of other influences on the microcirculation besides SNA. Collectively, in tetraplegia compared with controls, the powers of the low frequency oscillations in blood flow were reduced; in that the endothelium caused less vasodilatation while the SNA and intrinsic vascular smooth muscles induced smaller degrees of vasoconstriction. However, the high frequency and especially the cardiac powers were greater. The latter presenting an obvious important factor for the preservation of blood flow in the microcirculation. Conclusions: It is suggested that basal SNA to the cutaneous microcirculation occurs in complete tetraplegia, and the significant levels of circulating noradrenaline reported by others indicate this is also true in other parts of the body. This may explain the usual absence of severe, incapacitating, autonomic deficiency in this condition. Published by Elsevier Inc. C1 [Deitrick, G. A.] James J Peters VA Med Ctr, Dept Surg, Bronx, NY 10461 USA. [Deitrick, G. A.] Mt Sinai Med Ctr, Dept Surg, New York, NY 10029 USA. [Deitrick, G. A.] Mt Sinai Sch Med, SCI Patient Care Unit, New York, NY 10029 USA. [Bauman, W. A.; Tuckman, J.] Mt Sinai Sch Med, Spinal Cord Damage Res Ctr, New York, NY 10029 USA. [Bauman, W. A.; Tuckman, J.] Mt Sinai Sch Med, VA RR&D Ctr Excellence Med Consequences Spinal Co, New York, NY 10029 USA. [Bauman, W. A.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Bernjak, A.; Stefanovska, A.] Univ Lancaster, Dept Phys, Lancaster LA1 4YB, England. [Stefanovska, A.] Univ Ljubljana, Fac Elect Engn, Ljubljana, Slovenia. RP Deitrick, GA (reprint author), James J Peters VA Med Ctr, Dept Surg, 130 W Kingsbridge Rd, Bronx, NY 10461 USA. EM george.deitrick@va.gov FU VA RR&D Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162C]; Wellcome Trust; UK; Slovenia Research Agency, ARRS, Slovenia; ESRC, UK FX 1) VA RR&D Center of Excellence for the Medical Consequences of Spinal Cord Injury, #B4162C; 2) Wellcome Trust; UK; 3) Slovenia Research Agency, ARRS, Slovenia; 4) ESRC - New Dynamics of Ageing Research Programme, UK NR 28 TC 6 Z9 6 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0026-2862 J9 MICROVASC RES JI Microvasc. Res. PD MAY PY 2011 VL 81 IS 3 BP 313 EP 318 DI 10.1016/j.mvr.2011.01.005 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 756GY UT WOS:000290000900011 PM 21262239 ER PT J AU Ganguly, K Dimitrov, DF Wallis, JD Carmena, JM AF Ganguly, Karunesh Dimitrov, Dragan F. Wallis, Jonathan D. Carmena, Jose M. TI Reversible large-scale modification of cortical networks during neuroprosthetic control SO NATURE NEUROSCIENCE LA English DT Article ID BRAIN-COMPUTER INTERFACE; MOTOR CORTEX; REACHING MOVEMENTS; MACHINE INTERFACE; ARM MOVEMENTS; UNIT-ACTIVITY; FORCE-FIELD; PERFORMANCE; NEURONS; ADAPTATION AB Brain-machine interfaces (BMIs) provide a framework for studying cortical dynamics and the neural correlates of learning. Neuroprosthetic control has been associated with tuning changes in specific neurons directly projecting to the BMI (hereafter referred to as direct neurons). However, little is known about the larger network dynamics. By monitoring ensembles of neurons that were either causally linked to BMI control or indirectly involved, we found that proficient neuroprosthetic control is associated with large-scale modifications to the cortical network in macaque monkeys. Specifically, there were changes in the preferred direction of both direct and indirect neurons. Notably, with learning, there was a relative decrease in the net modulation of indirect neural activity in comparison with direct activity. These widespread differential changes in the direct and indirect population activity were markedly stable from one day to the next and readily coexisted with the long-standing cortical network for upper limb control. Thus, the process of learning BMI control is associated with differential modification of neural populations based on their specific relation to movement control. C1 [Ganguly, Karunesh; Wallis, Jonathan D.; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Ganguly, Karunesh] San Francisco VA Med Ctr, Dept Neurol & Rehabil, San Francisco, CA USA. [Ganguly, Karunesh; Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA. [Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Dimitrov, Dragan F.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Wallis, Jonathan D.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. [Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA. [Carmena, Jose M.] Univ Calif San Francisco, Joint Grad Grp Bioengn, San Francisco, CA 94143 USA. RP Carmena, JM (reprint author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu OI Wallis, Joni/0000-0001-7262-7417 FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development; American Heart Association/American Stroke Association; National Institute of Neurological Disorders and Stroke [NS21135]; Alfred P. Sloan Foundation; Christopher and Dana Reeve Foundation; National Science Foundation [0954243]; Defense Advanced Research Projects Agency [N66001-10-C-2008] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development, and the American Heart Association/American Stroke Association (to K. G.), the National Institute of Neurological Disorders and Stroke grant number NS21135 (to J.D.W.), the Alfred P. Sloan Foundation, the Christopher and Dana Reeve Foundation, the National Science Foundation CAREER Award #0954243 and the Defense Advanced Research Projects Agency contract N66001-10-C-2008 (to J.M.C.). NR 45 TC 85 Z9 85 U1 0 U2 11 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD MAY PY 2011 VL 14 IS 5 BP 662 EP U164 DI 10.1038/nn.2797 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 754VU UT WOS:000289886600024 PM 21499255 ER PT J AU Greenbaum, CJ McCulloch-Olson, M Chiu, HK Palmer, JP Brooks-Worrell, B AF Greenbaum, Carla J. McCulloch-Olson, Marli Chiu, Harvey K. Palmer, Jerry P. Brooks-Worrell, Barbara TI Parenteral insulin suppresses T cell proliferation to islet antigens SO PEDIATRIC DIABETES LA English DT Article DE diabetes prevention trial; T cell; type 1 diabetes ID BLOOD MONONUCLEAR-CELLS; TYPE-1 AB The diabetes prevention trial-type 1 (DPT-1) tested whether a combination of SQ and IV insulin therapy would delay the onset of disease in individuals at high risk of progression. We investigated whether this regimen altered T cell responses to human islet proteins using cellular immunoblotting. Among the 10 treated and 7 control subjects studied, we found that there was a significant effect of treatment on cellular immunoblotting responses. We conclude that parenteral insulin may suppress proliferation to islet antigens in individuals at risk for diabetes, but this effect may be transient. Further study is needed to determine whether a therapy that results in sustained suppression of T cell proliferation could yield a measurable clinical benefit. C1 [Greenbaum, Carla J.] Benaroya Res Inst, Seattle, WA 98101 USA. [McCulloch-Olson, Marli] Seattle Childrens Hosp, Seattle, WA USA. [Palmer, Jerry P.; Brooks-Worrell, Barbara] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Greenbaum, CJ (reprint author), Benaroya Res Inst, 1201 9th Ave, Seattle, WA 98101 USA. EM cjgreen@benaroyaresearch.org FU Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; National Center for Research Resources; American Diabetes Association; Juvenile Diabetes Research Foundation; Medical Research Services of the Department of Veterans Affairs; NIH/NIDDK [P30 DK17047, U01 DK46601]; NCRR [M01-RR-00037]; Benaroya Research Institute FX The DPT-1 study was supported by cooperative agreements with the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute of Allergy and Infectious Diseases; the National Institute of Child Health and Human Development; the National Center for Research Resources; the American Diabetes Association; and the Juvenile Diabetes Research Foundation. Supplies were provided by Eli Lilly, Bayer, Becton Dickinson, International Technidyne, LifeScan, the Mead Johnson Nutritionals Division of Bristol-Myers Squibb, the Medisense Division of Abbott Laboratories, MiniMed, and Roche Diagnostics. Harvey Chiu was an Endocrinology fellow supported (in part) by the Medical Research Services of the Department of Veterans Affairs. This research was also supported in part by NIH/NIDDK grants P30 DK17047, U01 DK46601 and a Clinical Research grant from the American Diabetes Association. DPT-1 subjects in this ancillary study and those in the pilot study for individuals with type 1 diabetes were observed at the GCRC of the University of Washington. This study is currently funded under NCRR Grant M01-RR-00037. Additional support is provided in part by the Buse Diabetes Research Fund at the Benaroya Research Institute. NR 16 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1399-543X J9 PEDIATR DIABETES JI Pediatr. Diabetes PD MAY PY 2011 VL 12 IS 3 BP 150 EP 155 DI 10.1111/j.1399-5448.2010.00674.x PN 1 PG 6 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 754XW UT WOS:000289892200003 PM 20522167 ER PT J AU Whitford, TJ Mathalon, DH Shenton, ME Roach, BJ Bammer, R Adcock, RA Bouix, S Kubicki, M De Siebenthal, J Rausch, AC Schneiderman, JS Ford, JM AF Whitford, T. J. Mathalon, D. H. Shenton, M. E. Roach, B. J. Bammer, R. Adcock, R. A. Bouix, S. Kubicki, M. De Siebenthal, J. Rausch, A. C. Schneiderman, J. S. Ford, J. M. TI Electrophysiological and diffusion tensor imaging evidence of delayed corollary discharges in patients with schizophrenia SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Arcuate fasciculus; conduction delays; efference copy; forward model; white matter ID HUMAN AUDITORY-CORTEX; NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; OPTIC NEURITIS; HUMAN BRAIN; OLIGODENDROCYTE; DYSFUNCTION; PATHWAYS; HALLUCINATIONS; RESPONSIVENESS AB Background. Patients with schizophrenia (SZ) characteristically exhibit supranormal levels of cortical activity to self-induced sensory stimuli, ostensibly because of abnormalities in the neural signals (corollary discharges, CDs) normatively involved in suppressing the sensory consequences of self-generated actions. The nature of these abnormalities is unknown. This study investigated whether SZ patients experience CDs that are abnormally delayed in their arrival at the sensory cortex. Method. Twenty-one patients with SZ and 25 matched control participants underwent electroencephalography (EEG). Participants' level of cortical suppression was calculated as the amplitude of the N1 component evoked by a button press-elicited auditory stimulus, subtracted from the N1 amplitude evoked by the same stimulus presented passively. In the three experimental conditions, the auditory stimulus was delivered 0, 50 or 100 ms subsequent to the button-press. Fifteen SZ patients and 17 healthy controls (HCs) also underwent diffusion tensor imaging (DTI), and the fractional anisotropy (FA) of participants' arcuate fasciculus was used to predict their level of cortical suppression in the three conditions. Results. While the SZ patients exhibited subnormal N1 suppression to undelayed, self-generated auditory stimuli, these deficits were eliminated by imposing a 50-ms, but not a 100-ms, delay between the button-press and the evoked stimulus. Furthermore, the extent to which the 50-ms delay normalized a patient's level of N1 suppression was linearly related to the FA of their arcuate fasciculus. Conclusions. These data suggest that SZ patients experience temporally delayed CDs to self-generated auditory stimuli, putatively because of structural damage to the white-matter (WM) fasciculus connecting the sites of discharge initiation and destination. C1 [Whitford, T. J.; Shenton, M. E.; Bouix, S.; Kubicki, M.; De Siebenthal, J.; Rausch, A. C.; Schneiderman, J. S.] Harvard Univ, Sch Med, Psychiat Neuroimaging Lab, Dept Psychiat,Brigham & Womens Hosp, Boston, MA 02215 USA. [Whitford, T. J.] Univ Melbourne & Melbourne Hlth, Melbourne Neuropsychiat Ctr, Dept Psychiat, Melbourne, Vic, Australia. [Mathalon, D. H.; Roach, B. J.; Ford, J. M.] Univ Calif San Francisco, Dept Psychiat, Brain Imaging & EEG Lab, San Francisco, CA 94143 USA. [Mathalon, D. H.; Roach, B. J.; Ford, J. M.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA USA. [Shenton, M. E.; Kubicki, M.] Harvard Univ, Clin Neurosci Div, Neurosci Lab,Brockton Div,Med Sch, Dept Psychiat,Boston Vet Affairs Healthcare Syst, Brockton, MA 02401 USA. [Bammer, R.] Stanford Univ, Radiol Sci Lab, Stanford, CA 94305 USA. [Adcock, R. A.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. RP Whitford, TJ (reprint author), Harvard Univ, Sch Med, Psychiat Neuroimaging Lab, Dept Psychiat,Brigham & Womens Hosp, 1249 Boylston St, Boston, MA 02215 USA. EM whitford@bwh.harvard.edu RI Schneiderman, Jason/E-1528-2013 OI Schneiderman, Jason/0000-0002-9313-0415; Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974; Rausch, Andrew/0000-0002-7246-4563 FU National Health and Medical Research Council of Australia [NHMRC 520627]; National institutes of Health (NIH) [R03 MH068464-0, R01 MH 50747, T32 MH 016259, K05 MH 070047, R01 MH 082918, R01 DA 027802, R01 MH076989, R01 MH058262, K02 MH067967]; Harvard Medical School; National Alliance for Research on Schizophrenia and Depression; Department of Veterans Affairs; Boston Center for Intervention Development and Applied Research (CIDAR) [P50 MH 080272]; Center for Integration of Medicine and Innovative Technology; Sloan Foundation; Esther A. & Joseph Klingenstein Fund; Dana Foundation FX T.J.W. is supported by an Overseas-Based Biomedical Training Fellowship from the National Health and Medical Research Council of Australia (NHMRC 520627), administered through the University of Melbourne. M.K. is supported by grants from the National institutes of Health (NIH) (R03 MH068464-0; R01 MH 50747 to MES), the Harvard Medical School (Milton Award), and the National Alliance for Research on Schizophrenia and Depression. J.S.S. is supported by a fellowship from the NIH (T32 MH 016259). M.E.S. is supported by grants from the NIH (K05 MH 070047 and R01 MH 50747), the Department of Veterans Affairs (VA Merit Award, VA Research Enhancement Award Program and VA Schizophrenia Research Center Grant), and the Boston Center for Intervention Development and Applied Research (CIDAR) funded through a center grant mechanism (P50 MH 080272). S.B. is supported by grants from the NIH (R01 MH 082918) and the Center for Integration of Medicine and Innovative Technology Soldier in Medicine Award. R.A.A. is supported by grants from the NIH (R01 DA 027802), Sloan Foundation, Esther A. & Joseph Klingenstein Fund, Dana Foundation, and the National Alliance for Research on Schizophrenia and Depression. D.H.M. is supported by the Department of Veterans Affairs and the NIH (R01 MH076989). J.M.F is supported by the Department of Veterans Affairs and the NIH (R01 MH058262, K02 MH067967). NR 52 TC 33 Z9 35 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD MAY PY 2011 VL 41 IS 5 BP 959 EP 969 DI 10.1017/S0033291710001376 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 753GK UT WOS:000289760100006 PM 20663254 ER PT J AU Hurford, IM Marder, SR Keefe, RSE Reise, SP Bilder, RM AF Hurford, Irene M. Marder, Stephen R. Keefe, Richard S. E. Reise, Steven P. Bilder, Robert M. TI A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians SO SCHIZOPHRENIA BULLETIN LA English DT Article DE schizophrenia; cognition; cognitive assessment; neurocognitive battery; clinical assessment ID III DIGIT SYMBOL; NEUROCOGNITIVE DEFICITS; NEUROPSYCHOLOGICAL STATUS; FUNCTIONAL-CAPACITY; REPEATABLE BATTERY; CATEGORY FLUENCY; HEALTHY CONTROLS; CODING SUBTEST; SCREENING-TEST; MEMORY AB Cognitive impairment in schizophrenia is often severe, enduring, and contributes significantly to chronic disability. But clinicians have difficulty in assessing cognition due to a lack of brief instruments. We evaluated whether a brief battery of cognitive tests derived from larger batteries could generate a summary score representing global cognitive function. Using data from 3 previously published trials, we calculated the corrected item-total correlations (CITCs) or the correlation of each test with the battery total score. We computed the proportion of variance that each test shares with the global score excluding that test (Rt2=CITC(2)) and the variance explained per minute of administration time for each test (Rt2/min). The 3 tests with the highest Rt2/min were selected for the brief battery. The composite score from the trail making test B, category fluency, and digit symbol correlated .86 with the global score of the larger battery in 2 of the studies and correlated between .73 and .82 with the total battery scores excluding these 3 tests. A Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) using the above 3 tests can be administered in 10-11 min. The full batteries of the larger studies have administration times ranging from 90 to 210 min. Given prior research suggesting that a single factor of global cognition best explains the pattern of cognitive deficit in schizophrenia, an instrument like B-CATS can provide clinicians with meaningful data regarding their patients' cognitive function. It can also serve researchers who want an estimate of global cognitive function without requiring a full neuropsychological battery. C1 [Hurford, Irene M.] Philadelphia VA Med Ctr, Dept Behav Hlth, Philadelphia, PA 19104 USA. [Hurford, Irene M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Marder, Stephen R.; Bilder, Robert M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Marder, Stephen R.] VA Greater Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Keefe, Richard S. E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Reise, Steven P.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Hurford, IM (reprint author), Philadelphia VA Med Ctr, Dept Behav Hlth, Rm 7A-113,Mail Code 116, Philadelphia, PA 19104 USA. EM ihurford@upenn.edu RI Bilder, Robert/A-8894-2008 OI Bilder, Robert/0000-0001-5085-7852 FU National Alliance for Research on Schizophrenia and Depression [20062767] FX National Alliance for Research on Schizophrenia and Depression Young Investigator grant (20062767 to I.M.H.). NR 36 TC 26 Z9 27 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2011 VL 37 IS 3 BP 538 EP 545 DI 10.1093/schbul/sbp095 PG 8 WC Psychiatry SC Psychiatry GA 753UF UT WOS:000289804500016 PM 19776205 ER PT J AU Loftis, JM Huckans, M AF Loftis, Jennifer M. Huckans, Marilyn TI COGNITIVE ENHANCEMENT IN COMBINATION WITH 'BRAIN REPAIR' MAY BE OPTIMAL FOR THE TREATMENT OF STIMULANT ADDICTION SO ADDICTION LA English DT Letter DE Cognition; depression; methamphetamine; pharmacotherapy; relapse ID METHAMPHETAMINE-DEPENDENT INDIVIDUALS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ABNORMALITIES; ACTIVATION; MODAFINIL; ABUSERS C1 [Loftis, Jennifer M.; Huckans, Marilyn] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Res & Dev Serv, Portland, OR 97239 USA. [Loftis, Jennifer M.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Res & Dev Serv, Portland, OR 97239 USA. EM loftisj@ohsu.edu FU NIDA NIH HHS [R41 DA029345, RC1DA028537, P50 DA018165, RC1 DA028537] NR 19 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0965-2140 J9 ADDICTION JI Addiction PD MAY PY 2011 VL 106 IS 5 BP 1021 EP 1022 DI 10.1111/j.1360-0443.2010.03354.x PG 2 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 747CC UT WOS:000289296900039 PM 21382112 ER PT J AU Hoo, GWS Wu, CC Vazirani, S Li, ZP Barack, BM AF Hoo, Guy W. Soo Wu, Carol C. Vazirani, Sondra Li, Zhaoping Barack, Bruce M. TI Does a Clinical Decision Rule Using D-Dimer Level Improve the Yield of Pulmonary CT Angiography? SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE clinical decision rule; D-dimer assay; pulmonary CT angiography; pulmonary embolism; Wells score ID DEEP-VEIN THROMBOSIS; COMPUTED-TOMOGRAPHY; VENOUS THROMBOEMBOLISM; EMERGENCY-DEPARTMENT; GUIDELINE IMPLEMENTATION; UTILIZATION PATTERNS; EMBOLISM; MANAGEMENT; DIAGNOSIS; PROBABILITY AB OBJECTIVE. The objective of our study was to evaluate the impact of incorporating a mandatory clinical decision rule and selective D-dimer use on the yield of pulmonary CT angiography (CTA). MATERIALS AND METHODS. Guidelines incorporating a clinical decision rule (Wells score: range, 0-12.5) and a highly sensitive D-dimer assay as decision points were placed into a computerized order entry menu. From December 2006 through November 2008, 261 pulmonary CTA examinations of 238 men and 14 women (mean age +/- SD, 65 +/- 12 years; range, 31-92 years) were performed. Eight patients underwent more than one pulmonary CTA examination. Charts were reviewed. The results of pulmonary CTA, the clinical decision rule, and D-dimer level (if obtained) were analyzed with the Student t test, chi-square test, or other comparisons using statistical software (MedCalc, version 11.0). RESULTS. Of the pulmonary CTA examinations, 16.5% (43/261) were positive for pulmonary embolism (PE) compared with 3.1% (6/196) during the previous 2 years. The mean clinical decision rule score and mean d-dimer level were 5.5 +/- 2.4 (SD) and 4956 +/- 2892 ng/mL, respectively, for those with PE compared with 4.5 +/- 2.1 and 2398 +/- 2100 ng/mL for those without PE (both, p < 0.01). The negative predictive value of a clinical decision rule score of 4 or less and d-dimer level of less than 1000 ng/mL was 1.0. A clinical decision rule of greater than 4 and a higher d-dimer level were better predictors for PE, especially a d-dimer level of greater than 3000 ng/mL (odds ratio = 6.69; 95% CI = 2.72-16.43). CONCLUSION. Guidelines combining a clinical decision rule with d-dimer level significantly improved the utilization of pulmonary CTA and positive yield for PE. C1 [Hoo, Guy W. Soo] W Los Angeles Med Ctr, Pulm & Crit Care Sect, Los Angeles, CA 90073 USA. [Hoo, Guy W. Soo; Vazirani, Sondra; Li, Zhaoping] VA Greater Angeles Healthcare Syst, Dept Med, W Los Angeles Med Ctr, Los Angeles, CA USA. [Wu, Carol C.; Barack, Bruce M.] VA Greater Angeles Healthcare Syst, Dept Imaging, W Los Angeles Med Ctr, Los Angeles, CA USA. RP Hoo, GWS (reprint author), W Los Angeles Med Ctr, Pulm & Crit Care Sect, 11301 Wilshire Blvd,111Q, Los Angeles, CA 90073 USA. EM Guy.Soohoo@va.gov NR 31 TC 6 Z9 7 U1 0 U2 2 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAY PY 2011 VL 196 IS 5 BP 1059 EP 1064 DI 10.2214/AJR.10.4200 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 753JS UT WOS:000289769000037 PM 21512071 ER PT J AU Pickerodt, PA Pickerodt, VW Boemke, W Swenson, ER AF Pickerodt, Philipp A. Pickerodt, Volker W. Boemke, Willehad Swenson, Erik R. TI Management of Severe Acute Anemia: Who Needs Blood? SO ANESTHESIA AND ANALGESIA LA English DT Letter C1 [Pickerodt, Philipp A.; Pickerodt, Volker W.; Boemke, Willehad] Charite, Dept Anesthesiol & Intens Care Med, Campus Virchow Klinikum, D-13353 Berlin, Germany. [Pickerodt, Philipp A.; Pickerodt, Volker W.; Boemke, Willehad] Charite, Dept Anesthesiol & Intens Care Med, Campus Charite Mitte, D-13353 Berlin, Germany. [Swenson, Erik R.] Univ Washington, Dept Med, Seattle, WA USA. [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Sect Pulm & Crit Care Med, Seattle, WA USA. RP Pickerodt, PA (reprint author), Charite, Dept Anesthesiol & Intens Care Med, Campus Virchow Klinikum, D-13353 Berlin, Germany. EM Philipp.pickerodt@charite.de NR 9 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAY PY 2011 VL 112 IS 5 BP 1251 EP 1252 DI 10.1213/ANE.0b013e31821245a6 PG 3 WC Anesthesiology SC Anesthesiology GA 753NI UT WOS:000289785100049 PM 21515657 ER PT J AU Reid, PR Bridges, TM Sheffler, DJ Cho, HP Lewis, LM Days, E Daniels, JS Jones, CK Niswender, CM Weaver, CD Conn, PJ Lindsley, CW Wood, MR AF Reid, Paul R. Bridges, Thomas M. Sheffler, Douglas J. Cho, Hyekyung P. Lewis, L. Michelle Days, Emily Daniels, J. Scott Jones, Carrie K. Niswender, Colleen M. Weaver, C. David Conn, P. Jeffrey Lindsley, Craig W. Wood, Michael R. TI Discovery and optimization of a novel, selective and brain penetrant M-1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Muscarinic; Acetylcholine; Positive allosteric modulator (PAM); ML169; BQCA; Alzheimer's disease; MLPCN ID ACETYLCHOLINE-RECEPTOR GENES; MUSCARINIC RECEPTORS; CNS DISORDERS; GPCRS AB This Letter describes a chemical lead optimization campaign directed at VU0108370, a weak M-1 PAM hit with a novel chemical scaffold from a functional HTS screen within the MLPCN. An iterative parallel synthesis approach rapidly established SAR for this series and afforded VU0405652 (ML169), a potent, selective and brain penetrant M-1 PAM with an in vitro profile comparable to the prototypical M-1 PAM, BQCA, but with an improved brain to plasma ratio. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Bridges, Thomas M.; Sheffler, Douglas J.; Cho, Hyekyung P.; Daniels, J. Scott; Jones, Carrie K.; Niswender, Colleen M.; Weaver, C. David; Conn, P. Jeffrey; Lindsley, Craig W.; Wood, Michael R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Lindsley, Craig W.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Sheffler, Douglas J.; Daniels, J. Scott; Jones, Carrie K.; Niswender, Colleen M.; Conn, P. Jeffrey; Lindsley, Craig W.; Wood, Michael R.] Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA. [Bridges, Thomas M.; Cho, Hyekyung P.; Daniels, J. Scott; Jones, Carrie K.; Niswender, Colleen M.; Weaver, C. David; Conn, P. Jeffrey; Lindsley, Craig W.; Wood, Michael R.] Vanderbilt Specialized Chem Ctr MLPCN, Nashville, TN 37232 USA. [Reid, Paul R.; Lewis, L. Michelle; Days, Emily; Weaver, C. David; Lindsley, Craig W.] Vanderbilt Inst Chem Biol Chem Synth Core, Nashville, TN 37232 USA. [Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37232 USA. RP Wood, MR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. EM michael.r.wood@vanderbilt.edu RI Conn, Peter/D-7848-2012 FU MLPCN [1U54 MH084659]; NIMH [1RO1 MH082867]; NIH; Alzheimer's Association [IIRG-07-57131] FX The authors thank the MLPCN (1U54 MH084659), NIMH (1RO1 MH082867), NIH and the Alzheimer's Association (IIRG-07-57131) for support of our Program in the development of subtype selective allosteric ligands of mAChRs. NR 21 TC 41 Z9 42 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD MAY 1 PY 2011 VL 21 IS 9 BP 2697 EP 2701 DI 10.1016/j.bmcl.2010.12.015 PG 5 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 753KW UT WOS:000289773300025 PM 21194936 ER PT J AU Lesselroth, BJ Yang, J McConnachie, J Brenk, T Winterbottom, L AF Lesselroth, Blake J. Yang, Jianji McConnachie, Judy Brenk, Thomas Winterbottom, Lisa TI Addressing the sociotechnical drivers of quality improvement: a case study of post-operative DVT prophylaxis computerised decision support SO BMJ QUALITY & SAFETY LA English DT Article ID HOSPITALIZED MEDICAL PATIENTS; VENOUS THROMBOEMBOLISM; HEALTH-CARE; ANTICOAGULANT PROPHYLAXIS; INFORMATION-TECHNOLOGY; PATIENT SAFETY; FRAMEWORK; SYSTEMS; MODEL; METAANALYSIS AB Background: Quality improvement (QI) initiatives characterised by iterative cycles of quantitative data analysis do not readily explain the organisational determinants of change. However, the integration of sociotechnical theory can inform more effective strategies. Our specific aims were to (1) describe a computerised decision support intervention intended to improve adherence with deep venous thrombosis (DVT) prophylaxis recommendations; and (2) show how sociotechnical theory expressed in 'Fit between Individuals, Task and Technology' framework (FITT) can identify and clarify the facilitators and barriers to QI work. Methods: A multidisciplinary team developed and implemented electronic menus with DVT prophylaxis recommendations. Stakeholders were interviewed and human factors were analysed to optimise integration. Menu exposure, order placement and clinical performance were measured. Vista tool extraction and chart review were used. Performance compliance pre-implementation was 77%. Results: There were 80-110 eligible cases per month. Initial menu use rate was 20%. After barriers were classified and addressed using the FITT framework, use improved 50% to 90%. Tasks, users and technology issues in the FITT model and their interfaces were identified and addressed. Workflow styles, concerns about validity of guidelines, cycle times and perceived ambiguity of risk were issues identified. Conclusions: DVT prophylaxis in a surgical setting is fraught with socio-political agendas, cognitive dissonance and misaligned expectations. These must be sought and articulated if organisations are to respond to internal resistance to change. This case study demonstrates that QI teams using information technology must understand the clinical context, even in mature electronic health record environments, in order to implement sustainable systems. C1 [Lesselroth, Blake J.; Yang, Jianji; Winterbottom, Lisa] Oregon Hlth & Sci Univ, Portland Oregon VA Med Ctr, Portland, OR 97201 USA. RP Lesselroth, BJ (reprint author), Portland VA Med Ctr, Portland Ctr Evaluat Clin Serv, P3 MED,3710 SW US Vet Hosp Dr, Portland, OR USA. EM blake.lesselroth@va.gov RI Johnson, Marilyn/E-7209-2011 FU Portland VA Informatics Center FX The authors wish to thank Dr. Jennifer Logan, Dr. Devan Kansagara, and Dr. Ana Quinones for their insightful comments during manuscript preparation. The authors also wish to thank Dr. David Douglas and the Portland VA Informatics Center for project support. NR 35 TC 12 Z9 12 U1 4 U2 15 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD MAY PY 2011 VL 20 IS 5 BP 381 EP 389 DI 10.1136/bmjqs.2010.042689 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 753JT UT WOS:000289769100001 PM 21209144 ER PT J AU Foy, R Ovretveit, J Shekelle, PG Pronovost, PJ Taylor, SL Dy, S Hempel, S McDonald, KM Rubenstein, LV Wachter, RM AF Foy, Robbie Ovretveit, John Shekelle, Paul G. Pronovost, Peter J. Taylor, Stephanie L. Dy, Sydney Hempel, Susanne McDonald, Kathryn M. Rubenstein, Lisa V. Wachter, Robert M. TI The role of theory in research to develop and evaluate the implementation of patient safety practices SO BMJ QUALITY & SAFETY LA English DT Article ID HEALTH-CARE; COMPLEX INTERVENTIONS; PSYCHOLOGICAL THEORY; QUALITY IMPROVEMENT; CLINICAL-PRACTICE; FEEDBACK; BEHAVIOR; STRATEGIES; KNOWLEDGE; DESIGN AB Theories provide a way of understanding and predicting the effects of patient safety practices (PSPs), interventions intended to prevent or mitigate harm caused by healthcare or risks of such harm. Yet most published evaluations make little or no explicit reference to theory, thereby hindering efforts to generalise findings from one context to another. Theories from a wide range of disciplines are potentially relevant to research on PSPs. Theory can be used in research to explain clinical and organisational behaviour, to guide the development and selection of PSPs, and in evaluating their implementation and mechanisms of action. One key recommendation from an expert consensus process is that researchers should describe the theoretical basis for chosen intervention components or provide an explicit logic model for 'why this PSP should work.' Future theory-driven evaluations would enhance generalisability and help build a cumulative understanding of the nature of change. C1 [Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9LJ, W Yorkshire, England. [Ovretveit, John] Karolinska Inst, Med Management Ctr, Stockholm, Sweden. [Shekelle, Paul G.; Taylor, Stephanie L.; Hempel, Susanne; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA. [Shekelle, Paul G.; Taylor, Stephanie L.; Rubenstein, Lisa V.] VA Greater Los Angeles, Los Angeles, CA USA. [Pronovost, Peter J.; Dy, Sydney] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [McDonald, Kathryn M.] Stanford Univ, Stanford, CA 94305 USA. [Wachter, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Foy, R (reprint author), Univ Leeds, Leeds Inst Hlth Sci, 101 Clarendon Rd, Leeds LS2 9LJ, W Yorkshire, England. EM r.foy@leeds.ac.uk FU AHRQ FX Funding AHRQ. NR 48 TC 40 Z9 40 U1 4 U2 19 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD MAY PY 2011 VL 20 IS 5 BP 453 EP 459 DI 10.1136/bmjqs.2010.047993 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 753JT UT WOS:000289769100012 PM 21317181 ER PT J AU Teitelman, AM Ratcliffe, SJ McDonald, CC Brawner, BM Sullivan, CM AF Teitelman, Anne M. Ratcliffe, Sarah J. McDonald, Catherine C. Brawner, Bridgette M. Sullivan, Cris M. TI Relationships Between Physical and Non-Physical Forms of Intimate Partner Violence and Depression among Urban Minority Adolescent Females SO CHILD AND ADOLESCENT MENTAL HEALTH LA English DT Article DE Violence; depression; adolescence ID AFRICAN-AMERICAN ADOLESCENTS; DATING VIOLENCE; RISK-FACTORS; SEXUAL RISK; CAUCASIAN ADOLESCENTS; YOUNG ADOLESCENTS; HEALTH OUTCOMES; MENTAL-HEALTH; UNITED-STATES; SYMPTOMS AB Background: Little is known about intimate partner violence (IPV) and depression among low income, urban African American and Hispanic adolescent females. Method: Interviews with 102 urban African American and Hispanic adolescent females examined physical abuse, emotional/verbal abuse, and threats, and their unique and combined associations with depression. Results: One-quarter of the sample experienced all three types of abuse. Non-physical forms of IPV were significantly associated with depression. Conclusions: Some urban adolescent females from lower income households experience high rates of IPV. Physical and non-physical forms of IPV are important in understanding and responding to depression in this population. Key Practitioner Message: Among urban adolescent females, it is important to assess for non-physical as well as physical forms of IPV, and if detected, to also screen for depression Adolescent females reporting higher levels of IPV may have higher levels of depression, and thus may need more extensive treatment, support, and require greater follow-up Adolescent females who present with depression should be screened for IPV It is important to assess for protective factors, such as social support, and make referrals accordingly. Early detection and intervention for both IPV and depression can reduce future vulnerabilities C1 [Teitelman, Anne M.; McDonald, Catherine C.; Brawner, Bridgette M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Ratcliffe, Sarah J.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Sullivan, Cris M.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. RP Teitelman, AM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Fagin Hall,2L Rm-244,418 Curie Blvd, Philadelphia, PA 19104 USA. EM teitelm@nursing.upenn.edu FU Michigan Department of Community Health and Michigan State University; National Institute of Nursing Research [F31NR011107] FX This research was supported by funds from Michigan Department of Community Health and Michigan State University. This research was also supported by Award Number F31NR011107 (PI: Catherine C. McDonald) from the National Institute of Nursing Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. Drs. Teitelman and Ratcliffe had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 61 TC 4 Z9 4 U1 2 U2 17 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1475-357X J9 CHILD ADOL MENT H-UK JI Child Adolesc. Ment. Health PD MAY PY 2011 VL 16 IS 2 BP 92 EP 100 DI 10.1111/j.1475-3588.2010.00572.x PG 9 WC Psychology, Clinical; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 749MS UT WOS:000289472500005 PM 21617762 ER PT J AU Valdez, C Locke, C Sloan, N AF Valdez, Christine Locke, Christy Sloan, Nancy TI Healing Touch (HT) as an Innovative Method of Care for Patients SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Valdez, Christine; Locke, Christy; Sloan, Nancy] US Dept Vet Affairs, Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAY-JUN PY 2011 VL 25 IS 3 BP 145 EP 145 PG 1 WC Nursing SC Nursing GA 748QH UT WOS:000289405000025 ER PT J AU Maguen, S Luxton, DD Skopp, NA Gahm, GA Reger, MA Metzler, TJ Marmar, CR AF Maguen, Shira Luxton, David D. Skopp, Nancy A. Gahm, Gregory A. Reger, Mark A. Metzler, Thomas J. Marmar, Charles R. TI Killing in combat, mental health symptoms, and suicidal ideation in Iraq war veterans SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Posttraumatic stress disorder; Suicide; OEF/OIF; Military ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; RISK; MILITARY; PTSD; MEDIATION AB This study examined combat and mental health as risk factors of suicidal ideation among 2854 U.S. soldiers returning from deployment in support of Operation Iraqi Freedom. Data were collected as part of a postdeployment screening program at a large Army medical facility. Overall, 2.8% of soldiers reported suicidal ideation. Postdeployment depression symptoms were associated with suicidal thoughts, while postdeployment PTSD symptoms were associated with current desire for self harm. Postdeployment depression and PTSD symptoms mediated the association between killing in combat and suicidal thinking, while postdeployment PTSD symptoms mediated the association between killing in combat and desire for self harm. These results provide preliminary evidence that suicidal thinking and the desire for self-harm are associated with different mental health predictors, and that the impact of killing on suicidal ideation may be important to consider in the evaluation and care of our newly returning veterans. Published by Elsevier Ltd. C1 [Maguen, Shira] San Francisco VA Med Ctr, PTSD Program 116 P, San Francisco, CA 94121 USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Luxton, David D.; Skopp, Nancy A.; Gahm, Gregory A.; Reger, Mark A.] Natl Ctr Telehlth & Technol, Def Ctr Excellence Psychol Hlth, OMAMC, Joint Base Lewis McChord, Tacoma, WA 98431 USA. [Marmar, Charles R.] NYU, Langone Med Ctr, Dept Psychiat, New York, NY 10016 USA. [Luxton, David D.; Skopp, Nancy A.; Gahm, Gregory A.; Reger, Mark A.] Natl Ctr Telehlth & Technol, Def Ctr Traumat Brain Injury, OMAMC, Joint Base Lewis McChord, Tacoma, WA 98431 USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, PTSD Program 116 P, 4150 Clement St, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov; David.Luxton@us.army.mil; Nancy.Skopp@us.army.mil; Gregory.Gahm@us.army.mil; Mark.Reger@us.army.mil; Thomas.Metzler@va.gov; Charles.Marmar@nyumc.org RI Schueter, nicos/A-3625-2014 NR 25 TC 38 Z9 41 U1 2 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD MAY PY 2011 VL 25 IS 4 BP 563 EP 567 DI 10.1016/j.janxdis.2011.01.003 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 750ZV UT WOS:000289588000014 PM 21333486 ER PT J AU Klein, R Moghadam-Kia, S Taylor, L Coley, C Okawa, J LoMonico, J Chren, MM Werth, VP AF Klein, Rachel Moghadam-Kia, Siamak Taylor, Lynne Coley, Christopher Okawa, Joyce LoMonico, Jonathan Chren, Mary-Margaret Werth, Victoria P. TI Quality of life in cutaneous lupus erythematosus SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE cutaneous lupus erythematosus; Cutaneous Lupus Erythematosus Disease Area and Severity Index; psychiatric comorbidity; quality of life; Short Form-36 (SF-36); Skindex-29 ID HEALTH SURVEY SF-36; PSYCHIATRIC MORBIDITY; DERMATOLOGICAL OUTPATIENTS; PSYCHOLOGICAL DISTRESS; OUTCOME INSTRUMENT; ATOPIC-DERMATITIS; SUICIDAL IDEATION; SEVERITY INDEX; SKIN DISEASES; PSORIASIS AB Background: Little is known about quality of life in patients with cutaneous lupus erythematosus. Objective: We sought to determine how cutaneous lupus affects quality of life and which independent variables are associated with poor quality of life. Methods: A total of 157 patients with cutaneous lupus completed surveys related to quality of life, including the Skindex-29 and the Short Form-36. Results: Quality of life in cutaneous lupus is severely impaired, particularly with respect to emotional wellbeing. Patients with cutaneous lupus have worse quality of life than those with other common dermatologic conditions, such as acne, nonmelanoma skin cancer, and alopecia. With respect to mental health status, patients with cutaneous lupus have similar or worse scores than patients with hypertension, type 2 diabetes mellitus, recent myocardial infarction, and congestive heart failure. Factors related to poor quality of life include female gender, generalized disease, severe disease, distribution of lesions, and younger age. Limitations: The study was done at a single referral-only center. Conclusion: Patients with cutaneous lupus have very impaired quality of life, particularly from an emotional perspective. (J Am Acad Dermatol 201164:849-58.) C1 [Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA. [Klein, Rachel; Moghadam-Kia, Siamak; Okawa, Joyce; LoMonico, Jonathan; Werth, Victoria P.] Philadelphia Dept Vet Affairs Med Ctr, Philadelphia, PA USA. [Taylor, Lynne; Coley, Christopher] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. RP Werth, VP (reprint author), Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU National Institutes of Health [NIH K24-AR 02207, NIH K24 AR052667, NIH T32-AR007465-25]; Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX This material is based on work supported by the National Institutes of Health, including NIH K24-AR 02207 (Dr Werth), NIH K24 AR052667 (Dr Chren), and training grant NIH T32-AR007465-25 (Ms Klein). This work was also partially supported by a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. NR 39 TC 36 Z9 36 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2011 VL 64 IS 5 BP 849 EP 858 DI 10.1016/j.jaad.2010.02.008 PG 10 WC Dermatology SC Dermatology GA 754PW UT WOS:000289869800006 PM 21397983 ER PT J AU Chen, BB Coon, TA Glasser, JR Mallampalli, RK AF Chen, Bill B. Coon, Tiffany A. Glasser, Jennifer R. Mallampalli, Rama K. TI Calmodulin Antagonizes a Calcium-Activated SCF Ubiquitin E3 Ligase Subunit, FBXL2, To Regulate Surfactant Homeostasis SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID F-BOX PROTEINS; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE SYNTHESIS; LUNG INJURY; PROTEOLYSIS; CALPAIN; DEGRADATION; IDENTIFICATION; RECEPTOR; INTERNALIZATION AB Calmodulin is a universal calcium-sensing protein that has pleiotropic effects. Here we show that calmodulin inhibits a new SCF (Skp1-Cullin-F-box) E3 ligase component, FBXL2. During Pseudomonas aeruginosa infection, SCF (FBXL2) targets the key enzyme, CCT alpha, for its monoubiquitination and degradation, thereby reducing synthesis of the indispensable membrane and surfactant component, phosphatidylcholine. P. aeruginosa triggers calcium influx and calcium-dependent activation of FBXL2 within the Golgi complex, where it engages CCT alpha. FBXL2 through its C terminus binds to the CCT alpha IQ motif. FBXL2 knockdown increases CCT alpha levels and phospholipid synthesis. The molecular interaction of FBXL2 with CCT alpha is opposed by calmodulin, which traffics to the Golgi complex, binds FBXL2 (residues 80 to 90) via its C terminus, and vies with the ligase for occupancy within the IQ motif. These observations were recapitulated in murine models of P. aeruginosa-induced surfactant deficiency, where calmodulin gene transfer reduced FBXL2 actions by stabilizing CCT alpha and lessening the severity of inflammatory lung injury. The results provide a unique model of calcium-regulated intermolecular competition between an E3 ligase subunit and an antagonist that is critically relevant to pneumonia and lipid homeostasis. C1 [Mallampalli, Rama K.] Univ Pittsburgh, UPMC Montefiore, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Dept Med, Acute Lung Injury Ctr Excellence, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; Department of Veterans Affairs; NIH [R01, HL081784, HL096376, HL097376, HL098174] FX This material is based upon work supported, in part, by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the Department of Veterans Affairs and NIH R01 grants HL081784, HL096376, HL097376, and HL098174 (to R.K.M.). NR 39 TC 28 Z9 30 U1 1 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAY PY 2011 VL 31 IS 9 BP 1905 EP 1920 DI 10.1128/MCB.00723-10 PG 16 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 751KV UT WOS:000289617300011 PM 21343341 ER PT J AU Sharma, MR Werth, B Werth, VP AF Sharma, Meena R. Werth, Benjamin Werth, Victoria P. TI Animal Models of Acute Photodamage: Comparisons of Anatomic, Cellular and Molecular Responses in C57BL/6J, SKH1 and Balb/c Mice SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; SOLAR ULTRAVIOLET-RADIATION; NORMAL HUMAN SKIN; HAIRLESS MOUSE; TNF-ALPHA; IN-VIVO; DERMATAN SULFATE; HYALURONIC-ACID; FACTOR-BETA; IRRADIATION AB Human cutaneous photodamage is a major medical problem that includes premature aging and fragility of the skin. Nonxenografted animal models have not been comparatively evaluated for how well they resemble the changes seen in human skin. Here, we sought to identify a suitable mouse model that recapitulates key anatomic, cellular and molecular responses observed in human skin during acute UV exposure. Adult females from three strains of mice, C57BL/6J, SKH1 and Balb/c were exposed to UVB and then evaluated 3 or 20 h after the last irradiation. Skin from UVB-exposed C57BL/6J mice showed features resembling human photodamage, including epidermal thickening, infiltration of the dermis with inflammatory cells, induction of tumor necrosis factor-alpha (TNF-alpha) mRNA, accumulation of glycosaminoglycans, particularly hyaluronan in the epidermis and loss of collagen. Hairless SKH1 mouse skin responded similarly, but without any induction of TNF-alpha mRNA or chondroitin sulfate. Irradiated Balb/c mice were the least similar to humans. Our results in C57BL/6J mice and to a lesser extent in SKH1 mice, show cutaneous responses to a course of UVB-irradiation that mirror those seen in human skin. Proper choice of model is critical for investigating cellular and molecular mechanisms of photodamage and photoaging. C1 [Sharma, Meena R.; Werth, Benjamin; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Sharma, Meena R.; Werth, Benjamin; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX This material is based upon work supported by a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. NR 42 TC 7 Z9 8 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD MAY-JUN PY 2011 VL 87 IS 3 BP 690 EP 698 DI 10.1111/j.1751-1097.2011.00911.x PG 9 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 753LD UT WOS:000289774200026 PM 21332482 ER PT J AU Sher, L AF Sher, L. TI Brain-derived neurotrophic factor and suicidal behavior SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; NEURODEGENERATIVE DISORDERS; GENE-EXPRESSION; BDNF; DEPRESSION; PATHOGENESIS; INJURY; 5-HT; AREA AB Studies of the neurobiology of suicidal behavior have become an important and integral part of psychiatric research. Over the past several years, studies of the role of brain-derived neurotrophic factor (BDNF) in the pathophysiology of suicidality have attracted significant interest of researchers. Multiple lines of evidence including studies of levels of BDNF in blood cells and plasma of suicidal patients, postmortem brain studies in suicidal subjects with or without depression, and genetic association studies linking BDNF to suicide suggest that suicidal behavior may be associated with a decrease in BDNF functioning. Studies of the BDNF function are important for suicide research and prevention because of the multiple reasons including the following: (i) BDNF plays a role in the pathophysiology of depression, post-traumatic stress disorder, substance use disorders and other conditions associated with suicidal behavior. Treatment-induced enhancements of BDNF can facilitate neural integrity and recovery of function in psychiatric disorders, and consequently prevent suicidal behavior; (ii) abnormal BDNF function may be associated with elevated suicidality independently of psychiatric diagnoses. It is possible that treatment-induced improvement in the BDNF function prevents suicidal behavior independently of improvement in psychiatric disorders; (iii) BDNF may be a biological marker of suicidal behavior in certain patient populations. It is to be hoped that the studies of the neurobiology of suicidal behavior will lead to the development of new methods of suicide prevention. C1 James J Peters Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10468 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Psychiat, 130 W Kingsbridge Rd, New York, NY 10468 USA. EM drleosher@gmail.com NR 33 TC 12 Z9 14 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1460-2725 EI 1460-2393 J9 QJM-INT J MED JI QJM-An Int. J. Med. PD MAY PY 2011 VL 104 IS 5 BP 455 EP 458 DI 10.1093/qjmed/hcq207 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 754EY UT WOS:000289838200017 PM 21051476 ER PT J AU Miller, RM Ford, JM Shanbhag, H Mathalon, DH AF Miller, Ryan M. Ford, Judith M. Shanbhag, Harshad Mathalon, Daniel H. TI Negative Symptom Severity and Schizophrenia: Abnormal Entrainment of Dorsal Striatum in Default Mode Network SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-of-Biological-Psychiatry CY MAY 12-14, 2011 CL San Francisco, CA SP Soc Biol Psychiat C1 [Miller, Ryan M.; Ford, Judith M.; Shanbhag, Harshad; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2011 VL 69 IS 9 SU S MA 873 BP 263S EP 263S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 764OR UT WOS:000290641800834 ER PT J AU Meeks, TW Culberson, JW Horton, MS AF Meeks, Thomas W. Culberson, John W. Horton, Monica S. TI Medications in Long-Term Care: When Less is More SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Long-term care; Inappropriate prescribing; Polypharmacy; Psychotropics; Opiates; Sedatives ID NURSING-HOME RESIDENTS; ATYPICAL ANTIPSYCHOTIC-DRUGS; RANDOMIZED CONTROLLED-TRIALS; ELDERLY-PATIENTS; OLDER-ADULTS; MUSCULOSKELETAL PAIN; TARDIVE-DYSKINESIA; EXPLICIT CRITERIA; NONMALIGNANT PAIN; ALZHEIMER-DISEASE AB Attention has been drawn to the potential risks of several medications in the long-term care setting. Most of these medications deemed as inappropriate affect the central nervous system and are indicated only for select populations with specific conditions. Many of these drugs are prescribed without clear indications and continued indefinitely without critical decision-making about the potentially salutary effects of discontinuing medications. This article describes the increasing awareness of potentially inappropriate prescribing in the long-term care setting and reviews the rationale for why various types of medications are deemed inappropriate, with a focus on agents that affect central nervous system functioning. C1 [Meeks, Thomas W.] Univ Calif San Diego, Dept Psychiat, Div Geriatr Psychiat, San Diego, CA 92093 USA. [Culberson, John W.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Culberson, John W.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Horton, Monica S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Horton, Monica S.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Meeks, TW (reprint author), 9300 Campus Point Dr,MC 7602, La Jolla, CA 92037 USA. EM tmeeks@ucsd.edu FU Geriatric Academic Career Awards [K01 HP00047-02, K01 HP00080-02, K01 HP00114-02] FX This work was supported by the following Geriatric Academic Career Awards: (1) K01 HP00047-02 (Dr. Meeks) (2) K01 HP00080-02 (Dr. Culberson) (3) K01 HP00114-02 (Dr. Horton). NR 67 TC 6 Z9 7 U1 2 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2011 VL 27 IS 2 BP 171 EP + DI 10.1016/j.cger.2011.01.003 PG 23 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 784PQ UT WOS:000292169600005 PM 21641504 ER PT J AU Andrews, J Cenzer, IS Yelin, E Covinsky, K AF Andrews, James Cenzer, Irena Stijacic Yelin, Ed Covinsky, Kenneth TI PAIN AND DISABILITY IN ELDERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Andrews, James] Univ Calif San Francisco, Burlingame, CA USA. [Cenzer, Irena Stijacic; Covinsky, Kenneth] San Francisco VA Med Ctr, San Francisco, CA USA. [Yelin, Ed] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S51 EP S51 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700088 ER PT J AU Arora, B Arora, B AF Arora, Bhaskar Arora, Bhaskar TI WEB BASED TOOL TO IMPROVE THROMBOEMBOLISM PROPHYLAXIS RATES IN HOSPITALIZED PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Arora, Bhaskar; Arora, Bhaskar] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S568 EP S568 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812703262 ER PT J AU Bachhuber, M Bachhuber, M AF Bachhuber, Melissa Bachhuber, Melissa TI DERMATOMYOSITIS IN A PATIENT WITH METASTATIC CHOLANGIOCARCINOMA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Bachhuber, Melissa; Bachhuber, Melissa] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S522 EP S523 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812703159 ER PT J AU Bean-Mayberry, B Goldzweig, C Washington, DL Yano, E Batuman, F Huang, C Miake-Lye, I Shekelle, P AF Bean-Mayberry, Bevanne Goldzweig, Caroline Washington, Donna L. Yano, Elizabeth Batuman, Fatma Huang, Christine Miake-Lye, Isomi Shekelle, Paul TI UPDATED SYSTEMATIC REVIEW OF THE LITERATURE ON WOMEN VETERAN'S HEALTH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Bean-Mayberry, Bevanne; Goldzweig, Caroline; Washington, Donna L.; Yano, Elizabeth; Batuman, Fatma; Huang, Christine; Miake-Lye, Isomi; Shekelle, Paul] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S296 EP S297 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812702015 ER PT J AU Borrero, S Mor, M Zhao, XH McNeil, M Ibrahim, S Hayes, P AF Borrero, Sonya Mor, Maria Zhao, Xinhua McNeil, Melissa Ibrahim, Said Hayes, Patricia TI CONTRACEPTIVE CARE IN THE VA HEALTHCARE SYSTEM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Borrero, Sonya; McNeil, Melissa] Univ Pittsburgh, Pittsburgh, PA USA. [Mor, Maria; Zhao, Xinhua] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ibrahim, Said] Va Med Ctr, Philadelphia, PA USA. [Hayes, Patricia] Women Vet Hlth Strateg Hlth Care Grp, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S114 EP S114 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700203 ER PT J AU Brooks, R Jasti, H AF Brooks, Robert Jasti, Harish TI TOWARD THE LEARNER-CENTERED PATIENT-CENTERED MEDICAL HOME: DIFFERENCES BETWEEN UNIVERSITY AND VA CLINICS IN FACTORS THAT AFFECT RESIDENT CONTINUITY WITH PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Brooks, Robert] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Jasti, Harish] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S339 EP S339 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812702096 ER PT J AU Burgo-Black, L Hunt, SC Burgo-Black, L Spelman, J AF Burgo-Black, Lucille Hunt, Stephen C. Burgo-Black, Lucille Spelman, Juliette TI POST COMBAT CARE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Burgo-Black, Lucille; Spelman, Juliette] VA Connecticut Healthcare, West Haven, CT USA. [Hunt, Stephen C.] VA Puget Sound, Seattle, WA USA. [Burgo-Black, Lucille] VA Connectict Healthcare Syst, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S509 EP S510 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812703131 ER PT J AU Cohen, B O'Donovan, A Neylan, T Metzler, T Whooley, M AF Cohen, Beth O'Donovan, Aoife Neylan, Thomas Metzler, Thomas Whooley, Mary TI LIFETIME EXPOSURE TO TRAUMATIC PSYCHOLOGICAL STRESS IS ASSOCIATED WITH GREATER INCREASES IN INFLAMMATORY ACTIVITY OVER TIME IN PATIENTS WITH CARDIOVASCULAR DISEASE: PROSPECTIVE FINDINGS FROM THE HEART AND SOUL STUDY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Cohen, Beth; O'Donovan, Aoife; Neylan, Thomas; Whooley, Mary] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Metzler, Thomas] San Francisco VA, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S288 EP S289 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812702003 ER PT J AU Cordasco, KM Ryan, G Dominguez, BX Huynh, A Homeier, DC Derose, KP Sarkisian, CA AF Cordasco, Kristina M. Ryan, Gery Dominguez, Blanca X. Huynh, Alexis Homeier, Diana C. Derose, Kathyrn Pitkin Sarkisian, Catherine A. TI LITERACY-COMPENSATORY STRATEGIES AND RESOURCES OF OLDER LATINOS WITH DIABETES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Cordasco, Kristina M.; Sarkisian, Catherine A.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Cordasco, Kristina M.] RAND Corp, Los Angeles, CA USA. [Cordasco, Kristina M.; Sarkisian, Catherine A.] Univ Calif Los Angeles, Los Angeles, CA USA. [Ryan, Gery; Dominguez, Blanca X.; Huynh, Alexis; Derose, Kathyrn Pitkin] RAND Corp, Santa Monica, CA USA. [Homeier, Diana C.] LAC USC Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S183 EP S183 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701103 ER PT J AU Englander, H Davis, M Kansagara, D AF Englander, Honora Davis, Melinda Kansagara, Devan TI UNDERSTANDING PROVIDER PERSPECTIVES ON CARE TRANSITIONS FROM HOSPITAL TO HOME: FINDINGS FROM A 360 DEGREE QUALITATIVE EVALUATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Englander, Honora; Davis, Melinda] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kansagara, Devan] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S199 EP S199 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701134 ER PT J AU Gellad, WF Mor, MK Zhao, XH Donohue, JM Good, CB Fine, MJ AF Gellad, Walid F. Mor, Maria K. Zhao, Xinhua Donohue, Julie M. Good, Chester B. Fine, Michael J. TI VARIATION IN PRESCRIPTION USE AMONG PATIENTS WITH DIABETES IN THE VA HEALTHCARE SYSTEM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Gellad, Walid F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Mor, Maria K.; Zhao, Xinhua; Good, Chester B.; Fine, Michael J.] VA Pittsburgh, Pittsburgh, PA USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S256 EP S256 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701241 ER PT J AU Gellad, WF Wang, XQ Handler, SM Aspinall, SL Stone, RA Castle, N Semla, TP Good, CB Fine, MJ Dysken, M Hanlon, JT AF Gellad, Walid F. Wang, Xiaoqiang Handler, Steven M. Aspinall, Sherrie L. Stone, Roslyn A. Castle, Nicholas Semla, Todd P. Good, Chester B. Fine, Michael J. Dysken, Maurice Hanlon, Joseph T. TI ANTIPSYCHOTIC PRESCRIBING IN OLDER VETERANS ADMINISTRATION NURSING HOME PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Gellad, Walid F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Wang, Xiaoqiang; Aspinall, Sherrie L.; Stone, Roslyn A.; Good, Chester B.; Fine, Michael J.; Hanlon, Joseph T.] VA Pittsburgh, Pittsburgh, PA USA. [Handler, Steven M.; Castle, Nicholas] Univ Pittsburgh, Pittsburgh, PA USA. [Semla, Todd P.] Dept Vet Affairs, Washington, DC USA. [Dysken, Maurice] VA Minneapolis, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S173 EP S173 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701083 ER PT J AU Gellad, WF Donohue, JM Zhao, XH Banthin, JS AF Gellad, Walid F. Donohue, Julie M. Zhao, Xinhua Banthin, Jessica S. TI TRENDS IN THE FINANCIAL BURDEN OF PRESCRIPTION DRUGS AMONG THE NON-ELDERLY, 1999-2007 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Gellad, Walid F.; Zhao, Xinhua] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Banthin, Jessica S.] AHRQ, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S96 EP S96 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700170 ER PT J AU Gopal, RK Yamashita, TE Prochazka, AV AF Gopal, Ravi K. Yamashita, Traci E. Prochazka, Allan V. TI RESEARCH WITHOUT RESULTS: INADEQUATE PUBLIC REPORTING OF CLINICAL TRIAL RESULTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Gopal, Ravi K.; Prochazka, Allan V.] Denver VAMC, Denver, CO USA. [Yamashita, Traci E.] Univ Colorado, Denver Hlth Sci Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S169 EP S170 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701076 ER PT J AU Gordon, HS Street, R Deswal, A AF Gordon, Howard S. Street, Richard Deswal, Anita TI FACTORS ASSOCIATED WITH ADHERENCE TO PHYSICIANS RECOMMENDATIONS IN A PROSPECTIVE COHORT AFTER HOSPITALIZATION WITH HEART FAILURE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Gordon, Howard S.] VAMC, Chicago, IL USA. [Gordon, Howard S.] Univ Illinois, Chicago, IL USA. [Street, Richard] Texas A&M Univ, College Stn, TX USA. [Deswal, Anita] Houston VAMC, Houston, TX USA. [Deswal, Anita] Baylor Coll Med, Houston, TX 77030 USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S351 EP S351 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812702118 ER PT J AU Hagler, BD Chandan, P Estrada, C Roy, B Huff, NG Castiglioni, A Centor, R AF Hagler, Beau Daniel Chandan, Priya Estrada, Carlos Roy, Brita Huff, Nidhi Gupta Castiglioni, Analia Centor, Robert TI PRIORITIES DURING WARD ATTENDING ROUNDS DIFFER BY TRAINING LEVEL OF TEAM MEMBERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Hagler, Beau Daniel] Univ Alabama Birmingham, SOM, Birmingham, AL USA. [Chandan, Priya; Roy, Brita; Castiglioni, Analia; Centor, Robert] Univ Alabama Birmingham, Birmingham, AL USA. [Estrada, Carlos] Univ Alabama Birmingham, Birmingham VAMC, Birmingham, AL USA. [Huff, Nidhi Gupta] Univ Alabama Birmingham, Fultondale, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S284 EP S284 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701295 ER PT J AU Hausmann, LRM Kwoh, CK Hannon, MJ Ibrahim, SA AF Hausmann, Leslie R. M. Kwoh, C. Kent Hannon, Michael J. Ibrahim, Said A. TI PATIENT RACE, PERCEPTIONS OF RACISM IN HEALTHCARE SETTINGS, AND PHYSICIAN TRUST SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Hausmann, Leslie R. M.; Kwoh, C. Kent; Hannon, Michael J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ibrahim, Said A.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S74 EP S74 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700131 ER PT J AU Huff, NG Roy, B Estrada, C Centor, R Castiglioni, A Willett, L Cohen, S AF Huff, Nidhi Gupta Roy, Brita Estrada, Carlos Centor, Robert Castiglioni, Analia Willett, Lisa Cohen, Stuart TI NOMINAL GROUP TECHNIQUE TO IDENTIFY ATTRIBUTES OF TOP ATTENDING PHYSICIANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Huff, Nidhi Gupta] Univ Alabama Birmingham, Fultondale, AL USA. [Roy, Brita; Castiglioni, Analia; Willett, Lisa; Cohen, Stuart] Univ Alabama Birmingham, Birmingham, AL USA. [Estrada, Carlos; Centor, Robert] Univ Alabama Birmingham, Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S176 EP S176 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701089 ER PT J AU Hunt, SC Burgo-Black, L AF Hunt, Stephen C. Burgo-Black, Lucille TI HEALTH IMPACTS OF WAR: AN EDUCATIONAL CAMPAIGN FOR VA PROVIDERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Hunt, Stephen C.] VA Puget Sound, Seattle, WA USA. [Burgo-Black, Lucille] VA Connecticut Healthcare Syst, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S589 EP S589 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812703303 ER PT J AU Inagami, S Gao, SS Shendge, M Probst, J Karimi, H Stone, R Sevick, MA Fine, M AF Inagami, Sanae Gao, Shasha Shendge, Martine Probst, Janice Karimi, Hassan Stone, Roslyn Sevick, Mary Ann Fine, Michael TI USING THE INDEX OF RELATIVE RURALITY (IRR) TO ESTIMATE DEGREE OF RURALITY AT THE SMALL-AREA LEVEL IN HEALTH SERVICES RESEARCH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Inagami, Sanae; Gao, Shasha; Shendge, Martine; Fine, Michael] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Probst, Janice] Univ S Carolina, Charleston, SC USA. [Karimi, Hassan; Stone, Roslyn] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S155 EP S155 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701048 ER PT J AU Kansagara, D Englander, H Salanitro, A Kagen, D Theobald, C Kripalani, S AF Kansagara, Devan Englander, Honora Salanitro, Amanda Kagen, David Theobald, Cecelia Kripalani, Sunil TI READMISSION RISK MODELING: A SYSTEMATIC REVIEW SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Kansagara, Devan] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Englander, Honora] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Salanitro, Amanda; Theobald, Cecelia; Kripalani, Sunil] Vanderbilt Univ, Nashville, TN 37235 USA. [Kagen, David] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S125 EP S125 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700226 ER PT J AU Kertesz, S Pollio, D Johnson-Roe, K Steward, J Borden, A Kim, T Stringfellow, E Young, JA Holt, C AF Kertesz, Stefan Pollio, David Johnson-Roe, Kay Steward, Jocelyn Borden, Allison Kim, Theresa Stringfellow, Erin Young, John Andrew Holt, Cheryl TI CROSSING QUALITY CHASM: PRIMARY CARE FROM THE PERSPECTIVE OF HOMELESS PATIENTS AND THEIR CAREGIVERS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA. [Pollio, David] Univ Alabama, Tuscaloosa, MD USA. [Johnson-Roe, Kay; Steward, Jocelyn; Borden, Allison; Young, John Andrew] Birmingham VAMC, Birmingham, AL USA. [Kim, Theresa] Boston Med Ctr, Boston, AL USA. [Stringfellow, Erin] Boston Hlth Care Homeless, Boston, AL USA. [Holt, Cheryl] Univ Maryland, Baltimore, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S122 EP S123 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700221 ER PT J AU Kullgren, JT Volpp, KG Polsky, DE AF Kullgren, Jeffrey T. Volpp, Kevin G. Polsky, Daniel E. TI UNDERSTANDING BEHAVIORAL RISK FACTORS IN HIGH-DEDUCTIBLE HEALTH PLANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Kullgren, Jeffrey T.; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kullgren, Jeffrey T.] Univ Penn, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.; Volpp, Kevin G.; Polsky, Daniel E.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Polsky, Daniel E.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Polsky, Daniel E.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S277 EP S277 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701281 ER PT J AU Kullgren, JT McLaughlin, CG Mitra, N Armstrong, K AF Kullgren, Jeffrey T. McLaughlin, Catherine G. Mitra, Nandita Armstrong, Katrina TI NON-AFFORDABILITY BARRIERS AND ACCESS TO CARE FOR US ADULTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Kullgren, Jeffrey T.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kullgren, Jeffrey T.] Univ Penn, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.; Armstrong, Katrina] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [McLaughlin, Catherine G.] Math Policy Res Inc, Ann Arbor, MI USA. [McLaughlin, Catherine G.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA. [Mitra, Nandita] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Armstrong, Katrina] Univ Penn, Abramson Canc Ctr, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S276 EP S277 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701280 ER PT J AU Laponis, R O'Sullivan, P Hollander, H Cornett, P Julian, K AF Laponis, Ryan O'Sullivan, Patricia Hollander, Harry Cornett, Patricia Julian, Katherine TI GENERATING GENERALISTS: FACTORS OF RESIDENT CONTINUITY CLINIC ASSOCIATED WITH PERCEIVED IMPACT ON CHOOSING A GENERALIST CAREER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Laponis, Ryan; O'Sullivan, Patricia; Hollander, Harry; Julian, Katherine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cornett, Patricia] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S281 EP S281 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701290 ER PT J AU Laxmisan, A Sittig, DF Espadas, D Pietz, K Singh, H AF Laxmisan, Archana Sittig, Dean Forrest Espadas, Donna Pietz, Kenneth Singh, Hardeep TI IMPROVING FOLLOW-UP OF ABNORMAL TEST RESULTS: EVALUATING THE IMPACT OF A MANDATORY NOTIFICATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Laxmisan, Archana; Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Sittig, Dean Forrest] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Espadas, Donna; Pietz, Kenneth] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S154 EP S155 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701047 ER PT J AU Liu, CF Manning, WG Burgess, JF Hebert, PL Bryson, CL Fortney, J Perkins, M Sharp, ND Maciejewski, ML AF Liu, Chuan-Fen Manning, Willard G. Burgess, James F. Hebert, Paul L. Bryson, Christopher L. Fortney, John Perkins, Mark Sharp, Nancy D. Maciejewski, Matthew L. TI RELIANCE ON VA OUTPATIENT SERVICES BY MEDICARE-ELIGIBLE VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Liu, Chuan-Fen] Dept Vet Affairs, Seattle, WA USA. [Manning, Willard G.] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Burgess, James F.] VA BostonHealthcare Syst, Boston, MA USA. [Burgess, James F.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Washington, DC USA. [Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bryson, Christopher L.; Perkins, Mark; Sharp, Nancy D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fortney, John] Cent Arkansas Vet Healthcare Syst, North Little Rock, AR USA. [Fortney, John] Univ Arkansas Med Sci, North Little Rock, AR USA. [Maciejewski, Matthew L.] Durham VA Med Ctr, Durham, NC USA. [Maciejewski, Matthew L.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S158 EP S159 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701055 ER PT J AU Long, JA Jahnle, E Richardson, D Volpp, K AF Long, Judith A. Jahnle, Erica Richardson, Diane Volpp, Kevin TI A RANDOMIZED CONTROLLED TRIAL OF PEER MENTORING AND FINANCIAL INCENTIVE TO IMPROVE GLUCOSE CONTROL IN AFRICAN AMERICAN VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Long, Judith A.; Richardson, Diane; Volpp, Kevin] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Jahnle, Erica] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S165 EP S165 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701067 ER PT J AU Mielke, B Perkins, M Wong, E Liu, CF Au, D Bryson, C AF Mielke, Beverly Perkins, Mark Wong, Edwin Liu, Chuan-Fen Au, David Bryson, Christopher TI PHARMACY SUPPORT IN VA PRIMARY CARE CLINICS AND MEDICATION ADHERENCE AMONG PATIENTS WITH DIABETES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Mielke, Beverly] VA Puget Sound Healthcare Syst, UW Med, Seattle, WA USA. [Perkins, Mark; Wong, Edwin; Bryson, Christopher] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Liu, Chuan-Fen] Dept Vet Affairs, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S165 EP S165 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701066 ER PT J AU Moy, N Pierluissi, E AF Moy, Nicholas Pierluissi, Edgar TI TRANSITION OF CARE FROM ACUTE HOSPITALIZATION TO THE PATIENT CENTERED MEDICAL HOME: A ELECTRONIC HANDOFF INTERVENTION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Moy, Nicholas] San Francisco VA Med Ctr, San Francisco, CA USA. [Pierluissi, Edgar] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S559 EP S560 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812703242 ER PT J AU Pevnick, J Asch, S Li, N Bell, DS AF Pevnick, Joshua Asch, Steven Li, Ning Bell, Douglas S. TI ELECTRONIC PRESCRIBING WITH FORMULARY DECISION SUPPORT REDUCES PATIENT COPAY AMOUNTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Pevnick, Joshua] Cedars Sinai Hlth Syst, Los Angeles, CA USA. [Asch, Steven] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Li, Ning] Cedars Sinai Hlth Syst, Biostat Core, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA. [Bell, Douglas S.] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S85 EP S86 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700150 ER PT J AU Preisner, R Jenkins, L Khurana, A AF Preisner, Ruth Jenkins, Leonard Khurana, Ajay TI PROCEDURE CLINIC DOUBLES MEDICAL RESIDENTS' EXPERIENCE DOING KNEE AND SHOULDER INJECTIONS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Preisner, Ruth] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Jenkins, Leonard; Khurana, Ajay] Vet Adm Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S601 EP S601 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812703323 ER PT J AU Roy, B Huff, N Castiglioni, A Willett, L Estrada, C Centor, R AF Roy, Brita Huff, Nidhi Castiglioni, Analia Willett, Lisa Estrada, Carlos Centor, Robert TI FACTORS AFFECTING LEARNERS' DAILY PRIORITIES DURING WARD ATTENDING ROUNDS AND ATTENDING PHYSICIANS' ADAPTABILITY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Roy, Brita; Huff, Nidhi; Castiglioni, Analia; Willett, Lisa; Centor, Robert] Univ Alabama Birmingham, Birmingham, AL USA. [Estrada, Carlos] Univ Alabama Birmingham, Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S170 EP S171 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701078 ER PT J AU Seal, KH Cohen, G Bertenthal, D Cohen, B Maguen, S Daley, A AF Seal, Karen Hope Cohen, Greg Bertenthal, Daniel Cohen, Beth Maguen, Shira Daley, Aaron TI REDUCING BARRIERS TO MENTAL HEALTH AND SOCIAL SERVICES FOR IRAQ AND AFGHANISTAN VETERANS: OUTCOMES OF A NEW INTEGRATED PRIMARY CARE CLINIC SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Seal, Karen Hope; Cohen, Beth] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cohen, Greg; Bertenthal, Daniel; Cohen, Beth; Daley, Aaron] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S210 EP S210 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701154 ER PT J AU Staton, L Panda, M Estrada, C Roddy, D Ortiz, D AF Staton, Lisa Panda, Mukta Estrada, Carlos Roddy, Donna Ortiz, David TI "I HAVE AWEALTH OF RESOURCES IN MY COMMUNITY" : A MULTI-METHOD APPROACH FOR CROSS CULTURAL TRAINING FOR INTERNAL MEDICINE RESIDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Staton, Lisa; Panda, Mukta] Univ Tennessee, Coll Med, Chattanooga, TN USA. [Estrada, Carlos] Univ Alabama Birmingham, Birmingham VAMC, Birmingham, AL USA. [Roddy, Donna] Blue Cross BlueShield Tennessee, Chattanooga, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S617 EP S618 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812703355 ER PT J AU Steinman, M Peterson, C Harlow, J AF Steinman, Michael Peterson, Carolyn Harlow, John TI PATIENT AGE, COMORBID BURDEN, AND THE USEFULNESS OF HEART FAILURE GUIDELINES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Steinman, Michael; Peterson, Carolyn; Harlow, John] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S72 EP S72 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700126 ER PT J AU Stickrath, C Shimek, D Prochazka, A AF Stickrath, Chad Shimek, Danielle Prochazka, Allan TI INTERVENTIONS TO IMPROVE ATTENDING ROUNDS IN MEDICINE: A SYSTEMATIC REVIEW SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Stickrath, Chad; Prochazka, Allan] Denver VA Med Ctr, Denver, CO USA. [Shimek, Danielle] Univ Colorado Denver, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S298 EP S298 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812702019 ER PT J AU Stickrath, C Anderson, M Prochazka, A Griffiths, M Deloughry, M Aagaard, E AF Stickrath, Chad Anderson, Melver Prochazka, Allan Griffiths, Megan Deloughry, Melissa Aagaard, Eva TI ATTENDING ROUNDS: WHAT IS NOT HAPPENING? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Stickrath, Chad; Anderson, Melver; Prochazka, Allan] Denver VA Med Ctr, Denver, CO USA. [Griffiths, Megan] Univ Colorado Denver, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S268 EP S269 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701265 ER PT J AU Sun, VK Cenzer, IS Williams, BA AF Sun, Vivien K. Cenzer, Irena Stijacic Williams, Brie A. TI HOW SAFE IS YOUR NEIGHBORHOOD? PERCEIVED NEIGHBORHOOD SAFETY AND FUNCTIONAL DECLINE IN OLDER ADULTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Sun, Vivien K.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Cenzer, Irena Stijacic; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Cenzer, Irena Stijacic; Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S95 EP S95 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700168 ER PT J AU Tonks, S Makwana, S Salanitro, A Foster, P Safford, M Houston, T Allison, J Curry, W Estrada, C AF Tonks, Stephen Makwana, Sohil Salanitro, Amanda Foster, Pamela Safford, Monika Houston, Thomas Allison, Jeroan Curry, William Estrada, Carlos TI THE RELATIONSHIP BETWEEN RURALITY AND DIABETES CONTROL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Tonks, Stephen; Makwana, Sohil; Safford, Monika; Curry, William] Univ Alabama Birmingham, Birmingham, AL USA. [Salanitro, Amanda] Vanderbilt Univ, Nashville, TN 37235 USA. [Foster, Pamela] Univ Alabama, Tuscaloosa, AL USA. [Houston, Thomas; Allison, Jeroan] Univ Massachusetts, Sch Med, Boston, MA 02125 USA. [Estrada, Carlos] Univ Alabama Birmingham, Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S252 EP S253 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812701233 ER PT J AU Walling, A Lorenz, K Asch, S Wenger, N AF Walling, Anne Lorenz, Karl Asch, Steven Wenger, Neil TI PATIENT AND SERVICE LEVEL ASSOCIATIONS WITH THE QUALITY OF END OF LIFE CARE AT AN ACADEMIC MEDICAL CENTER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Walling, Anne; Wenger, Neil] Univ Calif Los Angeles, Los Angeles, CA USA. [Lorenz, Karl; Asch, Steven] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S81 EP S82 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700142 ER PT J AU Wenger, NS Tarn, M Diamant, A Lorenz, K Citko, J O'Malley, K AF Wenger, Neil S. Tarn, Mimi Diamant, Allison Lorenz, Karl Citko, Judy O'Malley, Kate TI POLST USE IN CALIFORNIA NURSING HOMES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 [Wenger, Neil S.; Diamant, Allison] Univ Calif Los Angeles, GIM & HSR, Los Angeles, CA USA. [Tarn, Mimi] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA. [Lorenz, Karl] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Citko, Judy] Coalit Compassionate Care Calif, Sacramento, CA USA. [O'Malley, Kate] Calif HealthCare Fdn, Oakland, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 SU 1 BP S101 EP S101 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V30JQ UT WOS:000208812700179 ER PT J AU Meyer, JD Stegner, AJ Natelson, BH Cook, DB AF Meyer, Jacob D. Stegner, Aaron J. Natelson, Benjamin H. Cook, Dane B. TI Psychobiological Response To Exercise Differs Between Chronic Fatigue Syndrome (CFS) And CFS With Comorbid Fibromyalgia SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Meyer, Jacob D.; Stegner, Aaron J.] Univ Wisconsin, Madison, WI USA. [Natelson, Benjamin H.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. EM jdmeyer3@wisc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2011 VL 43 IS 5 SU 1 MA 1496 BP 325 EP 326 PG 3 WC Sport Sciences SC Sport Sciences GA V34IG UT WOS:000209079501253 ER PT J AU Figoni, SF Kunkel, CF Phillips, AC Scremin, AME AF Figoni, Stephen F. Kunkel, Charles F. Phillips, Amanda C. Scremin, A. M. Erika TI Cardiovascular Reponses during Treadmill Exercise in Men with Peripheral Arterial Disease and Intermittent Calf Claudication SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Figoni, Stephen F.; Kunkel, Charles F.; Phillips, Amanda C.; Scremin, A. M. Erika] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM sfigoni@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2011 VL 43 IS 5 SU 1 MA 2725 BP 761 EP 762 PG 2 WC Sport Sciences SC Sport Sciences GA V34IG UT WOS:000209079503194 ER PT J AU Jutras-Aswad, D Scimeca, MM AF Jutras-Aswad, Didier Scimeca, Michael M. TI Buprenorphine Plasma Concentration in the Management of Opioid Dependence SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID MAINTENANCE C1 [Jutras-Aswad, Didier] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada. [Jutras-Aswad, Didier; Scimeca, Michael M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Jutras-Aswad, Didier] Univ Montreal, CRCHUM, Ctr Hosp, Montreal, PQ H3C 3J7, Canada. RP Scimeca, MM (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM michael.scimeca@va.gov NR 6 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAY-JUN PY 2011 VL 20 IS 3 BP 304 EP 305 DI 10.1111/j.1521-0391.2011.00133.x PG 2 WC Substance Abuse SC Substance Abuse GA 746NQ UT WOS:000289254400017 PM 21477061 ER PT J AU Pai, S Ledoux, WR AF Pai, Shruti Ledoux, William R. TI The Quasi-Linear Viscoelastic Properties of Diabetic and Non-Diabetic Plantar Soft Tissue SO ANNALS OF BIOMEDICAL ENGINEERING LA English DT Article DE Foot; Subcutaneous; Compressive; Stress relaxation; Quasi-linear; Diabetes; Adipose; Ulcer; Viscoelastic; Heel pad ID MEDIAL COLLATERAL LIGAMENT; AORTIC-VALVE TISSUE; MECHANICAL-PROPERTIES; HEEL-PAD; STRESS-RELAXATION; FAT PAD; FOOT; MELLITUS; BEHAVIOR; SHEAR AB The purpose of this study was to characterize the viscoelastic behavior of diabetic and non-diabetic plantar soft tissue at six ulcer-prone/load-bearing locations beneath the foot to determine any changes that may play a role in diabetic ulcer formation and subsequent amputation in this predisposed population. Four older diabetic and four control fresh frozen cadaveric feet were each dissected to isolate plantar tissue specimens from the hallux, first, third, and fifth metatarsals, lateral midfoot, and calcaneus. Stress relaxation experiments were used to quantify the viscoelastic tissue properties by fitting the data to the quasi-linear viscoelastic (QLV) theory using two methods, a traditional frequency-insensitive approach and an indirect frequency-sensitive approach, and by measuring several additional parameters from the raw data including the rate and amount of overall relaxation. The stress relaxation response of both diabetic and non-diabetic specimens was unexpectedly similar and accordingly few of the QLV parameters for either fit approach and none of raw data parameters differed. Likewise, no differences were found between plantar locations. The accuracy of both fit methods was comparable, however, neither approach predicted the ramp behavior. Further, fit coefficients varied considerably from one method to the other, making it hard to discern meaningful trends. Future testing using alternate loading modes and intact feet may provide more insight into the role that time-dependent properties play in diabetic foot ulceration. C1 [Pai, Shruti; Ledoux, William R.] VA Puget Sound, VA RR&DCtr Excellence Limb Loss Prevent & Prosthe, Seattle, WA 98108 USA. [Pai, Shruti; Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, VA RR&DCtr Excellence Limb Loss Prevent & Prosthe, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU National Institutes of Health [1R01 DK75633-03]; Department of Veterans Affairs, RRD Service [A4843C] FX This study was funded by the National Institutes of Health grant 1R01 DK75633-03 and the Department of Veterans Affairs, RR&D Service grant A4843C. The authors would also like to thank Jane Shofer, M. S., for the statistical analysis, Michael Fassbind, M. S., for equipment design, and Paul Vawter for assisting with data analysis. NR 46 TC 14 Z9 14 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0090-6964 EI 1573-9686 J9 ANN BIOMED ENG JI Ann. Biomed. Eng. PD MAY PY 2011 VL 39 IS 5 BP 1517 EP 1527 DI 10.1007/s10439-011-0263-z PG 11 WC Engineering, Biomedical SC Engineering GA 746JR UT WOS:000289243100012 PM 21327701 ER PT J AU Li, PY Hu, XM Gan, Y Gao, YQ Liang, WM Chen, J AF Li, Peiying Hu, Xiaoming Gan, Yu Gao, Yanqin Liang, Weimin Chen, Jun TI Mechanistic Insight into DNA Damage and Repair in Ischemic Stroke: Exploiting the Base Excision Repair Pathway as a Model of Neuroprotection SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID GLOBAL CEREBRAL-ISCHEMIA; NEURONAL CELL-DEATH; DEPENDENT PROTEIN-KINASE; TRANSIENT FOCAL ISCHEMIA; DOUBLE-STRAND BREAKS; POLYMERASE-BETA; OXIDATIVE STRESS; RAT-BRAIN; POLY(ADP-RIBOSE) POLYMERASE-1; GERBIL HIPPOCAMPUS AB Stroke is a common cause of death and serious long-term adult disability. Oxidative DNA damage is a severe consequence of oxidative stress associated with ischemic stroke. The accumulation of DNA lesions, including oxidative base modifications and strand breaks, triggers cell death in neurons and other vulnerable cell populations in the ischemic brain. DNA repair systems, particularly base excision repair, are endogenous defense mechanisms that combat oxidative DNA damage. The capacity for DNA repair may affect the susceptibility of neurons to ischemic stress and influence the pathological outcome of stroke. This article reviews the accumulated understanding of molecular pathways by which oxidative DNA damage is triggered and repaired in ischemic cells, and the potential impact of these pathways on ischemic neuronal cell death/survival. Genetic or pharmacological strategies that target the signaling molecules in DNA repair responses are promising for potential clinically effective treatment. Further understanding of mechanisms for oxidative DNA damage and its repair processes may lead to new avenues for stroke management. Antioxid. Redox Signal. 14, 1905-1918. C1 [Li, Peiying; Hu, Xiaoming; Gan, Yu; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Li, Peiying; Hu, Xiaoming; Gan, Yu; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Li, Peiying; Gan, Yu; Gao, Yanqin; Liang, Weimin; Chen, Jun] Fudan Univ, Huashan Hosp, Dept Anesthesiol, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Li, Peiying; Gan, Yu; Gao, Yanqin; Liang, Weimin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Hu, Xiaoming; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU National Institutes of Health [NS36736, NS43802, NS45048]; Chinese Natural Science Foundation [30772079, 30870794, 30670642]; Shanghai Science and Technology Bureau [08410703000]; Chinese Ministry of Science and Technology; American Heart Association [10POST4150028] FX Jun Chen is supported by National Institutes of Health Grants NS36736, NS43802, and NS45048. Weimin Liang is supported by the Chinese Natural Science Foundation Grant 30772079. Yanqin Gao is supported by the Chinese Natural Science Foundation Grants 30870794 and 30670642. Jun Chen and Yanqin Gao are also supported by an International Collaboration grant (08410703000) from Shanghai Science and Technology Bureau and Special Research Funds from Chinese Ministry of Science and Technology to State Key laboratories. Xiaoming Hu is supported by a fellowship award (10POST4150028) from the American Heart Association. We thank Carol Culver for editorial assistance. NR 89 TC 14 Z9 15 U1 0 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD MAY PY 2011 VL 14 IS 10 BP 1905 EP 1918 DI 10.1089/ars.2010.3451 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 751NJ UT WOS:000289624500012 PM 20677909 ER PT J AU Lin, J Murrell, DF Marinovic, B Fivenson, D Borradori, L Hashimoto, T Cianchini, G Caux, F Iranzo, P Venugopal, S Martin, L Taylor, L Werth, VP AF Lin, J. Murrell, D. F. Marinovic, B. Fivenson, D. Borradori, L. Hashimoto, T. Cianchini, G. Caux, F. Iranzo, P. Venugopal, S. Martin, L. Taylor, L. Werth, V. P. TI Photovalidation of two outcome measure instruments for pemphigus SO AUSTRALASIAN JOURNAL OF DERMATOLOGY LA English DT Meeting Abstract C1 [Lin, J.] Univ Vermont, Dept Med, Burlington, VT USA. [Murrell, D. F.; Venugopal, S.; Martin, L.] Univ NSW, Dept Dermatol, St George Hosp, Sydney, NSW, Australia. [Marinovic, B.] Univ Zagreb, Ctr Hosp, Univ Dept Dermatol & Venereol, Zagreb 41000, Croatia. [Marinovic, B.] Univ Zagreb, Sch Med, Zagreb 41001, Croatia. [Fivenson, D.] St Joseph Mercy Hosp, Div Dermatol, Dept Internal Med, Ann Arbor, MI 48104 USA. [Borradori, L.] Univ Med Hosp Insel, Dept Dermatol, Bern, Switzerland. [Hashimoto, T.] Kurume Univ, Sch Med, Dept Dermatol, Kurume, Fukuoka 830, Japan. [Cianchini, G.] IRCCS, Dept Dermatol, Ist Dermopat Immacolata, Rome, Italy. [Caux, F.] Hop Avicenne Bobigny, Serv Dermatol, Bobigny, France. [Caux, F.] Hop Avicenne Bobigny, Ctr Reference Dermatoses Bulleuses Toxiques & Aut, Bobigny, France. [Iranzo, P.] Univ Barcelona, Sch Med, Dept Dermatol, Hosp Clin, Barcelona, Spain. [Taylor, L.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RI Cianchini, Giuseppe/I-8877-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-8380 J9 AUSTRALAS J DERMATOL JI Australas. J. Dermatol. PD MAY PY 2011 VL 52 SU 1 BP 34 EP 35 PG 2 WC Dermatology SC Dermatology GA 749MC UT WOS:000289470400099 ER PT J AU Jazwinski, CH Walcheski, CH AF Jazwinski, Christine H. Walcheski, Christina H. TI At the Mall With Children: Group Size and Pedestrian Economy of Movement SO ENVIRONMENT AND BEHAVIOR LA English DT Article DE pedestrian traffic patterns; pedestrian locomotion; groups; walking speed; behavior in shopping malls; movement in public places ID SOCIAL FACILITATION; BEHAVIOR; WALKING; CHOICE; CROWDS AB The study of pedestrian locomotion in public environments includes both velocity and trajectory of movement. Within public settings such as shopping malls, pedestrians display economy of movement by minimizing the distance (trajectory) walked to arrive at a destination (Bitgood & Dukes, 2006). Although groups of pedestrians have been found to walk more slowly than individuals (Finnis & Walton, 2008), there has been little systematic investigation of how the size of a group and the presence of accompanying children independently affect pedestrian trajectory and velocity. Five naturalistic observational studies with 1,050 observations were conducted at an enclosed retail shopping mall. Neither the size of groups nor the number of children had a significant effect on trajectory of movement. However, both group size and number of children independently predicted pedestrian velocity. Results have implications for predictions of pedestrian facility throughput. C1 [Jazwinski, Christine H.] St Cloud State Univ, Dept Psychol, St Cloud, MN 56301 USA. [Walcheski, Christina H.] St Paul Reg Off, US Dept Vet Affairs, St Paul, MN USA. RP Jazwinski, CH (reprint author), St Cloud State Univ, Dept Psychol, St Cloud, MN 56301 USA. EM chjazwinski@stcloudstate.edu NR 29 TC 2 Z9 2 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0013-9165 EI 1552-390X J9 ENVIRON BEHAV JI Environ. Behav. PD MAY PY 2011 VL 43 IS 3 BP 363 EP 386 DI 10.1177/0013916510364461 PG 24 WC Environmental Studies; Psychology, Multidisciplinary SC Environmental Sciences & Ecology; Psychology GA 749KB UT WOS:000289463500004 ER PT J AU Sudore, RL Covinsky, KE AF Sudore, Rebecca L. Covinsky, Kenneth E. TI Respecting Elders by Respecting Their Paid Caregivers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID LIMITED HEALTH LITERACY; SELF-MANAGEMENT; CONTROLLED-TRIAL; PATIENT C1 [Sudore, Rebecca L.; Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA 94122 USA. [Sudore, Rebecca L.; Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Sudore, RL (reprint author), San Francisco VA Med Ctr, 4150 Clement St,181G, San Francisco, CA 94122 USA. EM rebecca.sudore@ucsf.edu FU NIA NIH HHS [K24 AG029812] NR 13 TC 3 Z9 3 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 IS 5 BP 464 EP 465 DI 10.1007/s11606-011-1667-z PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 750QI UT WOS:000289562700004 PM 21424164 ER PT J AU Bhatnagar, D Morris, JL Rodriguez, M Centor, RM Estrada, CA Willett, LL AF Bhatnagar, Deepa Morris, Jason L. Rodriguez, Martin Centor, Robert M. Estrada, Carlos A. Willett, Lisa L. TI A Middle-Age Woman with Sudden Onset Dyspnea SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID STRATEGIES; MEDICINE C1 [Bhatnagar, Deepa; Morris, Jason L.; Centor, Robert M.; Estrada, Carlos A.; Willett, Lisa L.] Univ Alabama, Birmingham, AL 35294 USA. [Bhatnagar, Deepa; Rodriguez, Martin] Univ Alabama, Birmingham, AL USA. [Morris, Jason L.; Centor, Robert M.; Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA. RP Willett, LL (reprint author), Univ Alabama, BDB 341,1530 3rd Ave, Birmingham, AL 35294 USA. EM lwillett@uab.edu NR 6 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2011 VL 26 IS 5 BP 551 EP 554 DI 10.1007/s11606-011-1636-6 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 750QI UT WOS:000289562700020 PM 21301984 ER PT J AU Shang, SB Ordway, D Henao-Tamayo, M Bai, XY Oberley-Deegan, R Shanley, C Orme, IM Case, S Minor, M Ackart, D Hascall-Dove, L Ovrutsky, AR Kandasamy, P Voelker, DR Lambert, C Freed, BM Iseman, MD Basaraba, RJ Chan, ED AF Shang, Shaobin Ordway, Diane Henao-Tamayo, Marcela Bai, Xiyuan Oberley-Deegan, Rebecca Shanley, Crystal Orme, Ian M. Case, Stephanie Minor, Maisha Ackart, David Hascall-Dove, Laurel Ovrutsky, Alida R. Kandasamy, Pitchaimani Voelker, Dennis R. Lambert, Cherie Freed, Brian M. Iseman, Michael D. Basaraba, Randall J. Chan, Edward D. TI Cigarette Smoke Increases Susceptibility to Tuberculosis-Evidence From In Vivo and In Vitro Models SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID NICOTINIC ACETYLCHOLINE-RECEPTORS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; TOBACCO-SMOKE; CYTOKINE PRODUCTION; DENDRITIC CELLS; IMMUNE-RESPONSE; PASSIVE SMOKING; RISK-FACTOR; MICE AB Methods. We exposed C57BL/6 mice to CS for 14 weeks and examined their ability to control an aerosol infection of Mycobacterium tuberculosis Erdman. Results. CS-exposed mice had more M. tuberculosis isolated from the lungs and spleens after 14 and 30 d, compared with control mice. The CS-exposed mice had worse lung lesions and less lung and splenic macrophages and dendritic cells (DCs) producing interleukin12 and tumor necrosis factor alpha (TNF-alpha). There were significantly more interleukin 10-producing macrophages and DCs in the spleens of infected CS-exposed mice than in non-CS-exposed controls. CS-exposed mice also showed a diminished influx of interferon gamma-producing and TNF-alpha-producing CD4(+) and CD8(+) effector and memory T cells into the lungs and spleens. There was a trend toward an increased number of viable intracellular M. tuberculosis in macrophages isolated from humans who smoke compared with nonsmokers. THP-1 human macrophages and primary human alveolar macrophages exposed to CS extract, nicotine, or acrolein showed an increased burden of intracellular M. tuberculosis. Conclusion. CS suppresses the protective immune response to M. tuberculosis in mice, human THP-1 cells, and primary human alveolar macrophages. C1 [Shang, Shaobin; Ordway, Diane; Henao-Tamayo, Marcela; Shanley, Crystal; Orme, Ian M.; Ackart, David; Hascall-Dove, Laurel; Basaraba, Randall J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA. [Bai, Xiyuan; Ovrutsky, Alida R.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Oberley-Deegan, Rebecca; Case, Stephanie; Minor, Maisha; Kandasamy, Pitchaimani; Voelker, Dennis R.; Iseman, Michael D.; Chan, Edward D.] Natl Jewish Hlth, Dept Med, Denver, CO USA. [Oberley-Deegan, Rebecca; Case, Stephanie; Minor, Maisha; Kandasamy, Pitchaimani; Voelker, Dennis R.; Iseman, Michael D.; Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs, Denver, CO USA. [Bai, Xiyuan; Ovrutsky, Alida R.; Iseman, Michael D.; Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Denver, CO USA. [Lambert, Cherie; Freed, Brian M.] Univ Colorado Denver, Div Clin Immunol & Allergy, Denver, CO USA. RP Ordway, D (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA. EM d.ordway-rodriguez@colostate.edu RI Shang, Shaobin/K-5669-2015; Henao-Tamayo, Marcela/D-8189-2017 OI Shang, Shaobin/0000-0003-4407-1911; Henao-Tamayo, Marcela/0000-0002-4249-9650 FU College of Veterinary Medicine and Biomedical Sciences Research Council, Colorado State University [149106] FX This work was supported by the College of Veterinary Medicine and Biomedical Sciences Research Council, Colorado State University (grant number 149106). NR 49 TC 36 Z9 36 U1 1 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2011 VL 203 IS 9 BP 1240 EP 1248 DI 10.1093/infdis/jir009 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 747FQ UT WOS:000289306100007 PM 21357942 ER PT J AU Gould, MK Schultz, EM Wagner, TH Xu, XY Ghaus, SJ Wallace, RB Provenzale, D Au, DH AF Gould, Michael K. Schultz, Ellen M. Wagner, Todd H. Xu, Xiangyan Ghaus, Sharfun J. Wallace, Robert B. Provenzale, Dawn Au, David H. TI Disparities in Lung Cancer Staging with Positron Emission Tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) Study SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Lung neoplasms; Carcinoma; Non-small cell lung; Neoplasm staging; Tomography; Emission-computed; Healthcare disparities ID FORTHCOMING 7TH EDITION; GUIDELINES 2ND EDITION; MEDICARE BENEFICIARIES; RACIAL DISPARITIES; TNM CLASSIFICATION; MALIGNANT-TUMORS; RANDOMIZED-TRIAL; COMORBIDITY; PROPOSALS; GROUPINGS AB Introduction: Disparities in treatment exist for nonwhite and Hispanic patients with non-small cell lung cancer, but little is known about disparities in the use of staging tests or their underlying causes. Methods: Prospective, observational cohort study of 3638 patients with newly diagnosed non-small cell lung cancer from 4 large, geographically defined regions, 5 integrated health care systems, and 13 VA health care facilities. Results: Median age was 69 years, 62% were men, 26% were Hispanic or nonwhite, 68% graduated high school, 50% had private insurance, and 41% received care in the VA or another integrated health care system. After adjustment, positron emission tomography (PET) use was 13% lower among nonwhites and Hispanics than non-Hispanic whites (risk ratio [RR] 0.87, 95% confidence interval [CI] 0.77-0.97), 13% lower among those with Medicare than those with private insurance (RR 0.87, 95% CI 0.76-0.99), and 24% lower among those with an elementary school education than those with a graduate degree (RR 0.76, 95% CI 0.57-0.98). Disparate use of PET was not observed among patients who received care in an integrated health care setting, but the association between race/ethnicity and PET use was similar in magnitude across all other subgroups. Further analysis showed that income, education, insurance, and health care setting do not explain the association between race/ethnicity and PET use. Conclusions: Hispanics and nonwhites with non-small cell lung cancer are less likely to receive PET imaging. This finding is consistent across subgroups and not explained by differences in income, education, or insurance coverage. C1 [Gould, Michael K.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Gould, Michael K.; Wagner, Todd H.; Ghaus, Sharfun J.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Gould, Michael K.; Schultz, Ellen M.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. [Wagner, Todd H.] VA Hlth Econ Res Ctr, Menlo Pk, CA USA. [Xu, Xiangyan] Palo Alto Inst Res & Educ, Palo Alto, CA USA. [Wallace, Robert B.] Univ Iowa, Iowa City, IA USA. [Provenzale, Dawn] Durham VA Med Ctr, Durham Epidemiol Res & Informat Ctr, Durham, NC USA. [Provenzale, Dawn] Duke Univ, Durham, NC USA. [Au, David H.] Univ Washington, Hlth Serv Res & Dev Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Au, David H.] Univ Washington, Dept Med, Seattle, WA USA. RP Gould, MK (reprint author), Univ So Calif, Keck Sch Med, 2020 Zonal Ave,IRD 715, Los Angeles, CA 90033 USA. EM mgould@usc.edu FU NCI NIH HHS [P30 CA014089-34S4, P30 CA014089, U01 CA093324, U01 CA093326, U01 CA093329, U01 CA093332, U01 CA093339, U01 CA093344, U01 CA093344-01, U01 CA093348] NR 31 TC 4 Z9 4 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD MAY PY 2011 VL 6 IS 5 BP 875 EP 883 DI 10.1097/JTO.0b013e31821671b6 PG 9 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 750NF UT WOS:000289554100006 PM 21572580 ER PT J AU Barnes, JL Gorin, Y AF Barnes, Jeffrey L. Gorin, Yves TI Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases SO KIDNEY INTERNATIONAL LA English DT Review DE extracellular matrix; fibrosis; Nox4; reactive oxygen species; smooth muscle actin ID SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; MESSENGER-RNA TRANSLATION; OXYGEN SPECIES PRODUCTION; RAT MESANGIAL CELLS; RENAL TUBULOINTERSTITIAL FIBROSIS; FIBRONECTIN ISOFORM DISTRIBUTION; UNILATERAL URETERAL OBSTRUCTION; FIBROBLAST-SPECIFIC PROTEIN-1 AB Progression of fibrosis involves interstitial hypercellularity, matrix accumulation, and atrophy of epithelial structures, resulting in loss of normal function and ultimately organ failure. There is common agreement that the fibroblast/myofibroblast is the cell type most responsible for interstitial matrix accumulation and consequent structural deformations associated with fibrosis. During wound healing and progressive fibrotic events, fibroblasts transform into myofibroblasts acquiring smooth muscle features, most notably the expression of alpha-smooth muscle actin and synthesis of mesenchymal cell-related matrix proteins. In renal disease, glomerular mesangial cells also acquire a myofibroblast phenotype and synthesize the same matrix proteins. The origin of interstitial myofibroblasts during fibrosis is a matter of debate, where the cells are proposed to derive from resident fibroblasts, pericytes, perivascular adventitial, epithelial, and/or endothelial sources. Regardless of the origin of the cells, transforming growth factor-beta1 (TGF-beta 1) is the principal growth factor responsible for myofibroblast differentiation to a profibrotic phenotype and exerts its effects via Smad signaling pathways involving mitogen-activated protein kinase and Akt/protein kinase B. Additionally, reactive oxygen species (ROS) have important roles in progression of fibrosis. ROS are derived from a variety of enzyme sources, of which the nicotinamide adenine dinucleotide phosphate (NAD(P) H) oxidase family has been identified as a major source of superoxide and hydrogen peroxide generation in the cardiovasculature and kidney during health and disease. Recent evidence indicates that the NAD(P) H oxidase homolog Nox4 is most accountable for ROS-induced fibroblast and mesangial cell activation, where it has an essential role in TGF-beta 1 signaling of fibroblast activation and differentiation into a profibrotic myofibroblast phenotype and matrix production. Information on the role of ROS in mesangial cell and fibroblast signaling is incomplete, and further research on myofibroblast differentiation during fibrosis is warranted. Kidney International (2011) 79, 944-956; doi:10.1038/ki.2010.516; published online 9 February 2011 C1 [Barnes, Jeffrey L.; Gorin, Yves] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, San Antonio, TX 78229 USA. [Barnes, Jeffrey L.] S Texas Vet Hlth Care Syst, Med Res Serv, Audie Murphy Mem Vet Adm Hosp, San Antonio, TX USA. RP Barnes, JL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM barnesj@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU NIDDK NIH HHS [R01 DK079996, R01 DK080106] NR 221 TC 156 Z9 166 U1 2 U2 30 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAY PY 2011 VL 79 IS 9 BP 944 EP 956 DI 10.1038/ki.2010.516 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA 750AD UT WOS:000289514400004 PM 21307839 ER PT J AU Mcloughlin, MJ Colbert, LH Stegner, AJ Cook, DB AF Mcloughlin, Michael J. Colbert, Lisa H. Stegner, Aaron J. Cook, Dane B. TI Are Women with Fibromyalgia Less Physically Active than Healthy Women? SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE EXERCISE; CHRONIC PAIN; MUSCLE; ACTIGRAPHY; ACCELEROMETER; SELF-REPORT ID CHRONIC-FATIGUE-SYNDROME; ACTIVITY QUESTIONNAIRE; EXERCISE; ACCELEROMETER; PAIN; RELIABILITY; CALIBRATION; DEPRESSION; PREVALENCE; VALIDATION AB MCLOUGHLIN, M. J., L. H. COLBERT, A. J. STEGNER, and D. B. COOK. Are Women with Fibromyalgia Less Physically Active than Healthy Women? Med. Sci. Sports Exerc., Vol. 43, No. 5, pp. 905-912, 2011. Purpose: The primary purpose was to quantify and compare physical activity in fibromyalgia (FM) patients to age-matched healthy controls using both objective and self-report measures. Secondary purposes were to compare self-reported and objective measurement of physical activity and to evaluate the relationship between physical activity and pain and mood. Method: Patients with FM (n = 39) and healthy controls (n = 40) completed the International Physical Activity Questionnaire and wore an accelerometer at the hip for 7 d. Pain and mood were measured using the McGill Pain Questionnaire, Pain Catastrophizing Scale, Beck Depression Inventory, State-Trait Anxiety Inventory, Profile of Mood States, and Fibromyalgia Impact Questionnaire. Results: FM patients had significantly lower physical activity than controls measured by both the International Physical Activity Questionnaire and accelerometer (P < 0.05). Both groups self-reported significantly greater moderate and vigorous physical activities than were measured by the accelerometer (P < 0.05). Self-reported and objective measures of time spent in different intensities of activity showed significant correlations in healthy controls (r = 0.41-0.51, rho = 0.41, P < 0.05). No significant correlations between measures were found in FM patients (P > 0.05). Finally, physical activity levels were negatively related (r = -0.37, P < 0.05) to depressed mood for FM patients and positively related (r = -0.41, P < 0.05) to self-reported vigor for healthy controls. Conclusions: This controlled study objectively demonstrates that FM patients are less physically active than healthy controls, thus extending on two earlier investigations that did not show differences in total physical activity levels using wrist-mounted actigraphy methods. Physical activity levels were not predictive of pain in FM but were significantly related to depressed mood. FM patients may also have a greater variability in their manner of self-report than healthy controls. Therefore, physical activity measurement in FM patients should not be limited solely to self-report measures. C1 [Cook, Dane B.] Univ Wisconsin, Unit Gymnasium Natatorium 2, Dept Kinesiol, Madison, WI 53706 USA. [Mcloughlin, Michael J.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Cook, DB (reprint author), Univ Wisconsin, Unit Gymnasium Natatorium 2, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA. EM dcook@education.wisc.edu FU National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Disorders) [ROI 5R01AR050969] FX This research was supported by National Institutes of Health grant ROI 5R01AR050969 (the National Institute of Arthritis and Musculoskeletal and Skin Disorders). NR 35 TC 56 Z9 57 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2011 VL 43 IS 5 BP 905 EP 912 DI 10.1249/MSS.0b013e3181fca1ea PG 8 WC Sport Sciences SC Sport Sciences GA 750OF UT WOS:000289557100023 PM 20881881 ER PT J AU Schacht, JP Anton, RF Randall, PK Li, XB Henderson, S Myrick, H AF Schacht, Joseph P. Anton, Raymond F. Randall, Patrick K. Li, Xingbao Henderson, Scott Myrick, Hugh TI Stability of fMRI striatal response to alcohol cues: A hierarchical linear modeling approach SO NEUROIMAGE LA English DT Article DE Alcohol; fMRI; Cue reactivity; Ventral striatum; Dorsal striatum; HLM ID TEST-RETEST RELIABILITY; INDUCED BRAIN ACTIVATION; ABSTINENT ALCOHOLICS; VENTRAL STRIATUM; DORSAL STRIATUM; NUCLEUS-ACCUMBENS; FUNCTIONAL MRI; PREFRONTAL CORTEX; BOLD RESPONSE; DOPAMINE AB In functional magnetic resonance imaging (fMRI) studies of alcohol-dependent individuals, alcohol cues elicit activation of the ventral and dorsal aspects of the striatum (VS and DS), which are believed to underlie aspects of reward learning critical to the initiation and maintenance of alcohol dependence. Cue-elicited striatal activation may represent a biological substrate through which treatment efficacy may be measured. However, to be useful for this purpose, VS or DS activation must first demonstrate stability across time. Using hierarchical linear modeling (HLM), this study tested the stability of cue-elicited activation in anatomically and functionally defined regions of interest in bilateral VS and DS. Nine non-treatment-seeking alcohol-dependent participants twice completed an alcohol cue reactivity task during two fMRI scans separated by 14 clays. HLM analyses demonstrated that, across all participants, alcohol cues elicited significant activation in each of the regions of interest. At the group level, these activations attenuated slightly between scans, but session-wise differences were not significant. Within-participants stability was best in the anatomically defined right VS and DS and in a functionally defined region that encompassed right caudate and putamen (intraclass correlation coefficients of .75, .81, and .76, respectively). Thus, within this small sample, alcohol cue-elicited fMRI activation had good reliability in the right striatum, though a larger sample is necessary to ensure generalizability and further evaluate stability. This study also demonstrates the utility of FILM analytic techniques for serial fMRI studies, in which separating within-participants variance (individual changes in activation) from between-participants factors (time or treatment) is critical. (C) 2011 Elsevier Inc. All rights reserved. C1 [Schacht, Joseph P.; Anton, Raymond F.; Randall, Patrick K.; Li, Xingbao; Henderson, Scott; Myrick, Hugh] Med Univ S Carolina, Charleston Alcohol Res Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Li, Xingbao] Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [Myrick, Hugh] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Schacht, JP (reprint author), Med Univ S Carolina, Charleston Alcohol Res Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. EM schacht@musc.edu FU Oldham Research Fund; NIAAA [T32 AA007474, K05 AA017435]; Charleston Alcohol Research Center [NIAAA P50 AA10761] FX This work was funded by the Oldham Research Fund (Myrick). Dr. Schacht was supported by NIAAA T32 AA007474, Dr. Anton by NIAAA K05 AA017435, and Dr. Myrick by the Charleston Alcohol Research Center (NIAAA P50 AA10761). These funding sources had no role in the study design, collection, analysis and interpretation of data, writing of the paper, or decision to submit the paper for publication. Portions of this work were presented as an oral presentation and poster at the Research Society or Alcoholism annual meeting (June 2010). NR 65 TC 21 Z9 23 U1 5 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD MAY 1 PY 2011 VL 56 IS 1 BP 61 EP 68 DI 10.1016/j.neuroimage.2011.02.004 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 749HK UT WOS:000289454900008 PM 21316465 ER PT J AU Kilpatrick, LA Suyenobu, BY Smith, SR Bueller, JA Goodman, T Creswell, JD Tillisch, K Mayer, EA Naliboff, BD AF Kilpatrick, Lisa A. Suyenobu, Brandall Y. Smith, Suzanne R. Bueller, Joshua A. Goodman, Trudy Creswell, J. David Tillisch, Kirsten Mayer, Emeran A. Naliboff, Bruce D. TI Impact of mindfulness-based stress reduction training on intrinsic brain connectivity SO NEUROIMAGE LA English DT Article DE Mindfulness; Meditation; Functional connectivity; Resting state fMRI; Auditory; Attention ID STATE FUNCTIONAL CONNECTIVITY; HUMAN VISUAL-CORTEX; PREFRONTAL CORTEX; FMRI; MEDITATION; FLUCTUATIONS; ATTENTION; NETWORKS; SELF; ORGANIZATION AB The beneficial effects of mindful awareness and mindfulness meditation training on physical and psychological health are thought to be mediated in part through changes in underlying brain processes. Functional connectivity MRI (fcMRI) allows identification of functional networks in the brain. It has been used to examine state-dependent activity and is well suited for studying states such as meditation. We applied fcMRI to determine if Mindfulness-Based Stress Reduction (MBSR) training is effective in altering intrinsic connectivity networks (ICNs). Healthy women were randomly assigned to participate in an 8-week Mindfulness-Based Stress Reduction (MBSR) training course or an 8-week waiting period. After 8 weeks, fMRI data (1.5 T) was acquired while subjects rested with eyes closed, with the instruction to pay attention to the sounds of the scanner environment. Group independent component analysis was performed to investigate training-related changes in functional connectivity. Significant MBSR-related differences in functional connectivity were found mainly in auditory/salience and medial visual networks. Relative to findings in the control group, MBSR subjects showed (1) increased functional connectivity within auditory and visual networks, (2) increased functional connectivity between auditory cortex and areas associated with attentional and self-referential processes, (3) stronger anticorrelation between auditory and visual cortex, and (4) stronger anticorrelation between visual cortex and areas associated with attentional and self-referential processes. These findings suggest that 8 weeks of mindfulness meditation training alters intrinsic functional connectivity in ways that may reflect a more consistent attentional focus, enhanced sensory processing, and reflective awareness of sensory experience. (C) 2011 Elsevier Inc. All rights reserved. C1 [Kilpatrick, Lisa A.; Suyenobu, Brandall Y.; Smith, Suzanne R.; Bueller, Joshua A.; Tillisch, Kirsten; Mayer, Emeran A.; Naliboff, Bruce D.] Univ Calif Los Angeles, Ctr Neurobiol Stress, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naliboff, Bruce D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kilpatrick, Lisa A.; Suyenobu, Brandall Y.; Smith, Suzanne R.; Bueller, Joshua A.; Tillisch, Kirsten; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Naliboff, Bruce D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Creswell, J. David] Carnegie Mellon Univ, LA, Los Angeles, CA USA. [Goodman, Trudy] LA, Insight, Los Angeles, CA USA. RP Kilpatrick, LA (reprint author), Univ Calif Los Angeles, Ctr Neurobiol Stress, David Geffen Sch Med, Peter V Ueberroth Bldg,Room 2338C1,10945 Le Conte, Los Angeles, CA 90095 USA. EM lakilpatrick@mednet.ucla.edu RI Kilpatrick, Lisa/E-6995-2015 FU G. Oppenheimer Family Foundation; National Institutes of Health [AT 00268, DK64531]; UCLA Ahmanson-Lovelace Brain Mapping Center FX This study is supported by funds from G. Oppenheimer Family Foundation, National Institutes of Health grants AT 00268 and DK64531, and the UCLA Ahmanson-Lovelace Brain Mapping Center. NR 63 TC 87 Z9 89 U1 6 U2 59 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD MAY 1 PY 2011 VL 56 IS 1 BP 290 EP 298 DI 10.1016/j.neuroimage.2011.02.034 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 749HK UT WOS:000289454900029 PM 21334442 ER PT J AU Barry, DT Goulet, JL Kerns, RK Becker, WC Gordon, AJ Justice, AC Fiellin, DA AF Barry, Declan T. Goulet, Joseph L. Kerns, Robert K. Becker, William C. Gordon, Adam J. Justice, Amy C. Fiellin, David A. TI Nonmedical use of prescription opioids and pain in veterans with and without HIV SO PAIN LA English DT Article DE Opioids; Pain; HIV; Veterans ID UNITED-STATES; USE DISORDERS; ABUSE; DEPENDENCE; ALCOHOL AB Few studies have systematically evaluated nonmedical use of prescription opioids (NMU) among U. S. military veterans, those who report pain, and those with human immunodeficiency virus (HIV). An increased understanding of the factors associated with NMU may help providers to balance maintaining patient access to prescription opioids for legitimate medical reasons and reducing the risks of addiction. We analyzed self-report data and electronic medical and pharmacy record data from 4122 participants in the Veterans Aging Cohort Study. Bivariate associations were analyzed using chi-squared tests, t tests, and median tests, and multivariable associations were assessed using logistic regression. Median participant age was 52 years; 95% were men; 65% were black, and 53% were HIV infected. NMU was reported by 13% of participants. In multivariable analysis, NMU was associated with: being Hispanic (adjusted odds ratio [AOR] 1.8); aged 40-44 years (AOR 1.6); Alcohol Use Disorders Identification Test score >= 20 (AOR 2.0); drug use disorder (AOR 1.9); opioid use disorder (AOR 2.7); past month cigarette use (AOR 1.3); receiving a past-year Veterans Health Administration opioid prescription (AOR 1.9); hepatitis C (AOR 1.5); and pain interference (AOR 1.1). Being overweight (AOR 0.6) or obese (AOR 0.5) and having a higher 12-Item Short-Form Health Survey (SF-12) Mental Component Summary (AOR 0.98) were associated with less NMU. Patients with and without NMU did not differ on HIV status or SF-12 Physical Component Summary. Veterans in care have a high prevalence of NMU that is associated with substance use, medical status, and pain interference, but not HIV status. (C) 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Barry, Declan T.] Yale Univ, Sch Med, CMHC SAC, New Haven, CT 06519 USA. [Barry, Declan T.] APT Fdn Pain Treatment Serv, New Haven, CT USA. [Goulet, Joseph L.; Kerns, Robert K.; Justice, Amy C.] VA Connecticut Healthcare Syst, New Haven, CT USA. [Goulet, Joseph L.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06519 USA. [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. RP Barry, DT (reprint author), Yale Univ, Sch Med, CMHC SAC, 34 Pk St,Room 220, New Haven, CT 06519 USA. EM declan.barry@yale.edu RI barry, declan/G-4462-2011 OI Becker, William/0000-0002-0788-1467; Goulet, Joseph/0000-0002-0842-804X; Fiellin, David/0000-0002-4006-010X FU National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]; VHA Public Health Strategic Health Core Group; National Institute on Alcohol and Alcohol Abuse [U01 AA 13566]; Department of Veterans Affairs, Veterans Health Administration, Office of Health Services Research and Development [REA 08-266]; National Institute on Mental Health (NIMH) [P30MH062294]; National Institute on Drug Abuse (NIDA) [R01 DA019511-03, R01 DA025991, R01 DA020576-01A1, K23 DA024050-02] FX The Veterans Aging Cohort Study is funded by the National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566) and the VHA Public Health Strategic Health Core Group. The material presented in this study is based upon work supported in part by funding from the National Institute on Alcohol and Alcohol Abuse (U01 AA 13566); the Department of Veterans Affairs, Veterans Health Administration, Office of Health Services Research and Development (REA 08-266); the National Institute on Mental Health (NIMH P30MH062294); and the National Institute on Drug Abuse (NIDA R01 DA019511-03, R01 DA025991, R01 DA020576-01A1, K23 DA024050-02). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of any of the funding agencies, including the Department of Veterans Affairs, or the United States Government. The funding agencies had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 24 TC 20 Z9 20 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD MAY PY 2011 VL 152 IS 5 BP 1133 EP 1138 DI 10.1016/j.pain.2011.01.038 PG 6 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 749YI UT WOS:000289507500027 PM 21354703 ER PT J AU Leung, FW AF Leung, Felix W. TI A hypothesis-generating review of the water method for difficult colonoscopy SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Review DE Difficult colonoscopy; water method ID RANDOMIZED CONTROLLED-TRIAL; UNSEDATED COLONOSCOPY; INCOMPLETE COLONOSCOPY; TECHNICAL PERFORMANCE; CO2 INSUFFLATION; US VETERANS; SEDATION; COMPLICATION; SATISFACTION; DISCOMFORT AB Objective. Several factors such as significant procedure-related discomfort, excessive intubation time or failed cecal intubation have been associated with difficult colonoscopy. An update of these factors and colonoscopy techniques reported to be efficacious in enhancing completion of cecal intubation in difficult colonoscopy patients is provided in this review. Material and methods. A Medline search (January 2006 to July 2010) was conducted using the following search terms: colonoscopy, difficult, abdominal pain, and discomfort. Results. Reviewed data are tabulated for presentation. Several water-related techniques have been described separately as adjuncts to usual air insufflation to minimize discomfort, reduce intubation time and improve success rate of cecal intubation. A combination of these techniques was subjected to trial-and-error modifications followed by randomized controlled comparisons. Progressive improvement in colonoscopy outcomes that paralleled stepwise incorporation of exclusion of air insufflation, removal of residual colonic air by suction and removal of residual feces by water exchange during the insertion phase has been described. Conclusions. The water method is potentially important for improving results of colonoscopy (cecal intubation) especially in unsedated patients. The unsedated option may lower costs. The success of the water method in difficult cases should be evaluated in randomized controlled trials. The call should be considered and explored by endoscopists interested in improving the quality of colonoscopy. A multicenter study to optimize the number of cases will be most desirable. In pragmatic terms, the use of the water method in difficult (unsedated) colonoscopy in the United States did receive recent editorial endorsement. C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, N Hill, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, 111G,16111 Plummer St, North Hills, CA 91343 USA. EM felix.leung@va.gov FU Veterans Affairs Medical Research Funds; American College of Gastroenterology FX The study is supported in part by Veterans Affairs Medical Research Funds at Veterans Affairs Greater Los Angeles Healthcare System and an American College of Gastroenterology Clinical Research Award (FWL). NR 41 TC 9 Z9 11 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PD MAY PY 2011 VL 46 IS 5 BP 517 EP 521 DI 10.3109/00365521.2011.551885 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 749BN UT WOS:000289437200002 PM 21288188 ER PT J AU Nordenstedt, H El-Serag, H AF Nordenstedt, Helena El-Serag, Hashem TI The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992--2006) SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Age; esophageal cancer; male predominance; SEER; sex ratio ID GASTROESOPHAGEAL-REFLUX SYMPTOMS; ABDOMINAL OBESITY; HISTOLOGIC TYPES; GASTRIC CARDIA; HORMONES; WOMEN; RISK; ADENOCARCINOMA; COHORT; MEN AB Background. There is a striking male predominance in esophageal cancer patients. Sex hormones have been suggested as a contributing factor and these are influenced by age and race. In this study, we examined the male-to-female incidence rate ratios of esophageal cancer in the United States. Methods. We used data from 13 registries in the Surveillance, Epidemiology, and End Results (SEER) database to calculate male-to-female incidence rate ratios of esophageal adenocarcinoma (EA) and esophageal squamous cell carcinoma (ESCC) diagnosed during 1992--2006 in different age and race groups. Results. For EA, all races had similar sex and age-specific incidence patterns showing a peak in the male-to-female incidence rate ratio in the age group 50--59, and an age-related decline thereafter. The highest male-to-female ratio was seen in Hispanics (20.5) and the lowest in Blacks (7.0) compared with 10.8 in Whites. By contrast, the male-to-female incidence rate ratios were low and fairly stable throughout the different age groups in ESCC. Conclusion. The male-to-female incidence rate ratios in esophageal cancer vary considerably according to histology, age, and race. The highest sex ratios were seen in EA in the age group 50--59, rendering plausibility to the hypothesis that female sex hormone exposure may play a protective role in the development of this cancer. C1 [Nordenstedt, Helena] Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden. [Nordenstedt, Helena; El-Serag, Hashem] Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Nordenstedt, Helena; El-Serag, Hashem] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. RP Nordenstedt, H (reprint author), Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden. EM helena.nordenstedt@ki.se FU Public Health Service [DK078154-03, DK56338]; Houston VA HSR&D Center of Excellence [HFP90-020] FX This work was in part supported by Public Health Service Grant DK078154-03 to Dr. El-Serag, by Public Health Service Grant DK56338, which funds the Texas Medical Center Digestive Diseases Center, and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). NR 28 TC 21 Z9 22 U1 1 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PD MAY PY 2011 VL 46 IS 5 BP 597 EP 602 DI 10.3109/00365521.2011.551890 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 749BN UT WOS:000289437200012 PM 21271900 ER PT J AU Emmons, RR Garber, CE Cirnigliaro, CM Kirshblum, SC Spungen, AM Bauman, WA AF Emmons, Racine R. Garber, Carol Ewing Cirnigliaro, Christopher M. Kirshblum, Steven C. Spungen, Ann M. Bauman, William A. TI ASSESSMENT OF MEASURES FOR ABDOMINAL ADIPOSITY IN PERSONS WITH SPINAL CORD INJURY SO ULTRASOUND IN MEDICINE AND BIOLOGY LA English DT Article DE Spinal cord injury; Abdominal adiposity; Abdominal ultrasonography ID X-RAY ABSORPTIOMETRY; BODY-MASS INDEX; CORONARY-HEART-DISEASE; VISCERAL FAT; METABOLIC SYNDROME; WAIST CIRCUMFERENCE; COMPUTED-TOMOGRAPHY; SERUM-LIPIDS; RISK-FACTORS; ULTRASONOGRAPHY AB Ultrasound may be a useful tool to assess abdominal adiposity, but it has not been validated in the spinal cord injury (SCI) population. This study evaluated associations between abdominal ultrasound and other methods to assess adiposity in 24 men with SCI and 20 able-bodied (AB) men. Waist (WC) and hip circumference (HC) and waist-to-hip ratio (WHR) were measured. Trunk (TRK%), android (A%) and waist fat (W%) were determined by dual energy x-ray absorptiometry (DXA); ultrasonography determined abdominal subcutaneous (SF) and visceral fat (VF). The SCI group had greater TRK% (40.0 +/- 9.6 vs. 32.0 +/- 10.3), W%(47.0 +/- 9.7 vs. 40.6 +/- 9.4), A% (43.0 +/- 9.8 vs. 35.8 +/- 10.6) and WHR(0.99 +/- 0.1 vs. 0.92 +/- 0.06) than the AB group. WC and WHR correlated with VF in the SCI group. These associations suggest that ultrasound may be a useful tool in clinical practice for the measurement of VF in weight loss programs and for the assessment of cardiometabolic disorders. (E-mail: racine.emmons@va.gov) Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology. C1 [Emmons, Racine R.; Cirnigliaro, Christopher M.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Emmons, Racine R.; Garber, Carol Ewing] Columbia Univ, Teachers Coll, New York, NY 10027 USA. [Kirshblum, Steven C.] Univ Med Sch New Jersey, Dept Phys Med & Rehabil, Newark, NJ USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Emmons, RR (reprint author), James J Peters VA Med Ctr, VA Ctr Excellence Med Consequences SCI, Room 7A-13,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM racine.emmons@va.gov OI Garber, Carol/0000-0002-1268-576X FU Department of Veterans Affairs Rehabilitation Research & Development Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162C] FX This work was supported by the Department of Veterans Affairs Rehabilitation Research & Development Center of Excellence for the Medical Consequences of Spinal Cord Injury (#B4162C). NR 29 TC 11 Z9 12 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-5629 EI 1879-291X J9 ULTRASOUND MED BIOL JI Ultrasound Med. Biol. PD MAY PY 2011 VL 37 IS 5 BP 734 EP 741 DI 10.1016/j.ultrasmedbio.2011.02.002 PG 8 WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging GA 750PY UT WOS:000289561700009 PM 21439716 ER PT J AU Factor, SA Steenland, NK Higgins, DS Molho, ES Kay, DM Montimurro, J Rosen, AR Zabetian, CP Payami, H AF Factor, Stewart A. Steenland, N. Kyle Higgins, Donald S. Molho, Eric S. Kay, Denise M. Montimurro, Jennifer Rosen, Ami R. Zabetian, Cyrus P. Payami, Haydeh TI Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID QUALITY-OF-LIFE; ALPHA-SYNUCLEIN; DATATOP COHORT; DEMENTIA; FALLS; GAIT; RISK; ASSOCIATION; AGE; FREQUENCY AB Objective To test the hypothesis that postural instability with falling (PIF) and freezing of gait (FOG) are distinct subtypes of the postural instability/gait disturbance (PIGD) form of Parkinson's disease (PD). Methods 499 PD subjects from the NeuroGenetics Research Consortium were studied using logistic regression to examine, in a cross sectional analysis, predictors of FOG and PIF. Potential predictors were from four spheres; demographic, clinical motor, clinical non-motor and genetic. Results FOG and PIF were both associated with greater gait subscores and lower tremor subscores on the Unified Parkinson's Disease Rating Scale (p <= 0.02). However, they differed with regard to demographic, non-motor and genetic predictors. FOG was associated with greater duration of disease, with ORs of 3.01 (95% CI 1.35 to 6.72) and 4.91 (95% CI 2.29 to 10.54) for third and fourth quartiles of duration, respectively, versus the lowest half of duration. The risk of having psychotic symptoms was also significantly increased (OR 3.02, 95% CI 1.41 to 6.49; p=0.004). FOG was inversely associated with the presence of the CYP2D6*4 allele (OR 0.41, 95% CI 0.21 to 0.80; p=0.009) suggesting a protective effect. PIF was associated with depression (OR 1.08, 95% CI 1.01 to 1.15; p<0.02) and was inversely associated with APOE 34 (OR 0.21, 95% CI 0.05 to 0.87; p=0.03), again suggesting a protective effect. Conclusion FOG and PIF have different demographic, non-motor and genetic predictors suggesting that they may be pathophysiologically distinct subtypes of PIGD. These findings have implications in the discovery of therapeutic targets for these disabling features as well as for predicting outcomes of PD. C1 [Factor, Stewart A.] Emory Univ, Dept Neurol, Sch Med, Atlanta, GA 30329 USA. [Higgins, Donald S.; Molho, Eric S.] Albany Med Ctr, New York, NY USA. [Kay, Denise M.; Montimurro, Jennifer; Payami, Haydeh] New York State Dept Hlth, New York, NY USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Washington, DC USA. [Zabetian, Cyrus P.] Univ Washington, Washington, DC USA. RP Factor, SA (reprint author), Emory Univ, Dept Neurol, Sch Med, 1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM sfactor@emory.edu OI Kay, Denise/0000-0002-9928-2698; Zabetian, Cyrus/0000-0002-7739-4306 FU Michael J Fox Foundation; Close to a Cure Foundation; NIH, Washington, DC USA [R01-NS36960]; Department of Veterans Affairs; New York State Department of Health Wadsworth Center, Albany, NY, USA; Sartain Lanier Family Foundation, Atlanta, GA, USA; TEVA Neurosciences; Ipsen; Schering Plough; TEVA-speakers bureau; Allergan; Merz; Boehringer-Ingelheim-speakers bureau FX Michael J Fox Foundation: Edmond J Safra Global Genetics Consortia Grant, New York, NY USA. Close to a Cure Foundation: A Fund for Parkinson's Research of Foundation for the Carolinas, North Carolina USA. NIH: R01-NS36960, Washington, DC USA. Department of Veterans Affairs Merit Review Award. New York State Department of Health Wadsworth Center, Albany, NY, USA. The Sartain Lanier Family Foundation, Atlanta, GA, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. The funding agencies had no role in design of this study. The authors had full access to all of the data in the study and SAF takes responsibility for the integrity of the data and accuracy of the data analysis; SAF has research grants from TEVA Neurosciences, Ipsen and Schering Plough. He is also a consultant for Boehringer-Ingelheim, Allergan, UCB and Lundbeck. ESM has the following disclosures: TEVA-speakers bureau, research grant support; Allergan-research grant support, speakers bureau, consulting fee; Merz-research grant, consulting fee; Ipsen-research grant, consulting fee; Boehringer-Ingelheim-speakers bureau. NR 40 TC 38 Z9 40 U1 0 U2 8 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD MAY PY 2011 VL 82 IS 5 BP 564 EP 568 DI 10.1136/jnnp.2010.222042 PG 5 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 746HL UT WOS:000289234500021 PM 20884673 ER PT J AU Groessl, EJ Weingart, KR Stepnowsky, CJ Gifford, AL Asch, SM Ho, SB AF Groessl, E. J. Weingart, K. R. Stepnowsky, C. J. Gifford, A. L. Asch, S. M. Ho, S. B. TI The hepatitis C self-management programme: a randomized controlled trial SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE behavioural interventions; health-related quality of life; hepatitis C; self-management; US veterans ID QUALITY-OF-LIFE; DISORDERS IDENTIFICATION TEST; WELL-BEING SCALE; VIRUS-INFECTION; CHRONIC DISEASE; PLUS RIBAVIRIN; PRIMARY-CARE; ANTIVIRAL THERAPY; WEIGHT-REDUCTION; UNITED-STATES AB Chronic hepatitis C (HCV) infection afflicts millions of people worldwide. While antiviral treatments are effective for some patients, many either cannot or choose not to receive antiviral treatment. Education about behavioural changes like alcohol avoidance and symptom management, in contrast, is universally recommended, particularly in HCV-infected persons from disadvantaged groups where liver risk factors are most prevalent. Self-management interventions are one option for fostering improved HCV knowledge and health-related quality of life (HRQOL). One hundred and thirty-two patients with VA with HCV (mean age of 54.6, 95% men, 41% ethnic minority, 83% unmarried, 72% unemployed/disabled, 48% homeless in last 5 years) were randomized to either a 6-week self-management workshop or an information-only intervention. The weekly 2-h self-management sessions were based on cognitive-behavioural principles and were adapted from an existing self-management programme that has been efficacious with other chronic diseases. HCV-specific modules were added. Outcomes including HRQOL, HCV knowledge, self-efficacy, depression, energy and health distress were measured at baseline and 6 weeks later. Data were analysed using ANOVA. When compared to the information-only group, participants attending the self-management workshop improved more on HCV knowledge (P < 0.001), HCV self-efficacy (P = 0.011), and SF-36 energy/vitality (P = 0.040). Similar trends were found for SF-36 physical functioning (P = 0.055) and health distress (P = 0.055). Attending the self-management programme improved disease knowledge and HRQOL 6 weeks later in this disadvantaged population. The intervention can improve the health of people with hepatitis C, independent of antiviral therapy. Future research will study longer-term outcomes, effects on antiviral treatment and costs. C1 [Groessl, E. J.] VA San Diego Healthcare Syst, Hlth Serv Res & Dev, La Jolla, CA 92161 USA. [Groessl, E. J.; Stepnowsky, C. J.; Ho, S. B.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Gifford, A. L.] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Gifford, A. L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Asch, S. M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, S. M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Groessl, EJ (reprint author), VA San Diego Healthcare Syst, Hlth Serv Res & Dev, 3350 Jolla Village Dr 111 N-1, La Jolla, CA 92161 USA. EM egroessl@ucsd.edu FU VA HSRD [IAC 05-067] FX This study is funded by a research grant from the VA HSR&D, Project # IAC 05-067. This project is registered at clinical Trails. gov, registration # NCT00328042. NR 71 TC 9 Z9 9 U1 1 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD MAY PY 2011 VL 18 IS 5 BP 358 EP 368 DI 10.1111/j.1365-2893.2010.01328.x PG 11 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 746MR UT WOS:000289251900007 PM 20529203 ER PT J AU Yan-Meier, L Eberhart, NK Hammen, CL Gitlin, M Sokolski, K Altshuler, L AF Yan-Meier, Leslie Eberhart, Nicole K. Hammen, Constance L. Gitlin, Michael Sokolski, Kenneth Altshuler, Lori TI Stressful life events predict delayed functional recovery following treatment for mania in bipolar disorder SO PSYCHIATRY RESEARCH LA English DT Article DE Bipolar; Mania; Stress; Functional recovery ID UNIPOLAR DEPRESSION; SOCIAL-ADJUSTMENT; I DISORDER; STEP-BD; IMPAIRMENT; HOSPITALIZATION; RECURRENCE; OUTCOMES; DISABILITY; REACTIVITY AB Identifying predictors of functional recovery in bipolar disorder is critical to treatment efforts to help patients re-establish premorbid levels of role adjustment following an acute manic episode. The current study examined the role of stressful life events as potential obstacles to recovery of functioning in various roles. 65 patients with bipolar I disorder participated in a longitudinal study of functional recovery following clinical recovery from a manic episode. Stressful life events were assessed as predictors of concurrent vs. delayed recovery of role functioning in 4 domains (friends, family, home duties, work/school). Despite clinical recovery, a subset of patients experienced delayed functional recovery in various role domains. Moreover, delayed functional recovery was significantly associated with presence of one or more stressors in the prior 3 months, even after controlling for mood symptoms. Presence of a stressor predicted longer time to functional recovery in life domains, up to 112 days in work/school. Interventions that provide monitoring, support, and problem-solving may be needed to help prevent or mitigate the effects of stress on functional recovery. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Yan-Meier, Leslie; Hammen, Constance L.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Eberhart, Nicole K.] RAND Corp, Santa Monica, CA USA. [Hammen, Constance L.; Gitlin, Michael; Altshuler, Lori] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Sokolski, Kenneth] Vet Adm Long Beach Healthcare Syst, Mental Hlth Care Grp, Long Beach, CA USA. [Sokolski, Kenneth] Univ Calif Irvine, Dept Psychiat, Irvine, CA 92717 USA. [Altshuler, Lori] W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare System, Dept Psychiat, Los Angeles, CA USA. RP Hammen, CL (reprint author), 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA. EM hammen@psych.ucla.edu FU National Institute of Mental Health [1R01MH057762] FX Funding for this study was provided by the National Institute of Mental Health 1R01MH057762, awarded to Dr. Altshuler. NR 50 TC 10 Z9 10 U1 1 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD APR 30 PY 2011 VL 186 IS 2-3 BP 267 EP 271 DI 10.1016/j.psychres.2010.08.028 PG 5 WC Psychiatry SC Psychiatry GA 744YS UT WOS:000289131700018 PM 20888051 ER PT J AU Chen, DC Zhou, MA Zhou, DH Xiu, MH Wu, GY Kosten, TR Zhang, XY AF Chen, Da Chun Zhou, Ming Ai Zhou, Dong Hao Xiu, Mel Hong Wu, Gui Ying Kosten, Thomas R. Zhang, Xiang Yang TI Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics SO PSYCHIATRY RESEARCH LA English DT Article DE Schizophrenia; Gender differences; Diabetes mellitus ID HORMONE REPLACEMENT THERAPY; IMPAIRED FASTING GLUCOSE; 2ND-GENERATION ANTIPSYCHOTICS; METABOLIC ABNORMALITIES; TOLERANCE; INSULIN; RISK AB Gender-specific relationships between diabetes mellitus (DM) and schizophrenia have previously received little systematic study. The results showed that the overall DM prevalence was 20% with rates of 17% (58/343) in males and 27% (46/172) in females (p<0.01). Furthermore, increased body mass index (BMI), abdominal obesity and antipsychotic types were predictors of diabetes in these chronic schizophrenic patients. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Wu, Gui Ying; Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhou, Ming Ai; Zhou, Dong Hao] LinYi Chinese Med Hosp, Dept Immunol & Allergol, Linyi, Shandong, Peoples R China. [Chen, Da Chun; Xiu, Mel Hong; Zhang, Xiang Yang] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China. RP Kosten, TR (reprint author), VA Med Ctr, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA. EM kosten@bcm.edu; xyzhang@bcm.edu FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs; VISN 16; Mental Illness Research, Education, and Clinical Center, United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This study was supported by grants from the Stanley Medical Research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education, and Clinical Center, United States National Institute of Health K05-DA0454, P50-DA18827, and U01-MH79639. NR 20 TC 5 Z9 8 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD APR 30 PY 2011 VL 186 IS 2-3 BP 451 EP 453 DI 10.1016/j.psychres.2010.07.054 PG 3 WC Psychiatry SC Psychiatry GA 744YS UT WOS:000289131700052 PM 20797801 ER PT J AU Walterfang, M Looi, JCL Styner, M Walker, RH Danek, A Niethammer, M Evans, A Kotschet, K Rodrigues, GR Hughes, A Velakoulis, D AF Walterfang, Mark Looi, Jeffrey Chee Leong Styner, Martin Walker, Ruth H. Danek, Adrian Niethammer, Marc Evans, Andrew Kotschet, Katya Rodrigues, Guilherme R. Hughes, Andrew Velakoulis, Dennis TI Shape alterations in the striatum in chorea-acanthocytosis SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Neuroacanthocytosis; Chorea-acanthocytosis; Chorea; Caudate; Striatum; Neurodegeneration ID OBSESSIVE-COMPULSIVE DISORDER; VOXEL-BASED MORPHOMETRY; CAUDATE-NUCLEUS; BASAL GANGLIA; HUNTINGTONS-DISEASE; NEUROACANTHOCYTOSIS; CIRCUITS; PROTEIN; IMAGES; BRAIN AB Chorea-acanthocytosis (ChAc) is an uncommon autosomal recessive disorder due to mutations of the VPS13A gene, which encodes for the membrane protein chorein. ChAc presents with progressive limb and orobuccal chorea, but there is often a marked dysexecutive syndrome. ChAc may first present with neuropsychiatric disturbance such as obsessive-compulsive disorder (OCD), suggesting a particular role for disruption to striatal structures involved in non-motor frontostriatal loops, such as the head of the caudate nucleus. Two previous studies have suggested a marked reduction in volume in the caudate nucleus and putamen, but did not examine morphometric change. We investigated morphometric change in 13 patients with genetically or biochemically confirmed ChAc and 26 age- and gender-matched controls. Subjects underwent magnetic resonance imaging and manual segmentation of the caudate nucleus and putamen, and shape analysis using a non-parametric spherical harmonic technique. Both structures showed significant and marked reductions in volume compared with controls, with reduction greatest in the caudate nucleus. Both structures showed significant shape differences, particularly in the head of the caudate nucleus. No significant correlation was shown between duration of illness and striatal volume or shape, suggesting that much structural change may have already taken place at the time of symptom onset. Our results suggest that striatal neuron loss may occur early in the disease process, and follows a dorsal-ventral gradient that may correlate with early neuropsychiatric and cognitive presentations of the disease. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Walterfang, Mark; Evans, Andrew; Velakoulis, Dennis] Royal Melbourne Hosp, Neuropsychiat Unit, Melbourne, Vic 3050, Australia. [Looi, Jeffrey Chee Leong] Australian Natl Univ, Sch Med, Dept Neurosci Ageing, Canberra, ACT, Australia. [Styner, Martin] Univ N Carolina, Neuroimaging Res & Anal Labs, Chapel Hill, NC USA. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Danek, Adrian] Univ Munich, Dept Neurol, D-8000 Munich, Germany. [Niethammer, Marc] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC USA. [Kotschet, Katya] St Vincents Hosp, Dept Neurol, Melbourne, Vic, Australia. [Rodrigues, Guilherme R.] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurol, Sao Paulo, Brazil. [Hughes, Andrew] Austin Hosp, Dept Neurol, Melbourne, Vic 3084, Australia. RP Walterfang, M (reprint author), Royal Melbourne Hosp, Neuropsychiat Unit, Level 2,Joan Cade Bldg, Melbourne, Vic 3050, Australia. EM mark.walterfang@mh.org.au RI Rodrigues, Guilherme/D-3547-2009; Walterfang, Mark/H-4930-2011; Danek, Adrian/G-7339-2011 OI Rodrigues, Guilherme/0000-0002-4296-1016; Walterfang, Mark/0000-0002-1389-3691; Danek, Adrian/0000-0001-8857-5383; Styner, Martin/0000-0002-8747-5118; Looi, Jeffrey/0000-0003-3351-6911 FU Advocacy for Neuroacanthocytosis Patients; UNC Neurodevelopmental Disorders Research Centre [HD 03110]; NIH [U54 EB005149-01]; National Alliance for Medical Image Computing; Melbourne Neuropsychiatry Centre FX Dr Walterfang was supported by a grant from the Advocacy for Neuroacanthocytosis Patients (www.naadvocacy.org). Dr Walterfang takes responsibility for the integrity of the data and the accuracy of the data analysis. Furthermore, Dr Styner's work was funded by the UNC Neurodevelopmental Disorders Research Centre HD 03110, and the NIH Roadmap Grant U54 EB005149-01, National Alliance for Medical Image Computing. Dr. B. Bader performed the chorein Western blot with the help of G. Kwiatkowski at the Zentrum fur Neuropathologie und Prionforschung, University of Munich (director: Prof. Dr. H. Kretzschmar), financially supported by the Advocacy for Neuroacanthocytosis Patients. Dr. Looi self-funded travel and accommodation for his contribution to this project at Melbourne Neuropsychiatry Centre. NR 36 TC 20 Z9 21 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD APR 30 PY 2011 VL 192 IS 1 BP 29 EP 36 DI 10.1016/j.pscychresns.2010.10.006 PG 8 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 751FG UT WOS:000289602300004 PM 21377843 ER PT J AU Jacobson, EM Concepcion, E Ho, K Kopp, P Toniolo, JV Tomer, Y AF Jacobson, Eric M. Concepcion, Erlinda Ho, Kenneth Kopp, Peter Toniolo, Jussara Vono Tomer, Yaron TI cDNA Immunization of Mice with Human Thyroglobulin Generates Both Humoral and T Cell Responses: A Novel Model of Thyroid Autoimmunity SO PLOS ONE LA English DT Article ID RECEPTOR A-SUBUNIT; HASHIMOTOS-THYROIDITIS; GENE-TRANSFER; IN-VIVO; ANTITHYROGLOBULIN AUTOANTIBODIES; THYROTROPIN RECEPTOR; SKELETAL-MUSCLE; INTRAMUSCULAR INJECTION; GRAVES HYPERTHYROIDISM; DNA ELECTROTRANSFER AB Thyroglobulin (Tg) represents one of the largest known self-antigens involved in autoimmunity. Numerous studies have implicated it in triggering and perpetuating the autoimmune response in autoimmune thyroid diseases (AITD). Indeed, traditional models of autoimmune thyroid disease, experimental autoimmune thyroiditis (EAT), are generated by immunizing mice with thyroglobulin protein in conjunction with an adjuvant, or by high repeated doses of Tg alone, without adjuvant. These extant models are limited in their experimental flexibility, i.e. the ability to make modifications to the Tg used in immunizations. In this study, we have immunized mice with a plasmid cDNA encoding the full-length human Tg (hTG) protein, in order to generate a model of Hashimoto's thyroiditis which is closer to the human disease and does not require adjuvants to breakdown tolerance. Human thyroglobulin cDNA was injected and subsequently electroporated into skeletal muscle using a square wave generator. Following hTg cDNA immunizations, the mice developed both B and T cell responses to Tg, albeit with no evidence of lymphocytic infiltration of the thyroid. This novel model will afford investigators the means to test various hypotheses which were unavailable with the previous EAT models, specifically the effects of hTg sequence variations on the induction of thyroiditis. C1 [Jacobson, Eric M.] Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45221 USA. [Concepcion, Erlinda; Ho, Kenneth; Tomer, Yaron] Mt Sinai Sch Med, Dept Med, Div Endocrinol, New York, NY USA. [Kopp, Peter; Toniolo, Jussara Vono] Northwestern Univ, Div Endocrinol Metab & Mol Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY USA. RP Jacobson, EM (reprint author), Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45221 USA. EM Eric.Jacobson@uc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [DK061659, DK067555, DK073681, DK063024]; American Thyroid Association FX This work was supported in part by grants DK061659, DK067555, DK073681 (to YT) and DK063024 (to PK) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). EMJ was supported by a grant from the American Thyroid Association (http://www.thyroid.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study. NR 67 TC 5 Z9 5 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 29 PY 2011 VL 6 IS 4 AR e19200 DI 10.1371/journal.pone.0019200 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 756OZ UT WOS:000290024700100 PM 21559421 ER PT J AU Gu, TL Nardone, J Wang, Y Loriaux, M Villen, J Beausoleil, S Tucker, M Kornhauser, J Ren, JM MacNeill, J Gygi, SP Druker, BJ Heinrich, MC Rush, J Polakiewicz, RD AF Gu, Ting-lei Nardone, Julie Wang, Yi Loriaux, Marc Villen, Judit Beausoleil, Sean Tucker, Meghan Kornhauser, Jon Ren, Jianmin MacNeill, Joan Gygi, Steven P. Druker, Brian J. Heinrich, Michael C. Rush, John Polakiewicz, Roberto D. TI Survey of Activated FLT3 Signaling in Leukemia SO PLOS ONE LA English DT Article ID ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNAL TANDEM DUPLICATION; B-CELL DEVELOPMENT; RECEPTOR TYROSINE KINASE; HEMATOPOIETIC-CELLS; ONCOGENIC FLT3; PHOSPHORYLATION; EXPRESSION; MUTATIONS AB Activating mutations of FMS-like tyrosine kinase-3 (FLT3) are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 is therefore an attractive drug target. However, the molecular mechanisms by which FLT3 mutations lead to cell transformation in AML remain unclear. To develop a better understanding of FLT3 signaling as well as its downstream effectors, we performed detailed phosphoproteomic analysis of FLT3 signaling in human leukemia cells. We identified over 1000 tyrosine phosphorylation sites from about 750 proteins in both AML (wild type and mutant FLT3) and B cell acute lymphoblastic leukemia (normal and amplification of FLT3) cell lines. Furthermore, using stable isotope labeling by amino acids in cell culture (SILAC), we were able to quantified over 400 phosphorylation sites (pTyr, pSer, and pThr) that were responsive to FLT3 inhibition in FLT3 driven human leukemia cell lines. We also extended this phosphoproteomic analysis on bone marrow from primary AML patient samples, and identify over 200 tyrosine and 800 serine/threonine phosphorylation sites in vivo. This study showed that oncogenic FLT3 regulates proteins involving diverse cellular processes and affects multiple signaling pathways in human leukemia that we previously appreciated, such as Fc epsilon RI-mediated signaling, BCR, and CD40 signaling pathways. It provides a valuable resource for investigation of oncogenic FLT3 signaling in human leukemia. C1 [Gu, Ting-lei; Nardone, Julie; Wang, Yi; Beausoleil, Sean; Tucker, Meghan; Kornhauser, Jon; Ren, Jianmin; MacNeill, Joan; Rush, John; Polakiewicz, Roberto D.] Cell Signaling Technol Inc, Danvers, MA USA. [Loriaux, Marc] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Villen, Judit; Gygi, Steven P.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. [Druker, Brian J.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Hematol & Med Oncol, Portland, OR 97201 USA. [Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. RP Gu, TL (reprint author), Cell Signaling Technol Inc, Danvers, MA USA. EM tgu@cellsignal.com; rpolakiewicz@cellsignal.com OI Villen, Judit/0000-0002-1005-1739 NR 56 TC 18 Z9 18 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 28 PY 2011 VL 6 IS 4 AR e19169 DI 10.1371/journal.pone.0019169 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 756NX UT WOS:000290020700034 PM 21552520 ER PT J AU Goldberg, NRS Haack, AK Lim, NS Janson, OK Meshul, CK AF Goldberg, N. R. S. Haack, A. K. Lim, N. S. Janson, O. K. Meshul, C. K. TI DOPAMINERGIC AND BEHAVIORAL CORRELATES OF PROGRESSIVE LESIONING OF THE NIGROSTRIATAL PATHWAY WITH 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE SO NEUROSCIENCE LA English DT Article DE dopamine; progressive; tyrosine hydroxylase; motor control; Parkinson's disease ID PARKINSONS-DISEASE PATIENTS; MPTP-INDUCED PARKINSONISM; MULTIPLE SYSTEM ATROPHY; NIGRA PARS COMPACTA; MOUSE MODEL; SUBSTANTIA-NIGRA; CEREBROSPINAL-FLUID; ALPHA-SYNUCLEIN; TIME-COURSE; ORTHOSTATIC HYPOTENSION AB A number of neurotoxin- and gene-based rodent models of acute neurodegeneration of nigrostriatal dopamine (DA) neurons are used to study Parkinson's disease (PD). The rapid degeneration achieved by many of these current models limits the capacity of the model to develop pathogenic mechanisms and display the various stages of motor degradation representative of the human Parkinsonian condition. Chronic rodent models have been the only ones to reproduce these characteristics, yet do not show correlated progress of DA loss with multiple stepwise behavioral deficits as seen in humans. In the present study, we have developed a progressive model of increasing DA loss and motor dysfunction via progressively increased administration of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in the C57BI/6J mouse. Mice were administered a daily (5 d/wk) dose of MPTP that increased weekly over the course of 4 weeks (4 mg/kg, 8 mg/kg, 16 mg/kg and 32 mg/kg). Each treatment group was tested for exploratory and motor behavioral changes after every week leading up to their final dose, as well as changes in tyrosine hydroxylase immunoreactivity (TH-ir) of the substantia nigra pars compacta (SNpc) and caudate putamen (CPu). We detected a 24% decrease in the mean number of TH-ir SNpc neurons/section after 1 week, and a 62% decrease after 4 weeks as compared to the vehicle group. CPu TH-ir began at a 35% loss after 1 week and increased to a 74% loss after 4 weeks compared to the vehicle group. CPu DA content showed an initial decrease of 20% after 1 week, and a final decrease of 70% following week 4 versus the vehicle group. Free-standing rears (versus wall-assisted rears, in a cylinder), decreased from 35% to 8% of total rears as the dose of MPTP increased from 4 mg/kg to 32 mg/kg, respectively. However, motor impairment as measured by a Parallel Rod Activity Chamber test was not significant until week 4 at 32 mg/kg compared to the vehicle group. The present study is the first to show stepwise progression of behavioral deficits which correlate with gradual dopaminergic decline in the nigrostriatal pathway. This progressive lesioning regiment may be appropriate for future investigation of pathogenic mechanisms and various intervention therapies in PD. Published by Elsevier Ltd on behalf of IBRO. C1 [Goldberg, N. R. S.; Haack, A. K.; Lim, N. S.; Janson, O. K.; Meshul, C. K.] Portland VA Med Ctr, Portland, OR USA. [Meshul, C. K.] Dept Behav Neurosci & Pathol, Portland, OR USA. RP Meshul, CK (reprint author), Portland VA Med Ctr, Portland, OR USA. EM meshulc@ohsu.edu FU Department of Veterans Affairs Merit Review Program FX Supported by the Department of Veterans Affairs Merit Review Program. We also thank Dr. Deborah Finn for her consultation regarding the statistical analysis. NR 72 TC 24 Z9 25 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD APR 28 PY 2011 VL 180 BP 256 EP 271 DI 10.1016/j.neuroscience.2011.02.027 PG 16 WC Neurosciences SC Neurosciences & Neurology GA 748MV UT WOS:000289395600027 PM 21335067 ER PT J AU Wu, MF Nienhuis, R Maidment, N Lam, HA Siegel, JM AF Wu, Ming-Fung Nienhuis, Robert Maidment, Nigel Lam, Hoa A. Siegel, Jerome M. TI Role of the Hypocretin (Orexin) Receptor 2 (Hcrt-r2) in the Regulation of Hypocretin Level and Cataplexy SO JOURNAL OF NEUROSCIENCE LA English DT Article ID LATERODORSAL TEGMENTAL NEURONS; LOCUS-COERULEUS NEURONS; BLOOD-PRESSURE CHANGES; CANINE NARCOLEPSY; CHOLINERGIC SYSTEMS; MEDIAL MEDULLA; KNOCKOUT MICE; HEART-RATE; SLEEP; PEPTIDES AB Hypocretin receptor-2 (Hcrt-r2)-mutated dogs exhibit all the major symptoms of human narcolepsy and respond to drugs that increase or decrease cataplexy as do narcoleptic humans; yet, unlike narcoleptic humans, the narcoleptic dogs have normal hypocretin levels. We find that drugs that reduce or increase cataplexy in the narcoleptic dogs, greatly increase and decrease, respectively, hypocretin levels in normal dogs. The effects of these drugs on heart rate and blood pressure, which were considerable, were not correlated with their effects on cataplexy. Administration of these drugs to Hcrt-r2-mutated dogs produced indistinguishable changes in heart rate and blood pressure, indicating that neither central nor peripheral Hcrt-r2 is required for these cardiovascular effects. However, in contrast to the marked Hcrt level changes in the normal dogs, these drugs did not alter hypocretin levels in the Hcrt-r2 mutants. We conclude that Hcrt-r2 is a vital element in a feedback loop integrating Hcrt, acetylcholine, and norepinephrine function. In the absence of functional Hcrt-r2, Hcrt levels are not affected by monoaminergic and cholinergic drugs, despite the strong modulation of cataplexy by these drugs. Conversely, strong transient reductions of Hcrt level by these drugs do not produce episodes of cataplexy in normal dogs. The Hcrt-r2 mutation causes drug-induced cataplexy by virtue of its long-term effect on the functioning of other brain systems, rather than by increasing the magnitude of phasic changes in Hcrt level. A similar mechanism may be operative in spontaneous cataplexy in narcoleptic dogs as well as in narcoleptic humans. C1 [Wu, Ming-Fung; Nienhuis, Robert; Siegel, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA 91343 USA. [Maidment, Nigel; Lam, Hoa A.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. RP Siegel, JM (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, North Hills, CA 91343 USA. EM jsiegel@ucla.edu FU National Institutes of Health [NS14610, MH64109]; Medical Research Service of the Department of Veterans Affairs FX Supported by National Institutes of Health Grants NS14610 and MH64109, and the Medical Research Service of the Department of Veterans Affairs. NR 43 TC 12 Z9 13 U1 1 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR 27 PY 2011 VL 31 IS 17 BP 6305 EP 6310 DI 10.1523/JNEUROSCI.0365-11.2011 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 755MB UT WOS:000289934600006 PM 21525270 ER PT J AU Peterson, PN Shetterly, SM Clarke, CL Bekelman, DB Chan, PS Allen, LA Matlock, DD Magid, DJ Masoudi, FA AF Peterson, Pamela N. Shetterly, Susan M. Clarke, Christina L. Bekelman, David B. Chan, Paul S. Allen, Larry A. Matlock, Daniel D. Magid, David J. Masoudi, Frederick A. TI Health Literacy and Outcomes Among Patients With Heart Failure SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID LIMITED LITERACY; CONTROLLED-TRIAL; HOSPITAL ADMISSION; IDENTIFY PATIENTS; SKILLS; RISK; POPULATION; QUESTIONS; ENROLLEES; MORTALITY AB Context Little is known about the effects of low health literacy among patients with heart failure, a condition that requires self-management and frequent interactions with the health care system. Objective To evaluate the association between low health literacy and all-cause mortality and hospitalization among outpatients with heart failure. Design, Setting, and Patients Retrospective cohort study conducted at Kaiser Permanente Colorado, an integrated managed care organization. Outpatients with heart failure were identified between January 2001 and May 2008, were surveyed by mail, and underwent follow-up for a median of 1.2 years. Health literacy was assessed using 3 established screening questions and categorized as adequate or low. Responders were excluded if they did not complete at least 1 health literacy question or if they did not have at least 1 year of enrollment prior to the survey date. Main Outcome Measures All-cause mortality and all-cause hospitalization. Results Of the 2156 patients surveyed, 1547 responded (72% response rate). Of 1494 included responders, 262 (17.5%) had low health literacy. Patients with low health literacy were older, of lower socioeconomic status, less likely to have at least a high school education, and had higher rates of coexisting illnesses. In multivariable Cox regression, low health literacy was independently associated with higher mortality (unadjusted rate, 17.6% vs 6.3%; adjusted hazard ratio, 1.97 [95% confidence interval, 1.3-2.97]; P=.001) but not hospitalization (unadjusted rate, 30.5% vs 23.2%; adjusted hazard ratio, 1.05 [95% confidence interval, 0.8-1.37]; P=.73). Conclusion Among patients with heart failure in an integrated managed care organization, low health literacy was significantly associated with higher all-cause mortality. JAMA. 2011;305(16):1695-1701 www.jama.com C1 [Peterson, Pamela N.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO 80204 USA. [Peterson, Pamela N.; Shetterly, Susan M.; Clarke, Christina L.; Magid, David J.; Masoudi, Frederick A.] Kaiser Permanente Colorado Inst Hlth Res, Denver, CO USA. [Peterson, Pamela N.; Bekelman, David B.; Allen, Larry A.; Matlock, Daniel D.; Magid, David J.; Masoudi, Frederick A.] Univ Colorado Denver, Aurora, CO USA. [Bekelman, David B.] Denver VA Med Ctr, Denver, CO USA. [Chan, Paul S.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Chan, Paul S.] Univ Missouri, Kansas City, MO 64110 USA. RP Peterson, PN (reprint author), Denver Hlth Med Ctr, Div Cardiol, Mail Code 0960,777 Bannock St, Denver, CO 80204 USA. EM pamela.peterson@ucdenver.edu FU American Heart Association [067001N]; National Heart, Lung, and Blood Institute [K23HL102224] FX Dr Peterson is supported by American Heart Association Pharmaceutical Roundtable grant 067001N. Dr Chan is supported by a Career Development Grant Award (K23HL102224) from the National Heart, Lung, and Blood Institute. Dr Allen is supported by an American Heart Association Scientist Development Award. NR 32 TC 124 Z9 126 U1 3 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 27 PY 2011 VL 305 IS 16 BP 1695 EP 1701 DI 10.1001/jama.2011.512 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 754XG UT WOS:000289890500023 PM 21521851 ER PT J AU Singh, N AF Singh, Nina TI Unraveling the Biologic Basis of Late-Onset Cytomegalovirus Disease in High-Risk Organ Transplant Recipients SO TRANSPLANTATION LA English DT Editorial Material ID T-CELL RECONSTITUTION; PREEMPTIVE THERAPY; PROPHYLAXIS; CMV; VALGANCICLOVIR; IMMUNITY; CD4(+) C1 [Singh, Nina] VA Pittsburgh Healthcare Syst, Dept Med, Div Infect Dis, Pittsburgh, PA 15240 USA. [Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Dept Med, Div Infect Dis, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu NR 13 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR 27 PY 2011 VL 91 IS 8 BP 825 EP 826 DI 10.1097/TP.0b013e3182126eb9 PG 2 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 746VX UT WOS:000289277000004 PM 21372754 ER PT J AU Butt, AA Chang, CC Kuller, L Goetz, MB Leaf, D Rimland, D Gibert, CL Oursler, KK Rodriguez-Barradas, MC Lim, J Kazis, LE Gottlieb, S Justice, AC Freiberg, MS AF Butt, Adeel A. Chang, Chung-Chou Kuller, Lewis Goetz, Matthew Bidwell Leaf, David Rimland, David Gibert, Cynthia L. Oursler, Krisann K. Rodriguez-Barradas, Maria C. Lim, Joseph Kazis, Lewis E. Gottlieb, Stephen Justice, Amy C. Freiberg, Matthew S. TI Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID HIV-INFECTED PATIENTS; LEFT-VENTRICULAR MASS; HEPATITIS-C VIRUS; MYOCARDIAL-INFARCTION; ANTIRETROVIRAL TREATMENT; CARDIOVASCULAR-DISEASE; UNINFECTED VETERANS; ALCOHOL-ABUSE; CARDIOMYOPATHY; DYSFUNCTION AB Background: Whether human immunodeficiency virus (HIV) infection is a risk factor for heart failure (HF) is not clear. The presence of coronary heart disease and alcohol consumption in this population may confound this association. Methods: To determine whether HIV infection is a risk factor for incident HF, we conducted a population-based, retrospective cohort study of HIV-infected and HIV-uninfected veterans enrolled in the Veterans Aging Cohort Study Virtual Cohort (VACS-VC) and the 1999 Large Health Study of Veteran Enrollees (LHS) from January 1, 2000, to July 31, 2007. Results: There were 8486 participants (28.2% HIV-infected) enrolled in the VACS-VC who also participated in the 1999 LHS. During the median 7.3 years of follow-up, 286 incident HF events occurred. Age-and race/ethnicity-adjusted HF rates among HIV-infected and HIV-uninfected veterans were 7.12 (95% confidence interval [CI], 6.90-7.34) and 4.82 (95% CI, 4.72-4.91) per 1000 person-years, respectively. Compared with HIV-uninfected veterans, those who were HIV infected had an increased risk of HF (adjusted hazard ratio [HR], 1.81; 95% CI, 1.39-2.36). This association persisted among veterans who did not have a coronary heart disease event or a diagnosis related to alcohol abuse or dependence before the incident HF event (adjusted HR, 1.96; 95% CI, 1.29-2.98). Compared with HIV-uninfected veterans, those who were HIV infected with a baseline Human immunodeficiency virus 1 (HIV-1) RNA level of 500 or more copies/mL had a higher risk of HF (adjusted HR, 2.28; 95% CI, 1.57-3.32), while those with baseline and a recent HIV-1 RNA level less than 500 copies/mL did not (adjusted HR, 1.10; 95% CI, 0.64-1.89; P <.001 for comparison between high and low HIV-1 RNA groups). Conclusions: Our data suggest that HIV infection is a risk factor for HF. Ongoing viral replication is associated with a higher risk of developing HF. C1 [Butt, Adeel A.; Chang, Chung-Chou; Freiberg, Matthew S.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Butt, Adeel A.] Vet Affairs VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Goetz, Matthew Bidwell; Leaf, David] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Washington, DC USA. [Oursler, Krisann K.; Gottlieb, Stephen] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Oursler, Krisann K.] VA Maryland Healthcare Syst, Baltimore, MD USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Lim, Joseph; Justice, Amy C.] Yale Univ, Sch Med & Publ Hlth, New Haven, CT USA. [Gottlieb, Stephen] Baltimore VA Med Ctr, Baltimore, MD USA. [Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kuller, Lewis] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Kazis, Lewis E.] Boston Univ, Sch Publ Hlth, Ctr Assessment Pharmaceut Practices, Dept Hlth Policy & Management, Boston, MA USA. RP Butt, AA (reprint author), Univ Pittsburgh, Sch Med, Dept Med, 3601 5th Ave,Ste 3A, Pittsburgh, PA 15213 USA. EM aabutt@pitt.edu OI Goetz, Matthew/0000-0003-4542-992X FU National Institute on Alcohol Abuse and Alcoholism and Veterans Health Administration Public Health Strategic Health Core Group [U10 AA 13566]; National Heart, Lung, and Blood Institute [HL095136-03]; National Institute on Aging [AG024896] FX Funding for the Veterans Aging Cohort Study was provided by grant U10 AA 13566 from the National Institute on Alcohol Abuse and Alcoholism and Veterans Health Administration Public Health Strategic Health Core Group, grant HL095136-03 from the National Heart, Lung, and Blood Institute (Dr Freiberg), and grant AG024896 from the National Institute on Aging (Dr Oursler). NR 37 TC 57 Z9 57 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 25 PY 2011 VL 171 IS 8 BP 737 EP 743 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 754KK UT WOS:000289853300004 PM 21518940 ER PT J AU Teerlink, JR AF Teerlink, John R. TI Mind or Body Evaluating Mind-Body Therapy Efficacy in Heart Failure Trials SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu RI Teerlink, John/D-2986-2012 NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 25 PY 2011 VL 171 IS 8 BP 758 EP 759 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 754KK UT WOS:000289853300007 PM 21518943 ER PT J AU Simon, JA AF Simon, Joel A. TI Smoking Cessation Interventions: A Primer for Physicians SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID TREATING TOBACCO DEPENDENCE; CIGARETTE-SMOKING; UNITED-STATES; BUPROPION C1 [Simon, Joel A.] Univ Calif San Francisco, Sch Med, San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. RP Simon, JA (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA. NR 16 TC 4 Z9 4 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 25 PY 2011 VL 171 IS 8 BP 777 EP 778 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 754KK UT WOS:000289853300011 PM 21518947 ER PT J AU Trautner, BW Kelly, PA Petersen, N Hysong, S Kell, H Liao, KS Patterson, JE Naik, AD AF Trautner, Barbara W. Kelly, P. Adam Petersen, Nancy Hysong, Sylvia Kell, Harrison Liao, Kershena S. Patterson, Jan E. Naik, Aanand D. TI A hospital-site controlled intervention using audit and feedback to implement guidelines concerning inappropriate treatment of catheter-associated asymptomatic bacteriuria SO IMPLEMENTATION SCIENCE LA English DT Article ID URINARY-TRACT-INFECTION; CLINICAL-PRACTICE GUIDELINES; INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTIONS; DISEASES-SOCIETY; ADULTS; IMPACT; PHYSICIANS; DIAGNOSIS; FRAMEWORK AB Background: Catheter-associated urinary tract infection (CAUTI) is one of the most common hospital-acquired infections. However, many cases treated as hospital-acquired CAUTI are actually asymptomatic bacteriuria (ABU). Evidence-based guidelines recommend that providers neither screen for nor treat ABU in most catheterized patients, but there is a significant gap between these guidelines and clinical practice. Our objectives are (1) to evaluate the effectiveness of an audit and feedback intervention for increasing guideline-concordant care concerning catheter-associated ABU and (2) to measure improvements in healthcare providers' knowledge of and attitudes toward the practice guidelines associated with the intervention. Methods/Design: The study uses a controlled pre/post design to test an intervention using audit and feedback of healthcare providers to improve their compliance with ABU guidelines. The intervention and the control sites are two VA hospitals. For objective 1 we will review medical records to measure the clinical outcomes of inappropriate screening for and treatment of catheter-associated ABU. For objective 2 we will survey providers' knowledge and attitudes. Three phases of our protocol are proposed: the first 12-month phase will involve observation of the baseline incidence of inappropriate screening for and treatment of ABU at both sites. This surveillance for clinical outcomes will continue at both sites throughout the study. Phase 2 consists of 12 months of individualized audit and feedback at the intervention site and guidelines distribution at both sites. The third phase, also over 12 months, will provide unit-level feedback at the intervention site to assess sustainability. Healthcare providers at the intervention site during phase 2 and at both sites during phase 3 will complete pre/post surveys of awareness and familiarity (knowledge), as well as of acceptance and outcome expectancy (attitudes) regarding the relevant practice guidelines. Discussion: Our proposal to bring clinical practice in line with published guidelines has significant potential to decrease overdiagnosis of CAUTI and associated inappropriate antibiotic use. Our study will also provide information about how to maximize effectiveness of audit and feedback to achieve guideline adherence in the inpatient setting. C1 [Trautner, Barbara W.; Kelly, P. Adam; Petersen, Nancy; Hysong, Sylvia; Kell, Harrison; Naik, Aanand D.] Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Trautner, Barbara W.; Petersen, Nancy; Hysong, Sylvia; Liao, Kershena S.; Naik, Aanand D.] Baylor Coll Med, Houston, TX 77030 USA. [Kelly, P. Adam] SE Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA USA. [Kelly, P. Adam] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Patterson, Jan E.] S Texas Vet Healthcare Syst, Med Serv, San Antonio, TX USA. RP Trautner, BW (reprint author), Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. EM trautner@bcm.edu RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207 FU VA HSRD [IIR 09-104]; VA HSR&D Center of Excellence [HFP90-020]; VA HSR&D Career Development Award [07-018-1] FX Our project is funded by VA HSR&D IIR 09-104 and partly supported by the VA HSR&D Center of Excellence (HFP90-020). BWT has a VA Career Development Award from Rehabilitation Research & Development (B4623). ADN receives additional support from the National Institute on Aging (K23AG027144) and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. SH receives support from a VA HSR&D Career Development Award (07-018-1). NR 39 TC 14 Z9 14 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD APR 22 PY 2011 VL 6 AR 41 DI 10.1186/1748-5908-6-41 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 773LW UT WOS:000291309800001 PM 21513539 ER PT J AU Smith, BA Goldberg, NRS Meshul, CK AF Smith, Beth A. Goldberg, Natalie R. S. Meshul, Charles K. TI Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse SO BRAIN RESEARCH LA English DT Article DE Tyrosine hydroxylase; Dopamine; Dopamine transporter; MPTP; Parkinson's disease; Exercise ID PARKINSONS-DISEASE; NEUROCHEMICAL DEFICITS; MOTOR INCOORDINATION; CELL-PROLIFERATION; PHYSICAL-ACTIVITY; BASAL GANGLIA; MODEL; DOPAMINE; MPTP; MICE AB Our goal was to extend our understanding of the neural changes behind motor recovery with treadmill exercise in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse. We determined the extent of dopamine (DA) terminal changes using Western immunoblotting [striatal dopamine transporter (DAT) and tyrosine hydroxylase (TH)] and alterations in the mean number of DA cells/section by immunohistochemistry and Nissl staining [TH-labeled cells and thionin-stained cells in the substantia nigra pars compacta (SN-PC)]. We measured recovery of gait performance and amount of spontaneous physical activity using the parallel rod activity chamber (PRAC). We hypothesized that the decrease in TH-labeled neurons in the SN-PC due to MPTP will be partially reversed by treadmill exercise, leading to recovery of motor behavior as measured by the PRAC. Following MPTP or vehicle administration, mice ran on the treadmill for 1h/day at 18 cm/s, 5 days/week. Results showed that treadmill exercise improves gait performance and increases physical activity while promoting increased protein expression of striatal DAT and TH. Exercise was effective for all mice; however, effects of early treadmill-based intervention appear to have an additional and unique benefit in mice who received MPTP. We are the first to show that, even following a nearly 50% decrease in the mean number of TH-labeled neurons/section in the SN-PC following MPTP, treadmill exercise leads to an increase of neurons in the SN-PC and improved motor behavior. (C) 2011 Elsevier B.V. All rights reserved. C1 [Smith, Beth A.] Oregon Hlth & Sci Univ, Dept Neurol, Balance Disorders Lab, Beaverton, OR 97006 USA. [Smith, Beth A.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Balance Disorders Lab, Beaverton, OR 97006 USA. [Goldberg, Natalie R. S.; Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97239 USA. [Goldberg, Natalie R. S.; Meshul, Charles K.] Portland VA Med Ctr, Electron Microscopy Facil, Portland, OR 97239 USA. RP Smith, BA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Balance Disorders Lab, West Campus,505 NW 185th Ave, Beaverton, OR 97006 USA. EM smitbeth@ohsu.edu; natalie.r.sashkin@gmail.com; meshulc@ohsu.edu RI Smith, Beth/D-2914-2014 OI Smith, Beth/0000-0003-2531-5394 FU NIA [2T32AG023477-06]; Department of Veterans Affairs FX Beth A. Smith is currently supported on NIA 2T32AG023477-06 (H. Urbanski, PI). This work was further supported by the Department of Veterans Affairs Merit Review Program (to Charles K. Meshul). The authors have no conflicts of interest to disclose. The funding sources provided funds only and did not have any role in the research. NR 57 TC 25 Z9 25 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD APR 22 PY 2011 VL 1386 BP 70 EP 80 DI 10.1016/j.brainres.2011.02.003 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 755TD UT WOS:000289958700008 PM 21315689 ER PT J AU Peralta, CA Shlipak, MG Judd, S Cushman, M McClellan, W Zakai, NA Safford, MM Zhang, XA Muntner, P Warnock, D AF Peralta, Carmen A. Shlipak, Michael G. Judd, Suzanne Cushman, Mary McClellan, William Zakai, Neil A. Safford, Monika M. Zhang, Xiao Muntner, Paul Warnock, David TI Detection of Chronic Kidney Disease With Creatinine, Cystatin C, and Urine Albumin-to-Creatinine Ratio and Association With Progression to End-Stage Renal Disease and Mortality SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID GLOMERULAR-FILTRATION-RATE; RACIAL-DIFFERENCES; CARDIOVASCULAR EVENTS; ELDERLY PERSONS; STROKE REGARDS; US ADULTS; ALL-CAUSE; REASONS; POPULATION; RISK AB Context A triple-marker approach for chronic kidney disease (CKD) evaluation has not been well studied. Objective To evaluate whether combining creatinine, cystatin C, and urine albumin-to-creatinine ratio (ACR) would improve identification of risks associated with CKD compared with creatinine alone. Design, Setting, and Participants Prospective cohort study involving 26 643 US adults enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study from January 2003 to June 2010. Participants were categorized into 8 groups defined by estimated glomerular filtration rate (GFR) determined by creatinine and by cystatin C of either <60 or >= 60 mL/min/1.73 m(2) and ACR of either <30 or >= 30 mg/g. Main Outcome Measures All-cause mortality and incident end-stage renal disease with median follow-up of 4.6 years. Results Participants had a mean age of 65 years, 40% were black, and 54% were women. Of 26 643 participants, 1940 died and 177 developed end-stage renal disease. Among participants without CKD defined by creatinine, 24% did not have CKD by either ACR or cystatin C. Compared with those with CKD defined by creatinine alone, the hazard ratio for death in multivariable-adjusted models was 3.3 (95% confidence interval [CI], 2.0-5.6) for participants with CKD defined by creatinine and ACR; 3.2 (95% CI, 2.2-4.7) for those with CKD defined by creatinine and cystatin C, and 5.6 (95% CI, 3.9-8.2) for those with CKD defined by all biomarkers. Among participants without CKD defined by creatinine, 3863 (16%) had CKD detected by ACR or cystatin C. Compared with participants who did not have CKD by any measure, the HRs for mortality were 1.7 (95% CI, 1.4-1.9) for participants with CKD defined by ACR alone, 2.2 (95% CI, 1.9-2.7) for participants with CKD defined by cystatin C alone, and 3.0 (95% CI, 2.4-3.7) for participants with CKD defined by both measures. Risk of incident end-stage renal disease was higher among those with CKD defined by all markers (34.1 per 1000 person-years; 95% CI, 28.7-40.5 vs 0.33 per 1000 person-years; 95% CI, 0.05-2.3) for those with CKD defined by creatinine alone. The second highest end-stage renal disease rate was among persons missed by the creatinine measure but detected by both ACR and cystatin C (rate per 1000 person-years, 6.4; 95% CI, 3.6-11.3). Net reclassification improvement for death was 13.3% (P<.001) and for end-stage renal disease was 6.4% (P<.001) after adding estimated GFR cystatin C in fully adjusted models with estimated GFR creatinine and ACR. Conclusion Adding cystatin C to the combination of creatinine and ACR measures improved the predictive accuracy for all-cause mortality and end-stage renal disease. C1 [Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Judd, Suzanne; Zhang, Xiao] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL USA. [Muntner, Paul] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA. [Safford, Monika M.; Warnock, David] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Cushman, Mary; Zakai, Neil A.] Univ Vermont, Dept Med, Burlington, VT 05405 USA. [Cushman, Mary; Zakai, Neil A.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. [McClellan, William] Emory Univ, Dept Med, Atlanta, GA 30322 USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU Amgen; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services [U01 NS041588]; Amgen Corp.; National Institutes of Diabetes and Digestive and Kidney Diseases [1K23SK082793-01]; Robert Wood Johnson Harold Amos award; American Heart Association [0640012N]; [R01AG034853]; [R01DK066488]; [R01HL085757]; [R01DK078124]; [R21HL091217] FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Warnock reported that he is a consultant for Amgen Corp and has received research support from Amgen. Dr Cushman reported receiving research support from Amgen. Dr McClellen reported receiving research support from Amgen. Otherwise, no other conflicts of interest were reported.; This research project is supported by cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. Additional funding was provided by an investigator-initiated grant-in-aid from Amgen Corp. Dr Peralta is funded by the National Institutes of Diabetes and Digestive and Kidney Diseases grant 1K23SK082793-01 and a Robert Wood Johnson Harold Amos award. Dr Shlipak is funded by grants R01AG034853 (PI), R01DK066488 (PI), R01HL085757 (Co-Investigator), R01DK078124 (Co-Investigator), and R21HL091217 (Co-Investigator) and by an American Heart Association Established Investigator Award (0640012N; PI) NR 32 TC 194 Z9 202 U1 2 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 20 PY 2011 VL 305 IS 15 BP 1545 EP 1552 DI 10.1001/jama.2011.468 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 752HU UT WOS:000289683000023 PM 21482744 ER PT J AU Gellad, WF Good, CB AF Gellad, Walid F. Good, C. Bernie TI Angiotensin receptor blockers (ARBs) SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Letter C1 [Gellad, Walid F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15260 USA. [Good, C. Bernie] Univ Pittsburgh, Sch Med, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Gellad, WF (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15260 USA. NR 2 TC 0 Z9 0 U1 0 U2 1 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA SN 0820-3946 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD APR 19 PY 2011 VL 183 IS 7 BP 826 EP 826 DI 10.1503/cmaj.111-2036 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 748YD UT WOS:000289428200041 PM 21502367 ER PT J AU Nihal, M Stutz, N Schmit, T Ahmad, N Wood, GS AF Nihal, Minakshi Stutz, Nathalie Schmit, Travis Ahmad, Nihal Wood, Gary S. TI Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs) and its downregulation promotes cell cycle arrest and apoptosis SO CELL CYCLE LA English DT Article DE CTCL; Plk1; cell cycle; apoptosis ID SMALL-MOLECULE INHIBITOR; COMMON CLONAL ORIGIN; CANCER-CELLS; POLO-LIKE-KINASE-1; CYTOKINESIS; SURVIVIN; MITOSIS; TRANSFORMATION; INDUCTION; DEPLETION AB Polo-like kinases are serine/threonine kinases crucial for mitosis and DNA integrity. Plk1, the most well studied member of this family, is upregulated in several cancers, as well as in dividing cells with peak expression during G(2)/M phase. Recently, employing lesional skin from patients with cutaneous T-cell lymphoma (CTCL), we showed that Plk1 was increased mainly in advanced lesions. In this study, employing western blot and quantitative RT-PCR analyses, we demonstrated that Plk1 was overexpressed in multiple CTCL cell lines (HH, Hut78, MyLa, SeAx and SZ4). Further, a genetic knockdown (by short hairpin RNA) or enzyme activity inhibition (via a small molecule inhibitor, GW843682X) was found to result in a decrease in cell growth, viability and proliferation. Plk1 inhibition in CTCL cells also resulted in: (1) increased G(2)/M phase cell cycle arrest, (2) alteration in key mitotic proteins, (3) apoptosis and (4) multiple mitotic errors. Given our findings, clinical trials of Plk1 inhibitors in CTCL may be a promising area for further translational investigation. We speculate that overexpression of Plk1 may prove to be relevant to the progression and prognosis of CTCL through its direct impact on the regulation of tumor cell proliferation and indirect influence on the acquisition of somatic mutations by proliferating tumor cells. C1 [Wood, Gary S.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Nihal, Minakshi; Stutz, Nathalie; Ahmad, Nihal; Wood, Gary S.] Dept Dermatol, Madison, WI USA. [Schmit, Travis] Univ Wisconsin, Dept Pediat, Madison, WI USA. [Nihal, Minakshi; Ahmad, Nihal; Wood, Gary S.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Nihal, Minakshi; Ahmad, Nihal; Wood, Gary S.] Paul P Carbone Comprehens Canc Ctr, Madison, WI USA. RP Wood, GS (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. EM gwood@dermatology.wisc.edu FU Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research and Development Service. The contents do not represent the views of the Deptartment of Veterans Affairs or the U.S. Government. NR 47 TC 17 Z9 19 U1 0 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD APR 15 PY 2011 VL 10 IS 8 BP 1303 EP 1311 DI 10.4161/cc.10.8.15353 PG 9 WC Cell Biology SC Cell Biology GA 758EV UT WOS:000290145100026 PM 21436619 ER PT J AU Mathews, R Peterson, ED Chen, AY Wang, TY Chin, CT Fonarow, GC Cannon, CP Rumsfeld, JS Roe, MT Alexander, KP AF Mathews, Robin Peterson, Eric D. Chen, Anita Y. Wang, Tracy Y. Chin, Chee Tang Fonarow, Gregg C. Cannon, Christopher P. Rumsfeld, John S. Roe, Matthew T. Alexander, Karen P. TI In-Hospital Major Bleeding During ST-Elevation and Non ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry (R)-GWTG (TM) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE CORONARY SYNDROMES; QUALITY IMPROVEMENT; CLINICAL-OUTCOMES; RISK SCORE; IMPACT; INTERVENTION; REGISTRY; CRUSADE AB Bleeding, a common complication of acute myocardial infarction (AMI) treatment, is associated with worse outcomes. A contemporary model for major bleeding associated with AMI treatment can stratify patients at elevated risk for bleeding and is needed to risk-adjust AMI practice and outcomes. Using the Acute Coronary Treatment and Intervention Outcomes Network Registry Get With the Guidelines (ACTION Registry GWTG) database, an in-hospital major bleeding risk model was developed in a population of patients with ST-segment elevation myocardial infarction and non ST-segment elevation myocardial infarction. The model used only baseline variables and was developed (n = 72,313) and validated (n = 17,960) in patients with AMI (at 251 United States centers from January 2007 to December 2008). The 12 most statistically and clinically significant variables were incorporated into the final regression model. The calibration plots are shown, and the model discrimination is demonstrated in derivation and validation cohorts, as well as across key subgroups. The rate of major bleeding in the overall population was 10.8%. The 12 factors associated with major bleeding in the model were heart rate, baseline hemoglobin, female gender, baseline serum creatinine, age, electro-cardiographic changes, heart failure or shock, diabetes, peripheral artery disease, body weight, systolic blood pressure, and home warfarin use. The risk model discriminated well in the derivation (C-statistic = 0.73) and validation (C-statistic = 0.71) cohorts. A risk score for major bleeding corresponded well with observed bleeding: very low risk (3.9%), low risk (7.3%), moderate risk (16.1%), high risk (29.0%), and very high risk (39.8%). In conclusion, the ACTION Registry GWTG in-hospital major bleeding model stratifies risk for major bleeding using variables at presentation and enables risk-adjusted bleeding outcomes for quality improvement initiatives and clinical decision making. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1136-1143) C1 [Mathews, Robin; Peterson, Eric D.; Chen, Anita Y.; Wang, Tracy Y.; Chin, Chee Tang; Roe, Matthew T.; Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA. [Chin, Chee Tang] Natl Heart Ctr Singapore, Singapore, Singapore. [Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA. [Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Alexander, KP (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA. EM karen.alexander@duke.edu FU Bristol-Myers Squibb (New York, New York)/Sanofi Pharmaceuticals (St. Louis, Missouri); Agency for Healthcare Research and Quality, Rockville, Maryland [U18HS016964] FX The Acute Coronary Treatment and Intervention Outcomes Network Registry Get With the Guidelines (ACTION Registry-GWTG) is an initiative of the American College of Cardiology Foundation, Washington, District of Columbia, and the American Heart Association, Dallas, Texas, with partnering support from Society of Chest Pain Centers, Dublin, Ohio, the Society of Hospital Medicine, Philadelphia, Pennsylvania, and the American College of Emergency Physicians, Irving, Texas. The registry is sponsored by Bristol-Myers Squibb (New York, New York)/Sanofi Pharmaceuticals (St. Louis, Missouri). This project received infrastructure support from the Agency for Healthcare Research and Quality, Rockville, Maryland, under grant U18HS016964. The content is solely the responsibility of the investigators and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. The funding source had no role in the design or implementation of the study or in the decision to seek publication. NR 14 TC 65 Z9 66 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2011 VL 107 IS 8 BP 1136 EP 1143 DI 10.1016/j.amjcard.2010.12.009 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 752OQ UT WOS:000289702400006 PM 21324428 ER PT J AU Campuzano, S Kuralay, F Lobo-Castanon, MJ Bartosik, M Vyavahare, K Palecek, E Haake, DA Wang, J AF Campuzano, Susana Kuralay, Filiz Lobo-Castanon, M. Jesus Bartosik, Martin Vyavahare, Kedar Palecek, Emil Haake, David A. Wang, Joseph TI Ternary monolayers as DNA recognition interfaces for direct and sensitive electrochemical detection in untreated clinical samples SO BIOSENSORS & BIOELECTRONICS LA English DT Article DE Dithiols; Self-assembled monolayer; Clinical samples; Electrochemical detection; Hybridization; DNA ID SELF-ASSEMBLED MONOLAYERS; IMPEDANCE SPECTROSCOPY; GOLD; HYBRIDIZATION; ELECTRODES; IMMOBILIZATION; BIOSENSORS; SURFACES; AU(111); DEVICES AB Detection of specific DNA sequences in clinical samples is a key goal of studies on DNA biosensors and gene chips. Herein we present a highly sensitive electrochemical genosensor for direct measurements of specific DNA sequences in undiluted and untreated human serum and urine samples. Such genosensing relies on a new ternary interface involving hexanedithiol (HDT) co-immobilized with the thiolated capture probe (SHCP) on gold surfaces, followed by the incorporation of 6-mercapto-1-hexanol (MCH) as diluent. The performance of ternary monolayers prepared with linear dithiols of different lengths was systematically examined, compared and characterized by cyclic voltammetry and electrochemical impedance spectroscopy, with HDT exhibiting the most favorable analytical performance. The new SHCP/HDT + MCH monolayer led to a 80-fold improvement in the signal-to-noise ratio (S/N) for 1 nM target DNA in undiluted human serum over the common SHCP+MCH binary alkanethiol interface, and allowed the direct quantification of the target DNA down to 7 pM (28 amol) and 17 pM (68 amol) in undiluted/untreated serum and urine, respectively. It also displayed attractive antifouling properties, as indicated from the favorable S/N obtained after a prolonged exposure (24 h) to untreated biological matrices. These attractive features of the SHCP/HDT + MCH sensor interface indicate considerable promise for a wide range of clinical applications. (C) 2011 Elsevier B.V. All rights reserved. C1 [Campuzano, Susana; Kuralay, Filiz; Lobo-Castanon, M. Jesus; Vyavahare, Kedar; Wang, Joseph] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA. [Bartosik, Martin; Palecek, Emil] Acad Sci Czech Republic, Inst Biophys, CS-61265 Brno, Czech Republic. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Wang, J (reprint author), Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA. EM josephwang@ucsd.edu RI Campuzano Ruiz, Susana/C-6448-2011; Bartosik, Martin/B-5648-2011; Lobo Castanon, Maria Jesus/E-8757-2011; Palecek, Emil/C-1075-2013; Wang, Joseph/C-6175-2011 OI Lobo Castanon, Maria Jesus/0000-0002-2964-9490; Palecek, Emil/0000-0003-2561-8336; FU National Institutes of Health [U01 AI075565]; Programa Becas Complutense del Amo; University of Oviedo; Spanish Ministerio de Ciencia e Innovacion [PR 2009-0430]; Scientific and Technical Council of Turkey (TUBITAK) FX Financial support from the National Institutes of Health (Award U01 AI075565) is gratefully acknowledged. SC, MJLC and FK acknowledge fellowships from Programa Becas Complutense del Amo (2010-2011), University of Oviedo and Spanish Ministerio de Ciencia e Innovacion (PR 2009-0430), and The Scientific and Technical Council of Turkey (TUBITAK), respectively. EP and MB thank the Czech-Republic Ministry of Education, Youth and Sports (ME09038). NR 26 TC 54 Z9 55 U1 3 U2 43 PU ELSEVIER ADVANCED TECHNOLOGY PI OXFORD PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0956-5663 J9 BIOSENS BIOELECTRON JI Biosens. Bioelectron. PD APR 15 PY 2011 VL 26 IS 8 BP 3577 EP 3583 DI 10.1016/j.bios.2011.02.004 PG 7 WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical; Electrochemistry; Nanoscience & Nanotechnology SC Biophysics; Biotechnology & Applied Microbiology; Chemistry; Electrochemistry; Science & Technology - Other Topics GA 754OE UT WOS:000289863900030 PM 21377347 ER PT J AU Jenkins, RW Clarke, CJ Canals, D Snider, AJ Gault, CR Heffernan-Stroud, L Wu, BX Simbari, F Roddy, P Kitatani, K Obeid, LM Hannun, YA AF Jenkins, Russell W. Clarke, Christopher J. Canals, Daniel Snider, Ashley J. Gault, Christopher R. Heffernan-Stroud, Linda Wu, Bill X. Simbari, Fabio Roddy, Patrick Kitatani, Kazuyuki Obeid, Lina M. Hannun, Yusuf A. TI Regulation of CC Ligand 5/RANTES by Acid Sphingomyelinase and Acid Ceramidase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NIEMANN-PICK-DISEASE; DELTA-MEDIATED PHOSPHORYLATION; RANTES CHEMOKINE GENE; LUNG EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; BETA-GLUCOSIDASE 1; SECRETORY SPHINGOMYELINASE; SPHINGOSINE 1-PHOSPHATE; TNF-ALPHA; LYSOSOMAL SPHINGOMYELINASE AB Acid sphingomyelinase (aSMase) generates the bioactive lipid ceramide (Cer) from hydrolysis of sphingomyelin (SM). However, its precise roles in regulating specific sphingolipid-mediated biological processes remain ill defined. Interestingly, the aSMase gene gives rise to two distinct enzymes, lysosomal sphingomyelinase (L-SMase) and secretory sphingomyelinase (S-SMase) via alternative trafficking of a shared protein precursor. Previously, our laboratory identified Ser(508) as a crucial residue for the constitutive and regulated secretion of S-SMase in response to inflammatory cytokines, and demonstrated a role for S-SMase in formation of select cellular Cer species (Jenkins, R. W., Canals, D., Idkowiak-Baldys, J., Simbari, F., Roddy, P., Perry, D. M., Kitatani, K., Luberto, C., and Hannun, Y. A. (2010) J. Biol. Chem. 285, 35706-35718). In the present study using a chemokine/cytokine screen, we identified the chemokine CCL5 (formerly known as RANTES) as a candidate-specific downstream target for aSMase. Regulation of CCL5 by aSMase was subsequently validated using both loss-of-function and gain-of-function models indicating that aSMase is both necessary and sufficient for CCL5 production. Interestingly, cells deficient in acid ceramidase (aCDase) also exhibited defects in CCL5 induction, whereas cells deficient in sphingosine kinase- 1 and -2 exhibited higher levels of CCL5, suggesting that sphingosine and not sphingosine 1-phosphate (S1P) is responsible for the positive signal to CCL5. Consistent with this, co-expression of aSMase and aCDase was sufficient to strongly induce CCL5. Taken together, these data identify a novel role for aSMase (particularly S-SMase) in chemokine elaboration by pro-inflammatory cytokines and highlight a novel and shared function for aSMase and aCDase. C1 [Jenkins, Russell W.; Clarke, Christopher J.; Canals, Daniel; Wu, Bill X.; Roddy, Patrick; Kitatani, Kazuyuki; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Snider, Ashley J.; Gault, Christopher R.; Heffernan-Stroud, Linda; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Snider, Ashley J.; Gault, Christopher R.; Heffernan-Stroud, Linda; Obeid, Lina M.] Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29401 USA. [Simbari, Fabio] CSIC, Inst Adv Chem Catalonia, Dept Biomed Chem, ES-08034 Barcelona, Spain. [Kitatani, Kazuyuki] Tottori Univ Hosp, Dept Clin Lab, Yonago, Tottori 6838504, Japan. RP Hannun, YA (reprint author), 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA. EM hannun@musc.edu OI Canals, Daniel/0000-0002-9293-5123; Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [P01 CA097132]; NCI; MSTP Training [GM08716, GM062887]; NIGMS [CA097132]; American Heart Association [AHA 081509E]; Medical University of South Carolina Hollings Cancer Center Abney Foundation; Ministerio de Educacion y Ciencia (Spain) [AP2006-02190]; Japan Society for the Promotion of Science [21890144] FX This work was supported, in whole or in part, by National Institutes of Health Grant P01 CA097132 (to Y. A. H.) from the NCI, MSTP Training Grant GM08716 (to R. W. J.), Grant GM062887 from the NIGMS (to L. M. O.), Grant CA097132 from the NCI (to L M. O.), American Heart Association Pre-doctoral Fellowship AHA 081509E (to R. W. J.), a Medical University of South Carolina Hollings Cancer Center Abney Foundation Scholarship (to R. W. J.), Ministerio de Educacion y Ciencia (Spain) Predoctoral Fellowship AP2006-02190 (to F. S.), and the Japan Society for the Promotion of Science Grant-in-aid for Young Scientists (Start-up) 21890144 (to K. K.). NR 93 TC 19 Z9 19 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 15 PY 2011 VL 286 IS 15 BP 13292 EP 13303 DI 10.1074/jbc.M110.163378 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 746XH UT WOS:000289282200050 PM 21335555 ER PT J AU Rahman, SMJ Gonzalez, AL Li, M Seeley, EH Zimmerman, LJ Zhang, XQJ Manier, ML Olson, SJ Shah, RN Miller, AN Putnam, JB Miller, YE Franklin, WA Blot, WJ Carbone, DP Shyr, Y Caprioli, RM Massion, PP AF Rahman, S. M. Jamshedur Gonzalez, Adriana L. Li, Ming Seeley, Erin H. Zimmerman, Lisa J. Zhang, Xueqiong J. Manier, M. Lisa Olson, Sandra J. Shah, Ronak N. Miller, Alison N. Putnam, Joe B. Miller, York E. Franklin, Wilbur A. Blot, William J. Carbone, David P. Shyr, Yu Caprioli, Richard M. Massion, Pierre P. TI Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions SO CANCER RESEARCH LA English DT Article ID MIGRATION INHIBITORY FACTOR; IMAGING MASS-SPECTROMETRY; WHITE-LIGHT BRONCHOSCOPY; SQUAMOUS-CELL CARCINOMA; AUTOFLUORESCENCE BRONCHOSCOPY; PRECANCEROUS LESIONS; PROTEIN EXPRESSION; METASTASIS; INTEROBSERVER; ANGIOGENESIS AB Early detection may help improve survival from lung cancer. In this study, our goal was to derive and validate a signature from the proteomic analysis of bronchial lesions that could predict the diagnosis of lung cancer. Using previously published studies of bronchial tissues, we selected a signature of nine matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) mass-to-charge ratio features to build a prediction model diagnostic of lung cancer. The model was based on MALDI MS signal intensity (MALDI score) from bronchial tissue specimens from our 2005 published cohort of 51 patients. The performance of the prediction model in identifying lung cancer was tested in an independent cohort of bronchial specimens from 60 patients. The probability of having lung cancer based on the proteomic analysis of the bronchial specimens was characterized by an area under the receiver operating characteristic curve of 0.77 (95% CI 0.66-0.88) in this validation cohort. Eight of the nine features were identified and validated by Western blotting and immunohistochemistry. These results show that proteomic analysis of endobronchial lesions may facilitate the diagnosis of lung cancer and the monitoring of high-risk individuals for lung cancer in surveillance and chemoprevention trials. Cancer Res; 71(8); 3009-17. (C)2011 AACR. C1 [Massion, Pierre P.] Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Dept Med, Vanderbilt Ingram Canc Ctr,Med Ctr,Sch Med, Nashville, TN 37232 USA. [Gonzalez, Adriana L.; Olson, Sandra J.] Vanderbilt Univ, Dept Pathol, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA. [Seeley, Erin H.; Manier, M. Lisa; Carbone, David P.; Caprioli, Richard M.] Vanderbilt Univ, Mass Spectrometry Res Ctr, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA. [Seeley, Erin H.; Zimmerman, Lisa J.; Manier, M. Lisa; Carbone, David P.; Caprioli, Richard M.] Vanderbilt Univ, Dept Biochem, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA. [Zhang, Xueqiong J.; Shyr, Yu] Vanderbilt Univ, Div Canc Biostat, Vanderbilt Ingram Canc Ctr, Sch Med,Dept Biostat, Nashville, TN 37232 USA. [Carbone, David P.] Vanderbilt Univ, Div Hematol & Oncol, Vanderbilt Ingram Canc Ctr, Sch Med,Dept Med, Nashville, TN 37232 USA. [Putnam, Joe B.] Vanderbilt Univ, Dept Thorac Surg, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA. [Blot, William J.] Vanderbilt Univ, Div Epidemiol, Vanderbilt Ingram Canc Ctr, Sch Med,Dept Med, Nashville, TN 37232 USA. [Miller, Alison N.; Massion, Pierre P.] Vet Affairs Med Ctr, Nashville, TN 37212 USA. [Miller, York E.] Univ Colorado, Dept Med, Div Pulm, Denver Vet Affairs Med Ctr, Denver, CO USA. [Franklin, Wilbur A.] Univ Colorado, Dept Pathol, Denver, CO 80202 USA. RP Massion, PP (reprint author), Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Dept Med, Vanderbilt Ingram Canc Ctr,Med Ctr,Sch Med, 640 PRB, Nashville, TN 37232 USA. EM pierre.massion@vanderbilt.edu FU National Institute of Health [CA102353, P50 CA 90949, P50 CA58187]; Vanderbilt-Ingram Cancer Center [P30 CA68485]; Department of Defense [W81XWH-05-1-0179]; NIH/NIGMS [5R01-GM58008] FX This work was supported by the National Institute of Health (CA102353 to P. P. Massion, the Lung SPORE P50 CA 90949 to D. P. Carbone, and the Lung SPORE P50 CA58187 to Y.E. Miller and W. A. Franklin), Vanderbilt-Ingram Cancer Center Core Support Grant (P30 CA68485 to P. P. Massion and R. M. Caprioli), Department of Defense (W81XWH-05-1-0179 to R. M. Caprioli) and NIH/NIGMS (5R01-GM58008 to R. M. Caprioli). NR 42 TC 32 Z9 34 U1 1 U2 10 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 IS 8 BP 3009 EP 3017 DI 10.1158/0008-5472.CAN-10-2510 PG 9 WC Oncology SC Oncology GA 749YL UT WOS:000289507800021 PM 21487035 ER PT J AU Muldoon, LL Lewin, SJ Dosa, E Kraemer, DF Pagel, MA Doolittle, ND Neuwelt, EA AF Muldoon, Leslie L. Lewin, Seth J. Dosa, Edit Kraemer, Dale F. Pagel, Michael A. Doolittle, Nancy D. Neuwelt, Edward A. TI Imaging and Therapy with Rituximab Anti-CD20 Immunotherapy in an Animal Model of Central Nervous System Lymphoma SO CLINICAL CANCER RESEARCH LA English DT Article ID PRIMARY CNS LYMPHOMA; BLOOD-BRAIN-BARRIER; HIGH-DOSE METHOTREXATE; NON-HODGKINS-LYMPHOMA; TERM-FOLLOW-UP; TUMOR XENOGRAFT; RAT MODEL; PHASE-II; NUDE RAT; CHEMOTHERAPY AB Purpose: To evaluate the effect of rituximab monoclonal antibody (mAb) on MRI tumor volumetrics and efficacy in a rat model of central nervous system (CNS) lymphoma when delivery to the brain was optimized with osmotic blood-brain barrier disruption (BBBD). Experimental Design: Female nude rats with intracerebral MC116 human B-cell lymphoma xenografts underwent baseline MRI and were randomized into 5 groups (n = 6 per group): (i) BBBD saline control; (ii) methotrexate with BBBD; (iii) rituximab with BBBD; (iv) rituximab and methotrexate with BBBD; and (v) intravenous rituximab. Tumor volumes were assessed by MRI at 1 week, and rats were followed for survival. Results: BBBD increased delivery of yttrium-90-radiolabeled mAb in the model of CNS lymphoma. Control rats showed 201 +/- 102% increase in tumor volume on MRI 1 week after entering the study and median 14-day survival (range: 6-33). Tumor growth on MRI was slowed in the methotrexate treatment group, but survival time (median: 7 days; range: 5-12) was not different from controls. Among 17 evaluable rats treated with rituximab, 10 showed decreased tumor volume on MRI. All rituximab groups had increased survival compared with control, with a combined median of 43 days (range: 20-60, P < 0.001). There were no differences by route of delivery or combination with methotrexate. Conclusions: Rituximab was effective at decreasing tumor volume and improving survival in a model of CNS lymphoma and was not affected by combination with methotrexate or by BBBD. We suggest that rituximab warrants further study in human primary CNS lymphoma. Clin Cancer Res; 17(8); 2207-15. (C) 2011 AACR. C1 [Muldoon, Leslie L.; Lewin, Seth J.; Dosa, Edit; Doolittle, Nancy D.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Muldoon, Leslie L.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA. [Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [Kraemer, Dale F.] Oregon State Univ, Dept Pharm Practice, Portland, OR USA. [Pagel, Michael A.; Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU Veterans Administration Merit Review Grant; NIH [NS053468, CA137488, NS44687] FX This study was supported by a Veterans Administration Merit Review Grant and by NIH grants NS053468, CA137488, and NS44687 to E.A. Neuwelt. NR 38 TC 14 Z9 16 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 15 PY 2011 VL 17 IS 8 BP 2207 EP 2215 DI 10.1158/1078-0432.CCR-10-2923 PG 9 WC Oncology SC Oncology GA 750NP UT WOS:000289555500015 PM 21385922 ER PT J AU Mendez, E Lohavanichbutr, P Fan, WH Houck, JR Rue, TC Doody, DR Futran, ND Upton, MP Yueh, B Zhao, LP Schwartz, SM Chen, C AF Mendez, Eduardo Lohavanichbutr, Pawadee Fan, Wenhong Houck, John R. Rue, Tessa C. Doody, David R. Futran, Neal D. Upton, Melissa P. Yueh, Bevan Zhao, Lue Ping Schwartz, Stephen M. Chen, Chu TI Can a Metastatic Gene Expression Profile Outperform Tumor Size as a Predictor of Occult Lymph Node Metastasis in Oral Cancer Patients? SO CLINICAL CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL-CARCINOMA; EXTRACAPSULAR SPREAD; CAVITY; HEAD AB Purpose: To determine the differential gene expression between oral squamous cell carcinoma (OSCC) with and without metastasis to cervical lymph nodes and to assess prediction of nodal metastasis by using molecular features. Experimental Design: We used Affymetrix U133 2.0 plus arrays to compare the tumor genome-wide gene expression of 73 node-positive OSCCs with 40 node-negative OSCCs (>= 18 months). Multivariate linear regression was used to estimate the association between gene expression and nodal metastasis. Stepwise logistic regression and receiver operating characteristics (ROC) analysis were used to generate predictive models and to compare these with models by using tumor size alone. Results: We identified five genes differentially expressed between node-positive and node-negative OSCCs after adjusting for tumor size and human papillomavirus status: REEP1, RNF145, CTONG2002744, MYO5A, and FBXO32. Stepwise regression identified a four-gene model (MYO5A, RFN145, FBXO32, and CTONG2002744) as the most predictive of nodal metastasis. A leave-one-out ROC analysis revealed that our model had a higher area under the curve (AUC) for identifying occult nodal metastasis compared with that of a model by tumor size alone (respective AUC: 0.85 and 0.61; P = 0.011). A model combining tumor size and gene expression did not further improve the prediction of occult metastasis. Independent validation using 31 metastatic and 13 nonmetastatic cases revealed a significant underexpression of CTONG2002744 (P = 0.0004). Conclusions: These results suggest that our gene expression markers of OSCC metastasis hold promise for improving current clinical practice. Confirmation by others and functional studies of CTONG2002744 is warranted. Clin Cancer Res; 17(8); 2466-73. (C) 2011 AACR. C1 [Mendez, Eduardo; Lohavanichbutr, Pawadee; Houck, John R.; Doody, David R.; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA. [Fan, Wenhong; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98109 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Mendez, Eduardo; Futran, Neal D.; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Rue, Tessa C.; Zhao, Lue Ping] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,M-5C800,POB 19024, Seattle, WA 98109 USA. EM cchen@fhcrc.org OI Yueh, Bevan/0000-0003-1380-1053 FU National Cancer Institute, NIH, Bethesda, MD; National Center for Research Resources (NCRR) [1K1L2RR025015-01]; Robert Wood Johnson Foundation; Fred Hutchinson Cancer Research Center FX This study was supported by grant R01CA095419 from the National Cancer Institute, NIH, Bethesda, MD; grant 1K1L2RR025015-01 from the National Center for Research Resources (NCRR); the Harold Amos Medical Faculty Development Program from the Robert Wood Johnson Foundation; funds from the Fred Hutchinson Cancer Research Center; and resources from and use of facilities at the VA Puget Sound Health Care System, University of Washington Medical Center and Harborview Medical Center, Seattle, WA. NR 22 TC 11 Z9 11 U1 2 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 15 PY 2011 VL 17 IS 8 BP 2466 EP 2473 DI 10.1158/1078-0432.CCR-10-0175 PG 8 WC Oncology SC Oncology GA 750NP UT WOS:000289555500041 PM 21300763 ER PT J AU Hirata, H Hinoda, Y Majid, S Chen, Y Zaman, MS Ueno, K Nakajima, K Tabatabai, ZL Ishii, N Dahiya, R AF Hirata, Hiroshi Hinoda, Yuji Majid, Shahana Chen, Yi Zaman, Mohd S. Ueno, Koji Nakajima, Koichi Tabatabai, Z. Laura Ishii, Nobuhisa Dahiya, Rajvir TI DICKKOPF-4 Activates the Noncanonical c-Jun-NH2 Kinase Signaling Pathway While Inhibiting the Wnt-Canonical Pathway in Human Renal Cell Carcinoma SO CANCER LA English DT Article DE real-time reverse transcriptase-polymerase chain reaction; 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium assay; colony-formation assay; fluorescence-activated cell sorting; invasion assay; wound-healing assay; in vivo study; T-cell factor/lymphoid enhancer factor reporter assay; noncanonical pathway; canonical pathway ID CANCER CELLS; COLORECTAL-CANCER; ANTAGONIST GENE; BREAST-CANCER; FAMILY GENES; BETA-CATENIN; APOPTOSIS; JNK; EXPRESSION; REIC/DKK-3 AB BACKGROUND: To the authors' knowledge, the functional significance of the Wnt antagonist dickkopf homolog 4 (DKK4) has not been investigated previously in renal cancer. METHODS: The authors initially observed that the expression of DKK4 was significantly higher in renal cancer tissues compared with adjacent normal kidney tissues. To assess the function of DKK4, stable DKK4-transfected cells were established, and functional analyses were performed, including a T-cell factor/lymphoid enhancer factor (TCF/LEF) reporter assay and tests for cell viability, colony formation, apoptosis, cell cycle, invasive capability, wound-healing capability, and in vivo tumor growth. RESULTS: The relative TCF/LEF activity was significantly lower in DKK4-transfected cells compared with empty vector, and nuclear beta-catenin expression was decreased in DKK4 transfectants. In addition, expression levels of the beta-catenin downstream effector proteins cyclin D1 and c-Myc were decreased in DKK4 transfectants. However, greater invasiveness and migration were observed in stably transfected DKK4 cells. Increased growth of DKK4-transfected tumors also was observed in nude mice. Members of the Wnt noncanonical/c-Jun-NH2 kinase (JNK) signaling pathway also were effected, such as c-Jun, which had significantly increased expression and phosphorylation in DKK4-stable transfectants, and matrix metalloproteinase-2, which had significantly increased expression in DKK4-stable transfectants. CONCLUSIONS: This is the first study to indicate that DKK4 expression is increased in renal cancer tissues and that DKK4 activates the noncanonical JNK signaling pathway while inhibiting the Wnt-canonical pathway. Cancer 2011;117:1649-60. (C) 2010 American Cancer Society. C1 [Hirata, Hiroshi; Majid, Shahana; Chen, Yi; Zaman, Mohd S.; Ueno, Koji; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Hirata, Hiroshi; Majid, Shahana; Chen, Yi; Zaman, Mohd S.; Ueno, Koji; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan. [Nakajima, Koichi; Ishii, Nobuhisa] Toho Univ, Fac Med, Dept Urol, Tokyo, Japan. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu RI Chen, Yi /J-4807-2012 FU National Institutes of Health [RO1CA130860, RO1CA111470, T32-DK07790]; Veterans Affairs Research Enhancement Award Program (REAP); Merit Review grants; Yamada Science Foundation FX This study was supported by grants RO1CA130860, RO1CA111470, T32-DK07790 from the National Institutes of Health; by the Veterans Affairs Research Enhancement Award Program (REAP); by Merit Review grants, and by the Yamada Science Foundation. NR 35 TC 18 Z9 19 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD APR 15 PY 2011 VL 117 IS 8 BP 1649 EP 1660 DI 10.1002/cncr.25666 PG 12 WC Oncology SC Oncology GA 746AM UT WOS:000289213300013 PM 21472712 ER PT J AU Cadena, J Tierney, CJ Restrepo, MI AF Cadena, Jose Tierney, Carrie J. Restrepo, Marcos I. TI Preventing Ventilator Associated Pneumonia: Looking Beyond the Bundles SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID PROGRAM; IMPACT C1 [Cadena, Jose; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Cadena, Jose] S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. [Restrepo, Marcos I.] VERDICT Res Ctr, Dept Pulm & Crit Care Med, San Antonio, TX USA. RP Cadena, J (reprint author), 7703 Floyd Curl Dr MC 7881, San Antonio, TX 78229 USA. EM cadenazuluag@uthscsa.e-du RI Restrepo, Marcos/H-4442-2014 FU NHLBI NIH HHS [K23HL096054, K23 HL096054] NR 9 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2011 VL 52 IS 8 BP 1083 EP 1084 DI 10.1093/cid/cir127 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 747DI UT WOS:000289300100026 PM 21460331 ER PT J AU Qin, HX Zheng, XJ Zhong, XF Shetty, AK Elias, PM Bollag, WB AF Qin, Haixia Zheng, Xiangjian Zhong, Xiaofeng Shetty, Anita K. Elias, Peter M. Bollag, Wendy B. TI Aquaporin-3 in keratinocytes and skin: Its role and interaction with phospholipase D2 SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Review ID CALCIUM-SENSING RECEPTOR; STRATUM-CORNEUM HYDRATION; MURINE EPIDERMAL DIFFERENTIATION; ALTERNATIVELY SPLICED FORM; WATER CHANNEL AQUAPORIN-3; EXTRACELLULAR CALCIUM; PERMEABILITY BARRIER; ULTRASTRUCTURAL-LOCALIZATION; XENOPUS OOCYTES; POTENTIAL ROLE AB Aquaporin 3 (AQP3) is an aquaglyceroporin that transports water and glycerol and is expressed in the epidermis, among other epithelial tissues. We have recently shown that there is an association between this glycerol channel and phospholipase D2 (PLD2) in caveolin-rich membrane microdomains. While PLD2 is able to hydrolyze membrane phospholipids to generate phosphatidic acid, this enzyme also catalyzes, in the presence of primary alcohols, a transphosphatidylation reaction to produce a phosphatidylalcohol. We have proposed that AQP3 associated with PLD2 provides the physiological primary alcohol glycerol to PLD2 for use in the transphosphatidylation reaction to generate phosphatidylglycerol (PG). Further, we have proposed that PG functions as a signaling molecule to mediate early epidermal keratinocyte differentiation, and manipulation of this signaling module inhibits keratinocyte proliferation and enhances differentiation. In contrast, other investigators have suggested a proliferative role for AQP3 in keratinocytes. In addition, AQP3 knockout mice exhibit an epidermal phenotype, characterized by dry skin, decreased elasticity and delayed barrier repair and wound healing, which can be corrected by glycerol but not other humectants. AQP3 levels have also been found to be altered in human skin diseases. In this article the evidence supporting a role for AQP3 in the epidermis will be discussed. Published by Elsevier Inc. C1 [Bollag, Wendy B.] Georgia Hlth Sci Univ, Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA. [Bollag, Wendy B.] Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA. [Qin, Haixia; Zheng, Xiangjian; Zhong, Xiaofeng; Shetty, Anita K.; Bollag, Wendy B.] Georgia Hlth Sci Univ, Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA. [Elias, Peter M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Elias, Peter M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Bollag, WB (reprint author), Georgia Hlth Sci Univ, Med Coll Georgia, Dept Physiol, 1120 15th St, Augusta, GA 30912 USA. EM wbollag@georgiahealth.edu FU Veterans' Administration; National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases [AR45212] FX This project was supported by a Merit Award from the Veterans' Administration and a grant from the National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases #AR45212. NR 68 TC 14 Z9 15 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD APR 15 PY 2011 VL 508 IS 2 SI SI BP 138 EP 143 DI 10.1016/j.abb.2011.01.014 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 740DO UT WOS:000288772000003 PM 21276418 ER PT J AU Katiyar, SK AF Katiyar, Santosh K. TI Green tea prevents non-melanoma skin cancer by enhancing DNA repair SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Review DE Chemoprevention; Contact hypersensitivity; Cyclobutane pyrimidine dimers; Green tea polyphenols; Nucleotide excision repair; Non-melanoma skin cancer; Ultraviolet radiation ID RADIATION-INDUCED IMMUNOSUPPRESSION; ULTRAVIOLET-RADIATION; CONTACT HYPERSENSITIVITY; PYRIMIDINE DIMERS; MOUSE SKIN; XERODERMA-PIGMENTOSUM; TOPICAL APPLICATION; HYDROPHILIC CREAM; HAIRLESS MICE; RISK-FACTOR AB Excessive exposure of the skin to solar ultraviolet (UV) radiation is one of the major factors for the development of skin cancers, including non-melanoma. For the last several centuries the consumption of dietary phytochemicals has been linked to numerous health benefits including the photoprotection of the skin. Green tea has been consumed as a popular beverage world-wide and skin photoprotection by green tea polyphenols (GTPs) has been widely investigated. In this article, we have discussed the recent investigations and mechanistic studies which define the potential efficacy of GTPs on the prevention of non-melanoma skin cancer. UV-induced DNA damage, particularly the formation of cyclobutane pyrimidine dimers, has been implicated in immunosuppression and initiation of skin cancer. Topical application or oral administration of green tea through drinking water of mice prevents UVB-induced skin tumor development, and this prevention is mediated, at least in part, through rapid repair of DNA. The DNA repair by GTPs is mediated through the induction of interleukin (IL)-12 which has been shown to have DNA repair ability. The new mechanistic investigations support and explain the anti-photocarcinogenic activity, in particular anti-non-melanoma skin cancer, of green tea and explain the benefits of green tea for human health. (C) 2010 Elsevier Inc. All rights reserved. C1 [Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Nutr Obes Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, Ctr Comprehens Canc, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Institutes of Health [CA104428, CA140832, AT002536]; Veteran Affairs Merit Review Award FX The work reported from Dr. Katiyar's laboratory was supported by the funds from National Institutes of Health (CA104428, CA140832, and AT002536) and Veteran Affairs Merit Review Award. The content of this article does not necessarily reflect the views or policies of the funding agencies. Grateful thanks to all of the past and present members of my research group for their outstanding contributions. NR 67 TC 30 Z9 38 U1 2 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD APR 15 PY 2011 VL 508 IS 2 SI SI BP 152 EP 158 DI 10.1016/j.abb.2010.11.015 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 740DO UT WOS:000288772000005 PM 21094124 ER PT J AU Athar, M Walsh, SB Kopelovich, L Elmets, CA AF Athar, Mohammad Walsh, Stephanie B. Kopelovich, Levy Elmets, Craig A. TI Pathogenesis of nonmelanoma skin cancers in organ transplant recipients SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Review DE Immunosuppression; Skin cancer; Organ transplant recepients; Pathogenesis; Prevention ID ULTRAVIOLET-RADIATION; CYCLOSPORINE-A; IMMUNOSUPPRESSIVE THERAPY; ORNITHINE-DECARBOXYLASE; MEDICAL PROGRESS; CELL CARCINOMA; INDUCED TUMORS; HAIRLESS MICE; CHEMOPREVENTION; CARCINOGENESIS AB Nonmelanoma skin cancer (NMSC) is the most common human cancer, with an incidence of more than 1.2 million per year in the USA. The risk for the development of NMSCs increases by approximately 10-250 fold in chronically immune suppressed organ transplant recipients (OTRs). Solar UVB is the most common etiologic factor in the development of this neoplasm, both in immune competent and immune suppressed populations. This review provides a description of NMSC in OTRs. It also provides an account of the various immunologic and non-immune-dependent mechanisms involved in the pathogenesis and progression of NMSCs in OTRs. Finally, this review addresses possible strategies for the prevention of this cancer, particularly focusing on the aspects that may be incorporated to prevent negative effects of chemopreventive chemicals on graft survival. (C) 2011 Elsevier Inc. All rights reserved. C1 [Athar, Mohammad; Walsh, Stephanie B.; Elmets, Craig A.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Athar, Mohammad; Walsh, Stephanie B.; Elmets, Craig A.] Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA. [Kopelovich, Levy] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [Elmets, Craig A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Athar, M (reprint author), Univ Alabama, Dept Dermatol, Volker Hall,Room 509,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mathar@uab.edu FU NIH [R01 ES015323, N01-CN-43300, P30 AR050948, R21 ES017494, T32 AR053458] FX This work was supported in part by NIH grants R01 ES015323 (to MA), N01-CN-43300 (to MA), P30 AR050948, R21 ES017494 (to MA), and T32 AR053458 (SBW). NR 53 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD APR 15 PY 2011 VL 508 IS 2 SI SI BP 159 EP 163 DI 10.1016/j.abb.2011.01.004 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 740DO UT WOS:000288772000006 PM 21232524 ER PT J AU Siegle, GJ Steinhauer, SR Friedman, ES Thompson, WS Thase, ME AF Siegle, Greg J. Steinhauer, Stuart R. Friedman, Edward S. Thompson, Wesley S. Thase, Michael E. TI Remission Prognosis for Cognitive Therapy for Recurrent Depression Using the Pupil: Utility and Neural Correlates SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Affect; cognitive therapy; depression; emotion; psychophysiology; psychotherapy; pupilometry; remission ID EMOTIONAL INFORMATION; UNIPOLAR DEPRESSION; BEHAVIORAL THERAPY; MAJOR DEPRESSION; RESPONSES; INVENTORY; FMRI; RUMINATION; SEVERITY; DILATION AB Background: Although up to 60% of people with major depressive disorder respond to cognitive therapy (CT) in controlled trials, clinicians do not routinely use standardized assessments to inform which patients should receive this treatment. Inexpensive, noninvasive prognostic indicators could aid in matching patients with appropriate treatments. Pupillary response to emotional information is an excellent candidate, reflecting limbic reactivity and executive control. This study examined 1) whether pretreatment assessment of pupillary responses to negative information were associated with remission in CT and 2) their associated brain mechanisms. Methods: We examined whether pretreatment pupillary responses to emotional stimuli were prognostic for remission in an inception cohort of 32 unipolar depressed adults to 16 to 20 sessions of CT. Twenty patients were then assessed on the same task using functional magnetic resonance imaging. Pupillary responses were assessed in 51 never-depressed controls for reference. Results: Remission was associated with either low initial severity or the combination of higher initial severity and low sustained pupillary responses to negative words (87% correct classification of remitters and nonremitters, 93% sensitivity, 80% specificity; 88% correct classification of high-severity participants, p < .01, 90% sensitivity, 92% specificity). Increased pupillary responses were associated with increased activity in dorsolateral prefrontal regions associated with executive control and emotion regulation. Conclusions: For patients with higher severity, disruptions of executive control mechanisms responsible for initiating emotion regulation, which are indexed by low sustained pupil responses and targeted in therapy, maybe key to remitting in this intervention. These mechanisms can be measured using inexpensive noninvasive psychophysiological assessments. C1 [Siegle, Greg J.; Steinhauer, Stuart R.; Friedman, Edward S.; Thase, Michael E.] Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. [Siegle, Greg J.; Steinhauer, Stuart R.; Friedman, Edward S.; Thase, Michael E.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Thompson, Wesley S.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Siegle, GJ (reprint author), Western Psychiat Inst & Clin, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA. EM gsiegle@pitt.edu FU National Institute of Mental Health [MH082998, MH064159, MH60473, MH55762, MH58397, MH58356]; National Alliance for Research on Schizophrenia and Depression; Veteran's Administration; Veteran's Research Foundation; Agency for Healthcare Research and Quality; Eli Lilly and Co.; GlaxoSmithKline; National Institute of Mental Health; Sepracor, Inc.; American Psychiatric Publishing, Inc.; Guilford Publications; Herald House; Oxford University Press; W.W. Norton and Company, Inc.; Aspect Medical Systems; Indevus; AstraZeneca; Bristol-Myers Squibb; Sanofi-Aventis; Wyeth-Ayerst; Cyberonics; Novartis; North Star/St. Jude Medical; Medtronics; Respironics; Springer FX This work was supported by National Institute of Mental Health Grant Nos. MH082998, MH064159, MH60473, MH55762, MH58397, and MH58356; National Alliance for Research on Schizophrenia and Depression, the Veteran's Administration, and the Veteran's Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. This material is the result of work supported with resources and the use of facilities at the Pittsburgh VA Healthcare System, Highland Drive Division. We thank Roma Konecky, Lisa Farace, Agnes Haggerty, Mauri Cesare, Mandy Collier, Kelly Magee, and the staff of the Mood Disorders Treatment and Research Program at Western Psychiatric Institute and Clinic. Pupillary response data from a subset of the participants in the current study, on different tasks, has been published in other articles (19,23,34,36) but not with regard to therapeutic change. Data on a subset of these participants who were assessed with functional magnetic resonance imaging following their pupil dilation assessment has also been published (6,19,28), as have relationships of rumination to therapeutic response in a superset of these participants (5). The data presented in those publications do not overlap with this article. Portions of this article were presented at the meeting of the Association for Behavioral and Cognitive Therapies (2008), Orlando, Florida.; Greg Siegle is a consultant for Trial IQ. Michael Thase reported having served as an adviser/consultant for AstraZeneca; Bristol-Myers Squibb Company; Dey Pharma LP; Eli Lilly and Co.; Forest Laboratories; Gerson Lehman Group; GlaxoSmithKline; Guidepoint Global; H. Lundbeck A/S; MedAvante, Inc.; Merck and Co., Inc.; Neuronetics, Inc.; Novartis; Otsuka; Ortho-McNeil Pharmaceuticals; Pamlab, LLC; Pfizer (formerly Wyeth Ayerst Pharmaceuticals); Schering-Plough (formerly Organon, Inc.); Shire US, Inc.; Supernus Pharmaceuticals; Takeda (Lundbeck); and Transcept Pharmaceuticals. Dr. Thase has been a member of the Speakers Bureaus for AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Co.; Merck and Co., Inc.; and Pfizer (formerly Wyeth Ayerst Pharmaceuticals). He receives grant funding from the Agency for Healthcare Research and Quality, Eli Lilly and Co., GlaxoSmithKline, National Institute of Mental Health, and Sepracor, Inc. Dr. Thase has equity holdings in MedAvante, Inc. and receives royalty income from American Psychiatric Publishing, Inc., Guilford Publications, Herald House, Oxford University Press, and W.W. Norton and Company, Inc. His wife is employed as the group scientific director for Embryon (Formerly Advogent; Embryon does business with Bristol-Myers Squibb and Pfizer/Wyeth). Dr. Friedman has obtained grant/research support from Aspect Medical Systems, Indevus, AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Wyeth-Ayerst, Cyberonics, Novartis, North Star/St. Jude Medical, Medtronics, Respironics, National Institute of Mental Health, and Agency for Healthcare Research and Quality. Dr. Friedman also has received other financial or material support (expert testimony, patents, royalties) from Springer. The work was conducted at the University of Pittsburgh School of Medicine and VA Pittsburgh Healthcare System. All other authors reported no biomedical financial interests or potential conflicts of interest. NR 38 TC 44 Z9 47 U1 2 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2011 VL 69 IS 8 BP 726 EP 733 DI 10.1016/j.biopsych.2010.12.041 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 741GS UT WOS:000288852800009 PM 21447417 ER PT J AU Chang, I Liu, J Majid, S Saini, S Zaman, MS Chen, Y Singh, K Shahryari, V Sandhu, H Yamamura, S Dahiya, AV Deng, GR Tanaka, Y AF Chang, Inik Liu, Jan Majid, Shahana Saini, Sharanjot Zaman, Mohd S. Chen, Yi Singh, Kamaldeep Shahryari, Varahram Sandhu, Herman Yamamura, Soichiro Dahiya, Angela V. Deng, Guoren Tanaka, Yuichiro TI Protective effect of catechol-O-methyltransferase in human renal cell carcinogenesis SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Chang, Inik; Liu, Jan; Majid, Shahana; Saini, Sharanjot; Zaman, Mohd S.; Chen, Yi; Singh, Kamaldeep; Shahryari, Varahram; Sandhu, Herman; Yamamura, Soichiro; Dahiya, Angela V.; Deng, Guoren; Tanaka, Yuichiro] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1343 DI 10.1158/1538-7445.AM2011-1343 PG 2 WC Oncology SC Oncology GA V43SO UT WOS:000209701304257 ER PT J AU Keith, RL Blatchford, PJ Kittelson, JK Jackson, M Franklin, WA Minna, J Kelly, K Mao, J Massion, P Wilson, DO Hirsch, FR Bunn, PA Geraci, MW Miller, YE AF Keith, Robert L. Blatchford, Patrick J. Kittelson, John K. Jackson, Mary Franklin, Wilbur A. Minna, John Kelly, Karen Mao, Jenny Massion, Pierre Wilson, David O. Hirsch, Fred R. Bunn, Paul A. Geraci, Mark W. Miller, York E. CA SPORE LCBCC Iloprost Trial TI Oral iloprost improves endobronchial dysplasia in former smokers SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Keith, Robert L.; Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Blatchford, Patrick J.; Kittelson, John K.] Univ Colorado Denver, Aurora, CO USA. [Jackson, Mary; Franklin, Wilbur A.; Kelly, Karen; Hirsch, Fred R.; Bunn, Paul A.; Geraci, Mark W.] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA. [Minna, John] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Mao, Jenny] Univ Calif Los Angeles, Los Angeles, CA USA. [Massion, Pierre] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Wilson, David O.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA LB-90 DI 10.1158/1538-7445.AM2011-LB-90 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701404355 ER PT J AU Mortazavi, F Dubinett, SM Rettig, MB AF Mortazavi, Fariborz (Fred) Dubinett, Steven M. Rettig, Matthew B. TI c-Crk proto-oncogene and TGF-beta signaling pathway contribute to transcriptional repression of p120-catenin in non-small cell lung cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mortazavi, Fariborz (Fred); Rettig, Matthew B.] Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Los Angeles, CA USA. [Dubinett, Steven M.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1084 DI 10.1158/1538-7445.AM2011-1084 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402453 ER PT J AU Nitsche, CJ Moore, RM Maertin, S Mayerle, J Lerch, MM Grippo, P Gukovskaya, AS AF Nitsche, Claudia J. Moore, Ryan M. Maertin, Sandrina Mayerle, Julia Lerch, Markus M. Grippo, Paul Gukovskaya, Anna S. TI Autophagy in pancreatic cancer cells is mediated through a non-canonical Beclin-1 independent pathway SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Nitsche, Claudia J.; Maertin, Sandrina; Mayerle, Julia; Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Internal Med A, Greifswald, Germany. [Moore, Ryan M.; Gukovskaya, Anna S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Moore, Ryan M.; Gukovskaya, Anna S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Grippo, Paul] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3775 DI 10.1158/1538-7445.AM2011-3775 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701400098 ER PT J AU Ueno, K Hirata, H Tabatabai, ZL Hinoda, Y Dahiya, R AF Ueno, Koji Hirata, Hiroshi Tabatabai, Z. Laura Hinoda, Yuji Dahiya, Rajvir TI IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Ueno, Koji; Hirata, Hiroshi; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Ueno, Koji; Hirata, Hiroshi; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Ube, Yamaguchi 755, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 1124 DI 10.1158/1538-7445.AM2011-1124 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403346 ER PT J AU Venkatesan, N Issakhanian, SP Ginther, CG Slamon, DJ Srivatsan, ES Veena, MS AF Venkatesan, Natarajan Issakhanian, Shawnt P. Ginther, Charles G. Slamon, Dennis J. Srivatsan, Eri S. Veena, Mysore S. TI Involvement of somatic mutations in silencing cystatin E/M tumor suppressor gene in breast cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Venkatesan, Natarajan; Issakhanian, Shawnt P.; Ginther, Charles G.; Slamon, Dennis J.] Univ Calif Los Angeles, David Sch Med, Los Angeles, CA USA. [Srivatsan, Eri S.; Veena, Mysore S.] Univ Calif Los Angeles, VA Greater Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 2201 DI 10.1158/1538-7445.AM2011-2201 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701402296 ER PT J AU Yamamura, S Saini, S Majid, S Hirata, H Ueno, K Deng, GR Tanaka, Y Carroll, P Dahiya, R AF Yamamura, Soichiro Saini, Sharanjot Majid, Shahana Hirata, Hiroshi Ueno, Koji Deng, Guoren Tanaka, Yuichiro Carroll, Peter Dahiya, Rajvir TI MicroRNA-34a inhibits proliferation and invasion by targeting c-Myc in prostate cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yamamura, Soichiro; Saini, Sharanjot; Majid, Shahana; Hirata, Hiroshi; Ueno, Koji; Deng, Guoren; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, San Francisco, CA USA. [Carroll, Peter] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2011 VL 71 SU 8 MA 3968 DI 10.1158/1538-7445.AM2011-3968 PG 1 WC Oncology SC Oncology GA V43SP UT WOS:000209701403401 ER PT J AU Akeno, N Smith, EP Stefan, M Huber, AK Zhang, WJ Keddache, M Tomer, Y AF Akeno, Nagako Smith, Eric P. Stefan, Mihaela Huber, Amanda K. Zhang, Weijia Keddache, Mehdi Tomer, Yaron TI IFN-alpha Mediates the Development of Autoimmunity both by Direct Tissue Toxicity and through Immune Cell Recruitment Mechanisms SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CHRONIC HEPATITIS-C; INTERFERON-ALPHA; GENE-EXPRESSION; THYROID AUTOIMMUNITY; I INTERFERONS; HASHIMOTOS-THYROIDITIS; LUPUS-ERYTHEMATOSUS; SJOGRENS-SYNDROME; FAMILY PROTEINS; TRANSGENIC MICE AB IFN-alpha is known to play a key role in autoimmunity, but the mechanisms are uncertain. Although the induction of autoimmunity by IFN-alpha is consistent with primarily immunomodulatory effects, the high frequency of nonautoimmune inflammation suggests other mechanisms. We used thyroiditis as a model to dissect these possibilities. IFN-alpha treatment of cultured thyrocytes increased expression of thyroid differentiation markers, thyroglobulin, thyroid-stimulating hormone receptor, thyroid peroxidase, and sodium iodide transporter. RNAseq analysis demonstrated that pathways of Ag presentation, pattern recognition receptors, and cytokines/chemokines were also stimulated. These changes were associated with markedly increased nonapoptotic thyroid cell death, suggesting direct toxicity. To corroborate these in vitro findings, we created transgenic mice with thyroid-specific overexpression of IFN-alpha under control of the thyroglobulin promoter. Transgenic mice developed marked inflammatory thyroid destruction associated with immune cell infiltration of thyroid and surrounding tissues leading to profound hypothyroidism, findings consistent with our in vitro results. In addition, transgenic mice thyroids showed upregulation of pathways similar to those observed in cultured thyrocytes. In particular, expression of granzyme B, CXCL10, a subset of the tripartite motif-containing family, and other genes involved in recruitment of bystander cytotoxic immune responses were increased. Pathways associated with apoptosis and autophagy were not induced. Taken together, our data demonstrate that the induction of tissue inflammation and autoimmunity by IFN-alpha involves direct tissue toxic effects as well as provocation of destructive bystander immune responses. The Journal of Immunology, 2011, 186: 4693-4706. C1 [Stefan, Mihaela; Huber, Amanda K.; Tomer, Yaron] Mt Sinai Med Ctr, Dept Med, Div Endocrinol, Genome Ctr, New York, NY 10029 USA. [Akeno, Nagako; Smith, Eric P.] Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA. [Zhang, Weijia] Mt Sinai Sch Med, Genome Ctr, Dept Med Bioinformat Core, New York, NY 10029 USA. [Keddache, Mehdi] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Tomer, Yaron] James J Peters Vet Adm Med Ctr, New York, NY USA. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Dept Med, Div Endocrinol, Genome Ctr, Box 1118,1 Gustave L Levy Pl, New York, NY 10029 USA. EM yaron.tomer@mssm.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK61659, DK073681]; Veterans Administration FX This work was supported in part by Grants DK61659 and DK073681 from the National Institute of Diabetes and Digestive and Kidney Diseases and by a Veterans Administration Merit Award (to Y.T.). NR 73 TC 27 Z9 29 U1 0 U2 4 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 15 PY 2011 VL 186 IS 8 BP 4693 EP 4706 DI 10.4049/jimmunol.1002631 PG 14 WC Immunology SC Immunology GA 744FY UT WOS:000289081500021 PM 21402899 ER PT J AU Goldstein, KE Hazlett, EA Savage, KR Berlin, HA Hamilton, HK Zelmanova, Y Look, AE Koenigsberg, HW Mitsis, EM Tang, CY McNamara, M Siever, LJ Cohen, BH New, AS AF Goldstein, Kim E. Hazlett, Erin A. Savage, Kimberley R. Berlin, Heather A. Hamilton, Holly K. Zelmanova, Yuliya Look, Amy E. Koenigsberg, Harold W. Mitsis, Effie M. Tang, Cheuk Y. McNamara, Margaret Siever, Larry J. Cohen, Barry H. New, Antonia S. TI Dorso- and ventro-lateral prefrontal volume and spatial working memory in schizotypal personality disorder SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE Working memory; Borderline personality disorder; Schizotypal personality disorder; Dorsolateral prefrontal cortex; Ventrolateral prefrontal cortex; MRI ID UNMEDICATED SCHIZOPHRENIA-PATIENTS; BORDERLINE PERSONALITY; FRONTAL-LOBE; INDIVIDUAL-DIFFERENCES; AUTOMATED BATTERY; NONHUMAN-PRIMATES; FUNCTIONAL MRI; LARGE-SAMPLE; CORTEX; DEFICITS AB Schizotypal personality disorder (SPD) individuals and borderline personality disorder (BPD) individuals have been reported to show neuropsychological impairments and abnormalities in brain structure. However, relationships between neuropsychological function and brain structure in these groups are not well understood. This study compared visual-spatial working memory (SWM) and its associations with dorsolateral prefrontal cortex (DLPFC) and ventrolateral prefrontal cortex (VLPFC) gray matter volume in 18 unmedicated SPD patients with no BPD traits, 18 unmedicated BPD patients with no SPD traits, and 16 healthy controls (HC). Results showed impaired SWM in SPD but not BPD, compared with HC. Moreover, among the HC group, but not SPD patients, better SWM performance was associated with larger VLPFC (BA44/45) gray matter volume (Fisher's Z p-values < 0.05). Findings suggest spatial working memory impairments may be a core neuropsychological deficit specific to SPD patients and highlight the role of VLPFC subcomponents in normal and dysfunctional memory performance. Published by Elsevier B.V. C1 [Hazlett, Erin A.; Look, Amy E.; Koenigsberg, Harold W.; McNamara, Margaret; Siever, Larry J.; New, Antonia S.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Hazlett, Erin A.; Look, Amy E.; Koenigsberg, Harold W.; McNamara, Margaret; Siever, Larry J.; New, Antonia S.] VISN 3 Mental Illness Res Educ & Clin Ctr MIRECC, Bronx, NY 10468 USA. [Goldstein, Kim E.; Hazlett, Erin A.; Savage, Kimberley R.; Berlin, Heather A.; Hamilton, Holly K.; Zelmanova, Yuliya; Koenigsberg, Harold W.; Mitsis, Effie M.; McNamara, Margaret; Siever, Larry J.; New, Antonia S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Mitsis, Effie M.] James J Peters Vet Affairs Med Ctr Rehabil Med, Bronx, NY USA. [Tang, Cheuk Y.] Mt Sinai Sch Med, Dept Radiol, New York, NY USA. [Cohen, Barry H.] NYU, Dept Psychol, New York, NY 10003 USA. RP Hazlett, EA (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd,Rm 6A-45, Bronx, NY 10468 USA. EM erin.hazlett@mssm.edu FU NIMH [R01MH073911]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [MO1-RR00071]; Mental Illness Research, Education and Clinical Center FX This work was supported by NIMH grant R01MH073911 to Dr. Hazlett. Other support came from Grant Number MO1-RR00071 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and the Mental Illness Research, Education and Clinical Center, VISN 3 Veterans Health Administration. We thank Dr. Monte Buchsbaum who kindly allowed the use of in-house MIPS software. NR 65 TC 10 Z9 10 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD APR 15 PY 2011 VL 218 IS 2 BP 335 EP 340 DI 10.1016/j.bbr.2010.11.042 PG 6 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 730OF UT WOS:000288042600010 PM 21115066 ER PT J AU Hirata, H Hinoda, Y Nakajima, K Kawamoto, K Kikuno, N Ueno, K Yamamura, S Zaman, MS Khatri, G Chen, Y Saini, S Majid, S Deng, GR Ishii, N Dahiya, R AF Hirata, Hiroshi Hinoda, Yuji Nakajima, Koichi Kawamoto, Ken Kikuno, Nobuyuki Ueno, Koji Yamamura, Soichiro Zaman, Mohd S. Khatri, Gaurav Chen, Yi Saini, Sharanjot Majid, Shahana Deng, Guoren Ishii, Nobuhisa Dahiya, Rajvir TI Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE DKK1; methylation; RCC; real-time RT-PCR; TCF/LEF reporter assay; Immunohistochemistry; Western blot; ChIP assay; apoptosis; FACS; cell cycle; invasion assay; in vivo ID SIGNALING PATHWAY; CANCER-CELLS; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; BETA-CATENIN/TCF; DICKKOPF FAMILY; DNA METHYLATION; PROGRESSION; EXPRESSION; REGULATOR AB The functional significance of Wnt antagonist DKK1 has not been investigated in renal cell carcinoma (RCC). Therefore, we hypothesized that DKK1 may be a tumor suppressor gene and is epigenetically silenced, thus decreased DKK1 may cause progression of RCC. To assess the function of DKK1, we established stable DKK1 transfected cells and monitored them regarding cell viability, colony formation, apoptosis, cell cycle, and invasive capability. RCC cell lines had decreased levels of DKK1, which were increased after treatment with 5-Aza-20-deoxycytidine and trichostatin A. In chromatin immunoprecipitation assay, the level of dimethyl H3K9 and trimethyl H3K27 was decreased after 5-Aza-20-deoxycytidine/ trichostatin A treatment in RCC cell lines. Increased methylation was also associated with higher pathological stages in primary RCC tissues. T-cell factor/ lymphoid enhancer factor activity and nuclear beta-catenin expression were not changed in DKK1 transfectants. Also the expression of cyclinD1 and c-Myc was not changed in DKK1 transfectants. These results suggest that DKK1 may not be involved in the beta-catenin dependent pathway. We also evaluated the expression of various related genes. Cleaved caspase3, p53, p21 and puma expression were significantly upregulated in the DKK1 transfected cells. The population of apoptotic cells was increased in stable DKK1 cells and tumor growth suppression was also observed in nude mice with DKK1 transfected cells. In conclusion, this is the first report to show that DKK1 expression is epigenetically silenced in kidney cancer and its reexpression induces apoptosis and cell cycle arrest in RCC. C1 [Hirata, Hiroshi; Kawamoto, Ken; Kikuno, Nobuyuki; Ueno, Koji; Yamamura, Soichiro; Zaman, Mohd S.; Khatri, Gaurav; Chen, Yi; Saini, Sharanjot; Majid, Shahana; Deng, Guoren; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Hirata, Hiroshi; Kawamoto, Ken; Kikuno, Nobuyuki; Ueno, Koji; Yamamura, Soichiro; Zaman, Mohd S.; Khatri, Gaurav; Chen, Yi; Saini, Sharanjot; Majid, Shahana; Deng, Guoren; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan. [Nakajima, Koichi; Ishii, Nobuhisa] Toho Univ, Fac Med, Dept Urol, Tokyo, Japan. RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu RI Chen, Yi /J-4807-2012 FU NIH [RO1CA130860, RO1CA111470, T32-DK07790]; VA Research Enhancement Award Program (REAP); Yamada Science Foundation FX Grant sponsor: NIH; Grant numbers: RO1CA130860, RO1CA111470, T32-DK07790; Grant sponsors: VA Research Enhancement Award Program (REAP), Merit Review grants, and Yamada Science Foundation NR 34 TC 45 Z9 51 U1 1 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD APR 15 PY 2011 VL 128 IS 8 BP 1793 EP 1803 DI 10.1002/ijc.25507 PG 11 WC Oncology SC Oncology GA 730MM UT WOS:000288037400005 PM 20549706 ER PT J AU Qureshi, AA Karpen, CW Qureshi, N Papasian, CJ Morrison, DC Folts, JD AF Qureshi, Asaf A. Karpen, Charles W. Qureshi, Nilofer Papasian, Christopher J. Morrison, David C. Folts, John D. TI Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries SO LIPIDS IN HEALTH AND DISEASE LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; VITAMIN-E SUPPLEMENTATION; RICH FRACTION TRF25; ALPHA-TOCOPHEROL; HYPERCHOLESTEROLEMIC HUMANS; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR-DISEASE; GAMMA-TOCOPHEROL; BRAN; ATHEROGENESIS AB Background: Dietary supplementation with tocotrienols has been shown to decrease the risk of coronary artery disease. Tocotrienols are plant-derived forms of vitamin E, which have potent anti-inflammatory, antioxidant, anticancer, hypocholesterolemic, and neuroprotective properties. Our objective in this study was to determine the extent to which tocotrienols inhibit platelet aggregation and reduce coronary thrombosis, a major risk factor for stroke in humans. The present study was carried out to determine the comparative effects of alpha-tocopherol, alpha-tocotrienol, or tocotrienol rich fraction (TRF; a mixture of alpha(-) + gamma(-) + delta tocotrienols) on in vivo platelet thrombosis and ex vivo platelet aggregation (PA) after intravenous injection in anesthetized dogs, by using a mechanically stenosed circumflex coronary artery model (Folts' cyclic flow model). Results: Collagen-induced platelet aggregation (PA) in platelet rich plasma (PRP) was decreased markedly after treatment with alpha-tocotrienol (59%; P < 0.001) and TRF (92%; P < 0.001). alpha-Tocopherol treatment was less effective, producing only a 22% (P < 0.05) decrease in PA. Adenosine diphosphate-induced (ADP) PA was also decreased after treatment with alpha-tocotrienol (34%; P < 0.05) and TRF (42%; P < 0.025). These results also indicate that intravenously administered tocotrienols were significantly better than tocopherols in inhibiting cyclic flow reductions (CFRs), a measure of the acute platelet-mediated thrombus formation. Tocotrienols (TRF) given intravenously (10 mg/kg), abolished CFRs after a mean of 68 min (range 22 - 130 min), and this abolition of CFRs was sustained throughout the monitoring period (50 - 160 min). Next, pharmacokinetic studies were carried out and tocol levels in canine plasma and platelets were measured. As expected, alpha-Tocopherol treatment increased levels of total tocopherols in post-vs pre-treatment specimens (57 vs 18 mu g/mL in plasma, and 42 vs 10 mu g/mL in platelets). However, treatment with alpha-tocopherol resulted in slightly decreased levels of tocotrienols in post-vs pre-treatment samples (1.4 vs 2.9 mu g/mL in plasma and 2.3 vs 2.8 mu g/mL in platelets). alpha-Tocotrienol treatment increased levels of both tocopherols and tocotrienols in post-vs pre-treatment samples (tocopherols, 45 vs 10 mu g/mL in plasma and 28 vs 5 mu g/mL in platelets; tocotrienols, 2.8 vs 0.9 mu g/mL in plasma and 1.28 vs 1.02 mu g/mL in platelets). Treatment with tocotrienols (TRF) also increased levels of tocopherols and tocotrienols in post-vs pre-treatment samples (tocopherols, 68 vs 20 mu g/mL in plasma and 31.4 vs 7.9 mu g/mL in platelets; tocotrienols, 8.6 vs 1.7 mu g/mL in plasma and 3.8 vs 3.9 mu g/mL in platelets). Conclusions: The present results indicate that intravenously administered tocotrienols inhibited acute platelet-mediated thrombus formation, and collagen and ADP-induced platelet aggregation. alpha-Tocotrienols treatment induced increases in alpha-tocopherol levels of 4-fold and 6-fold in plasma and platelets, respectively. Interestingly, tocotrienols (TRF) treatment induced a less pronounced increase in the levels of tocotrienols in plasma and platelets, suggesting that intravenously administered tocotrienols may be converted to tocopherols. Tocotrienols, given intravenously, could potentially prevent pathological platelet thrombus formation and thus provide a therapeutic benefit in conditions such as stroke and myocardial infarction. C1 [Qureshi, Asaf A.; Qureshi, Nilofer; Papasian, Christopher J.; Morrison, David C.] Univ Missouri, Dept Basic Med Sci, Sch Med, Kansas City, MO 64108 USA. [Qureshi, Asaf A.] Adv Med Res, Madison, WI 53719 USA. [Karpen, Charles W.] Prairie Cardiovasc Consultants, Springfield, IL 62701 USA. [Qureshi, Nilofer] Univ Missouri, Dept Pharmacol Toxicol, Kansas City, MO 64108 USA. [Folts, John D.] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Cardiovasc Sect, Madison, WI 53705 USA. RP Qureshi, AA (reprint author), Univ Missouri, Dept Basic Med Sci, Sch Med, 2411 Holmes St, Kansas City, MO 64108 USA. EM qureshia@umkc.edu FU Advanced Medical Research (AMR); NIH [GM-50870] FX We thank Ms. Lei He of Department of Nutrition Sciences, University of Wisconsin, Madison for helpful discussions and technical assistance for carrying out the estimation of tocols (tocopherols and tocotrienols) by HPLC of all dog's samples (plasma and platelets) at Advanced Medical Research, 8251 Raymond Road, Madison, Wisconsin, 53719, USA. We also thank Mr. Keith Gilchrist (USDA, ARS, MWA, Cereals and Crops Research Laboratory, Madison, WI, 53726, USA) for carrying out statistical analyses of the data. The TRF (mixture of alpha-tocopherol + alpha-, alpha-, delta-tocotrienols) of palm oil was supplied by Malaysian Palm Oil Board, Kuala Lumpur, Malaysia (previously known as Palm Oil Research Institute of Malaysia [PORIM]). This study was supported in part by Advanced Medical Research (AMR) and NIH grant GM-50870 (NQ). The study was carried out under a FDA approved IND number 36906. NR 66 TC 7 Z9 7 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-511X J9 LIPIDS HEALTH DIS JI Lipids Health Dis. PD APR 14 PY 2011 VL 10 AR 58 DI 10.1186/1476-511X-10-58 PG 13 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA 765ME UT WOS:000290710200001 PM 21489303 ER PT J AU Jain, R Kralovic, SM Evans, ME Ambrose, M Simbartl, LA Obrosky, DS Render, ML Freyberg, RW Jernigan, JA Muder, RR Miller, LJ Roselle, GA AF Jain, Rajiv Kralovic, Stephen M. Evans, Martin E. Ambrose, Meredith Simbartl, Loretta A. Obrosky, D. Scott Render, Marta L. Freyberg, Ron W. Jernigan, John A. Muder, Robert R. Miller, LaToya J. Roselle, Gary A. TI Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus aureus Infections SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; BLOOD-STREAM INFECTIONS; NOSOCOMIAL TRANSMISSION; COLONIZATION PRESSURE; HOSPITAL ADMISSION; RISK; MRSA; SURVEILLANCE; MULTICENTER; PRECAUTIONS AB BACKGROUND Health care-associated infections with methicillin-resistant Staphylococcus aureus (MRSA) have been an increasing concern in Veterans Affairs (VA) hospitals. METHODS A "MRSA bundle" was implemented in 2007 in acute care VA hospitals nationwide in an effort to decrease health care-associated infections with MRSA. The bundle consisted of universal nasal surveillance for MRSA, contact precautions for patients colonized or infected with MRSA, hand hygiene, and a change in the institutional culture whereby infection control would become the responsibility of everyone who had contact with patients. Each month, personnel at each facility entered into a central database aggregate data on adherence to surveillance practice, the prevalence of MRSA colonization or infection, and health care-associated transmissions of and infections with MRSA. We assessed the effect of the MRSA bundle on health care-associated MRSA infections. RESULTS From October 2007, when the bundle was fully implemented, through June 2010, there were 1,934,598 admissions to or transfers or discharges from intensive care units (ICUs) and non-ICUs (ICUs, 365,139; non-ICUs, 1,569,459) and 8,318,675 patient-days (ICUs, 1,312,840; and non-ICUs, 7,005,835). During this period, the percentage of patients who were screened at admission increased from 82% to 96%, and the percentage who were screened at transfer or discharge increased from 72% to 93%. The mean (+/- SD) prevalence of MRSA colonization or infection at the time of hospital admission was 13.6 +/- 3.7%. The rates of health care-associated MRSA infections in ICUs had not changed in the 2 years before October 2007 (P = 0.50 for trend) but declined with implementation of the bundle, from 1.64 infections per 1000 patient-days in October 2007 to 0.62 per 1000 patient-days in June 2010, a decrease of 62% (P<0.001 for trend). During this same period, the rates of health care-associated MRSA infections in non-ICUs fell from 0.47 per 1000 patient-days to 0.26 per 1000 patient-days, a decrease of 45% (P<0.001 for trend). CONCLUSIONS A program of universal surveillance, contact precautions, hand hygiene, and institutional culture change was associated with a decrease in health care-associated transmissions of and infections with MRSA in a large health care system. C1 [Jain, Rajiv; Evans, Martin E.; Ambrose, Meredith; Miller, LaToya J.] Vet Affairs Cent Off, Patient Care Serv, Vet Hlth Adm MRSA Program Off, Pittsburgh, PA USA. [Jain, Rajiv; Evans, Martin E.; Ambrose, Meredith; Miller, LaToya J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Jain, Rajiv; Muder, Robert R.] VA Pittsburgh Healthcare Syst, Dept Internal Med, Pittsburgh, PA USA. [Jain, Rajiv; Muder, Robert R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Obrosky, D. Scott] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] VA Cent Off, Patient Care Serv, Natl Infect Dis Program Off, Cincinnati, OH USA. [Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Kralovic, Stephen M.; Render, Marta L.; Roselle, Gary A.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA. [Render, Marta L.; Freyberg, Ron W.] VA Inpatient Evaluat Ctr, Cincinnati, OH USA. [Evans, Martin E.] Univ Kentucky, Sch Med, Dept Internal Med, Lexington, KY 40506 USA. [Jernigan, John A.] Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Atlanta, GA USA. RP Evans, ME (reprint author), Lexington VAMC, VHA MDRO Program, 1101 Vet Dr,11I-CDD, Lexington, KY 40502 USA. EM martin.evans@va.gov NR 35 TC 244 Z9 258 U1 3 U2 21 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 14 PY 2011 VL 364 IS 15 BP 1419 EP 1430 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 749LD UT WOS:000289467200006 PM 21488764 ER PT J AU Hysong, SJ Sawhney, MK Wilson, L Sittig, DF Esquivel, A Singh, S Singh, H AF Hysong, Sylvia J. Sawhney, Mona K. Wilson, Lindsey Sittig, Dean F. Esquivel, Adol Singh, Simran Singh, Hardeep TI Understanding the management of electronic test result notifications in the outpatient setting SO BMC MEDICAL INFORMATICS AND DECISION MAKING LA English DT Article DE Decision Support Systems Clinical; Automated notification; diagnostic errors; abnormal diagnostic test results; Medical Records Systems; Computerized; patient follow-up; patient safety; health information technology; communication; primary care ID DRUG INTERACTION ALERTS; FOLLOW-UP; CLINICAL REMINDERS; CANCER-DIAGNOSIS; OPPORTUNITIES; MEDICINE; BARRIERS; IMPROVE; SYSTEM; RECORD AB Background: Notifying clinicians about abnormal test results through electronic health record (EHR) -based "alert" notifications may not always lead to timely follow-up of patients. We sought to understand barriers, facilitators, and potential interventions for safe and effective management of abnormal test result delivery via electronic alerts. Methods: We conducted a qualitative study consisting of six 6-8 member focus groups (N = 44) at two large, geographically dispersed Veterans Affairs facilities. Participants included full-time primary care providers, and personnel representing diagnostic services (radiology, laboratory) and information technology. We asked participants to discuss barriers, facilitators, and suggestions for improving timely management and follow-up of abnormal test result notifications and encouraged them to consider technological issues, as well as broader, human-factor-related aspects of EHR use such as organizational, personnel, and workflow. Results: Providers reported receiving a large number of alerts containing information unrelated to abnormal test results, many of which were believed to be unnecessary. Some providers also reported lacking proficiency in use of certain EHR features that would enable them to manage alerts more efficiently. Suggestions for improvement included improving display and tracking processes for critical alerts in the EHR, redesigning clinical workflow, and streamlining policies and procedures related to test result notification. Conclusion: Providers perceive several challenges for fail-safe electronic communication and tracking of abnormal test results. A multi-dimensional approach that addresses technology as well as the many non-technological factors we elicited is essential to design interventions to reduce missed test results in EHRs. C1 [Hysong, Sylvia J.; Sawhney, Mona K.; Wilson, Lindsey; Singh, Hardeep] Baylor Coll Med, Houston VA Hlth Sci Res & Dev Ctr Excellence, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Hysong, Sylvia J.; Sawhney, Mona K.; Wilson, Lindsey; Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Esquivel, Adol] St Lukes Episcopal Hlth Syst, Houston, TX USA. [Singh, Simran] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. RP Hysong, SJ (reprint author), Baylor Coll Med, Houston VA Hlth Sci Res & Dev Ctr Excellence, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM sylvia.hysong@va.gov RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207 FU VA Career Development Award [CD2-07-0181]; NIH [K23CA125585]; VA National Center of Patient Safety; Houston VA HSR&D Center of Excellence [HFP90 020]; W. M. Keck Center for Interdisciplinary Bioscience Training of the Gulf Coast Consortia [T32 HS017586] FX This study was supported by a VA Career Development Award (CD2-07-0181) to Dr. Hysong, an NIH K23 career development award (K23CA125585) awarded to Dr Singh, the VA National Center of Patient Safety, and in part by the Houston VA HSR&D Center of Excellence (HFP90 020) and AHRQ Training Program of the W. M. Keck Center for Interdisciplinary Bioscience Training of the Gulf Coast Consortia (AHRQ Grant No. T32 HS017586). The views expressed in this article are solely those of the authors and do not necessarily reflect the position or policy of the authors' affiliated institutions or the granting agencies supporting this work. NR 34 TC 18 Z9 18 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6947 J9 BMC MED INFORM DECIS JI BMC Med. Inform. Decis. Mak. PD APR 12 PY 2011 VL 11 AR 22 DI 10.1186/1472-6947-11-22 PG 9 WC Medical Informatics SC Medical Informatics GA 768BT UT WOS:000290907200001 PM 21486478 ER PT J AU White, MR Jacobson, IG Smith, B Wells, TS Gackstetter, GD Boyko, EJ Smith, TC AF White, Martin R. Jacobson, Isabel G. Smith, Besa Wells, Timothy S. Gackstetter, Gary D. Boyko, Edward J. Smith, Tyler C. CA Millennium Cohort Study Team TI Health care utilization among complementary and alternative medicine users in a large military cohort SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID UNITED-STATES; MILLENNIUM COHORT; DRUG-INTERACTIONS; PREVALENCE; THERAPIES; SELECTION; SYMPTOMS; PATTERNS; SCORES; TRENDS AB Background: Complementary and Alternative Medicine use and how it impacts health care utilization in the United States Military is not well documented. Using data from the Millennium Cohort Study we describe the characteristics of CAM users in a large military population and document their health care needs over a 12-month period. The aim of this study was to determine if CAM users are requiring more physician-based medical services than users of conventional medicine. Methods: Inpatient and outpatient medical services were documented over a 12-month period for 44,287 participants from the Millennium Cohort Study. Equal access to medical services was available to anyone needing medical care during this study period. The number and types of medical visits were compared between CAM and non-CAM users. Chi square test and multivariable logistic regression was applied for the analysis. Results: Of the 44,287 participants, 39% reported using at least one CAM therapy, and 61% reported not using any CAM therapies. Those individuals reporting CAM use accounted for 45.1% of outpatient care and 44.8% of inpatient care. Individuals reporting one or more health conditions were 15% more likely to report CAM use than non-CAM users and 19% more likely to report CAM use if reporting one or more health symptoms compared to non-CAM users. The unadjusted odds ratio for hospitalizations in CAM users compared to non-CAM users was 1.29 (95% CI: 1.16-1.43). The mean number of days receiving outpatient care for CAM users was 7.0 days and 5.9 days for non-CAM users (p < 0.001). Conclusions: Our study found those who report CAM use were requiring more physician-based medical services than users of conventional medicine. This appears to be primarily the result of an increase in the number of health conditions and symptoms reported by CAM users. C1 [White, Martin R.; Jacobson, Isabel G.; Smith, Besa; Wells, Timothy S.; Smith, Tyler C.] USN, Dept Def Ctr Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92152 USA. [Gackstetter, Gary D.] Analyt Serv Inc ANSER, Arlington, VA USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. RP White, MR (reprint author), USN, Dept Def Ctr Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92152 USA. EM martin.white@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X FU Department of Veterans Affairs; Henry M. Jackson Foundation FX We appreciate the support of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD.; The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of the Army, Department of the Air Force, Department of Defense, or the US Government. The Department of Veterans Affairs supported Dr. Boyko's involvement in this research. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (protocol NHRC.2000.0007). NR 39 TC 14 Z9 14 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD APR 11 PY 2011 VL 11 AR 27 DI 10.1186/1472-6882-11-27 PG 11 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 755SF UT WOS:000289956000001 PM 21481260 ER PT J AU Stengel, A Coskun, T Goebel-Stengel, M Craft, LS Alsina-Fernandez, J Wang, LX Rivier, J Tache, Y AF Stengel, Andreas Coskun, Tamer Goebel-Stengel, Miriam Craft, Libbey S. Alsina-Fernandez, Jorge Wang, Lixin Rivier, Jean Tache, Yvette TI Chronic injection of pansomatostatin agonist ODT8-SST differentially modulates food intake and decreases body weight gain in lean and diet-induced obese rats SO REGULATORY PEPTIDES LA English DT Article DE Body weight; Brain; Diet-induced obesity; Fat mass; Lean body mass; Somatostatin ID CORTICOTROPIN-RELEASING-FACTOR; GROWTH-HORMONE-SECRETION; CENTRAL-NERVOUS-SYSTEM; SOMATOSTATIN RECEPTOR; NEUROPEPTIDE-Y; PERIVENTRICULAR NUCLEUS; STIMULATING HORMONE; INHIBITS SECRETION; FEEDING RESPONSE; BARREL ROTATION AB The aim of this study was to investigate the central actions of the stable pansomatostatin peptide agonist. ODT8-SST on body weight. ODT8-SST or vehicle was acutely (1 mu g/rat) injected or chronically infused (5 mu g/rat/d, 14 d) intracerebroventricularly and daily food intake, body weight and composition were monitored. In lean rats, neither acute nor chronic ODT8-SST influenced daily food intake while body weight was reduced by 2.2% after acute injection and there was a 14 g reduction of body weight gain after 14 d compared to vehicle (p < 0.01). In diet-induced obese (DIO) rats, chronic ODT8-SST increased cumulative 2-week food intake compared to vehicle (+14%, p < 0.05) and also blunted body weight change (-11 g, p<0.05). ODT8-SST for 14 d reduced lean mass (-22 g and -25 g respectively, p < 0.001) and total water (-19g and -22 g respectively, p<0.001) in lean and DIO rats and increased fat mass in DIO (+16 g, p<0.001) but not lean rats (+1 g, p > 0.05) compared to vehicle. In DIO rats, ODT8-SST reduced ambulatory (-27%/24 h, p<0.05) and fine movements (-38%, p<0.01) which was associated with an increased positive energy balance compared to vehicle (+ 50g. p<0.01). Chronic central somatostatin receptor activation in lean rats reduces body weight gain and lean mass independently of food intake which is likely related to growth hormone inhibition. In DIO rats, ODT8-SST reduces lean mass but promotes food intake and fat mass, indicating differential responsiveness to somatostatin under obese conditions. (C) 2011 Elsevier B.V. All rights reserved. C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. [Stengel, Andreas; Goebel-Stengel, Miriam; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress,Digest Dis Div, Los Angeles, CA 90024 USA. [Coskun, Tamer; Craft, Libbey S.; Alsina-Fernandez, Jorge] Eli Lilly & Co, Biotechnol Discovery Res, Indianapolis, IN 46285 USA. [Rivier, Jean] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU German Research Foundation [STE 1765/1-1, GO 1718/1-1, NIH R01 DK-33061, DK-41301]; VA FX This study was supported by German Research Foundation Grants STE 1765/1-1 (A.S.), GO 1718/1-1 (M.G.-S.), NIH R01 DK-33061, Center Grant DK-41301 (Animal Core) (Y.T.), VA Research Career Scientist Award (Y.T.) and VA Rehabilitation Research and Development Grant (Y.T., A.S.). J.R. is the Dr. Frederik Paulsen Chair in Neurosciences Professor. We are grateful to Mrs. Honghui Liang and Mrs. Hsui-Chiung Yang for their excellent technical support and we thank Ms. Eugenia Hu for reviewing the manuscript. NR 47 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD APR 11 PY 2011 VL 167 IS 2-3 BP 201 EP 208 DI 10.1016/j.regpep.2011.01.006 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 755JT UT WOS:000289927000007 PM 21315111 ER PT J AU Casarett, D Johnson, M Smith, D Richardson, D AF Casarett, David Johnson, Megan Smith, Dawn Richardson, Diane TI The Optimal Delivery of Palliative Care A National Comparison of the Outcomes of Consultation Teams vs Inpatient Units SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LIFE CARE; ADVANCED CANCER; FAMILY-MEMBERS; QUALITY MEASURE; TERMINALLY-ILL; END; IMPACT; DEATH; COMMUNICATION AB Background: Growing attention to end-of-life care has led to intensive efforts to provide better palliative care. However, it is not known whether palliative care is best provided by consultative teams or in dedicated units. Methods: This nationwide telephone survey was conducted in 77 Veterans Affairs medical centers that offer palliative care consultation services and dedicated palliative care units. One family member per patient who died at a participating Veterans Affairs medical center between July 1, 2008, and December 31, 2009, was invited to participate. The telephone survey included 1 global rating item and 9 core items describing the patient's care in the last month of life. Results: Interviews were completed with family members for 5901 of 9546 patients. Of these, 1873 received usual care, 1549 received a palliative care consultation, and 2479 received care in a palliative care unit. After non-response weighting and propensity score adjustment, families of patients who received a palliative care consultation were more likely than those who received usual care to report that the patient's care in the last month of life had been "excellent" (adjusted proportions: 51% vs 46%; odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02-1.55; P=.04). However, families of patients who received care in a palliative care unit were even more likely to report excellent care (adjusted proportions: 63% vs 53%; OR, 1.52; 95% CI, 1.25-1.85; P <.001). Conclusion: Care received in palliative care units may offer more improvements in care than those achieved with palliative care consultations. C1 [Casarett, David] Univ Penn, Div Geriatr Med, Sch Med, Philadelphia, PA 19104 USA. [Johnson, Megan; Smith, Dawn; Richardson, Diane] Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Med Ctr, Philadelphia, PA USA. RP Casarett, D (reprint author), Univ Penn, Div Geriatr Med, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Human Services Research and Development; Department of Veterans Affairs Comprehensive End-of-Life Care Initiative FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Human Services Research and Development. This work was funded as part of a grant from the Department of Veterans Affairs Comprehensive End-of-Life Care Initiative (Dr Casarett). NR 46 TC 38 Z9 38 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 11 PY 2011 VL 171 IS 7 BP 649 EP 655 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 754PI UT WOS:000289867700009 PM 21482838 ER PT J AU Laitman, BM DaSilva, JK Ross, RJ Tejani-Butt, S Morrison, AR AF Laitman, Benjamin M. DaSilva, Jamie K. Ross, Richard J. Tejani-Butt, Shanaz Morrison, Adrian R. TI Reduced gamma range activity at REM sleep onset and termination in fear-conditioned Wistar-Kyoto rats SO NEUROSCIENCE LETTERS LA English DT Article DE Gamma power; Rapid eye movement sleep; Fear conditioning; Posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; WKY RATS; DEPENDENT PLASTICITY; DEPRESSIVE BEHAVIOR; SPRAGUE-DAWLEY; TWIN; OSCILLATION; PERFORMANCE; MECHANISMS; STATES AB Recent investigations of rapid eye movement sleep (REMS) continuity have emphasized the importance of transitions both into and out of REMS. We have previously reported that, compared to Wistar rats (WIS), Wistar-Kyoto rats (WIN) responded to fear conditioning (FC) with more fragmented REMS. Gamma oscillations in the electroencephalogram (EEG) are synchronized throughout the brain in periods of focused attention, and such synchronization of cell assemblies in the brain may represent a temporal binding mechanism. Therefore, we examined the effects of FC on EEG gamma range activity (30-50 Hz) at REMS transitions in WKY compared to WIS. Relative power in the gamma range (measured as a percent of total power) at Baseline and upon re-exposure to the fear-inducing conditioning stimulus was measured 35s before REMS onset to 105s after REMS onset (ARO) and 85s before REMS termination (BRT) to 35 s after REMS termination. After baseline recording, rats received 10 tones, each co-terminating with an electric foot shock. On Days 1 and 14 post-conditioning, rats were re-exposed to three tones. Fast-Fourier transforms created power spectral data in the gamma frequency domain. Relative power was extracted from an average of 4-5 REMS transitions. Relative gamma power was always higher in WIS. On Day 14, at 15 s and 25s ARO, WIN had significant increases in relative gamma power from Baseline. WIS had a significant increase on Day 1 at 25 s ARO. Despite the increases in relative gamma power, WIN never achieved levels attained by WIS. Moreover, at 5 s BRT, only WKY had a significant decrease in relative gamma power from Baseline to Day 14. Gamma range activity may indicate neural activity underlying maintenance of REMS continuity. Low relative gamma power at REMS transitions may be associated with increased REMS fragmentation in WKY after FC. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Laitman, Benjamin M.; Ross, Richard J.; Morrison, Adrian R.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA. [DaSilva, Jamie K.; Tejani-Butt, Shanaz] Univ Sci Philadelphia, Dept Pharmaceut Sci, Philadelphia, PA 19104 USA. [Ross, Richard J.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Ross, Richard J.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA 19104 USA. RP Laitman, BM (reprint author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA. EM laitman@sas.upenn.edu FU UPSHS [MH072897, AA015921] FX Supported by UPSHS grants MH072897 to Adrian R. Morrison and AA015921 to Shanaz Tejani-Butt. The content of this article does not reflect the views of the Department of Veterans Affairs or of the U.S. Government. We also gratefully acknowledge contributions of Graziella L Mann and Dr. Philip R. Gehrman. NR 35 TC 3 Z9 3 U1 1 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD APR 8 PY 2011 VL 493 IS 1-2 BP 14 EP 17 DI 10.1016/j.neulet.2011.02.003 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 745QN UT WOS:000289180800003 PM 21316420 ER PT J AU Reed, MC Dhaliwal, G Saint, S Nallamothu, BK AF Reed, Michael C. Dhaliwal, Gurpreet Saint, Sanjay Nallamothu, Brahmajee K. TI The Right Angle SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CENTRAL VENOUS-PRESSURE; CONSTRICTIVE PERICARDITIS; RESTRICTIVE CARDIOMYOPATHY; CRITICALLY ILL; MODERN-ERA; PATIENT; IMPACT C1 [Reed, Michael C.; Saint, Sanjay; Nallamothu, Brahmajee K.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Saint, Sanjay; Nallamothu, Brahmajee K.] Ann Arbor Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Internal Med, San Francisco, CA USA. RP Reed, MC (reprint author), Univ Michigan, Dept Internal Med, 1500 E Med Ctr Dr,SPC 5869, Ann Arbor, MI 48109 USA. EM micreed@med.umich.edu NR 15 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 7 PY 2011 VL 364 IS 14 BP 1350 EP 1356 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 745WS UT WOS:000289202800012 PM 21470013 ER PT J AU Lee, SJ Eng, C AF Lee, Sei J. Eng, Catherine TI Goals of Glycemic Control in Frail Older Patients With Diabetes SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID POPULATION; DISABILITY C1 [Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. [Lee, Sei J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Eng, Catherine] On Lok Lifeways, San Francisco, CA USA. RP Lee, SJ (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Bldg 1,Room 211A, San Francisco, CA 94121 USA. EM sei.lee@ucsf.edu FU NCRR NIH HHS [KL2 RR024130] NR 10 TC 24 Z9 25 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 6 PY 2011 VL 305 IS 13 BP 1350 EP 1351 DI 10.1001/jama.2011.404 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 745JT UT WOS:000289162400026 PM 21467289 ER PT J AU Streb, JW Long, XC Lee, TH Sun, QA Kitchen, CM Georger, MA Slivano, OJ Blaner, WS Carr, DW Gelman, IH Miano, JM AF Streb, Jeffrey W. Long, Xiaochun Lee, Ting-Hein Sun, Qiang Kitchen, Chad M. Georger, Mary A. Slivano, Orazio J. Blaner, William S. Carr, Daniel W. Gelman, Irwin H. Miano, Joseph M. TI Retinoid-Induced Expression and Activity of an Immediate Early Tumor Suppressor Gene in Vascular Smooth Muscle Cells SO PLOS ONE LA English DT Article ID PROLIFERATION IN-VITRO; SERUM RESPONSE FACTOR; KINASE-C SUBSTRATE; PROTEIN-KINASE; INTIMAL HYPERPLASIA; NEOINTIMA FORMATION; ANGIOTENSIN-II; CYTOSKELETAL ARCHITECTURE; BALLOON ANGIOPLASTY; NUCLEAR RECEPTORS AB Retinoids are used clinically to treat a number of hyper-proliferative disorders and have been shown in experimental animals to attenuate vascular occlusive diseases, presumably through nuclear receptors bound to retinoic acid response elements (RARE) located in target genes. Here, we show that natural or synthetic retinoids rapidly induce mRNA and protein expression of a specific isoform of A-Kinase Anchoring Protein 12 (AKAP12 beta) in cultured smooth muscle cells (SMC) as well as the intact vessel wall. Expression kinetics and actinomycin D studies indicate Akap12 beta is a retinoid-induced, immediate-early gene. Akap12 beta promoter analyses reveal a conserved RARE mildly induced with atRA in a region that exhibits hyperacetylation. Immunofluorescence microscopy and protein kinase A (PKA) regulatory subunit overlay assays in SMC suggest a physical association between AKAP12 beta and PKA following retinoid treatment. Consistent with its designation as a tumor suppressor, inducible expression of AKAP12 beta attenuates SMC growth in vitro. Further, immunohistochemistry studies establish marked decreases in AKAP12 expression in experimentally-injured vessels of mice as well as atheromatous lesions in humans. Collectively, these results demonstrate a novel role for retinoids in the induction of an AKAP tumor suppressor that blocks vascular SMC growth thus providing new molecular insight into how retiniods may exert their anti-proliferative effects in the injured vessel wall. C1 [Streb, Jeffrey W.; Long, Xiaochun; Lee, Ting-Hein; Sun, Qiang; Kitchen, Chad M.; Georger, Mary A.; Slivano, Orazio J.; Miano, Joseph M.] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA. [Miano, Joseph M.] Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY USA. [Blaner, William S.] Columbia Univ, Dept Med, New York, NY USA. [Carr, Daniel W.] Portland VA Med Ctr, Portland, OR USA. [Gelman, Irwin H.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA. RP Streb, JW (reprint author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA. EM j.m.miano@rochester.edu FU National Institutes of Health [HL070077, CA094108, DK079221, DK068437, T32HL07949]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service FX This research was supported by National Institutes of Health grants HL070077 to JMM; CA094108 to IHG; DK079221 and DK068437 to WSB; and Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service to DWC. JWS was funded through an NIH training grant (#T32HL07949). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 60 TC 4 Z9 4 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 5 PY 2011 VL 6 IS 4 AR e18538 DI 10.1371/journal.pone.0018538 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 745UD UT WOS:000289191300028 PM 21483686 ER PT J AU Hage, FG Bhatia, V Dean, P Iqbal, F Heo, J Iskandrian, AE AF Hage, Fadi G. Bhatia, Vikas Dean, Phillip Iqbal, Fahad Heo, Jaekyeong Iskandrian, Ami E. TI THE HEART RATE RESPONSE TO ADENOSINE CAN RISK STRATIFY PATIENTS WITH DIABETES MELLITUS UNDERGOING MYOCARDIAL PERFUSION IMAGING SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 60th Annual Scientific Session and Expo of the American-College-of-Cardiology CY APR 03-05, 2011 CL New Orleans, LA SP Amer Coll Cardiol C1 Univ Alabama, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2011 VL 57 IS 14 SU 1 BP E743 EP E743 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 778HR UT WOS:000291695100744 ER PT J AU Ryan, G Berrebi, C Beckett, M Taylor, S Quiter, E Cho, M Pincus, H Kahn, K AF Ryan, Gery Berrebi, Claude Beckett, Megan Taylor, Stephanie Quiter, Elaine Cho, Michelle Pincus, Harold Kahn, Katherine TI Reengineering the clinical research enterprise to involve more community clinicians SO IMPLEMENTATION SCIENCE LA English DT Article ID NIH ROADMAP; TRANSLATION; NETWORKS; TRIALS; US AB Background: The National Institutes of Health has called for expansion of practice-based research to improve the clinical research enterprise. Methods: This paper presents a model for the reorganization of clinical research to foster long-term participation by community clinicians. Based on the literature and interviews with clinicians and other stakeholders, we posited a model, conducted further interviews to test the viability of the model, and further adapted it. Results: We propose a three-dimensional system of checks and balances to support community clinicians using research support organizations, community outreach, a web-based registry of clinicians and studies, web-based training services, quality audits, and a feedback mechanism for clinicians engaged in research. Conclusions: The proposed model is designed to offer a systemic mechanism to address current barriers that prevent clinicians from participation in research. Transparent mechanisms to guarantee the safety of patients and the integrity of the research enterprise paired with efficiencies and economies of scale are maintained by centralizing some of the functions. Assigning other responsibilities to more local levels assures flexibility with respect to the size of the clinician networks and the changing needs of researchers. C1 [Ryan, Gery; Berrebi, Claude; Beckett, Megan; Taylor, Stephanie; Kahn, Katherine] RAND Hlth, Santa Monica, CA USA. [Pincus, Harold] RAND Univ Pittsburgh, Hlth Inst, Pittsburgh, PA USA. [Pincus, Harold] Columbia Univ, Dept Psychiat, New York, NY USA. [Pincus, Harold] New York Presbyterian Hosp, New York, NY USA. [Kahn, Katherine] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Taylor, Stephanie] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Off, US Dept Vet Affairs, Los Angeles, CA USA. [Quiter, Elaine] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Cho, Michelle] Compass Lexecon, Oakland, CA USA. RP Kahn, K (reprint author), RAND Hlth, Santa Monica, CA USA. EM kahn@rand.org RI Berrebi, Claude/K-8329-2012 FU National Institute of Child Health and Human Development (NICHD) [HHSN275200403390C] FX This publication was made possible by Contract Number HHSN275200403390C from the National Institute of Child Health and Human Development (NICHD). NR 21 TC 4 Z9 4 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD APR 4 PY 2011 VL 6 AR 36 DI 10.1186/1748-5908-6-36 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 754MN UT WOS:000289858900001 PM 21463518 ER PT J AU Wang, Y Hancock, AM Bradner, J Chung, KA Quinn, JF Peskind, ER Galasko, D Jankovic, J Zabetian, CP Kim, HM Leverenz, JB Montine, TJ Ginghina, C Edwards, KL Snapinn, KW Goldstein, DS Shi, M Zhang, J AF Wang, Yu Hancock, Aneeka M. Bradner, Joshua Chung, Kathryn A. Quinn, Joseph F. Peskind, Elaine R. Galasko, Douglas Jankovic, Joseph Zabetian, Cyrus P. Kim, Hojoong M. Leverenz, James B. Montine, Thomas J. Ginghina, Carmen Edwards, Karen L. Snapinn, Katherine W. Goldstein, David S. Shi, Min Zhang, Jing TI Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID CSF AMYLOID-BETA; CONSENSUS STATEMENT; COGNITIVE DECLINE; NERVOUS-SYSTEM; PHOSPHO-TAU; LEWY BODY; DEMENTIA; BIOMARKERS; DIAGNOSIS; EXPRESSION AB Complement activation, a key component of neuroinflammation, has been reported in both Parkinson's disease (PD) and Alzheimer's disease (AD). However, it is unclear whether complement activation and neuroinflammation in general are distinctly different from each another in major neurodegenerative disorders. In the present study, cerebrospinal fluid complement 3 (C3) and factor H (FH) were measured and evaluated together with amyloid-beta(42) (A beta(42)), which in recent investigations was decreased in patients with PD, in particular those with cognitive impairment. The study included 345 participants: 126 patients with PD at various stages with or without cognitive impairment, 50 with AD, and 32 with multiple-system atrophy, and 137 healthy control individuals. In addition to changes in A beta(42) concentrations, there were clear differences in the patterns of complement profiles among neurodegenerative disorders. The C3/FH ratio demonstrated high sensitivity and specificity in differentiating patients with multiple-system atrophy from those with AD or PD and control individuals. In addition, the C3/A beta(42) and FH/A beta(42) ratios not only correlated with PD severity approximated using the Unified Parkinson's Disease Rating Scale but also with the presence of cognitive impairment or dementia in PD. Both C3 and FH correlated with the severity of impairment in AD as indicated using Mini-Mental State Examination scores. (Am J Pathol 2011, 178:1509-1516; DOI: 10.1016/j.ajpath.2011.01.006) C1 [Wang, Yu; Hancock, Aneeka M.; Bradner, Joshua; Montine, Thomas J.; Ginghina, Carmen; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Peskind, Elaine R.; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Zabetian, Cyrus P.; Kim, Hojoong M.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA. [Wang, Yu] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430074, Peoples R China. [Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Peskind, Elaine R.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Kim, Hojoong M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Jankovic, Joseph] Baylor Coll Med, Parkinsons Dis Ctr, Dept Neurol, Houston, TX 77030 USA. [Jankovic, Joseph] Baylor Coll Med, Movement Disorders Clin, Dept Neurol, Houston, TX 77030 USA. [Edwards, Karen L.; Snapinn, Katherine W.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Goldstein, David S.] NINDS, Clin Neurocardiol Sect, Clin Neurosci Program, Div Intramural Res,NIH, Bethesda, MD 20892 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558; Zabetian, Cyrus/0000-0002-7739-4306 FU National Institutes of Health [ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG005136, AG008017]; Michael J. Fox Foundation; Cheng-Mei Shaw Endowment; Nancy and Buster Alvord Endowment FX Supported by grants ES004696, NS057567, AG025327, AG033398, and NS060252 (J.Z.), NS062684 (T.J.M., C.P.Z., J.B.L., and J.Z.), AG005136 (ERR. and T.J.M.), and AG008017 (K.A.C. and J.F.Q.) from the National Institutes of Health, and grants from the Michael J. Fox Foundation and the Cheng-Mei Shaw Endowment (J.Z.) and the Nancy and Buster Alvord Endowment (T.J.M.). NR 37 TC 38 Z9 41 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD APR PY 2011 VL 178 IS 4 BP 1509 EP 1516 DI 10.1016/j.ajpath.2011.01.006 PG 8 WC Pathology SC Pathology GA 865JH UT WOS:000298306700012 PM 21435440 ER PT J AU Leong, JVB Boro, MS Winter, ME AF Leong, Julie V. B. Boro, Maureen S. Winter, Michael E. TI Determining vancomycin clearance in an overweight and obese population SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE Antibiotics; Dosage; Excretion; Hospitals; Methodology; Obesity; Vancomycin; Weight ID PHARMACOKINETIC PARAMETERS; CREATININE CLEARANCE; VETERANS; THERAPY AB Purpose. Two methods of calculating vancomycin clearance were compared to determine the best body weight measure to use when dosing vancomycin for overweight and obese patients. Methods. Hospitalized veterans weighing more than 120% of their ideal body weight (IBW) with serum vancomycin concentrations (SVCs) drawn between January 1, 2003, and June 30, 2005, were eligible for study inclusion. Exclusion criteria included weight of more than 300% the IBW, unstable renal function, dialysis, uncertain vancomycin dosing or sampling times, and distribution-phase sampling. Data from January 1 through December 31, 2003 (phase 1) determined the best-fit weight for vancomycin clearance for the Leonard and Boro method. The bias and precision of the modified Leonard and Boro method using the best-fit weight for vancomycin clearance were then compared with those of the Rushing and Ambrose method for predicting SVCs from January 1, 2004, through June 30, 2005 (phase 2). Results. Forty-eight patients were included in phase 1, with 67 SVCs for analysis. During phase 1, adjusted body weight (ABW), using the Leonard and Boro method, was superior in predicting vancomycin clearance and the resultant SVCs.. A total of 96 patients were included in phase 2 of the study, with 160 SVCs for analysis. The modified Leonard and Boro method was significantly more precise than the Rushing and Ambrose method in predicting vancomycin clearance. Conclusion. Use of ABW proved to be superior compared with total body weight when estimating vancomycin clearance in overweight and obese patients. While there was no difference in bias between methods, the modified Leonard and Boro method was significantly more precise than the Rushing and Ambrose method in predicting SVCs when dosing vancomycin for obese patients. C1 [Boro, Maureen S.] San Francisco VA Med Ctr, Pharm Informat & Pharmacokinet Program, San Francisco, CA 94121 USA. [Boro, Maureen S.; Winter, Michael E.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. RP Boro, MS (reprint author), San Francisco VA Med Ctr, Pharm Informat & Pharmacokinet Program, 4150 Clement St, San Francisco, CA 94121 USA. EM maureen.boro@va.gov NR 21 TC 12 Z9 13 U1 2 U2 6 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD APR 1 PY 2011 VL 68 IS 7 BP 599 EP 603 DI 10.2146/ajhp100410 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 858CF UT WOS:000297772800011 PM 21411801 ER PT J AU Sano, M Raman, R Emond, J Thomas, RG Petersen, R Schneider, LS Aisen, PS AF Sano, Mary Raman, Rema Emond, Jennifer Thomas, Ronald G. Petersen, Ronald Schneider, Lon S. Aisen, Paul S. TI Adding Delayed Recall to the Alzheimer Disease Assessment Scale is Useful in Studies of Mild Cognitive Impairment But Not Alzheimer Disease SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; mild cognitive impairment; Alzheimer Disease Assessment Scale; delayed recall; clinical trial outcomes ID CLINICAL-TRIALS; INSTRUMENTS; PLACEBO AB Objective: To determine if the addition of delayed recall (DR) assessment adds sensitivity to the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) in clinical trials in mild cognitive impairment (MCI) and Alzheimer Disease (AD). Background: Memory, particularly DR, is the most sensitive test for early detection of AD and MCI. However, it is not clear that assessment of DR adds benefit for measuring change over time after a diagnosis is made or in clinical trials. The ADAS-cog is the most commonly used tool to assess treatment efficacy in AD clinical trials. In an attempt to improve sensitivity to change, assessment of DR after the 3-trial, 10-word list was added to the standard 11-item ADAS-cog. We examined the added value of the DR in participants with MCI and AD followed for at least 1 year. Design/Methods: Data from 111 subjects with AD and 259 subjects with MCI who were randomly assigned to the placebo arm of 2 clinical trials were included. Participants with AD had Mini-Mental State Examination scores of 13 to 27 and those with MCI had 24 to 30. We calculated the ADAS-cog11 score based on the original 11 items (range: best to worse, 0 to 70), the DR item score (range: 0 to 10 words not recalled), and the ADAS-cog12 (range: 0 to 80). We assessed the rate of missing items for DR over time, the change scores, the association between scores and baseline performance, and used longitudinal mixed effects regression models to examine the rate of change. Results: At baseline AD subjects were near floor on DR (8.93 +/- 1.6 SD) and showed little change over 1 year (0.12 +/- 1.34); the MCI subjects baseline DR was 6.2 +/- 2.2 with 1-year change of 0.20 +/- 1.7. We compared standardized change (change/SD) for ADAS-cog11, and 12 in MCI and found a 10% improvement with ADAS-cog12; there was no improvement in the AD group. In a subset of MCI and AD cases with matching Mini-Mental State Examination (23 to 27), the ADAS-cog12 provided an 18% improvement in standardized change in MCI subjects, with no benefit in the AD cohort, primarily owing to increased variance. Conclusions/Relevance: The addition of DR to the ADAS-cog score increased the ability to detect change in subjects with MCI over 1 year compared with the ADAS-cog11 but increased the variance in subjects with AD, even in those with mild impairment These findings speak to the need to tailor outcome measures to the specific study population and diagnosis for maximal efficiency and economy when conducting clinical trials. C1 [Sano, Mary] James J Peters VAMC, Bronx, NY 10468 USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Raman, Rema; Thomas, Ronald G.] UCSD, Dept Family & Prevent Med, La Jolla, CA USA. [Raman, Rema; Thomas, Ronald G.] UCSD, Dept Neurosci, La Jolla, CA USA. [Emond, Jennifer] UCSD, Alzheimers Dis Res Ctr, La Jolla, CA USA. [Aisen, Paul S.] UCSD, Dept Neurosci, La Jolla, CA USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. [Petersen, Ronald] Mayo Clin, Dept Neurol, Rochester, MN USA. RP Sano, M (reprint author), James J Peters VAMC, 130 W Kingsbridge Rd,Code 150,Room 1F01, Bronx, NY 10468 USA. EM Mary.sano@mssm.edu FU NIA [U01AG10483, AG005138, P50 AG05142]; California Alzheimer Disease Center FX Supported by the following NIA grants: U01AG10483 and AG005138, P50 AG05142, and California Alzheimer Disease Center Program. NR 14 TC 12 Z9 12 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD APR-JUN PY 2011 VL 25 IS 2 BP 122 EP 127 DI 10.1097/WAD.0b013e3181f883b7 PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 766MR UT WOS:000290787700004 PM 20921876 ER PT J AU Kim, J Artinyan, A Mailey, B Christopher, S Lee, W McKenzie, S Chen, SL Bhatia, S Pigazzi, A Garcia-Aguilar, J AF Kim, Joseph Artinyan, Avo Mailey, Brian Christopher, Stefanie Lee, Wendy McKenzie, Shaun Chen, Steven L. Bhatia, Smita Pigazzi, Alessio Garcia-Aguilar, Julio TI An Interaction of Race and Ethnicity With Socioeconomic Status in Rectal Cancer Outcomes SO ANNALS OF SURGERY LA English DT Article ID COLORECTAL-CANCER; AFRICAN-AMERICANS; TREATMENT DISPARITIES; RACIAL DISPARITIES; UNITED-STATES; SURVIVAL; STAGE; POPULATION; CARCINOMA AB Objective: Because appropriate rectal cancer care and subsequent outcomes can be influenced by several variables, our objective was to investigate how race, ethnicity, and socioeconomic status (SES) may impact rectal cancer outcomes. Background: The management of rectal cancer requires a multidisciplinary approach utilizing medical and surgical subspecialties. Methods: We performed an investigation of patients with rectal adenocarcinoma from Los Angeles County from 1988 to 2006 using the Los Angeles County Cancer Surveillance Program. Clinical and pathologic characteristics were compared among groups and overall survival was stratified by race/ethnicity and SES. Results: Of 9504 patients with rectal cancer, 53% (n = 4999) were white, 10% black, 18% Hispanic, and 14% Asian. Stratified by race/ethnicity, Asians had the best overall survival followed by Hispanics, whites, and blacks (median survival 7.7 vs. 5.7, 5.5, and 3.4 years, respectively; P < 0.001). Stratified by SES group, the highest group had the best overall survival followed by middle and lowest groups (median survival 8.4 vs. 5.1 and 3.8 years, respectively, P < 0.001). Similar results were observed for surgical patients. On multivariate analysis, race/ethnicity, and SES remained independent predictors of overall survival in patients with rectal adenocarcinoma. Furthermore, interaction analysis indicated that the improved survival for select racial/ethnic groups was not dependent on SES classification. Conclusions: Within the diverse Los Angeles County population, both race/ethnicity, and SES result in inequities in rectal cancer outcomes. Although SES may directly impact outcomes via access to care, the reasons for the association between race/ethnicity and outcomes remain uncertain. C1 [Kim, Joseph; Mailey, Brian; Christopher, Stefanie; Lee, Wendy; McKenzie, Shaun; Pigazzi, Alessio; Garcia-Aguilar, Julio] Div Surg Oncol, Dept Surg, Duarte, CA 91010 USA. [Artinyan, Avo] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Artinyan, Avo] Baylor Coll Med, Houston Hlth Serv, Houston, TX 77030 USA. [Artinyan, Avo] Baylor Coll Med, Res Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Chen, Steven L.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA. [Bhatia, Smita] Dept Populat Sci, Duarte, CA USA. RP Kim, J (reprint author), Div Surg Oncol, Dept Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM jokim@coh.org FU Houston VA HSR&D Center of Excellence [HFP90-020] FX Supported in part by the Houston VA HSR&D Center of Excellence (HFP90-020) for Dr. Avo Artinyan. NR 20 TC 21 Z9 21 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD APR PY 2011 VL 253 IS 4 BP 647 EP 654 DI 10.1097/SLA.0b013e3182111102 PG 8 WC Surgery SC Surgery GA 734VQ UT WOS:000288368600003 PM 21475002 ER PT J AU Vance, DE Eagerton, G Harnish, B McKie, P Fazeli, PL AF Vance, David E. Eagerton, Greg Harnish, Brenna McKie, Peggy Fazeli, Pariya L. TI Cognitive Prescriptions: A Nursing Approach to Increasing Cognitive Reserve SO JOURNAL OF GERONTOLOGICAL NURSING LA English DT Article ID OLDER-ADULTS; TAXI DRIVERS; NEUROPLASTICITY; INTERVENTION; NEUROGENESIS; DEMENTIA; PROTECT; NUTRITION; BEHAVIOR; LIFE AB Nonpathological cognitive declines occur with aging and negatively affect everyday functioning and reduce quality of life. Many older adults, aware of such cognitive changes, seek ways to bolster their cognitive functioning. Evidence based on the cognitive aging literature supports a number of factors associated with cognitive functioning. These factors include physical exercise, intellectual exercise, nutrition, sleep hygiene, social interaction, and mood and emotional state. These factors can be manipulated and woven together by nurses and other health professionals to develop an easy-to-use, non-invasive cognitive prescription for improving the cognitive health of older adults. An example and directions for developing and implementing cognitive prescriptions are described. C1 [Vance, David E.; Harnish, Brenna] Univ Alabama, Sch Nursing, Birmingham, AL 35294 USA. [McKie, Peggy] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Fazeli, Pariya L.] Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. [Fazeli, Pariya L.] Univ Alabama, Ctr Res Appl Gerontol, Birmingham, AL 35294 USA. [Eagerton, Greg] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Vance, DE (reprint author), Univ Alabama, Sch Nursing, Room 456,1701 Univ Blvd, Birmingham, AL 35294 USA. EM devance@uab.edu RI AUDIFFREN, MICHEL/H-5649-2011 OI Vance, David/0000-0002-0498-6263 FU University of Alabama at Birmingham Edward R. Roybal Center [2 P30 AG022838-06] FX Dr. Vance, Dr. Eagerton, Ms. Harnish, Ms. McKie, and Ms. Fazeli disclose that they have no significant financial interests in any product or class of products discussed directly or indirectly in this activity. This article was written with partial support from the University of Alabama at Birmingham Edward R. Roybal Center for Translational Research on Aging and Mobility Project (grant 2 P30 AG022838-06). NR 37 TC 18 Z9 18 U1 0 U2 7 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0098-9134 J9 J GERONTOL NURS JI J. Gerontol. Nurs. PD APR PY 2011 VL 37 IS 4 BP 22 EP 29 DI 10.3928/00989134-20101202-03 PG 8 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA 811WW UT WOS:000294249700006 PM 21175110 ER PT J AU Church, EC Mauldin, PD Bosso, JA AF Church, E. Chandler Mauldin, Patrick D. Bosso, John A. TI Antibiotic Resistance in Pseudomonas aeruginosa Related to Quinolone Formulary Changes: An Interrupted Time Series Analysis SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID STAPHYLOCOCCUS-AUREUS; RATES; SUSCEPTIBILITY C1 [Church, E. Chandler; Mauldin, Patrick D.; Bosso, John A.] S Carolina Coll Pharm, Dept Pharm & Clin Sci, Charleston, SC 29425 USA. [Mauldin, Patrick D.] S Carolina Coll Pharm, Ctr Medicat Safety, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bosso, John A.] Med Univ S Carolina, Dept Med, Coll Med, Charleston, SC USA. RP Bosso, JA (reprint author), S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, Med Univ S Carolina Campus, Charleston, SC 29425 USA. EM bossoja@musc.edu NR 10 TC 2 Z9 2 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2011 VL 32 IS 4 BP 400 EP 402 DI 10.1086/659157 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 790UO UT WOS:000292614900015 PM 21460495 ER PT J AU Hall, DE AF Hall, Daniel E. TI The Guild of Surgeons as a Tradition of Moral Enquiry SO JOURNAL OF MEDICINE AND PHILOSOPHY LA English DT Article DE apprenticeship; phronesis; practical wisdom; surgery; surgical training AB Alisdair MacIntyre argues that the virtues necessary for good work are everywhere and always embodied by particular communities of practice. As a general surgeon, MacIntyre's work has deeply influenced my own understanding of the practice of good surgery. The task of this essay is to describe how the guild of surgeons functions as a more-or-less coherent tradition of moral enquiry, embodying and transmitting the virtues necessary for the practice of good surgery. Beginning with an example of surgeons engaged in a process of moral discernment, I describe how the practice of surgery depends on the cultivation of a certain kind of practical wisdom (phronesis) that effectively orders the techniques of surgery toward particular notions of human flourishing within the limits of what is possible with the particular body on which the surgeon operates. I then argue that one reason why surgeons train in an apprenticeship model of "residency" is to cultivate not only the technical skill but also the practical wisdom to perform good surgery. I conclude by noting that the surgical profession is enduring necessary, but unprecedented, changes in the way it practices and transmits its art; and without deliberate and sustained attention to the character formation of surgeons, the profession runs the risk of creating excellent technicians who are nonetheless ill-equipped to practice wise and good surgery. C1 [Hall, Daniel E.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA 15213 USA. [Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Hall, DE (reprint author), Univ Pittsburgh, Med Ctr, Dept Surg, 200 Lothrop St,Suite F1200, Pittsburgh, PA 15213 USA. EM hallde@upmc.edu RI Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 NR 13 TC 4 Z9 4 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-5310 J9 J MED PHILOS JI J. Med. Philos. PD APR PY 2011 VL 36 IS 2 BP 114 EP 132 DI 10.1093/jmp/jhr005 PG 19 WC Ethics; Social Sciences, Biomedical SC Social Sciences - Other Topics; Biomedical Social Sciences GA 766UJ UT WOS:000290811700002 PM 21576372 ER PT J AU Kim, JH Muder, RR AF Kim, J. H. Muder, R. R. TI Clostridium difficile enteritis: A review and pooled analysis of the cases SO ANAEROBE LA English DT Review DE Clostridium difficile; Enteritis ID INFLAMMATORY-BOWEL-DISEASE; PSEUDOMEMBRANOUS ENTERITIS; TOTAL PROCTOCOLECTOMY; TOTAL COLECTOMY; CROHNS-DISEASE; INFECTION; TOXIN; COLITIS; MANIFESTATIONS; POUCHITIS AB Introduction: Clostridium difficile is the most common cause of healthcare-associated infection diarrhea and usually restricted to infection of the colon. However, small bowel involvement of C difficile infection has been reported. We performed a literature review and pooled analysis of the reported cases of C. difficile enteritis Method: A Pubmed literature database search and pooled analysis of the reported cases of C. difficile enteritis. Results: 56 cases of C. difficile enteritis have been reported from 1980 to 2010; 48 cases were published since 2001. Median age was 55 years. 27 patients (48.2%) were female. 29 patients (51.8%) had inflammatory bowel disease (IBD) - Crohn's disease or ulcerative colitis and 20 patients (35.7%) had predisposing medical condition(s) that might lead to an immunoincompetent state. 33 patients (58.9%) had colectomy with ileostomy and 13 patients (23.2%) had other small and/or large bowel surgery. Thirty four patients (60.7%) received ICU management and 18 patients (32.1%) died. We categorized the patients into two groups, 38 survivors (67.9%) 18 non-survivors (32.1%). Significantly older age was noted in non-survivors. Median age was 48 years and 66 years, respectively for survivors and non-survivors, P < 0.001. There were more patients with predisposing medical condition(s) among non-survivors, (13/18, 72.2%) than among survivors (7/38, 18.4%), P < 0.001. Conclusions: C. difficile enteritis is still rare, however it seems to be increasingly reported in recent years. Surgically altered intestinal anatomies, advanced age, predisposing medical condition(s) that might lead to immunoincompetence appear to be at risk for developing C. difficile enteritis. Recognition of C. difficile infection not only in the colon but also in the small bowel may lead to improved outcomes. Published by Elsevier Ltd. C1 [Muder, R. R.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. [Kim, J. H.; Muder, R. R.] Univ Pittsburgh, Med Ctr, Div Infect Dis, Pittsburgh, PA 15213 USA. RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM robert.muder@va.gov NR 41 TC 20 Z9 23 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD APR PY 2011 VL 17 IS 2 BP 52 EP 55 DI 10.1016/j.anaerobe.2011.02.002 PG 4 WC Microbiology SC Microbiology GA 781CI UT WOS:000291907800002 PM 21334446 ER PT J AU Peterson, CL Kautz, SA Neptune, RR AF Peterson, Carrie L. Kautz, Steven A. Neptune, Richard R. TI Braking and propulsive impulses increase with speed during accelerated and decelerated walking SO GAIT & POSTURE LA English DT Article DE Non-steady-state; Ground reaction forces; Step length; Step frequency; Joint moments ID GROUND REACTION FORCES; HUMAN LOCOMOTION; MUSCLE-ACTIVITY; CHANGING SPEED; JOINT MOMENTS; LEVEL WALKING; PROGRESSION; SUPPORT; TRANSITION; FREQUENCY AB The ability to accelerate and decelerate is important for daily activities and likely more demanding than maintaining a steady-state walking speed. Walking speed is modulated by anterior-posterior (AP) ground reaction force (GRF) impulses. The purpose of this study was to investigate AP impulses across a wide range of speeds during accelerated and decelerated walking. Kinematic and GRF data were collected from 10 healthy subjects walking on an instrumented treadmill. Subjects completed trials at steady-state speeds and at four rates of acceleration and deceleration across a speed range of 0-1.8 m/s. Mixed regression models were generated to predict AP impulses, step length and frequency from speed, and joint moment impulses from AP impulses during non-steady-state walking. Braking and propulsive impulses were positively related to speed. The braking impulse had a greater relationship with speed than the propulsive impulse, suggesting that subjects modulate the braking impulse more than the propulsive impulse to change speed. Hip and knee extensor, and ankle plantarflexor moment impulses were positively related to the braking impulse, and knee flexor and ankle plantarflexor moment impulses were positively related to the propulsive impulse. Step length and frequency increased with speed and were near the subjects' preferred combination at steady-state speeds, at which metabolic cost is minimized in nondisabled walking. Thus, these variables may be modulated to minimize metabolic cost while accelerating and decelerating. The outcomes of this work provide the foundation to investigate motor coordination in pathological subjects in response to the increased task demands of non-steady-state walking. (C) 2011 Elsevier B.V. All rights reserved. C1 [Peterson, Carrie L.; Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 1 Univ Stn,C2200, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu RI Peterson, Carrie/C-6007-2016 OI Peterson, Carrie/0000-0002-7169-2089; Kautz, Steven/0000-0003-3151-8235 FU NIH [R01 HD46820]; Rehabilitation Research and Development Service of the Department of Veteran Affairs; National Science Foundation FX This work was supported by NIH Grant R01 HD46820, the Rehabilitation Research and Development Service of the Department of Veteran Affairs and the National Science Foundation Graduate Research Fellowship Program. The authors are grateful to members of the Brain Rehabilitation Research Center for their help with subject recruitment and data collection. NR 22 TC 17 Z9 18 U1 0 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD APR PY 2011 VL 33 IS 4 BP 562 EP 567 DI 10.1016/gaitpost.2011.01.010 PG 6 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 771EI UT WOS:000291139600008 PM 21356590 ER PT J AU Whittaker, EC Aubin, PM Ledoux, WR AF Whittaker, Eric C. Aubin, Patrick M. Ledoux, William R. TI Foot bone kinematics as measured in a cadaveric robotic gait simulator SO GAIT & POSTURE LA English DT Article DE Robotics; Gait simulation; Cadaveric simulations; Kinematics; Foot and ankle ID 1ST METATARSOPHALANGEAL JOINT; STANCE PHASE; IN-VITRO; MOTION; MODEL; WALKING; VIVO AB The bony motion of the foot during the stance phase of gait is useful to further our understanding of joint function, disease etiology, injury prevention and surgical intervention. In this study, we used a 10-segment in vitro foot model with anatomical coordinate systems and a robotic gait simulator (RGS) to measure the kinematics of the tibia, talus, calcaneus, cuboid, navicular, medial cuneiform, first metatarsal, hallux, third metatarsal, and fifth metatarsal from six cadaveric feet. The RGS accurately reproduced in vivo vertical ground reaction force (5.9% body weight RMS error) and tibia to ground kinematics. The kinematic data from the foot model generally agree with invasive in vivo descriptions of bony motion and provides the most realistic description of bony motion currently available for an in vitro model. These data help to clarify the function of several joints that are difficult to study in vivo; for example, the combined range of motion of the talonavicular, naviculocuneiform, metatarsocuneiform joints provided more sagittal plane mobility (27.4 degrees) than the talotibial joint alone (23.2 degrees). Additionally, the anatomical coordinate systems made it easier to meaningfully determine bone-to-bone motion, describing uniplanar motion as rotation about a single axis rather than about three. The data provided in this study allow for many kinematic interpretations to be made about dynamic foot bone motion, and the methodology presents a means to explore many invasive foot biomechanics questions under near-physiologic conditions. Published by Elsevier B.V. C1 [Whittaker, Eric C.; Aubin, Patrick M.; Ledoux, William R.] VA RR&D Ctr Excellence Limb Loss Prevent & Prosth, Seattle, WA USA. [Aubin, Patrick M.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs Rehabilitation Research and Development Service [A3923R, A6669R] FX This work was funded in part by the Department of Veterans Affairs Rehabilitation Research and Development Service grants A3923R and A6669R. NR 22 TC 21 Z9 21 U1 1 U2 19 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD APR PY 2011 VL 33 IS 4 BP 645 EP 650 DI 10.1016/j.gaitpost.2011.02.011 PG 6 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 771EI UT WOS:000291139600023 PM 21458991 ER PT J AU Copeland, LA Zeber, JE Bingham, MO Pugh, MJ Noel, PH Schmacker, ER Lawrence, VA AF Copeland, Laurel A. Zeber, John E. Bingham, Mona O. Pugh, Mary Jo Noel, Polly Hitchcock Schmacker, Eric R. Lawrence, Valerie A. TI Transition from military to VHA care: Psychiatric health services for Iraq/Afghanistan combat-wounded SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Combat disorders; Health services; Iraq War 2003-; Mental health services; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; IRAQ; VETERANS; AFGHANISTAN; DEPRESSION; DEPLOYMENT; DIAGNOSES AB Objective: Veterans from the wars in Afghanistan and Iraq (OEF/OIF) report high rates of mental distress especially affective disorders. Ensuring continuity of care across institutions is a priority for both the Department of Defense (DOD) and the Veterans Health Administration (VHA), yet this process is not monitored nor are medical records integrated. This study assessed transition from DoD to VHA and subsequent psychiatric care of service members traumatically injured in OEF/OIF. Methods: Inpatients at a DoD trauma treatment facility discharged in FY02-FY06 (n = 994) were tracked into the VHA via archival data (n = 216 OEF/OIF veterans). Mental health utilization in both systems was analyzed. Results: VHA users were 9% female, 15% Hispanic; mean age 32 (SD= 10; range 19-59). No DoD inpatients received diagnoses of post-traumatic stress disorder (PTSD); 21% had other mental health diagnoses, primarily drug abuse. In the VHA, 38% sought care within 6 months of DoD discharge; 75% within 1 year. VHA utilization increased over time, with 88-89% of the transition cohort seeking care in FY07-FY09. Most accessed VHA mental health services (81%) and had VHA psychiatric diagnoses (71%); half met criteria for depression (27%) or PTSD (38%). Treatment retention through FY09 was significantly greater for those receiving psychiatric care: 98% vs 62% of those not receiving psychiatric care (chi(2)=53.3; p <.001). Limitations: DoD outpatient data were not available. The study relied on administrative data. Conclusions: Although physical trauma led to hospitalization in the DoD, high rates of psychiatric disorders were identified in subsequent VHA care, suggesting delay in development or recognition of psychiatric problems. Published by Elsevier B.V. C1 [Copeland, Laurel A.; Zeber, John E.] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX 76502 USA. [Copeland, Laurel A.; Zeber, John E.] Vet Affairs, Cent Texaas Vet Hlth Care Syst, Temple, TX USA. [Bingham, Mona O.; Pugh, Mary Jo; Noel, Polly Hitchcock; Lawrence, Valerie A.] Vet Affairs, VERDICT Res, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, Mary Jo; Noel, Polly Hitchcock; Lawrence, Valerie A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Schmacker, Eric R.] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA. RP Copeland, LA (reprint author), Scott & White Healthcare, Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA. EM LaurelACopeland@gmail.com RI Schueter, nicos/A-3625-2014 OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs HSRD [SHP-08-0140]; VHA; DoD; Department of Veterans Affairs; VERDICT Research Center at South Texas Veterans Health Care System; Central Texas Veterans Health Care System; Scott & White Healthcare System; University of Texas Health Science Center at San Antonio; Brooke Army Medical Center at Fort Sam Houston; Nursing Research Services and the Department of Health Care Operations FX Funding for this study was provided by the Department of Veterans Affairs HSR&D Grant # SHP-08-0140. The funding agency had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.; The authors are employed as researchers by the Department of Veterans Affairs (VHA) or Department of Defense (DoD). The DoD researchers are stationed at the DoD hospital studied. The VHA researchers are supported by grants from non-profit agencies including VHA and DoD. The authors report no conflicts of interest.; This research was supported by the Department of Veterans Affairs with additional support from VERDICT Research Center at South Texas Veterans Health Care System, Central Texas Veterans Health Care System, Scott & White Healthcare System, and the University of Texas Health Science Center at San Antonio. The work was also supported by Brooke Army Medical Center at Fort Sam Houston, Nursing Research Services and the Department of Health Care Operations. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the Department of Defense. NR 21 TC 13 Z9 13 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2011 VL 130 IS 1-2 BP 226 EP 230 DI 10.1016/j.jad.2010.10.017 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 759KO UT WOS:000290241600033 PM 21051088 ER PT J AU Lemaire, CM Graham, DP AF Lemaire, Chad M. Graham, David P. TI Factors associated with suicidal ideation in OEF/OIF veterans SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Veterans; Suicide; Posttraumatic Stress; Disorder; Depression ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; MILITARY-PERSONNEL; RISK-FACTOR; DEPRESSION; SYMPTOMS; COMORBIDITY; IMPAIRMENT; AFFAIRS; PATIENT AB Background: The purpose of this project was to examine factors associated with suicidal ideation in returning Iraq and Afghanistan war veterans. Methods: A cross-sectional review of 1740 veterans' initial mental health screening evaluations. One-hundred and thirteen (6.5%) OEF/OIF veterans reported active suicidal ideation at the time of the interview. Results: Prior exposures of physical or sexual abuse and having a history of a prior suicide attempt(s) were associated with the presence of current suicidal ideation, as were having a diagnosis of a psychotic disorder, a depressive disorder, or posttraumatic stress disorder (PTSD). Deployment concerns related to training (protective), the deployment environment, family concerns, deployment concerns, post-deployment support (protective), and postdeployment stressors were also associated with current suicidal ideation. Logistic regression analysis revealed the major risk factors were having a prior suicide attempt, female gender, and a depressive disorder diagnosis; while more perceived current social support was a protective factor. Logistic regression analysis also revealed having comorbid PTSD and depression carried a higher odds ratio for risk than did having either PTSD or depression alone; and that the PTSD avoidance symptom-cluster was associated with more risk than either the re-experiencing or hyper-arousal symptom clusters for current suicidal ideation. Limitations: As a cross-sectional retrospective medical chart review, limitations include limited generalizability and causal relationships cannot be evaluated. Conclusions: Further investigation of these risk factors is warranted to aid in suicide risk assessment and in the development of targeted interventions to mitigate the identified risk factors and bolster the identified protective factor. Published by Elsevier B.V. C1 [Lemaire, Chad M.; Graham, David P.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Lemaire, Chad M.] Legacy Community Hlth Serv, Houston, TX USA. [Graham, David P.] Michael E DeBakey Dept Vet Affairs Med Ctr, Rehabil Res & Dev Serv, Neurorehabil Neurons Networks TBI Ctr Excellence, Houston, TX USA. [Graham, David P.] Michael E DeBakey Dept Vet Affairs Med Ctr, Res & Dev Serv, Hlth Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. RP Graham, DP (reprint author), Michael E DeBakey VA Med Ctr 116A, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM david.graham@va.gov RI Schueter, nicos/A-3625-2014; Graham, David /J-1158-2014 FU Veterans' Affairs Administration's Substance Use Disorders Quality Enhancement Research initiative (SUD-QUERI) FX We would like to thank all the helpers and assistants whose hard work helped to perform the chart reviews and data extraction, and particularly all the veterans who, through their time and efforts to become familiar with VA services, underwent a Mental Health evaluation, without which this project could not have been done. This project was funded by a grant from the Veterans' Affairs Administration's Substance Use Disorders Quality Enhancement Research initiative (SUD-QUERI) Program. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 44 TC 53 Z9 54 U1 2 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2011 VL 130 IS 1-2 BP 231 EP 238 DI 10.1016/j.jad.2010.10.021 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 759KO UT WOS:000290241600034 PM 21055828 ER PT J AU Benitez, A Horner, MD Bachman, D AF Benitez, Andreana Horner, Michael David Bachman, David TI Intact Cognition in Depressed Elderly Veterans Providing Adequate Effort SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Depression; Elderly/geriatrics/aging; Suboptimal effort; Cognition; Repeatable Battery for the Assessment of Neuropsychological Status; Geriatric Depression Scale ID MEMORY MALINGERING TOMM; SYMPTOM VALIDITY TESTS; DWELLING OLDER-ADULTS; GERIATRIC DEPRESSION; LATE-LIFE; EXECUTIVE DYSFUNCTION; MOOD DISORDERS; DEMENTIA; ASSOCIATION; PERFORMANCE AB Geriatric depression has been associated with cognitive impairments, but whether suboptimal effort contributes to these deficits is unknown. This study investigated differences in cognitive functioning between depressed and nondepressed elderly veterans, before and after excluding patients who provided suboptimal effort on testing at a memory disorders clinic. Patients diagnosed with a depressive disorder performed more poorly than nondepressed patients on almost all Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) indices, but these differences became nonstatistically significant after excluding patients who provided suboptimal effort. However, when patients were classified as normal, mildly, or severely depressed based on Geriatric Depression Scale scores, these groups were not significantly different on RBANS indices, regardless of whether patients who provided suboptimal effort were included or excluded from analyses. The findings suggest that cognitive deficits in depression reported in previous research may be attributable to suboptimal effort and that identifying depression via clinical diagnosis or psychometric data may affect this trend. C1 [Benitez, Andreana] Kent State Univ, Dept Psychol, Kent, OH 44242 USA. [Horner, Michael David; Bachman, David] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Benitez, Andreana; Horner, Michael David; Bachman, David] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Bachman, David] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Benitez, A (reprint author), 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA. EM abenitez@mednet.ucla.edu NR 50 TC 11 Z9 11 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD APR PY 2011 VL 26 IS 3 BP 184 EP 193 DI 10.1093/arclin/acr001 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA 756WV UT WOS:000290046400003 PM 21278197 ER PT J AU Gallardo, G Guardia, J Villasenor, T McNeil, MR AF Gallardo, Geisa Guardia, Joan Villasenor, Teresita McNeil, Malcolm R. TI Psychometric Data for the Revised Token Test in Normally Developing Mexican Children Ages 4-12 Years SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Auditory language comprehension; Pediatric population; Psychometric study; Spanish-speaking population; Revised Token Test ID NORMATIVE DATA; PERFORMANCE; LANGUAGE; INTELLIGENCE; MODELS AB Language comprehension is vital to social and educational development but few pediatric tests are available for its assessment. To approach this problem, two versions of the Token Test (TT), "TT short form" (DeRenzi & Faglioni, 1978) and "Revised Token Test" (RTT), were first compared. Using a sample of 88 normally developing Spanish-speaking children, the tests were compared on their: (a) established psychometric development and (b) internal consistency. The RTT was judged to be superior and was selected for additional experimentation. The RTT was compared with a developmental measure of lexical knowledge on a cross-sectional sample of 250 4-12-year-old normally developing Spanish-speaking children. A significant positive and high correlation supports its concurrent validity. Significant differences across the age groups, along with a principal component analysis that yielded a three-factor structure, support its construct validity. Preliminary normative data across the nine age groups are provided. C1 [Guardia, Joan] Univ Barcelona, Dept Metodol Ciencias Comportamiento, Fac Psicol, Inst Recerca Cervell Cognicio & Conducta, Barcelona, Spain. [Gallardo, Geisa; Villasenor, Teresita] Univ Guadalajara, Dept Neurociencias, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico. [McNeil, Malcolm R.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [McNeil, Malcolm R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Guardia, J (reprint author), Fac Psicol, Dept Ciencies Comportament, Passeig Vall dHebron 171, Barcelona 08035, Spain. EM jguardia@ub.edu FU MINISTERIO DE CIENCIA E INNOVACION [PSI2010 - 21214 - C02 - 01] FX Funding received from MINISTERIO DE CIENCIA E INNOVACION grant number PSI2010 - 21214 - C02 - 01. NR 41 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD APR PY 2011 VL 26 IS 3 BP 225 EP 234 DI 10.1093/arclin/acr018 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA 756WV UT WOS:000290046400007 PM 21441259 ER PT J AU Weintraub, D Mamikonyan, E Papay, K Shea, J Xie, S Siderowf, A AF Weintraub, D. Mamikonyan, E. Papay, K. Shea, J. Xie, S. Siderowf, A. TI Validity and reliability of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 25th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY MAY 13, 2011 CL Irving, TX C1 [Weintraub, D.; Mamikonyan, E.; Papay, K.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, D.; Siderowf, A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. [Shea, J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Shea, J.] Philadelphia Vet Affairs Med Ctr, CHERP, Philadelphia, PA USA. [Xie, S.] Univ Penn, Dept Biostat & Epidemiol, Sch Med Philadelphia, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP III EP III PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400006 ER PT J AU Peterson, A Quinn, J Woltjer, R AF Peterson, A. Quinn, J. Woltjer, R. TI Gluten Ataxia - Pathological Results of a Case of Rapidly Progressive Ataxia with Positive Anti-gliadin antibodies SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 25th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY MAY 13, 2011 CL Irving, TX C1 [Peterson, A.; Quinn, J.; Woltjer, R.] Oregon Hlth & Sci Univ OHSU Portland, Portland, OR USA. [Peterson, A.; Quinn, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP VIII EP IX PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400024 ER PT J AU Mata, IF Yearout, D Alvarez, V Coto, E de Mena, L Ribacoba, R Lorenzo-Betancor, O Samaranch, L Pastor, P Cervantes, S Infante, J Garcia-Gorostiaga, I Sierra, M Combarros, O Snapinn, KW Edwards, KL Zabetian, CP AF Mata, Ignacio F. Yearout, Dora Alvarez, Victoria Coto, Eliecer de Mena, Lorena Ribacoba, Renee Lorenzo-Betancor, Oswaldo Samaranch, Lluis Pastor, Pau Cervantes, Sebastian Infante, Jon Garcia-Gorostiaga, Ines Sierra, Maria Combarros, Onofre Snapinn, Katherine W. Edwards, Karen L. Zabetian, Cyrus P. TI Replication of MAPT and SNCA, but not PARK16-18, as Susceptibility Genes for Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; genome-wide; replication ID GENOME-WIDE ASSOCIATION; ALPHA-SYNUCLEIN; POPULATION STRATIFICATION; RISK-FACTORS; HLA REGION; VARIANTS; SNPS; LOCI; TAU AB Recent genome-wide association studies of Parkinson's disease have nominated 3 new susceptibility loci (PARK16-18) and confirmed 2 known risk genes (MAPT and SNCA) in populations of European ancestry. We sought to replicate these findings. We genotyped single-nucleotide polymorphisms in each of these genes/loci in 1445 Parkinson's disease patients and 1161 controls from northern Spain. Logistic regression was used to test for association between genotype and Parkinson's disease under an additive model, adjusting for sex, age, and site. We also performed analyses stratified by age at onset. Single-nucleotide polymorphisms in MAPT (rs1800547; P = 3.1 x 10(-4)) and SNCA (rs356219; P = 5.5 x 10(-4)) were significantly associated with Parkinson's disease. However, none of the markers in PARK16-18 associated with Parkin-son's disease in the overall sample, or in any age stratum, with P values ranging from .09 to .88. Although our data further validate MAPT and SNCA as Parkinson's disease susceptibility genes, we failed to replicate PARK16, PARK17, and PARK18. Potential reasons for the discordance between our study and previous genome-wide association studies include effects of population structure, power, and population-specific environmental interactions. Our findings suggest that additional studies of PARK16-18 are necessary to establish the role of these loci in modifying risk for Parkinson's disease in European-derived populations. (C) 2011 Movement Disorder Society C1 [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, Seattle, WA 98108 USA. [Mata, Ignacio F.; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Alvarez, Victoria; Coto, Eliecer; de Mena, Lorena] Hosp Univ Cent de Asturias, Lab Genet Mol, Inst Invest Nefrol IRSINFRIAT, Oviedo, Spain. [Ribacoba, Renee] Hosp Alvarez Buylla, Dept Neurol, Mieres, Spain. [Lorenzo-Betancor, Oswaldo; Samaranch, Lluis; Pastor, Pau; Cervantes, Sebastian] Univ Navarra, Ctr Appl Med Res, Div Neurosci, Neurogenet Lab, E-31080 Pamplona, Spain. [Lorenzo-Betancor, Oswaldo; Pastor, Pau; Cervantes, Sebastian] Univ Navarra, Sch Med, Clin Univ Navarra, Dept Neurol, E-31080 Pamplona, Spain. [Pastor, Pau] Inst Salud Carlos III, CIBERNED, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain. [Infante, Jon; Sierra, Maria; Combarros, Onofre] Marques de Valdecilla Univ Hosp, Dept Neurol, Santander, Spain. [Infante, Jon; Sierra, Maria; Combarros, Onofre] Marques de Valdecilla Univ Hosp, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Santander, Spain. [Garcia-Gorostiaga, Ines] Hosp Galdakao, Neurol Serv, Vizcaya, Spain. [Snapinn, Katherine W.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Pastor, Pau/C-9834-2009 OI Pastor, Pau/0000-0002-7493-8777; Fernandez Mata, Ignacio/0000-0003-1198-0633; Zabetian, Cyrus/0000-0002-7739-4306 FU Department of Veterans Affairs [1I01BX000531]; National Institutes of Health [P50 NS062684, R01 NS065070]; Spanish Ministry of Education and Science [SAF2006-10126: 2006-2009]; Fondo de Investigacion Sanitaria (FIS) [PI070014]; Spanish Ministry of Science and Technology; European Social Fund; Asociacion Parkinson Asturias FX This work was supported by funding from the Department of Veterans Affairs (1I01BX000531), National Institutes of Health (P50 NS062684 and R01 NS065070), Spanish Ministry of Education and Science (SAF2006-10126: 2006-2009), Fondo de Investigacion Sanitaria (FIS, PI070014), Spanish Ministry of Science and Technology, European Social Fund, and the Asociacion Parkinson Asturias. NR 22 TC 41 Z9 43 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP 819 EP 823 DI 10.1002/mds.23642 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400035 PM 21425343 ER PT J AU Fogelgren, B Lin, SY Zuo, XF Jaffe, KM Park, KM Reichert, RJ Bell, PD Burdine, RD Lipschutz, JH AF Fogelgren, Ben Lin, Shin-Yi Zuo, Xiaofeng Jaffe, Kimberly M. Park, Kwon Moo Reichert, Ryan J. Bell, P. Darwin Burdine, Rebecca D. Lipschutz, Joshua H. TI The Exocyst Protein Sec10 Interacts with Polycystin-2 and Knockdown Causes PKD-Phenotypes SO PLOS GENETICS LA English DT Article ID LEFT-RIGHT AXIS; REGULATED KINASE PATHWAY; CYST EPITHELIAL-CELLS; KIDNEY-DISEASE; INTRAFLAGELLAR TRANSPORT; PRIMARY CILIUM; KUPFFERS VESICLE; COLLECTING DUCT; CATION CHANNEL; MDCK CELLS AB Autosomal dominant polycystic kidney disease (ADPKD) is characterized by formation of renal cysts that destroy the kidney. Mutations in PKD1 and PKD2, encoding polycystins-1 and -2, cause ADPKD. Polycystins are thought to function in primary cilia, but it is not well understood how these and other proteins are targeted to cilia. Here, we provide the first genetic and biochemical link between polycystins and the exocyst, a highly-conserved eight-protein membrane trafficking complex. We show that knockdown of exocyst component Sec10 yields cellular phenotypes associated with ADPKD, including loss of flow-generated calcium increases, hyperproliferation, and abnormal activation of MAPK. Sec10 knockdown in zebrafish phenocopies many aspects of polycystin-2 knockdown-including curly tail up, left-right patterning defects, glomerular expansion, and MAPK activation-suggesting that the exocyst is required for pkd2 function in vivo. We observe a synergistic genetic interaction between zebrafish sec10 and pkd2 for many of these cilia-related phenotypes. Importantly, we demonstrate a biochemical interaction between Sec10 and the ciliary proteins polycystin-2, IFT88, and IFT20 and co-localization of the exocyst and polycystin-2 at the primary cilium. Our work supports a model in which the exocyst is required for the ciliary localization of polycystin-2, thus allowing for polycystin-2 function in cellular processes. C1 [Fogelgren, Ben; Zuo, Xiaofeng; Park, Kwon Moo; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Lin, Shin-Yi; Jaffe, Kimberly M.; Burdine, Rebecca D.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA. [Park, Kwon Moo] Kyungpook Natl Univ, Dept Anat, Taegu, South Korea. [Park, Kwon Moo] Kyungpook Natl Univ, Project BK 21, Taegu, South Korea. [Reichert, Ryan J.; Bell, P. Darwin] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. RP Fogelgren, B (reprint author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA. EM jhlipsch@mail.med.upenn.edu OI Burdine, Rebecca/0000-0001-6620-5015 FU National Institutes of Health [DK069909, DK070980, 1RO1HD048584, KO1 DK087852]; Satellite Healthcare FX The authors and this work were supported by the National Institutes of Health (DK069909 and DK070980 to JHL, 1RO1HD048584 to RDB, and KO1 DK087852 to BF) and Satellite Healthcare (Norman S. Coplon Extramural Research Grant to JHL, URL: http://www.satellitehealth.com/pdf/Coplon_Grant_2011.pdf The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 28 Z9 29 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1001361 DI 10.1371/journal.pgen.1001361 PG 17 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000043 PM 21490950 ER PT J AU Magid, DJ Ho, PM Olson, KL Brand, DW Welch, LK Snow, KE Lambert-Kerzner, AC Plomondon, ME Havranek, EP AF Magid, David J. Ho, P. Michael Olson, Kari L. Brand, David W. Welch, Lesley K. Snow, Karen E. Lambert-Kerzner, Anne C. Plomondon, Mary E. Havranek, Edward P. TI A Multimodal Blood Pressure Control Intervention in 3 Healthcare Systems SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED-TRIAL; HYPERTENSION CONTROL; MANAGEMENT; PREVENTION; PHARMACIST; DISEASE AB Objective: To determine if a multimodal intervention composed of patient education, home blood pressure (BP) monitoring, BP measurement reporting to an interactive voice response (IVR) phone system, and clinical pharmacist follow-up improves BP control compared with usual care. Study Design: Prospective study with patient enrollment, medication consultation and adjustment, remote BP monitoring, and follow-up at 6 months. Methods: This randomized controlled trial was conducted at 3 healthcare systems in Denver, Colorado, including a large health maintenance organization, a Veterans Affairs medical center, and a county hospital. At each site, patients with uncontrolled BP were randomized to the multimodal intervention vs usual care for 6 months, with the primary end point of BP reduction. Results: Of 338 patients randomized, 283 (84%) completed the study, including 138 intervention patients and 145 usual care patients. Baseline BP was higher in the intervention group vs the usual care group (150.5/89.4 vs 143.8/85.3 mm Hg). At 6 months, BPs were similar in the intervention group vs the usual care group (137.4 vs 136.7 mm Hg, P = .85 for systolic; 82.9 vs 81.1 mm Hg, P = .14 for diastolic). However, BP reductions were greater in the intervention group vs the usual care group (-13.1 vs -7.1 mm Hg, P = .006 for systolic; -6.5 vs -4.2 mm Hg, P = .07 for diastolic). Adherence to medications was similar between the 2 groups, but intervention patients had a greater increase in medication regimen intensity. Conclusions: A multimodal intervention of patient education, home BP monitoring, BP measurement reporting to an IVR system, and clinical pharmacist follow-up achieved greater reductions in BP compared with usual care. (Am J Manag Care. 2011;17(4):e96-e103) C1 [Magid, David J.; Brand, David W.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80231 USA. [Ho, P. Michael; Lambert-Kerzner, Anne C.; Plomondon, Mary E.] Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO USA. [Olson, Kari L.] Kaiser Permanente Colorado, Dept Pharm, Denver, CO 80231 USA. [Welch, Lesley K.] Denver Vet Affairs Med Ctr, Dept Pharm, Denver, CO USA. [Snow, Karen E.] Denver Hlth Med Ctr, Dept Pharm, Denver, CO USA. [Magid, David J.; Ho, P. Michael; Olson, Kari L.; Havranek, Edward P.] Univ Colorado Denver, Aurora, CO USA. [Havranek, Edward P.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO USA. RP Magid, DJ (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 10065 E Harvard Ave,Ste 300, Denver, CO 80231 USA. EM david.j.magid@kp.org FU American Heart Association [0535086N]; Colorado Department of Public Health and Environment [99]; Veterans Affairs Research and Development Career Development Award [05-026-2] FX Funding Source: This work was funded in part by grant 0535086N from the American Heart Association and by grant CCPD#99 from the Colorado Department of Public Health and Environment. Dr Ho is supported by Veterans Affairs Research and Development Career Development Award 05-026-2. The funders had no involvement in the design or conduct of the study or in the collection, management, analysis, or interpretation of the data. NR 16 TC 33 Z9 35 U1 0 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2011 VL 17 IS 4 BP E96 EP E103 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 755XS UT WOS:000289974300002 PM 21774100 ER PT J AU Jayadev, S Nochlin, D Poorkaj, P Steinbart, EJ Mastrianni, JA Montine, TJ Ghetti, B Schellenberg, GD Bird, TD Leverenz, JB AF Jayadev, Suman Nochlin, David Poorkaj, Parvoneh Steinbart, Ellen J. Mastrianni, James A. Montine, Thomas J. Ghetti, Bernardino Schellenberg, Gerard D. Bird, Thomas D. Leverenz, James B. TI Familial Prion Disease with Alzheimer Disease-Like Tau Pathology and Clinical Phenotype SO ANNALS OF NEUROLOGY LA English DT Article ID STRAUSSLER-SCHEINKER-DISEASE; CREUTZFELDT-JAKOB-DISEASE; NEUROFIBRILLARY TANGLES; AMYLOID DEPOSITS; PROTEIN; DEMENTIA; PRNP; MUTATIONS; COMPONENT; INDIANA AB Objective: To describe the Alzheimer disease (AD)-like clinical and pathological features, including marked neurofibrillary tangle (NFT) pathology, of a familial prion disease due to a rare nonsense mutation of the prion gene (PRNP). Methods: Longitudinal clinical assessments were available for the proband and her mother. After death, both underwent neuropathological evaluation. PRNP was sequenced after failure to find immunopositive A beta deposits in the proband and the documentation of prion protein (PrP) immunopositive pathology. Results: The proband presented at age 42 years with a 3-year history of progressive short-term memory impairment and depression. Neuropsychological testing found impaired memory performance, with relatively preserved attention and construction. She was diagnosed with AD and died at age 47 years. Neuropathologic evaluation revealed extensive limbic and neocortical NFT formation and neuritic plaques consistent with a Braak stage of VI. The NFTs were immunopositive, with multiple tau antibodies, and electron microscopy revealed paired helical filaments. However, the neuritic plaques were immunonegative for A beta, whereas immunostaining for PrP was positive. The mother of the proband had a similar presentation, including depression, and had been diagnosed clinically and pathologically as AD. Reevaluation of her brain tissue confirmed similar tau and PrP immunostaining findings. Genetic analysis revealed that both the proband and her mother had a rare PRNP mutation (Q160X) that resulted in the production of truncated PrP. Interpretation: We suggest that PRNP mutations that result in a truncation of PrP lead to a prolonged clinical course consistent with a clinical diagnosis of AD and severe AD-like NFTs. ANN NEUROL 2011; 69: 712-720 C1 [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Mental Illness Clin & Educ Ctr, Seattle Div, Seattle, WA 98108 USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Clin & Educ Ctr, Seattle Div, Seattle, WA 98108 USA. [Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Jayadev, Suman; Bird, Thomas D.; Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Nochlin, David] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA. [Poorkaj, Parvoneh; Steinbart, Ellen J.; Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Clin & Educ Ctr, Seattle Div, Seattle, WA 98108 USA. [Mastrianni, James A.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol Neuropathol, Seattle, WA 98195 USA. [Ghetti, Bernardino] Indiana Univ Sch Med, Indiana Alzheimer Dis Ctr, Indianapolis, IN USA. [Ghetti, Bernardino] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA. [Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA. RP Leverenz, JB (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Clin & Educ Ctr, Seattle Div, GRECC 182,1660 S Columbian Way, Seattle, WA 98108 USA. EM leverenz@u.washington.edu FU US Department of Veterans Affairs, Office of Research and Development; National Institutes of Health (NIH)/National Institute on Aging (NIA) [2P50AG005136-27, 5P50NS062684-02, 5R01NS051480-05, 5P30AG010133-20]; Athena Diagnostics FX This work supported in part by the US Department of Veterans Affairs, Office of Research and Development Clinical R&D Program, and National Institutes of Health (NIH)/National Institute on Aging (NIA) 2P50AG005136-27, 5P50NS062684-02, 5R01NS051480-05, 5P30AG010133-20. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA or the NIH.; T.D.B. has received speaking fees and royalties from Athena Diagnostics. NR 23 TC 36 Z9 37 U1 1 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 2011 VL 69 IS 4 BP 712 EP 720 DI 10.1002/ana.22264 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 758HV UT WOS:000290155800017 PM 21416485 ER PT J AU Polley, KH Navarro, R Avery, DH George, MS Holtzheimer, PE AF Polley, Kurt H. Navarro, Rita Avery, David H. George, Mark S. Holtzheimer, Paul E. TI 2010 Updated Avery-George-Holtzheimer Database of rTMS depression studies SO BRAIN STIMULATION LA English DT Editorial Material C1 [Polley, Kurt H.; George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. [Navarro, Rita; Avery, David H.] Univ Washington, Harborview Med Ctr, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Holtzheimer, Paul E.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. RP George, MS (reprint author), Med Univ S Carolina, Brain Stimulat Lab, 67 President St, Charleston, SC 29425 USA. EM georgem@musc.edu RI Holtzheimer, Paul/B-6212-2015 OI Holtzheimer, Paul/0000-0002-3552-3296 NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X J9 BRAIN STIMUL JI Brain Stimul. PD APR PY 2011 VL 4 IS 2 BP 115 EP 116 DI 10.1016/j.brs.2010.09.001 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 758TZ UT WOS:000290191100009 PM 21511213 ER PT J AU Ramirez, JA Anzueto, AR AF Ramirez, Julio Alberto Anzueto, Antonio R. TI Changing needs of community-acquired pneumonia SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE antimicrobial therapy; PSI/CURB-65 score; clinical outcomes ID RESISTANT STAPHYLOCOCCUS-AUREUS; PANTON-VALENTINE LEUKOCIDIN; STREPTOCOCCUS-PNEUMONIAE; HOSPITALIZED-PATIENTS; UNITED-STATES; EARLY SWITCH; ANTIMICROBIAL RESISTANCE; SEVERITY CRITERIA; PREDICTION RULE; STRAIN USA300 AB Community-acquired pneumonia (CAP) is a serious condition associated with significant morbidity and potential long-term mortality. Although the majority of patients with CAP are treated as outpatients, the greatest proportion of pneumonia-related mortality and healthcare expenditure occurs among the patients who are hospitalized. There has been considerable interest in determining risk factors and severity criteria assessments to assist with site-of-care decisions. For both inpatients and outpatients, the most common pathogens associated with CAP include Streptococcus pneumoniae, Haemophilus influenzae, group A streptococci and Moraxella catarrhalis. Atypical pathogens, Gram-negative bacilli, methicillin-resistant Staphylococcus aureus (MRSA) and viruses are also recognized aetiological agents of CAP. Despite the availability of antimicrobial therapies, the recent emergence of drug-resistant pneumococcal and staphylococcal isolates has limited the effectiveness of currently available agents. Because early and rapid initiation of empirical antimicrobial treatment is critical for achieving a favourable outcome in CAP, newer agents with activity against drug-resistant strains of S. pneumoniae and MRSA are needed for the management of patients with CAP. C1 [Ramirez, Julio Alberto] Univ Louisville, Louisville, KY 40202 USA. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Ramirez, JA (reprint author), Univ Louisville, Louisville, KY 40202 USA. EM j.ramirez@louisville.edu FU Forest Laboratories, Inc.; Astra-Zeneca; Bayer-Schering Pharma; Pfizer; GlaxoSmithKline; Cubist Pharmaceuticals; Merck; Boehringer Ingelheim; BARD; Lilly; NIH FX Funding for editorial assistance was provided by Forest Laboratories, Inc.; J. A. R. has participated as a speaker in scientific meetings or courses organized and financed by various pharmaceutical companies, including Astra-Zeneca, Bayer-Schering Pharma, Pfizer, GlaxoSmithKline and Cubist Pharmaceuticals. J. A. R. has been a consultant for Pfizer. J. A. R. has been the principal investigator for research grants sponsored by Bayer-Schering Pharma, Pfizer, Cubist Pharmaceuticals and Merck. A. R. A. has participated as a speaker in scientific meetings or courses organized and financed by various pharmaceutical companies, including Astra-Zeneca, Boehringer Ingelheim, Bayer-Schering Pharma, Pfizer, GlaxoSmithKline and Forest Laboratories, Inc. A. R. A. has been a consultant for Astra-Zeneca, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Forest Laboratories, Inc. and Bayer-Schering Pharma. A. R. A. has been the principal investigator for research grants and the University of Texas Health Science Center at San Antonio was paid for participating in multicentre clinical trials sponsored by GlaxoSmithKline, Bayer-Schering Pharma, BARD, Lilly and NIH. NR 61 TC 7 Z9 8 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2011 VL 66 SU 3 BP III3 EP III9 DI 10.1093/jac/dkr094 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 758HA UT WOS:000290153500002 ER PT J AU Ruperto, N Hanrahan, LM Alarcon, GS Belmont, HM Brey, RL Brunetta, P Buyon, JP Costner, MI Cronin, ME Dooley, MA Filocamo, G Fiorentino, D Fortin, PR Franks, AG Gilkeson, G Ginzler, E Gordon, C Grossman, J Hahn, B Isenberg, DA Kalunian, KC Petri, M Sammaritano, L Sanchez-Guerrero, J Sontheimer, RD Strand, V Urowitz, M von Feldt, JM Werth, VP Merrill, JT AF Ruperto, N. Hanrahan, L. M. Alarcon, G. S. Belmont, H. M. Brey, R. L. Brunetta, P. Buyon, J. P. Costner, M. I. Cronin, M. E. Dooley, M. A. Filocamo, G. Fiorentino, D. Fortin, P. R. Franks, A. G., Jr. Gilkeson, G. Ginzler, E. Gordon, C. Grossman, J. Hahn, B. Isenberg, D. A. Kalunian, K. C. Petri, M. Sammaritano, L. Sanchez-Guerrero, J. Sontheimer, R. D. Strand, V. Urowitz, M. von Feldt, J. M. Werth, V. P. Merrill, J. T. CA Lupus Fdn Amer Inc TI International consensus for a definition of disease flare in lupus SO LUPUS LA English DT Article DE autoimmune disease; flare; systemic lupus erythematosus AB The Lupus Foundation of America (LFA) convened an international working group to obtain a consensus definition of disease flare in lupus. With help from the Paediatric Rheumatology International Trials Organization (PRINTO), two web-based Delphi surveys of physicians were conducted. Subsequently, the LFA held a second consensus conference followed by a third Delphi survey to reach a community-wide agreement for flare definition. Sixty-nine of the 120 (57.5%) polled physicians responded to the first survey. Fifty-nine of the responses were available to draft 12 preliminary statements, which were circulated in the second survey. Eighty-seven of 118 (74%) physicians completed the second survey, with an agreement of 70% for 9/12 (75%) statements. During the second conference, three alternative flare definitions were consolidated and sent back to the international community. One hundred and sixteen of 146 (79.5%) responded, with agreement by 71/116 (61%) for the following definition: "A flare is a measurable increase in disease activity in one or more organ systems involving new or worse clinical signs and symptoms and/or laboratory measurements. It must be considered clinically significant by the assessor and usually there would be at least consideration of a change or an increase in treatment.'' The LFA proposes this definition for lupus flare on the basis of its high face validity. Lupus (2011) 20, 453-462. C1 [Merrill, J. T.] Oklahoma Med Res Fdn, Res Program, Oklahoma City, OK 73104 USA. [Ruperto, N.; Filocamo, G.] PRINTO, Genoa, Italy. [Hanrahan, L. M.] Lupus Fdn Amer Inc, Washington, DC USA. [Alarcon, G. S.] Univ Alabama, Birmingham, AL USA. [Belmont, H. M.] NYU, Hosp Joint Dis, New York, NY USA. [Brey, R. L.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. [Brunetta, P.] Genentech Inc, San Francisco, CA USA. [Buyon, J. P.; Franks, A. G., Jr.] NYU, Sch Med, New York, NY USA. [Costner, M. I.] UT SW Med Ctr, Dallas, TX USA. [Cronin, M. E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Dooley, M. A.] Univ N Carolina, Chapel Hill, NC USA. [Fiorentino, D.; Strand, V.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Fortin, P. R.; Urowitz, M.] Univ Toronto, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada. [Gilkeson, G.] Med Univ S Carolina, Charleston, SC 29425 USA. [Ginzler, E.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Gordon, C.] Univ Birmingham, Sch Med, Birmingham, W Midlands, England. [Grossman, J.; Hahn, B.] Univ Calif Los Angeles, Los Angeles, CA USA. [Isenberg, D. A.] UCL, London, England. [Kalunian, K. C.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA. [Petri, M.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Sammaritano, L.] Hosp Special Surg, New York, NY 10021 USA. [Sanchez-Guerrero, J.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Salvador Zubiran Mexico, Mexico. [Sontheimer, R. D.] Univ Utah, Sch Med, Salt Lake City, UT USA. [von Feldt, J. M.; Werth, V. P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Merrill, JT (reprint author), Oklahoma Med Res Fdn, Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM Joan-Merrill@omrf.org OI Hough, Douglas/0000-0001-7728-816X; Fiorentino, David/0000-0001-7951-3674; Isenberg, David/0000-0001-9514-2455; Belmont, Howard/0000-0003-3389-2976; Franks, Andrew/0000-0001-5427-6369 FU Lupus Foundation of America, Inc. FX This work was supported by the Lupus Foundation of America, Inc. NR 28 TC 40 Z9 41 U1 0 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PD APR PY 2011 VL 20 IS 5 BP 453 EP 462 DI 10.1177/0961203310388445 PG 10 WC Rheumatology SC Rheumatology GA 759BC UT WOS:000290213800003 PM 21148601 ER PT J AU Moitra, E Sperry, JA Mongold, D Kyle, BN Selby, J AF Moitra, Ethan Sperry, Jeannie A. Mongold, Derek Kyle, Brandon N. Selby, Joseph TI A Group Medical Visit Program for Primary Care Patients With Chronic Pain SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE integrated care; chronic pain; primary care; group medical visit ID RANDOMIZED-TRIAL; HEALTH-CARE; DEPRESSION; ANXIETY; METAANALYSIS; PREVALENCE; DISORDERS; QUESTIONNAIRE; MANAGEMENT; SERVICES AB Chronic pain is a significant public health problem, which leads to physical disability, psychological distress, and reduced quality of life. Furthermore, patients with chronic pain conditions place a high burden on the healthcare system because of the nature of their disease and their ongoing treatment needs. The treatment of chronic pain lends itself well to the primary care setting, where an integrated care approach involving physicians and behavioral health specialists can play a significant role in patient outcomes. One such integrated care model, Group Medical Visits (GMVs), was used to provide medical and behavioral interventions for primary care patients with chronic pain problems. The primary objective of this report is to discuss the GMV model and its feasibility. Additionally, notable baseline data are discussed. A program description is provided, as well as practical considerations for the future use of GMVs in the treatment of patients with chronic conditions. C1 [Moitra, Ethan] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Sperry, Jeannie A.; Mongold, Derek; Selby, Joseph] W Virginia Univ, Dept Family Med, Morgantown, WV 26506 USA. [Sperry, Jeannie A.; Mongold, Derek] W Virginia Univ, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA. [Mongold, Derek; Selby, Joseph] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA. S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. RP Moitra, E (reprint author), Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Box G BH, Providence, RI 02912 USA. EM ethan_moitra@brown.edu NR 40 TC 1 Z9 2 U1 1 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD APR PY 2011 VL 42 IS 2 BP 153 EP 159 DI 10.1037/a0022240 PG 7 WC Psychology, Multidisciplinary SC Psychology GA 755JW UT WOS:000289927300008 ER PT J AU Kamat, A Nijland, MJ McDonald, TJ Cox, LA Nathanielsz, PW Li, C AF Kamat, Amrita Nijland, Mark J. McDonald, Thomas J. Cox, Laura A. Nathanielsz, Peter W. Li, Cun TI Moderate Global Reduction in Maternal Nutrition Has Differential Stage of Gestation Specific Effects on beta(1)- and beta(2)-Adrenergic Receptors in the Fetal Baboon Liver SO REPRODUCTIVE SCIENCES LA English DT Article DE beta-adrenergic receptor; immunolocalization; gene expression; protein expression; baboon ID ADRENERGIC-RECEPTORS; MESSENGER-RNA; BETA(1)-ADRENERGIC RECEPTORS; RAT; GENE; EXPRESSION; GLYCOGENOLYSIS; OVEREXPRESSION; IDENTIFICATION; CYCLASE AB Hepatic beta-adrenergic receptors (beta-ARs) play a pivotal role in mobilization of reserves via gluconeogenesis and glycogenolysis to supply the animal with its energy needs during decreased nutrient availability. Using a unique nutrient-deprived baboon model, we have demonstrated for the first time that immunoreactive hepatic beta(1)- and beta(2)-AR subtypes are regionally distributed and localized on cells around the central lobular vein in 0.5 and 0.9 gestation (G) fetuses of ad libitum fed control (CTR) and maternal nutrient restricted (MNR) mothers. Furthermore, MNR decreased fetal liver immunoreactive beta(1)-AR and increased immunoreactive beta(2)-AR at 0.5G. However, at 0.9G, immunohistochemistry and Western blot analysis revealed a decrease in beta(1)-AR and no change in beta(2)-AR levels. Thus, MNR in a nonhuman primate species has effects on hepatic beta(1)- and beta(2)-ARs that are receptor- and gestation stage-specific and may represent compensatory systems whose effects would increase glucose availability in the presence of nutrient deprivation. C1 [Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Kamat, Amrita] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX USA. [Nijland, Mark J.; McDonald, Thomas J.; Nathanielsz, Peter W.; Li, Cun] Univ Texas Hlth Sci Ctr San Antonio, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA. [McDonald, Thomas J.; Cox, Laura A.; Nathanielsz, Peter W.; Li, Cun] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Nijland, Mark J.; Cox, Laura A.] SW Fdn Biomed Res, SW Natl Primate Res Ctr, San Antonio, TX 78284 USA. RP Kamat, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7875, San Antonio, TX 78229 USA. EM kamat@uthscsa.edu OI Nathanielsz, Peter/0000-0001-8410-6280 FU NIH [HD 21350]; Department of Veterans Affairs [17]; American Heart Association FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: Grant support from NIH grant HD 21350, Department of Veterans Affairs VISN 17 Award (AK) and Grant-in-Aid American Heart Association Award (AK). NR 40 TC 4 Z9 4 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 J9 REPROD SCI JI Reprod. Sci. PD APR PY 2011 VL 18 IS 4 BP 398 EP 405 DI 10.1177/1933719110386496 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 758KW UT WOS:000290164600010 PM 21079239 ER PT J AU Chaiwat, O Vavilala, MS Philip, S Malakouti, A Neff, MJ Deem, S Treggiari, MM Wang, J Lang, JD AF Chaiwat, Onuma Vavilala, Monica S. Philip, Shaji Malakouti, Amin Neff, Margaret J. Deem, Steven Treggiari, Miriam M. Wang, Jin Lang, John D. TI Intraoperative adherence to a low tidal volume ventilation strategy in critically ill patients with preexisting acute lung injury SO JOURNAL OF CRITICAL CARE LA English DT Article DE Lung injury; ALI; ARDS; Low tidal volume; Mechanical ventilation; Intraoperative; Anesthesia ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CLINICAL-TRIAL; MECHANICAL VENTILATION; PROTECTIVE-VENTILATION; INFLAMMATORY RESPONSES; CARDIOPULMONARY BYPASS; PULMONARY-FUNCTION; CARDIAC-SURGERY; THERAPY; RELEASE AB Purpose: Low tidal volume (LTV) ventilation reduces mortality in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). This study investigates adherence of intraoperative LTV and whether patient outcomes were different with or without continued intraoperative LTV ventilation in patients with previously established ALI or ARDS. Materials and Methods: A retrospective analysis was performed of adults with ALI/ARDS over a 2-year period who underwent surgery between 24 hours and 14 days after the diagnosis of ALI/ARDS. The main outcome was intraoperative LTV use. Secondary outcomes included perioperative respiratory and clinical outcomes. Results: Of the 249 patients who underwent surgery between 24 hours and 14 days after ALI/ARDS diagnosis, 101 (41%) received preoperative LTV ventilation. Fifty-four (53%) received intraoperative LTV ventilation, whereas 47 (47%) did not. Use of preoperative LTV ventilation was associated with use of intraoperative LTV ventilation (P < .01). No differences in respiratory or clinical outcomes between patients with or without intraoperative LTV ventilation were observed. Conclusions: Adherence to intraoperative LTV in surgical patients was low. Adherence of LTV intraoperatively was not associated with improved oxygenation, reductions in hospital length of stay, or in-hospital mortality. The importance of adhering to an intraoperative LTV strategy remains unclear. Published by Elsevier Inc. C1 [Lang, John D.] Univ Washington, Sch Med, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Lang, John D.] Univ Washington, Sch Med, Dept Pulm & Crit Care Med, Seattle, WA USA. [Neff, Margaret J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Deem, Steven] Univ Washington, Sch Med, Dept Anesthesiol & Med Pulm & Crit Care Med, Seattle, WA USA. [Treggiari, Miriam M.] Univ Washington, Sch Med, Dept Anesthesiol & Neurol Surg, Seattle, WA USA. [Wang, Jin] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA USA. RP Lang, JD (reprint author), Univ Washington, Sch Med, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM jdlang@u.washington.edu FU Harborview Anesthesiology Research Center; National Institutes of Health [HL067982] FX Funded by Harborview Anesthesiology Research Center and National Institutes of Health HL067982. NR 25 TC 10 Z9 11 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9441 J9 J CRIT CARE JI J. Crit. Care PD APR PY 2011 VL 26 IS 2 BP 144 EP 151 DI 10.1016/j.jcrc.2010.08.002 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 754WG UT WOS:000289887800008 PM 20869200 ER PT J AU Denisenko, O Lin, B Louey, S Thornburg, K Bomsztyk, K Bagby, S AF Denisenko, O. Lin, B. Louey, S. Thornburg, K. Bomsztyk, K. Bagby, S. TI Maternal malnutrition and placental insufficiency induce global downregulation of gene expression in fetal kidneys SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE LA English DT Article DE epigenetics; gene expression; histone modifications; intrauterine growth restriction; transcription ID GESTATIONAL-AGE FETUSES; DEVELOPMENTAL ORIGINS; CHROMATIN-STRUCTURE; GROWTH RESTRICTION; RNA-POLYMERASE; POSTNATAL-GROWTH; DNA METHYLATION; ADULT DISEASE; BIRTH-WEIGHT; RAT-KIDNEY AB Malnutrition during pregnancy causes intrauterine growth restriction and long-term changes in the offspring's physiology and metabolism. To explore molecular mechanisms by which the intrauterine environment conveys programming in fetal kidneys, an organ known to undergo substantial changes in many animal models of late gestational undernutrition, we used a microswine model of maternal protein restriction (MPR) in which sows were exposed to isocaloric low protein (LP) diet during late gestation/early lactation to encompass the bulk of nephrogenesis. To define general v. model-specific effects, we also used a sheep model of placental insufficiency. In kidneys from near-term fetal and neonatal microswine LP offspring, per cell levels of total RNA, poly(A)+ mRNA and transcripts of several randomly chosen housekeeping genes were significantly reduced compared to controls. Microarray analysis revealed only a few MPR-resistant genes that escape such downregulation. The ratio of histone modifications H3K4m3/H3K9m3 (active/silenced) was reduced at promoters of downregulated but not MPR-resistant genes suggesting that transcriptional suppression is the point of control. In juvenile offspring, on a normal diet from weaning, cellular RNA levels and histone mark patterns were recovered to near control levels, indicating that global repression of transcription is dependent on ongoing MPR. Importantly, cellular RNA content was also reduced in ovine fetal kidneys during placental insufficiency. These studies show that global repression of transcription may be a universal consequence of a poor intrauterine environment that contributes to fetal restriction. C1 [Denisenko, O.; Bomsztyk, K.] Univ Washington, Dept Med, Seattle, WA 98109 USA. [Louey, S.; Thornburg, K.; Bagby, S.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. [Louey, S.; Thornburg, K.] Oregon Hlth & Sci Univ, Div Cardiovasc Med, Portland, OR 97201 USA. [Lin, B.; Bagby, S.] Oregon Hlth & Sci Univ, Div Nephrol, Portland, OR 97201 USA. [Lin, B.; Bagby, S.] Portland VA Med Ctr, Res Serv, Portland, OR USA. RP Denisenko, O (reprint author), Univ Washington, Dept Med, 815 Mercer St,Room 244, Seattle, WA 98109 USA. EM odenis@uw.edu FU NIH/NICHD [P01HD34430, RO1 HD042570]; Medical Research Foundation of Oregon; M. Lowell Edwards Endowment; NIH [R37 DK45978]; Gates Foundation FX This study was supported by grants P01HD34430 and RO1 HD042570 (SB) from NIH/NICHD, the Medical Research Foundation of Oregon (SB), M. Lowell Edwards Endowment (KT), NIH grant R37 DK45978 (KB) and a grant from Gates Foundation (OD). Microarray assays were performed in the OHSU Gene Microarray Shared Resource. The authors are grateful to Dr Chris Harrington for microarray assistance and Dr G. Bagby for discussions and critical reading of the manuscript. NR 64 TC 8 Z9 8 U1 0 U2 6 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2040-1744 J9 J DEV ORIG HLTH DIS JI J. Dev. Orig. Health Dis. PD APR PY 2011 VL 2 IS 2 BP 124 EP 133 DI 10.1017/S2040174410000632 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 755MC UT WOS:000289934700006 PM 25140926 ER PT J AU Hilsabeck, RC Anstead, GM Webb, AL Stern, SL Hoyumpa, A AF Hilsabeck, Robin C. Anstead, Gregory M. Webb, Amy L. Stern, Stephen L. Hoyumpa, Anastasio TI Impact of Helicobacter pylori on chronic hepatitis C-related cognitive dysfunction Response SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Letter ID CENTRAL-NERVOUS-SYSTEM; VIRUS; EFFICIENCY; LIVER C1 [Hilsabeck, Robin C.; Anstead, Gregory M.; Webb, Amy L.; Stern, Stephen L.] S Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX 78229 USA. [Anstead, Gregory M.; Webb, Amy L.; Stern, Stephen L.; Hoyumpa, Anastasio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Hilsabeck@uthscsa.edu NR 11 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD APR PY 2011 VL 233 IS 1-2 BP 257 EP 258 DI 10.1016/j.jneuroim.2010.10.003 PG 2 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 757FD UT WOS:000290070000036 ER PT J AU Cardenas, VA Chao, LL Studholme, C Yaffe, K Miller, BL Madison, C Buckley, ST Mungas, D Schuff, N Weiner, MW AF Cardenas, V. A. Chao, L. L. Studholme, C. Yaffe, K. Miller, B. L. Madison, C. Buckley, S. T. Mungas, D. Schuff, N. Weiner, M. W. TI Brain atrophy associated with baseline and longitudinal measures of cognition SO NEUROBIOLOGY OF AGING LA English DT Article DE Deformation morphometry; Longitudinal; Brain; MRI; Cognition; Memory; Executive function ID VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; QUANTITATIVE VALIDATION; INDIVIDUAL-DIFFERENCES; SEMANTIC KNOWLEDGE; OLDER PERSONS; IMPAIRMENT; DEMENTIA; MRI AB The overall goal was to identify patterns of brain atrophy associated with cognitive impairment and future cognitive decline in non-demented elders. Seventy-one participants were studied with structural MRI and neuropsychological testing at baseline and 1-year follow-up. Deformation-based morphometry was used to examine the relationship between regional baseline brain tissue volume with baseline and longitudinal measures of delayed verbal memory, semantic memory, and executive function. Smaller right hippocampal and entorhinal cortex (ERC) volumes at baseline were associated with worse delayed verbal memory performance at baseline while smaller left ERC volume was associated with greater longitudinal decline. Smaller left superior temporal cortex at baseline was associated with worse semantic memory at baseline, while smaller left temporal white and gray matter volumes were associated with greater semantic memory decline. Increased CSF and smaller frontal lobe volumes were associated with impaired executive function at baseline and greater longitudinal executive decline. These findings suggest that baseline volumes of prefrontal and temporal regions may underlie continuing cognitive decline due to aging, pathology, or both in non-demented elderly individuals. (C) 2009 Elsevier Inc. All rights reserved. C1 [Cardenas, V. A.; Chao, L. L.; Studholme, C.; Yaffe, K.; Miller, B. L.; Schuff, N.; Weiner, M. W.] Univ Calif San Francisco, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Cardenas, V. A.; Chao, L. L.; Studholme, C.; Yaffe, K.; Buckley, S. T.; Schuff, N.; Weiner, M. W.] San Francisco VA Med Ctr, San Francisco, CA USA. [Madison, C.] Calif Pacific Med Ctr, San Francisco, CA 94115 USA. [Mungas, D.] Univ Calif Davis, Davis, CA 95616 USA. RP Cardenas, VA (reprint author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, 4150 Clement St,114M, San Francisco, CA 94121 USA. EM valerie.cardenas-nicolson@ucsf.edu RI Mungas, Dan/E-6810-2011 FU NIH [R01 AG10897, R01 MH65392, R03 EB008136]; Department of Veterans Affairs FX This work was supported in part by NIH grants R01 AG10897, R01 MH65392 and R03 EB008136, and the Department of Veterans Affairs. We thank Diana Truran and her staff for MRI scanning, image quality control, and data organization. NR 44 TC 47 Z9 48 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2011 VL 32 IS 4 BP 572 EP 580 DI 10.1016/j.neurobiolaging.2009.04.011 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 755SL UT WOS:000289956600002 PM 19446370 ER PT J AU AkhavanHeidari, M Akoad, M Wagener, M Karuman, P Cacciarelli, TV AF AkhavanHeidari, M. Akoad, M. Wagener, M. Karuman, P. Cacciarelli, T. V. TI Pretransplant Ablative Therapy (PAT) Improves Short-Term Outcome in Liver Transplantation for Hepatocellular Carcinoma (HCC). SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [AkhavanHeidari, M.; Wagener, M.; Karuman, P.; Cacciarelli, T. V.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [AkhavanHeidari, M.; Wagener, M.; Cacciarelli, T. V.] Univ Pittsburgh, Pittsburgh, PA USA. [Akoad, M.] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1509 BP 468 EP 469 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401727 ER PT J AU AkhavanHeidari, M Akoad, M Wagener, M Karuman, P Frye, R Cacciarelli, TV AF AkhavanHeidari, M. Akoad, M. Wagener, M. Karuman, P. Frye, R. Cacciarelli, T. V. TI A Comparison of the Milan Pathologic vs the American Joint Committee on Cancer (AJCC) Staging for Hepatocellular Carcinoma (HCC) and Liver Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [AkhavanHeidari, M.; Wagener, M.; Karuman, P.; Frye, R.; Cacciarelli, T. V.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [AkhavanHeidari, M.; Wagener, M.; Cacciarelli, T. V.] Univ Pittsburgh, Pittsburgh, PA USA. [Akoad, M.] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1508 BP 468 EP 468 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401726 ER PT J AU AkhavanHeidari, M Akoad, M Wagener, M Karuman, P Cacciarelli, TV AF AkhavanHeidari, M. Akoad, M. Wagener, M. Karuman, P. Cacciarelli, T. V. TI Predictors of Outcome in Patients with Hepatocellular Carcinoma (HCC) Treated with Liver Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [AkhavanHeidari, M.; Wagener, M.; Karuman, P.; Cacciarelli, T. V.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [AkhavanHeidari, M.; Wagener, M.; Cacciarelli, T. V.] Univ Pittsburgh, Pittsburgh, PA USA. [Akoad, M.] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1510 BP 469 EP 469 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401728 ER PT J AU Ahnen, D AF Ahnen, Dennis TI LYNCH SYNDROME SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ahnen, Dennis] Denver VA Med Ctr, Denver, CO USA. [Ahnen, Dennis] Univ Colorado, Sch Med, Denver, CO 80202 USA. EM ssg19@columbia.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S128 EP S128 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700503 ER PT J AU Bailey, K Ruderman, A Diviak, K Mermelstein, R AF Bailey, Katherine Ruderman, Audrey Diviak, Kathi Mermelstein, Robin TI WEIGHT-RELATED CONSTRUCTS AND TRAJECTORIES OF ADOLESCENT CIGARETTE SMOKING OVER TIME SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Bailey, Katherine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Ruderman, Audrey; Diviak, Kathi; Mermelstein, Robin] Univ Illinois, Chicago, IL USA. EM kcbailey@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S118 EP S118 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700465 ER PT J AU Ferguson, MJ Russell, SW Knight, S Spring, B AF Ferguson, Molly J. Russell, Stephanie W. Knight, Sara Spring, Bonnie TI A DELPHI POLL ON CLOSING THE RESEARCH TO PRACTICE GAP IN EVIDENCE-BASED PRACTICE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ferguson, Molly J.; Russell, Stephanie W.; Spring, Bonnie] Northwestern Univ, Chicago, IL 60611 USA. [Knight, Sara] San Francisco VA Med Ctr, San Francisco, CA USA. EM m-ferguson@northwestern.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S171 EP S171 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701154 ER PT J AU Geyer, EJ Hawkins, LC Piper, HA Knisley, EA Elliot, BA Lovejoy, TI AF Geyer, Eric J. Hawkins, Liana C. Piper, Heather A. Knisley, Elisabeth A. Elliot, Blake A. Lovejoy, Travis I. TI BRIEF MOTIVATIONAL INTERVIEWING ENHANCES ATTITUDES AND SELF-EFFICACY FOR CONDOM USE IN HIV+ OLDER ADULTS: A RANDOMIZED CONTROLLED TRIAL SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Geyer, Eric J.; Hawkins, Liana C.; Piper, Heather A.; Knisley, Elisabeth A.; Elliot, Blake A.; Lovejoy, Travis I.] Ohio Univ, Athens, OH 45701 USA. [Lovejoy, Travis I.] Portland VA Med Ctr, Portland, OR USA. EM tl399805@ohio.edu NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S94 EP S94 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700367 ER PT J AU Groessl, EJ Weingart, K Johnson, N Gifford, A Asch, S Ho, S AF Groessl, Erik J. Weingart, Kim Johnson, Neil Gifford, Allen Asch, Steve Ho, Samuel TI EFFECTS OF THE HEPATITIS C SELF-MANAGEMENT PROGRAM AT 1-YEAR SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Groessl, Erik J.; Weingart, Kim; Johnson, Neil; Ho, Samuel] VA San Diego, HSR&D, San Diego, CA 92161 USA. [Groessl, Erik J.; Ho, Samuel] UCSD, La Jolla, CA USA. [Gifford, Allen] Bedford VA, Bedford, MA USA. [Asch, Steve] VA Greater Los Angeles, Los Angeles, CA USA. EM egroessl@ucsd.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S105 EP S105 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700410 ER PT J AU Norton, WE Glanz, K Collins, CB Mittman, BS Glasgow, RE AF Norton, Wynne E. Glanz, Karen Collins, Charles B. Mittman, Brian S. Glasgow, Russell E. TI SCALING-UP EVIDENCE-BASED HEALTH PROMOTION/DISEASE PREVENTION INTERVENTIONS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Norton, Wynne E.] Univ Alabama, Birmingham, AL 35293 USA. [Glanz, Karen] Univ Penn, Philadelphia, PA 19104 USA. [Collins, Charles B.] Ctr Dis Control & Prevent, Capac Bldg Branch, Atlanta, GA USA. [Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, Ctr Implementat Practice & Res Support, Los Angeles, CA USA. [Glasgow, Russell E.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. EM wenorton@uab.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S152 EP S152 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701080 ER PT J AU Fiorentino, D Werth, VP AF Fiorentino, David Werth, Victoria P. TI Dermatomyositis Autoantibodies Clinical Markers of Patients Past, Present, and Future SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material ID INTERSTITIAL LUNG-DISEASE; IDIOPATHIC INFLAMMATORY MYOPATHY; MYOSITIS-SPECIFIC AUTOANTIBODIES; AMYOPATHIC DERMATOMYOSITIS; MYCOPHENOLATE-MOFETIL; JAPANESE PATIENTS; CLASSIFICATION; EXPRESSION C1 [Fiorentino, David] Stanford Univ, Dept Dermatol & Med Immunol & Rheumatol, Redwood City, CA USA. [Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, 3400 Civ Ctr Blvd,Ste 1-330A, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu OI Fiorentino, David/0000-0001-7951-3674 FU NIAMS NIH HHS [K24-AR 02207] NR 24 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2011 VL 147 IS 4 BP 492 EP 494 PG 3 WC Dermatology SC Dermatology GA 752FY UT WOS:000289677800020 PM 21482900 ER PT J AU Peacock, WF Varon, J Ebrahimi, R Dunbar, L Pollack, CV AF Peacock, W. Frank Varon, Joseph Ebrahimi, Ramin Dunbar, Lala Pollack, Charles V., Jr. TI Clevidipine for severe hypertension in patients with renal dysfunction: A VELOCITY trial analysis SO BLOOD PRESSURE LA English DT Article DE Calcium-channel blocker; clevidipine; hypertension; intravenous antihypertensive agent; renal insufficiency ID ACTING CALCIUM-ANTAGONIST; CARDIAC-SURGERY PATIENTS; HEALTHY-VOLUNTEERS; NITROPRUSSIDE; EFFICACY; CYANIDE AB Introduction. Acute and severe hypertension is common, especially in patients with renal dysfunction (RD). Clevidipine is a rapidly acting (t(1/2)similar to 1 mm) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue esterases and may be useful in patients with RD. The purpose of this analysis was to assess the safety and efficacy of clevidipine in patients with RD. Methods. VELOCITY, a multicenter open-label study of severe hypertension, enrolled 126 patients with persistent systolic blood pressure (SBP) >180 mmHg. Investigators pre-specified a SBP initial target range (ITR) for each patient to be achieved within 30 min. Blood pressure monitoring was by cuff. Clevidipine was infused via peripheral IV at 2 mg/h for at least 3 min, then doubled every 3 min as needed to a maximum of 32 mg/h (non-weight-based treat-to-target protocol). Per protocol, clevidipine was continued for at least 18 h (96 h maximum). RD was diagnosed and reported as an end-organ injury by the investigator and was defined as requiring dialysis or an initial creatinine >2.0 mg/dl. Primary endpoints were the percentage of patients within the ITR by 30 min and the percentage below the ITR after 3 min of clevidipine infusion. Results. Of the 24 patients with moderate to severe RD, most (13/24) were dialysis dependent. Forty-six percent were male, with mean age 51 +/- 14 years; 63% were black and 96% had a hypertension history. Median time to achieve the ITR was 8.5 min. Almost 90% of patients reached the ITR in 30 min without evidence of overshoot and were maintained on clevidipine through 18 h. Most patients (88%) transitioned to oral antihypertensive therapy within 6 h of clevidipine termination. Conclusions. This report is the first demonstrating that clevidipine is safe and effective in RD complicated by severe hypertension. Prolonged infusion maintained blood pressure within a target range and allowed successful transition to oral therapy. C1 [Peacock, W. Frank] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44195 USA. [Varon, Joseph] Univ Texas Hlth Sci Ctr, Houston, TX USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA USA. [Ebrahimi, Ramin] VA Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Dunbar, Lala] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Pollack, Charles V., Jr.] Univ Penn, Philadelphia, PA 19104 USA. RP Peacock, WF (reprint author), Cleveland Clin, Dept Emergency Med, Desk E19,9500 Euclid Ave, Cleveland, OH 44195 USA. EM Peacocw@ccf.org OI Varon, Joseph/0000-0002-7622-9974 FU Abbott; BAS; Biosite; Brahms; PCT; CHF Solutions; Heartscape Technologies, Inc.; Inovise Medical; Inverness Medical Innovations, Inc.; PDL Pharmaceuticals; Medicines Company FX W.F.P. has received honoraria for lectures from Abbott, Biosite, Otsuka Pharmaceuticals, Ortho Clinical Diagnostics, PDL Pharmaceuticals, Scios, Inc. and The Medicines Company. He has served as a consultant for Abbott, Beckman-Coulter, Inc., Biosite, Inovise Medical, Inc., Inverness Medical Innovations, Inc., Otsuka Pharmaceuticals, Ortho Clinical Diagnostics and The Medicines Company, Heartscape Technologies, Inc.; and he has received support in the form of research grants from Abbott, BAS, Biosite, Brahms, PCT, CHF Solutions, Heartscape Technologies, Inc., Inovise Medical, Inverness Medical Innovations, Inc., PDL Pharmaceuticals, and The Medicines Company. NR 21 TC 3 Z9 3 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0803-7051 J9 BLOOD PRESSURE JI Blood Pressure PD APR PY 2011 VL 20 SU 1 BP 20 EP 25 DI 10.3109/08037051.2010.539317 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 752NU UT WOS:000289699700003 ER PT J AU Mortazavi, F Dubinett, S Rettig, M AF Mortazavi, Fariborz Dubinett, Steven Rettig, Matthew TI c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Article DE Cell adhesion; c-Crk; Lung cancer; Metastasis; p120 catenin; Signal transduction; Transcription factors ID P120 CATENIN; CADHERIN EXPRESSION; GENE-EXPRESSION; LOCALIZATION; TURNOVER; PROTEINS; INVASION; BINDING AB As a member of adherens junction, p120-catenin (p120ctn) plays a major role in cell adhesions through stabilization of E-cadherin. p120ctn is transcriptionally down-regulated in non-small cell lung cancer (NSCLC), although the molecular mechanisms underlying p120ctn repression are incompletely defined. Here we further investigated transcriptional regulation of p120ctn in NSCLC. We prepared a promoter reporter plasmid construct that contained p120ctn promoter region from position -1082 to +320 relative to transcription start site. Through serial deletion mutation analysis of the p120ctn promoter, we pinpointed cis-acting elements involved in regulation of p120ctn. We identified transcription factor SP1 as a transcriptional repressor of p120ctn that directly binds to segment (-9 to +36) of the p120ctn promoter. SP1 can receive multiple signals from several intracellular signaling pathways. Through examination of SP1 binding partners, we identified proto-oncogene c-Crk to be involved in transcriptional down-regulation of p120ctn. RNAi mediated silencing of CRK in A549, H157 and H358 cells increased p120ctn protein levels. On the other hand, over-expression of CRK-I and CRK-II in NSCLC cells down-regulated p120ctn, an effect that was abrogated by simultaneous silencing of SP1. In summary, our data provide evidence for the role of c-Crk proto-oncogene in transcriptional repression of p120ctn that further clarifies the mechanism by which this biochemical signal promotes metastasis in NSCLC. C1 [Mortazavi, Fariborz; Dubinett, Steven; Rettig, Matthew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Mortazavi, Fariborz; Rettig, Matthew] W Los Angeles VA, Div Hematol & Oncol, Los Angeles, CA USA. [Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Dubinett, Steven] Div Pulm & Crit Care Med, Los Angeles, CA USA. [Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. RP Mortazavi, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM fredmortazavi@ucla.edu NR 30 TC 7 Z9 12 U1 0 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD APR PY 2011 VL 28 IS 4 BP 391 EP 404 DI 10.1007/s10585-011-9378-8 PG 14 WC Oncology SC Oncology GA 753RN UT WOS:000289797400006 PM 21336985 ER PT J AU Steinman, MA Lund, BC Miao, YH Boscardin, WJ Kaboli, PJ AF Steinman, Michael A. Lund, Brian C. Miao, Yinghui Boscardin, W. John Kaboli, Peter J. TI Geriatric Conditions, Medication Use, and Risk of Adverse Drug Events in a Predominantly Male, Older Veteran Population SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE drug therapy; adverse effects; frail elderly; polypharmacy ID HOSPITALIZED-PATIENTS; EMERGENCY-DEPARTMENT; DEPRESSIVE SYMPTOMS; COGNITIVE FUNCTION; ELDERLY-PATIENTS; ADULTS; COMMUNITY; MORTALITY; FRAILTY; DISCHARGE AB OBJECTIVES To determine whether geriatric conditions and functional impairment are independent risk factors for adverse drug events (ADEs). DESIGN Prospective cohort study. SETTING Veterans Affairs Medical Center. PARTICIPANTS Three hundred seventy-seven veterans aged 65 and older and taking five or more medications. MEASUREMENTS Geriatric conditions and functional status were assessed using participant interviews and structured assessments at study baseline. ADEs were elicited during participant interviews 3 and 12 months after study enrollment using validated methods. RESULTS The strong majority (97%) of participants were male, with a mean age of 74 +/- 5; 123 (33%) had one or more dependencies in instrumental activities of daily living (IADLs). Over the 1-year study period, 126 participants (33%) developed 167 ADEs. Upon multivariable analysis, risk of ADEs was not associated with any of the geriatric conditions that there was sufficient power to evaluate, including IADL function, cognitive impairment, depression, visual impairment, incontinence, constipation, and a summative measure of geriatric burden comprising the above and history of falls or gait instability. In exploratory analyses, the strongest factor associated with ADEs was the number of drugs added to a participant's medication regimen during the 1-year study period (incidence rate ratio 1.11 per each added drug, 95% confidence interval=1.03-1.19). CONCLUSION Common geriatric conditions and IADL function were not associated with ADEs in a predominantly male, older veteran population. Although it is important to consider the unique circumstances of each participant, excessive caution in prescribing to older adults with these geriatric conditions may not be warranted. C1 [Steinman, Michael A.; Miao, Yinghui; Boscardin, W. John] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Steinman, Michael A.; Miao, Yinghui] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Lund, Brian C.; Kaboli, Peter J.] Iowa City Vet Affairs Med Ctr, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA. [Lund, Brian C.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Div Gen Internal Med, Iowa City, IA 52242 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU National Institute on Aging; American Federation for Aging Research [1K23-AG030999]; Health Services Research and Development Service, Department of Veterans Affairs [SAF98-152]; Research Career Development award [RCD 03-033-1]; Center for Research in the Implementation of Innovative Strategies in Practice at the Iowa City Veterans Affairs Medical Center [HFP 04-149] FX Supported by the National Institute on Aging and the American Federation for Aging Research (1K23-AG030999), by the Health Services Research and Development Service, Department of Veterans Affairs, through an investigator-initiated research award (SAF98-152); by a Research Career Development award (RCD 03-033-1); and by the Center for Research in the Implementation of Innovative Strategies in Practice (HFP 04-149) at the Iowa City Veterans Affairs Medical Center (Kaboli and Lund). NR 39 TC 12 Z9 12 U1 4 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 IS 4 BP 615 EP 621 DI 10.1111/j.1532-5415.2011.03331.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DS UT WOS:000289525500006 PM 21410446 ER PT J AU Lee, SJ Boscardin, WJ Cenzer, IS Huang, ES Rice-Trumble, K Eng, C AF Lee, Sei J. Boscardin, W. John Cenzer, Irena Stijacic Huang, Elbert S. Rice-Trumble, Kathy Eng, Catherine TI The Risks and Benefits of Implementing Glycemic Control Guidelines in Frail Older Adults with Diabetes Mellitus SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE glycemic control; guideline; hypoglycemia; PACE; diabetes mellitus ID LONG-TERM-CARE; BLOOD-GLUCOSE CONTROL; ELDERLY-PEOPLE; FOLLOW-UP; TYPE-2; INSULIN; QUALITY; COMPLICATIONS; HYPOGLYCEMIA; INTERVENTIONS AB OBJECTIVES To determine the hypo- and hyperglycemic outcomes associated with implementing the American Geriatrics Society (AGS) guideline for a glycosylated hemoglobin (HbA1c) level of less than 8% in frail older adults with diabetes mellitus (DM). DESIGN Guideline implementation. SETTING Program of All-Inclusive Care for the Elderly. PARTICIPANTS All participants in the before (October 2002-December 2004, n=338), early (January 2005-June 2006, n=289) and late (July 2006-December 2008, n=385) periods of guideline implementation with a diagnosis of DM and at least one HbA1c measurement. INTERVENTION Clinician education in 2005 with annual monitoring of the proportion of each clinician's patients with DM with HbA1c less than 8%. MEASUREMENTS Hypoglycemia (blood glucose < 50 mg/dL), hyperglycemia (blood glucose > 400 mg/dL), and severe hypoglycemia (emergency department (ED) visit for hypoglycemia). RESULTS Participants in the before, early, and late periods were similar in age, race and ethnicity, comorbidities, and functional dependence. Antihyperglycemic medication use was greater in the late period, with more participants using metformin (28% before, 42% late, P <.001) and insulin (23% before, 34% late, P <.001) and achieving the AGS glycemic target of HbA1c of less than 8% (74% before, 84% late, P <.001). Episodes of hyperglycemia (per 100 person-years) were dramatically lower in the late period (159 before, 46 late, P <.001), and episodes of hypoglycemia were similar (10.1 before, 9.3 late, P=.50). There were more episodes of severe hypoglycemia in the early period (1.1 before, 2.9 early, P=.03). CONCLUSION Implementing the AGS glycemic control guideline for frail older adults led to fewer hyperglycemic episodes but more severe hypoglycemic episodes requiring ED visits in the early implementation period. Future glycemic control guideline implementation efforts should be coupled with close monitoring for severe hypoglycemia in the early guideline implementation period. C1 [Lee, Sei J.; Boscardin, W. John; Cenzer, Irena Stijacic] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Lee, Sei J.; Boscardin, W. John; Cenzer, Irena Stijacic] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Huang, Elbert S.] Univ Chicago, Med Ctr, Gen Internal Med Sect, Chicago, IL 60637 USA. [Rice-Trumble, Kathy; Eng, Catherine] On Lok Lifeways, San Francisco, CA USA. RP Lee, SJ (reprint author), SFVAMC UCSF Geriatr, 4150 Clement St,Bldg 1,Rm 211A, San Francisco, CA 94121 USA. EM sei.lee@ucsf.edu FU Hartford Geriatrics Health Outcomes Research Scholars Award; University of California at San Francisco; National Center for Research Resources, a component of the National Institutes of Health [KL2RR024130] FX Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.; Dr. Sei Lee was funded by a Hartford Geriatrics Health Outcomes Research Scholars Award, the Hellman Family Award for Early Career Faculty at the University of California at San Francisco and the KL2RR024130 from the National Center for Research Resources, a component of the National Institutes of Health. NR 44 TC 27 Z9 27 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 IS 4 BP 666 EP 672 DI 10.1111/j.1532-5415.2011.03362.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DS UT WOS:000289525500012 PM 21480838 ER PT J AU Allman, RM Sawyer, P Bowling, CB Ritchie, CS Ahmed, A AF Allman, R. M. Sawyer, P. Bowling, C. B. Ritchie, C. S. Ahmed, A. TI Pulse Irregularity Predicts Functional Decline in Older Adults with Hypertension SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Allman, R. M.; Bowling, C. B.; Ritchie, C. S.; Ahmed, A.] Birmingham VA Med Ctr, Birmingham Atlanta GRECC, Birmingham, AL USA. [Allman, R. M.; Sawyer, P.; Bowling, C. B.; Ritchie, C. S.; Ahmed, A.] Univ Alabama, Ctr Aging, Birmingham, AL USA. [Allman, R. M.; Sawyer, P.; Bowling, C. B.; Ritchie, C. S.; Ahmed, A.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S72 EP S72 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600209 ER PT J AU Aye, L Chen, BH Hahn, TJ Seeman, T Lee, CC AF Aye, L. Chen, B. H. Hahn, T. J. Seeman, T. Lee, C. C. TI Gender Difference in Association of Testosterone Levels with the Metabolic Syndrome in Healthy Older Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Hahn, T. J.; Seeman, T.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Aye, L.] Univ Med & Dent New Jersey, Stratford, NJ USA. [Chen, B. H.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Program Genom & Nutr, Los Angeles, CA 90024 USA. [Chen, B. H.] Univ Calif Los Angeles, Sch Publ Hlth, Ctr Metab Dis Prevent, Los Angeles, CA 90024 USA. [Hahn, T. J.; Lee, C. C.] VA Greater Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S107 EP S108 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600310 ER PT J AU Boockvar, KS Hung, W Liu, S Siegel, J Kwak, J Singleton, J Signor, D AF Boockvar, K. S. Hung, W. Liu, S. Siegel, J. Kwak, J. Singleton, J. Signor, D. TI Delirium during Acute Illness (AI) in Nursing Home Residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Boockvar, K. S.; Hung, W.; Kwak, J.; Signor, D.] James J Peters VA Med Ctr, Bronx, NY USA. [Boockvar, K. S.; Singleton, J.] Jewish Home Lifecare, New York, NY USA. [Hung, W.; Singleton, J.] Mt Sinai Sch Med, New York, NY USA. [Liu, S.] New York Presbyterian Hosp, New York, NY USA. [Siegel, J.] Virginia Commonwealth Univ, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S16 EP S16 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600045 ER PT J AU Bowling, C Feller, MA Mujib, M Zhang, Y Ekundayo, O Sanders, PW Fonarow, GC Allman, RM Ahmed, A AF Bowling, C. Feller, M. A. Mujib, M. Zhang, Y. Ekundayo, O. Sanders, P. W. Fonarow, G. C. Allman, R. M. Ahmed, A. TI Chronic Kidney Disease and Incident Heart Failure in Older Adults: Predictor but Not a Risk Factor? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Bowling, C.] Birmingham VA Med Ctr, Birmingham Atlanta VA GRECC, Birmingham, AL USA. [Bowling, C.; Allman, R. M.; Ahmed, A.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Ekundayo, O.; Fonarow, G. C.] Univ Calif Los Angeles, Los Angeles, CA USA. RI Mujib, Marjan/J-2709-2013 OI Mujib, Marjan/0000-0002-3261-8599 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S107 EP S107 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600308 ER PT J AU Edes, T Skupien, M Finke, B Greene, R AF Edes, T. Skupien, M. Finke, B. Greene, R. TI Expanding Comprehensive Home Care to Rural Indian Country. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Edes, T.; Skupien, M.; Greene, R.] US Dept Vet Affairs, Washington, DC USA. [Finke, B.] Indian Hlth Serv, Hlth & Human Serv, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S149 EP S149 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600432 ER PT J AU Espinoza, S Jung, I Hazuda, H AF Espinoza, S. Jung, I. Hazuda, H. TI Predictors of Dependence in Activities of Daily Living and Instrumental Activities of Daily Living in Mexican American and European American Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Espinoza, S.; Hazuda, H.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Espinoza, S.; Hazuda, H.] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Jung, I.] Yonsei Univ, Coll Med, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S72 EP S72 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600210 ER PT J AU Fischer, BL Gleason, CE Gangnon, RE Mahoney, JE AF Fischer, B. L. Gleason, C. E. Gangnon, R. E. Mahoney, J. E. TI Cognitive Impairment Predisposes Older Adults to Risky Behaviors and Falls. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Fischer, B. L.] Wm S Middleton Mem Vet Hosp, Madison, WI USA. [Gleason, C. E.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Mahoney, J. E.] Univ Wisconsin, Dept Med, Sect Geriatr & Gerontol, Madison, WI USA. [Gleason, C. E.] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Gangnon, R. E.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Gangnon, R. E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S90 EP S90 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600260 ER PT J AU France, A Andrews, C Garza, M Lee, S Ross, J Sanchez-Reilly, S AF France, A. Andrews, C. Garza, M. Lee, S. Ross, J. Sanchez-Reilly, S. TI Comparison of Advance Directive Completion Rates and Pain Assessment and Management between Geriatric Oncology and Non-Oncology Clinics. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [France, A.; Andrews, C.; Ross, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Garza, M.; Lee, S.; Ross, J.; Sanchez-Reilly, S.] S Texas Vet Hlth Care Syst, Geriatr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S201 EP S202 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600588 ER PT J AU Garcia, CH Espinoza, SE Hazuda, HP AF Garcia, C. H. Espinoza, S. E. Hazuda, H. P. TI Ethnic Differences in Perceived Caregiver Burden between Mexican American and European Older Caregivers. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Garcia, C. H.; Espinoza, S. E.; Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S92 EP S92 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600266 ER PT J AU Goldstein, MK Martins, SB Tu, SW Heidenreich, P Massie, B Furmaga, E AF Goldstein, M. K. Martins, S. B. Tu, S. W. Heidenreich, P. Massie, B. Furmaga, E. TI Developing Heart Failure (HF) Clinical Decision Support for Patients with Comorbidities. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Goldstein, M. K.; Martins, S. B.; Tu, S. W.; Heidenreich, P.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA. [Goldstein, M. K.; Tu, S. W.; Heidenreich, P.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Massie, B.] San Francisco VA Med Ctr, San Francisco, CA USA. [Massie, B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Furmaga, E.] VA Cent Off, Pharm Benefits Management Serv, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S146 EP S146 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600424 ER PT J AU Healy, JM Patel, T Lee, S Sanchez-Reilly, S AF Healy, J. M. Patel, T. Lee, S. Sanchez-Reilly, S. TI Do Symptoms Matter When Considering Patients For Phase I Clinical Trials? A Pilot Study Of Older Adults With Advanced Cancer SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Healy, J. M.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, Dept Med, San Antonio, TX USA. [Patel, T.; Lee, S.; Sanchez-Reilly, S.] S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S60 EP S61 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600176 ER PT J AU Hung, WW Ross, JS Siu, AL AF Hung, W. W. Ross, J. S. Siu, A. L. TI Evaluation of a Mobile Acute Care for the Elderly Team for hospitalized older adults: a prospective outcomes study. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Hung, W. W.; Siu, A. L.] Mt Sinai Sch Med, New York, NY USA. [Hung, W. W.; Siu, A. L.] James J Peters VA Med Ctr, Bronx, NY USA. [Ross, J. S.] Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S100 EP S101 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600290 ER PT J AU Kashif, F Tubbesing, S Bluen, H Schwartz, M Sohn, L AF Kashif, F. Tubbesing, S. Bluen, H. Schwartz, M. Sohn, L. TI Purple Urine Bag Syndrome in an Elderly Male Nursing Home Resident. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kashif, F.] Univ Calif Los Angeles, Kern Med Ctr, Bakersfield, CA USA. [Tubbesing, S.; Bluen, H.; Schwartz, M.; Sohn, L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sohn, L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Geriatr, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S119 EP S119 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600345 ER PT J AU Kelley, AS Ettner, SL Morrison, R Du, Q Wenger, NS Sarkisian, CA AF Kelley, A. S. Ettner, S. L. Morrison, R. Du, Q. Wenger, N. S. Sarkisian, C. A. TI Determinants of Treatment Intensity in Last 6 Months of Life: The Importance of Patient Characteristics. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kelley, A. S.; Morrison, R.; Du, Q.] Mt Sinai Sch Med, New York, NY USA. [Ettner, S. L.; Wenger, N. S.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Morrison, R.] James J Peters VA Med Ctr, Bronx, NY USA. [Sarkisian, C. A.] Univ Calif Los Angeles, Dept Med, Div Geriatr, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Sarkisian, C. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S2 EP S3 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600008 ER PT J AU Kinosian, B Edes, T Becker, P Klepac, L AF Kinosian, B. Edes, T. Becker, P. Klepac, L. TI Reduction in 30-day Readmissions with VA's Home Based Primary Care. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA. [Edes, T.; Becker, P.; Klepac, L.] Dept Vet Affairs, Washington, DC USA. [Kinosian, B.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S98 EP S99 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600284 ER PT J AU Kinosian, B Edes, T Hossain, M Klepac, L AF Kinosian, B. Edes, T. Hossain, M. Klepac, L. TI Predicted and Observed Costs of Veterans receiving Home Based Primary Care Among 23 Veteran Integrated Service Networks (VISN). SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA. [Edes, T.; Hossain, M.; Klepac, L.] Dept Vet Affairs, Washington, DC USA. [Kinosian, B.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S6 EP S7 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600020 ER PT J AU Lo, S Hirano, L Matsumoto, AM AF Lo, S. Hirano, L. Matsumoto, A. M. TI Evaluation and treatment of low vitamin D levels in veterans over 70 years old. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Lo, S.; Hirano, L.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Lo, S.; Hirano, L.; Matsumoto, A. M.] Univ Washington, Dept Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S35 EP S35 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600100 ER PT J AU Marcum, ZA Amuan, ME Hanlon, JT Aspinall, SL Handler, SM Ruby, CM Pugh, MV AF Marcum, Z. A. Amuan, M. E. Hanlon, J. T. Aspinall, S. L. Handler, S. M. Ruby, C. M. Pugh, M. V. TI Adverse Drug Reactions Leading to Hospitalization among Older Outpatient Veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Marcum, Z. A.; Hanlon, J. T.; Handler, S. M.; Ruby, C. M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Marcum, Z. A.; Hanlon, J. T.; Handler, S. M.] VAPHS, GRECC, Pittsburgh, PA USA. [Amuan, M. E.] Bedford VA Hosp, Bedford, MA USA. [Aspinall, S. L.] VA Ctr Medicat Safety, Hines, IL USA. [Aspinall, S. L.] VAPHS, CHERP, Pittsburgh, PA USA. [Ruby, C. M.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Pugh, M. V.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S97 EP S97 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600279 ER PT J AU Rahman, A Nakashima, B Mortensen, E AF Rahman, A. Nakashima, B. Mortensen, E. TI Impact of Prior Antibiotic Use on Outcomes for Patients Hospitalized with Pneumonia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Mortensen, E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Rahman, A.; Nakashima, B.; Mortensen, E.] S Texas Vet Healthcare Syst, VERDICT Res Program, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S73 EP S74 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600213 ER PT J AU Ramaswamy, R Clark, EM AF Ramaswamy, R. Clark, E. M. TI Shooting in the Dark - Use of Donepezil in Non-Alzheimer's Dementia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Ramaswamy, R.; Clark, E. M.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Ramaswamy, R.; Clark, E. M.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S21 EP S21 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600059 ER PT J AU Stephens, LA Foley, KT Lowman, JD McGwin, G Jones, LS Brown, C AF Stephens, L. A. Foley, K. T. Lowman, J. D. McGwin, G. Jones, L. S. Brown, C. TI Frequency and Duration of Out of Bed Mobility Episodes During Hospitalization. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [McGwin, G.; Brown, C.] Birmighma Atlanta VA GRECC, Birmingham, AL USA. [Jones, L. S.] Birmingham VAMC, Birmingham, AL USA. [Stephens, L. A.; Foley, K. T.; Lowman, J. D.; McGwin, G.; Brown, C.] Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S111 EP S111 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600320 ER PT J AU Wang, L Sarkisian, C Kelley, AS AF Wang, L. Sarkisian, C. Kelley, A. S. TI Religion, Spirituality, and Culture-Based Preferences in End-of-Life Medical Decision-Making SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Wang, L.; Kelley, A. S.] Mt Sinai Sch Med, New York, NY USA. [Sarkisian, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sarkisian, C.] GRECC, Los Angeles, CA USA. [Sarkisian, C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S179 EP S179 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600521 ER PT J AU Wilson, BZ Nakashima, B Restrepo, MI Anzueto, A Mortensen, EM AF Wilson, B. Z. Nakashima, B. Restrepo, M. I. Anzueto, A. Mortensen, E. M. TI Comparative Efficacy of Two Antimicrobial Combinations in Elderly Patients Hospitalized with Severe Pneumonia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Wilson, B. Z.; Restrepo, M. I.; Anzueto, A.; Mortensen, E. M.] UTHSCSA, San Antonio, TX USA. [Nakashima, B.; Restrepo, M. I.; Mortensen, E. M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S66 EP S66 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600192 ER PT J AU Womack, JA Goulet, J Gibert, C Brandt, C Gulanski, B Rimland, D Rodriguez-Barradas, M Yin, M Justice, AC AF Womack, J. A. Goulet, J. Gibert, C. Brandt, C. Gulanski, B. Rimland, D. Rodriguez-Barradas, M. Yin, M. Justice, A. C. TI HIV Infection, Fragility Fractures and Age SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Womack, J. A.; Goulet, J.; Brandt, C.; Gulanski, B.; Justice, A. C.] VHA Connecticut, West Haven, CT USA. [Gibert, C.] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Gibert, C.] George Washington Univ, Washington, DC USA. [Brandt, C.] Yale Univ, Yale Ctr Med Informat, New Haven, CT USA. [Gulanski, B.; Justice, A. C.] Yale Univ, Sch Med, New Haven, CT USA. [Rimland, D.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA. [Rimland, D.] Emory Univ, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, M.] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M.] Baylor Coll Med, Houston, TX 77030 USA. [Yin, M.] Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S70 EP S71 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600205 ER PT J AU Gourcerol, G Adelson, DW Million, M Wang, LX Tache, Y AF Gourcerol, Guillaume Adelson, David W. Million, Mulugeta Wang, Lixin Tache, Yvette TI Modulation of gastric motility by brain-gut peptides using a novel non-invasive miniaturized pressure transducer method in anesthetized rodents SO PEPTIDES LA English DT Article DE Cold; CRF; Ghrelin; Intragastric pressure; Surgery; TRH agonist ID CORTICOTROPIN-RELEASING-FACTOR; DORSAL MOTOR NUCLEUS; CONSCIOUS RATS; TRANSGENIC MICE; ACID-SECRETION; GASTROINTESTINAL MOTILITY; GASTRODUODENAL MOTILITY; MYOELECTRIC ACTIVITY; ABDOMINAL-SURGERY; COLONIC TRANSIT AB Acute in vivo measurements are often the initial, most practicable approach used to investigate the effects of novel compounds or genetic manipulations on the regulation of gastric motility. Such acute methods typically involve either surgical implantation of devices or require intragastric perfusion of solutions, which can substantially alter gastric activity and may require extended periods of time to allow stabilization or recovery of the preparation. We validated a simple, non-invasive novel method to measure acutely gastric contractility, using a solid-state catheter pressure transducer inserted orally into the gastric corpus, in fasted, anesthetized rats or mice. The area under the curve of the phasic component (pAUC) of intragastric pressure (IGP) was obtained from continuous manometric recordings of basal activity and in responses to central or peripheral activation of cholinergic pathways, or to abdominal surgery. In rats, intravenous ghrelin or intracisternal injection of the thyrotropin-releasing hormone agonist, RX-77368, significantly increased pAUC while coeliotomy and cacal palpation induced a rapid onset inhibition of phasic activity lasting for the 1-h recording period. In mice, RX-77368 injected into the lateral brain ventricle induced high-amplitude contractions, and carbachol injected intraperitoneally increased pAUC significantly, while coeliotomy and cecal palpation inhibited baseline contractile activity. In wild-type mice, cold exposure (15 min) increased gastric phasic activity and tone, while there was no gastric response in corticotropin releasing factor (CRF)-overexpressing mice, a model of chronic stress. Thus the novel solid-state manometric approach provides a simple, reliable means for acute pharmacological studies of gastric motility effects in rodents. Using this method we established in mice that the gastric motility response to central vagal activation is impaired under chronic expression of CRF. Published by Elsevier Inc. C1 [Tache, Yvette] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu OI Adelson, David/0000-0002-4623-6030 FU NIH [R01 DK-33061]; Center grant [DK-41301]; VA; French Society of Gastroenterology; French Foreign Office FX This work was supported by NIH grants R01 DK-33061 (YT), Center grant DK-41301 (Animal Core; YT), VA Career Scientist and Merit Awards (YT), the French Society of Gastroenterology (S.N.F.G.E.; GG), and the French Foreign Office (EGIDE Program, GG). We thank Dr. Serge St Pierre (University of Quebec, Montreal, Canada) for the generous supply of ghrelin, Dr Michael Fanzelow (Department of Psychology, UCLA, Los Angeles) for the supply of CRF-OE and wild type mice and Ms. Honghui Liang for technical assistance and Eugenia Hu for helping in the preparation of the manuscript. NR 74 TC 3 Z9 3 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD APR PY 2011 VL 32 IS 4 BP 737 EP 746 DI 10.1016/j.peptides.2011.01.007 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 752QK UT WOS:000289707300016 PM 21262308 ER PT J AU Kent, BW Weinstein, ZA Passarelli, V Chen, Y Siever, LJ AF Kent, Brendon W. Weinstein, Zachary A. Passarelli, Vincent Chen, Yue Siever, Larry J. TI Deficient visual sensitivity in schizotypal personality disorder SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Vision; Perception; Contrast sensitivity; Schizophrenia; Schizotypal personality disorder; Dopamine ID WORKING-MEMORY; NEUROPSYCHOLOGICAL PERFORMANCE; SCHIZOPHRENIA SPECTRUM; DOPAMINE; CONTRAST; AMPHETAMINE; MOTION; SPECIFICITY; PERCEPTION; VISION AB Schizotypal personality disorder is a personality disorder in the schizophrenia spectrum, sharing genetic and neurobiologic characteristics with schizophrenia. Visual contrast detection, found to be abnormal in chronic schizophrenia, was investigated in schizotypal personality disorder (SPD). Since dopamine in the retina enhances visual contrast detection and SPD patients have relatively reduced dopaminergic activity in the brain compared to schizophrenia patients, it was hypothesized that SPD patients would have decreased to normal contrast sensitivity. Twenty-one subjects with DSM-IV diagnosed SPD, 18 healthy controls, and 12 subjects with a personality disorder unrelated to schizophrenia (OPD) were evaluated for contrast detection using a sinusoidal grating presented at varying temporal frequencies. Subjects also were evaluated neuropsychologically using several standardized neurocognitive tests. A significant effect of subject group was found on the contrast detection threshold (p < 0.01) with a significant difference between the SPD group and the healthy control group but not between the OPD group and the healthy control group. The SPD group had higher contrast detection thresholds at all temporal frequencies tested. Correlations were found between contrast detection and performance on the Trail-Making, N-Back, and CPT tasks in SPD patients. These results, based upon a paradigm reflecting dopamine activity in the early visual system, highlight the differences as well as similarities between SPD and schizophrenia with regard to the dopamine system in schizophrenia spectrum (Siever and Davis, 2004). Published by Elsevier B.V. C1 [Kent, Brendon W.; Weinstein, Zachary A.; Passarelli, Vincent; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Chen, Yue] Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Belmont, MA 02178 USA. [Siever, Larry J.] VISN3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Psychiat Program, Bronx, NY USA. RP Siever, LJ (reprint author), James J Peters Vet Affairs Med Ctr OOMH, Mental Illness Res Educ & Clin Ctr MIRECC, 130 W Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM Larry.Siever@va.gov FU National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [MO1-RR-00071]; National Institute of Mental Health [MH56140]; Veterans Affairs Merit Review Grant [7609-028]; NCRR [MO1-RR-00071] FX This publication was made possible by grant # MO1-RR-00071 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. This research was also supported in part by grant # MH56140 from the National Institute of Mental Health to Dr. Siever, and by a Veterans Affairs Merit Review Grant (7609-028).; Funding for this study was provided by NCRR grant MO1-RR-00071, by a Veterans Affairs Merit Review Grant (7609-028) and NIMH grant MH56140: Neither NCRR, NIMH, nor NIH had any further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 50 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2011 VL 127 IS 1-3 BP 144 EP 150 DI 10.1016/j.schres.2010.05.013 PG 7 WC Psychiatry SC Psychiatry GA 748MQ UT WOS:000289395100023 PM 20541911 ER PT J AU Harvey, PO Lee, J Horan, WP Ochsner, K Green, MF AF Harvey, Philippe-Olivier Lee, Junghee Horan, William P. Ochsner, Kevin Green, Michael F. TI Do patients with schizophrenia benefit from a self-referential memory bias? SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Self-referential processing; Recognition memory; Social cognition; Schizophrenia ID MEDIAL PREFRONTAL CORTEX; SOCIAL COGNITION; EPISODIC MEMORY; EMOTIONAL MEMORY; DEFAULT MODE; METAANALYSIS; BRAIN; FMRI; RECOGNITION; FEELINGS AB Background: Self-referential processing (i.e. linking internal and external stimuli to one's own self) has received scant attention thus far in schizophrenia. This type of processing is a key component of social cognition and thought to be important for adaptive social functioning. Memory studies in healthy subjects have shown that stimuli processed with reference to the self are better remembered than stimuli processed in other semantic forms. It is not known whether schizophrenia patients benefit from such a memory boost for self-referenced information. Methods: Twenty-five schizophrenia patients and 22 controls were assessed with a self-referential recognition memory paradigm. During an encoding phase, participants rated personality adjectives in each of three conditions: (1) structural features (uppercase or lowercase letters?); (2) social desirability (is adjective socially desirable or not?); or (3) self-referential (does adjective describe me or not?). Recognition memory for these personality adjectives was then tested during an unexpected yes-no recognition test. Results: Patients and controls were comparable in memory performance for the structural (p = 0.12) and social desirability (p = 0.30) conditions. In contrast, patients showed significantly reduced recognition sensitivity compared to controls for the self-referential condition (p = 0.03). Discussion: Compared to healthy controls, patients with schizophrenia did not benefit from a memory boost for self-referenced information. Such impaired self-referential memory may be associated with abnormal function of the medial prefrontal cortex. The inability to enhance memory for personally relevant information may partly explain poor social functioning in schizophrenia patients. (C) 2010 Elsevier By. All rights reserved. C1 [Harvey, Philippe-Olivier; Lee, Junghee; Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Harvey, Philippe-Olivier; Lee, Junghee; Horan, William P.; Green, Michael F.] Healthcare Ctr Syst, VA Greater Angeles, Los Angeles, CA USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. RP Harvey, PO (reprint author), UCLA Semel Inst, W VA Healthcare Ctr, 11301,Wilshire Blvd,210A,Room 131, Los Angeles, CA 90073 USA. EM poharvey@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU Canadian Institutes of Health Research; NIMH NIH HHS [R01 MH043292-09, MH043292, R01 MH043292, R01 MH065707, R29 MH043292] NR 56 TC 16 Z9 18 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2011 VL 127 IS 1-3 BP 171 EP 177 DI 10.1016/j.schres.2010.11.011 PG 7 WC Psychiatry SC Psychiatry GA 748MQ UT WOS:000289395100027 PM 21147520 ER PT J AU Merchant, RM Becker, LB Yang, FF Groeneveld, PW AF Merchant, Raina M. Becker, Lance B. Yang, Feifei Groeneveld, Peter W. TI Hospital racial composition: A neglected factor in cardiac arrest survival disparities SO AMERICAN HEART JOURNAL LA English DT Article ID BYSTANDER CARDIOPULMONARY-RESUSCITATION; ACUTE MYOCARDIAL-INFARCTION; ARTERY-BYPASS-GRAFT; RESIDENTIAL SEGREGATION; TRANSPORT INTERVAL; MORTALITY; RACE; CARE; OUTCOMES; ACCESS AB Background Racial disparities in survival after out-of-hospital cardiac arrest have been reported, but their causes remain uncertain. We sought to determine if hospital racial composition accounted for survival differences for patients hospitalized after cardiac arrest. Methods We evaluated hospitalizations of white and black Medicare beneficiaries (2000-2007) admitted from the emergency department to the intensive care unit with a diagnosis of cardiac arrest or ventricular fibrillation. We examined unadjusted survival rates and developed a multivariable logistic regression model that included patient and hospital factors. Results We analyzed 68,115 cardiac arrest admissions. Unadjusted survival to hospital discharge was worse for blacks (n = 7,942) compared with whites (n = 60,173) (30% vs 33%, P < .001). In multivariate analyses accounting for patient and hospital factors, adjusted probability of survival was worse for black patients at hospitals with higher proportions of black patients (31%, 95% CI 29%-32%) compared with predominately white hospitals (46%, 95% CI 36%-57%; P = .003). Similarly, whites had worse risk-adjusted survival at hospitals with higher proportions of black patients (28%, 95% CI 27%-30%) compared with predominately white hospitals (32%, 95% CI 31%-33%, P = .006). Blacks were more likely to be admitted to hospitals with low survival rates (23% vs 15%, P < .001). Conclusion Hospitals with large black patient populations had worse cardiac arrest outcomes than predominantly white hospitals, and blacks were more likely to be admitted to these high-mortality hospitals. Understanding these differences in survival outcomes may uncover the causes for these disparities and lead to improved survival for all cardiac arrest victims. (Am Heart J 2011; 161: 705-11.) C1 [Merchant, Raina M.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Merchant, Raina M.; Becker, Lance B.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Yang, Feifei] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Merchant, RM (reprint author), Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, 423 Guardian St,13th Floor, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu FU Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington FX Becker: Speaker honoraria/consultant fees: Philips Healthcare, Seattle, WA. Institutional grant/research support: Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington. NR 42 TC 11 Z9 11 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD APR PY 2011 VL 161 IS 4 BP 705 EP 711 DI 10.1016/j.ahj.2011.01.011 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 745TW UT WOS:000289190500013 PM 21473969 ER PT J AU George, MS Post, RM AF George, Mark S. Post, Robert M. TI Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Acute Treatment of Medication-Resistant Depression SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; COIL-CORTEX DISTANCE; DEEP BRAIN-REGIONS; HEALTHY-YOUNG MEN; MAJOR DEPRESSION; MOTOR CORTEX; ANTIDEPRESSANT RESPONSE; CORTICAL EXCITABILITY; ELECTROCONVULSIVE-THERAPY; ELECTRICAL-STIMULATION C1 George Washington Univ, Sch Med, Dept Psychiat, Washington, DC USA. Bipolar Collaborat Network, Bethesda, MD USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. [George, Mark S.] Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP George, MS (reprint author), Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Dept Psychiat & Behav Sci, 67 President St,502 N, Charleston, SC 29425 USA. EM georgem@musc.edu NR 88 TC 59 Z9 62 U1 4 U2 18 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2011 VL 168 IS 4 BP 356 EP 364 DI 10.1176/appi.ajp.2010.10060864 PG 9 WC Psychiatry SC Psychiatry GA 746KM UT WOS:000289245500007 PM 21474597 ER PT J AU Hoerster, KD Mayer, JA Gabbard, S Kronick, RG Roesch, SC Malcarne, VL Zuniga, ML AF Hoerster, Katherine D. Mayer, Joni A. Gabbard, Susan Kronick, Richard G. Roesch, Scott C. Malcarne, Vanessa L. Zuniga, Maria L. TI Impact of Individual-, Environmental-, and Policy-Level Factors on Health Care Utilization Among US Farmworkers SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID OF-THE-LITERATURE; SEASONAL FARMWORKERS; UNITED-STATES; MEDICAL-CARE; CALIFORNIA FARMWORKERS; MIGRANT FARMWORKERS; BEHAVIORAL-MODEL; FARM-WORKERS; ACCESS; SERVICES AB Objectives. We examined individual-, environmental-, and policy-level correlates of US farmworker health care utilization, guided by the behavioral model for vulnerable populations and the ecological model. Methods. The 2006 and 2007 administrations of the National Agricultural Workers Survey (n=2884) provided the primary data. Geographic information systems, the 2005 Uniform Data System, and rurality and border proximity indices provided environmental variables. To identify factors associated with health care use, we performed logistic regression using weighted hierarchical linear modeling. Results. Approximately half (55.3%) of farmworkers utilized US health care in the previous 2 years. Several factors were independently associated with use at the individual level (gender, immigration and migrant status, English proficiency, transportation access, health status, and non-US health care utilization), the environmental level (proximity to US-Mexico border), and the policy level (insurance status and workplace payment structure). County Federally Qualified Health Center resources were not independently associated. Conclusions. We identified farmworkers at greatest risk for poor access. We made recommendations for change to farmworker health care access at all 3 levels of influence, emphasizing Federally Qualified Health Center service delivery. (Am J Public Health. 2011;101:685-692. doi:10.2105/AJPH.2009.190892) C1 [Hoerster, Katherine D.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92103 USA. [Mayer, Joni A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Gabbard, Susan] JBS Int, Burlingame, CA USA. [Kronick, Richard G.; Zuniga, Maria L.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Roesch, Scott C.; Malcarne, Vanessa L.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA. RP Hoerster, KD (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, 1660 S Columbian Way S-116, Seattle, WA 98108 USA. EM Katherine.Hoerster@va.gov FU US Department of Health and Human Services, Health Resources and Services Administration (Bureau of Primary Health Care, Office of Minority and Special Populations); US Department of Labor; JBS International FX The US Department of Health and Human Services, Health Resources and Services Administration (Bureau of Primary Health Care, Office of Minority and Special Populations) funded this work.; We are grateful to Marcia Gomez and Henry Lopez for initiating this partnership. We thank the US Department of Labor (especially Daniel Carroll) and JBS International for their support and for granting access to the National Agricultural Workers Survey (NAWS). Harry Johnson and Andre Skupin from the San Diego State University Geography Department provided guidance and access to ArcInfo software. Access to the Uniform Data System data was provided through collaboration with the National Center for Farmworker Health. We are grateful to the farmworker participants who provided their time and insights for the NAWS and for the work they do on US farms every day. NR 58 TC 12 Z9 12 U1 5 U2 20 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2011 VL 101 IS 4 BP 685 EP 692 DI 10.2105/AJPH.2009.190892 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 740UN UT WOS:000288820000024 PM 21330594 ER PT J AU Weintraub, D Fraessdorf, M Potenza, MN Siderowf, AD Stacy, M Voon, V Whetteckey, J Wunderlich, GR Lang, AE AF Weintraub, Daniel Fraessdorf, Mandy Potenza, Marc N. Siderowf, Andrew D. Stacy, Mark Voon, Valerie Whetteckey, Jacqueline Wunderlich, Glen R. Lang, Anthony E. TI Dopamine Agonists vs Levodopa in Impulse Control Disorders reply SO ARCHIVES OF NEUROLOGY LA English DT Letter ID PARKINSONS-DISEASE; AMANTADINE C1 [Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Fraessdorf, Mandy] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. [Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Stacy, Mark] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA. [Voon, Valerie] Univ Cambridge, Cambridge, England. [Whetteckey, Jacqueline] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. [Wunderlich, Glen R.] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada. [Lang, Anthony E.] Univ Toronto, Dept Neurol, Toronto, ON, Canada. RP Weintraub, D (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,Rm 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0003-9942 EI 1538-3687 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD APR PY 2011 VL 68 IS 4 BP 545 EP 546 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 748CY UT WOS:000289368800031 ER PT J AU Kop, WJ Seliger, SL Fink, JC Katz, R Odden, MC Fried, LF Rifkin, DE Sarnak, MJ Gottdiener, JS AF Kop, Willem J. Seliger, Stephen L. Fink, Jeffrey C. Katz, Ronit Odden, Michelle C. Fried, Linda F. Rifkin, Dena E. Sarnak, Mark J. Gottdiener, John S. TI Longitudinal Association of Depressive Symptoms with Rapid Kidney Function Decline and Adverse Clinical Renal Disease Outcomes SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID QUALITY-OF-LIFE; SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR HEALTH; DIALYSIS PATIENTS; OLDER-ADULTS; RISK-FACTORS; HEMODIALYSIS-PATIENTS; PSYCHOLOGICAL-FACTORS; REACTIVE PROTEIN AB Background and objectives Depression is a risk indicator for adverse outcomes in dialysis patients, but its prognostic impact in individuals who are not yet on dialysis is unknown. This study examines whether depressive symptoms are longitudinally associated with renal function decline, new-onset chronic kidney disease (CKD), ESRD, or hospitalization with acute kidney injury (AKI). Design, setting, participants, & measurements Depressive symptoms were measured in a longitudinal cohort study with the 10-item Centers for Epidemiologic Studies Depression scale using a previously validated cut-off value (>= 8). CKD at study entry and during follow-up was defined as an estimated GFR (eGFR) < 60 ml/min per m(2). Outcomes were rapid decline in eGFR (> 3 ml/min per m(2) per year), new-onset CKD, ESRD (U.S. Renal Data System-based), and AKI (based on adjudicated medical record review). The median follow-up duration was 10.5 years. Results Depressed participants (21.2%) showed a higher prevalence of CKD at baseline compared with non-depressed participants in multivariable analysis. Depression was associated with a subsequent risk of rapid decline in eGFR, incident ESRD, and AKI, but not incident CKD in unadjusted models. In multivariable analyses, only associations of depressive symptoms with AKI remained significant. Conclusions Elevated depressive symptoms are associated with subsequent adverse renal disease outcomes. The depression-related elevated risk of AKI was independent of traditional renal disease risk factors and may in part be explained by the predictive value of depression for acute coronary syndromes and heart failure hospitalizations that can be complicated by AM. Clin J Am Soc Nephrol 6: 834-844, 2011. doi: 10.2215/CJN.03840510 C1 [Kop, Willem J.] Tilburg Univ, Dept Med Psychol & Neuropsychol, Ctr Res Psychol Somat Dis, NL-5000 LE Tilburg, Netherlands. [Kop, Willem J.; Seliger, Stephen L.; Fink, Jeffrey C.; Gottdiener, John S.] Univ Maryland, Dept Med, Baltimore, MD 21201 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Odden, Michelle C.] Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Rifkin, Dena E.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Rifkin, Dena E.] Vet Affairs Med Ctr, San Diego, CA 92161 USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Boston, MA USA. RP Kop, WJ (reprint author), Tilburg Univ, Dept Med Psychol & Neuropsychol, Ctr Res Psychol Somat Dis, POB 90153, NL-5000 LE Tilburg, Netherlands. EM w.j.kop@uvt.nl OI Fink, Jeffrey/0000-0002-5622-5052 FU National Heart, Lung, and Blood institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295, R0-1 HL079376]; [CHS RO1 AG 027002] FX The first author, in collaboration with the Cardiovascular Heath Study coordinating center, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This research was supported by Contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, Grant U01 HL080295, and Grant R0-1 HL079376 from the National Heart, Lung, and Blood institute, with additional contributions from the National Institute of Neurological Disorders and Stroke, the American Heart Association, and Grant CHS RO1 AG 027002 supporting the CHS Renal Working Group. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. NR 58 TC 20 Z9 20 U1 1 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2011 VL 6 IS 4 BP 834 EP 844 DI 10.2215/CJN.03840510 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 746DU UT WOS:000289223600022 PM 21393483 ER PT J AU Werner, RM Kolstad, JT Stuart, EA Polsky, D AF Werner, Rachel M. Kolstad, Jonathan T. Stuart, Elizabeth A. Polsky, Daniel TI The Effect Of Pay-For-Performance In Hospitals: Lessons For Quality Improvement SO HEALTH AFFAIRS LA English DT Article ID OF-CARE; HEALTH-CARE; MORTALITY; OUTCOMES; STATE AB The payment approach known as "pay-for-performance" has been widely adopted with the aim of improving the quality of health care. Nonetheless, little is known about how to use the approach most effectively to improve care. We examined the effects in 260 hospitals of a pay-for-performance demonstration project carried out by the Centers for Medicare and Medicaid Services in partnership with Premier Inc., a nationwide hospital system. We compared these results to those of a control group of 780 hospitals not in the demonstration project. The performance of the hospitals in the project initially improved more than the performance of the control group: More than half of the pay-for-performance hospitals achieved high performance scores, compared to fewer than a third of the control hospitals. However, after five years, the two groups' scores were virtually identical. Improvements were largest among hospitals that were eligible for larger bonuses, were well financed, or operated in less competitive markets. These findings suggest that tailoring pay-for-performance programs to hospitals' specific situations could have the greatest effect on health care quality. C1 [Werner, Rachel M.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Werner, Rachel M.; Polsky, Daniel] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kolstad, Jonathan T.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Werner, RM (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu OI Stuart, Elizabeth/0000-0002-9042-8611 FU Agency for Healthcare Research and Quality [R01 HS018409-01]; Department of Veterans Affairs FX This research was supported by a grant from the Agency for Healthcare Research and Quality (R01 HS018409-01). Rachel Werner is supported in part by a Department of Veterans Affairs Health Services Research and Development Career Development Award. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States government. NR 36 TC 80 Z9 81 U1 5 U2 29 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD APR PY 2011 VL 30 IS 4 BP 690 EP 698 DI 10.1377/hlthaff.2010.1277 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 746HE UT WOS:000289233400021 PM 21471490 ER PT J AU Trivedi, AN Grebla, RC Wright, SM Washington, DL AF Trivedi, Amal N. Grebla, Regina C. Wright, Steven M. Washington, Donna L. TI Despite Improved Quality Of Care In The Veterans Affairs Health System, Racial Disparity Persists For Important Clinical Outcomes SO HEALTH AFFAIRS LA English DT Article ID ETHNIC DISPARITIES; BLOOD-PRESSURE; MANAGED CARE; RACE; TRANSFORMATION; DISEASE; TRENDS AB Both government and private health care systems have engaged in efforts to improve quality, but the effect of these initiatives on racial and ethnic disparities has not been well studied. In the decade following an organizational transformation, the Veterans Affairs (VA) health care system achieved substantial improvements in quality of care with minimal racial disparities for most process-of-care measures, such as rates of cholesterol screenings. However, in our study we observed a striking disconnect between high levels of performance on widely used process measures and modest levels of improvement in clinical outcomes, such as control of blood pressure, blood glucose, and cholesterol levels. We also observed a gap in clinical outcomes of as much as nine percentage points between African American veterans and white veterans. Almost all of the disparity in outcomes in the VA was explained by within-facility disparity, which suggests that VA medical centers need to measure and address racial gaps in care for their patient populations. Moreover, because cardiovascular disease and diabetes are major contributors to racial disparities in life expectancy, the findings of this study and others underscore the urgency of focused efforts to improve intermediate outcomes among African Americans in the VA and other settings. C1 [Trivedi, Amal N.] Brown Univ, Providence Vet Affairs VA Med Ctr, Providence, RI 02912 USA. [Trivedi, Amal N.; Grebla, Regina C.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Wright, Steven M.] VA Off Qual & Performance, Washington, DC USA. [Washington, Donna L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Washington, Donna L.] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Trivedi, AN (reprint author), Brown Univ, Providence Vet Affairs VA Med Ctr, Providence, RI 02912 USA. EM Amal_Trivedi@brown.edu FU Veterans Affairs Health Services Research and Development Service [CDA-2, IIR IAA-08-087]; Robert Wood Johnson Foundation FX Early versions of this article were presented at the VA Equity Research Meeting, Boston, Massachusetts, September 13, 2010; and the VA Health Services Research and Development Annual Meeting, Washington, D. C., February 17, 2011. This research was supported by a Career Development Award (CDA-2) (Amal Trivedi) and Investigator Initiated Award (IIR IAA-08-087) (Donna Washington) from the Veterans Affairs Health Services Research and Development Service and by a Physician Faculty Scholars Award from the Robert Wood Johnson Foundation (Amal Trivedi). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. The authors thank Kenneth Kizer for helpful comments on a previous version. NR 32 TC 59 Z9 59 U1 0 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD APR PY 2011 VL 30 IS 4 BP 707 EP 715 DI 10.1377/hlthaff.2011.0074 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 746HE UT WOS:000289233400023 PM 21471492 ER PT J AU Loftis, JM Morasco, BJ Hauser, P AF Loftis, Jennifer M. Morasco, Benjamin J. Hauser, Peter TI Depression and Antiviral Response to Interferon-Based Therapy for Hepatitis C Virus Infection SO HEPATOLOGY LA English DT Letter ID RIBAVIRIN; SYMPTOMS; ALPHA C1 [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. [Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Loftis, Jennifer M.; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Hauser, Peter] Long Beach Vet Affairs Med Ctr, Long Beach, CA USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. FU NIDA NIH HHS [K23 DA023467]; NIMH NIH HHS [F32 MH071137-03, F32 MH071137] NR 7 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD APR PY 2011 VL 53 IS 4 BP 1413 EP 1414 DI 10.1002/hep.24064 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 748VA UT WOS:000289419600051 PM 21480359 ER PT J AU Dixit, S Lavi, N Robinson, M Riley, MP Callans, DJ Marchlinski, FE Lin, D AF Dixit, Sanjay Lavi, Nimrod Robinson, Melissa Riley, Michael P. Callans, David J. Marchlinski, Francis E. Lin, David TI Noncontact Electroanatomic Mapping to Characterize Typical Atrial Flutter: Participation of Right Atrial Posterior Wall in the Reentrant Circuit SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE atrial flutter entrainment; catheter ablation; 3-dimensional mapping ID INTRACARDIAC ECHOCARDIOGRAPHY; CATHETER ABLATION; VENA-CAVA; ENTRAINMENT; CONDUCTION; ISTHMUS; FIBRILLATION; ACTIVATION; AMIODARONE; DEFINES AB Methods: Fifteen patients (pts) undergoing ablation for typical AFLT participated. Multipolar catheters were deployed in RA and coronary sinus. RA shell was created during AFLT. Entrainment was performed to confirm CTI dependence and assess participation of various RA regions (septum-Sep, PW, lateral wall-LW). Data were analyzed for (1) RA activation patterns and (2) conduction time (CT) through various RA regions. Results: Mean pt age was 70 +/- 13 years (all males; CCW = 10; CW = 5). Mean AFLT cycle length was 255 +/- 15 ms. Single activation wave front traversing sequentially CTI, Sep, and LW was seen in all pts and in 12 (80%; 9 CCW, 3 CW) this also traversed PW. Entrainment confirmed PW participation in 7 of these. Mean CT (in ms) through various RA regions was as follows: CTI = 69 +/- 27, Sep = 50 +/- 39, PW = 65 +/- 35, and LW = 76 +/- 35; P = NS. Conclusion: These observations offer new insights regarding the participation of PW in the reentrant circuit of typical AFLT in some patients. (J Cardiovasc Electrophysiol, Vol. 22, pp. 422-430). C1 [Dixit, Sanjay; Lavi, Nimrod; Robinson, Melissa; Riley, Michael P.; Callans, David J.; Marchlinski, Francis E.; Lin, David] Hosp Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA. [Dixit, Sanjay] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Dixit, S (reprint author), Hosp Univ Penn, Div Cardiovasc, 9 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM Sanjay.Dixit@uphs.upenn.edu OI Marchlinski, Francis/0000-0001-7962-9423 NR 23 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD APR PY 2011 VL 22 IS 4 BP 422 EP 430 DI 10.1111/j.1540-8167.2010.01917.x PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 749ME UT WOS:000289470700011 PM 20958830 ER PT J AU Reust, DL Dixon, JA McKinney, RA Patel, RK Rivers, WT Mukherjee, R Stroud, RE Madden, K Groves, K Rajopadhye, M Reeves, ST Abernathy, JH Spinale, FG AF Reust, Daryl L. Dixon, Jennifer A. McKinney, Richard A. Patel, Risha K. Rivers, William T. Mukherjee, Rupak Stroud, Robert E. Madden, Karen Groves, Kevin Rajopadhye, Milind Reeves, Scott T. Abernathy, James H., III Spinale, Francis G. TI Continuous Localized Monitoring of Plasmin Activity Identifies Differential and Regional Effects of the Serine Protease Inhibitor Aprotinin: Relevance to Antifibrinolytic Therapy SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE aprotinin; plasmin inhibition; fibrinolysis; plasma; interstitial; microdialysis probe ID EPSILON-AMINOCAPROIC ACID; PATIENTS RECEIVING APROTININ; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; RENAL-FUNCTION; TRANEXAMIC ACID; DOSE REGIMENS; DYSFUNCTION; RELEASE; INJURY AB Background: Antifibrinolytic therapy, such as the use of the serine protease inhibitor aprotinin, was a mainstay for hemostasis after cardiac surgery. However, aprotinin was empirically dosed, and although the pharmacological target was the inhibition of plasmin activity (PLact), this was never monitored, off-target effects occurred, and led to withdrawn from clinical use. The present study developed a validated fluorogenic microdialysis method to continuously measure PLact and tested the hypothesis that standardized clinical empirical aprotinin dosing would impart differential and regional effects on PLact. Methods/Results: Pigs (30 kg) were instrumented with microdialysis probes to continuously measure PLact in myocardial, kidney, and skeletal muscle compartments (deltoid) and then randomized to high-dose aprotinin administration (2 mKIU load/0.5 mKIU/hr infusion; n = 7), low-dose aprotinin administration (1 mKIU load/0.250 mKIU/hr infusion; n = 6). PLact was compared with time-matched vehicle (n = 4), and PLact was also measured in plasma by an in vitro fluorogenic method. Aprotinin suppressed PLact in the myocardium and kidney at both high and low doses, indicative that both doses exceeded a minimal concentration necessary for PLact inhibition. However, differential effects of aprotinin on PLact were observed in the skeletal muscle, indicative of different compartmentalization of aprotinin. Conclusions: Using a large animal model and a continuous method to monitor regional PLact, these unique results demonstrated that an empirical aprotinin dosing protocol causes maximal and rapid suppression in the myocardium and kidney and in turn would likely increase the probability of off-target effects and adverse events. Furthermore, this proof of principle study demonstrated that continuous monitoring of determinants of fibrinolysis might provide a novel approach for managing fibrinolytic therapy. C1 [Dixon, Jennifer A.; McKinney, Richard A.; Patel, Risha K.; Rivers, William T.; Mukherjee, Rupak; Stroud, Robert E.; Spinale, Francis G.] Med Univ S Carolina, Dept Cardiothorac Surg, Charleston, SC 29403 USA. [Reust, Daryl L.; Reeves, Scott T.; Abernathy, James H., III] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA. [Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Madden, Karen; Groves, Kevin; Rajopadhye, Milind] VisEn Med Inc, Bedford, MA USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Dept Cardiothorac Surg, Strom Thurmond Res Bldg,114 Doughty St,Room 625, Charleston, SC 29403 USA. EM wilburnm@musc.edu FU National Institutes of Health [HL059165, HL078650]; Veterans' Affairs Health Administration FX Supported in part by National Institutes of Health grants HL059165 and HL078650 and a Merit Award form the Veterans' Affairs Health Administration. NR 37 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD APR PY 2011 VL 57 IS 4 BP 400 EP 406 DI 10.1097/FJC.0b013e31820b7df1 PG 7 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 749YR UT WOS:000289508500005 PM 21502925 ER PT J AU Chren, M Linos, E Parvalaneni, R Torres, J Stuart, S Boscardin, WJ Landefeld, CS AF Chren, M. Linos, E. Parvalaneni, R. Torres, J. Stuart, S. Boscardin, W. J. Landefeld, C. S. TI Treatment for nonmelanoma skin cancer among patients with limited life expectancies SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Chren, M.; Parvalaneni, R.; Boscardin, W. J.; Landefeld, C. S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Chren, M.; Torres, J.; Stuart, S.; Landefeld, C. S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Linos, E.] Stanford Univ, Stanford, CA 94305 USA. RI Linos, Eleni/C-4392-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 256 BP S43 EP S43 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600256 ER PT J AU Gamble, RG Aalborg, J Asdigian, NL Gonzalez, V Huff, LS Box, NF Crane, LA Dellavalle, RP AF Gamble, R. G. Aalborg, J. Asdigian, N. L. Gonzalez, V. Huff, L. S. Box, N. F. Crane, L. A. Dellavalle, R. P. TI Severity of sun damage in full-face ultraviolet photographs of 12 year-old children relates to phenotypic skin cancer risk factors SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Gamble, R. G.; Gonzalez, V.; Huff, L. S.; Box, N. F.; Dellavalle, R. P.] Univ Colorado, Denver, CO 80202 USA. [Aalborg, J.; Asdigian, N. L.; Crane, L. A.; Dellavalle, R. P.] Colorado Sch Publ Hlth, Aurora, CO USA. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Denver, CO USA. RI Box, Neil/F-3591-2010 OI Box, Neil/0000-0002-3486-0346 NR 0 TC 1 Z9 1 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 240 BP S40 EP S40 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600240 ER PT J AU Jensen, JD Luo, Y Liu, W Dellavalle, RP Fujita, M AF Jensen, J. D. Luo, Y. Liu, W. Dellavalle, R. P. Fujita, M. TI Ellagic acid induces apoptosis and cell cycle arrest through upregulation of p53 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Jensen, J. D.; Luo, Y.; Liu, W.; Dellavalle, R. P.; Fujita, M.] Univ Colorado Denver, Aurora, CO USA. [Dellavalle, R. P.] Colorado Sch Publ Hlth, Aurora, CO USA. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 778 BP S130 EP S130 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600775 ER PT J AU Katiyar, SK Singh, T AF Katiyar, S. K. Singh, T. TI Green tea catechins inhibit melanoma cell migration and invasion by inhibiting the expression of cyclooxygenase-2 and NF-kappa B activation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Katiyar, S. K.; Singh, T.] Univ Alabama, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 713 BP S119 EP S119 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600711 ER PT J AU Piette, EW Foering, KP Chang, AY Okawa, J Werth, VP AF Piette, E. W. Foering, K. P. Chang, A. Y. Okawa, J. Werth, V. P. TI The impact of smoking in cutaneous lupus erythematosus and dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Piette, E. W.; Foering, K. P.; Chang, A. Y.; Okawa, J.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Piette, E. W.; Foering, K. P.; Chang, A. Y.; Okawa, J.; Werth, V. P.] Univ PA, Sch Med, Philadelphia, PA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 514 BP S86 EP S86 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600513 ER PT J AU Vaid, M Singh, T Katiyar, SK AF Vaid, M. Singh, T. Katiyar, S. K. TI Silymarin inhibits UV-induced immunosuppression through inactivation of CD4+T cells and stimulation of CD8+effector T cells SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Vaid, M.; Singh, T.; Katiyar, S. K.] Univ Alabama, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 672 BP S112 EP S112 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600670 ER PT J AU Han, LH Wu, SM Condit, JC Kemp, NJ Milner, TE Feldman, MD Chen, SC AF Han, Li-Hsin Wu, Shaomin Condit, J. Christopher Kemp, Nate J. Milner, Thomas E. Feldman, Marc D. Chen, Shaochen TI Light-Powered Micromotor: Design, Fabrication, and Mathematical Modeling SO JOURNAL OF MICROELECTROMECHANICAL SYSTEMS LA English DT Article DE Crookes; DSMC; light mill; microactuator; micromotor; Monte Carlo; nanoparticles AB This paper reports on the experimental and theoretical studies of a light-driven micromotor, which is a "light mill" that rotates by absorbing photon energy. This light mill has four curved blades to form an axially asymmetric geometry. Upon lateral irradiation, the shape of the light mill induces an asymmetric photon heating to the surrounding gas molecules, leading to a gas convection that forces the light mill to rotate. The light mill was applied to actuate a scanning mirror for a laser beam. Using a Direct Simulation Monte Carlo (DSMC) model, we investigated the working principle behind the operation of the light mill. The DSMC simulation yielded results consistent to our experimental data. The simulation results were used to explain the heat-induced light-mill rotation, in which the mean free path of the surrounding gas takes an important role. [2010-0149] C1 [Han, Li-Hsin] Stanford Univ, Dept Orthopaed Surg, Stanford, CA 94305 USA. [Condit, J. Christopher; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Kemp, Nate J.] Volcano Corp, Billerica, MA 01821 USA. [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Chen, Shaochen] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA. RP Han, LH (reprint author), Stanford Univ, Dept Orthopaed Surg, Stanford, CA 94305 USA. EM leohan17@gmail.com; wushaomin@yahoo.com; condit.chris@gmail.com; natekemp@gmail.com; terra.laser@gmail.com; shc064@ucsd.edu RI Han, Li-Hsin/C-5440-2015 OI Han, Li-Hsin/0000-0002-0135-2863 FU Office of Naval Research [N00014-07-1-0609]; National Science Foundation [CMMI 0555275] FX The work of S. Chen was supported by grants from the Office of Naval Research (N00014-07-1-0609) and the National Science Foundation (CMMI 0555275). Subject Editor L. Lin. NR 21 TC 0 Z9 0 U1 3 U2 13 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1057-7157 EI 1941-0158 J9 J MICROELECTROMECH S JI J. Microelectromech. Syst. PD APR PY 2011 VL 20 IS 2 BP 487 EP 496 DI 10.1109/JMEMS.2011.2105249 PG 10 WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Applied SC Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA 745XR UT WOS:000289205400017 ER PT J AU Singh, JA Sperling, J Buchbinder, R McMaken, K AF Singh, Jasvinder A. Sperling, John Buchbinder, Rachelle McMaken, Kelly TI Surgery for Shoulder Osteoarthritis: A Cochrane Systematic Review SO JOURNAL OF RHEUMATOLOGY LA English DT Review DE SURGERY; SHOULDER; OSTEOARTHRITIS; BENEFIT; SAFETY; COCHRANE SYSTEMATIC REVIEW ID KEELED GLENOID COMPONENTS; RANDOMIZED-TRIAL; PRIMARY-CARE; ARTHROPLASTY; PAIN; HEMIARTHROPLASTY; LIFE; INSTABILITY; PREVALENCE; DISABILITY AB Objective. To determine the benefits and harm of surgery for shoulder osteoarthritis (OA). Methods. We performed a Cochrane Systematic Review of clinical trials of adults with shoulder OA, comparing surgical techniques total shoulder arthroplasty (TSA), hemiarthroplasty, implant types, and fixation] to placebo, sham surgery, nonsurgical modalities, and no treatment. We also reviewed trials that compared various surgical techniques, reporting patient-reported outcomes (pain, function, quality of life, etc.) or revision rates. We calculated the risk ratio for categorical outcomes and mean differences for continuous outcomes with 95% CI. Results. There were no controlled trials of surgery versus placebo or nonsurgical interventions. Seven studies with 238 patients were included. Two studies compared TSA to hemiarthroplasty (n = 88). Significantly worse scores on the 0-100 American Shoulder and Elbow Surgeons scale (mean difference, -10.05 at 24-34 mo; 95% CI -18.97 to -1.13; p = 0.03) and a nonsignificant trend toward higher revision rate in hemiarthroplasty compared to TSA (relative risk 6.18; 95% CI 0.77 to 49.52; p = 0.09) were noted. With 1 study providing data (n = 41), no differences were noted between groups for pain scores (mean difference 7.8; 95% CI -5.33 to 20.93), quality of life on Medical Outcomes Study Short-Form 36 physical component summary (mean difference 0.80; 95% CI -6.63 to -8.23), and adverse events (relative risk 1.2; 95% CI 0.4 to 3.8). Conclusion. TSA was associated with better shoulder function, with no other demonstrable clinical benefits compared to hemiarthroplasty. More studies are needed to compare clinical outcomes between them and comparing shoulder surgery to sham, placebo. and other nonsurgical treatment options. (First Release Jan 15 2011; J Rheumatol 2011;38:598-605; doi:10.3899/jrheum.101008) C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham Vet Adm VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Buchbinder, Rachelle] Cabrini Hosp, Monash Dept Clin Epidemiol, Malvern, Vic, Australia. [Buchbinder, Rachelle] Monash Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Malvern, Vic, Australia. [McMaken, Kelly] Minneapolis VA Med Ctr, Med Serv, Minneapolis, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, 510 20th St S,Fac Off Tower,Room 805B, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com RI Buchbinder, Rachelle/G-2952-2011 OI singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health [1 KL2 RR024151-01]; Australian National Health and Medical Research FX Supported by the National Institutes of Health Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and from the resources and facilities at the Birmingham VA Medical Center. Dr. Buchbinder is supported in part by an Australian National Health and Medical Research Practitioner Fellowship. NR 52 TC 20 Z9 21 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD APR PY 2011 VL 38 IS 4 BP 598 EP 605 DI 10.3899/jrheum.101008 PG 8 WC Rheumatology SC Rheumatology GA 747QF UT WOS:000289333800005 PM 21239751 ER PT J AU Zajac, K Ruggiero, KJ Smith, DW Saunders, BE Kilpatrick, DG AF Zajac, Kristyn Ruggiero, Kenneth J. Smith, Daniel W. Saunders, Benjamin E. Kilpatrick, Dean G. TI Adolescent Distress in Traumatic Stress Research: Data From the National Survey of Adolescents-Replication SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID PARTICIPATION; VIOLENCE AB Small numbers of adults report distress in response to traumatic stress surveys. Less is known about adolescent research participants. We examined distress in response to a survey on traumatic stress using data from the National Survey of Adolescents-Replication, a nationally representative sample of 3,614 youth aged 12-17 years. Although 204 (5.7%) adolescents found some questions distressing, only 8 (0.2%) remained upset at the end of the interview, and 2 (< 0.1%) wished to speak to a counselor. Adolescents reporting traumatic experiences or mental health problems were significantly more likely to report distress compared to those not endorsing such problems. Significantly more girls (7.5%) reported distress than boys (3.9%). Findings suggest that survey questions about trauma pose minimal risk to adolescents. C1 [Zajac, Kristyn] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Zajac, K (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC861, Charleston, SC 29425 USA. EM zajac@musc.edu FU NICHD NIH HHS [R01 HD046830-01, R01 HD046830]; NIMH NIH HHS [T32 MH018869, R01 MH081056, R01 MH81056] NR 9 TC 7 Z9 7 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD APR PY 2011 VL 24 IS 2 BP 226 EP 229 DI 10.1002/jts.20621 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 750ER UT WOS:000289528300013 PM 21412852 ER PT J AU Primack, BA Silk, JS DeLozier, CR Shadel, WG Carpentier, FRD Dahl, RE Switzer, GE AF Primack, Brian A. Silk, Jennifer S. DeLozier, Christian R. Shadel, William G. Carpentier, Francesca R. Dillman Dahl, Ronald E. Switzer, Galen E. TI Using Ecological Momentary Assessment to Determine Media Use by Individuals With and Without Major Depressive Disorder SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID MOOD MANAGEMENT; RISK-FACTORS; ALCOHOL-USE; SCHOOL-AGE; ADOLESCENTS; CHILDREN; TELEVISION; HEALTH; MUSIC; ADULTHOOD AB Objective: To use ecological momentary assessment techniques to measure the association of major depressive disorder (MDD) with media use. Design: Data were collected using an ecological momentary assessment protocol with cellular telephone-based brief interviews. Setting: Participants received as many as 60 telephone calls from a trained staff member during 5 extended weekends in an 8-week period. Participants: One hundred six adolescent participants who were part of a larger neurobehavioral study of depression in Pittsburgh from January 1, 2003, through December 31, 2008. Main Exposure: At each call, participants were asked whether they were using the following 5 types of media: television or movies, music, video games, Internet, and print media, such as magazines, newspapers, and books. Main Outcome Measures: We developed multivariable models to determine the independent association of each type of media use with MDD, controlling for sociodemographic variables. Results: Of the 106 participants, 46 were diagnosed as having MDD. In multivariable models controlling for age, sex, and race, each increasing quartile of audio use was associated with an 80% increase in the odds of having MDD (odds ratio, 1.8; 95% confidence interval, 1.1-2.8; P = .01 for trend). Conversely, each increasing quartile of print media use was associated with a 50% decrease in the odds of having MDD(odds ratio, 0.5; 95% confidence interval, 0.30.9; P = .009 for trend). Conclusions: Major depressive disorder is positively associated with popular music exposure and negatively associated with reading print media such as books. Further research elucidating the directionality and strength of these relationships may help advance understanding of the relationships between media use and MDD. C1 [Primack, Brian A.; DeLozier, Christian R.; Switzer, Galen E.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sch Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15213 USA. [Silk, Jennifer S.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Shadel, William G.] RAND Corp, Pittsburgh, PA USA. [Switzer, Galen E.] Ctr Heath Equ Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Carpentier, Francesca R. Dillman] Univ N Carolina, Sch Journalism & Mass Commun, Chapel Hill, NC USA. [Dahl, Ronald E.] Univ Calif Berkeley, Sch Publ Hlth, Joint Med Program, Berkeley, CA 94720 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu OI Silk, Jennifer/0000-0002-8638-4337 FU National Cancer Institute [R01-CA140150, K07-CA114315]; Maurice Falk Foundation; National Institute of Mental Health [P01-MH41712]; RAND-University of Pittsburgh Health Institute FX Funding/Support: This study was supported in part by research grant R01-CA140150 from the National Cancer Institute, career development award K07-CA114315 from the National Cancer Institute, and a grant from the Maurice Falk Foundation (Dr Primack); by grant P01-MH41712 from the National Institute of Mental Health (Neal D. Ryan, MD [principal investigator], and Dr Dahl [coprincipal investigator]); and by the RAND-University of Pittsburgh Health Institute (http://www.ruphi.pitt.edu/), a formal collaboration among the RAND Corporation, RAND Health, and the University of Pittsburgh Schools of the Health Sciences. NR 52 TC 7 Z9 7 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD APR PY 2011 VL 165 IS 4 BP 360 EP 365 PG 6 WC Pediatrics SC Pediatrics GA 745LF UT WOS:000289166200012 PM 21464384 ER PT J AU Winters-Stone, KM Torgrimson, B Horak, F Eisner, A Nail, L Leo, MC Chui, S Luoh, SW AF Winters-Stone, Kerri M. Torgrimson, Britta Horak, Fay Eisner, Alvin Nail, Lillian Leo, Michael C. Chui, Steve Luoh, Shiuh-Wen TI Identifying Factors Associated With Falls in Postmenopausal Breast Cancer Survivors: A Multi-Disciplinary Approach SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Drug therapy; Muscle strength; Neoplasms; Postural balance; Rehabilitation ID VISUAL IMPAIRMENT; OLDER-ADULTS; ADJUVANT TREATMENT; RANDOMIZED-TRIAL; FRACTURE RISK; NURSING-HOME; WOMEN; TAMOXIFEN; CHEMOTHERAPY; POSTUROGRAPHY AB Winters-Stone KM, Torgrimson B, Horak F, Eisner A, Nail L, Leo MC, Chui S, Luoh S-W. Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach. Arch Phys Med Rehabil 2011;92:646-52. Objective: To identify neuromuscular, balance, and vision factors that contribute to falls in recently treated breast cancer survivors (BCS) and explore links between fall risk factors and cancer treatment. Design: Case-control plus prospective observation. Setting: Comprehensive cancer center. Participants: BCS (N=59; mean age, 58y) within 2 years of chemotherapy completion and/or on adjuvant endocrine therapy. Interventions: Not applicable. Main Outcome Measures: Objective measures of postural control, vision, and neuromuscular function included: (1) a sensory organization test (SOT), (2) a visual assessment battery, (3) muscle mass by dual energy x-ray absorptiometry, and (4) neuromuscular function with strength by repetition maximum, power by timed stair climb, and gait speed by 4m walk. Falls were self-reported for the past year (retrospective) and monthly for 6 months (prospective). Results: Fifty eight percent of BCS reported falls in the past year. BCS with a history of falls had lower SOT scores with a vestibular deficit pattern in postural control (P<.01) and took longer to read letters on the contrast sensitivity chart (P<.05). Vestibular score on the SOT mediated the relationship between treatment and falls among BCS who received chemotherapy only, but not adjuvant endocrine therapy. Conclusions: Results of this project suggest that balance disturbances of vestibular origin and delays in detecting low contrast visual stimuli are associated with falls in BCS. Future studies that track falls and fall risk factors in BCS from diagnosis through treatment are warranted, as are studies that can identify treatment-related vestibular dysfunction and altered visual processing. C1 [Winters-Stone, Kerri M.; Torgrimson, Britta; Nail, Lillian; Leo, Michael C.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA. [Horak, Fay; Eisner, Alvin; Chui, Steve; Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. [Luoh, Shiuh-Wen] Portland VA Med Ctr, Portland, OR USA. RP Winters-Stone, KM (reprint author), Oregon Hlth & Sci Univ, Sch Nursing, 3455 SW US Vet Hosp Rd,Mailcode SN ORD, Portland, OR 97239 USA. EM wintersk@ohsu.edu FU Oregon Clinical and Translational Research Institute (OCTRI); National Center for Research Resources (NCRR), National Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical Research FX This publication was made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 42 TC 25 Z9 25 U1 3 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2011 VL 92 IS 4 BP 646 EP 652 DI 10.1016/j.apmr.2010.10.039 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 743VT UT WOS:000289047500018 PM 21367394 ER PT J AU Tosun, D Dabbs, K Caplan, R Siddarth, P Toga, A Seidenberg, M Hermann, B AF Tosun, Duygu Dabbs, Kevin Caplan, Rochelle Siddarth, Prabha Toga, Arthur Seidenberg, Michael Hermann, Bruce TI Deformation-based morphometry of prospective neurodevelopmental changes in new onset paediatric epilepsy SO BRAIN LA English DT Article DE MRI; prospective neurodevelopment changes; deformation-based morphometry; new and recent onset epilepsy; localization-related epilepsy; idiopathic generalized epilepsy ID TEMPORAL-LOBE EPILEPSY; JUVENILE MYOCLONIC EPILEPSY; VOXEL-BASED MORPHOMETRY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; IDIOPATHIC GENERALIZED EPILEPSY; TENSOR-BASED MORPHOMETRY; CEREBELLAR VOLUME REDUCTION; CHILDHOOD ABSENCE EPILEPSY; COMPLEX PARTIAL SEIZURES; BRAIN-DEVELOPMENT AB Epilepsy is a prevalent childhood neurological disorder, but there are few prospective quantitative magnetic resonance imaging studies examining patterns of brain development compared to healthy controls. Controlled prospective investigations initiated at or near epilepsy onset would best characterize the nature, timing and course of neuroimaging abnormalities in paediatric epilepsy. In this study, we report the results of a deformation-based morphometry technique to examine baseline and 2-year prospective neurodevelopmental brain changes in children with new and recent onset localization-related epilepsies (n = 24) and idiopathic generalized epilepsies (n = 20) compared to healthy controls (n = 36). Children with epilepsy demonstrated differences from controls in baseline grey and white matter volumes suggesting antecedent anomalies in brain development, as well as abnormal patterns of prospective brain development that involved not only slowed white matter expansion, but also abnormalities of cortical grey matter development involving both greater and lesser volume changes compared to controls. Furthermore, abnormal neurodevelopmental changes extended outside the cortex affecting several subcortical structures including thalamus, cerebellum, brainstem and pons. Finally, there were significant differences between the epilepsy syndromes (localization-related epilepsies and idiopathic generalized epilepsies) with the idiopathic generalized epilepsies group showing a more disrupted pattern of brain structure both at baseline and over the 2-year interval. C1 [Tosun, Duygu] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Dabbs, Kevin; Hermann, Bruce] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Caplan, Rochelle; Siddarth, Prabha] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Toga, Arthur] Univ Calif Los Angeles, David Geffen Sch Med, Lab Neuro Imaging, Dept Neurol, Los Angeles, CA 90095 USA. [Seidenberg, Michael] Rosalind Franklin Univ Med & Sci, Dept Psychol, Madison, WI USA. RP Tosun, D (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. EM duygu.tsn@gmail.com FU National Institutes of Health (NIH) through the NIH Roadmap for Medical Research [U54 RR021813]; Center for Computational Biology (CCB); National Institutes of Health (NIH)/National Center for Research Resources [P41 RR013642]; [NS32070]; [MH 67187]; [RO1 44352] FX This work was supported by the National Institutes of Health (NIH) through the NIH Roadmap for Medical Research, Grant No. U54 RR021813, Center for Computational Biology (CCB). Additional support was provided by the National Institutes of Health (NIH)/National Center for Research Resources Grant No. P41 RR013642 and grants NS32070 (RC), MH 67187 (RC), and RO1 44352 (NINDS). NR 97 TC 28 Z9 28 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2011 VL 134 BP 1003 EP 1014 DI 10.1093/brain/awr027 PN 4 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 745KC UT WOS:000289163300016 PM 21398377 ER PT J AU Tosun, D Schuff, N Mathis, CA Jagust, W Weiner, MW AF Tosun, Duygu Schuff, Norbert Mathis, Chester A. Jagust, William Weiner, Michael W. CA Alzheimer's Dis NeuroImaging Initi TI Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment SO BRAIN LA English DT Article DE MRI; (11)C-PiB PET; Alzheimer's disease; mild cognitive impairment; amyloid-beta; amyloid; brain atrophy rate; multimodal brain imaging ID PITTSBURGH COMPOUND-B; NEUROIMAGING INITIATIVE ADNI; CEREBROSPINAL-FLUID TAU; VOXEL-BASED ANALYSIS; ALZHEIMERS-DISEASE; HIPPOCAMPAL ATROPHY; ENTORHINAL CORTEX; IN-VIVO; ELDERLY CONTROLS; FUNCTIONAL MRI AB Amyloid-beta accumulation in the brain is thought to be one of the earliest events in Alzheimer's disease, possibly leading to synaptic dysfunction, neurodegeneration and cognitive/functional decline. The earliest detectable changes seen with neuroimaging appear to be amyloid-beta accumulation detected by (11)C-labelled Pittsburgh compound B positron emission tomography imaging. However, some individuals tolerate high brain amyloid-beta loads without developing symptoms, while others progressively decline, suggesting that events in the brain downstream from amyloid-beta deposition, such as regional brain atrophy rates, play an important role. The main purpose of this study was to understand the relationship between the regional distributions of increased amyloid-beta and the regional distribution of increased brain atrophy rates in patients with mild cognitive impairment. To simultaneously capture the spatial distributions of amyloid-beta and brain atrophy rates, we employed the statistical concept of parallel independent component analysis, an effective method for joint analysis of multimodal imaging data. Parallel independent component analysis identified significant relationships between two patterns of amyloid-beta deposition and atrophy rates: (i) increased amyloid-beta burden in the left precuneus/cuneus and medial-temporal regions was associated with increased brain atrophy rates in the left medial-temporal and parietal regions; and (ii) in contrast, increased amyloid-beta burden in bilateral precuneus/cuneus and parietal regions was associated with increased brain atrophy rates in the right medial temporal regions. The spatial distribution of increased amyloid-beta and the associated spatial distribution of increased brain atrophy rates embrace a characteristic pattern of brain structures known for a high vulnerability to Alzheimer's disease pathology, encouraging for the use of (11)C-labelled Pittsburgh compound B positron emission tomography measures as early indicators of Alzheimer's disease. These results may begin to shed light on the mechanisms by which amyloid-beta deposition leads to neurodegeneration and cognitive decline and the development of a more specific Alzheimer's disease-specific imaging signature for diagnosis and use of this knowledge in the development of new anti-therapies for Alzheimer's disease. C1 [Tosun, Duygu] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, PET Facil, Pittsburgh, PA USA. [Jagust, William] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Jagust, William] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. RP Tosun, D (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, 4150 Clement St,Bldg 13,114 M, San Francisco, CA 94121 USA. EM duygu.tosun@ucsf.edu RI ; Olde Rikkert, Marcel/D-9773-2012; MOSCATO, PABLO/G-7668-2013; Saykin, Andrew/A-1318-2007; Strittmatter, Stephen/F-5739-2011; Juengling, Freimut/L-8071-2016 OI Browndyke, Jeffrey/0000-0002-8573-7073; Saykin, Andrew/0000-0002-1376-8532; Strittmatter, Stephen/0000-0001-8188-3092; Juengling, Freimut/0000-0002-2538-3074; Lemaitre, Herve/0000-0002-5952-076X; Whitcher, Brandon/0000-0002-6452-2399; Looi, Jeffrey/0000-0003-3351-6911 FU National Institutes of Health (NIH) [P41 RR023953, P30 AG010129, K01 AG030514]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Abbott; AstraZeneca AB; Bayer Schering Pharma AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan Corporation; Genentech; GE Healthcare; GlaxoSmithKline; Innogenetics; Johnson and Johnson; Eli Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG; Pfizer Inc; F. Hoffman-La Roche; Schering-Plough; Synarc, Inc.; Wyeth; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Dana Foundation FX This work is funded by the National Institutes of Health (NIH) (Grant P41 RR023953). Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc. and Wyeth, as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego, USA. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants (P30 AG010129, K01 AG030514) and the Dana Foundation. NR 96 TC 58 Z9 59 U1 1 U2 29 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2011 VL 134 BP 1077 EP 1088 DI 10.1093/brain/awr044 PN 4 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 745KC UT WOS:000289163300021 PM 21429865 ER PT J AU Nandakumar, V Vaid, M Katiyar, SK AF Nandakumar, Vijayalakshmi Vaid, Mudit Katiyar, Santosh K. TI (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16(INK4a), by reducing DNA methylation and increasing histones acetylation in human skin cancer cells SO CARCINOGENESIS LA English DT Article ID GREEN TEA POLYPHENOLS; REPAIR; MECHANISMS; PHOTOPROTECTION; ANGIOGENESIS; INHIBITION; GENISTEIN; LINES; MICE AB The anti-skin carcinogenic effects of green tea catechins have been studied extensively in vitro and in vivo models but the precise epigenetic molecular mechanisms are still unclear. Accumulating data suggest that dietary phytochemicals may alter cancer risk by modifications of epigenetic processes in the cells. The present study was designed to investigate whether tea catechins, particularly (-)-epigallocatechin-3-gallate (EGCG), would modify epigenetic events to regulate DNA methylation-silenced tumor suppressor genes in skin cancer cells. DNA methylation, histone modifications and tumor suppressor gene expressions were studied in detail using human epidermoid carcinoma A431 cells as an in vitro model after EGCG treatment using cytostaining, western blotting, dot blot analysis, real-time polymerase chain reaction and enzymatic activity assays. Our study shows that EGCG treatment decreased global DNA methylation levels in A431 cells in a dose-dependent manner. EGCG decreased the levels of 5-methylcytosine, DNA methyltransferase (DNMT) activity, messenger RNA (mRNA) and protein levels of DNMT1, DNMT3a and DNMT3b. EGCG decreased histone deacetylase activity and increased levels of acetylated lysine 9 and 14 on histone H3 (H3-Lys 9 and 14) and acetylated lysine 5, 12 and 16 on histone H4 but decreased levels of methylated H3-Lys 9. Additionally, EGCG treatment resulted in re-expression of the mRNA and proteins of silenced tumor suppressor genes, p16(INK4a) and Cip1/p21. Together, our study provides new insight into the epigenetic mechanism of action of EGCG that may contribute to the chemoprevention of skin cancer and may have important implications for epigenetic therapy. C1 [Nandakumar, Vijayalakshmi; Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama, Dermatol 1Dept, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dermatol 1Dept, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Institutes of Health [CA140832]; Veterans Administration FX National Institutes of Health (CA140832 to S. K. K.); Veterans Administration Merit Review Award (S. K. K.). NR 24 TC 118 Z9 128 U1 1 U2 20 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD APR PY 2011 VL 32 IS 4 BP 537 EP 544 DI 10.1093/carcin/bgq285 PG 8 WC Oncology SC Oncology GA 745KM UT WOS:000289164300013 PM 21209038 ER PT J AU Nandakumar, V Vaid, M Tollefsbol, TO Katiyar, SK AF Nandakumar, Vijayalakshmi Vaid, Mudit Tollefsbol, Trygve O. Katiyar, Santosh K. TI Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice SO CARCINOGENESIS LA English DT Article ID GREEN TEA POLYPHENOLS; CPG BINDING-PROTEIN; ULTRAVIOLET-RADIATION; MELANOMA PATIENTS; METHYLATION; CANCER; CARCINOGENESIS; EPIGENETICS; ACTIVATION; REPRESSION AB Overexposure of the human skin to solar ultraviolet (UV) radiation is the major etiologic factor for development of skin cancers. Here, we report the results of epigenetic modifications in UV-exposed skin and skin tumors in a systematic manner. The skin and tumor samples were collected after chronic exposure of the skin of SKH-1 hairless mice to UVB radiation using a well-established photocarcinogenesis protocol. We found a distinct DNA hypermethylation pattern in the UVB-exposed epidermal skin and UVB-induced skin tumors that was associated with the elevated expression and activity of the DNA methyltransferases (Dnmt) 1, Dnmt3a and Dnmt3b. To explore the role of hypermethylation in skin photocarcinogenesis, we focused on the p16(INK4a) and RASSF1A tumor suppressor genes, which are transcriptionally silenced on methylation. We established that the silencing of these genes in UVB-exposed epidermis and UVB-induced skin tumors is associated with a network of epigenetic modifications, including hypoacetylation of histone H3 and H4 and increased histone deacetylation, as well as recruitment of methyl-binding proteins, including MeCP2 and MBD1, to the methylated CpGs. Higher levels of DNA methylation and DNMT activity in human squamous cell carcinoma specimens than in normal human skin suggest that the data are relevant clinically. Our data indicate for the first time that UVB-induced DNA hypermethylation, enhanced Dnmt activity and histone modifications occur in UVB-exposed skin and UVB-induced skin tumors and suggest that these events are involved in the silencing of tumor suppressor genes and in skin tumor development. C1 [Nandakumar, Vijayalakshmi; Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Tollefsbol, Trygve O.] Univ Alabama, Dept Biol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Institutes of Health [CA140832]; Veterans Administration FX National Institutes of Health (CA140832 to S.K.K.); Veterans Administration Merit Review Award (S.K.K.) NR 48 TC 42 Z9 44 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD APR PY 2011 VL 32 IS 4 BP 597 EP 604 DI 10.1093/carcin/bgq282 PG 8 WC Oncology SC Oncology GA 745KM UT WOS:000289164300021 PM 21186298 ER PT J AU Lee, BY Wettstein, ZS McGlone, SM Bailey, RR Umscheid, CA Smith, KJ Muder, RR AF Lee, B. Y. Wettstein, Z. S. McGlone, S. M. Bailey, R. R. Umscheid, C. A. Smith, K. J. Muder, R. R. TI Economic value of norovirus outbreak control measures in healthcare settings SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article DE Economics; hospital; infection control; interventions; norovirus; outbreak ID NORWALK VIRUS; GASTROENTERITIS; INFECTION; TRANSMISSION; VOLUNTEERS; HYGIENE; ILLNESS; COSTS AB P>Although norovirus is a significant cause of nosocomial viral gastroenteritis, the economic value of hospital outbreak containment measures following identification of a norovirus case is currently unknown. We developed computer simulation models to determine the potential cost-savings from the hospital perspective of implementing the following norovirus outbreak control interventions: (i) increased hand hygiene measures, (ii) enhanced disinfection practices, (iii) patient isolation, (iv) use of protective apparel, (v) staff exclusion policies, and (vi) ward closure. Sensitivity analyses explored the impact of varying intervention efficacy, number of initial norovirus cases, the norovirus reproductive rate (R(0)), and room, ward size, and occupancy. Implementing increased hand hygiene, using protective apparel, staff exclusion policies or increased disinfection separately or in bundles provided net cost-savings, even when the intervention was only 10% effective in preventing further norovirus transmission. Patient isolation or ward closure was cost-saving only when transmission prevention efficacy was very high (>= 90%), and their economic value decreased as the number of beds per room and the number of empty beds per ward increased. Increased hand hygiene, using protective apparel or increased disinfection practices separately or in bundles are the most cost-saving interventions for the control and containment of a norovirus outbreak. C1 [Lee, B. Y.; Wettstein, Z. S.; McGlone, S. M.; Bailey, R. R.; Smith, K. J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Lee, B. Y.; Wettstein, Z. S.; McGlone, S. M.; Bailey, R. R.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Lee, B. Y.; Wettstein, Z. S.; McGlone, S. M.; Bailey, R. R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Umscheid, C. A.] Univ Penn, Philadelphia, PA 19104 USA. [Muder, R. R.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Lee, BY (reprint author), Univ Pittsburgh, Sch Med, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM BYL1@pitt.edu OI Slayton, Rachel/0000-0003-4699-8040 FU National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [1U54GM088491-0109] FX This study was supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 16 Z9 16 U1 1 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD APR PY 2011 VL 17 IS 4 BP 640 EP 646 DI 10.1111/j.1469-0691.2010.03345.x PG 7 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 736NP UT WOS:000288501700029 PM 20731684 ER PT J AU Young, AS Niv, N Chinman, M Dixon, L Eisen, SV Fischer, EP Smith, J Valenstein, M Marder, SR Owen, RR AF Young, Alexander S. Niv, Noosha Chinman, Matthew Dixon, Lisa Eisen, Susan V. Fischer, Ellen P. Smith, Jeffrey Valenstein, Marcia Marder, Stephen R. Owen, Richard R. TI Routine Outcomes Monitoring to Support Improving Care for Schizophrenia: Report from the VA Mental Health QUERI SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Quality improvement; Outcomes assessment; Mental disorders; Community mental health; Evidence-based care ID BRIEF-SYMPTOM-INVENTORY; QUALITY-OF-CARE; IDENTIFICATION TEST AUDIT; ALCOHOL-USE DISORDERS; PSYCHIATRIC RATING-SCALE; SEXUAL EXPERIENCE SCALE; ABUSE SCREENING-TEST; MEDICATION ADHERENCE; ANTIPSYCHOTIC MEDICATION; SCHIZOAFFECTIVE DISORDER AB In schizophrenia, treatments that improve outcomes have not been reliably disseminated. A major barrier to improving care has been a lack of routinely collected outcomes data that identify patients who are failing to improve or not receiving effective treatments. To support high quality care, the VA Mental Health QUERI used literature review, expert interviews, and a national panel process to increase consensus regarding outcomes monitoring instruments and strategies that support quality improvement. There was very good consensus in the domains of psychotic symptoms, side-effects, drugs and alcohol, depression, caregivers, vocational functioning, and community tenure. There are validated instruments and assessment strategies that are feasible for quality improvement in routine practice. C1 [Young, Alexander S.; Niv, Noosha; Marder, Stephen R.] MIRECC, VA Desert Pacific Mental Illness Res, W Los Angeles VA, Los Angeles, CA 90073 USA. [Young, Alexander S.; Niv, Noosha; Marder, Stephen R.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Chinman, Matthew] VA Stars & Stripes MIRECC, Pittsburgh, PA 15206 USA. [Chinman, Matthew] RAND Corp, Pittsburgh, PA USA. [Dixon, Lisa] VA Maryland Hlth Care Syst, VA Capitol MIRECC, Baltimore, MD 21201 USA. [Dixon, Lisa] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Eisen, Susan V.] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Eisen, Susan V.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Fischer, Ellen P.; Smith, Jeffrey; Owen, Richard R.] VA Mental Hlth QUERI, Cent Arkansas Vet Healthcare Syst HSR&D NLR 152, N Little Rock, AR 72114 USA. [Fischer, Ellen P.; Smith, Jeffrey; Owen, Richard R.] Univ Arkansas Med Sci, Dept Psychiat & Behav Sci, Little Rock, AR 72205 USA. [Valenstein, Marcia] Ann Arbor VA Med Ctr, Ann Arbor, MI 48113 USA. [Valenstein, Marcia] Univ Michigan, Ann Arbor, MI 48109 USA. RP Young, AS (reprint author), MIRECC, VA Desert Pacific Mental Illness Res, W Los Angeles VA, 11301 Wilshire Blvd,210A, Los Angeles, CA 90073 USA. EM ayoung@ucla.edu RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU NIMH NIH HHS [MH082760, P30 MH082760] NR 100 TC 12 Z9 12 U1 4 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD APR PY 2011 VL 47 IS 2 BP 123 EP 135 DI 10.1007/s10597-010-9328-y PG 13 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 735WQ UT WOS:000288451700001 PM 20658320 ER PT J AU Mather, M Alford, K AF Mather, Mary Alford, Kaye TI Creating a Healthy Work Environment With Civility and Respect SO CRITICAL CARE NURSE LA English DT Meeting Abstract C1 [Mather, Mary; Alford, Kaye] S Texas Vet Hlth Care Syst, San Antonio, TX USA. EM mary.mather@va.gov NR 0 TC 0 Z9 0 U1 0 U2 6 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 J9 CRIT CARE NURSE JI Crit. Care Nurse PD APR PY 2011 VL 31 IS 2 BP E21 EP E22 PG 2 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 744AX UT WOS:000289065500021 ER PT J AU Richardson, J Hendricks-Jensen, J Vann, C AF Richardson, Jeannette Hendricks-Jensen, Jadene Vann, Christina TI Analysis of Practice and Performance Improvement in Patients with Severe Sepsis and Septic Shock SO CRITICAL CARE NURSE LA English DT Meeting Abstract C1 [Richardson, Jeannette; Hendricks-Jensen, Jadene; Vann, Christina] Portland VA Med Ctr, Portland, OR USA. EM jeannette.richardson@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 J9 CRIT CARE NURSE JI Crit. Care Nurse PD APR PY 2011 VL 31 IS 2 BP E15 EP E16 PG 2 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 744AX UT WOS:000289065500010 ER PT J AU Egede, LE Gebregziabher, M Hunt, KJ Axon, RN Echols, C Gilbert, GE Mauldin, PD AF Egede, Leonard E. Gebregziabher, Mulugeta Hunt, Kelly J. Axon, Robert N. Echols, Carrae Gilbert, Gregory E. Mauldin, Patrick D. TI Regional, Geographic, and Racial/Ethnic Variation in Glycemic Control in a National Sample of Veterans With Diabetes SO DIABETES CARE LA English DT Article ID HEMOGLOBIN A(1C); CARE; HEALTH; GLUCOSE; DISPARITIES; BENEFICIARIES; PREVALENCE; OUTCOMES; CLINICS; ADULTS AB OBJECTIVE-We performed a retrospective analysis of a national cohort of veterans with diabetes to better understand regional, geographic, and racial/ethnic variation in diabetes control as measured by HbA(1c). RESEARCH DESIGN AND METHODS-A retrospective cohort study was conducted in a national cohort of 690,968 veterans with diabetes receiving prescriptions for insulin or oral hypoglycemic agents in 2002 that were followed over a 5-year period. The main outcome measures were HbA(1c) levels (as continuous and dichotomized at >= 8.0%). RESULTS-Relative to non-Hispanic whites (NHWs), HbA(1c) levels remained 0.25% higher in non-Hispanic blacks (NHBs), 0.31% higher in Hispanics, and 0.14% higher in individuals with other/unknown/missing racial/ethnic group after controlling for demographics, type of medication used, medication adherence, and comorbidities. Small but statistically significant geographic differences were also noted with HbA(1c) being lowest in the South and highest in the Mid-Atlantic. Rural/urban location of residence was not associated with HbA(1c) levels. For the dichotomous outcome poor control, results were similar with race/ethnic group being strongly associated with poor control (i.e., odds ratios of 1.33 [95% CI 1.31-1.35] and 1.57 [1.54-1.61] for NHBs and Hispanics vs. NHWs, respectively), geographic region being weakly associated with poor control, and rural/urban residence being negligibly associated with poor control. CONCLUSIONS-In a national longitudinal cohort of veterans with diabetes, we found racial/ethnic disparities in HbA(1c) levels and HbA(1c) control; however, these disparities were largely, but not completely, explained by adjustment for demographic characteristics, medication adherence, type of medication used to treat diabetes, and comorbidities. C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Hunt, Kelly J.; Axon, Robert N.; Echols, Carrae; Gilbert, Gregory E.; Mauldin, Patrick D.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Egede, Leonard E.; Axon, Robert N.; Mauldin, Patrick D.] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Mauldin, Patrick D.] S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, Charleston, SC USA. RP Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. EM egedel@musc.edu RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher, Mulugeta/0000-0002-4826-481X FU VHA Health Services Research and Development [IIR-06-219] FX This study was supported by Grant IIR-06-219 funded by the VHA Health Services Research and Development program. The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The article represents the views of the authors and not those of the VA or Health Services Research and Development. NR 23 TC 35 Z9 35 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2011 VL 34 IS 4 BP 938 EP 943 DI 10.2337/dc10-1504 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 746DE UT WOS:000289221800026 PM 21335370 ER PT J AU Matlock, DD Kutner, JS Emsermann, CB Al-Khatib, SM Sanders, GD Dickinson, LM Rumsfeld, JS Davidson, AJ Crane, LA Masoudi, FA AF Matlock, Dan D. Kutner, Jean S. Emsermann, Caroline B. Al-Khatib, Sana M. Sanders, Gillian D. Dickinson, L. Miriam Rumsfeld, John S. Davidson, Arthur J. Crane, Lori A. Masoudi, Frederick A. TI Regional Variations in Physicians' Attitudes and Recommendations Surrounding Implantable Cardioverter-Defibrillators SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; frailty; survey ID LIFE TREATMENT INTENSITY; PRIMARY-CARE PHYSICIANS; HEART-FAILURE; HEALTH-CARE; RESOURCE USE; MEDICARE; QUALITY; VALIDATION; PREFERENCES; PERCEPTIONS AB Introduction: This study was designed to determine if physicians' attitudes and recommendations surrounding implantable cardioverter-defibrillators (ICDs) are regionally associated with ICD use. Methods and Results: A national sample of 9969 members of the American College of Cardiology was surveyed electronically. Responses were merged with rates of ICD implantation from the National Cardiovascular Data Registry. Multivariable regression was used to assess trends between regional use and responses. We received 1210 responses (12%) and used 1124 after exclusions. Across regions, physicians were equally likely to recommend ICDs to males or females with ischemic (similar to 99% for both; P = NS) or nonischemic cardiomyopathy (85 vs. 88% P = 0.85). Significant increasing trends in the probability recommending ICD therapy were found when the patient was "frail" (21% to 32%; P = .03) or had a life expectancy < 1 year (5% to 10%; P = .05). These differences were not associated with attitudes toward ICDs. Conclusions: Independent of variations in physicians' attitudes towards ICDs, physicians in regions of low ICD use are not less likely to recommend ICDs in situations clearly supported by guidelines while those in regions of high ICD use are more likely to recommend ICDs to patients who might have limited benefit. (J Cardiac Fail 2011;17:318-324) C1 [Matlock, Dan D.] Univ Colorado, Denver Sch Med, Div Gen Internal Med, Aurora, CO 80045 USA. [Matlock, Dan D.; Rumsfeld, John S.; Masoudi, Frederick A.] Kaiser Permanente, Colorado Inst Hlth Res, Denver, CO USA. [Matlock, Dan D.; Rumsfeld, John S.; Masoudi, Frederick A.] Colorado Cardiovasc Outcomes Res Inst, Denver, CO USA. [Al-Khatib, Sana M.; Sanders, Gillian D.] Duke Cardiovasc Ctr Educ & Res Therapeut, Duke Clin Res Inst, Durham, NC USA. [Al-Khatib, Sana M.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Davidson, Arthur J.; Crane, Lori A.] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. [Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA. RP Matlock, DD (reprint author), Univ Colorado, Denver Sch Med, Div Gen Internal Med, Acad Off 1,12631 E 17th Ave, Aurora, CO 80045 USA. EM daniel.matlock@ucdenver.edu FU Medtronic; Biotronik; American College of Cardiology; Oklahoma Foundation for Medical Quality; Agency for Healthcare Research and Quality [U18 HS016964]; The Division of General Internal Medicine at The University of Colorado; [T32HP10006] FX S.M.A.-K. has received research funding and speaking fees from Medtronic and Biotronik. G.D.S. has received research support from Medtronic. F.A.M. has contracts with the American College of Cardiology and the Oklahoma Foundation for Medical Quality; and serves on an advisory board for Amgen. This research was conducted while D.D.M. was supported by an institutional T32HP10006 as well as while he was a Hartford Geriatrics Health Outcomes Scholar. This project was supported in part by cooperative agreement number U18 HS016964 from the Agency for Healthcare Research and Quality. Additional funds were provided by The Division of General Internal Medicine at The University of Colorado. NR 30 TC 5 Z9 5 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2011 VL 17 IS 4 BP 318 EP 324 DI 10.1016/j.cardfail.2010.11.009 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 747KK UT WOS:000289318500008 PM 21440870 ER PT J AU Riegel, B Moelter, ST Ratcliffe, SJ Pressler, SJ De Geest, S Potashnik, S Fleck, D Sha, DH Sayers, SL Weintraub, WS Weaver, TE Goldberg, LR AF Riegel, Barbara Moelter, Stephen T. Ratcliffe, Sarah J. Pressler, Susan J. De Geest, Sabina Potashnik, Sheryl Fleck, Desiree Sha, Daohang Sayers, Steven L. Weintraub, William S. Weaver, Terri E. Goldberg, Lee R. TI Excessive Daytime Sleepiness is Associated With Poor Medication Adherence in Adults With Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; sleep; excessive daytime sleepiness; cognition; vigilance; patient compliance; self-care ID GLOBAL PERCEIVED HEALTH; PRIMARY-CARE PATIENTS; OF-THE-LITERATURE; SELF-CARE; IMPACT; APNEA; NONCOMPLIANCE; DEPRIVATION; WAKEFULNESS; PREVALENCE AB Background: A relationship between excessive daytime sleepiness (EDS) and poor treatment adherence has been suspected but not confirmed. We hypothesized that medication adherence would be poorer in adults with heart failure (HF) and EDS and that cognitive status would be the mechanism of effect. Methods and Results: A sample of 280 adults with chronic HF were enrolled into a prospective cohort comparison study. We identified a cohort with EDS and a control group without EDS and further divided both groups into those with and without mild cognitive decline. Data on medication adherence were obtained at baseline and 3 and 6 months by using the Basel Assessment of Adherence Scale. Regression analysis was used to clarify the contribution of EDS and cognition to medication adherence and to assess relationships over 6 months after adjusting for age, enrollment site, gender, race, functional class, depression, and premorbid intellect. At baseline, 62% of subjects were nonadherent to their medication regime. Nonadherence was significantly more common in those with EDS, regardless of cognitive status (P = .035). The odds of nonadherence increased by 11% for each unit increase in EDS (adjusted odds ratio 1.11; 95% confidence interval 1.05-1.19; P = .001). In longitudinal models, there was a 10% increase in the odds of nonadherence for each unit increase in EDS (P = .008). The only cognition measure significantly associated with medication adherence was attention (P = .047). Conclusions: Adults with HF and EDS are more likely to have problems adhering to their medication regimen than those without EDS, regardless of their cognitive status. Identifying and correcting factors that interfere with sleep may improve medication adherence. (J Cardiac Fail 2011;17:340-348) C1 [Riegel, Barbara; Potashnik, Sheryl] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Ratcliffe, Sarah J.; Sha, Daohang; Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Moelter, Stephen T.] Univ Sci, Philadelphia, PA USA. [Fleck, Desiree] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Pressler, Susan J.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [De Geest, Sabina] Univ Basel, Inst Nursing Sci, Basel, Switzerland. [De Geest, Sabina] Katholieke Univ Leuven, Ctr Hlth Serv & Nursing Res, Louvain, Belgium. [Weintraub, William S.] Christiana Care Hlth Syst, Christiana Care Ctr Outcomes Res, Newark, DE USA. [Weaver, Terri E.] Univ Illinois, Coll Nursing, Chicago, IL USA. RP Riegel, B (reprint author), Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA. EM briegel@nursing.upenn.edu OI Goldberg, Lee/0000-0002-7906-9638; Ratcliffe, Sarah/0000-0002-6644-8284 FU National Heart, Lung, and Blood Institute [RO1 HL084394-01A1]; VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center FX Supported by the National Heart, Lung, and Blood Institute (RO1 HL084394-01A1) and the VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center. NR 66 TC 42 Z9 42 U1 3 U2 5 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2011 VL 17 IS 4 BP 340 EP 348 DI 10.1016/j.cardfail.2010.11.002 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 747KK UT WOS:000289318500011 PM 21440873 ER PT J AU Roth, MY Page, ST Lin, K Anawalt, BD Matsumoto, AM Marck, B Bremner, WJ Amory, JK AF Roth, M. Y. Page, S. T. Lin, K. Anawalt, B. D. Matsumoto, A. M. Marck, B. Bremner, W. J. Amory, J. K. TI The Effect of Gonadotropin Withdrawal and Stimulation with Human Chorionic Gonadotropin on Intratesticular Androstenedione and DHEA in Normal Men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID HUMAN TESTICULAR STEROIDOGENESIS; HORMONE ANTAGONIST; MASS-SPECTROMETRY; STEROID-LEVELS; HUMAN TESTIS; RAT TESTIS; YOUNG MEN; TESTOSTERONE; SPERMATOGENESIS; SECRETION AB Introduction: Concentrations of intratesticular (IT) testosterone (T) are known to be 100-200 times those of serum T; however, the IT concentrations of T's precursors, their testicular to serum gradients, gonadotropin dependence, and response to stimulation with human chorionic gonadotropin (hCG) have not been studied in detail. We hypothesized that serum and IT androstenedione (ADD) and IT dehydroepiandrosterone (DHEA) would be significantly suppressed by the administration of a GnRH antagonist and increased when stimulated by hCG, without a similar suppression of serum DHEA. Methods: We suppressed gonadotropins in 23 normal men with the GnRH antagonist acyline and randomly assigned them to one of four doses of hCG, 0, 15, 60, or 125 IU sc every other day for 10 d. Blood and IT fluid for the measurement of serum and IT hormones were obtained at baseline and after 10 d of treatment. Results: Baseline ITADD[median (25th, 75th percentile)] was 629 (308, 860) nmol/liter, and ITDHEA was 564 (411, 879) nmol/liter, which were 175 and 27 times higher than their respective serum concentrations. IT ADD and IT DHEA were suppressed by 98 and 82%, respectively, by acyline and significantly increased with hCG administration. Likewise, serum ADD was suppressed by 50%, but serum DHEA was unchanged. Discussion: ADD and DHEA are highly concentrated within the human testes compared with serum. Serum and IT ADD and IT DHEA are markedly suppressed with GnRH administration and stimulated by hCG, but serum DHEA is not, suggesting that most circulating DHEA is not of testicular origin. (J Clin Endocrinol Metab 96: 1175-1181, 2011) C1 [Roth, M. Y.; Page, S. T.; Anawalt, B. D.; Matsumoto, A. M.; Bremner, W. J.; Amory, J. K.] Univ Washington, Dept Internal Med, Seattle, WA USA. [Lin, K.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA USA. [Roth, M. Y.; Page, S. T.; Anawalt, B. D.; Matsumoto, A. M.; Bremner, W. J.; Amory, J. K.] Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA USA. [Marck, B.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA 98105 USA. RP Roth, MY (reprint author), Univ Washington, Dept Internal Med, 1959 NE Pacific St,Box 357138, Seattle, WA USA. EM mylang@u.washington.edu FU National Institute of Child Health and Human Development [U54 HD-12629, U54 HD-42454]; Cooperative Contraceptive Research Center; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12 HD053984]; National Institute of Aging, a Division of the National Institutes of Health [K23 AG027238]; Department of Veterans Affairs FX The National Institute of Child Health and Human Development supported this work through cooperative agreements U54 HD-12629 and U54 HD-42454 as part of the specialized Cooperative Centers Program in Reproductive Research and the Cooperative Contraceptive Research Centers Program. M.Y.R. is supported, in part, by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Grant K12 HD053984. S. T. P. is supported by the National Institute of Aging, a Division of the National Institutes of Health, Grant K23 AG027238. A. M. M. is supported by the Department of Veterans Affairs. NR 27 TC 4 Z9 4 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2011 VL 96 IS 4 BP 1175 EP 1181 DI 10.1210/jc.2010-2518 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 746JO UT WOS:000289242800064 PM 21289266 ER PT J AU Mohr, DC Carmody, T Erickson, L Jin, L Leader, J AF Mohr, David C. Carmody, Timothy Erickson, Lauren Jin, Ling Leader, Julie TI Telephone-Administered Cognitive Behavioral Therapy for Veterans Served by Community-Based Outpatient Clinics SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE depression; psychotherapy; telemental health; randomized controlled trial; cognitive behavioral therapy ID POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE; RANDOMIZED-TRIAL; RATING-SCALE; DEPRESSION; PSYCHOTHERAPY; HEALTH; METAANALYSIS; MANAGEMENT; SYMPTOMS AB Objective.. Multiple:trials have found telephone-administered cognitive behavioral therapy (T-CBT) to be effective for the treatment of depression. The aim of this study was to evaluate T-CBT for the treatment of depression among veterans served by community-based outpatient clinics (CBOCs) outside of major urban areas. Method: Eighty-five veterans meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed.; American Psychiatric Association. 1994) criteria for major depressive disorder were randomized to receive 16 sessions of T-CBT over 20 weeks or treatment as usual through the CBOC. Veterans were assessed at baseline, 12 weeks. 20 weeks (posttreatment), and 6-month follow-up using the Hamilton Depression Rating Scale (Hamilton. 1960), the Patient Health Questionnaire-9 (Kroenke, Spitzer. & Williams. 2001). and a standardized psychiatric interview. Results: There were no significant Time X Treatment effects (ps >.20). Patients were compliant, with 38(92.7%) completing at least 12 sessions, and 32(78.0%) having no missed sessions whatsoever. Ratings of audiotaped sessions showed the therapists to be highly competent. Conclusions: This trial yielded negative results for an intervention that has been shown to be effective under other circumstances. We speculate that veterans served within the Veterans Affairs system are more refractory to treatment than other populations, and they may require a more rigorous intervention. Trial Registration: clinicaltrials.gov NCr00223652 C1 [Mohr, David C.; Jin, Ling] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Mohr, David C.] Hines Vet Affairs Med Ctr, Ctr Management Complex Chron Care, Hines, IL USA. [Carmody, Timothy; Erickson, Lauren] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Carmody, Timothy; Leader, Julie] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP Mohr, DC (reprint author), Northwestern Univ, Dept Prevent Med, 680 N Lakeshore Dr,Suite 1220, Chicago, IL 60611 USA. EM d-mohr@northwestern.edu NR 25 TC 16 Z9 16 U1 6 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD APR PY 2011 VL 79 IS 2 BP 261 EP 265 DI 10.1037/a0022395 PG 5 WC Psychology, Clinical SC Psychology GA 742EP UT WOS:000288924400014 PM 21299274 ER PT J AU Iturrizaga, J Pamboukian, SV George, J Brown, RN Cadeiras, M Smallfield, M Bourge, RC Kirklin, JK McGiffin, DC Hubbard, M Tallaj, JA AF Iturrizaga, J. Pamboukian, S. V. George, J. Brown, R. N. Cadeiras, M. Smallfield, M. Bourge, R. C. Kirklin, J. K. McGiffin, D. C. Hubbard, M. Tallaj, J. A. TI Post-Transplant Diastolic Dysfunction beyond the First Year: Incidence and Prognostic Significance SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Meeting Abstract CT 31st Annual Meeting and Scientific Sessions on International-Society-for-Heart-and-Lung-Transplantation CY APR 13-16, 2011 CL San Diego, CA SP Int Soc Heart & Lung Transplantat C1 [Iturrizaga, J.; Pamboukian, S. V.; George, J.; Brown, R. N.; Cadeiras, M.; Smallfield, M.; Bourge, R. C.; Kirklin, J. K.; McGiffin, D. C.; Hubbard, M.; Tallaj, J. A.] Univ Alabama, Birmingham, AL USA. [Tallaj, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD APR PY 2011 VL 30 IS 4 SU S MA 523 BP S176 EP S177 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Transplantation GA 742EO UT WOS:000288924300519 ER PT J AU Jakupcak, M Hoerster, KD Varra, A Vannoy, S Felker, B Hunt, S AF Jakupcak, Matthew Hoerster, Katherine D. Varra, Alethea Vannoy, Steven Felker, Bradford Hunt, Stephen TI Hopelessness and Suicidal Ideation in Iraq and Afghanistan War Veterans Reporting Subthreshold and Threshold Posttraumatic Stress Disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Suicide risk; Iraq and Afghanistan war veterans; subthreshold PTSD ID MENTAL-HEALTH PROBLEMS; PRIMARY-CARE; PREVALENCE; PTSD; IMPAIRMENT; COMBAT; TRAUMA; RISK AB We examined hopelessness and suicidal ideation in association with subthreshold and threshold posttraumatic stress disorder (PTSD) in a sample of Iraq and Afghanistan War Veterans (U.S., N = 275) assessed within a specialty VA postdeployment health clinic. Veterans completed paper-and-pencil questionnaires at intake. The military version of the PTSD Checklist was used to determine PTSD levels (No PTSD; subthreshold PTSD; PTSD), and endorsement of hopelessness or suicidal ideation were used as markers of elevated suicide risk. Veterans were also asked if they received mental health treatment in the prior 6 months. Veterans reporting subthreshold PTSD were 3 times more likely to endorse these markers of elevated suicide risk relative to the Veterans without PTSD. We found no significant differences in likelihood of endorsing hopelessness or suicidal ideation comparing subthreshold and threshold PTSD groups, although the subthreshold PTSD group was less likely to report prior mental health treatment. Clinicians should be attentive to suicide risk in returned Veterans reporting both subthreshold and threshold PTSD. C1 [Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN NW Mental Illness Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. [Jakupcak, Matthew; Hoerster, Katherine D.; Varra, Alethea; Vannoy, Steven] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN NW Mental Illness Res Educ & Clin Ctr 20, 1660 S Columbian Way, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov RI Schueter, nicos/A-3625-2014 OI Vannoy, Steven/0000-0003-3029-8306 FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 23 TC 40 Z9 40 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD APR PY 2011 VL 199 IS 4 BP 272 EP 275 DI 10.1097/NMD.0b013e3182124604 PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 742ZX UT WOS:000288985400012 PM 21451353 ER PT J AU Nguyen, DN Zierler, B Nguyen, HQ AF Nguyen, Diane N. Zierler, Brenda Nguyen, Huong Q. TI A Survey of Nursing Faculty Needs for Training in Use of New Technologies for Education and Practice SO JOURNAL OF NURSING EDUCATION LA English DT Article ID STUDENTS EXPERIENCES; DISTANCE EDUCATION; MEDICAL INFORMATICS; ONLINE; COURSES; WEB; NURSES; UNDERGRADUATE; PERSPECTIVES; INSTRUCTION AB This study describes nursing faculty's use, knowledge of, and training needs associated with distance learning, simulation, telehealth, and informatics tools in nursing education and practice. Web-based surveys were completed by 193 faculty members from nursing schools in the western United States. More than half of the respondents were frequent users of distance learning and informatics tools. Approximately 66% of faculty reported they were competent with distance learning and informatics tools. Training and technical support for the use of distance learning was highest, yet 69% of faculty still reported a need for additional training. The availability of training and financial and technical support was associated with greater use of distance learning technologies (p < 0.05 for all). Although a key limitation of this survey was the overlapping definitions across the four technologies, the findings suggest nursing faculty perceive a need for training and support to effectively use educational technologies in nursing education. C1 [Nguyen, Diane N.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Zierler, Brenda; Nguyen, Huong Q.] Univ Washington, Seattle, WA 98195 USA. RP Nguyen, DN (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mail Stop S-118-NOD, Seattle, WA 98108 USA. EM Diane.Nguyen@va.gov FU NCRR NIH HHS [KL2 RR025015] NR 62 TC 14 Z9 16 U1 1 U2 16 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0148-4834 J9 J NURS EDUC JI J. Nurs. Educ. PD APR PY 2011 VL 50 IS 4 BP 181 EP 189 DI 10.3928/01484834-20101130-06 PG 9 WC Nursing SC Nursing GA 742TV UT WOS:000288968300002 PM 21117532 ER PT J AU Fineberg, IC Kawashima, M Asch, SM AF Fineberg, Iris Cohen Kawashima, Michie Asch, Steven M. TI Communication with Families Facing Life-Threatening Illness: A Research-Based Model for Family Conferences SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; PALLIATIVE CARE; DECISION-MAKING; SOCIAL SUPPORT; END; CAREGIVERS; SATISFACTION; COLLABORATE; PERCEPTIONS; TRANSITIONS AB Background: Communication is an ongoing challenge for clinicians working with people facing life-threatening illnesses and end of life. Family conferences offer patient-focused, family-oriented care that brings together patients, family members, and health care providers. Objective: The aim of this study was to develop a research-based model for family conferences to help physicians and other health care providers conduct such conferences effectively and improve communication with patients and families. Design: We prospectively studied family conferences for patients facing life-threatening illness in two inpatient medical centers. We videotape and audiotape recorded real-life conferences and postconference interviews with participants. Participants: Twenty-four family conferences were included in the study. Participants consisted of 24 patients, 10 of whom took part in the family conferences, 49 family members, and 85 health care providers. Approach: A multidisciplinary team conducted a qualitative analysis of the videotaped and audiotaped materials using thematic analysis. The team used a multistage approach to independently and collectively analyze and integrate three data sources. Main Results: The resulting theoretical model for family conferences has 4 main components. These include the underlying structural context of conference organization and the key process components of negotiation and personal stance. Emotional engagement by health care providers, emotion work, appears central to the impact of these components on the successful outcome of the conference. In addition to the theoretical model, the authors found that family conference participants place specific value on the "simultaneous presence" of conference attendees that leads to being on the "same page." Conclusions: Physicians and other health care professionals can use the model as a guide for conducting family conferences and strengthening communication with patients, families and colleagues. C1 [Fineberg, Iris Cohen] Univ Lancaster, Int Observ End Life Care, Sch Hlth & Med, Div Hlth Res, Lancaster LA1 4YT, England. [Kawashima, Michie] Japan Soc Promot Sci, Tokyo, Japan. [Kawashima, Michie] Saitama Univ, Saitama 3388570, Japan. [Kawashima, Michie] Tokyo Med & Dent Univ, Tokyo, Japan. [Asch, Steven M.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Fineberg, IC (reprint author), Univ Lancaster, Int Observ End Life Care, Sch Hlth & Med, Div Hlth Res, Bowland Tower E, Lancaster LA1 4YT, England. EM i.fineberg@lancaster.ac.uk FU UniHealth Foundation in Los Angeles, California FX This research was conducted under a grant from the UniHealth Foundation in Los Angeles, California. We appreciate the foundation's support and interest in this work. Thank you to the medical and palliative care teams at the participating medical centers for their crucial collaboration, to Marc Roseboro for his sensitive and skillful videotaping, and to Joya F. Golden for her thoughtful administrative assistance. Most of all, we thank the family conference participants-patients, family members, and staff-who graciously shared their experiences with us and made the research possible. NR 63 TC 17 Z9 17 U1 1 U2 10 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 421 EP 427 DI 10.1089/jpm.2010.0436 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100011 PM 21385083 ER PT J AU Smith, KA Goy, ER Harvath, TA Ganzini, L AF Smith, Kathryn A. Goy, Elizabeth R. Harvath, Theresa A. Ganzini, Linda TI Quality of Death and Dying in Patients who Request Physician-Assisted Death SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID FAMILY-MEMBERS; EXPERIENCES; OREGONIANS; SUICIDE AB Background: Physician-assisted death (PAD) was legalized in 1997 by Oregon's Death with Dignity Act (ODDA). Through 2009, 460 Oregonians have died by lethal prescription under the ODDA. Objective: To determine whether there was a difference in the quality of the dying experience, from the perspective of family members, between 52 Oregonians who received lethal prescriptions, 34 who requested but did not receive lethal prescriptions, and 63 who did not pursue PAD. Design: Cross-sectional survey. Measurements: Family members retrospectively rated the dying experience of their loved one with the 33 item Quality of Death and Dying Questionnaire (QODD). Results: There were differences reported in 9 of the 33 quality item indicators. Few significant differences were noted in items that measured domains of connectedness, transcendence, and overall quality of death. Those receiving PAD prescriptions had higher quality ratings on items measuring symptom control (e. g., control over surroundings and control of bowels/bladder) and higher ratings on items related to preparedness for death (saying goodbye to loved ones, and possession of a means to end life if desired) than those who did not pursue PAD or, in some cases, those who requested but did not receive a lethal prescription. Conclusions: The quality of death experienced by those who received lethal prescriptions is no worse than those not pursuing PAD, and in some areas it is rated by family members as better. C1 [Goy, Elizabeth R.; Ganzini, Linda] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97239 USA. [Smith, Kathryn A.; Harvath, Theresa A.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Goy, Elizabeth R.; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Div Mental Hlth, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Linda.Ganzini@va.gov FU Greenwall Foundation FX Funded by a grant from the Greenwall Foundation. This material is the result of work supported with resources and the use of facilities at the Portland VAMC in Portland, Oregon. NR 19 TC 11 Z9 11 U1 3 U2 21 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 445 EP 450 DI 10.1089/jpm.2010.0425 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100014 PM 21417741 ER PT J AU Morss, S Asch, SM Lorenz, KA Weeks, K Sharma, RK Wolff, AC Malin, JL AF Morss, Sydney Asch, Steven M. Lorenz, Karl A. Weeks, Kristina Sharma, Rashmi K. Wolff, Antonio C. Malin, Jennifer L. TI Quality of End-of-Life Care for Patients with Advanced Cancer in an Academic Medical Center SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID HEALTH AB Purpose: We assessed key aspects of the quality of end-of-life care using validated explicit process quality measures in an academic medical center (hospital and cancer center) before expanding to a broader palliative care initiative. Methods: We evaluated 21 indicators most relevant to end-of-life care from the Cancer Quality-ASSIST supportive oncology indicator set for 238 patients with advanced/metastatic solid tumors who died between 2-15 months after diagnosis. These included outpatient and hospital indicators for cancer symptoms and information and care planning that met criteria for feasibility, reliability, and validity. We abstracted detailed information from medical records to specify the necessary data elements. Results: Overall adherence was 53% (95% confidence interval [CI], 50%-56%); this varied widely among indicators. Adherence was highest for pain indicators; in particular, 97% of eligible subjects' hospitalizations had documented screening for pain, and, after an outpatient pain medication was changed, 97% of patients had a pain assessment at the subsequent visit. For other symptoms, adherence ranged from 0% for documentation of life expectancy for patients starting parenteral or enteral nutrition to 87% for assessment of nausea or vomiting on hospital admission. For information and care planning, results ranged from 6% for documentation of ventilation preferences prior to intubation to 68% for documented communication of risks and benefits or prognosis prior to starting chemotherapy. Conclusion: In conclusion, Cancer Quality-ASSIST indicators are useful for practical quality assessment of cancer end-of-life care in an academic medical center. These results will serve as useful data for targeting areas for quality improvement and measuring progress. C1 [Morss, Sydney] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21205 USA. [Weeks, Kristina] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA. [Wolff, Antonio C.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21205 USA. [Asch, Steven M.; Lorenz, Karl A.; Malin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, RAND Hlth, Los Angeles, CA 90095 USA. [Sharma, Rashmi K.] Northwestern Univ, Div Hosp Med, Chicago, IL 60611 USA. RP Morss, S (reprint author), Johns Hopkins Univ, Dept Hlth Policy & Management, Room 609,624 N Broadway, Baltimore, MD 21205 USA. EM sdy@jhsph.edu OI Wolff, Antonio/0000-0003-3734-1063 FU Agency for Healthcare Research and Quality, US Department of Health and Human Services [290-2005-0034I] FX The research reported here was supported under Contract No. 290-2005-0034I from the Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. The authors of this paper are responsible for its content. Statements in this paper should not be construed as endorsement by the Agency for Healthcare Research and Quality. NR 13 TC 0 Z9 0 U1 1 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 451 EP 457 DI 10.1089/jpm.2010.0434 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100015 ER PT J AU Steinman, MA Hanlon, JT Sloane, RJ Boscardin, WJ Schmader, KE AF Steinman, Michael A. Hanlon, Joseph T. Sloane, Richard J. Boscardin, W. John Schmader, Kenneth E. TI Do Geriatric Conditions Increase Risk of Adverse Drug Reactions in Ambulatory Elders? Results From the VA GEM Drug Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Adverse drug reactions; Geriatric syndromes; Drug utilization ID OLDER-ADULTS; EVENTS; FRAILTY; AGE; ASSOCIATION; OUTPATIENTS; MANAGEMENT; DISCHARGE; CARE AB Background. Many clinicians prescribe cautiously to older adults with common geriatric conditions for fear of causing adverse drug reactions (ADRs). However, little is known about the association between these conditions and risk of ADRs. Methods. Using data from the VA Geriatric Evaluation and Management Drug Study, we determined any, preventable, and serious ADRs in 808 elders for 12 months after hospital discharge using a validated process involving patient self-report and chart review adjudicated by two health care professionals. Eight common geriatric conditions (activities of daily living, dementia, incontinence, falls, difficulty ambulating, malnourishment, depression, and prolonged bed rest) were evaluated at study baseline through self-report and structured assessments. We used Poisson regression to model the relationship between these geriatric conditions and ADRs. Results. Participants had a mean of 2.9 +/- 1.2 geriatric conditions. Over the 12-month follow-up period, 497 ADRs occurred in 269 participants, including 187 ADRs considered preventable and 127 considered severe. On multivariable analyses, participants with dependency in one or more activities of daily living were less likely to suffer ADRs than those who were fully independent (incidence rate ratio: 0.78, 95% confidence interval = 0.62-1.00). None of the other seven geriatric conditions assessed were associated with ADR risk. Results were similar for preventable and serious ADRs, although participants with a history of falls were more likely to develop serious ADRs (incidence rate ratio: 1.49, 95% confidence interval = 1.00-2.21). Conclusions. Many geriatric conditions were not associated with risk of ADRs. Although it is prudent to prescribe judiciously in patients with these conditions, excessive caution may not be warranted. C1 [Steinman, Michael A.; Boscardin, W. John] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Steinman, Michael A.; Boscardin, W. John] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Sloane, Richard J.; Schmader, Kenneth E.] Duke Univ, Dept Med, Div Geriatr, Durham, NC USA. [Sloane, Richard J.; Schmader, Kenneth E.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St, Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU National Institute on Aging [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056]; American Federation for Aging Research [K23 AG030999]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [HS017695, HS018721]; VA Health Services Research [IIR-06-062] FX This work was supported by a grant from the National Institute on Aging and the American Federation for Aging Research (K23 AG030999). Dr Hanlon was supported by National Institute of Aging grants (R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056), a National Institute of Mental Health grant (R34 MH082682), a National Institute of Nursing Research grant (R01 NR010135), Agency for Healthcare Research and Quality grants (HS017695 and HS018721 and a VA Health Services Research grant (IIR-06-062). NR 33 TC 7 Z9 8 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2011 VL 66 IS 4 BP 444 EP 451 DI 10.1093/gerona/glq236 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 741AX UT WOS:000288836600010 PM 21321003 ER PT J AU Sun, HY Singh, N AF Sun, Hsin-Yun Singh, Nina TI Mucormycosis: its contemporary face and management strategies SO LANCET INFECTIOUS DISEASES LA English DT Review ID ORGAN TRANSPLANT RECIPIENTS; INVASIVE FUNGAL-INFECTIONS; LIPOSOMAL AMPHOTERICIN-B; COLONY-STIMULATING FACTOR; STEM-CELL TRANSPLANTATION; SURVEILLANCE NETWORK TRANSNET; CALCINEURIN-INHIBITOR AGENTS; VERSUS-HOST-DISEASE; CARE CANCER CENTER; LIPID COMPLEX AB Several countries have seen rising frequencies of mucormycosis among patients with haematological disorders, malignancies, or diabetes mellitus, and among transplant recipients. Growing numbers of immunocompromised hosts, widespread use of antifungal agents inactive against mucormycosis, or other unidentified factors, could be contributing to this situation. The predominant clinical manifestations of mucormycosis vary from host to host. Additionally, risk factors specific to different subgroups have been identified, such as leukaemia, allogeneic haemopoietic stem-cell transplant, voriconazole prophylaxis, diabetes, and malnutrition. We summarise the current state of knowledge of characteristics and risk factors and discuss topical developments in therapeutic methods and strategies in the management of mucormycosis. C1 [Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Singh, Nina] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA. RP Singh, N (reprint author), VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 FU Pfizer FX NS has received support from Pfizer. H-YS declares that she has no conflicts of interest. NR 137 TC 48 Z9 50 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2011 VL 11 IS 4 BP 301 EP 311 PG 11 WC Infectious Diseases SC Infectious Diseases GA 746VK UT WOS:000289275600018 PM 21453871 ER PT J AU Graville, DJ Palmer, AD Andersen, PE Cohen, JI AF Graville, Donna J. Palmer, Andrew D. Andersen, Peter E. Cohen, James I. TI Determining the Efficacy and Cost-Effectiveness of the ActiValve: Results of a Long-Term Prospective Trial SO LARYNGOSCOPE LA English DT Article DE Candidiasis; costs and cost analysis; laryngeal neoplasms; laryngectomy; larynx; artificial prosthesis failure; prosthetic voice rehabilitation; treatment outcome; voice disorders ID SECONDARY TRACHEOESOPHAGEAL PUNCTURE; SALVAGE TOTAL LARYNGECTOMY; VOICE RESTORATION; ALARYNGEAL SPEECH; PROVOX ACTIVALVE; REHABILITATION; PROSTHESIS; COMPLICATIONS; REPLACEMENTS; EXPERIENCE AB Objectives/Hypothesis: To investigate 1) whether the Provox ActiValve results in increased device-life in individuals with below average device-life, 2) whether it is cost-effective, and 3) whether it has any impact on voice-related quality of life. Study Design: Prospective study. Methods: Individuals who experienced below-average tracheoesophageal prosthesis (TEP) life were studied. Results: Individuals with persistent below-average TEP life were enrolled in the study and underwent periodic re-evaluation. The majority (73%) experienced significant improvement as a result of use of the device. Those who continued to wear the device were followed for an average of 30.45 months (range, 14.70-43.49 months) and wore a total of 31 devices over this time. They demonstrated an average increase in device-life of more than 500%, going from an average of 1.93 months with a traditional indwelling device to 10.30 months with the ActiValve. The majority of individuals found that voicing with the ActiValve was either the same or better than with their previous indwelling TEP. Voice-related quality of life was not significantly different from that of a group of controls. Overall satisfaction with the device was high, and the majority would have chosen the ActiValve in the future. Overall, there were estimated to be cost savings to third-party payers through use of the ActiValve in this population. Conclusions: The ActiValve is effective in increasing device-life in selected patients who have failed conservative measures. Our protocol for use of the device requires individuals to meet several usage criteria before initial placement and to return for periodic monitoring. C1 [Graville, Donna J.; Palmer, Andrew D.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, NW Clin Voice & Swallowing, Portland, OR 97239 USA. [Cohen, James I.] Portland VA Med Ctr, Dept Otolaryngol Head & Neck Surg, Portland, OR USA. RP Graville, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, NW Clin Voice & Swallowing, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM graville@ohsu.edu NR 24 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD APR PY 2011 VL 121 IS 4 BP 769 EP 776 DI 10.1002/lary.21380 PG 8 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 740TS UT WOS:000288817900014 PM 21381042 ER PT J AU Maciejewski, ML Weaver, EM Hebert, PL AF Maciejewski, Matthew L. Weaver, Emily M. Hebert, Paul L. TI Synonyms in Health Services Research Methodology SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article DE explanatory variables; quantitative methods; study design; synonyms; terminology ID SAMPLE SELECTION BIAS; INSTRUMENTAL VARIABLES; PROPENSITY SCORE; RISK-FACTORS; BODY-WEIGHT; OBESITY; MODELS; EXPENDITURES; PREDICTORS; OVERWEIGHT AB There are often multiple discipline-specific terms for a given statistical concept, which can sow confusion in multidisciplinary teams or study sections if researchers are not aware of the synonyms from other disciplines. This article incorporates synonyms and a uniform definition of terminology related to study designs, elements of an equation, and types of bias. Greater multidisciplinary collaboration and exploration of new methods can be facilitated by this methods thesaurus. C1 [Maciejewski, Matthew L.] Durham VA Med Ctr, Durham, NC 27705 USA. [Weaver, Emily M.] Univ N Carolina, Chapel Hill, NC USA. [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Maciejewski, ML (reprint author), Durham VA Med Ctr, 508 Fulton St, Durham, NC 27705 USA. EM mlm34@duke.edu FU AcademyHealth; Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs FX The authors disclosed that they received the following support for their research and/or authorship of this article: Funded by AcademyHealth and supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs. NR 76 TC 2 Z9 2 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 EI 1552-6801 J9 MED CARE RES REV JI Med. Care Res. Rev. PD APR PY 2011 VL 68 IS 2 BP 156 EP 176 DI 10.1177/1077558710372809 PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 738OG UT WOS:000288648900002 PM 20675352 ER PT J AU Sittig, DF Singh, H AF Sittig, Dean F. Singh, Hardeep TI Legal, Ethical, and Financial Dilemmas in Electronic Health Record Adoption and Use SO PEDIATRICS LA English DT Article DE electronic health records; ethics; medical; confidentiality ID ORDER ENTRY SYSTEMS; INFORMATION-TECHNOLOGY; MISSED OPPORTUNITIES; CANCER DIAGNOSIS; MEDICAL-RECORD; PATIENT; CARE; LIABILITY; PRIVACY; ERRORS AB Electronic health records (EHRs) facilitate several innovations capable of reforming health care. Despite their promise, many currently unanswered legal, ethical, and financial questions threaten the widespread adoption and use of EHRs. Key legal dilemmas that must be addressed in the near-term pertain to the extent of clinicians' responsibilities for reviewing the entire computer-accessible clinical synopsis from multiple clinicians and institutions, the liabilities posed by overriding clinical decision support warnings and alerts, and mechanisms for clinicians to publically report potential EHR safety issues. Ethical dilemmas that need additional discussion relate to opt-out provisions that exclude patients from electronic record storage, sale of deidentified patient data by EHR vendors, adolescent control of access to their data, and use of electronic data repositories to redesign the nation's health care delivery and payment mechanisms on the basis of statistical analyses. Finally, one overwhelming financial question is who should pay for EHR implementation because most users and current owners of these systems will not receive the majority of benefits. The authors recommend that key stakeholders begin discussing these issues in a national forum. These actions can help identify and prioritize solutions to the key legal, ethical, and financial dilemmas discussed, so that widespread, safe, effective, interoperable EHRs can help transform health care. Pediatrics 2011; 127: e1042-e1047 C1 [Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Mem Hermann Ctr Healthcare Qual & Safety, Hlth Sci Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev, Ctr Excellence, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. RP Sittig, DF (reprint author), Univ Texas Houston, Sch Biomed Informat, Mem Hermann Ctr Healthcare Qual & Safety, Hlth Sci Ctr, 6410 Fannin St,UTPB 1100-43, Houston, TX 77030 USA. EM dean.f.sittig@uth.tmc.edu FU National Institutes of Health (NIH) [K23CA125585]; National Library of Medicine [R01-LM006942]; Veterans Affairs National Center for Patient Safety; Agency for Healthcare Research and Quality; Houston Veterans Affairs Health Services Research and Development Center of Excellence [HFP90-020]; Office of the National Coordinator for Health Information Technology [10510592] FX Funded by the National Institutes of Health (NIH).; Dr Sittig is supported in part by National Library of Medicine grant R01-LM006942; Dr Singh is supported by a National Institutes of Health K23 career development award (K23CA125585), the Veterans Affairs National Center for Patient Safety, Agency for Healthcare Research and Quality, and in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020); and Drs Sittig and Singh are supported by a SHARP (Strategic Health IT Advanced Research Projects) contract from the Office of the National Coordinator for Health Information Technology (ONC #10510592). NR 64 TC 21 Z9 21 U1 0 U2 30 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2011 VL 127 IS 4 BP E1042 EP E1047 DI 10.1542/peds.2010-2184 PG 6 WC Pediatrics SC Pediatrics GA 744DQ UT WOS:000289074800025 PM 21422090 ER PT J AU Kasckow, J Ingram, E Brown, C Tew, JD Conner, KO Morse, JQ Haas, GL Reynolds, CF Oslin, DW AF Kasckow, John Ingram, Erin Brown, Charlotte Tew, James D. Conner, Kyaien O. Morse, Jennifer Q. Haas, Gretchen L. Reynolds, Charles F. Oslin, David W. TI Differences in Treatment Attitudes Between Depressed African-American and Caucasian Veterans in Primary Care SO PSYCHIATRIC SERVICES LA English DT Article ID MINOR DEPRESSION; SERVICE USE; ETHNICITY; RACE; SYMPTOMS; TRIAL AB Objectives: Depressive disorders are common, and it is important to understand the factors that contribute to racial disparities in depression treatment. This primary care study of veterans with subsyndromal depression examined two hypotheses: that African Americans would be less likely than Caucasians to believe that medication is beneficial in depression treatment and would be more likely to believe that counseling or psychotherapy is beneficial. Methods: Primary care patients with subsyndromal depression were referred to the Philadelphia Department of Veterans Affairs Behavioral Health Laboratory and asked about past experiences and attitudes toward depression treatment. Results: Among 111 African-American and 95 Caucasian participants, logistic regression analyses determined that African Americans were less likely to view medication as beneficial (odds ratio=.44). No racial differences were found in participants' attitude toward counseling or psychotherapy. Conclusions: The findings support the premise that clinicians treating patients with subsyndromal depressive syndromes should take into account racial differences in attitudes toward treatment. (Psychiatric Services 62: 426-429, 2011) C1 [Kasckow, John; Tew, James D.] Dept Vet Affairs VA Pittsburgh Hlth Care Syst, Behav Hlth Div, Pittsburgh, PA 15206 USA. [Kasckow, John; Tew, James D.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. [Brown, Charlotte; Conner, Kyaien O.; Morse, Jennifer Q.; Haas, Gretchen L.; Reynolds, Charles F.] VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA USA. [Ingram, Erin; Oslin, David W.] Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA. [Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Kasckow, J (reprint author), Dept Vet Affairs VA Pittsburgh Hlth Care Syst, Behav Hlth Div, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu RI Schueter, nicos/A-3625-2014 FU Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, National Institutes of Health [P30-MH-71944, P60-MD00107]; University of Pittsburgh Medical Center Endowment in Geriatric Psychiatry; Robert Wood Johnson Foundation FX This research was supported by the Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4; grants P30-MH-71944 and P60-MD00107 to Dr. Reynolds from the National Institutes of Health; the University of Pittsburgh Medical Center Endowment in Geriatric Psychiatry (Dr. Reynolds); and the Robert Wood Johnson Foundation. The authors thank Steven Sayers, Ph.D., for letting them use the "perceived barriers" portion of the "watchful waiting medical care questions." NR 12 TC 8 Z9 8 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2011 VL 62 IS 4 BP 426 EP 429 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 743ZM UT WOS:000289060200016 PM 21459996 ER PT J AU Harner, HM Hentz, PM Evangelista, MC AF Harner, Holly M. Hentz, Patricia M. Evangelista, Maria Carmela TI Grief Interrupted: The Experience of Loss Among Incarcerated Women SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE bereavement / grief; phenomenology; prisons, prisoners; women's health ID BEREAVEMENT AB Incarcerated women face a number of stressors apart from the actual incarceration. Nearly half of all women in prison experience the death of a loved one during their incarceration. Our purpose for this study was to explore the experience of grief and loss among incarcerated women using a phenomenological method. Our study approach followed van Manen's method of phenomenology and Munhall's description of existential lifeworlds. Our analysis revealed four existential lifeworlds: temporality: frozen in time; spatiality: no place, no space to grieve; corporeality: buried emotions; and relationality: never alone, yet feeling so lonely. The findings generated from this study can help mental health providers as well as correctional professionals develop policies and programs that facilitate the grief process of incarcerated women within the confines of imprisonment. C1 [Harner, Holly M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Hentz, Patricia M.] Univ Penn, Sch Nursing, Adv Practice Psychiat Mental Hlth Nursing Program, Philadelphia, PA 19104 USA. [Evangelista, Maria Carmela] Columbia Univ, Sch Nursing, New York, NY USA. RP Harner, HM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. EM harnerh@nursing.upenn.edu FU NINR NIH HHS [T32 NR007100] NR 35 TC 5 Z9 5 U1 1 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 J9 QUAL HEALTH RES JI Qual. Health Res. PD APR PY 2011 VL 21 IS 4 BP 454 EP 464 DI 10.1177/1049732310373257 PG 11 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA 738OY UT WOS:000288651900002 PM 20581074 ER PT J AU Chen, LLK Haneef, Z Dorsch, A Keselman, I Stern, JM AF Chen, Leo L. K. Haneef, Zulfi Dorsch, Andrew Keselman, Inna Stern, John M. TI Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Article DE Lacosamide; Levetiracetam; Focal status epilepticus; Simple partial status epilepticus; Refractory status epilepticus; Epilepsia partialis continua AB Lacosamide has been reported to have been successfully used for non-convulsive status epilepticus after benzodiazepine failure, and convulsive status epilepticus after benzodiazepine and levetiracetam failure. We report a case of simple motor status epilepticus refractory to benzodiazepines and multiple anti-epileptic medications (AEDs) over 4 days. The addition of lacosamide in combination with existing levetiracetam aborted the continuous seizure with maintenance of seizure freedom through the most recent follow-up at 4 weeks. Published by Elsevier Ireland Ltd on behalf of British Epilepsy Association. C1 [Chen, Leo L. K.; Haneef, Zulfi; Dorsch, Andrew; Keselman, Inna; Stern, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Chen, Leo L. K.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Chen, LLK (reprint author), 710 Westwood Plz Rm 1-240 Box 951769, Los Angeles, CA 90095 USA. EM llchen@mednet.ucla.edu FU UCB, Sepracor, Lundbeck; Cyberonics FX Dr. Stern has received support or served as a consultant for UCB, Sepracor, Lundbeck, and Cyberonics. The remaining authors report no conflicts of interest. NR 6 TC 17 Z9 17 U1 0 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1059-1311 J9 SEIZURE-EUR J EPILEP JI Seizure PD APR PY 2011 VL 20 IS 3 BP 263 EP 265 DI 10.1016/j.seizure.2010.11.004 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 742GL UT WOS:000288929200014 PM 21109468 ER PT J AU Fujitani, S George, WL Morgan, MA Nichols, S Murthy, AR AF Fujitani, Shigeki George, W. Lance Morgan, Margie A. Nichols, Stephen Murthy, A. Rekha TI Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Clostridium difficile; vancomycin-resistant Enterococcus; multidrug-resistant pathogens ID LIVER-TRANSPLANT CANDIDATES; INTENSIVE-CARE-UNIT; LONG-TERM-CARE; STAPHYLOCOCCUS-AUREUS; RISK-FACTORS; SURVEILLANCE; RECIPIENTS; DISEASE; COSTS AB Background: Vancomycin-resistant Enterococcus (VRE) colonization of the gastrointestinal tract shares similar risk factors with Clostridium difficile infection. We sought to elucidate the prevalence and risk factors of VRE colonization associated with C difficile infection. Methods: All adult inpatients with C difficile infection from July 2006 to October 2006 were prospectively evaluated. All C difficile toxin-positive stool samples were screened for detection of VRE. Risk factors for VRE colonization were compared in patients with C difficile infection with and without VRE colonization. Results: Of the 158 cases of C difficile infection evaluated, 88 (55.7%) involved VRE colonization. Independent risk factors for VRE colonization were admission from long-term care facilities (P = .013), dementia (P = .017), and hospitalization in the previous 2 months (P = .014). No statistically significant difference between C difficile infection cases with and without VRE colonization in terms of previous receipt (within 1 month) of antibiotics, including metronidazole and vancomycin, was found on multivariate analysis. C difficile infection cases with VRE colonization had a higher prevalence of coinfection with methicillin-resistant Staphylococcus aureus (P = .002) and Acinetobacter spp (P = .006). Conclusion: VRE colonization was associated with >50% of C difficile infection cases and with a higher rate of coinfection with multidrug-resistant pathogens. Given the high rate of C difficile infection associated with VRE colonization, active surveillance of VRE in patients with C difficile infection is reasonable in high-risk settings. C1 [Fujitani, Shigeki] St Marianna Univ Hosp, Dept Emergency & Crit Care Med, Miyamae Ku, Kanagawa, Japan. [Fujitani, Shigeki] Cedars Sinai Med Ctr, Div Infect Dis, Los Angeles, CA 90048 USA. [George, W. Lance] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Morgan, Margie A.; Nichols, Stephen; Murthy, A. Rekha] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Murthy, A. Rekha] Cedars Sinai Med Ctr, Dept Hosp Epidemiol, Los Angeles, CA 90048 USA. RP Fujitani, S (reprint author), St Marianna Univ Hosp, Dept Emergency & Crit Care Med, Miyamae Ku, 2-16-1 Sugao, Kanagawa, Japan. EM shigekifujitani@marianna-u.ac.jp FU Society's Young Fellow Award FX This study was presented at the 26th annual Infectious Diseases Society of America meeting, San Diego, California, October 5, 2007, and was awarded the Society's Young Fellow Award in 2007. NR 25 TC 11 Z9 11 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD APR PY 2011 VL 39 IS 3 BP 188 EP 193 DI 10.1016/j.ajic.2010.10.024 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 743ZQ UT WOS:000289060600004 PM 21458682 ER PT J AU Fitzgibbons, LN Puls, DL Mackay, K Forrest, GN AF Fitzgibbons, Lynn N. Puls, Darcy L. Mackay, Kimberly Forrest, Graeme N. TI Management of Gram-Positive Coccal Bacteremia and Hemodialysis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Staphylococcus aureus; hemodialysis; Enterococcus; catheter-related bacteremia; dialysis access-related infection ID STAPHYLOCOCCUS-AUREUS BACTEREMIA; CATHETER-RELATED BACTEREMIA; BLOOD-STREAM INFECTIONS; COAGULASE-NEGATIVE STAPHYLOCOCCI; RANDOMIZED CONTROLLED-TRIAL; VANCOMYCIN-RESISTANT ENTEROCOCCI; RENAL REPLACEMENT THERAPY; ANTIBIOTIC-LOCK THERAPY; ENDOCARDITIS MERGED DATABASE; SINGLE-CENTER EXPERIENCE AB Gram-positive cocci are the most common cause of bloodstream infections in hemodialysis patients, with Staphylococcus aureus and coagulase-negative staphylococci causing most infections. Management of these infections often is complicated by limited vascular access options, as well as an increasing prevalence of drug-resistant bacteria in hemodialysis centers, including the emergence of strains of methicillin-resistant S aureus with vancomycin heteroresistance and increasing rates of vancomycin-resistant enterococci, both of which have limited antibiotic treatment options. This article describes the management of these infections based on the organism and its susceptibility profile, including catheter management, antibiotic lock therapies, and systemic antibiotic choices. Although coagulase-negative staphylococci bacteremia often may be managed with preservation of the catheter, antibiotic lock therapy, and intravenous antibiotics, this is rarely the case with S aureus bacteremia because of frequent relapse and the risk of complications, including endocarditis. Enterococcal bacteremia requires more individualization of care, but catheters are less likely to be salvaged, especially when vancomycin-resistant Enterococcus is the causative organism. Finally, strong infection control policies in the hemodialysis unit, conversion from catheter to arteriovenous access when possible, and appropriate use of antibiotics are essential factors in the prevention of these bloodstream infections. Am J Kidney Dis. 57(4):624-640. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Forrest, Graeme N.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Fitzgibbons, Lynn N.; Puls, Darcy L.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Mackay, Kimberly] Portland VA Med Ctr, Dept Pharm, Portland, OR 97239 USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3701 SW US Vet Hosp Rd,P3-ID, Portland, OR 97239 USA. EM forrestg@ohsu.edu FU Cubist Pharmaceuticals Inc.; Pfizer Inc; Astellas Pharmaceuticals Inc FX Financial Disclosure: Dr Forrest had previously received research support and honoraria from Astellas Pharmaceuticals Inc (manufacturer of telavancin), Cubist Pharmaceuticals Inc (manufacturer of daptomycin), and Pfizer Inc (manufacturer of cefazolin and linezolid) between 2004 and 2007. He also had consulted for AdvanDx Inc (develops and markets PNA FISH tests) and Cepheid, which markets PCR-based in vitro diagnostic tests for S aureus. Currently, he receives research support from Cubist Pharmaceuticals Inc. The remaining authors report that they have no relevant financial interests. NR 173 TC 15 Z9 15 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2011 VL 57 IS 4 BP 624 EP 640 DI 10.1053/j.ajkd.2010.12.013 PG 17 WC Urology & Nephrology SC Urology & Nephrology GA 738QN UT WOS:000288657100387 PM 21333430 ER PT J AU Provenzano, LF Piraino, B Steenkiste, A Sevick, MA AF Provenzano, Laura Ferreira Piraino, Beth Steenkiste, Ann Sevick, Mary Ann TI SODIUM INTAKE IN TYPE 2 DM IS HIGH SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT 2011 Spring Clinical Meeting on National Kidney Foundation CY APR 26-30, 2011 CL Las Vegas, NV SP Natl Kidney Fdn C1 [Provenzano, Laura Ferreira; Piraino, Beth; Sevick, Mary Ann] Univ Pittsburgh, Pittsburgh, PA USA. [Steenkiste, Ann; Sevick, Mary Ann] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2011 VL 57 IS 4 MA 91 BP A39 EP A39 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 738QN UT WOS:000288657100092 ER PT J AU Figlewicz, DP Bennett-Jay, JL Kittleson, S Sipols, AJ Zavosh, A AF Figlewicz, Dianne P. Bennett-Jay, Jennifer L. Kittleson, Sepideh Sipols, Alfred J. Zavosh, Aryana TI Sucrose self-administration and CNS activation in the rat SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE food reward; c-Fos; hypothalamus ID VENTRAL TEGMENTAL AREA; BETA-ENDORPHIN LEVELS; NUCLEUS-ACCUMBENS; FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; LATERAL HYPOTHALAMUS; STRIA TERMINALIS; REWARD CIRCUITRY; CHRONIC STRESS; BED NUCLEUS AB We have previously reported that administration of insulin into the arcuate nucleus of the hypothalamus decreases motivation for sucrose, assessed by a self-administration task, in rats. Because the pattern of central nervous system (CNS) activation in association with sucrose self-administration has not been evaluated, in the present study, we measured expression of c-Fos as an index of neuronal activation. We trained rats to bar-press for sucrose, according to a fixed-ratio (FR) or progressive-ratio (PR) schedule and mapped expression of c-Fos immunoreactivity in the CNS, compared with c-Fos expression in handled controls. We observed a unique expression of c-Fos in the medial hypothalamus (the arcuate, paraventricular, retrochiasmatic, dorsomedial, and ventromedial nuclei) in association with the onset of PR performance, and expression of c-Fos in the lateral hypothalamus and the bed nucleus of stria terminalis in association with the onset of FR performance. c-Fos expression was increased in the nucleus accumbens of both FR and PR rats. Our study emphasizes the importance of both hypothalamic energy homeostasis circuitry and limbic circuitry in the performance of a food reward task. Given the role of the medial hypothalamus in regulation of energy balance, our study suggests that this circuitry may contribute to reward regulation within the larger context of energy homeostasis. C1 [Figlewicz, Dianne P.; Kittleson, Sepideh] VA Puget Sound Hlth Care Syst 151, Seattle, WA USA. [Figlewicz, Dianne P.; Bennett-Jay, Jennifer L.; Zavosh, Aryana] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Sipols, Alfred J.] Univ Latvia, Fac Med, Riga, Latvia. [Sipols, Alfred J.] Univ Latvia, Inst Expt & Clin Med, Riga, Latvia. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Metab Endocrinol 151, 1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu FU National Institutes of Health [DK40963]; Latvian Council of Science [04.1116] FX This research was supported by National Institutes of Health Grant DK40963. Dr. Dianne Figlewicz Lattemann is a Senior Research Career Scientist, Biomedical Laboratory Research Program, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington. Dr. Sipols is supported by Latvian Council of Science Grant 04.1116. NR 50 TC 14 Z9 14 U1 1 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR PY 2011 VL 300 IS 4 BP R876 EP R884 DI 10.1152/ajpregu.00655.2010 PG 9 WC Physiology SC Physiology GA 744GH UT WOS:000289082400011 PM 21307361 ER PT J AU Gvilia, I Suntsova, N Angara, B McGinty, D Szymusiak, R AF Gvilia, Irma Suntsova, Natalia Angara, Bryan McGinty, Dennis Szymusiak, Ronald TI Maturation of sleep homeostasis in developing rats: a role for preoptic area neurons SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE postnatal development; sleep-promoting systems; sleep homeostasis; preoptic hypothalamus ID C-FOS EXPRESSION; WAKING DISCHARGE PATTERNS; SLOW-WAVE SLEEP; SUPRACHIASMATIC NUCLEUS; INFANT RATS; PARAVENTRICULAR NUCLEUS; GALANINERGIC NEURONS; HYPOTHALAMUS; DEPRIVATION; INNERVATION AB The present study evaluated the hypothesis that developmental changes in hypothalamic sleep-regulatory neuronal circuits contribute to the maturation of sleep homeostasis in rats during the fourth postnatal week. In a longitudinal study, we quantified electrographic measures of sleep during baseline and in response to sleep deprivation (SD) on postnatal days 21/29 (P21/29) and P22/30 (experiment 1). During 24-h baseline recordings on P21, total sleep time (TST) during the light and dark phases did not differ significantly. On P29, TST during the light phase was significantly higher than during the dark phase. Mean duration of non-rapid-eye-movement (NREM) sleep bouts was significantly longer on P29 vs. P21, indicating improved sleep consolidation. On both P22 and P30, rats exhibited increased NREM sleep amounts and NREM electroencephalogram delta power during recovery sleep (RS) compared with baseline. Increased NREM sleep bout length during RS was observed only on P30. In experiment 2, we quantified activity of GABAergic neurons in median preoptic nucleus (MnPN) and ventrolateral preoptic area (VLPO) during SD and RS in separate groups of P22 and P30 rats using c-Fos and glutamic acid decarboxylase (GAD) immunohistochemistry. In P22 rats, numbers of Fos(+)GAD(+) neurons in VLPO did not differ among experimental conditions. In P30 rats, Fos(+)GAD(+) counts in VLPO were elevated during RS. MnPN neuronal activity was state-dependent in P22 rats, but Fos(+)GAD(+) cell counts were higher in P30 rats. These findings support the hypothesis that functional emergence of preoptic sleep-regulatory neurons contributes to the maturation of sleep homeostasis in the developing rat brain. C1 Vet Affairs Greater Los Angeles, Healthcare system, Res Serv 151A3, North Hills, CA 91344 USA. [Gvilia, Irma; Szymusiak, Ronald] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Suntsova, Natalia; McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Gvilia, Irma] Ilia State Univ, Tbilisi, Rep of Georgia. RP Gvilia, I (reprint author), Vet Affairs Greater Los Angeles, Healthcare system, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA. EM magvilia@hotmail.com FU Department of Veterans Affairs, National Institute of Mental Health [MH-63323, GNSF/ST09-722-6-274] FX This work was supported by the Department of Veterans Affairs, National Institute of Mental Health Grant MH-63323, and GNSF/ST09-722-6-274. NR 50 TC 10 Z9 10 U1 0 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR PY 2011 VL 300 IS 4 BP R885 EP R894 DI 10.1152/ajpregu.00727.2010 PG 10 WC Physiology SC Physiology GA 744GH UT WOS:000289082400012 PM 21325650 ER PT J AU Subramanya, AR Welling, PA AF Subramanya, Arohan R. Welling, Paul A. TI Toward an understanding of hypertension resistance SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article ID BLOOD-PRESSURE; ASSOCIATION; MECHANISMS C1 [Subramanya, Arohan R.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Sch Med, Pittsburgh, PA 15261 USA. [Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Welling, Paul A.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA. RP Subramanya, AR (reprint author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Sch Med, S828A Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM ars129@pitt.edu FU NIDDK NIH HHS [R01DK63049, RC1DK086817, R01DK54231, R01 DK054231, DK084566] NR 11 TC 3 Z9 3 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2011 VL 300 IS 4 BP F838 EP F839 DI 10.1152/ajprenal.00078.2011 PG 2 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 744LF UT WOS:000289095300004 PM 21325498 ER PT J AU Espinosa-Aguilar, L Green, JS Forrest, GN Ball, ED Maziarz, RT Strasfeld, L Taplitz, RA AF Espinosa-Aguilar, Luis Green, Jaime S. Forrest, Graeme N. Ball, Edward D. Maziarz, Richard T. Strasfeld, Lynne Taplitz, Randy Allison TI Novel H1N1 Influenza in Hematopoietic Stem Cell Transplantation Recipients: Two Centers' Experiences SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE 2009 Influenza virus; Immunocompromised; Lower respiratory tract infection ID RESPIRATORY VIRUS-INFECTIONS; CRITICALLY-ILL PATIENTS; NEW-YORK-CITY; A H1N1; HEMATOLOGIC MALIGNANCIES; MARROW-TRANSPLANTATION; HOSPITALIZED-PATIENTS; CLINICAL-FEATURES; ANTIVIRAL THERAPY; ADULT RECIPIENTS AB Respiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell transplantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in this patient population is not yet well defined, however. HSCT recipients diagnosed with proven or probable H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from two medical centers were identified. Fever and cough were the most common presenting symptoms. The incidence of influenza lower respiratory tract infection (LRTI) was 52% (14/27). Compared with patients with LRTI, those with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P = .03; 95% confidence interval [CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22% (6/27), and that in patients with LRTI was 43% (6/14). Chronic steroid use (>= 20 mg/day of prednisone equivalent) at the time of presentation was associated with LRTI (P = .006) and mortality (P = .003) on univariate analysis. Five cases were hospital-acquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality. Biol Blood Marrow Transplant 17: 566-573 (2011) (C) 2011 American Society for Blood and Marrow Transplantation C1 [Green, Jaime S.; Ball, Edward D.; Taplitz, Randy Allison] Univ Calif San Diego, La Jolla, CA 92093 USA. [Espinosa-Aguilar, Luis; Maziarz, Richard T.; Strasfeld, Lynne] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Forrest, Graeme N.] Portland VA Med Ctr, Portland, OR USA. RP Taplitz, RA (reprint author), Univ Calif San Diego, 3855 Hlth Sci Dr,0960, La Jolla, CA 92093 USA. EM rtaplitz@ucsd.edu NR 41 TC 16 Z9 16 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD APR PY 2011 VL 17 IS 4 BP 566 EP 573 DI 10.1016/j.bbmt.2010.07.018 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 742DJ UT WOS:000288920000014 PM 20708084 ER PT J AU Wilkin, TJ Goetz, MB Leduc, R Skowron, G Su, ZH Chan, ES Heera, J Chapman, D Spritzler, J Reeves, JD Gulick, RM Coakley, E AF Wilkin, Timothy J. Goetz, Mathew Bidwell Leduc, Robert Skowron, Gail Su, Zhaohui Chan, Ellen S. Heera, Jayyant Chapman, Doug Spritzler, John Reeves, Jacqueline D. Gulick, Roy M. Coakley, Eoin TI Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID TREATMENT-EXPERIENCED PATIENTS; HIV-1 INFECTION; NAIVE SUBJECTS; PROGRESSION; MARAVIROC; AIDS; CCR5 AB The enhanced-sensitivity Trofile assay (TF-ES; Monogram Biosciences) was used to retest coreceptor tropism samples from 4 different cohorts of HIV-1-infected patients. Nine percent to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. Lower CD4 cell counts were associated with CXCR4-using virus in all cohorts. C1 [Wilkin, Timothy J.; Gulick, Roy M.] Weill Cornell Med Coll, Div Infect Dis, New York, NY 10011 USA. [Chapman, Doug] Pfizer, New York, NY USA. [Goetz, Mathew Bidwell] Univ Calif Los Angeles, Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Mathew Bidwell] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Reeves, Jacqueline D.; Coakley, Eoin] Monogram Biosci, San Francisco, CA USA. [Leduc, Robert] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Skowron, Gail] Roger Williams Med Ctr, Div Infect Dis, Providence, RI USA. [Reeves, Jacqueline D.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Chan, Ellen S.; Spritzler, John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Su, Zhaohui] Outcome Sci, Cambridge, MA USA. [Heera, Jayyant] Pfizer Global Res & Dev, New London, CT USA. RP Wilkin, TJ (reprint author), Weill Cornell Med Coll, Div Infect Dis, New York, NY 10011 USA. EM tiw2001@med.cornell.edu RI Reeves, Jacqueline/I-5379-2012 FU NCRR NIH HHS [RR024996, UL1 RR024996]; NIAID NIH HHS [R44 AI050321, AI-46381, AI-68634, AI-69419, K23 AI055038, K23 AI55038, K24 AI051966, K24 AI51966, R44AI050321, U01 AI-42170, U01 AI-46362, U01 AI-68636, U01 AI-68641, U01 AI042170, U01 AI046362, U01 AI046381, U01 AI068634, U01 AI068636, U01 AI068641, U01 AI069419, UM1 AI068634, UM1 AI069419] NR 13 TC 32 Z9 32 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2011 VL 52 IS 7 BP 925 EP 928 DI 10.1093/cid/cir072 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 740NW UT WOS:000288802600018 PM 21427401 ER PT J AU Choi, AI Lo, JC Mulligan, K Schnell, A Kalapus, SC Li, YM Hunt, PW Martin, JN Deeks, SG Hsue, PY AF Choi, Andy I. Lo, Joan C. Mulligan, Kathleen Schnell, Amanda Kalapus, S. Craig Li, Yongmei Hunt, Peter W. Martin, Jeffrey N. Deeks, Steven G. Hsue, Priscilla Y. TI Association of Vitamin D Insufficiency with Carotid Intima-Media Thickness in HIV-Infected Persons SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID POPULATION; RISK AB We observed an independent association between vitamin D insufficiency and higher carotid intima-media thickness in a cross-sectional analysis of 139 HIV-infected persons. If confirmed, these findings support a clinical trial of vitamin D supplementation to reduce cardiovascular events in HIV-infected persons. C1 [Choi, Andy I.; Lo, Joan C.; Mulligan, Kathleen; Li, Yongmei; Hunt, Peter W.; Deeks, Steven G.; Hsue, Priscilla Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Choi, Andy I.; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Choi, Andy I.; Li, Yongmei] San Francisco VA Med Ctr, San Francisco, CA USA. [Mulligan, Kathleen; Schnell, Amanda; Kalapus, S. Craig; Hsue, Priscilla Y.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Hunt, Peter W.; Deeks, Steven G.] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA. [Lo, Joan C.] Kaiser Permanente Div Res, Oakland, CA USA. RP Hsue, PY (reprint author), San Francisco Gen Hosp, Dept Cardiol, Rm 5G1,1001 Potrero Ave, San Francisco, CA 94110 USA. EM phsue@medsfgh.ucsf.edu FU NCRR NIH HHS [KL2 RR024130, UL1 RR024131, UL1 RR024131-01]; NHLBI NIH HHS [R01 HL095130, R01HL095130]; NIAID NIH HHS [K23 AI065244, K23AI65244, P30 AI027763, K23AI066885, K24AI069994, K23 AI066885, K24 AI069994]; NIDDK NIH HHS [K23 DK080645, K23DK080645-01A1] NR 13 TC 32 Z9 33 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2011 VL 52 IS 7 BP 941 EP 944 DI 10.1093/cid/ciq239 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 740NW UT WOS:000288802600020 PM 21273298 ER PT J AU Flood, KL Brown, CJ Carroll, MB Locher, JL AF Flood, Kellie L. Brown, Cynthia J. Carroll, Maria B. Locher, Julie L. TI Nutritional processes of care for older adults admitted to an oncology-acute care for elders unit SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY LA English DT Review DE Cancer; Hospital nutritional support; OACE unit; Older adults ID PROTEIN-ENERGY UNDERNUTRITION; HOSPITALIZED MEDICAL PATIENTS; INCREASED LENGTH; MALNUTRITION; STAY; ADMISSION; CANCER; IMPACT; MASS AB Background: Acute care for elders (ACE) units have been established in the United States to prevent functional decline in older hospitalized patients. Purpose: We sought to examine whether an ace unit that focused specifically on care of older oncology patients (OACE) compared with a usual care cancer ward (UCCW) demonstrated improved nutritional processes of care in patients who had documentation of nutritional deficits. Methods: We conducted a retrospective chart review to examine whether orders had been placed for a nutritional consult or use of nutritional supplements. Logistic regression analyses, controlling for confounding variables, were conducted to evaluate differences between the wards. Results: OACE unit patients were 2.1 times more likely than UCCW patients to have a nutrition consult placed and 2.5 times more likely to have nutritional supplements ordered. Conclusions: An OACE unit model of care resulted in increased nutritional interventions. Future work is warranted to evaluate outcomes of care. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Locher, Julie L.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham, AL USA. [Flood, Kellie L.; Brown, Cynthia J.; Locher, Julie L.] UAB Ctr Aging, Birmingham, AL USA. [Brown, Cynthia J.] Birmingham Vet Affairs Med Ctr, Fall Prevent & Mobil Clin, Birmingham, AL USA. [Carroll, Maria B.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Locher, Julie L.] UAB Dept Hlth Care Org & Policy, Birmingham, AL USA. [Locher, Julie L.] UAB Lister Hill Ctr Hlth Policy, Birmingham, AL USA. RP Locher, JL (reprint author), CH19,Room 218F,1530 3rd Ave S, Birmingham, AL 35294 USA. EM jlocher@uab.edu FU Barnes-Jewish Hospital Foundation; Division of State, Community, and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Department of Health and Human Services [K01HP00079]; VA Research Career Development Award [E6329W] FX This work was supported by grants from the Barnes-Jewish Hospital Foundation and the Division of State, Community, and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Department of Health and Human Services under Grant No. K01HP00079 to Dr. Flood. Dr. Brown is a recipient of a VA Research Career Development Award (E6329W). The study sponsors had no role in the study design, collection, analysis, and interpretation of data; writing of manuscript; or decision to submit the manuscript for publication. NR 28 TC 2 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1040-8428 J9 CRIT REV ONCOL HEMAT JI Crit. Rev. Oncol./Hematol. PD APR PY 2011 VL 78 IS 1 BP 73 EP 78 DI 10.1016/j.critrevonc.2010.02.011 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 745CB UT WOS:000289140400007 PM 20299236 ER PT J AU Herman, J Chavalitdhamrong, D Jensen, DM Cortina, G Manuyakorn, A Jutabha, R AF Herman, J. Chavalitdhamrong, D. Jensen, D. M. Cortina, G. Manuyakorn, A. Jutabha, R. TI The significance of gastric and duodenal histological ischemia reported on endoscopic biopsy SO ENDOSCOPY LA English DT Article ID CHRONIC MESENTERIC ISCHEMIA; ABDOMINAL-PAIN; REVASCULARIZATION; GASTROPATHY; ULCERATION; INSUFFICIENCY; DISSECTION; INFARCTION; DISEASE; ARTERY AB Although frequently reported, it is unknown whether pathological reports of ischemia obtained from gastroduodenal biopsies suggest a diagnosis, prognosis or a requirement for additional evaluation. The aim of this study was to review the natural history, clinical presentation, endoscopic appearance, treatments, and major clinical outcomes of patients with gastroduodenal ischemia. A case series of 14 patients with variable etiologies (seven gastric and seven duodenal) was obtained from a search of our endoscopic pathological database for reports of histological ischemia. The results were as follows. The most common presentation was upper gastrointestinal bleeding (71%). Half of the endoscopic lesions appeared very severe (large or circumferential lesions, exudative, pseudomembranous, black or pale mucosa). There were six cases of rebleeding (43%) and four deaths (29%). Computed tomography scanning was frequently used (12 cases, 86%), but led to an underlying diagnosis in only three cases. In our series, patients with underlying vascular pathology have substantial 6-month mortality (29%). C1 [Herman, J.; Chavalitdhamrong, D.; Jensen, D. M.; Jutabha, R.] Digest Dis Res Ctr, CURE, Los Angeles, CA USA. [Jensen, D. M.; Jutabha, R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Jensen, D. M.; Jutabha, R.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Cortina, G.; Manuyakorn, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. RP Jutabha, R (reprint author), 100 UCLA Med Plaza,Suite 310, Los Angeles, CA 90095 USA. EM rjutabha@ucla.edu FU NIH-NIDDK Human Studies Core of NIH-NIDDK [AM41301]; CURE Digestive Diseases Research Center; NIH [02650] FX Dr. Jensen's contribution was partially supported by NIH-NIDDK Human Studies Core of NIH-NIDDK AM41301 CURE Digestive Diseases Research Center and an NIH K24 grant (02650). NR 30 TC 4 Z9 4 U1 0 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD APR PY 2011 VL 43 IS 4 BP 365 EP 368 DI 10.1055/s-0030-1256040 PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 743YP UT WOS:000289056300014 PM 21360426 ER PT J AU Bodhankar, S Wang, CH Vandenbark, AA Offner, H AF Bodhankar, Sheetal Wang, Chunhe Vandenbark, Arthur A. Offner, Halina TI Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE EAE; Estrogen; MS; Regulatory B cells ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; REGULATORY T-CELLS; PROGRAMMED DEATH 1; MULTIPLE-SCLEROSIS; MICE; DISEASE; ACTIVATION; PREGNANCY; PROTEIN; INTERLEUKIN-17 AB Increased remissions in multiple sclerosis (MS) during pregnancy suggest that elevated levels of sex steroids exert immunoregulatory activity. Estrogen (E2=17 beta-estradiol) protects against experimental autoimmune encephalomyelitis (EAE), but the cellular basis for E2-induced protection remains unclear. Studies demonstrate that depletion of B cells prior to induction of EAE exacerbates disease severity, implicating regulatory B cells. We thus evaluated pathogenic and E2-induced protective mechanisms in B-cell-deficient (mu MT-/-) mice. EAE-protective effects of E2 were abrogated in mu MT-/- mice, with no reduction in disease severity, cellular infiltration or pro-inflammatory factors in the central nervous system compared to untreated controls. E2 treatment of WT mice selectively upregulated expression of PD-L1 on B cells and increased the percentage of IL-10-producing CD1d(high)CD5(+) regulatory B cells. Upregulation of PD-L1 was critical for E2-mediated protection since E2 did not inhibit EAE in PD-L1(-/-) mice. Direct treatment of B cells with E2 significantly reduced proliferation of MOG(35-55)-specific T cells that required estrogen receptor-alpha (ER alpha). These results demonstrate, for the first time, a requirement for B cells in E2-mediated protection against EAE involving direct E2 effects on regulatory B cells mediated through ER alpha and the PD-1/PD-L1 negative co-stimulatory pathway. E2-primed B cells may represent an important regulatory mechanism in MS and have strong implications for women receiving current MS therapies that cause B-cell depletion. C1 [Offner, Halina] Portland VA Med Ctr, R&D 31, Portland, OR 97239 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH [NS45445, NS49210]; National Multiple Sclerosis Society [RG3405-C-6]; Biomedical Laboratory R&D Service, Department of Veterans' Affairs FX The authors thank Dr Sushmita Sinha and Ms Sandhya Subramanian for helpful discussions and Ms Eva Niehaus for assistance with manuscript preparation. This work was supported by NIH grants NS45445 and NS49210; National Multiple Sclerosis Society grant RG3405-C-6; and the Biomedical Laboratory R&D Service, Department of Veterans' Affairs. NR 41 TC 34 Z9 40 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD APR PY 2011 VL 41 IS 4 BP 1165 EP 1175 DI 10.1002/eji.201040992 PG 11 WC Immunology SC Immunology GA 740UX UT WOS:000288821000029 PM 21413005 ER PT J AU Park, J Konetzka, RT Werner, RM AF Park, Jeongyoung Konetzka, R. Tamara Werner, Rachel M. TI Performing Well on Nursing Home Report Cards: Does It Pay Off? SO HEALTH SERVICES RESEARCH LA English DT Article DE Public reporting; quality of care; nursing homes; financial performance ID COMPARE REPORT CARD; QUALITY-OF-CARE; LONG-TERM-CARE; UNINTENDED CONSEQUENCES; DISPARITIES; PUBLICATION; TRENDS AB Objective To examine whether high performance or improvement on quality measures leads to economic rewards for nursing homes in the presence of public reporting. Data Sources Data from 6,286 freestanding Medicare-certified nursing homes between 1999 and 2005 were identified in Medicare Cost Reports, Minimum Data Set, and Online Survey and Certification Reporting System. Study Design Using a facility-level fixed-effects model, the effect of public reporting on financial performance was measured by comparing each of four financial outcomes (revenues, expenses, operating, and total profit margins) before (1999-2002) to after (2003-2005) public reporting was initiated. The effects were estimated separately by level of performance and improvement over time. Principal Findings Facilities that improved on publicly reported performance had increased revenues and higher profit margins after public reporting, mainly through increased Medicare admissions. High-scoring facilities showed similar patterns, though differences were not statistically significant. Conclusions Providers that improve their performance under public reporting may receive a return on their investment in quality improvement. This supports the business case for public reporting. C1 [Park, Jeongyoung] Amer Board Internal Med, Philadelphia, PA 19106 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Park, J (reprint author), Amer Board Internal Med, 510 Walnut St,Suite 1700, Philadelphia, PA 19106 USA. EM jpark@abim.org FU Agency for Healthcare Research and Quality [R01 HS016478-01]; VA HSRD FX This research was funded by a grant from the Agency for Healthcare Research and Quality (R01 HS016478-01). Rachel M. Werner is supported in part by a VA HSR&D Career Development Award. An earlier version of the study was presented at the 2009 AcademyHealth Annual Research Meeting. NR 27 TC 6 Z9 6 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2011 VL 46 IS 2 BP 531 EP 554 DI 10.1111/j.1475-6773.2010.01197.x PG 24 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 729QL UT WOS:000287965600011 PM 21029093 ER PT J AU Werner, RM Konetzka, RT Stuart, EA Polsky, D AF Werner, Rachel M. Konetzka, R. Tamara Stuart, Elizabeth A. Polsky, Daniel TI Changes in Patient Sorting to Nursing Homes under Public Reporting: Improved Patient Matching or Provider Gaming? SO HEALTH SERVICES RESEARCH LA English DT Article DE Public reporting; quality of care; nursing home quality ID REPORT CARDS; PERFORMANCE DATA; QUALITY MEASURES; ASSESSMENTS; SURGERY; COMPARE; IMPACT; PAIN AB Objective To test whether public reporting in the setting of postacute care in nursing homes results in changes in patient sorting. Data Sources/Study Setting All postacute care admissions from 2001 to 2003 in the nursing home Minimum Data Set. Study Design We test changes in patient sorting (or the changes in the illness severity of patients going to high- versus low-scoring facilities) when public reporting was initiated in nursing homes in 2002. We test for changes in sorting with respect to pain, delirium, and walking and then examine the potential roles of cream skimming and downcoding in changes in patient sorting. We use a difference-in-differences framework, taking advantage of the variation in the launch of public reporting in pilot and nonpilot states, to control for underlying trends in patient sorting. Principal Findings There was a significant change in patient sorting with respect to pain after public reporting was initiated, with high-risk patients being more likely to go to high-scoring facilities and low-risk patients more likely to go to low-scoring facilities. There was also an overall decrease in patient risk of pain with the launch of public reporting, which may be consistent with changes in documentation of pain levels (or downcoding). There was no significant change in sorting for delirium or walking. Conclusions Public reporting of nursing home quality improves matching of high-risk patients to high-quality facilities. However, efforts should be made to reduce the incentives for downcoding by nursing facilities. C1 [Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Sch Med, Ctr Hlth Equ Res & Promot,Philadelphia VAMC, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Polsky, Daniel] Univ Penn, Div Gen Internal Med, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), Univ Penn, Div Gen Internal Med, Sch Med, Ctr Hlth Equ Res & Promot,Philadelphia VAMC, 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu OI Stuart, Elizabeth/0000-0002-9042-8611 FU Agency for Healthcare Research and Quality [R01 HS016478-01]; VA HSRD FX This research was funded by a grant from the Agency for Healthcare Research and Quality (R01 HS016478-01). Rachel M. Werner is supported in part by a VA HSR&D Career Development Award. NR 21 TC 9 Z9 9 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2011 VL 46 IS 2 BP 555 EP 571 DI 10.1111/j.1475-6773.2010.01205.x PG 17 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 729QL UT WOS:000287965600012 PM 21105869 ER PT J AU Alsanafi, S Kovarik, C Mermelstein, AL Werth, VP AF Alsanafi, Shamael Kovarik, Carrie Mermelstein, Andrew L. Werth, Victoria P. TI Rituximab in the Treatment of Bullous Systemic Lupus Erythematosus SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE bullous systemic lupus erythematosus; rituximab; CD20 antibody ID DEPLETION; LYMPHOMA; DISEASES; TRIAL AB Rituximab is a CD20 chimeric monoclonal antibody. It was approved by the US Food and Drug Administration for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin lymphoma and for the treatment of moderate to severely active rheumatoid arthritis. It has been used as an off-label treatment in many autoimmune diseases, where B cells play a major role in the pathogenesis. We report a case of successful use of rituximab in the treatment of refractory bullous systemic lupus erythematosus in an African American patient. C1 [Alsanafi, Shamael; Kovarik, Carrie; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Alsanafi, Shamael; Kovarik, Carrie; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Mermelstein, Andrew L.] Rheumatol Associates Ltd, E Norriton, PA USA. RP Alsanafi, S (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM dr_shamael@yahoo.com FU National Institutes of Health [K24-AR 02207]; Kuwaiti Government FX This study was supported in part by the National Institutes of Health (K24-AR 02207) to Dr Werth. It was also supported by a grant from the Kuwaiti Government (S.A.). NR 13 TC 10 Z9 14 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD APR PY 2011 VL 17 IS 3 BP 142 EP 144 DI 10.1097/RHU.0b013e318214f30c PG 3 WC Rheumatology SC Rheumatology GA 745EM UT WOS:000289148500007 PM 21441817 ER PT J AU Mandal, CC Ghosh-Choudhury, N Yoneda, T Choudhury, GG Ghosh-Choudhury, N AF Mandal, Chandi Charan Ghosh-Choudhury, Nayana Yoneda, Toshi Choudhury, Goutam Ghosh Ghosh-Choudhury, Nandini TI Simvastatin Prevents Skeletal Metastasis of Breast Cancer by an Antagonistic Interplay between p53 and CD44 SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NF-KAPPA-B; CELL-LINES; STEM-CELLS; LUNG METASTASIS; ANTICANCER AGENTS; BINDING PROTEIN; BONE METASTASES; MUTANT P53; EXPRESSION; GROWTH AB Substantial data from clinical trials and epidemiological studies show promising results for use of statins in many cancers, including mammary carcinoma. Breast tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological fracture. Here, we report that simvastatin acts as an inhibitor of osteolysis in a mouse model of breast cancer skeletal metastasis of human mammary cancer cell MDA-MB-231, which expresses the mutant p53R280K. Simvastatin and lovastatin attenuated migration and invasion of MDA-MB- 231 and BT-20 breast tumor cells in culture. Acquisition of phenotype to express the cancer stem cell marker, CD44, leads to invasive potential of the tumor cells. Interestingly, statins significantly decreased the expression of CD44 protein via a transcriptional mechanism. shRNA-mediated down-regulation of CD44 markedly reduced the migration and invasion of breast cancer cells in culture. We identified that in the MDA-MB-231 cells, simvastatin elevated the levels of mutated p53R280K, which was remarkably active as a transcription factor. shRNA-derived inhibition of mutant p53R280K augmented the expression of CD44, leading to increased migration and invasion. Finally, we demonstrate an inverse correlation between expression of p53 and CD44 in the tumors of mice that received simvastatin. Our results reveal a unique function of statins, which foster enhanced expression of mutant p53R280K to prevent breast cancer cell metastasis to bone. C1 [Yoneda, Toshi; Choudhury, Goutam Ghosh; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Mandal, Chandi Charan; Ghosh-Choudhury, Nayana; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhury@uthscsa.edu; choudhuryg@uthscsa.edu; choudhury@uthscsa.edu FU National Institutes of Health [RO1 AR52425, ROI DK50190]; Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants RO1 AR52425 (to N.G.-C.) and ROI DK50190 (to G.G.C.) This work was also supported by Veterans Affairs merit review grants (to N.G.-C. and G.G.C.). NR 71 TC 44 Z9 45 U1 1 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 1 PY 2011 VL 286 IS 13 BP 11314 EP 11327 DI 10.1074/jbc.M110.193714 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 740LW UT WOS:000288797100044 PM 21199873 ER PT J AU Alef, MJ Vallabhaneni, R Carchman, E Morris, SM Shiva, S Wang, YN Kelley, EE Tarpey, MM Gladwin, MT Tzeng, E Zuckerbraun, BS AF Alef, Matthew J. Vallabhaneni, Raghuveer Carchman, Evie Morris, Sidney M., Jr. Shiva, Sruti Wang, Yinna Kelley, Eric E. Tarpey, Margaret M. Gladwin, Mark T. Tzeng, Edith Zuckerbraun, Brian S. TI Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID MUSCLE-CELL-PROLIFERATION; OXIDE SYNTHASE GENE; SELECTIVE PULMONARY VASODILATOR; ORAL L-ARGININE; DIETARY NITRATE; IN-VIVO; NEOINTIMA FORMATION; ISCHEMIA/REPERFUSION INJURY; XANTHINE OXIDOREDUCTASE; ISCHEMIA-REPERFUSION AB Vascular disease, a significant cause of morbidity and mortality in the developed world, results from vascular injury. Following vascular injury, damaged or dysfunctional endothelial cells and activated SMCs engage in vasoproliferative remodeling and the formation of flow-limiting intimal hyperplasia (IH). We hypothesized that vascular injury results in decreased bioavailability of NO secondary to dysregulated arginine-dependent NO generation. Furthermore, we postulated that nitrite-dependent NO generation is augmented as an adaptive response to limit vascular injury/proliferation and can be harnessed for its protective effects. Here we report that sodium nitrite (intraperitoneal, inhaled, or oral) limited the development of IH in a rat model of vascular injury. Additionally, nitrite led to the generation of NO in vessels and SMCs, as well as limited SMC proliferation via p21(Waf1/Cip1) signaling. These data demonstrate that IH is associated with increased arginase-1 levels, which leads to decreased NO production and bioavailability. Vascular injury also was associated with increased levels of xanthine oxidoreductase (XOR), a known nitrite reductase. Chronic inhibition of XOR and a diet deficient in nitrate/nitrite each exacerbated vascular injury. Moreover, established IH was reversed by dietary supplementation of nitrite. The vasoprotective effects of nitrite were counteracted by inhibition of XOR. These data illustrate the importance of nitrite-generated NO as an endogenous adaptive response and as a pathway that can be harnessed for therapeutic benefit. C1 [Alef, Matthew J.; Vallabhaneni, Raghuveer; Carchman, Evie; Tzeng, Edith; Zuckerbraun, Brian S.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Morris, Sidney M., Jr.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA. [Shiva, Sruti; Wang, Yinna; Kelley, Eric E.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. [Tarpey, Margaret M.] Univ Pittsburgh, Sch Med, Dept Anesthesia, Dept Med, Pittsburgh, PA 15261 USA. [Tarpey, Margaret M.; Tzeng, Edith; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gladwin, Mark T.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. RP Tzeng, E (reprint author), A1010 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM tzenge@upmc.edu; zuckerbraunbs@upmc.edu RI Morris, Sidney/I-3440-2015 FU American Heart Association [09GRNT2050220]; NIH [R01HL098032, RO1HL096973, RC1DK085852, R01GM57384]; Institute for Transfusion Medicine; Hemophilia Center of Western Pennsylvania FX We are appreciative of the excellent technical assistance of Diane Kepka-Lenhart. This work was supported in part by the American Heart Association, Great Rivers Affiliate grant 09GRNT2050220 (to B.S. Zuckerbraun); NIH grants R01HL098032, RO1HL096973, and RC1DK085852 (to M.T. Gladwin) and R01GM57384 (to S.M. Morris); and the Institute for Transfusion Medicine and the Hemophilia Center of Western Pennsylvania (to M.T. Gladwin). NR 63 TC 55 Z9 59 U1 1 U2 6 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2011 VL 121 IS 4 BP 1646 EP 1656 DI 10.1172/JCI44079 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 745OK UT WOS:000289174600045 PM 21436585 ER PT J AU Cordasco, KM Ponce, NA Gatchell, MS Traudt, B Escarce, JJ AF Cordasco, Kristina M. Ponce, Ninez A. Gatchell, Melissa S. Traudt, Brandon Escarce, Jose J. TI English Language Proficiency and Geographical Proximity to a Safety Net Clinic as a Predictor of Health Care Access SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article; Proceedings Paper CT Academy Health Annual Research Meeting CY JUN 08-10, 2008 CL Washington, DC SP Acad Hlth DE Linguistic disparities; Access to care; Uninsured; Health care safety net; Geographic analysis; Secondary analysis ID INSURANCE-COVERAGE; UNINSURED ADULTS; UNITED-STATES; MEDICAL-CARE; DISPARITIES; CHILDREN; CONTINUITY; SERVICES; LATINOS; NEEDS AB Studies suggest that proximity to a safety net clinic (SNC) promotes access to care among the uninsured. Distance-based barriers to care may be greater for people with limited English proficiency (LEP), compared to those who are English proficient (EP), but this has not been explored. We assessed the relationship between distance to the nearest SNC and access in non-rural uninsured adults in California, and examined whether this relationship differs by language proficiency. Using the 2005 California Health Interview Survey and a list we compiled of California's SNCs, we calculated distance between uninsured interviewee residence and the exact address of the nearest SNC. Using multivariate regression to adjust for other relevant characteristics, we examined associations between this distance and interviewee's probability of having a usual source of health care (USOC) and having visited a physician in the prior 12 months. To examine differences by language proficiency, we included interactions between distance and language proficiency. Uninsured LEP adults living within 2 miles of a SNC were 9.3% less likely than their EP counterparts to have a USOC (P = 0.046). Further, distance to the nearest SNC was inversely associated with the probability of having a USOC among LEP, but not among EP; consequently, the difference between LEP and EP in the probability of having a USOC widened with increasing distance to the nearest SNC. There was no difference between LEP and EP adults living within 2 miles of a SNC in likelihood of having a physician visit; however, as with USOC, distance to the nearest SNC was inversely associated with the probability of having a physician visit among LEP but not EP. The effect sizes diminished, but remained significant, when we included county fixed effects in the models. Having LEP is a barrier to health care access, which compounds when combined with increased distance to the nearest SNC, among uninsured adults. Future studies should explore potential mechanisms so that appropriate interventions can be implemented. C1 [Cordasco, Kristina M.] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. [Cordasco, Kristina M.; Escarce, Jose J.] Univ Calif Los Angeles, Dept Med, Sch Med, Los Angeles, CA 90073 USA. [Ponce, Ninez A.; Gatchell, Melissa S.; Traudt, Brandon] Univ Calif Los Angeles, Sch Publ Hlth, Ctr Hlth Policy Res, Los Angeles, CA 90095 USA. [Cordasco, Kristina M.; Escarce, Jose J.] RAND Corp, Santa Monica, CA USA. [Traudt, Brandon] So Calif Permanente Med Grp, Dept Clin Anal, Pasadena, CA 91188 USA. [Escarce, Jose J.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RP Cordasco, KM (reprint author), Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM kcordasco@mednet.ucla.edu; nponce@ucla.edu; gatchell@ucla.edu; Brandon.C.Traudt@kp.org; jescarce@mednet.ucla.edu OI Ponce, Ninez/0000-0001-5151-6718 FU NCI NIH HHS [K07 CA100097, K07 CA100097-01A2] NR 35 TC 18 Z9 18 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD APR PY 2011 VL 13 IS 2 BP 260 EP 267 DI 10.1007/s10903-010-9425-6 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 733IQ UT WOS:000288256800010 PM 21170588 ER PT J AU Mendez, M Shapira, JS AF Mendez, Mario Shapira, Jill S. TI Pedophilic Behavior from Brain Disease SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Pedophilia; Hypersexuality; Brain Disorders; Child Molestation ID VISUAL SEXUAL STIMULI; TEMPORAL-LOBE EPILEPSY; KLUVER-BUCY SYNDROME; FRONTOTEMPORAL DEMENTIA; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; PREFRONTAL CORTEX; ACTIVATION; HYPERSEXUALITY; AMYGDALA AB Introduction. Child molestation or other pedophilic behavior may result as a consequence of a brain disorder. Aim. To characterize the mechanisms of pedophilic behavior associated with neurological diseases. Methods. We report eight patients with pedophilic behavior as a manifestation of their brain disorder and review the literature. Main Outcome Measures. The sexual, neuropsychiatric, and neurological aspects of a series of patients. Results. All eight developed sexual behavior toward prepubescent children in mid- to late-life coincident with the development of a neurological disorder. Five had limited insight, anxiety, or concern for their behavior and tended to have frontal lobe executive deficits. Most of this group had frontally predominant disorders. Two others retained insight and concern in the context of marked hypersexuality. This second group had treated Parkinson's disease and resembled reports of pedophilic behavior from subcortical lesions. The further presence of right temporal lobe-amygdala involvement may have predisposed to specific sexual preoccupation in some patients. Conclusions. Brain disorders may release a predisposition to sexual attraction for children through disinhibition with frontal disease, sexual preoccupation with right temporal disease, or hypersexuality with subcortical disease in non-motor basal ganglia, hypothalamus, or septal nuclei. Differentiating these mechanisms of pedophilic behavior from brain disease could facilitate targeted interventions. Mendez M and Shapira JS. Pedophilic behavior from brain disease. J Sex Med 2011;8:1092-1100. C1 [Mendez, Mario] UCLA Neurol & Psychiat, Neurol Clin, Los Angeles, CA 90095 USA. [Mendez, Mario] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shapira, Jill S.] UCLA Neurol, Los Angeles, CA USA. RP Mendez, M (reprint author), UCLA Neurol & Psychiat, Neurol Clin, 300 UCLA Med Plaza, Los Angeles, CA 90095 USA. EM mmendez@ucla.edu NR 72 TC 19 Z9 19 U1 2 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 J9 J SEX MED JI J. Sex. Med. PD APR PY 2011 VL 8 IS 4 BP 1092 EP 1100 DI 10.1111/j.1743-6109.2010.02172.x PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 744SS UT WOS:000289115400016 PM 21235721 ER PT J AU Ayer, L Danielson, CK Amstadter, AB Ruggiero, K Saunders, B Kilpatrick, D AF Ayer, Lynsay Danielson, Carla Kmett Amstadter, Ananda B. Ruggiero, Ken Saunders, Ben Kilpatrick, Dean TI Latent Classes of Adolescent Posttraumatic Stress Disorder Predict Functioning and Disorder After 1 Year SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE posttraumatic stress disorder; functional impairment; latent class analysis ID NATIONAL COMORBIDITY SURVEY; CONFIRMATORY FACTOR-ANALYSIS; SURVEY REPLICATION; MENTAL-HEALTH; PTSD; PREVALENCE; SYMPTOMS; SAMPLES; INSTRUMENTS; IMPAIRMENT AB Objective: To identify latent classes of posttraumatic stress disorder (PTSD) symptoms in a national sample of adolescents, and to test their associations with PTSD and functional impairment 1 year later. Method: A total of 1,119 trauma-exposed youth aged 12 through 17 years (mean = 14.99 years, 51% female and 49% male) participating in the National Survey of Adolescents Replication were included in this study. Telephone interviews were conducted to assess PTSD symptoms and functional impairment at Waves 1 and 2. Results: Latent Class Analysis revealed three classes of adolescent PTSD at each time point: pervasive disturbance, intermediate disturbance, and no disturbance. Three numbing and two hyperarousal symptoms best distinguished the pervasive and intermediate disturbance classes at Wave 1. Three re-experiencing, one avoidance, and one hyperarousal symptom best distinguished these classes at Wave 2. The Wave 1 intermediate disturbance class was less likely to have a PTSD diagnosis, belong to the Wave 2 pervasive disturbance class, and report functional impairment 1 year later compared with the Wave 1 pervasive disturbance class. The Wave 1 no disturbance class was least likely to have PTSD, belong to the pervasive disturbance class, and report functional impairment at Wave 2. Conclusions: This study suggests that PTSD severity distinguishing symptoms change substantially in adolescence and are not characterized by the numbing cluster, contrary to studies in adult samples. These results may help to explain inconsistent factor analytic findings on the structure and diagnosis of PTSD, and emphasize that developmental context is critical to consider in both research and clinical work in PTSD assessment and diagnosis. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(4):364-375. C1 [Ayer, Lynsay] Univ Vermont, Dept Psychiat, Vermont Ctr Children Youth & Families, Burlington, VT 05401 USA. [Danielson, Carla Kmett; Ruggiero, Ken; Saunders, Ben; Kilpatrick, Dean] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Ken] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. RP Ayer, L (reprint author), Univ Vermont, Dept Psychiat, Vermont Ctr Children Youth & Families, Room 3213,1 S Prospect St, Burlington, VT 05401 USA. EM Lynsay.Ayer@uvm.edu OI Ayer, Lynsay/0000-0003-1111-8197 FU National Institute of Child Health and Human Development [1R01 HD046830-01]; [K23DA018686]; [R21MH086313]; [R01 MH81056]; [5RC2MH089995-02] FX This research was supported by National Institute of Child Health and Human Development Grant 1R01 HD046830-01 (PI: D.G.K.). The preparation of this article was partially supported by Grant K23DA018686 (C.K.D.), Grant R21MH086313 (C.K.D.), grant R01 MH81056 (KR.), and Grant 5RC2MH089995-02 (PI: James J. Hudziak). NR 45 TC 21 Z9 22 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD APR PY 2011 VL 50 IS 4 BP 364 EP 375 DI 10.1016/j.jaac.2011.01.004 PG 12 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 742EV UT WOS:000288925000008 PM 21421176 ER PT J AU Mendez, MF Fras, IA AF Mendez, M. F. Fras, I. A. TI The false memory syndrome: Experimental studies and comparison to confabulations SO MEDICAL HYPOTHESES LA English DT Article ID REPORTING RECOVERED MEMORIES; STRATEGIC RETRIEVAL; DRM PARADIGM; TRUE MEMORY; BRAIN; RECOLLECTION; RECOGNITION; DISTORTION; DEFICITS; LESIONS AB False memories, or recollections that are factually incorrect but strongly believed, remain a source of confusion for both psychiatrists and neurologists. We propose model for false memories based on recent experimental investigations, particularly when analyzed in comparison to confabulations, which are the equivalent of false memories from neurological disease. Studies using the Deese/Roedinger-McDermott experimental paradigm indicate that false memories are associated with the need for complete and integrated memories, self-relevancy, imagination and wish fulfillment, familiarity, emotional facilitation, suggestibility, and sexual content. In comparison, confabulations are associated with the same factors except for emotional facilitation, suggestibility, and sexual content. Both false memories and confabulations have an abnormal sense of certainty for their recollections, and neuroanatomical findings implicate decreased activity in the ventromedial frontal lobe in this certainty. In summary, recent studies of false memories in comparison to confabulations support a model of false memories as internally-generated but suggestible and emotionally-facilitated fantasies or impulses, rather than repressed memories of real events. Furthermore, like confabulations, in order for false memories to occur there must be an attenuation of the normal, nonconscious, right frontal "doubt tag" regarding their certainty. Published by Elsevier Ltd. C1 VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU [R01AG034499-02] FX This work was supported by Grant #R01AG034499-02. NR 77 TC 3 Z9 3 U1 3 U2 23 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0306-9877 J9 MED HYPOTHESES JI Med. Hypotheses PD APR PY 2011 VL 76 IS 4 BP 492 EP 496 DI 10.1016/j.mehy.2010.11.033 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 742FK UT WOS:000288926500010 PM 21177042 ER PT J AU Sen, HN Sangave, AA Goldstein, DA Suhler, EB Cunningham, D Vitale, S Nussenblatt, RB AF Sen, H. Nida Sangave, Amit A. Goldstein, Debra A. Suhler, Eric B. Cunningham, Denise Vitale, Susan Nussenblatt, Robert B. TI A Standardized Grading System for Scleritis SO OPHTHALMOLOGY LA English DT Article ID UVEITIS; INFLAMMATION; AGREEMENT AB Objective: This study evaluated the performance of a standardized grading system for scleritis using standard digital photographs. Design: Cross-sectional interobserver agreement study. Participants: Photo archives from the National Eye Institute. Methods: Three uveitis specialists from 3 different centers graded 79 randomly arranged images of the sclera with various degrees of inflammation. Grading was done using standard screen resolution (1024x768 pixels) on a 0 to 4+ scale in 2 sessions: (1) without using reference photographs and (2) with reference to a set of standard photographs (proposed grading system). The graders were masked to the order of images, and the order of images was randomized. Interobserver agreement in grading the severity of inflammation with and without the use of grading system was evaluated. Main Outcome Measures: Interobserver agreement. Results: The proposed grading system for assessing activity in scleritis demonstrated a good interobserver agreement. Interobserver agreement (pooled kappa) was poor (0.289) without photographic guidance and improved substantially when the "grading system" with standardized photographs was used (kappa = 0.603). Conclusions: This system of standardized images for scleritis grading provides significantly more consistent grading of scleral inflammation in this study and has clear applications in clinical settings and clinical research. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011;118:768-771 (C) 2011 by the American Academy of Ophthalmology. C1 [Sen, H. Nida; Sangave, Amit A.; Cunningham, Denise; Vitale, Susan; Nussenblatt, Robert B.] NEI, NIH, Bethesda, MD 20892 USA. [Goldstein, Debra A.] Univ Illinois, Chicago, IL USA. [Suhler, Eric B.] Oregon Hlth & Sci Univ, Portland, OR USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. RP Sen, HN (reprint author), NEI, NIH, 10 Ctr Dr,Bldg 10,Room 10N112, Bethesda, MD 20892 USA. EM senh@nei.nih.gov FU Celgene; Abbott; Genentech; Novartis; Department of Veterans' Affairs; National Eye Institute FX Dr Eric Suhler receives financial support from Celgene, Abbott, Genentech, Novartis, and the Department of Veterans' Affairs, and institutional support from Research to Prevent Blindness.; Supported by the National Eye Institute Intramural research program support (HNS, RBN, AS, SV). NR 9 TC 13 Z9 15 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD APR PY 2011 VL 118 IS 4 BP 768 EP 771 DI 10.1016/j.ophtha.2010.08.027 PG 4 WC Ophthalmology SC Ophthalmology GA 744DS UT WOS:000289075200025 PM 21093921 ER PT J AU Sher, L AF Sher, Leo TI Is it possible to predict suicide? SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA. NR 7 TC 0 Z9 0 U1 1 U2 3 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0004-8674 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD APR PY 2011 VL 45 IS 4 PG 1 WC Psychiatry SC Psychiatry GA 736OK UT WOS:000288503800012 ER PT J AU Taylor, L Zhou, XH AF Taylor, Leslie Zhou, Xiao-Hua TI Methods for clustered encouragement design studies with noncompliance and missing data SO BIOSTATISTICS LA English DT Article DE Causal inference; Clustered encouragement design; Complier average causal effect; Missing data; Multiple imputation; Noncompliance; Nonresponse; Principal stratification ID PRINCIPAL STRATIFICATION APPROACH; BROKEN RANDOMIZED EXPERIMENTS; CHRONIC HEART-FAILURE; TO-TREAT ANALYSIS; CLINICAL-TRIALS; BAYESIAN-INFERENCE; CAUSAL INFERENCE; POTENTIAL OUTCOMES; IGNORABILITY; NONRESPONSE AB Encouragement design studies are particularly useful for estimating the effect of an intervention that cannot itself be randomly administered to some and not to others. They require a randomly selected group receive extra encouragement to undertake the treatment of interest, where the encouragement typically takes the form of additional information or incentives. We consider a "clustered encouragement design" (CED), where the randomization is at the level of the clusters (e.g. physicians), but the compliance with assignment is at the level of the units (e.g. patients) within clusters. Noncompliance and missing data are particular problems in encouragement design studies, where encouragement to take the treatment, rather than the treatment itself, is randomized. The motivating study looks at whether computer-based care suggestions can improve patient outcomes in veterans with chronic heart failure. Since physician adherence has been inadequate, the original study focused on methods to improve physician adherence, although an equally important question is whether physician adherence improves patient outcomes. Here, we reanalyze the data to determine the effect of physician adherence on patient outcomes. We propose causal inference methodology for the effect of a treatment versus a control in a randomized CED study with all-or-none compliance at the unit level. These methods extend the current approaches to account for nonignorable missing data and use an alternative approach to inference using multiple imputation methods, which have been successfully applied to a wide variety of missing data problems and have recently been applied to the potential outcomes framework of causal inference (Taylor and Zhou, 2009b). C1 [Taylor, Leslie; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Taylor, Leslie; Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, Biostat Unit, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA. EM taylorl@u.washington.edu; azhou@u.washington.edu FU VA Puget Sound Health Care System; Dr. Zhou's VA Research Career Scientist Award [RCD 05-196] FX The VA Puget Sound Health Care System and Dr. Zhou's VA Research Career Scientist Award (RCD 05-196). NR 37 TC 1 Z9 1 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1465-4644 J9 BIOSTATISTICS JI Biostatistics PD APR PY 2011 VL 12 IS 2 BP 313 EP 326 DI 10.1093/biostatistics/kxq065 PG 14 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 740ND UT WOS:000288800600010 PM 20974677 ER PT J AU Laghi, F AF Laghi, Franco TI Ventilator-induced diaphragmatic dysfunction: Is there a dim light at the end of the tunnel? SO CRITICAL CARE MEDICINE LA English DT Editorial Material ID ANTIOXIDANT SUPPLEMENTATION; FAILURE; HUMANS; DISUSE; MUSCLE; TRIAL C1 [Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Laghi, Franco] Loyola Univ, Maywood, IL 60153 USA. RP Laghi, F (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 16 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2011 VL 39 IS 4 BP 903 EP 905 DI 10.1097/CCM.0b013e31820a5135 PG 3 WC Critical Care Medicine SC General & Internal Medicine GA 736ZD UT WOS:000288533000055 PM 21613847 ER PT J AU Dionne, KR Leser, JS Lorenzen, KA Beckham, JD Tyler, KL AF Dionne, Kalen R. Leser, J. Smith Lorenzen, Kristi A. Beckham, J. David Tyler, Kenneth L. TI A brain slice culture model of viral encephalitis reveals an innate CNS cytokine response profile and the therapeutic potential of caspase inhibition SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Reovirus; Virus; Viral; Apoptosis; Caspase; Encephalitis; Neuron; Ex vivo; Organotypic; Brain slice; Cytokine; IL6; KC; IL8; CXCL10; RANTES; Q-VD-OPh ID CENTRAL-NERVOUS-SYSTEM; HERPES-SIMPLEX-VIRUS; ORGANOTYPIC HIPPOCAMPAL CULTURES; N-TERMINAL KINASE; JAPANESE ENCEPHALITIS; REOVIRUS INFECTION; CELL-DEATH; IN-VITRO; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE AB Viral encephalitis is a significant cause of human morbidity and mortality in large part due to suboptimal diagnosis and treatment. Murine reovirus infection serves as a classic experimental model of viral encephalitis. Infection of neonatal mice with T3 reoviruses results in lethal encephalitis associated with neuronal infection, apoptosis, and CNS tissue injury. We have developed an ex vivo brain slice culture (BSC) system that recapitulates the basic pathological features and kinetics of viral replication seen in vivo. We utilize the BSC model to identify an innate, brain-tissue specific inflammatory cytokine response to reoviral infection, which is characterized by the release of IL6, CXCL10, RANTES, and murine IL8 analog (KC). Additionally, we demonstrate the potential utility of this system as a pharmaceutical screening platform by inhibiting reovirus-induced apoptosis and CNS tissue injury with the pan-caspase inhibitor, Q-VD-OPh. Cultured brain slices not only serve to model events occurring during viral encephalitis, but can also be utilized to investigate aspects of pathogenesis and therapy that are not experimentally accessible in vivo. Published by Elsevier Inc. C1 [Leser, J. Smith; Beckham, J. David; Tyler, Kenneth L.] Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. [Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado Denver, Med Scientist Training Program, Aurora, CO 80045 USA. [Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado Denver, Neurosci Program, Aurora, CO 80045 USA. [Lorenzen, Kristi A.; Beckham, J. David; Tyler, Kenneth L.] Univ Colorado Denver, Dept Med, Aurora, CO 80045 USA. [Beckham, J. David; Tyler, Kenneth L.] Univ Colorado Denver, Dept Microbiol, Aurora, CO 80045 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Tyler, KL (reprint author), Univ Colorado Denver, Dept Neurol, Res Complex 2,12700 E 19th Ave,B182, Aurora, CO 80045 USA. EM Ken.Tyler@UCDenver.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU VA; Mentored Clinical Science Development award [5K08AI076518, 5K08AI076518-02S1, 5K08AI076518-03S1]; MST Program [T32 GM008497]; National Research Service [F30 NS071630]; [RO1NS050138]; [RO1NS051403] FX This work was supported by RO1NS050138 (K.L.T), RO1NS051403 (K.L.T), and a VA Merit Grant (K.L.T).; J.D.B. was supported by a Mentored Clinical Science Development award (5K08AI076518, 5K08AI076518-02S1, and 5K08AI076518-03S1).; K.R.D. was supported by an institutional MST Program training grant (T32 GM008497) and a National Research Service Award for Predoctoral MD/PhD Fellows (F30 NS071630). NR 60 TC 14 Z9 14 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 2011 VL 228 IS 2 BP 222 EP 231 DI 10.1016/j.expneurol.2011.01.006 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 740YI UT WOS:000288829900010 PM 21241693 ER PT J AU Kanwal, F Hoang, T Kramer, JR Asch, SM Goetz, MB Zeringue, A Richardson, P El-Serag, HB AF Kanwal, Fasiha Tuyen Hoang Kramer, Jennifer R. Asch, Steven M. Goetz, Matthew Bidwell Zeringue, Angelique Richardson, Peter El-Serag, Hashem B. TI Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection SO GASTROENTEROLOGY LA English DT Article DE Liver Cancer; Epidemiology; Virology ID CHRONIC LIVER-DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-B-HEPATITIS; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; NON-A; VETERANS; FIBROSIS; PROGRESSION AB BACKGROUND & AIMS: Patients with hepatitis C virus (HCV) infection are at risk for developing costly and morbid complications, although the actual prevalence of these complications is unknown. We examined time trends in the prevalence of cirrhosis and its related complications, such as hepatic decompensation and hepatocellular carcinoma (HCC). METHODS: We calculated the annual prevalence of cirrhosis, decompensated cirrhosis, and HCC in a national sample of veterans diagnosed with HCV between 1996 and 2006. Patients with HCV who had at least one physician visit in a given calendar year were included in the analysis of prevalence for that year. We used direct standardization to adjust the prevalence of cirrhosis and related complications for increasing age of the cohort as well as sex and changes in clinical characteristics. RESULTS: In this cohort, the number of individuals with HCV increased from 17,261 in 1996 to 106,242 in 2006. The prevalence of cirrhosis increased from 9% in 1996 to 18.5% in 2006. The prevalence of patients with decompensated cirrhosis doubled, from 5% in 1996 to 11% in 2006, whereas the prevalence of HCC increased approximately 20-fold (0.07% in 1996 to 1.3% in 2006). After adjustment, the time trend in the prevalence of cirrhosis (and its complications) was lower than the crude trend, although it still increased significantly. CONCLUSIONS: The prevalence of cirrhosis and HCC in HCV-infected patients has increased significantly over the past 10 years. An aging cohort of patients with HCV could partly explain our findings. Clinicians and health care systems should develop strategies to provide timely and effective care to this high-risk population of patients. C1 [Kanwal, Fasiha; Zeringue, Angelique] John Cochran VA Med Ctr, Dept Gastroenterol & Hepatol, St Louis, MO USA. [Kanwal, Fasiha] St Louis Univ, Sch Med, St Louis, MO USA. [Tuyen Hoang; Asch, Steven M.; Goetz, Matthew Bidwell] Greater Los Angeles VA Healthcare Syst, Dept Med & Hlth Serv Res, Los Angeles, CA USA. [Kramer, Jennifer R.; Richardson, Peter; El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Hlth Serv Res & Dev Serv, Houston, TX USA. [Kramer, Jennifer R.; Richardson, Peter; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Asch, Steven M.; Richardson, Peter; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Asch, Steven M.; Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Kanwal, F (reprint author), St Louis VA Med Ctr, 915 N Grand,111-JC-GI, St Louis, MO 63141 USA. EM fasiha.kanwal@va.gov RI Zeringue, Angelique/I-1755-2012 OI Goetz, Matthew/0000-0003-4542-992X FU Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs [IIR-07-111, K24DK078154-03, R01CA125487-03] FX Supported in part by Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs, grant IIR-07-111 (to F. K.) and K24DK078154-03 and R01CA125487-03 (to H.B.E.). NR 35 TC 167 Z9 174 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2011 VL 140 IS 4 BP 1182 EP + DI 10.1053/j.gastro.2010.12.032 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 740JV UT WOS:000288789900025 PM 21184757 ER PT J AU Schmittdiel, J Selby, JV Swain, B Daugherty, SL Leong, TK Ho, M Margolis, KL O'Connor, P Magid, DJ Bibbins-Domingo, K AF Schmittdiel, Julie Selby, Joe V. Swain, Bix Daugherty, Stacie L. Leong, Thomas K. Ho, Michael Margolis, Karen L. O'Connor, Patrick Magid, David J. Bibbins-Domingo, Kirsten TI Missed Opportunities in Cardiovascular Disease Prevention? Low Rates of Hypertension Recognition for Women at Medicine and Obstetrics-Gynecology Clinics SO HYPERTENSION LA English DT Article DE hypertension; sex; CVD prevention; primary care; OBGYN ID ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; HIGH BLOOD-PRESSURE; PRIMARY-CARE; HEALTH-CARE; RACIAL-DIFFERENCES; PRACTICE PATTERNS; SEX-DIFFERENCES; SERVICES; GUIDELINES AB Younger women use both internal medicine and obstetrics-gynecology (OBGYN) clinics as primary sources of health care. However, the role of OBGYN clinics in cardiovascular disease prevention is largely unexplored. The objective of this study was to examine rates of hypertension recognition in women <50 years of age who presented with elevated blood pressures in family practice and internal medicine (medicine) OBGYN clinics and to compare these rates across clinic type. The study's population consisted of 34 627 nonpregnant women ages 18 to 49 years with new-onset hypertension (defined as 2 consecutive visits with elevated blood pressures of systolic blood pressure >140 mm Hg or diastolic blood pressure >= 90 mm Hg with no previous hypertension history) from 2002 to 2006. Multivariate logistic regressions predicting the clinical recognition of hypertension (a recorded diagnosis of hypertension and/or an antihypertensive prescription by any provider within 1 year of the second elevated blood pressure) assessed the association between hypertension recognition and the clinic where the second elevated blood pressure was recorded. Analysis showed that hypertension was recognized in <33% of women with new-onset hypertension. Women whose second consecutive elevated blood pressure was recorded in OBGYN clinics were less likely to be recognized as having hypertension within 12 months by any provider compared with women whose second consecutive elevated blood pressure was recorded in a medicine clinic (odds ratio: 0.51 [95% CI: 0.48 to 0.54]). This study suggests that further attention be paid to identifying and treating cardiovascular disease risk factors in women <50 years of age presenting in both medicine and OBGYN clinics and that improved coordination across care settings has the potential to improve cardiovascular disease prevention in young women. (Hypertension. 2011;57:717-722.) C1 [Schmittdiel, Julie; Selby, Joe V.; Swain, Bix; Leong, Thomas K.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Daugherty, Stacie L.; Ho, Michael] Univ Colorado, Aurora, CO USA. [Margolis, Karen L.; O'Connor, Patrick] HealthPartners, Minneapolis, MN USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA. [Ho, Michael] Denver Vet Affairs Med Ctr, Denver, CO USA. [Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. RP Schmittdiel, J (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM Julie.A.Schmittdiel@kp.org FU National Heart, Lung, and Blood Institute [U19 HL91179-01, K08HL103776]; Office of Research in Women's Health Building Interdisciplinary Careers in Women's Health [K12HD052163]; Veterans Affairs Health Services Research and Development Service [05-026-1] FX This study was funded by the National Heart, Lung, and Blood Institute (U19 HL91179-01). The work by J.S. on this study was supported by the Office of Research in Women's Health Building Interdisciplinary Careers in Women's Health K12 Career Development Award (K12HD052163). M. H. is supported by a Veterans Affairs Health Services Research and Development Service Career Development Award (05-026-1). S. L. D. is supported by Award No. K08HL103776 from the National Heart, Lung, and Blood Institute. NR 41 TC 16 Z9 17 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD APR PY 2011 VL 57 IS 4 BP 717 EP 722 DI 10.1161/HYPERTENSIONAHA.110.168195 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 735RL UT WOS:000288434600017 PM 21339475 ER PT J AU Trombetta-ESilva, J Yu, H Arias, DN Rossa, C Kirkwood, KL Bradshaw, AD AF Trombetta-eSilva, J. Yu, H. Arias, D. N. Rossa, C., Jr. Kirkwood, K. L. Bradshaw, A. D. TI LPS Induces Greater Bone and PDL Loss in SPARC-null Mice SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE SPARC; periodontal ligament; collagen; BM-40; osteonectin; extracellular matrix; matricellular; periodontal diseases; alveolar bone resorption ID PERIODONTAL-LIGAMENT; EXTRACELLULAR-MATRIX; CYSTEINE SPARC; COLLAGEN; PROTEIN; REGENERATION; FIBROBLASTS; TISSUES; MODEL; RICH AB Individuals with periodontal disease have increased risk of tooth loss, particularly in cases with associated loss of alveolar bone and periodontal ligament (PDL). Current treatments do not predictably regenerate damaged PDL. Collagen I is the primary component of bone and PDL extracellular matrix. SPARC/Osteonectin (SP/ON) is implicated in the regulation of collagen content in healthy PDL. In this study, periodontal disease was induced by injections of lipopolysaccharide (LPS) from Aggregatibacter actinomycetemcomitans in wild-type (WT) and SP/ON-null C57/B16 mice. A 20-mu g quantity of LPS was injected between the first and second molars 3 times a week for 4 weeks, whereas PBS control was injected into the contralateral maxilla. LPS injection resulted in a significant decrease in bone volume fraction in both genotypes; however, significantly greater bone loss was detected in SP/ON-null maxilla. SP/ON-null PDL exhibited more extensive degradation of connective tissue in the gingival tissues. Although total cell numbers in the PDL of SP/ON-null were not different from those in WT, the inflammatory infiltrate was reduced in SP/ON-null PDL. Histology of collagen fibers revealed marked reductions in collagen volume fraction and in thick collagen volume fraction in the PDL of SP/ON-null mice. SP/ON protects collagen content in PDL and in alveolar bone in experimental periodontal disease. C1 [Trombetta-eSilva, J.; Yu, H.; Rossa, C., Jr.; Kirkwood, K. L.; Bradshaw, A. D.] Med Univ S Carolina, Ctr Oral Hlth Res, Charleston, SC 29425 USA. [Bradshaw, A. D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Trombetta-eSilva, J.; Bradshaw, A. D.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Arias, D. N.] Erskine Coll, Due West, SC USA. [Bradshaw, A. D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Rossa, C., Jr.] Univ Estadual Paulista UNESP, Dept Diag & Surg, Fac Odontol Araraquara, Araraquara, SP, Brazil. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Craniofacial Biol, 114 Doughty St,Rm 223, Charleston, SC 29425 USA. EM bradshad@musc.edu RI Rossa Jr, Carlos/D-8328-2012 OI Rossa Jr, Carlos/0000-0003-1705-5481 FU National Institutes of Health [T32DE017551, R25 HL092611, 2P20RR017696, HL094517, R01DE018290]; Veteran's Administration FX We thank Kylie Martin, Yuhua Zhang, Lauren Card, and Robert Zinna for technical support. This work was supported by the National Institutes of Health [T32DE017551, R25 HL092611, 2P20RR017696, HL094517, R01DE018290] and by a Veteran's Administration Merit Award. NR 31 TC 7 Z9 7 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD APR PY 2011 VL 90 IS 4 BP 477 EP 482 DI 10.1177/0022034510391800 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 740MK UT WOS:000288798600013 PM 21191126 ER PT J AU Wilson, RS Krueger, KR Boyle, PA Bennett, DA AF Wilson, Robert S. Krueger, Kristin R. Boyle, Patricia A. Bennett, David A. TI Loss of basic lexical knowledge in old age SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID ADULT READING TEST; ALZHEIMERS-DISEASE; PREMORBID INTELLIGENCE; COGNITIVE FUNCTION; DEMENTIA; DECLINE; NEUROPATHOLOGY; IMPAIRMENT; VALIDATION; ABILITY AB Background Basic lexical skills are hypothesised to be relatively preserved in mild dementia, but clinical studies have reported inconsistent results. Methods More than 400 older Catholic nuns, priests and brothers recruited from groups across the USA completed annual evaluations for up to 15 years, died and underwent brain autopsy. Each clinical evaluation included administration of a 20-item word reading test and a 15-item vocabulary test, which were combined to form a composite measure of word knowledge. In a uniform neuropathological examination, Alzheimer's disease pathology was quantified with a composite index of plaques and tangles, and the presence of gross and microscopic cerebral infarctions and Lewy bodies was recorded. Results The post-mortem level of Alzheimer's disease neuropathology was linearly related to rate of decline in word knowledge. Decline was nearly fourfold faster at a relatively high level of pathology (75th percentile) compared with a relatively low level (25th percentile). Neocortical (but not nigral or limbic) Lewy bodies and gross (but not microscopic) cerebral infarction were also associated with a more rapid decline in word knowledge. Effects for word reading and vocabulary were similar, except that gross cerebral infarction was associated with accelerated decline in vocabulary, but not in word reading. Conclusion Common neuropathological changes associated with late-life dementia impair word knowledge in old age, calling into question the use of word knowledge tests to estimate premorbid cognitive ability. C1 [Wilson, Robert S.; Boyle, Patricia A.; Bennett, David A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Wilson, Robert S.; Bennett, David A.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Wilson, Robert S.; Boyle, Patricia A.] Rush Univ, Med Ctr, Dept Behav Sci, Chicago, IL 60612 USA. [Krueger, Kristin R.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. RP Wilson, RS (reprint author), Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, 600 S Paulina Ave,Suite 1038, Chicago, IL 60612 USA. EM rwilson@rush.edu FU National Institute on Aging [P30AG10161, R01AG15819] FX Support for this project was provided by federal grants from the National Institute on Aging: P30AG10161 and R01AG15819. NR 29 TC 7 Z9 7 U1 0 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD APR PY 2011 VL 82 IS 4 BP 369 EP 372 DI 10.1136/jnnp.2010.212589 PG 4 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 734ZY UT WOS:000288384100006 PM 20802026 ER PT J AU Reidling, JC Rubin, SA AF Reidling, Jack C. Rubin, Stanley A. TI Promoter analysis of the human ascorbic acid transporters SVCT1 and 2: mechanisms of adaptive regulation in liver epithelial cells SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY LA English DT Article DE Ascorbic acid; Nutrient transport; Promoter regulation; SVCT ID VITAMIN-C UPTAKE; THIAMIN UPTAKE; WILD-TYPE; ANTIOXIDANT; EXPRESSION; SLC23A2; HSVCT1 AB Ascorbic acid, the active form of vitamin C, is a vital antioxidant in the human liver, yet the molecular mechanisms involved in the regulation of ascorbic acid transporters [human sodium-dependent vitamin C transporters (hSVCT) 1 and 2] in liver cells are poorly understood. Therefore, we characterized the minimal promoter regions of hSVCT1 and 2 in cultured human liver epithelial cells (HepG2) and examined the effects of ascorbic acid deprivation and supplementation on activity and regulation of the transport systems. Identified minimal promoters required for basal activity were found to include multiple cis regulatory elements, whereas mutational analysis demonstrated that HNF-1 sites in the hSVCT1 promoter and KLF/Sp1 sites in the hSVCT2 promoter were essential for activities. When cultured in ascorbic acid deficient or supplemented media, HepG2 cells demonstrated significant (P<.01) and specific reciprocal changes in [(14)C]-Ascorbic acid uptake, and in hSVCT1 mRNA and protein levels as well as hSVCT1 promoter activity. However, no significant changes in hSVCT2 expression or promoter activity were observed during ascorbic acid deficient or supplemented conditions. We mapped the ascorbic acid responsive region in the hSVCT1 promoter and determined that HNF-1 sites are important for the adaptive regulation response. The results of these studies further characterize the hSVCT1 and 2 promoters establish that ascorbic acid uptake by human liver epithelial cells is adaptively regulated and show that transcriptional mechanisms via HNF-1 in the hSVCT1 promoter may, in part, be involved in this regulation. Published by Elsevier Inc. C1 [Reidling, Jack C.] VA Med Ctr, Long Beach, CA 90822 USA. [Reidling, Jack C.] Univ Calif Irvine, Coll Med, Irvine, CA 92697 USA. [Rubin, Stanley A.] UCLA Sch Med, VA Greater Los Angeles Med Ctr, Dept Med, Los Angeles, CA 90073 USA. RP Reidling, JC (reprint author), VA Med Ctr, Long Beach, CA 90822 USA. EM jreidlin@uci.edu FU National Institutes of Health [DK73032]; Department of Veterans Affairs FX The work was supported by grants from the National Institutes of Health DK73032 and the Department of Veterans Affairs. NR 26 TC 8 Z9 8 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0955-2863 J9 J NUTR BIOCHEM JI J. Nutr. Biochem. PD APR PY 2011 VL 22 IS 4 BP 344 EP 350 DI 10.1016/j.jnutbio.2010.03.001 PG 7 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA 740DT UT WOS:000288772500006 PM 20471816 ER PT J AU Stengel, A Goebel, M Tache, Y AF Stengel, A. Goebel, M. Tache, Y. TI Nesfatin-1: a novel inhibitory regulator of food intake and body weight SO OBESITY REVIEWS LA English DT Article DE Food intake; hypothalamus; nesfatin-1; NUCB2; X; A-like cells ID CORTICOTROPIN-RELEASING-FACTOR; MELANOCYTE-STIMULATING HORMONE; SATIETY MOLECULE NESFATIN-1; EDINGER-WESTPHAL NUCLEUS; BLOOD-BRAIN-BARRIER; BINDING-PROTEIN; INSULIN-SECRETION; ARCUATE NUCLEUS; PARAVENTRICULAR NUCLEUS; TRANSCRIPT PEPTIDE AB P>The protein nucleobindin 2 (NUCB2) or NEFA (DNA binding/EF-hand/acidic amino acid rich region) was identified over a decade ago and implicated in intracellular processes. New developments came with the report that post-translational processing of hypothalamic NUCB2 may result in nesfatin-1, nesfatin-2 and nesfatin-3 and convergent studies showing that nesfatin-1 and full length NUCB2 injected in the brain potently inhibit the dark phase food intake in rodents including leptin receptor deficient Zucker rats. Nesfatin-1 also reduces body weight gain, suggesting a role as a new anorexigenic factor and modulator of energy balance. In light of the obesity epidemic and its associated diseases, underlying new mechanisms regulating food intake may be promising targets in the drug treatment of obese patients particularly as the vast majority of them display reduced leptin sensitivity or leptin resistance while nesfatin-1's mechanism of action is leptin independent. Although much progress on the localization of NUCB2/nesfatin-1 in the brain and periphery as well as on the understanding of nesfatin-1's anorexic effect have been achieved during the past three years, several important mechanisms have yet to be unraveled such as the identification of the nesfatin-1 receptor and the regulation of NUCB2 processing and nesfatin-1 release. C1 [Tache, Y.] Univ Calif Los Angeles, Ctr Neurobiol Stress, VA GLA Healthcare Syst, Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, Ctr Neurobiol Stress, VA GLA Healthcare Syst, Div Digest Dis, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU German Research Foundation [STE 1765/1-1, GO 1718/1-1]; NIHDK [33061]; [DK-41301] FX Supported by: German Research Foundation Grants STE 1765/1-1 (A.S.), GO 1718/1-1 (M.G.), VA Research Career Scientist Award, NIHDK 33061, Center Grant DK-41301 (Animal Core) (Y.T.). NR 61 TC 30 Z9 36 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1467-7881 J9 OBES REV JI Obes. Rev. PD APR PY 2011 VL 12 IS 4 BP 261 EP 271 DI 10.1111/j.1467-789X.2010.00770.x PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 738ZA UT WOS:000288679900004 PM 20546141 ER PT J AU Yuferov, V Nielsen, DA Levran, O Randesi, M Hamon, S Ho, A Morgello, S Kreek, MJ AF Yuferov, Vadim Nielsen, David A. Levran, Orna Randesi, Matthew Hamon, Sara Ho, Ann Morgello, Susan Kreek, Mary Jeanne TI Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs SO PHARMACOGENETICS AND GENOMICS LA English DT Article DE anterior cingulate cortex; bisulfite sequencing; caudate; CpG island; DNA methylation; dynorphin; human post-mortem brain; prodynorphin gene expression ID IMMUNODEFICIENCY-VIRUS TYPE-1; MESSENGER-RNA EXPRESSION; CPG ISLANDS; EPIGENETIC REGULATION; DIFFERENT REGIONS; PDYN EXPRESSION; BINDING FACTOR; BINGE COCAINE; TRANSCRIPTION; DYNORPHIN AB Objective Dynorphins, the endogenous ligands for the kappa opioid receptor, are implicated in neuropsychiatric disorders through modulation of basal and stimuli-induced dopaminergic, glutamatergic, and serotonergic tones. Expression of the prodynorphin gene (PDYN) is critical for rewarding properties of drugs of abuse and stress-induced responses. Epigenetic factors, such as DNA methylation, play an important role in modulation of gene expression. Methods We analyzed DNA methylation patterns of three CpG-rich regions of PDYN, a CpG island, and cluster A in the proximal promoter, and cluster B in coding exon 4, by bisulfite sequencing of DNA from the caudate and anterior cingulate cortex from post-mortem brain of 35 individuals (22 HIV seropositive), and in peripheral blood mononuclear cells from 21 of these individuals. Results We found remarkably similar patterns of methylation across CpG sites in these tissues. However, there were tissue-specific differences in methylation levels (P=0.000001) of the CpG island: higher levels in peripheral blood mononuclear cells (82%) than in the brain tissues, the caudate (62%), and the anterior cingulate cortex (44%). But there was higher PDYN expression in the caudate than in the anterior cingulate cortex. In contrast, cluster A near the transcription start site is hypomethylated. Conclusion This DNA methylation profile of the PDYN gene is typical for primary responsive genes with regulatory elements for both basal and tissue-specific transcription. Our findings provide a rationale for further studies of the role of other epigenetic factors in the regulation of PDYN expression in individuals with psychiatric and neurological disorders. Pharmacogenetics and Genomics 21: 185-196 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Yuferov, Vadim; Nielsen, David A.; Levran, Orna; Randesi, Matthew; Hamon, Sara; Ho, Ann; Kreek, Mary Jeanne] Rockefeller Univ, Lab Biol Addict Dis, New York, NY 10065 USA. [Morgello, Susan] Mt Sinai Med Ctr, New York, NY 10029 USA. [Nielsen, David A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Nielsen, David A.] Michael E DeBakey Med Ctr, Houston, TX USA. RP Yuferov, V (reprint author), Rockefeller Univ, Lab Biol Addict Dis, Box 171,1230 York Ave, New York, NY 10065 USA. EM yuferov@rockefeller.edu RI Nielsen, David/B-4655-2009 FU NIH-NIDA [P60-DA05130]; NIH-NIMH [R01-MH79880, R24-MH59724, U01MH-083501] FX This study was supported by the NIH-NIDA P60-DA05130 (M.J.K.), the NIH-NIMH R01-MH79880 (M.J.K.), the NIH-NIMH R24-MH59724 and U01MH-083501 (S.M.). NR 60 TC 26 Z9 26 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1744-6872 EI 1744-6880 J9 PHARMACOGENET GENOM JI Pharmacogenet. Genomics PD APR PY 2011 VL 21 IS 4 BP 185 EP 196 DI 10.1097/FPC.0b013e32833eecbc PG 12 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy GA 735UH UT WOS:000288444500004 PM 20808262 ER PT J AU Scibelli, AC McKinnon, CS Reed, C Burkhart-Kasch, S Li, N Baba, H Wheeler, JM Phillips, TJ AF Scibelli, Angela C. McKinnon, Carrie S. Reed, Cheryl Burkhart-Kasch, Sue Li, Na Baba, Harue Wheeler, Jeanna M. Phillips, Tamara J. TI Selective breeding for magnitude of methamphetamine-induced sensitization alters methamphetamine consumption SO PSYCHOPHARMACOLOGY LA English DT Article DE Reward; Addiction; Stimulation; Locomotor activity; Drinking; Saccharin; Quinine; Potassium chloride; Heritability; Clearance ID RECOMBINANT INBRED MICE; BEHAVIORAL SENSITIZATION; NUCLEUS-ACCUMBENS; EXTRACELLULAR DOPAMINE; LOCOMOTOR RESPONSES; ETHANOL-CONSUMPTION; STIMULANT-DRUGS; ALCOHOL INTAKE; D-AMPHETAMINE; TIME-COURSE AB Genetically determined differences in susceptibility to drug-induced sensitization could be related to risk for drug consumption. Studies were performed to determine whether selective breeding could be used to create lines of mice with different magnitudes of locomotor sensitization to methamphetamine (MA). MA sensitization (MASENS) lines were also examined for genetically correlated responses to MA. Beginning with the F2 cross of C57BL/6J and DBA/2J strains, mice were tested for locomotor sensitization to repeated injections of 1 mg/kg MA and bred based on magnitude of sensitization. Five selected offspring generations were tested. All generations were also tested for MA consumption, and some were tested for dose-dependent locomotor-stimulant responses to MA, consumption of saccharin, quinine, and potassium chloride as a measure of taste sensitivity, and MA clearance after acute and repeated MA. Selective breeding resulted in creation of two lines [MA high sensitization (MAHSENS) and MA low sensitization (MALSENS)] that differed in magnitude of MA-induced sensitization. Initially, greater MA consumption in MAHSENS mice reversed over the course of selection so that MALSENS mice consumed more MA. MAHSENS mice exhibited greater sensitivity to the acute stimulant effects of MA, but there were no significant differences between the lines in MA clearance from blood. Genetic factors influence magnitude of MA-induced locomotor sensitization and some of the genes involved in magnitude of this response also influence MA sensitivity and consumption. Genetic factors leading to greater MA-induced sensitization may serve a protective role against high levels of MA consumption. C1 [Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR 97239 USA. [Scibelli, Angela C.; McKinnon, Carrie S.; Reed, Cheryl; Burkhart-Kasch, Sue; Li, Na; Baba, Harue; Wheeler, Jeanna M.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Methamphetamine, Abuse Res Ctr, Portland, OR 97201 USA. [Scibelli, Angela C.; McKinnon, Carrie S.; Reed, Cheryl; Burkhart-Kasch, Sue; Li, Na; Baba, Harue; Wheeler, Jeanna M.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Phillips, TJ (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,R&D 32, Portland, OR 97239 USA. EM phillipt@ohsu.edu FU NIDA [P50 DA018165, T32 DA07262]; Department of Veterans Affairs FX This work was supported by grants from NIDA (P50 DA018165 and T32 DA07262) and by the Department of Veterans Affairs. We are grateful to John Belknap for providing statistical software for performance of heritability calculations. All experiments were conducted in compliance with current laws in the United States of America. NR 63 TC 15 Z9 17 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD APR PY 2011 VL 214 IS 4 BP 791 EP 804 DI 10.1007/s00213-010-2086-2 PG 14 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 739XQ UT WOS:000288755500002 PM 21088960 ER PT J AU Wang, JH Wu, Q Yang, P Li, H Li, J Mountz, JD Hsu, HC AF Wang, John H. Wu, Qi Yang, PingAr Li, Hao Li, Jun Mountz, John D. Hsu, Hui-Chen TI Type I Interferon-Dependent CD86(high) Marginal Zone Precursor B Cells Are Potent T Cell Costimulators in Mice SO ARTHRITIS AND RHEUMATISM LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PLASMACYTOID DENDRITIC CELLS; PATHOGENIC AUTOANTIBODIES; DISEASE-ACTIVITY; LYMPH-NODES; BXD2 MICE; BLOOD; ACTIVATION; EXPRESSION; RECEPTOR AB Objective. To investigate the role of CD86(high) marginal zone (MZ) precursor B cells in type I interferon (IFN)-induced T cell-dependent responses in autoimmune BXD2 mice. Methods. Confocal microscopic imaging was used to determine the location of plasmacytoid dendritic cells (DCs), MZ precursor B cells, and CD4 T cells in the spleens of BXD2 and BXD2-Ifnar(-/-) mice. Immunohistochemical staining was used to determine IgG(bright) cells in the spleens of BXD2 and BXD2-Ifnar(-/-) mice. Enzyme-linked immunosorbent assay was used to determine serum levels of IFN alpha and autoantibodies, and 4-hydroxy-3-nitrophenylacetyl hapten (NP)-chicken gamma-globulin (CGG) (NP-CGG)-or NP-Ficoll-induced anti-NP2 antibody titers. Real-time quantitative polymerase chain reaction was used to determine the levels of type I IFN transcripts. T cell proliferation was measured using H-3-thymidine. The expression of CD86 and CD80 was determined by fluorescence-activated cell sorting analysis. Results. The deletion of type I IFN receptor abrogated the development of IgGbright cells and sup-pressed a T cell-dependent antibody response. Type I IFN signaling was associated with the expression of CD86, but not CD80, on follicular, MZ, and MZ precursor B cells. However, MZ precursor B cells demonstrated the highest expression of CD86 and the highest capacity for T cell costimulation with intact type I IFN receptor. This effect was blocked by an antibody that neutralizes CD86. In IFN receptor-intact BXD2 mouse spleens, MZ precursor B cells clustered at the T cell-B cell border. CD86 deletion suppressed germinal center formation, autoantibody production, and development of autoimmune diseases in BXD2 mice. Conclusion. Type I IFN can promote autoimmune responses in BXD2 mice through up-regulation of CD86(high) expression on MZ precursor B cells and trafficking of MZ precursor B cells to the T cell-B cell border to provide costimulation of CD4 T cells. C1 [Hsu, Hui-Chen] Univ Alabama, Div Clin Immunol & Rheumatol, Dept Med, Birmingham, AL 35294 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Hsu, HC (reprint author), Univ Alabama, Div Clin Immunol & Rheumatol, Dept Med, 1825 Univ Blvd,SHELB 311, Birmingham, AL 35294 USA. EM rheu078@uab.edu RI Li, Hao/N-7406-2015 OI Li, Hao/0000-0002-2171-8826 FU American College of Rheumatology Research and Education Foundation; Alliance for Lupus Research; Department of Veterans Affairs [1I01BX000600-01]; Daiichi-Sankyo Co., Ltd; NIH [1-AI-071110-01A1, ARRA-3-R01-AI-71110-02S1, P30-AR-48311]; Lupus Research Institute; Arthritis Foundation FX Supported by grants to Dr. Mountz from the American College of Rheumatology Research and Education Foundation (Within Our Reach research grant), the Alliance for Lupus Research (Target Identification in Lupus program grant), the Department of Veterans Affairs (Merit Review grant 1I01BX000600-01), Daiichi-Sankyo Co., Ltd, and the NIH (grants 1-AI-071110-01A1, ARRA-3-R01-AI-71110-02S1, and P30-AR-48311) and by grants to Dr. Hsu from the Lupus Research Institute (Novel Research project grant) and the Arthritis Foundation (Arthritis Investigator Award). NR 32 TC 10 Z9 10 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD APR PY 2011 VL 63 IS 4 BP 1054 EP 1064 DI 10.1002/art.30231 PG 11 WC Rheumatology SC Rheumatology GA 748VO UT WOS:000289421100024 PM 21225691 ER PT J AU Boserup, MW Lichota, J Haile, D Moos, T AF Boserup, Michael W. Lichota, Jacek Haile, David Moos, Torben TI Heterogenous distribution of ferroportin-containing neurons in mouse brain SO BIOMETALS LA English DT Article DE Blood-brain barrier; Iron; Neurodegeneration; Oxidative stress; qPCR; Transferrin ID DIVALENT METAL TRANSPORTER-1; CENTRAL-NERVOUS-SYSTEM; TRANSFERRIN RECEPTOR; IRON-METABOLISM; RAT; EXPRESSION; CELLS; CERULOPLASMIN; PROTEINS; FERRITIN AB Iron is crucial for a variety of cellular functions in neuronal cells. Neuronal iron uptake is reflected in a robust and consistent expression of transferrin receptors and divalent metal transporter 1 (DMT 1). Conversely, the mechanisms by which neurons neutralize and possibly excrete iron are less clear. Studies indicate that neurons express ferroportin which could reflect a mechanism for iron export. We mapped the distribution of ferroportin in the adult mouse brain using an antibody prepared from a peptide representing amino acid sequences 223-303 of mouse ferroportin. The antibody specifically detected ferroportin in brain homogenates, whereas homogenates of cultured endothelial cells were devoid of immunoreactivity. In brain sections, ferroportin was confined to neuronal cell bodies and peripheral processes of cerebral cortex, hippocampus, thalamus, brain stem, and cerebellum. In brain stem ferroportin-labeling was particularly high in neurons of cranial nerve nuclei and reticular formation. Ferroportin was hardly detectable in striatum, pallidum, or hypothalamus. Among non-neuronal cells, ferroportin was detected in oligodendrocytes and choroid plexus epithelial cells. A comparison with previous studies on the distribution of transferrin receptors in neurons shows that many neuronal pools coincide with those expressing ferroportin. The data therefore indicate that neuronal iron homeostasis consists of a delicate balance between transferrin receptor-mediated uptake of iron-transferrin and ferroportin-related iron excretion. The findings also suggest a particular high turnover of iron in neuronal regions, such as habenula, hippocampus, reticular formation and cerebellum, as several neurons in these regions exhibit a prominent co-expression of transferrin receptors and ferroportin. C1 [Boserup, Michael W.; Lichota, Jacek; Moos, Torben] Univ Aalborg, Dept Hlth Sci & Technol, Neurobiol Sect, DK-9220 Aalborg, Denmark. [Haile, David] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Moos, T (reprint author), Univ Aalborg, Dept Hlth Sci & Technol, Neurobiol Sect, Fr Bajers Vej 3B,1-216, DK-9220 Aalborg, Denmark. EM tmoos@hst.aau.dk OI Moos, Torben/0000-0001-9989-0207 FU Lundbeck Fund; Danish Parkinson's Disease Fund; Carlsberg Foundation; Spar Nord Fund; Obelske Familiefond FX We would like to thank Susan Peters at University of Copenhagen, Denmark and Merete Fredsgaard, Aalborg University, Denmark for excellent technical assistance. Murine brain endothelioma cells, bEnd3, were kindly obtained from Dr. Sara Gosk, University of Bonn, Germany. This work was supported by grants from the Lundbeck Fund, the Danish Parkinson's Disease Fund, the Carlsberg Foundation, the Spar Nord Fund, and the Obelske Familiefond. NR 42 TC 13 Z9 15 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0966-0844 J9 BIOMETALS JI Biometals PD APR PY 2011 VL 24 IS 2 BP 357 EP 375 DI 10.1007/s10534-010-9405-2 PG 19 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 735BF UT WOS:000288387700015 PM 21213119 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Time Trends of Mortality from Gastric Cancer in Europe SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Birth-cohorts; Duodenal ulcer; Epidemiology; Gastric cancer; Gastric ulcer; Helicobacter pylori; Mortality; Time trends ID PEPTIC-ULCER; HELICOBACTER-PYLORI; CENTURIES; DISEASE AB The time trends of gastric and duodenal ulcer disease are shaped by a birth-cohort phenomenon. The aim of this study was to assess the extent by which a birth-cohort phenomenon also affected the long-term time trends of gastric cancer among different European countries. Mortality data from France, Germany, Netherlands, Scotland, Spain, and Sweden of the past 56-85 years were analyzed. The age-specific death rates were plotted against the period of death as period-age contours and against the period of birth as cohort-age contours. The long-term time trends of gastric cancer mortality were found to have risen among generations born during the 18th century until the mid-19th century and then to have declined in all subsequent generations. The rise and fall of gastric cancer preceded similar birth-cohort patterns of gastric and duodenal ulcer by about 10-30 years. With the exception of gastric cancer in Germany, similar birth-cohort phenomena were found in all countries, as well as in men and women. The time trends of mortality from gastric cancer and peptic are shaped by birth-cohort patterns that have affected all countries of Europe. It remains an enigma why mortality associated with gastric cancer and peptic ulcer suddenly started to rise within a short time period during the 19th century. C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 21 TC 12 Z9 13 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2011 VL 56 IS 4 BP 1112 EP 1118 DI 10.1007/s10620-010-1553-2 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 736RR UT WOS:000288512300023 PM 21234687 ER PT J AU Beard, RS Henry, JN Price, TO Ercal, N Banks, WA Bearden, SE AF Beard, Richard Scott Henry, Jamie N. Price, Tulin Otamis Ercal, Nuran Banks, William A. Bearden, Shawn E. TI Homocysteine disrupts NO metabolism in brain microvascular endothelial cells by an mGluR5-dependent mechanism SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Beard, Richard Scott; Henry, Jamie N.; Bearden, Shawn E.] Idaho State Univ, Pocatello, ID 83209 USA. [Price, Tulin Otamis] St Louis Univ, St Louis, MO 63103 USA. [Ercal, Nuran] Missouri Univ Sci & Technol, Rolla, MO USA. [Banks, William A.] VA Puget Sound, Seattle, WA USA. [Banks, William A.] Univ Washington, Seattle, WA 98195 USA. RI Beard Jr., Richard/E-2051-2013 OI Beard Jr., Richard/0000-0001-8545-3014 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708405604 ER PT J AU Chen, YX Gelfond, JA McManus, LM Shireman, PK AF Chen, Yongxin Gelfond, Jonathan A. McManus, Linda M. Shireman, Paula K. TI MiR-682 Antisense Inhibits Skeletal Muscle Regeneration SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Chen, Yongxin; McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708402405 ER PT J AU Clayton, CC Neve, KA AF Clayton, Cecilea C. Neve, Kim A. TI Analysis of dopamine D2 receptor mutants deficient in arrestin binding using bioluminescence resonance energy transfer SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708403585 ER PT J AU Farrell, S Brecha, N Barnes, S AF Farrell, Spring Brecha, Nicholas Barnes, Steven TI Somatostatin receptor subtype 4 modulation of L-type Ca2+ channels in rat retinal ganglion cells SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Farrell, Spring; Barnes, Steven] Dalhousie Univ, Halifax, NS, Canada. [Brecha, Nicholas; Barnes, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Brecha, Nicholas] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708401102 ER PT J AU Harston, RK McKillop, JC Moschella, PC Van Laer, A Quinones, LS Baicu, CF Balasubramanian, S Zile, MR Kuppuswamy, D AF Harston, Rebecca Kate McKillop, John C. Moschella, Phillip C. Van Laer, An Quinones, Lakeya S. Baicu, Catalin F. Balasubramanian, Sundaravadivel Zile, Michael R. Kuppuswamy, Dhandapani TI Acute rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Harston, Rebecca Kate] ABL Inc, Prod Dev, Kensington, MD USA. [McKillop, John C.; Moschella, Phillip C.; Van Laer, An; Quinones, Lakeya S.; Baicu, Catalin F.; Balasubramanian, Sundaravadivel; Zile, Michael R.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Charleston, SC 29425 USA. [Zile, Michael R.; Kuppuswamy, Dhandapani] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708404524 ER PT J AU Hernandez-Corbacho, M Mather, AR Jenkins, R Clarke, C Hannun, Y Obeid, L Snider, A Siskind, L AF Hernandez-Corbacho, Maria Mather, Andrew R. Jenkins, Rusell Clarke, Christopher Hannun, Yusuf Obeid, Lina Snider, Ashley Siskind, Leah TI Long-Chain Glycosphingolipids Mediate Renal Aging SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Hernandez-Corbacho, Maria; Mather, Andrew R.; Jenkins, Rusell; Clarke, Christopher; Hannun, Yusuf; Obeid, Lina; Snider, Ashley; Siskind, Leah] Med Univ S Carolina, Charleston, SC 29425 USA. [Obeid, Lina; Snider, Ashley; Siskind, Leah] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708402724 ER PT J AU Hsiao, PYL Mitchell, DC Hartman, TJ Jensen, GL Coffman, DL Still, CD Allman, RM Sawyer, P AF Hsiao, Pao Ying Lin Mitchell, Diane C. Hartman, Terryl J. Jensen, Gordon L. Coffman, Donna L. Still, Christopher D. Allman, Richard M. Sawyer, Patricia TI Characterizing dietary patterns in older adults using a novel approach SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Hsiao, Pao Ying Lin; Mitchell, Diane C.; Hartman, Terryl J.; Jensen, Gordon L.] Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA. [Coffman, Donna L.] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Still, Christopher D.] Geisinger Med Ctr, Danville, PA 17822 USA. [Allman, Richard M.] Birmingham VA Med Ctr, Birmingham, AL USA. [Allman, Richard M.; Sawyer, Patricia] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. RI Coffman, Donna/C-3038-2013 OI Coffman, Donna/0000-0001-6305-6579 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708405192 ER PT J AU Sas, KM Amria, MY Bell, PD AF Sas, Kelli Margot Amria, May Y. Bell, P. Darwin TI Diabetes accelerates cystogenesis in the adult conditional ift88 knockout mouse SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Sas, Kelli Margot; Amria, May Y.; Bell, P. Darwin] Med Univ S Carolina, Charleston, SC 29425 USA. [Bell, P. Darwin] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708404141 ER PT J AU Soto-Pina, AE Kadapakkam, S Mehring, C Hinojosa-Laborde, C Strong, R AF Soto-Pina, Alexandra Estela Kadapakkam, Sheela Mehring, Cinthya Hinojosa-Laborde, Carmen Strong, Randy TI Inhibition of tyrosine hydroxylase reduces dexamethasone-induced hypertension SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Soto-Pina, Alexandra Estela; Kadapakkam, Sheela; Mehring, Cinthya; Hinojosa-Laborde, Carmen; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Soto-Pina, Alexandra Estela; Kadapakkam, Sheela; Strong, Randy] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708405701 ER PT J AU Spassieva, SD Rahmaniyan, M Bielawski, J Kraveka, JM Obeid, LM AF Spassieva, Stefka D. Rahmaniyan, Mehrdad Bielawski, Jacek Kraveka, Jacqueline M. Obeid, Lina M. TI Cell Density Dependent Inhibition of Dihydroceramide Desaturase SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Spassieva, Stefka D.; Rahmaniyan, Mehrdad; Bielawski, Jacek; Kraveka, Jacqueline M.; Obeid, Lina M.] Med Univ S Carolina, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Hosp, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708404667 ER PT J AU Trager, RE Wills, L Lindsey, C Beeson, G Beeson, C Schnellmann, R Peterson, Y AF Trager, Richard Edwin Wills, Lauren Lindsey, Christopher Beeson, Gyda Beeson, Craig Schnellmann, Rick Peterson, Yuri TI High throughput identification of mitochondrial toxicophores SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Trager, Richard Edwin; Wills, Lauren; Lindsey, Christopher; Beeson, Gyda; Beeson, Craig; Schnellmann, Rick; Peterson, Yuri] Med Univ S Carolina, Charleston, SC 29425 USA. [Schnellmann, Rick] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708403539 ER PT J AU Wang, HZ Porter, L Sarwar, ZU Wells, JT McManus, LM Shireman, PK AF Wang, Hanzhou Porter, Laurel Sarwar, Zaheer U. Wells, Jason T. McManus, Linda M. Shireman, Paula K. TI Macrophage Ablation in CD11b-diphtheria Toxin Receptor (DTR) Transgenic Mice Impairs Skeletal Muscle Regeneration SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Wang, Hanzhou; Porter, Laurel; Sarwar, Zaheer U.; Wells, Jason T.; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708403413 ER PT J AU Wick, MJ Loomis, ZL Buesing, EJ Wehling, CA Cool, CD Hersh, LB Voelkel, NF Dempsey, EC AF Wick, Marilee J. Loomis, Zoe L. Buesing, Erica J. Wehling, Carol A. Cool, Carlyne D. Hersh, Louis B. Voelkel, Norbert F. Dempsey, Edward C. TI Decreased lung neprilysin gene expression in humans with COPD and pulmonary vascular remodeling SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Wick, Marilee J.; Loomis, Zoe L.; Buesing, Erica J.; Cool, Carlyne D.; Voelkel, Norbert F.; Dempsey, Edward C.] Univ Colorado Denver, CVP Res Lab, Aurora, CO USA. [Wick, Marilee J.; Loomis, Zoe L.; Buesing, Erica J.; Cool, Carlyne D.; Voelkel, Norbert F.; Dempsey, Edward C.] Univ Colorado Denver, Div Pulm, Aurora, CO USA. [Wick, Marilee J.; Loomis, Zoe L.; Wehling, Carol A.; Dempsey, Edward C.] Denver VAMC, Denver, CO USA. [Hersh, Louis B.] Univ Kentucky, Lexington, KY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708400449 ER PT J AU Zhong, Z Liu, QL Rehman, H He, SQ Shi, YJ Krishnasamy, Y Schnellmann, RG AF Zhong, Zhi Liu, Qinlong Rehman, Hasibur He, Songqing Shi, Yanjun Krishnasamy, Yasodha Schnellmann, Rick G. TI Supplementation of amphiregulin improves fatty liver regeneration after partial hepatectomy (PHX): the role of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinases (ERK) SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting 2011 CY APR 09-13, 2011 CL Washington, DC SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET) C1 [Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Zhong, Zhi; Liu, Qinlong; Rehman, Hasibur; He, Songqing; Shi, Yanjun; Krishnasamy, Yasodha; Schnellmann, Rick G.] Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IE UT WOS:000310708407181 ER PT J AU Guyatt, GH Oxman, AD Kunz, R Atkins, D Brozek, J Vist, G Alderson, P Glasziou, P Falck-Ytter, Y Schunemann, HJ AF Guyatt, Gordon H. Oxman, Andrew D. Kunz, Regina Atkins, David Brozek, Jan Vist, Gunn Alderson, Philip Glasziou, Paul Falck-Ytter, Yngve Schuenemann, Holger J. TI GRADE guidelines: 2. Framing the question and deciding on important outcomes SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE GRADE; PICO; Patient-important outcomes; Surrogate; Guideline development; Quality of evidence; Indirectness ID PATIENT-IMPORTANT OUTCOMES; ATRIAL-FIBRILLATION; CONTROLLED-TRIALS; CLINICAL-TRIALS; METAANALYSIS; THERAPY AB GRADE requires a clear specification of the relevant setting, population, intervention, and comparator. It also requires specification of all important outcomes whether evidence from research studies is, or is not, available. For a particular management question, the population, intervention, and outcome should be sufficiently similar across studies that a similar magnitude of effect is plausible. Guideline developers should specify the relative importance of the outcomes before gathering the evidence and again when evidence summaries are complete. In considering the importance of a surrogate outcome, authors should rate the importance of the patient-important outcome for which the surrogate is a substitute and subsequently rate down the quality of evidence for indirectness of outcome. (C) 2011 Elsevier Inc. All rights reserved. C1 [Guyatt, Gordon H.; Brozek, Jan; Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Oxman, Andrew D.; Vist, Gunn] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway. [Kunz, Regina] Univ Basel Hosp, Acad Swiss Insurance Med, CH-4031 Basel, Switzerland. [Atkins, David] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA. [Alderson, Philip] Natl Inst Hlth & Clin Excellence, Ctr Clin Practice, Manchester, Lancs, England. [Glasziou, Paul] Bond Univ, Gold Coast, Qld, Australia. [Falck-Ytter, Yngve] Case Western Reserve Univ, Div Gastroenterol, Case & VA Med Ctr, Cleveland, OH 44106 USA. RP Guyatt, GH (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Room 2C12,1200 Main St, W Hamilton, ON L8N 3Z5, Canada. EM guyatt@mcmaster.ca RI Glasziou, Paul/A-7832-2008 OI Glasziou, Paul/0000-0001-7564-073X NR 16 TC 304 Z9 317 U1 1 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 EI 1878-5921 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD APR PY 2011 VL 64 IS 4 BP 395 EP 400 DI 10.1016/j.jclinepi.2010.09.012 PG 6 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 734UF UT WOS:000288364300008 PM 21194891 ER PT J AU Balshem, H Helfand, M Schunemann, HJ Oxman, AD Kunz, R Brozek, J Vist, GE Falck-Ytter, Y Meerpohl, J Norris, S Guyatt, GH AF Balshem, Howard Helfand, Mark Schuenemann, Holger J. Oxman, Andrew D. Kunz, Regina Brozek, Jan Vist, Gunn E. Falck-Ytter, Yngve Meerpohl, Joerg Norris, Susan Guyatt, Gordon H. TI GRADE guidelines: 3. Rating the quality of evidence SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE Quality assessment; Body of evidence; Imprecision; Indirectness; Inconsistency; Publication bias ID REYES-SYNDROME; VENOUS THROMBOEMBOLISM; 1ST EPISODE; RISK-FACTOR; ANTICOAGULATION AB This article introduces the approach of GRADE to rating quality of evidence. GRADE specifies four categories high, moderate, low, and very low that are applied to a body of evidence, not to individual studies. In the context of a systematic review, quality reflects our confidence that the estimates of the effect are correct. In the context of recommendations, quality reflects our confidence that the effect estimates are adequate to support a particular recommendation. Randomized trials begin as high-quality evidence, observational studies as low quality. "Quality" as used in GRADE means more than risk of bias and so may also be compromised by imprecision, inconsistency, indirectness of study results, and publication bias. In addition, several factors can increase our confidence in an estimate of effect. GRADE provides a systematic approach for considering and reporting each of these factors. GRADE separates the process of assessing quality of evidence from the process of making recommendations. Judgments about the strength of a recommendation depend on more than just the quality of evidence. (C) 2011 Elsevier Inc. All rights reserved. C1 [Balshem, Howard] Oregon Hlth & Sci Univ, BICC, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA. [Helfand, Mark] Portland VA Med Ctr, Portland, OR USA. [Schuenemann, Holger J.; Brozek, Jan; Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada. [Oxman, Andrew D.; Vist, Gunn E.] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway. [Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland. [Falck-Ytter, Yngve] Case Western Reserve Univ, Div Gastroenterol, Case Med Ctr & VA, Cleveland, OH 44106 USA. [Meerpohl, Joerg] Univ Med Ctr Freiburg, German Cochrane Ctr, Inst Med Biometry & Med Informat, D-79104 Freiburg, Germany. [Meerpohl, Joerg] Univ Med Ctr Freiburg, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany. [Norris, Susan] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. RP Balshem, H (reprint author), Oregon Hlth & Sci Univ, BICC, Oregon Evidence Based Practice Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM balshemh@ohsu.edu RI Meerpohl, Joerg/J-4224-2013 OI Meerpohl, Joerg/0000-0002-1333-5403 NR 13 TC 979 Z9 1007 U1 11 U2 50 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD APR PY 2011 VL 64 IS 4 BP 401 EP 406 DI 10.1016/j.jclinepi.2010.07.015 PG 6 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 734UF UT WOS:000288364300009 PM 21208779 ER PT J AU Guyatt, GH Oxman, AD Vist, G Kunz, R Brozek, J Alonso-Coello, P Montori, V Akl, EA Djulbegovic, D Falck-Ytter, Y Norris, SL Williams, JW Atkins, D Meerpohl, J Schunemann, HJ AF Guyatt, Gordon H. Oxman, Andrew D. Vist, Gunn Kunz, Regina Brozek, Jan Alonso-Coello, Pablo Montori, Victor Akl, Elie A. Djulbegovic, Ben Falck-Ytter, Yngve Norris, Susan L. Williams, John W., Jr. Atkins, David Meerpohl, Joerg Schuenemann, Holger J. TI GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias) SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE GRADE; quality of evidence; risk of bias; confidence in estimates; blinding; concealment ID RANDOMIZED CONTROLLED-TRIALS; OUTCOME REPORTING BIAS; SPINAL-CORD-INJURY; EMPIRICAL-EVIDENCE; VENOUS THROMBOEMBOLISM; CLINICAL-TRIALS; HEART-FAILURE; METAANALYSIS; THERAPY; BENEFIT AB In the GRADE approach, randomized trials start as high-quality evidence and observational studies as low-quality evidence, but both can be rated down if most of the relevant evidence comes from studies that suffer from a high risk of bias. Well-established limitations of randomized trials include failure to conceal allocation, failure to blind, loss to follow-up, and failure to appropriately consider the intention-to-treat principle. More recently recognized limitations include stopping early for apparent benefit and selective reporting of outcomes according to the results. Key limitations of observational studies include use of inappropriate controls and failure to adequately adjust for prognostic imbalance. Risk of bias may vary across outcomes (e.g., loss to follow-up may be far less for all-cause mortality than for quality of life), a consideration that many systematic reviews ignore. In deciding whether to rate down for risk of bias whether for randomized trials or observational studies-authors should not take an approach that averages across studies. Rather, for any individual outcome, when there are some studies with a high risk, and some with a low risk of bias, they should consider including only the studies with a lower risk of bias. (C) 2011 Elsevier Inc. All rights reserved. C1 [Guyatt, Gordon H.; Brozek, Jan; Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada. [Oxman, Andrew D.; Vist, Gunn] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway. [Kunz, Regina] Univ Basel Hosp, Acad Swiss Insurance Med, CH-4031 Basel, Switzerland. [Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland. [Alonso-Coello, Pablo] Univ Autonoma Barcelona, Iberoamer Cochrane Ctr, Serv Epidemiol Clin & Salud Publ, Hosp St Pau, Barcelona 08041, Spain. [Alonso-Coello, Pablo] Univ Autonoma Barcelona, CIBERESP, Hosp St Pau, Barcelona 08041, Spain. [Montori, Victor] Mayo Clin, Knowledge & Encounter Res Unit, Rochester, MN USA. [Akl, Elie A.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA. [Djulbegovic, Ben] Univ S Florida, Ctr Evidence Based Med & Hlth Outcomes Res, Tampa, FL 33612 USA. [Djulbegovic, Ben] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL 33612 USA. [Djulbegovic, Ben] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL 33612 USA. [Falck-Ytter, Yngve] Case Western Reserve Univ, Div Gastroenterol, Case & VA Med Ctr, Cleveland, OH 44106 USA. [Norris, Susan L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [Williams, John W., Jr.] Duke Univ, Med Ctr, Durham, NC 27705 USA. [Williams, John W., Jr.] Durham Vet Affairs Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. [Atkins, David] US Dept Vet Affairs, QUERI Program, Off Res & Dev, Washington, DC USA. [Meerpohl, Joerg] Univ Med Ctr Freiburg, German Cochrane Ctr, Inst Med Biometry & Med Informat, D-79104 Freiburg, Germany. [Meerpohl, Joerg] Univ Med Ctr Freiburg, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany. RP Guyatt, GH (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Room 2C12,1200 Main St, W Hamilton, ON L8N 3Z5, Canada. EM guyatt@mcmaster.ea RI Djulbegovic, Benjamin/I-3661-2012; Meerpohl, Joerg/J-4224-2013 OI Djulbegovic, Benjamin/0000-0003-0671-1447; Meerpohl, Joerg/0000-0002-1333-5403; Montori, Victor/0000-0003-0595-2898 NR 37 TC 510 Z9 523 U1 7 U2 29 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD APR PY 2011 VL 64 IS 4 BP 407 EP 415 DI 10.1016/j.jclinepi.2010.07.017 PG 9 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 734UF UT WOS:000288364300010 PM 21247734 ER PT J AU Dalrymple, LS Katz, R Kestenbaum, B Shlipak, MG Sarnak, MJ Stehman-Breen, C Seliger, S Siscovick, D Newman, AB Fried, L AF Dalrymple, Lorien S. Katz, Ronit Kestenbaum, Bryan Shlipak, Michael G. Sarnak, Mark J. Stehman-Breen, Catherine Seliger, Stephen Siscovick, David Newman, Anne B. Fried, Linda TI Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE renal disease; cardiovascular disease; clinical epidemiology ID CARDIOVASCULAR HEALTH; COMPETING RISK; UNITED-STATES; OLDER-ADULTS; MORTALITY; OUTCOMES; EVENTS; POPULATION AB Among older adults with chronic kidney disease (CKD), the comparative event rates of end-stage renal disease (ESRD) and cause-specific death are unknown. To compare the rates of ESRD, cardiovascular and non-cardiovascular death and examine risk factors for ESRD and all-cause mortality in Cardiovascular Health Study (CHS) participants. The CHS is a longitudinal cohort study of community-dwelling adults aged 65 years and older. 1,268 participants with an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m(2) were followed until the time of first event (ESRD, cardiovascular or non-cardiovascular death) or until March 31, 2003. The outcomes were ESRD, cardiovascular- and non-cardiovascular death. Rates of each event were calculated, and a Cox Proportional Hazards Model with a competing risk framework was used to examine risk factors for ESRD as compared with death. Predictors included age, gender, race, BMI, hypertension, diabetes, cardiovascular disease, heart failure, tobacco use, eGFR, and total cholesterol. During 9.7 years of follow-up, 5% of the cohort progressed to ESRD, and 61% of the cohort died. The rate (per 100 person-years) was 0.5 for ESRD and 6.8 for all-cause mortality (3.0 for cardiovascular and 3.8 for non-cardiovascular mortality). In the competing risk framework, lower eGFR, male gender, African-American race, and higher BMI were associated with an increased risk of ESRD. Older adults with CKD are 13-fold more likely to die from any cause than progress to ESRD and are 6-fold more likely to die from cardiovascular causes than develop ESRD. C1 [Dalrymple, Lorien S.] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Kestenbaum, Bryan] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Shlipak, Michael G.] Vet Affairs Med Ctr, Med Serv, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Boston, MA USA. [Stehman-Breen, Catherine] Amgen Inc, Thousand Oaks, CA 91320 USA. [Seliger, Stephen] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Newman, Anne B.; Fried, Linda] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Newman, Anne B.; Fried, Linda] Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA USA. [Fried, Linda] VA Pittsburgh Hlth Care Syst, Renal Sect, Pittsburgh, PA USA. RP Dalrymple, LS (reprint author), Univ Calif Davis, Dept Med, 4150V St,3500 PSSB, Sacramento, CA 95817 USA. EM lorien.dalrymple@ucdmc.ucdavis.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU Amgen Inc.; Tap Pharmaceuticals; Merck FX Drs. Dalrymple, Katz, Shlipak, Seliger, Siscovick, and Newman report no conflicts of interest. Dr. Kestenbaum has received honoraria from Shire, Abbott, and Genzyme Inc., and has received grant funding from Amgen Inc. Dr. Sarnak has received funding from Tap Pharmaceuticals. Dr. Stehman-Breen is an employee of Amgen. Dr. Fried has provided expert testimony for Bayer and received a grant from Merck. NR 25 TC 62 Z9 66 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2011 VL 26 IS 4 BP 379 EP 385 DI 10.1007/s11606-010-1511-x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 733KD UT WOS:000288260700007 PM 20853156 ER PT J AU Walz, SE Smith, M Cox, E Sattin, J Kind, AJH AF Walz, Stacy E. Smith, Maureen Cox, Elizabeth Sattin, Justin Kind, Amy J. H. TI Pending Laboratory Tests and the Hospital Discharge Summary in Patients Discharged To Sub-Acute Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE laboratory tests; hospital discharge; sub-acute care ID MEDICAL REHABILITATION REPORT; UNIFORM DATA SYSTEM; BLOOD CULTURES; TIME; COMMUNICATION; PREVALENCE; BACTEREMIA; PHYSICIANS; ATTITUDES; PROGRAMS AB Previous studies have noted a high (41%) prevalence and poor discharge summary communication of pending laboratory (lab) tests at the time of hospital discharge for general medical patients. However, the prevalence and communication of pending labs within a high-risk population, specifically those patients discharged to sub-acute care (i.e., skilled nursing, rehabilitation, long-term care), remains unknown. To determine the prevalence and nature of lab tests pending at hospital discharge and their inclusion within hospital discharge summaries, for common sub-acute care populations. Retrospective cohort study. Stroke, hip fracture, and cancer patients discharged from a single large academic medical center to sub-acute care, 2003-2005 (N = 564) Pending lab tests were abstracted from the laboratory information system (LIS) and from each patient's discharge summary, then grouped into 14 categories and compared. Microbiology tests were sub-divided by culture type and number of days pending prior to discharge. Of sub-acute care patients, 32% (181/564) were discharged with pending lab tests per the LIS; however, only 11% (20/181) of discharge summaries documented these. Patients most often left the hospital with pending microbiology tests (83% [150/181]), particularly blood and urine cultures, and reference lab tests (17% [30/181]). However, 82% (61/74) of patients' pending urine cultures did not have 24-hour preliminary results, and 19% (13/70) of patients' pending blood cultures did not have 48-hour preliminary results available at the time of hospital discharge. Approximately one-third of the sub-acute care patients in this study had labs pending at discharge, but few were documented within hospital discharge summaries. Even after considering the availability of preliminary microbiology results, these omissions remain common. Future studies should focus on improving the communication of pending lab tests at discharge and evaluating the impact that this improved communication has on patient outcomes. C1 [Walz, Stacy E.; Smith, Maureen; Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53706 USA. [Smith, Maureen] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Smith, Maureen] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. [Cox, Elizabeth] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA. [Sattin, Justin] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI USA. [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Div Geriatr, Dept Med, Madison, WI USA. [Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, GRECC, US Dept Vet Affairs, Madison, WI USA. RP Walz, SE (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53706 USA. EM sewalz@wisc.edu FU University of Wisconsin (UW) Hartford Center of Excellence in Geriatrics; UW; NIH [1KL2RR025012-01]; National Center for Research Resources, National Institute of Health [1UL1RR025011]; University of Wisconsin Institute for Clinical and Translational Research (UW ICTR); National Center for Research Resources, National Institutes of Health [1UL1RR025011]; National Institute on Aging [K23AG034551] FX Funding for this project was provided by the University of Wisconsin (UW) Hartford Center of Excellence in Geriatrics and the UW Health Innovation Program. Dr. Kind is supported by a K-L2 through the NIH grant 1KL2RR025012-01 [Institutional Clinical and Translational Science Award (UW-Madison) 1UL1RR025011 (KL2) program of the National Center for Research Resources, National Institute of Health]. Additional support was provided by the Health Innovation Program and the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. The project described was supported by Award Number K23AG034551 from the National Institute on Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. NR 29 TC 14 Z9 14 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2011 VL 26 IS 4 BP 393 EP 398 DI 10.1007/s11606-010-1583-7 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 733KD UT WOS:000288260700009 PM 21116868 ER PT J AU Barnett, L Goenka, R Silver, J O'Neill, P Hunter, C Cancro, M Laufer, T AF Barnett, Lisa Goenka, Radhika Silver, Jonathan O'Neill, Patrick Hunter, Christopher Cancro, Michael Laufer, Terri TI T follicular helper cells require cognate B cell interactions for acquisition of full effector function SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Barnett, Lisa; Goenka, Radhika; O'Neill, Patrick; Cancro, Michael; Laufer, Terri] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Silver, Jonathan; Hunter, Christopher] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA. [Laufer, Terri] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 63.4 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751702037 ER PT J AU Basher, F Harrell, M Richard, E Nowling, T AF Basher, Fahmin Harrell, Maria Richard, Erin Nowling, Tamara TI Effects of Fli1 on T cell function in systemic lupus erythematosus SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Basher, Fahmin; Harrell, Maria; Richard, Erin; Nowling, Tamara] Med Univ S Carolina, Med Rheumatol, Charleston, SC 29425 USA. [Nowling, Tamara] Ralph H Johnson VA Med, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 44.44 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751700006 ER PT J AU Bodhankar, S Wang, CH Vandenbark, A Offner, H AF Bodhankar, Sheetal Wang, Chunhe Vandenbark, Arthur Offner, Haling TI Indispensable role of B cells in mediating protective effects of estrogen against EAE SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Bodhankar, Sheetal; Wang, Chunhe; Vandenbark, Arthur; Offner, Haling] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bodhankar, Sheetal; Vandenbark, Arthur; Offner, Haling] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 167.20 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751708025 ER PT J AU De Costala, AM Walker, D Schuyler, C Young, R AF De Costala, Anna-Maria Walker, David Schuyler, Corinne Young, Rita TI Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate stimulates Th1 and Th17 immunity in mice bearing carcinogen-induced premalignant oral lesions SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [De Costala, Anna-Maria; Young, Rita] Med Univ South Carolina, Microbiol & Immunol, Charleston, SC USA. [De Costala, Anna-Maria; Walker, David; Schuyler, Corinne; Young, Rita] Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 165.13 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751708014 ER PT J AU Ding, YN Hsu, HC Wu, Q Yang, P Mountz, J AF Ding, Yanna Hsu, Hui-Chen Wu, Qi Yang, Pingar Mountz, John TI Sequential effects of IL-21 and IL-17 to regulate spleen CXCR5(+) follicular T helper cells in autoimmune BXD2 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Ding, Yanna; Hsu, Hui-Chen; Wu, Qi; Yang, Pingar; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 101.44 PG 2 WC Immunology SC Immunology GA V44LY UT WOS:000209751703111 ER PT J AU Li, H Wu, Q Yang, PA Cua, D Hsu, HC Mountz, J AF Li, Hao Wu, Qi Yang, PingAr Cua, Daniel Hsu, Hui-Chen Mountz, John TI IL-23 induces apoptosis of self-reactive thymocytes in thymic negative selection by an Rorc dependent mechanism SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Li, Hao] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Li, Hao; Wu, Qi; Yang, PingAr; Hsu, Hui-Chen; Mountz, John] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Cua, Daniel] Merck Res Labs, Palo Alto, CA USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 64.19 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751702078 ER PT J AU Li, J Hsu, HC Yang, PA Wu, Q Li, H Mountz, J AF Li, Jun Hsu, Hui-Chen Yang, PingAr Wu, Qi Li, Hao Mountz, John TI Anti-DR5 antibody eliminates inflammatory macrophages rebalancing IL-23/Th17 axis and regulatory T cells in arthritis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Li, Hao; Mountz, John] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Mountz, John] Birmingham VA Med Ctr, Birmigham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 147.26 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751705167 ER PT J AU Nowling, T Richard, EM Harrell, M Basher, F Zhang, J AF Nowling, Tamara Richard, Erin Morris Harrell, Maria Basher, Fahmin Zhang, John TI Specific effects of Fli1 levels on T cells in the MRL/Ipr lupus prone model SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Nowling, Tamara; Richard, Erin Morris; Harrell, Maria; Basher, Fahmin; Zhang, John] Med Univ S Carolina, Med Rheumatol, Charleston, SC 29425 USA. [Nowling, Tamara; Zhang, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 44.30 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751700025 ER PT J AU Paintlia, A Paintlia, M Singh, A Singh, I AF Paintlia, Ajaib Paintlia, Manjeet Singh, Avtar Singh, Inderjit TI Lovastatin exhibits synergy with Vitamin D hormone to confer protection from experimental autoimmune encephalomylitis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Paintlia, Ajaib; Paintlia, Manjeet; Singh, Inderjit] Med Univ S Carolina, Charleston, SC 29425 USA. [Singh, Avtar] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 148.5 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751705190 ER PT J AU Paintlia, M Paintlia, A Singh, A Singh, I AF Paintlia, Manjeet Paintlia, Ajaib Singh, Avtar Singh, Inderjit TI Interleukin-17 exacerbates tumor necrosis Factor-alpha induced apoptotic cell death of oligodendrocytes SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Paintlia, Manjeet; Paintlia, Ajaib; Singh, Inderjit] MUSC, Charleston, SC USA. [Singh, Avtar] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 148.8 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751705192 ER PT J AU Suzuki, E Williams, S Karam, E Zhang, X AF Suzuki, Eiji Williams, Sarah Karam, Eva Zhang, Xian TI Transcription factor Fli-1 is involved in regulation of dendritic cell and monocyte development SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Suzuki, Eiji; Karam, Eva; Zhang, Xian] Med Univ S Carolina, Charleston, SC 29425 USA. [Williams, Sarah; Zhang, Xian] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 153.33 PG 2 WC Immunology SC Immunology GA V44LY UT WOS:000209751706107 ER PT J AU Walker, D Reeves, T De Costa, AM Schuyler, C Young, MR AF Walker, David Reeves, Travis De Costa, Anna-Maria Schuyler, Corinne Young, M. Rita TI The effects of 1,25-dihydroxy vitamin D3 on tumor-associated immunosuppression in squamous cell carcinoma of the head and neck. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Walker, David; Reeves, Travis; Young, M. Rita] Med Univ S Carolina, Otolaryngol, Charleston, SC 29425 USA. [Schuyler, Corinne; Young, M. Rita] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [De Costa, Anna-Maria] Med Univ S Carolina, Microbiol & Immunol, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR PY 2011 VL 186 SU 1 MA 165.29 PG 1 WC Immunology SC Immunology GA V44LY UT WOS:000209751707188 ER EF